PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kimura, T; Takeda, S; Sagiya, Y; Gotoh, M; Nakamura, Y; Arakawa, H				Kimura, T; Takeda, S; Sagiya, Y; Gotoh, M; Nakamura, Y; Arakawa, H			Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools	NATURE GENETICS			English	Article							DNA-DAMAGE; RIBONUCLEOTIDE REDUCTASE; P53-DEPENDENT APOPTOSIS; POTENTIAL MEDIATOR; GENE; IDENTIFICATION; PROTEIN; PATHWAY; CELLS	p53R2, which is regulated by tumor suppressor p53, is a small subunit of ribonucleotide reductase(1). To determine whether it is involved in DNA repair by supplying deoxyribonucleotides (dNTPs) for resting cells in vivo(2 5), we generated a strain of mice lacking Rrm2b (encoding p53R2). These mice developed normally until they were weaned but from then on had growth retardation and early mortality. Pathological examination indicated that multiple organs had failed, and all Rrm2b-null mice died from severe renal failure by the age of 14 weeks. TUNEL staining showed a greater number of apoptotic cells in kidneys of 8-week-old Rrm2b(-/-) mice relative to wild-type mice. p53 was activated in kidney tissues of Rrm2b(-/-) mice, leading to transcriptional induction of p53 target genes. Rrm2b(-/-) mouse embryonic fibroblasts (MEFs) became immortal much earlier than Rrm2b(+/+) MEFs. dNTP pools were severely attenuated in Rrm2b(-/-) MEFs under oxidative stress. Rrm2b deficiency caused higher rates of spontaneous mutation in the kidneys of Rrm2b(-/-) mice. Our results suggest that p53R2 has a pivotal role in maintaining dNTP levels for repair of DNA in resting cells. Impairment of this pathway may enhance spontaneous mutation frequency and activate p53-dependent apoptotic pathway(s) in vivo, causing severe renal failure, growth retardation and early mortality.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Fukushima Med Univ, Sch Med, Dept Surg 1, Fukushima 9601295, Japan; Otsuka Pharmaceut Co Ltd, Otsuka GEN Res Inst, Tokushima 7710192, Japan	University of Tokyo; Fukushima Medical University; Otsuka Pharmaceutical	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P5373, DOI 10.1128/MCB.9.12.5373; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; HARPER JW, 1993, CELL, V75, P805; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Matsuda K, 2002, CANCER RES, V62, P2883; MIYASHITA T, 1995, CELL, V80, P293; Nohmi T, 2000, MUTAT RES-FUND MOL M, V455, P191, DOI 10.1016/S0027-5107(00)00077-4; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	21	114	122	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					440	445		10.1038/ng1212	http://dx.doi.org/10.1038/ng1212			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12858174				2022-12-25	WOS:000184470500023
J	Mburu, P; Mustapha, M; Varela, A; Weil, D; El-Amraoui, A; Holme, RH; Rump, A; Hardisty, RE; Blanchard, S; Coimbra, RS; Perfettini, I; Parkinson, N; Mallon, AM; Glenister, P; Rogers, MJ; Paige, AJ; Moir, L; Clay, J; Rosenthal, A; Liu, XZ; Blanco, G; Steel, KP; Petit, C; Brown, SDM				Mburu, P; Mustapha, M; Varela, A; Weil, D; El-Amraoui, A; Holme, RH; Rump, A; Hardisty, RE; Blanchard, S; Coimbra, RS; Perfettini, I; Parkinson, N; Mallon, AM; Glenister, P; Rogers, MJ; Paige, AJ; Moir, L; Clay, J; Rosenthal, A; Liu, XZ; Blanco, G; Steel, KP; Petit, C; Brown, SDM			Defects in whirlin, a PDZ domain molecule involved in stereocilia elongation, cause deafness in the whirler mouse and families with DFNB31	NATURE GENETICS			English	Article							HAIR CELL STEREOCILIA; MYOSIN VIIA; UNCONVENTIONAL MYOSIN; RECESSIVE DEAFNESS; PROTEINS; MUTATIONS; GENE; HARMONIN; COMPLEX; IDENTIFICATION	The whirler mouse mutant (wi) does not respond to sound stimuli, and detailed ultrastructural analysis of sensory hair cells in the organ of Corti of the inner ear indicates that the whirler gene encodes a protein involved in the elongation and maintenance of stereocilia in both inner hair cells (IHCs) and outer hair cells (OHCs). BAC-mediated transgene correction of the mouse phenotype and mutation analysis identified the causative gene as encoding a novel PDZ protein called whirlin. The gene encoding whirlin also underlies the human autosomal recessive deafness locus DFNB31. In the mouse cochlea, whirlin is expressed in the sensory IHC and OHC stereocilia. Our findings suggest that this novel PDZ domain containing molecule acts as an organizer of submembranous molecular complexes that control the coordinated actin polymerization and membrane growth of stereocilia.	Inst Pasteur, INSERM, U587, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Oxon, England; MRC, UK Mouse Genome Ctr, Harwell OX11 0RD, Oxon, England; Univ Nottingham, MRC, Inst Hearing Res, Nottingham NG7 2RD, England; MetaGen Pharmaceut Gmbh, D-13347 Berlin, Germany; Inst Mol Biotechnol, Dept Genome Anal, D-07445 Jena, Germany; Univ Miami, Dept Otolaryngol, Miami, FL 33101 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Nottingham; University of Miami	Petit, C (corresponding author), Inst Pasteur, INSERM, U587, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr	Coimbra, Roney/B-3102-2013; Blanco, Gonzalo/D-8735-2014; Paige, Adam/CAF-2088-2022; Coimbra, Roney/ABA-0586-2022	Blanco, Gonzalo/0000-0003-3827-3111; Coimbra, Roney/0000-0002-9204-0573; EL-AMRAOUI, Aziz/0000-0003-2692-4984; Rump, Andreas/0000-0001-7116-6364; Petit, Christine/0000-0002-9069-002X; Moir, Lee/0000-0003-4829-3597	MRC [MC_U142684171] Funding Source: UKRI; Medical Research Council [MC_U142684171] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmed ZM, 2002, HUM GENET, V110, P527, DOI 10.1007/s00439-002-0732-4; Alagramam KN, 2001, HUM MOL GENET, V10, P1709, DOI 10.1093/hmg/10.16.1709; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BAUMANN H, 1985, MOL GEN GENET, V201, P505, DOI 10.1007/BF00331347; Bitner-Glindzicz M, 2000, NAT GENET, V26, P56, DOI 10.1038/79178; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Evans AL, 2000, NAT GENET, V24, P424, DOI 10.1038/74286; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gong TWL, 1996, HEARING RES, V96, P20, DOI 10.1016/0378-5955(96)00013-5; Harris BZ, 2001, J CELL SCI, V114, P3219; Holme RH, 2002, J COMP NEUROL, V450, P94, DOI 10.1002/cne.10301; Hudspeth AJ, 1997, NEURON, V19, P947, DOI 10.1016/S0896-6273(00)80385-2; KALTENBACH JA, 1994, J COMP NEUROL, V340, P87, DOI 10.1002/cne.903400107; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kollmar R, 1999, CURR OPIN NEUROBIOL, V9, P394, DOI 10.1016/S0959-4388(99)80059-2; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mallon AM, 2000, GENOME RES, V10, P758, DOI 10.1101/gr.10.6.758; Muller U, 2001, TRENDS CELL BIOL, V11, P334, DOI 10.1016/S0962-8924(01)02046-3; Mustapha M, 2002, EUR J HUM GENET, V10, P210, DOI 10.1038/sj.ejhg.5200780; Ouyang XM, 2002, HUM GENET, V111, P26, DOI 10.1007/s00439-002-0736-0; Paige AJW, 2000, MAMM GENOME, V11, P51, DOI 10.1007/s003350010010; Parkinson N, 2002, GENOME BIOL, V3; PETIT C, 2001, METABOLIC MOL BASES, V4, P6281; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Rogers MJC, 1999, MAMM GENOME, V10, P513, DOI 10.1007/s003359901032; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Self T, 1998, DEVELOPMENT, V125, P557; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Siddiqa A, 2001, NATURE, V410, P383, DOI 10.1038/35066602; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; Taudien S, 2000, TRENDS GENET, V16, P519, DOI 10.1016/S0168-9525(00)02127-2; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8; Zwaenepoel I, 2002, P NATL ACAD SCI USA, V99, P6240, DOI 10.1073/pnas.082515999	45	236	251	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					421	428		10.1038/ng1208	http://dx.doi.org/10.1038/ng1208			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12833159				2022-12-25	WOS:000184470500020
J	Reginato, MJ; Mills, KR; Paulus, JK; Lynch, DK; Sgroi, DC; Debnath, J; Muthuswamy, SK; Brugge, JS				Reginato, MJ; Mills, KR; Paulus, JK; Lynch, DK; Sgroi, DC; Debnath, J; Muthuswamy, SK; Brugge, JS			Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY; CELL-DEATH; PROAPOPTOTIC ACTIVITY; BH3-ONLY PROTEINS; EPITHELIAL-CELLS; DOWN-REGULATION; MOTOR COMPLEX; SURVIVAL; KINASE	Epithelial cells must adhere to the extracellular matrix (ECM) for survival, as detachment from matrix triggers apoptosis or anoikis(1). Integrins are major mediators of adhesion between cells and ECM proteins, and transduce signals required for cell survival(2). Recent evidence suggests that integrin receptors are coupled to growth factor receptors in the regulation of multiple biological functions(2); however, mechanisms involved in coordinate regulation of cell survival are poorly understood and mediators responsible for anoikis have not been well characterized. Here, we identify the pro-apoptotic protein Bim as a critical mediator of anoikis in epithelial cells. Bim is strongly induced after cell detachment and downregulation of Bim expression by RNA interference (RNAi) inhibits anoikis. Detachment-induced expression of Bim requires a lack of beta(1)-integrin engagement, downregulation of EGF receptor (EGFR) expression and inhibition of Erk signalling. Overexpressed EGFR was uncoupled from integrin regulation, resulting in the maintenance of Erk activation in suspension, and a block in Bim expression and anoikis. Thus, Bim functions as a key sensor of integrin and growth factor signals to the Erk pathway, and loss of such coordinate regulation may contribute to tumour progression.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Muthuswamy, Senthil K/AGY-2834-2022; Sgroi, Dennis/AAV-2487-2021; Reginato, Mauricio/I-6155-2013	Muthuswamy, Senthil K/0000-0001-6564-9634; Reginato, Mauricio/0000-0002-7541-4094; Debnath, Jayanta/0000-0002-8745-4069				Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Edwards P A, 1996, Cancer Treat Res, V83, P23; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; HOWLETT AR, 1995, J CELL SCI, V108, P1945; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SOULE HD, 1990, CANCER RES, V50, P6075; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	35	410	424	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					733	740		10.1038/ncb1026	http://dx.doi.org/10.1038/ncb1026			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12844146				2022-12-25	WOS:000184687300015
J	Schaible, UE; Winau, F; Sieling, PA; Fischer, K; Collins, HL; Hagens, K; Modlin, RL; Brinkmann, V; Kaufmann, SHE				Schaible, UE; Winau, F; Sieling, PA; Fischer, K; Collins, HL; Hagens, K; Modlin, RL; Brinkmann, V; Kaufmann, SHE			Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis	NATURE MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; DENDRITIC CELLS; INFECTED MACROPHAGES; ANTIMICROBIAL ACTIVITY; PRESENTING CELLS; RECOGNITION; PHAGOSOMES; COMPARTMENTS; TRAFFICKING; GLYCOLIPIDS	Protective immunity against Mycobacterium tuberculosis involves major histocompatibility complex class I (MHC-I)- and CD1-restricted CD8 T cells, but the mechanisms underlying antigen delivery to antigen-presenting molecules remain enigmatic. Macrophages, the primary host cells for mycobacteria, are CD1-negative. Here we show that M. tuberculosis phagosomes are secluded from the cytosolic MHC-I processing pathway and that mycobacteria-infected cells lose their antigen-presenting capacity. We also show that mycobacteria induce apoptosis in macrophages, causing the release of apoptotic vesicles that carry mycobacterial antigens to uninfected antigen-presenting cells (APCs). Inhibition of apoptosis reduced transfer of antigens to bystander cells and activation of CD8 T cells. Uninfected dendritic cells, which engulfed extracellular vesicles, were indispensable for subsequent cross-presentation of antigens, through MHC-I and CD1b, to T cells from mycobacteria-sensitized donors. This new 'detour' pathway for presentation of antigens from a phagosome-contained pathogen shows the functional significance of infection-induced apoptosis in the activation of CD8 T cells specific for both protein and glycolipid antigens in tuberculosis.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Max Planck Inst Infect Biol, Cent Core Facil Microscopy, D-10117 Berlin, Germany	Max Planck Society; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Max Planck Society	Schaible, UE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.		Modlin, Robert L/M-7941-2014; Brinkmann, Volker/A-6015-2009; Kaufmann, Stefan HE/I-5454-2014	Modlin, Robert L/0000-0003-4720-031X; Kaufmann, Stefan HE/0000-0001-9866-8268				Beatty WL, 2000, TRAFFIC, V1, P235, DOI 10.1034/j.1600-0854.2000.010306.x; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; Beauregard KE, 1997, J EXP MED, V186, P1159, DOI 10.1084/jem.186.7.1159; Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973; BEHAR SM, 1995, J EXP MED, V182, P2007, DOI 10.1084/jem.182.6.2007; Canaday DH, 1999, J IMMUNOL, V162, P372; Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; den Haan JMM, 2001, CURR OPIN IMMUNOL, V13, P437, DOI 10.1016/S0952-7915(00)00238-7; Denzer K, 2000, J CELL SCI, V113, P3365; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Fayyazi A, 2000, J PATHOL, V191, P417, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH664&gt;3.0.CO;2-R; Fischer K, 2001, J IMMUNOL, V167, P2187, DOI 10.4049/jimmunol.167.4.2187; Herrmann JL, 1996, EMBO J, V15, P3547, DOI 10.1002/j.1460-2075.1996.tb00724.x; Jiao XN, 2002, J IMMUNOL, V168, P1294, DOI 10.4049/jimmunol.168.3.1294; Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Larsson M, 2001, TRENDS IMMUNOL, V22, P141, DOI 10.1016/S1471-4906(01)01860-9; Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Rojas M, 1997, J IMMUNOL, V159, P1352; Rolph MS, 2001, EUR J IMMUNOL, V31, P1944, DOI 10.1002/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R; Ronchetti A, 1999, J IMMUNOL, V163, P130; Russell DG, 1997, PHILOS T ROY SOC B, V352, P1303, DOI 10.1098/rstb.1997.0114; Schaible U E, 1999, Adv Immunol, V71, P267; Schaible UE, 2000, J IMMUNOL, V164, P4843, DOI 10.4049/jimmunol.164.9.4843; Schaible UE, 1999, J CELL SCI, V112, P681; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Stenger S, 1998, J IMMUNOL, V161, P3582; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Teitelbaum R, 1999, P NATL ACAD SCI USA, V96, P15190, DOI 10.1073/pnas.96.26.15190; Wilhelm S, 1999, EUR J CELL BIOL, V78, P127, DOI 10.1016/S0171-9335(99)80014-4; XU SM, 1994, J IMMUNOL, V153, P2568; Yrlid U, 2000, J EXP MED, V191, P613, DOI 10.1084/jem.191.4.613; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zocchi MR, 1997, AIDS, V11, P1227, DOI 10.1097/00002030-199710000-00005	40	399	419	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1039	1046		10.1038/nm906	http://dx.doi.org/10.1038/nm906			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872166				2022-12-25	WOS:000184484900028
J	Mootha, VK; Lindgren, CM; Eriksson, KF; Subramanian, A; Sihag, S; Lehar, J; Puigserver, P; Carlsson, E; Ridderstrale, M; Laurila, E; Houstis, N; Daly, MJ; Patterson, N; Mesirov, JP; Golub, TR; Tamayo, P; Spiegelman, B; Lander, ES; Hirschhorn, JN; Altshuler, D; Groop, LC				Mootha, VK; Lindgren, CM; Eriksson, KF; Subramanian, A; Sihag, S; Lehar, J; Puigserver, P; Carlsson, E; Ridderstrale, M; Laurila, E; Houstis, N; Daly, MJ; Patterson, N; Mesirov, JP; Golub, TR; Tamayo, P; Spiegelman, B; Lander, ES; Hirschhorn, JN; Altshuler, D; Groop, LC			PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes	NATURE GENETICS			English	Article							IMPAIRED GLUCOSE-TOLERANCE; GAMMA COACTIVATOR-1 PGC-1; SKELETAL-MUSCLE; MITOCHONDRIAL BIOGENESIS; EXPRESSION PROFILE; DETERMINANTS; RESPIRATION; MECHANISMS; DISCOVERY; DISEASE	DNA microarrays can be used to identify gene expression changes characteristic of human disease. This is challenging, however, when relevant differences are subtle at the level of individual genes. We introduce an analytical strategy, Gene Set Enrichment Analysis, designed to detect modest but coordinate changes in the expression of groups of functionally related genes. Using this approach, we identify a set of genes involved in oxidative phosphorylation whose expression is coordinately decreased in human diabetic muscle. Expression of these genes is high at sites of insulin-mediated glucose disposal, activated by PGC-1alpha and correlated with total-body aerobic capacity. Our results associate this gene set with clinically important variation in human metabolism and illustrate the value of pathway relationships in the analysis of genomic profiling experiments.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Harvard Med Sch, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Lund Univ, Dept Endocrinol, Wallenberg Lab, Univ Hosp MAS, S-20502 Malmo, Sweden; Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA; MIT, Dept Biol, Cambridge, MA USA; Harvard Med Sch, Dept Genet, Boston, MA USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Lund University; Skane University Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Altshuler, D (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	altshuler@molbio.mgh.harvard.edu; leif.groop@endo.mas.lu.se	Mesirov, Jill/AGF-7626-2022; Altshuler, David M/A-4476-2009; Daly, Mark J/B-2453-2017; Ridderstråle, Martin/F-7678-2012	Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; Lindgren, Cecilia/0000-0002-4903-9374	Wellcome Trust [090532] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BJOMTORP P, 1967, DIABETOLOGIA, V3, P346; BROWN GC, 1992, BIOCHEM J, V284, P1; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; ERIKSSON KF, 1994, DIABETES, V43, P805, DOI 10.2337/diabetes.43.6.805; ERIKSSON KF, 1990, DIABETOLOGIA, V33, P526, DOI 10.1007/BF00404139; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; FLOREZ JC, IN PRESS ANN REV GEN; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Groop L, 1996, DIABETES, V45, P1585, DOI 10.2337/diabetes.45.11.1585; Hara K, 2002, DIABETOLOGIA, V45, P740, DOI 10.1007/s00125-002-0803-z; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kropf S, 2002, BIOMETRICAL J, V44, P789, DOI 10.1002/1521-4036(200210)44:7<789::AID-BIMJ789>3.0.CO;2-#; Lacquemant C, 2002, DIABETOLOGIA, V45, P602, DOI 10.1007/s00125-002-0783-z; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; SCHALINJANTTI C, 1995, EUR J CLIN INVEST, V25, P693, DOI 10.1111/j.1365-2362.1995.tb01988.x; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang X, 2002, DIABETOLOGIA, V45, P1584, DOI 10.1007/s00125-002-0905-7; Zimmet P, 2000, J INTERN MED, V247, P301, DOI 10.1046/j.1365-2796.2000.00625.x	32	5754	5860	6	252	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2003	34	3					267	273		10.1038/ng1180	http://dx.doi.org/10.1038/ng1180			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12808457				2022-12-25	WOS:000183815300013
J	Sansom, OJ; Berger, J; Bishop, SM; Hendrich, B; Bird, A; Clarke, AR				Sansom, OJ; Berger, J; Bishop, SM; Hendrich, B; Bird, A; Clarke, AR			Deficiency of Mbd2 suppresses intestinal tumorigenesis	NATURE GENETICS			English	Article							NEOPLASIA; MOUSE; GENE; DNA; HYPERMETHYLATION; PROTEIN; LOCUS; MICE	Gene silencing through de novo methylation of CpG island promoters contributes to cancer. We find that Mbd2, which recruits co-repressor complexes to methylated DNA, is essential for efficient tumorigenesis in the mouse intestine. As Mbd2-deficient mice are viable and fertile, their resistance to intestinal cancer may be of therapeutic relevance.	Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Bird, A (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales.		clarke, alan r/P-2820-2014; Hendrich, Brian/AAG-5898-2020; Clarke, Alan R/A-6256-2008	Hendrich, Brian/0000-0002-0231-3073; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Billard LM, 2002, ONCOGENE, V21, P2704, DOI 10.1038/sj/onc/1205357; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Eads CA, 2002, CANCER RES, V62, P1296; Esteller M, 2000, CANCER RES, V60, P4366; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lin XH, 2003, CANCER RES, V63, P498; LUONGO C, 1994, CANCER RES, V54, P5947; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108	15	140	151	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					145	147		10.1038/ng1155	http://dx.doi.org/10.1038/ng1155			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12730693				2022-12-25	WOS:000183200500017
J	Kozower, BD; Christofidou-Solomidou, M; Sweitzer, TD; Muro, S; Buerk, DG; Solomides, CC; Albelda, SM; Patterson, GA; Muzykantov, VR				Kozower, BD; Christofidou-Solomidou, M; Sweitzer, TD; Muro, S; Buerk, DG; Solomides, CC; Albelda, SM; Patterson, GA; Muzykantov, VR			Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury	NATURE BIOTECHNOLOGY			English	Article							CELL-ADHESION MOLECULE-1; IN-VIVO; REPERFUSION INJURY; GLUCOSE-OXIDASE; NEUTROPHIL RECRUITMENT; SUPEROXIDE-DISMUTASE; VASCULAR ENDOTHELIUM; DELIVERY; ISCHEMIA; STRATEGY	Vascular immunotargeting may facilitate the rapid and specific delivery of therapeutic agents to endothelial cells. We investigated whether targeting of an antioxidant enzyme, catalase, to the pulmonary endothelium alleviates oxidative stress in an in vivo model of lung transplantation. Intravenously injected enzymes, conjugated with an antibody to platelet-endothelial cell adhesion molecule-1, accumulate in the pulmonary vasculature and retain their activity during prolonged cold storage and transplantation. Immunotargeting of catalase to donor rats augments the antioxidant capacity of the pulmonary endothelium, reduces oxidative stress, ameliorates ischemia-reperfusion injury, prolongs the acceptable cold ischemia period of lung grafts, and improves the function of transplanted lung grafts. These findings validate the therapeutic potential of vascular immunotargeting as a drug delivery strategy to reduce endothelial injury. Potential applications of this strategy include improving the outcome of clinical lung transplantation and treating a wide variety of endothelial disorders.	Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Temple Univ Hosp & Med Sch, Dept Pathol, Philadelphia, PA 19140 USA; Washington Univ, Sch Med, Div Cardiothorac Surg, St Louis, MO 63110 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Washington University (WUSTL)	Muzykantov, VR (corresponding author), Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Buerk, Donald G/F-6888-2014		NHLBI NIH HHS [HL 60290, R01 HL41281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290, R01HL041281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Atochina EN, 1997, AM J RESP CRIT CARE, V156, P1114, DOI 10.1164/ajrccm.156.4.96-12116; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; BUERK DG, 1993, BIOSENSORS THEORY AP, P39; Chabot F, 1998, EUR RESPIR J, V11, P745; Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51; Christofidou-Solomidou M, 2000, AM J PHYSIOL-LUNG C, V278, pL794, DOI 10.1152/ajplung.2000.278.4.L794; Christofidou-Solomidou M, 2002, AM J PATHOL, V160, P1155, DOI 10.1016/S0002-9440(10)64935-8; CORVO M, 1999, BIOCHIM BIOPHYS ACTA, P1; Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335; DAVIES MG, 1993, ANN SURG, V218, P593, DOI 10.1097/00000658-199321850-00003; DUO L, 2000, NAT BIOTECHNOL, V18, P33; ECKENHOFF RG, 1992, J APPL PHYSIOL, V72, P1454, DOI 10.1152/jappl.1992.72.4.1454; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; FREEMAN BA, 1982, LAB INVEST, V47, P412; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Gow AJ, 1999, AM J PHYSIOL-LUNG C, V277, pL271, DOI 10.1152/ajplung.1999.277.2.L271; Hiratsuka M, 1998, J HEART LUNG TRANSPL, V17, P1238; Kelly RF, 2000, J LAB CLIN MED, V136, P427, DOI 10.1067/mlc.2000.110906; King RC, 2000, ANN THORAC SURG, V69, P1681, DOI 10.1016/S0003-4975(00)01425-9; Kozower BD, 2002, AM J TRANSPLANT, V2, P837, DOI 10.1034/j.1600-6143.2002.20905.x; Langer R, 1998, NATURE, V392, P5; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Li S, 2000, AM J PHYSIOL-LUNG C, V278, pL504, DOI 10.1152/ajplung.2000.278.3.L504; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; MIZUTA T, 1989, J THORAC CARDIOV SUR, V97, P578; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2; Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Novick RJ, 1996, ANN THORAC SURG, V62, P302, DOI 10.1016/0003-4975(96)00333-5; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Reynolds PN, 2001, NAT BIOTECHNOL, V19, P838, DOI 10.1038/nbt0901-838; Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777; Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com; SIFLINGERBIRNBOIM A, 1993, J CELL PHYSIOL, V155, P234, DOI 10.1002/jcp.1041550203; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wiewrodt R, 2002, BLOOD, V99, P912, DOI 10.1182/blood.V99.3.912; Williams A, 1999, FREE RADICAL RES, V30, P383, DOI 10.1080/10715769900300421; Yabe Y, 1999, J PHARMACOL EXP THER, V289, P1176	46	116	124	3	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					392	398		10.1038/nbt806	http://dx.doi.org/10.1038/nbt806			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	664VH	12652312				2022-12-25	WOS:000182082400020
J	Mitchell, P				Mitchell, P			In the pursuit of industrial proteomics	NATURE BIOTECHNOLOGY			English	Article							PROTEIN COMPLEXES; MASS-SPECTROMETRY											Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Fountoulakis M, 2001, ELECTROPHORESIS, V22, P1747, DOI 10.1002/1522-2683(200105)22:9<1747::AID-ELPS1747>3.0.CO;2-H; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Patton WF, 2002, CURR OPIN BIOTECH, V13, P321, DOI 10.1016/S0958-1669(02)00333-6; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Zhou HL, 2002, NAT BIOTECHNOL, V20, P512, DOI 10.1038/nbt0502-512	12	8	8	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					233	237		10.1038/nbt0303-233	http://dx.doi.org/10.1038/nbt0303-233			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610565				2022-12-25	WOS:000181312500014
J	Veazey, RS; Shattock, RJ; Pope, M; Kirijan, JC; Jones, J; Hu, QX; Ketas, T; Marx, PA; Klasse, PJ; Burton, DR; Moore, JP				Veazey, RS; Shattock, RJ; Pope, M; Kirijan, JC; Jones, J; Hu, QX; Ketas, T; Marx, PA; Klasse, PJ; Burton, DR; Moore, JP			Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120	NATURE MEDICINE			English	Article							SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS; SEXUAL TRANSMISSION; DENDRITIC CELLS; IN-VITRO; NEUTRALIZATION; REDUCTION; INFECTION; SEMEN; LOAD	A topical microbicide reduces the probability of virus transmission when applied to the vagina or rectum of a person at risk of sexually acquiring HIV-1 infection(1-3). An effective microbicide could significantly reduce the global spread of HIV-1, particularly if women were able to use it covertly to protect themselves. A microbicide could target the incoming virus and either permanently inactivate it or reduce its infectivity, or it could block receptors on susceptible cells near the sites of transmission(1-3). We describe here how vaginal administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from simian-human immunodeficiency virus (SHIV) infection through the vagina. Only 3 of 12 animals receiving 5 mg b12 vaginally in either saline or a gel and then challenged vaginally (up to 2 h later) with SHIV-162P4 became infected. In contrast, infection occurred in 12 of 13 animals given various control agents under similar conditions. Lower amounts of b12 were less effective, suggesting that protection was dose dependent. These observations support the concept that viral entry inhibitors can help prevent the sexual transmission of HIV-1 to humans.	Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA; Tulane Univ, Tulane Natl Primate Res Ctr, Hlth Sci Ctr, Covington, LA USA; Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Jefferiss Res Trust Labs, Wright Fleming Inst, London, England; Scripps Res Inst, Dept Immunol, La Jolla, CA USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA USA	Cornell University; Tulane University; St Georges University London; Population Council; Imperial College London; Scripps Research Institute; Scripps Research Institute	Moore, JP (corresponding author), Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.		Klasse, P.J./AEX-0142-2022	Klasse, P.J./0000-0001-8222-278X; Hu, Qinxue/0000-0002-4594-9215	NCRR NIH HHS [RR00164] Funding Source: Medline; NIAID NIH HHS [AI40877, AI52048, AI52057, AI49080, AI33292] Funding Source: Medline; NICHD NIH HHS [HD36310] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD036310] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI052048, R37AI033292, R01AI049080, R01AI052057, R01AI033292, R37AI040877, R01AI040877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Dove A, 2002, NAT BIOTECHNOL, V20, P777, DOI 10.1038/nbt0802-777; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Frank I., 2002, Current Molecular Medicine (Hilversum), V2, P229, DOI 10.2174/1566524024605716; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Haase AT, 2001, AIDS, V15, pS10, DOI 10.1097/00002030-200102001-00013; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Idemyor V, 2002, PHARMACOTHERAPY, V22, P1074, DOI 10.1592/phco.22.12.1074.33610; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MILLER CJ, IN PRESS MICROBES IN; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Saltzman WM, 2000, BIOTECHNOL BIOENG, V67, P253, DOI 10.1002/(SICI)1097-0290(20000205)67:3<253::AID-BIT1>3.0.CO;2-T; Shattock RJ, 2000, NAT MED, V6, P607, DOI 10.1038/76138; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077; van de Wijgert Janneke, 2002, BETA, V15, P23; Vernazza PL, 1999, AIDS, V13, P155, DOI 10.1097/00002030-199902040-00003	26	396	417	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					343	346		10.1038/nm833	http://dx.doi.org/10.1038/nm833			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579198				2022-12-25	WOS:000181312300036
J	Wingren, C; Ingvarsson, J; Lindstedt, M; Borrebaeck, CAK				Wingren, C; Ingvarsson, J; Lindstedt, M; Borrebaeck, CAK			Recombinant antibody microarrays - a viable option?	NATURE BIOTECHNOLOGY			English	Editorial Material									Lund Univ, Dept Immunotechnol, SE-22007 Lund, Sweden	Lund University	Wingren, C (corresponding author), Lund Univ, Dept Immunotechnol, SE-22007 Lund, Sweden.	carl.borrebaeck@immun.lth.se	Lindstedt, Malin/A-3855-2009	Lindstedt, Malin/0000-0001-9136-1087				Haab BB, 2001, GENOME BIOL, V2; HALLBORN J, 2002, BIOTECHNIQUES S, V33, P4; James P, 2002, BIOTECHNIQUES, P4; Kingsmore SF, 2003, CURR OPIN BIOTECH, V14, P74, DOI 10.1016/S0958-1669(02)00019-8; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; MacBeath G, 2000, SCIENCE, V289, P1760; Mitchell P, 2002, NAT BIOTECHNOL, V20, P225, DOI 10.1038/nbt0302-225; Service RF, 2001, SCIENCE, V294, P2080, DOI 10.1126/science.294.5549.2080; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; Steinhauer C, 2002, BIOTECHNIQUES, P38	10	45	48	2	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					223	223		10.1038/nbt0303-223	http://dx.doi.org/10.1038/nbt0303-223			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610559				2022-12-25	WOS:000181312500008
J	Seidel-Rogol, BL; McCulloch, V; Shadel, GS				Seidel-Rogol, BL; McCulloch, V; Shadel, GS			Human mitochondrial transcription factor B1 methylates ribosomal RNA at a conserved stem-loop	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; DIMETHYLATION; YEAST; GENE	Human mitochondrial transcription factor B1 (h-mtTFB1) has an unprecedented relationship to RNA methyltransferases. Here, we show that this protein methylates a conserved stem-loop in bacterial 16S rRNA and that the homologous sequence in the human mitochondrial 12S molecule is similarly modified. Thus, h-mtTFB1 appears to be dual-function protein, acting both as a transcription factor and an rRNA-modification enzyme.	Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Shadel, GS (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA.							DUBIN DT, 1974, J MOL BIOL, V84, P257, DOI 10.1016/0022-2836(74)90584-1; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; HELSER TL, 1971, NATURE-NEW BIOL, V233, P12, DOI 10.1038/newbio233012a0; Huntington KM, 2000, BIOCHEMISTRY-US, V39, P4543, DOI 10.1021/bi992452y; LAFONTAINE D, 1994, J MOL BIOL, V241, P492, DOI 10.1006/jmbi.1994.1525; Lafontaine DLJ, 1998, MOL CELL BIOL, V18, P2360, DOI 10.1128/MCB.18.4.2360; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; VANBUUL CPJJ, 1985, GENE, V38, P65, DOI 10.1016/0378-1119(85)90204-5; Vila-Sanjurjo A, 1999, J MOL BIOL, V293, P1, DOI 10.1006/jmbi.1999.3160	10	135	142	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					23	24		10.1038/ng1064	http://dx.doi.org/10.1038/ng1064			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12496758				2022-12-25	WOS:000180136100012
J	Chen, A; Ganor, Y; Rahimipour, S; Ben-Aroya, N; Koch, Y; Levite, M				Chen, A; Ganor, Y; Rahimipour, S; Ben-Aroya, N; Koch, Y; Levite, M			The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs	NATURE MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; BINDING PROTEIN; LYMPHOCYTES; BRAIN; INTEGRIN; ISOFORMS; PEPTIDE; SYSTEM; LINES	Can T cells be directly activated to de novo gene expression by gonadotropin-releasing hormone-II (GnRH-II), a unique 10-amino-acid neuropeptide conserved through 500 million years of evolution? GnRH-II, which has been identified in mammals(1,2), shares 70% homology with the mammalian hypothalamic neurohormone GnRH (GnRH-I), the primary regulator of reproduction, but is encoded by a different gene(3). Although both neuropeptides are produced mainly in brain, their localization(1,2) and promoter regulation(4,5) differ, suggestive of distinct functions. Indeed, GnRH-II barely affects reproduction(1) and its role in mammalian physiology is unknown. We find here that human normal and leukemic T cells produce GnRH-II and GnRH-I. Further, exposure of normal or cancerous human or mouse T cells to GnRH-II or GnRH-I triggered de novo gene transcription and cell-surface expression of a 67-kD non-integrin laminin receptor that is involved in cellular adhesion and migration and in tumor invasion and metastasis. GnRH-II or GnRH-I also induced adhesion to laminin and chemotaxis toward SDF-1alpha, and augmented entry in vivo of metastatic T-lymphoma into the spleen and bone marrow. Homing of normal T cells into specific organs was reduced in mice lacking GnRH-I. A specific GnRH-I-receptor antagonist blocked GnRH-I- but not GnRH-II-induced effects, which is suggestive of signaling through distinct receptors. We suggest that GnRH-II and GnRH-I, secreted from nerves or autocrine or paracrine sources, interact directly with T cells and trigger gene transcription, adhesion, chemotaxis and homing to specific organs, which may be of clinical relevance.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Levite, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Rahimipour, Shai/P-4770-2019; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Ganor, Yonatan/0000-0003-4430-7744; Chen, Alon/0000-0003-3625-8233; Rahimipour, Shai/0000-0002-3210-1645				AZAD N, 1993, ENDOCRINOLOGY, V133, P215, DOI 10.1210/en.133.1.215; Canfield SM, 1999, J IMMUNOL, V163, P3430; Chen A, 2002, CANCER RES, V62, P1036; Chen A, 2002, J MOL NEUROSCI, V18, P67; Chen A, 2001, ENDOCRINOLOGY, V142, P3483, DOI 10.1210/en.142.8.3483; Chen A, 1998, FEBS LETT, V435, P199, DOI 10.1016/S0014-5793(98)01064-3; Chen AL, 2001, ENDOCRINOLOGY, V142, P830, DOI 10.1210/en.142.2.830; Dorsam G, 2000, ANN NY ACAD SCI, V921, P79; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HAND PH, 1985, CANCER RES, V45, P2713; Josefsson E, 1996, IMMUNOLOGY, V88, P140, DOI 10.1046/j.1365-2567.1996.d01-653.x; Krantic S, 2000, PEPTIDES, V21, P1941, DOI 10.1016/S0196-9781(00)00347-8; Lescheid DW, 1997, ENDOCRINOLOGY, V138, P5618, DOI 10.1210/en.138.12.5618; Levite M, 1998, P NATL ACAD SCI USA, V95, P12544, DOI 10.1073/pnas.95.21.12544; Levite M, 2001, EUR J IMMUNOL, V31, P3504, DOI 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Levite M, 1998, J IMMUNOL, V160, P993; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678; SARZOTTI M, 1987, INT J CANCER, V39, P118, DOI 10.1002/ijc.2910390121; SATOH K, 1992, CANCER LETT, V62, P199, DOI 10.1016/0304-3835(92)90096-E; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Suzuki H, 1999, HUM PATHOL, V30, P361, DOI 10.1016/S0046-8177(99)90023-0; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; White RB, 1998, P NATL ACAD SCI USA, V95, P305, DOI 10.1073/pnas.95.1.305	25	95	102	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1421	1426		10.1038/nm801	http://dx.doi.org/10.1038/nm801			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12447356				2022-12-25	WOS:000179552000039
J	Wang, YQ; Cui, HJ; Schroering, A; Ding, JL; Lane, WS; McGill, G; Fisher, DE; Ding, HF				Wang, YQ; Cui, HJ; Schroering, A; Ding, JL; Lane, WS; McGill, G; Fisher, DE; Ding, HF			NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function	NATURE CELL BIOLOGY			English	Article							NF-KAPPA-B; CELL-DEATH; SPLENIC MICROARCHITECTURE; CANCER; ALPHA; ACTIVATION; GENE; INHIBITION; RECEPTORS; RESPONSES	Nuclear factor-kappaB (NIF-kappaB) promotes cell survival by upregulating expression of anti-apoptotic genes, a process that is antagonized by inhibitors of kappaB (IkappaB) factors(1) The only NF-kappaB family member known to be mutated in human cancer is NF-kappaB2 p100 (ref. 2), a factor with IkappaB activity. Here, we report the isolation from irradiated mouse tumour cells of a complex that induces caspase-8 activity in cell-free assays and identify p100 as an essential component of this complex. Expression of p100 profoundly sensitizes cells to death-receptor-mediated apoptosis through a pathway that is independent of IkappaB-like activity. The carboxyl terminus of p100 contains a death domain(3) that is absent from all known tumour-derived mutants. This death domain mediates recruitment of p100 into death machinery complexes after ligand stimulation and is essential for p100's pro-apoptotic activity. p100 also sensitizes NIH3T3 cells to apoptosis triggered by oncogenic Ras, resulting in a marked inhibition of transformation that is rescued by suppression of endogenous caspase-8. These observations thus identify an IkappaB-independent apoptotic activity of NF-kappaB2 p100 and help explain its unique tumour suppressor role.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Wang, YQ (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.			Ding, Han-Fei/0000-0001-5702-3439				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; THAKUR S, 1994, ONCOGENE, V9, P2335; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	29	55	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					888	893		10.1038/ncb872	http://dx.doi.org/10.1038/ncb872			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12389034				2022-12-25	WOS:000179137700018
J	Sahai, E; Marshall, CJ				Sahai, E; Marshall, CJ			Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis	NATURE CELL BIOLOGY			English	Article							MATRIX-METALLOPROTEINASE INHIBITORS; RHO-ASSOCIATED KINASE; PROTEIN-KINASE; IN-VIVO; BINDING PROTEIN; FOCAL ADHESIONS; CANCER; METASTASIS; GROWTH; ACTIVATION	Rho family GTPases regulate the cytoskeleton and cell migration and are frequently overexpressed in tumours. Here, we identify two modes of tumour-cell motility in 3D matrices that involve different usage of Rho signalling. Rho signalling through ROCK promotes a rounded bleb-associated mode of motility that does not require pericellular proteolysis. This form of motility requires ezrin, which is localized in the direction of cell movement. In contrast, elongated cell motility is associated with Rac-dependent F-actin-rich protrusions and does not require Rho, ROCK or ezrin function. Combined blockade of extracellular proteases and ROCK negates the ability of tumour cells to switch between modes of motility and synergises to prevent tumour cell invasion.	Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.			Sahai, Erik/0000-0002-3932-5086				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Decaudin D, 2002, CANCER RES, V62, P1388; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takamura M, 2001, HEPATOLOGY, V33, P577, DOI 10.1053/jhep.2001.22652; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; VIAL E, IN PRESS CANC CELL; Wang WG, 2002, CANCER RES, V62, P6278; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wyckoff JB, 2000, CANCER RES, V60, P2504; Yonemura S, 2002, J CELL SCI, V115, P2569	34	900	932	0	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					711	719		10.1038/ncb1019	http://dx.doi.org/10.1038/ncb1019			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12844144				2022-12-25	WOS:000184687300012
J	Paramithiotis, E; Pinard, M; Lawton, T; LaBoissiere, S; Leathers, VL; Zou, WQ; Estey, LA; Lamontagne, J; Lehto, MT; Kondejewski, LH; Francoeur, GP; Papadopoulos, M; Haghighat, A; Spatz, SJ; Head, M; Will, R; Ironside, J; O'Rourke, K; Tonelli, Q; Ledebur, HC; Chakrabartty, A; Cashman, NR				Paramithiotis, E; Pinard, M; Lawton, T; LaBoissiere, S; Leathers, VL; Zou, WQ; Estey, LA; Lamontagne, J; Lehto, MT; Kondejewski, LH; Francoeur, GP; Papadopoulos, M; Haghighat, A; Spatz, SJ; Head, M; Will, R; Ironside, J; O'Rourke, K; Tonelli, Q; Ledebur, HC; Chakrabartty, A; Cashman, NR			A prion protein epitope selective for the pathologically misfolded conformation	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; FOLLICULAR DENDRITIC CELLS; SCRAPIE PRION; MONOCLONAL-ANTIBODY; DOMAIN PRP(121-231); CELLULAR ISOFORM; ACIDIC PH; CONVERSION; VARIANT; PATHOGENESIS	Conformational conversion of proteins in disease is likely to be accompanied by molecular surface exposure of previously sequestered amino-acid side chains. We found that induction of beta-sheet structures in recombinant prion proteins is associated with increased solvent accessibility of tyrosine. Antibodies directed against the prion protein repeat motif, tyrosine-tyrosine-arginine, recognize the pathological isoform of the prion protein but not the normal cellular isoform, as assessed by immunoprecipitation, plate capture immunoassay and flow cytometry. Antibody binding to the pathological epitope is saturable and specific, and can be created in vitro by partial denaturation of normal brain prion protein. Conformation-selective exposure of Tyr-Tyr-Arg provides a probe for the distribution and structure of pathologically misfolded prion protein, and may lead to new diagnostics and therapeutics for prion diseases.	Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; IDEXX Labs Inc, Westbrook, ME 04092 USA; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Washington State Univ, USDA ARS, ADRU, Pullman, WA 99164 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenrat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Edinburgh; United States Department of Agriculture (USDA); Washington State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Cashman, NR (corresponding author), Caprion Pharmaceut Inc, 7150 Alexander Fleming, St Laurent, PQ H4S 2C8, Canada.		Zou, Wenquan/GWQ-3489-2022; Zou, Wenquan/ABF-2875-2020	Chakrabartty, Avi/0000-0001-7002-8381; Head, Mark/0000-0003-2034-8613; Ledebur, Harry/0000-0001-8011-8655; Ironside, James/0000-0001-5869-2108				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Cioni P, 2000, BIOPHYS CHEM, V87, P15, DOI 10.1016/S0301-4622(00)00174-5; Coulthart MB, 2001, CAN MED ASSOC J, V165, P51; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; GAJDUSEK DC, 1986, VIROLOGY, P1516; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lezmi S, 2001, VET IMMUNOL IMMUNOP, V82, P1, DOI 10.1016/S0165-2427(01)00323-3; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mabbott NA, 2001, J GEN VIROL, V82, P2307, DOI 10.1099/0022-1317-82-10-2307; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RACE RE, 1992, J GEN VIROL, V73, P3319, DOI 10.1099/0022-1317-73-12-3319; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; SELA M, 1992, BEHRING I MITT, V91, P54; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; SZAKAL AK, 1985, J IMMUNOL, V134, P1349; SZAKAL AK, 1992, CANCER RES, V52, pS5554; Tang L, 2001, VET IMMUNOL IMMUNOP, V80, P259, DOI 10.1016/S0165-2427(01)00318-X; Tatzelt J, 1999, J NEUROPATH EXP NEUR, V58, P1244, DOI 10.1097/00005072-199912000-00005; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	45	219	236	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					893	899		10.1038/nm883	http://dx.doi.org/10.1038/nm883			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12778138	Green Submitted			2022-12-25	WOS:000183979300030
J	Abifadel, M; Varret, M; Rabes, JP; Allard, D; Ouguerram, K; Devillers, M; Cruaud, C; Benjannet, S; Wickham, L; Erlich, D; Derre, A; Villeger, L; Farnier, M; Beucler, I; Bruckert, E; Chambaz, J; Chanu, B; Lecerf, JM; Luc, G; Moulin, P; Weissenbach, J; Prat, A; Krempf, M; Junien, C; Seidah, NG; Boileau, C				Abifadel, M; Varret, M; Rabes, JP; Allard, D; Ouguerram, K; Devillers, M; Cruaud, C; Benjannet, S; Wickham, L; Erlich, D; Derre, A; Villeger, L; Farnier, M; Beucler, I; Bruckert, E; Chambaz, J; Chanu, B; Lecerf, JM; Luc, G; Moulin, P; Weissenbach, J; Prat, A; Krempf, M; Junien, C; Seidah, NG; Boileau, C			Mutations in PCSK9 cause autosomal dominant hypercholesterolemia	NATURE GENETICS			English	Article							LOCUS	Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.	Univ Paris 05, INSERM, U383, Hop Necker Enfants Malad,APHP, F-75743 Paris 15, France; Univ St Joseph, Fac Pharm, Beirut 5076, Lebanon; Univ Versailles St Quentin Yvelines, Lab Biochim Hormonol & Genet Mol, CHU Ambroise Pare, APHP, F-92104 Boulogne, France; CHU Hotel Dieu, Serv Endocrinol, F-44093 Nantes, France; Genoscope, Ctr Natl Sequencage, Evry, France; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Rond Point Nat, Point Med, F-21000 Dijon, France; Hop La Pitie Salpetriere, Lab Lipides, Serv Endocrinol Metab, F-75013 Paris, France; Inst Biomed Cordeliers, INSERM, U505, F-75006 Paris, France; Hop Henri Mondor, Serv Med Interne, F-94010 Creteil, France; Hop Huriez, Serv Med Interne, F-59019 Lille, France; Hop Antiquaille, Serv Endocrinol & Maladies Nutr, F-69005 Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Saint Joseph University Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Nantes Universite; CHU de Nantes; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite de Lille - ISITE; CHU Lille; CHU Lyon	Boileau, C (corresponding author), Univ Paris 05, INSERM, U383, Hop Necker Enfants Malad,APHP, 149-161 Rue Sevres, F-75743 Paris 15, France.		boileau, catherine/M-4482-2017; Girelli, Domenico/B-1183-2008; VARRET, Mathilde/C-2279-2016; Seidah, Nabil/I-3596-2013; Abifadel, Marianne/ABH-5370-2020; Prat, Annik/S-6757-2018	boileau, catherine/0000-0002-0371-7539; Girelli, Domenico/0000-0001-9684-1899; VARRET, Mathilde/0000-0001-9261-1551; Seidah, Nabil/0000-0001-6503-9342; Prat, Annik/0000-0002-8007-5277; Cruaud, Corinne/0000-0002-4752-7278; ABIFADEL, Marianne/0000-0001-7645-8323; Rabes, Jean-Pierre/0000-0002-1215-1493; Krempf, Michel/0000-0002-4353-9511; ALLARD, Delphine/0000-0001-7534-8982				Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Hunt SC, 2000, ARTERIOSCL THROM VAS, V20, P1089, DOI 10.1161/01.ATV.20.4.1089; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Varret M, 1999, AM J HUM GENET, V64, P1378, DOI 10.1086/302370	6	1991	2178	4	180	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					154	156		10.1038/ng1161	http://dx.doi.org/10.1038/ng1161			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12730697				2022-12-25	WOS:000183200500020
J	Carlson, CS; Eberle, MA; Rieder, MJ; Smith, JD; Kruglyak, L; Nickerson, DA				Carlson, CS; Eberle, MA; Rieder, MJ; Smith, JD; Kruglyak, L; Nickerson, DA			Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; COMMON DISEASE GENES; SEQUENCE VARIATION; CANDIDATE GENES; IDENTIFICATION; DISCOVERY; MAP	More than 5 million single-nucleotide polymorphisms (SNPs) with minor-allele frequency greater than 10% are expected to exist in the human genome(1). Some of these SNPs may be associated with risk of developing common diseases(2-4). To assess the power of currently available SNPs to detect such associations, we resequenced 50 genes in two ethnic samples and measured patterns of linkage disequilibrium between the subset of SNPs reported in dbSNP and the complete set of common SNPs. Our results suggest that using all 2.7 million SNPs currently in the database would detect nearly 80% of all common SNPs in European populations but only 50% of those common in the African American population and that efficient selection of a minimal subset of SNPs for use in association studies requires measurement of allele frequency and linkage disequilibrium relationships for all SNPs in dbSNP.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Howard Hughes Med Inst, Chevy Chase, MD USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Carlson, CS (corresponding author), Univ Washington, Dept Genome Sci, 1705 NE Pacific, Seattle, WA 98195 USA.			Eberle, Michael/0000-0001-8965-1253				Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Cambien F, 1999, AM J HUM GENET, V65, P183, DOI 10.1086/302448; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Devlin B, 1996, GENOMICS, V36, P1, DOI 10.1006/geno.1996.0419; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HILL WG, 1974, HEREDITY, V33, P229, DOI 10.1038/hdy.1974.89; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Irizarry K, 2000, NAT GENET, V26, P233, DOI 10.1038/79981; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Marth G, 2001, NAT GENET, V27, P371, DOI 10.1038/86864; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; REICH DE, 2003, NAT GENET, V33; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149	24	247	259	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					518	521		10.1038/ng1128	http://dx.doi.org/10.1038/ng1128			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12652300	Bronze			2022-12-25	WOS:000181928600025
J	Dernick, G; de Toledo, GA; Lindau, M				Dernick, G; de Toledo, GA; Lindau, M			Exocytosis of single chromaffin granules in cell-free inside-out membrane patches	NATURE CELL BIOLOGY			English	Letter							DENSE-CORE VESICLES; FUSION PORE; SECRETORY PRODUCTS; CAPACITANCE; MECHANISMS; RESOLUTION; RELEASE	In chromaffin cells, exocytosis of single granules and properties of the fusion pore - the first connection between vesicular lumen and extracellular space(1) -can be studied by cell-attached patch amperometry(2,3), which couples patch-clamp capacitance measurements(4-7) with simultaneous amperometric recordings of transmitter release(8,9). Here we have studied exocytosis of single chromaffin granules and endocytosis of single vesicles in cell-free inside-out membrane patches by patch capacitance measurements and patch amperometry. We excised patches from chromaffin cells by using methods developed for studying properties of single ion channels(10). With low calcium concentrations in the pipette and bath, the patches showed no spontaneous exocytosis, but exocytosis could be induced in some patches by applying calcium to the cytoplasmic side of the patch. Exocytosis was also stimulated by calcium entry through the patch membrane. Initial conductances of the fusion pore were undistinguishable in cell-attached and excised patch recordings, but the subsequent pore expansion was slower in excised patches. The properties of exocytotic fusion pores in chromaffin cells are very similar to those observed in mast cells and granulocytes. Excised patches provide a tool with which to study the mechanisms of fusion pore formation and endocytosis in vitro.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Univ Seville, Dept Physiol & Biophys, E-41009 Seville, Spain	Cornell University; University of Sevilla	Dernick, G (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.		Alvarez de Toledo, Guillermo/I-2888-2015; Lindau, Manfred/ABD-3449-2021	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Lindau, Manfred/0000-0002-5722-9557	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038200] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS038200, R01 NS038200-02, R01 NS038200-01A2, R01 NS038200-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; Burgoyne RD, 1996, BIOCHEM SOC T, V24, P653, DOI 10.1042/bst0240653; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; Debus K, 2000, BIOPHYS J, V78, P2983, DOI 10.1016/S0006-3495(00)76837-8; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; LINDAU M, 1991, Q REV BIOPHYS, V24, P75, DOI 10.1017/S0033583500003279; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; Lollike K, 1998, BIOPHYS J, V75, P53, DOI 10.1016/S0006-3495(98)77494-6; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	22	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					358	362		10.1038/ncb956	http://dx.doi.org/10.1038/ncb956			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12652310	Green Published			2022-12-25	WOS:000182080700021
J	Ishihara, H; Maechler, P; Gjinovci, A; Herrera, PL; Wollheim, CB				Ishihara, H; Maechler, P; Gjinovci, A; Herrera, PL; Wollheim, CB			Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells	NATURE CELL BIOLOGY			English	Article							PANCREATIC A-CELLS; ENDOCRINE PANCREAS; TRANSGENIC MICE; LANGERHANS; GLUCOSE; EXPRESSION; CHANNELS; GENE; ACTIVATION; GRANULES	Homeostasis of blood glucose is maintained by hormone secretion from the pancreatic islets of Langerhans. Glucose stimulates insulin secretion from beta-cells but suppresses the release of glucagon, a hormone that raises blood glucose, from alpha-cells(1). The mechanism by which nutrients stimulate insulin secretion has been studied extensively: ATP has been identified as the main messenger and the ATP-sensitive potassium channel as an essential transducer in this process(2). By contrast, much less is known about the mechanisms by which nutrients modulate glucagon secretion. Here we use conventional pancreas perfusion and a transcriptional targeting strategy to analyse cell-type-specific signal transduction and the relationship between islet alpha- and beta-cells. We find that pyruvate, a glycolytic intermediate and principal substrate of mitochondria, stimulates glucagon secretion. Our analyses indicate that, although alpha-cells, like beta-cells, possess the inherent capacity to respond to nutrients, secretion from alpha-cells is normally suppressed by the simultaneous activation of beta-cells. Zinc released from beta-cells may be implicated in this suppression. Our results define the fundamental mechanisms of differential responses to identical stimuli between cells in a microorgan.	Univ Geneva, Ctr Med, Div Clin Biochem, Dept Internal Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Ctr Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Ishihara, H (corresponding author), Univ Geneva, Ctr Med, Div Clin Biochem, Dept Internal Med, CH-1211 Geneva 4, Switzerland.			Herrera Merino, Pedro Luis/0000-0003-0771-9504; Maechler, Pierre/0000-0002-2005-1433				BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; BJAALAND T, 1988, J MOL ENDOCRINOL, V1, P171, DOI 10.1677/jme.0.0010171; Bokvist K, 1999, PFLUG ARCH EUR J PHY, V438, P428, DOI 10.1007/s004240051058; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; GERBER PPG, 1981, DIABETES, V30, P40, DOI 10.2337/diabetes.30.1.40; GOEPEL SO, 2000, J PHYSIOL-LONDON, V528, P508; GREENBAUM CJ, 1991, J CLIN INVEST, V88, P767, DOI 10.1172/JCI115375; GRODSKY GM, 1977, FED PROC, V36, P2714; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HURLEY LS, 1969, J CLIN NUTR, V22, P1669; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P817, DOI 10.1210/endo-117-3-817; Qian WJ, 2000, ANAL CHEM, V72, P711, DOI 10.1021/ac991085t; Quesada I, 1999, DIABETES, V48, P2390, DOI 10.2337/diabetes.48.12.2390; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SAMOLS E, 1998, DIABETES REV, V4, P205; Sato Y, 1998, BIOCHEM BIOPH RES CO, V244, P455, DOI 10.1006/bbrc.1997.8087; Tang XH, 2001, J NUTR, V131, P1414, DOI 10.1093/jn/131.5.1414; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6	28	316	318	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					330	335		10.1038/ncb951	http://dx.doi.org/10.1038/ncb951			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12640462				2022-12-25	WOS:000182080700016
J	Kalaitzandonakes, N; Bijman, J				Kalaitzandonakes, N; Bijman, J			Who is driving biotechnology acceptance?	NATURE BIOTECHNOLOGY			English	Article									Univ Missouri, Econ & Management Agrobiotechnol Ctr, Columbia, MO 65212 USA; Univ Wageningen & Res Ctr, NL-6700 HB Wageningen, Netherlands; Agr Econ Res Inst, LEI, The Hague, Netherlands	University of Missouri System; University of Missouri Columbia; Wageningen University & Research; Wageningen University & Research	Kalaitzandonakes, N (corresponding author), Univ Missouri, Econ & Management Agrobiotechnol Ctr, Columbia, MO 65212 USA.		bijman, jos/C-2929-2015	bijman, jos/0000-0001-9143-7870				BALLENGER N, 2000, AGR OUTLOOK, V270, P24; FITZELL P, 1992, PRIVATE LABEL MARKET; Gaskell G, 2000, NAT BIOTECHNOL, V18, P935, DOI 10.1038/79403; Kalaitzandonakes N, 2001, CAN J AGR ECON, V49, P605, DOI 10.1111/j.1744-7976.2001.tb00330.x; Kalaitzandonakes NG, 2000, AM J AGR ECON, V82, P1224, DOI 10.1111/0002-9092.00125	5	26	28	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					366	369		10.1038/nbt0403-366	http://dx.doi.org/10.1038/nbt0403-366			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	664VH	12665818				2022-12-25	WOS:000182082400014
J	Plant, PJ; Fawcett, JP; Lin, DCC; Holdorf, AD; Binns, K; Kulkarni, S; Pawson, T				Plant, PJ; Fawcett, JP; Lin, DCC; Holdorf, AD; Binns, K; Kulkarni, S; Pawson, T			A polarity complex of mPar-6 and atypical PKC binds, phosphorylates and regulates mammalian Lgl	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; EPITHELIAL TIGHT JUNCTION; ADHESION MOLECULE JAM; II HEAVY-CHAIN; CELL-POLARITY; TUMOR-SUPPRESSOR; CAENORHABDITIS-ELEGANS; PLASMA-MEMBRANE; EMBRYONIC POLARITY; HUMAN HOMOLOG	The evolutionarily conserved proteins Par-6, atypical protein kinase C (aPKC), Cdc42 and Par-3 associate to regulate cell polarity and asymmetric cell division, but the downstream targets of this complex are largely unknown. Here we identify direct physiological interactions between mammalian aPKC, murine Par-6C (mPar-6C) and Mlgl, the mammalian orthologue of the Drosophila melanogaster tumour suppressor Lethal (2) giant larvae. In cultured cell lines and in mouse brain, aPKC, mPar-6C and Mlgl form a multiprotein complex in which Mlgl is targeted for phosphorylation on conserved serine residues. These phosphorylation sites are important for embryonic fibroblasts to polarize correctly in response to wounding and may regulate the ability of Mlgl to direct protein trafficking. Our data provide a direct physical and regulatory link between proteins of distinct polarity complexes, identify Mlgl as a functional substrate for aPKC in cell polarization and indicate that aPKC is directed to cell polarity substrates through a network of protein-protein interactions.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Plant, PJ (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013	Holdorf, Amy/0000-0001-5699-4081; Fawcett, Jim/0000-0003-0043-2164				Arquier N, 2001, DEVELOPMENT, V128, P2209; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; COUCHMAN JR, 1979, J CELL SCI, V39, P149; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; ETTENSON DS, 1992, LAB INVEST, V66, P722; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; GATEFF E, 1969, NATL CANCER I MONOGR, P365; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose T, 2002, J CELL SCI, V115, P2485; Horne-Badovinac S, 2001, CURR BIOL, V11, P1492, DOI 10.1016/S0960-9822(01)00458-4; Hung TJ, 1999, DEVELOPMENT, V126, P127; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Kaibuchi K, 1999, Prog Mol Subcell Biol, V22, P23; Kalmes A, 1996, J CELL SCI, V109, P1359; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Peterson RT, 2001, CURR BIOL, V11, P1481, DOI 10.1016/S0960-9822(01)00482-1; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRAND D, 1995, ONCOGENE, V11, P291; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8	50	305	314	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					301	308		10.1038/ncb948	http://dx.doi.org/10.1038/ncb948			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12629547				2022-12-25	WOS:000182080700013
J	Brentjens, RJ; Latouche, JB; Santos, E; Marti, F; Gong, MC; Lyddane, C; King, PD; Larson, S; Weiss, M; Riviere, I; Sadelain, M				Brentjens, RJ; Latouche, JB; Santos, E; Marti, F; Gong, MC; Lyddane, C; King, PD; Larson, S; Weiss, M; Riviere, I; Sadelain, M			Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ANTIGEN-PRESENTING CELLS; IN-VIVO; IMMUNOTHERAPY; LEUKEMIA; EXPRESSION; RECEPTORS; CANCER; DEATH; CHAIN	The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Nucl Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Gene Transfer & Somat Cell Engn Lab, New York, NY 10021 USA; Cornell Univ, Hosp Special Surg, Dept Immunol, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Grad Sch, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	King, Phil/C-7104-2013	Latouche, Jean-Baptiste/0000-0003-4802-5429	NCI NIH HHS [CA-08748, P30 CA008748, CA-59350, CA-83084, CA-86438] Funding Source: Medline; NIAID NIH HHS [AI44926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA059350, P30CA008748, P50CA086438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adonai N, 2002, P NATL ACAD SCI USA, V99, P3030, DOI 10.1073/pnas.052709599; Blazar BR, 1997, J IMMUNOL, V159, P3460; Boussiotis VA, 1997, J IMMUNOL, V159, P3156; Brocker T, 2000, BLOOD, V96, P1999, DOI 10.1182/blood.V96.5.1999.h8001999_1999_2001; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Chen X, 2000, BRIT J HAEMATOL, V111, P817, DOI 10.1046/j.1365-2141.2000.02415.x; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Eshhar Z, 1996, SPRINGER SEMIN IMMUN, V18, P199, DOI 10.1007/BF00820666; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Gallardo HF, 1997, GENE THER, V4, P1115, DOI 10.1038/sj.gt.3300506; Geiger TL, 2001, BLOOD, V98, P2364, DOI 10.1182/blood.V98.8.2364; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; Haynes NM, 2002, BLOOD, V100, P3155, DOI 10.1182/blood-2002-04-1041; Hombach A, 2001, J IMMUNOL, V167, P6123, DOI 10.4049/jimmunol.167.11.6123; Jourdan P, 2000, J IMMUNOL, V165, P716, DOI 10.4049/jimmunol.165.2.716; Krause A, 1998, J EXP MED, V188, P619, DOI 10.1084/jem.188.4.619; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maric M, 1998, CANCER RES, V58, P3376; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Oppenheimer-Marks N, 1998, J CLIN INVEST, V101, P1261, DOI 10.1172/JCI1986; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rossi E, 1996, LEUKEMIA, V10, P494; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Sadelain M, 2002, MOL THER, V5, P655, DOI 10.1006/mthe.2002.0619; Savoldo B, 2000, LEUKEMIA LYMPHOMA, V39, P455, DOI 10.3109/10428190009113376; Schumacher TNM, 2002, NAT REV IMMUNOL, V2, P512, DOI 10.1038/nri841; TEDDER TF, 1989, J IMMUNOL, V143, P712; UCKUN FM, 1988, BLOOD, V71, P13; Vella AT, 1997, J IMMUNOL, V158, P4714; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	44	466	548	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					279	286		10.1038/nm827	http://dx.doi.org/10.1038/nm827			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579196				2022-12-25	WOS:000181312300027
J	Dumont, P; Leu, JIJ; Della Pietra, AC; George, DL; Murphy, M				Dumont, P; Leu, JIJ; Della Pietra, AC; George, DL; Murphy, M			The codon 72 polymorphic variants of p53 have markedly different apoptotic potential	NATURE GENETICS			English	Article							WILD-TYPE P53; RING-FINGER DOMAIN; LUNG-CANCER; PROTEIN; CELLS; MDM2; TRANSLOCATION; PRO-CASPASE-3; MITOCHONDRIA; SUPPRESSION	The gene TP53, encoding p53, has a common sequence polymorphism that results in either proline or arginine at amino-acid position 72. This polymorphism occurs in the proline-rich domain of p53, which is necessary for the protein to fully induce apoptosis. We found that in cell lines containing inducible versions of alleles encoding the Pro72 and Arg72 variants, and in cells with endogenous p53, the Arg72 variant induces apoptosis markedly better than does the Pro72 variant. Our data indicate that at least one source of this enhanced apoptotic potential is the greater ability of the Arg72 variant to localize to the mitochondria; this localization is accompanied by release of cytochrome c into the cytosol. These data indicate that the two polymorphic variants of p53 are functionally distinct, and these differences may influence cancer risk or treatment.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania	Murphy, M (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Murphy, Maureen/0000-0001-7644-7296				Attardi LD, 2000, GENE DEV, V14, P704; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Berger M, 2001, J BIOL CHEM, V276, P3785, DOI 10.1074/jbc.M008879200; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Landers JE, 1997, CANCER RES, V57, P3562; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thomas M, 1999, MOL CELL BIOL, V19, P1092; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	36	1060	1104	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					357	365		10.1038/ng1093	http://dx.doi.org/10.1038/ng1093			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12567188				2022-12-25	WOS:000181312700012
J	Nimnual, AS; Taylor, LJ; Bar-Sagi, D				Nimnual, AS; Taylor, LJ; Bar-Sagi, D			Redox-dependent downregulation of Rho by Rac	NATURE CELL BIOLOGY			English	Article							PHOSPHOTYROSINE-PROTEIN PHOSPHATASE; GROWTH-FACTOR STIMULATION; TYROSINE-PHOSPHATASE; ENDOTHELIAL-CELLS; GTPASES; MORPHOLOGY; MECHANISM; INTEGRIN; ADHESION; SRC	Rac and Rho GTPases function as critical regulators of actin cytoskeleton remodelling during cell spreading and migration. Here we demonstrate that Rac-mediated reactive oxygen species (ROS) production results in the downregulation of Rho activity. The redox-dependent decrease in Rho activity is required for Rac-induced formation of membrane ruffles and integrin-mediated cell spreading. The pathway linking generation of ROS to downregulation of Rho involves inhibition of the low-molecular-weight protein tyrosine phosphatase (LMW-PTP) and then an increase in the tyrosine phosphorylation and activation of its target, p190Rho-GAP. Our findings define a novel mechanism for the coupling of changes in cellular redox state to the control of actin cytoskeleton rearrangements by Rho GTPases.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol Biol & Biochem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948; Taylor, Laura/0000-0002-4031-6312	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R56CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fincham VJ, 1999, J CELL SCI, V112, P947; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RHEE SG, 2000, HYDROGEN PEROXIDE KE; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; van Wetering S, 2002, J CELL SCI, V115, P1837; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	32	411	415	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					236	U7		10.1038/ncb938	http://dx.doi.org/10.1038/ncb938			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598902				2022-12-25	WOS:000181322500017
J	Song, EW; Lee, SK; Wang, J; Ince, N; Ouyang, N; Min, J; Chen, JS; Shankar, P; Lieberman, J				Song, EW; Lee, SK; Wang, J; Ince, N; Ouyang, N; Min, J; Chen, JS; Shankar, P; Lieberman, J			RNA interference targeting Fas protects mice from fulminant hepatitis	NATURE MEDICINE			English	Article							GENE-EXPRESSION; CONCANAVALIN-A; CELL-CULTURE; LIVER; LIGAND; APOPTOSIS; INJURY; INVOLVEMENT; INHIBITION; FIBROSIS	RNA interference (RNAi) is a powerful tool to silence gene expression post-transcriptionally(1). However, its potential to treat or prevent disease remains unproven. Fas-mediated apoptosis is implicated in a broad spectrum of liver diseases, where inhibiting hepatocyte death is life-saving(2). We investigated the in vivo silencing effect of small interfering RNA (siRNA) duplexes targeting the gene Fas (also known as Tnfrsf6), encoding the Fas receptor, to protect mice from liver failure and fibrosis in two models of autoimmune hepatitis. Intravenous injection of Fas siRNA specifically reduced Fas mRNA levels and expression of Fas protein in mouse hepatocytes, and the effects persisted without diminution for 10 days. Hepatocytes isolated from mice treated with Fas siRNA were resistant to apoptosis when exposed to Fas-specific antibody or co-cultured with concanavalin A (ConA)-stimulated hepatic mononuclear cells. Treatment with Fas siRNA 2 days before ConA challenge abrogated hepatocyte necrosis and inflammatory infiltration and markedly reduced serum concentrations of transaminases. Administering Fas siRNA beginning one week after initiating weekly ConA injections protected mice from liver fibrosis. In a more fulminant hepatitis induced by injecting agonistic Fas-specific antibody, 82% of mice treated with siRNA that effectively silenced Fas survived for 10 days of observation, whereas all control mice died within 3 days. Silencing Fas expression with RNAi holds therapeutic promise to prevent liver injury by protecting hepatocytes from cytotoxicity.	Harvard Med Sch, Ctr Blood Res, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA; Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China; Guangzhou Med Inst, Dept Cell Pathol, Guangzhou, Peoples R China	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Sun Yat Sen University	Lieberman, J (corresponding author), Harvard Med Sch, Ctr Blood Res, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015	Ince, Nedim/0000-0003-3451-3421	NIAID NIH HHS [AI45306, AI49792, AI45406, AI42510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045406, R21AI049792, R21AI045306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badawy AA, 1996, PHARMACOL RES, V33, P319, DOI 10.1006/phrs.1996.0044; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Dhiman RK, 1998, DIGEST DIS SCI, V43, P1311, DOI 10.1023/A:1018876328561; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faouzi S, 2001, J BIOL CHEM, V276, P49077, DOI 10.1074/jbc.M109791200; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kimura K, 1999, INT IMMUNOL, V11, P1491, DOI 10.1093/intimm/11.9.1491; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li XK, 2001, TRANSPLANTATION, V71, P503, DOI 10.1097/00007890-200102270-00004; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyazawa Y, 1998, HEPATOLOGY, V27, P497, DOI 10.1002/hep.510270225; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Ryo K, 2000, AM J GASTROENTEROL, V95, P2047; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Siegel RM, 1999, J ALLERGY CLIN IMMUN, V103, P729, DOI 10.1016/S0091-6749(99)70412-4; TAKAHASHI S, 1987, BIOCHEM J, V241, P49, DOI 10.1042/bj2410049; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takeda K, 2000, P NATL ACAD SCI USA, V97, P5498, DOI 10.1073/pnas.040566697; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475	30	900	1160	3	221	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					347	351		10.1038/nm828	http://dx.doi.org/10.1038/nm828			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579197				2022-12-25	WOS:000181312300037
J	Winer, S; Tsui, H; Lau, A; Song, AH; Li, XM; Cheung, RK; Sampson, A; Afifiyan, F; Elford, A; Jackowski, G; Becker, DJ; Santamaria, P; Ohashi, P; Dosch, HM				Winer, S; Tsui, H; Lau, A; Song, AH; Li, XM; Cheung, RK; Sampson, A; Afifiyan, F; Elford, A; Jackowski, G; Becker, DJ; Santamaria, P; Ohashi, P; Dosch, HM			Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; CD8(+) T-CELLS; SCHWANN-CELLS; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; SELF-ANTIGEN; MICE; EXPRESSION; MELLITUS; MOUSE	Pancreatic islets of Langerhans are enveloped by peri-islet Schwann cells (pSC), which express glial fibrillary acidic protein (GFAP) and S100beta. SC-autoreactive T- and B-cell responses arise in 3- to 4-week- old diabetes-prone non-obese diabetic (NOD) mice, followed by progressive pSC destruction before detectable beta-cell death. Humans with probable prediabetes generate similar autoreactivities, and autoantibodies in islet-cell autoantibody (lCA)-positive sera co-localize to pSC. Moreover, GFAP-specific NOD T- cell lines transferred pathogenic peri-insulitis to NOD/severe combined immunodeficient (NOD/SCID) mice, and immunotherapy with GFAP or S100beta prevented diabetes. pSC survived in rat insulin promoter lymphocytic choriomeningitis virus (rip-LCMV) glycoprotein/CD8(+) T-cell receptor(9p) double-transgenic mice with virus-induced diabetes, suggesting that pSC death is not an obligate consequence of local inflammation and cell destruction. However, pSC were deleted in spontaneously diabetic NOD mice carrying the CD8(+) /8.3 T-cell receptor transgene, a T cell receptor commonly expressed in earliest islet infiltrates. Autoimmune targeting of pancreatic nervous system tissue elements seems to be an integral, early part of natural type 1 diabetes.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Syn X Pharma Inc, Toronto, ON, Canada; UHN, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; UHN, Ontario Canc Inst, Dept Immunol, Toronto, ON, Canada; Childrens Hosp, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Fac Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Julia MacFarlane Diabet Res Ctr, Fac Med, Calgary, AB, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Dosch, HM (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hmdosch@sickkids.ca	Santamaria, Pere/ABF-6823-2021	Ohashi, Pamela S./0000-0003-2915-9317				Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Austen BM, 2000, J PEPT SCI, V6, P459, DOI 10.1002/1099-1387(200009)6:9<459::AID-PSC286>3.0.CO;2-B; Brooks-Worrell B, 2001, J IMMUNOL, V166, P5265, DOI 10.4049/jimmunol.166.8.5265; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Delaney CL, 1996, J NEUROSCI, V16, P6908; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; DONEV SR, 1984, CELL TISSUE RES, V237, P343, DOI 10.1007/BF00217154; Dosch HM, 1999, J IMMUNOL, V163, P6933; Hahn von Dorsche H, 1994, Adv Anat Embryol Cell Biol, V130, P1; Karges W, 1996, DIABETES, V45, P513, DOI 10.2337/diabetes.45.4.513; KARGES WJP, 1995, MOL ASPECTS MED, V16, P79, DOI 10.1016/0098-2997(95)00001-W; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; LIPTON RB, 1992, AM J EPIDEMIOL, V136, P503; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Marrosu MG, 2002, LANCET, V359, P1461, DOI 10.1016/S0140-6736(02)08431-3; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Merchant M, 2000, ELECTROPHORESIS, V21, P1164, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; SaraviaFernandez F, 1996, ENDOCRINOLOGY, V137, P3497, DOI 10.1210/en.137.8.3497; SERREZE DV, 1994, CURR OPIN IMMUNOL, V6, P900, DOI 10.1016/0952-7915(94)90011-6; Serreze DV, 2001, J IMMUNOL, V166, P1352, DOI 10.4049/jimmunol.166.2.1352; Shimada A, 1996, DIABETES, V45, P1063, DOI 10.2337/diabetes.45.8.1063; SMITH PH, 1975, AM J ANAT, V144, P513, DOI 10.1002/aja.1001440412; Spierings E, 2001, J IMMUNOL, V166, P5883, DOI 10.4049/jimmunol.166.10.5883; Sunami E, 2001, ARCH HISTOL CYTOL, V64, P191, DOI 10.1679/aohc.64.191; Teitelman G, 1998, J NEUROBIOL, V34, P304, DOI 10.1002/(SICI)1097-4695(199803)34:4<304::AID-NEU2>3.0.CO;2-A; Tisch R, 1999, J IMMUNOL, V163, P1178; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; Verdaguer J, 1996, J IMMUNOL, V157, P4726; WEKERLE H, 1986, EUR J IMMUNOL, V16, P1551, DOI 10.1002/eji.1830161214; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WICKER LS, 1986, DIABETES, V35, P855, DOI 10.2337/diabetes.35.8.855; Winer S, 2001, J IMMUNOL, V166, P2831, DOI 10.4049/jimmunol.166.4.2831; Winer S, 2002, J IMMUNOL, V168, P475, DOI 10.4049/jimmunol.168.1.475; Winer S, 2000, J IMMUNOL, V165, P4086, DOI 10.4049/jimmunol.165.7.4086; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465	44	159	176	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					198	205		10.1038/nm818	http://dx.doi.org/10.1038/nm818			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539039				2022-12-25	WOS:000180801900024
J	Diez, E; Lee, SH; Gauthier, S; Yaraghi, Z; Tremblay, M; Vidal, S; Gros, P				Diez, E; Lee, SH; Gauthier, S; Yaraghi, Z; Tremblay, M; Vidal, S; Gros, P			Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila	NATURE GENETICS			English	Article							SPINAL MUSCULAR-ATROPHY; APOPTOSIS INHIBITORY PROTEIN; LEGIONNAIRES-DISEASE; NATURAL-RESISTANCE; SEQUENCE-ANALYSIS; MOUSE; NAIP; MACROPHAGES; INFECTION; IAP	In inbred mouse strains, permissiveness to intracellular replication of Legionella pneumophila is controlled by a single locus (Lgn1), which maps to a region within distal Chromosome 13 that contains multiple copies of the gene baculoviral IAP repeat-containing 1 (Birc1, also called Naip; refs. 1-3). Genomic BAC clones from the critical interval were transferred into transgenic mice to functionally complement the Lgn1-associated susceptibility of A/J mice to L. pneumophila. Here we report that two independent BAC clones that rescue susceptibility have an overlapping region of 56 kb in which the entire Lgn1 transcript must lie. The only known full-length transcript coded in this region is Birc1e (also called Naip5).	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	McGill University; University of Ottawa; University of Ottawa; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							BECKERS MC, 1995, MAMM GENOME, V6, P540, DOI 10.1007/BF00356173; Diez E, 1997, MAMM GENOME, V8, P682, DOI 10.1007/s003359900536; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Endrizzi M, 1999, GENOMICS, V60, P137, DOI 10.1006/geno.1999.5910; Endrizzi MG, 2000, GENOME RES, V10, P1095, DOI 10.1101/gr.10.8.1095; Gao LY, 1999, INFECT IMMUN, V67, P862, DOI 10.1128/IAI.67.2.862-870.1999; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; Growney JD, 2000, GENOMICS, V64, P62, DOI 10.1006/geno.1999.6111; Haider MZ, 2001, J BIOMED SCI, V8, P191, DOI 10.1007/BF02256412; Holcik M, 2000, P NATL ACAD SCI USA, V97, P2286, DOI 10.1073/pnas.040469797; HORWITZ MA, 1980, J CLIN INVEST, V66, P441, DOI 10.1172/JCI109874; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; MCDADE JE, 1977, NEW ENGL J MED, V297, P1197, DOI 10.1056/NEJM197712012972202; Muller A, 1996, INFECT IMMUN, V64, P4900; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Scharf JM, 1996, GENOMICS, V38, P405, DOI 10.1006/geno.1996.0644; Somerville MJ, 1997, AM J MED GENET, V69, P159, DOI 10.1002/(SICI)1096-8628(19970317)69:2<159::AID-AJMG8>3.3.CO;2-6; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Watarai M, 2001, J EXP MED, V194, P1081, DOI 10.1084/jem.194.8.1081; WRIGHT EK, 2003, IN PRESS CURR BIOL, V13; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; YAMAMOTO Y, 1988, INFECT IMMUN, V56, P370, DOI 10.1128/IAI.56.2.370-375.1988; Yamamoto Y, 1988, Adv Exp Med Biol, V239, P89; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; YOSHIDA SI, 1991, INFECT IMMUN, V59, P428, DOI 10.1128/IAI.59.1.428-432.1991	29	221	231	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					55	60		10.1038/ng1065	http://dx.doi.org/10.1038/ng1065			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12483212				2022-12-25	WOS:000180136100017
J	Duncan, MC; Costaguta, G; Payne, GS				Duncan, MC; Costaguta, G; Payne, GS			Yeast epsin-related proteins required for Golgi-endosome traffic define a gamma-adaptin ear-binding motif	NATURE CELL BIOLOGY			English	Article							CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; TRANS-GOLGI; DOMAIN; FAMILY; ENDOCYTOSIS; APPENDAGE; DELIVERY; NETWORK; GENE	Clathrin-coated vesicles (CCVs) are a central component of endocytosis and traffic between the trans-Golgi network (TGN) and endosomes. Although endocytic CCV formation is well characterized, much less is known about CCV formation at internal membranes. Here we describe two epsin amino-terminal homology (ENTH) domain-containing proteins, Ent3p and Eht5p, that are intimately involved in clathrin function at-the Golgi. Both proteins associate with the clathrin adaptor Gga2p in vivo; Ent5p also interacts with the clathrin adaptor complex AP-1 and clathrin. A novel, conserved motif that mediates the interaction of Ent3p and Ent5p with gamma-ear domains of Gga2p and AP-1 is defined. Ent3p and Ent5p colocalize with clathrin, and cells lacking both Ent proteins exhibit defects in clathrin localization and traffic between the Golgi and endosomes. The findings suggest that Ent3p and Ent5p constitute a functionally related pair that cooperate with Gga proteins and AP-1 to recruit clathrin and promote formation of clathrin coats at the Golgi/endosomes. On the basis of our results and the established roles of epsin and epsin-related proteins in endocytosis, we propose that ENTH-domain-containing proteins are a universal component of CCV formation.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Payne, GS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.		Duncan, Mara/Z-6236-2019	Duncan, Mara/0000-0002-2383-0109	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039040] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39040] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; James P, 1996, GENETICS, V144, P1425; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; LINDNER R, 1992, J BIOL CHEM, V267, P16567; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; Pishvaee B, 2000, NAT CELL BIOL, V2, P958, DOI 10.1038/35046619; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Vowels JJ, 1998, MOL BIOL CELL, V9, P1351, DOI 10.1091/mbc.9.6.1351; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078	30	80	84	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					77	81		10.1038/ncb901	http://dx.doi.org/10.1038/ncb901			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12483220				2022-12-25	WOS:000180223700017
J	Hergovich, A; Lisztwan, J; Barry, R; Ballschmieter, P; Krek, W				Hergovich, A; Lisztwan, J; Barry, R; Ballschmieter, P; Krek, W			Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL	NATURE CELL BIOLOGY			English	Article							BIOLOGICALLY-ACTIVE PRODUCT; GENE-PRODUCT; VHL GENE; GERMLINE MUTATIONS; HUMAN TISSUES; DISEASE; LOCALIZATION; COMPLEX; UBIQUITINATION; ASSOCIATION	Von Hippel-Lindau (VHL) tumour suppressor gene inactivation is linked to the development of haemangioblastomas in the central nervous system and retina, often in association with other tumours, such as clear-cell carcinomas of the kidney and phaeochromocytomas. Here we show that the VHL protein (pVHL) is a microtubule-associated protein that can protect microtubules from depolymerization in vivo. Both the microtubule binding and stabilization functions of pVHL depend on amino acids 95-123 of pVHL, a mutational 'hot-spot' in VHL disease. From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL(Y98H) and pVHL(Y112H) (that predispose to haemangioblastoma and phaeochromocytoma, but not to renal cell carcinoma) disrupt pVHL's microtubule-stabilizing function. Our data identify a role for pVHL in the regulation of microtubule dynamics and potentially provide a link between this function of pVHL and the pathogenesis of haemangioblastoma and phaeochromocytoma in the context of VHL disease.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Krek, W (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	wilhelm.krek@fmi.ch		Hergovich, Alexander/0000-0001-7018-5635				Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; BRANCH H, 1995, HUM GENET, V95, P551; Brauch H, 2000, CANCER RES, V60, P1942; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; GAO JZ, 1995, CANCER RES, V55, P743; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Reichardt P, 2002, J PEDIAT HEMATOL ONC, V24, P145, DOI 10.1097/00043426-200202000-00018; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Shiao YH, 2000, CANCER RES, V60, P2816; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	38	275	280	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					64	70		10.1038/ncb899	http://dx.doi.org/10.1038/ncb899			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510195				2022-12-25	WOS:000180223700015
J	Niethammer, AG; Xiang, R; Becker, JC; Wodrich, H; Pertl, U; Karsten, G; Eliceiri, BP; Reisfeld, RA				Niethammer, AG; Xiang, R; Becker, JC; Wodrich, H; Pertl, U; Karsten, G; Eliceiri, BP; Reisfeld, RA			A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth	NATURE MEDICINE			English	Article							PROTECTIVE IMMUNITY; GENE-THERAPY; MICE; EXPRESSION; INDUCTION; ANTIGEN; IMMUNOTHERAPY; ENDOTHELIUM; ENDOSTATIN; VESSELS	Tumor cells are elusive targets for immunotherapy due to their heterogeneity and genetic instability. Here we describe a novel, oral DNA vaccine that targets stable, proliferating endothelial cells in the tumor vasculature rather than tumor cells. Targeting occurs through upregulated vascular-endothelial growth factor receptor 2 (FLK-1) of proliferating endothelial cells in the tumor vasculature. This vaccine effectively protected mice from lethal challenges with melanoma, colon carcinoma and lung carcinoma cells and reduced growth of established metastases in a therapeutic setting. CTL-mediated killing of endothelial cells indicated breaking of peripheral immune tolerance against this self antigen, resulting in markedly reduced dissemination of spontaneous and experimental pulmonary metastases. Angiogenesis in the tumor vasculature was suppressed without impairment of fertility, neuromuscular performance or hematopoiesis, albeit with a slight delay in wound healing. Our strategy circumvents problems in targeting of genetically unstable tumor cells. This approach may provide a new strategy for the rational design of cancer therapies.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Wurzburg, Hautklin, Wurzburg, Germany; La Jolla Inst Mol Med, San Diego, CA USA	Scripps Research Institute; Scripps Research Institute; University of Wurzburg	Reisfeld, RA (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	reisfeld@scripps.edu	Wodrich, Harald/P-1777-2019	Wodrich, Harald/0000-0002-4764-1708; Eliceiri, Brian/0000-0003-1811-1916	NATIONAL CANCER INSTITUTE [R01CA083856] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073396] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83856] Funding Source: Medline; NHLBI NIH HHS [HL 69046, R01 HL073396, R01 HL073396-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Augustin HG, 1998, TRENDS PHARMACOL SCI, V19, P216, DOI 10.1016/S0165-6147(98)01211-5; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI200112346; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744; Eberhard A, 2000, CANCER RES, V60, P1388; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Folkman J, 1997, EXS, V79, P1; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Goede V, 1998, ANTICANCER RES, V18, P2199; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; Heidenreich R, 2000, CANCER RES, V60, P6142; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; Kaesler S, 2002, CYTOKINE, V17, P157, DOI 10.1006/cyto.2001.0981; Kisker O, 2001, CANCER RES, V61, P7669; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Niethammer AG, 2001, VACCINE, V20, P421, DOI 10.1016/S0264-410X(01)00362-0; Niethammer AG, 2001, CANCER RES, V61, P6178; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; ORTEGA N, 1999, FRONT BIOSCI, V4, P141; Paylor R, 1998, LEARN MEMORY, V5, P302; Ruiter D J, 1991, Semin Cancer Biol, V2, P35; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(01)00094-2; St Croix B, 2000, SCIENCE, V289, P1197; Strawn LM, 1996, CANCER RES, V56, P3540; Taraboletti Giulia, 2001, Current Opinion in Pharmacology, V1, P378, DOI 10.1016/S1471-4892(01)00065-0; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	37	313	350	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1369	1375		10.1038/nm794	http://dx.doi.org/10.1038/nm794			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415261				2022-12-25	WOS:000179552000032
J	Obici, S; Zhang, BB; Karkanias, G; Rossetti, L				Obici, S; Zhang, BB; Karkanias, G; Rossetti, L			Hypothalamic insulin signaling is required for inhibition of glucose production	NATURE MEDICINE			English	Article							SENSITIVE K+ CHANNELS; Y GENE-EXPRESSION; BODY-WEIGHT; FOOD-INTAKE; MELANOCORTIN RECEPTORS; MESSENGER-RNA; RAT-BRAIN; INFUSION; NEURONS; HYPERPHAGIA	Circulating insulin inhibits endogenous glucose production. Here we report that bidirectional changes in hypothalamic insulin signaling affect glucose production. The infusion of either insulin or a small-molecule insulin mimetic in the third cerebral ventricle suppressed glucose production independent of circulating levels of insulin and of other glucoregulatory hormones. Conversely, central antagonism of insulin signaling impaired the ability of circulating insulin to inhibit glucose production. Finally, third-cerebral-ventricle administration of inhibitors of ATP-sensitive potassium channels, but not of antagonists of the central melanocortin receptors, also blunted the effect of hyperinsulinemia on glucose production. These results reveal a new site of action of insulin on glucose production and suggest that hypothalamic insulin resistance can contribute to hyperglycemia in type 2 diabetes mellitus.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10467 USA; Merck Res Labs, Rahway, NJ USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Merck & Company	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10467 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048321, R01DK048321, R01DK045024, P60DK020541, R29DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48321, DK 45024, DK 20541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; BASKIN DG, 1993, REGUL PEPTIDES, V48, P257, DOI 10.1016/0167-0115(93)90355-C; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Gerozissis K, 1998, PHYSIOL BEHAV, V65, P271, DOI 10.1016/S0031-9384(98)00158-9; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Hopkins DFC, 1997, DIABETIC MED, V14, P1044, DOI 10.1002/(SICI)1096-9136(199712)14:12<1044::AID-DIA508>3.0.CO;2-F; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; LIANG CS, 1982, J CLIN INVEST, V69, P1321, DOI 10.1172/JCI110572; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; MARKS JL, 1990, ENDOCRINOLOGY, V127, P3234, DOI 10.1210/endo-127-6-3234; MCGOWAN MK, 1992, PHYSIOL BEHAV, V51, P753, DOI 10.1016/0031-9384(92)90112-F; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; Numan S, 1999, MOL BRAIN RES, V72, P97, DOI 10.1016/S0169-328X(99)00160-6; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; RICHARDSON RD, 1994, AM J PHYSIOL, V266, pR59, DOI 10.1152/ajpregu.1994.266.1.R59; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SAHU A, 1995, ENDOCRINOLOGY, V136, P5718, DOI 10.1210/en.136.12.5718; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/en.130.6.3608; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Sindelar DK, 1998, DIABETES, V47, P523, DOI 10.2337/diabetes.47.4.523; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Unger JW, 1998, HISTOL HISTOPATHOL, V13, P1215, DOI 10.14670/HH-13.1215; Wang J, 1997, BRAIN RES, V777, P231, DOI 10.1016/S0006-8993(97)00963-3; WILLIAMS P, 1997, AM J PHYSIOL, V272, pE567; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	42	690	710	1	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1376	1382		10.1038/nm798	http://dx.doi.org/10.1038/nm798			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426561				2022-12-25	WOS:000179552000033
J	Yoshida, CA; Furuichi, T; Fujita, T; Fukuyama, R; Kanatani, N; Kobayashi, S; Satake, M; Takada, K; Komori, T				Yoshida, CA; Furuichi, T; Fujita, T; Fukuyama, R; Kanatani, N; Kobayashi, S; Satake, M; Takada, K; Komori, T			Core-binding factor beta interacts with Runx2 and is required for skeletal development	NATURE GENETICS			English	Article							FETAL LIVER HEMATOPOIESIS; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CBFA1-DEFICIENT MICE; CBF-BETA; CHONDROCYTE DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; BONE-FORMATION; GENE; EXPRESSION	Core-binding factor beta(CBFbeta, also called polyomavirus enhancer binding protein 2beta (PEBP2B)) is associated with an inversion of chromosome 16 and is associated with acute myeloid leukemia in humans(1). CBFbeta forms a heterodimer with RUNX1 (runt-related transcription factor 1), which has a DNA binding domain homologous to the pair-rule protein runt in Drosophila melanogaster. Both RUNX1 and CBFbeta are essential for hematopoiesis(2-6). Haploinsufficiency of another runt-related protein, RUNX2 (also called CBFA1), causes cleidocranial dysplasia in humans(7) and is essential in skeletal development by regulating osteoblast differentiation and chondrocyte maturation(8-15). Mice deficient in Cbfb (Cbfb(-/-)) die at midgestation(4-6), so the function of Cbfbeta in skeletal development has yet to be ascertained. To investigate this issue, we rescued hematopoiesis of Cbfb(-/-) mice by introducing Cbfb using the Gata1 promoter. The rescued Cbfb(-/-) mice recapitulated fetal liver hematopoiesis in erythroid and megakaryocytic lineages and survived until birth, but showed severely delayed bone formation. Although mesenchymal cells differentiated into immature osteoblasts, intramembranous bones were poorly formed. The maturation of chondrocytes into hypertrophic cells was markedly delayed, and no endochondral bones were formed. Electrophoretic mobility shift assays and reporter assays showed that Cbfbeta was necessary for the efficient DNA binding of Runx2 and for Runx2-dependent transcriptional activation. These findings indicate that Cbfbeta is required for the function of Runx2 in skeletal development.	Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Orthodont & Dentofacial Orthoped, Suita, Osaka 5650871, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Osaka, Japan; Teijin Inst Biomed Res, Tokyo, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Sendai, Miyagi 980, Japan; Japan Sci & Technol Corp, Tokyo, Japan	Osaka University; Osaka University; Setsunan University; Tohoku University; Japan Science & Technology Agency (JST)	Komori, T (corresponding author), Osaka Univ, Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; Deguchi K, 1999, BIOCHEM BIOPH RES CO, V255, P352, DOI 10.1006/bbrc.1999.0163; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Onishi M, 1996, EXP HEMATOL, V24, P324; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	32	228	252	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					633	638		10.1038/ng1015	http://dx.doi.org/10.1038/ng1015			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12434152				2022-12-25	WOS:000179593000016
J	Fahmy, RG; Dass, CR; Sun, LQ; Chesterman, CN; Khachigian, LM				Fahmy, RG; Dass, CR; Sun, LQ; Chesterman, CN; Khachigian, LM			Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth	NATURE MEDICINE			English	Article							BREAST-CARCINOMA CELLS; RESPONSE FACTOR-I; MESSENGER-RNA; FACTOR RECEPTOR; DNA ENZYME; GENE-EXPRESSION; CANCER CELLS; ACTIVATION; INJURY; METASTASIS	Current understanding of key transcription factors regulating angiogenesis is limited. Here we show that RNA-cleaving phosphodiester- linked DNA-based enzymes (DNAzymes), targeting a specific motif in the 5 untranslated region of early growth response (Egr-1) mRNA, inhibit Egr-1 protein expression, microvascular endothelial cell replication and migration, and microtubule network formation on basement membrane matrices. Egr-1 DNAzymes blocked angiogenesis in subcutaneous Matrigel plugs in mice, an observation that was independently confirmed by plug analysis in Egr-1-deficient animals, and inhibited MCF-7 human breast carcinoma growth in nude mice. Egr-1 DNAzymes suppressed tumor growth without influencing body weight, wound healing, blood coagulation or other hematological parameters. These agents inhibited endothelial expression of fibroblast growth factor (FGF)-2, a proangiogenic factor downstream of Egr-1, but not that of vascular endothelial growth factor (VEGF). Egr-1 DNAzymes also repressed neovascularization of rat cornea. Thus, microvascular endothelial cell growth, neovascularization, tumor angiogenesis and tumor growth are processes that are critically dependent on Egr-1.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia; Johnson & Johnson Res Labs, Sydney, NSW, Australia	University of New South Wales Sydney; Johnson & Johnson	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BATTEGAY EJ, 1995, J MOL MED, V73, P333; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Cieslak M, 2002, J BIOL CHEM, V277, P6779, DOI 10.1074/jbc.M102325200; DENNIS PA, 1990, J CELL PHYSIOL, V144, P84, DOI 10.1002/jcp.1041440112; EYETECH, 2002, RETINA, V22, P143; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Goldberg EP, 2002, J PHARM PHARMACOL, V54, P159, DOI 10.1211/0022357021778268; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Herold-Mende C, 1999, LAB INVEST, V79, P1573; Karpanen T, 2001, CANCER RES, V61, P1786; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Li YW, 2002, J EXP MED, V195, P1575, DOI 10.1084/jem.20020072; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; McLeskey SW, 1998, AM J PATHOL, V153, P1993, DOI 10.1016/S0002-9440(10)65713-6; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Ogawa T, 2002, CANCER GENE THER, V9, P633, DOI 10.1038/sj.cgt.7700478; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Prewett M, 1999, CANCER RES, V59, P5209; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; Shiose S, 2000, INVEST OPHTH VIS SCI, V41, P2395; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Visvanathan S, 2000, J IMMUNOL, V165, P2258, DOI 10.4049/jimmunol.165.4.2258; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Wedge SR, 2002, CANCER RES, V62, P4645; Zhang LR, 1999, CANCER RES, V59, P5023; Zhang LR, 1998, CANCER RES, V58, P352	45	296	312	0	36	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1026	1032		10.1038/nm905	http://dx.doi.org/10.1038/nm905			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872165				2022-12-25	WOS:000184484900026
J	Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G				Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G			Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury	NATURE MEDICINE			English	Article							PAIN-LIKE BEHAVIOR; SELECTIVE ANTAGONIST; LOCAL INJECTION; RAT; IDENTIFICATION; INVOLVEMENT; MECHANISMS; CHANNEL; POTENT; OPIATE	Endothelin-1 (ET-1) is a newly described pain mediator that is involved in the pathogenesis of pain states ranging from trauma to cancer. ET-1 is synthesized by keratinocytes in normal skin and is locally released after cutaneous injury. While it is able to trigger pain through its actions on endothelin-A (ETA) receptors of local nociceptors, it can coincidentally produce analgesia through endothelin-B (ETB) receptors. Here we map a new endogenous analgesic circuit, in which ETB receptor activation induces the release of beta-endorphin from keratinocytes and the activation of G-protein-coupled inwardly rectifying potassium channels (GIRKs, also named Kir-3) linked to opioid receptors on nociceptors. These results indicate the existence of an intrinsic feedback mechanism to control peripheral pain in skin, and establish keratinocytes as an ETB receptor-operated opioid pool.	Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Sensory Neurophysiol Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Pain Res Ctr, Neurogenom Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Albany Medical College; Rockefeller University; Harvard University; Brigham & Women's Hospital	Davar, G (corresponding author), Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	gdavar@zeus.bwh.harvard.edu						Ahn Gun Young, 1998, Journal of Dermatology (Tokyo), V25, P78; AKIL H, 1976, SCIENCE, V191, P961, DOI 10.1126/science.1251210; AKIL H, 1972, CR ACAD SCI D NAT, V274, P3603; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; BLEDNOV YA, 2003, P NATL ACAD SCI USA, V100, P77; Broadbear JH, 2000, J PHARMACOL EXP THER, V294, P933; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carducci MA, 2002, J CLIN ONCOL, V20, P2171, DOI 10.1200/JCO.2002.08.028; Davar G, 1998, NEUROREPORT, V9, P2279, DOI 10.1097/00001756-199807130-00025; De-Melo JD, 1998, PAIN, V77, P261, DOI 10.1016/S0304-3959(98)00098-0; Fareed MU, 2000, J PAIN, V1, P46, DOI 10.1016/S1526-5900(00)90087-7; FERREIRA SH, 1989, J CARDIOVASC PHARM, V13, pS220, DOI 10.1097/00005344-198900135-00065; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; Gokin AP, 2001, J NEUROSCI, V21, P5358, DOI 10.1523/JNEUROSCI.21-14-05358.2001; Gutstein HB, 1998, NEUROREPORT, V9, P1777, DOI 10.1097/00001756-199806010-00019; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; Harris JA, 1996, J PHYSIOL-PARIS, V90, P15, DOI 10.1016/0928-4257(96)87165-8; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Jarvis MF, 2000, EUR J PHARMACOL, V388, P29, DOI 10.1016/S0014-2999(99)00865-1; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khodorova A, 2002, J NEUROSCI, V22, P7788; Luscher TF, 2000, CIRCULATION, V102, P2434, DOI 10.1161/01.CIR.102.19.2434; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MCQUAY H, 1998, EVIDENCE BASED RESOU, P23; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Piovezan AP, 2000, BRIT J PHARMACOL, V129, P961, DOI 10.1038/sj.bjp.0703154; Pomonis JD, 2001, J NEUROSCI, V21, P999, DOI 10.1523/JNEUROSCI.21-03-00999.2001; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001; Wettstein JG, 1996, PHARMACOL BIOCHEM BE, V53, P411, DOI 10.1016/0091-3057(95)02043-8; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zanello SB, 1999, ANN NY ACAD SCI, V885, P85; Zhou QL, 2001, NEUROREPORT, V12, P3853, DOI 10.1097/00001756-200112040-00050; Zhou ZR, 2002, J NEUROSCI, V22, P6325; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	185	188	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1055	1061		10.1038/nm885	http://dx.doi.org/10.1038/nm885			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847519				2022-12-25	WOS:000184484900030
J	Murciano, JC; Medinilla, S; Eslin, D; Atochina, E; Cines, DB; Muzykantov, VR				Murciano, JC; Medinilla, S; Eslin, D; Atochina, E; Cines, DB; Muzykantov, VR			Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes	NATURE BIOTECHNOLOGY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; RED-BLOOD-CELLS; MONOCLONAL-ANTIBODIES; THROMBOLYTIC THERAPY; MEDIATED DELIVERY; IN-VITRO; T-PA; LYSIS; ATTACHMENT; BIOTIN	A fibrinolytic agent consisting of a tissue-type plasminogen activator (tPA) coupled to the surface of red blood cells (RBCs) can dissolve nascent clots from within the clot, in a Trojan horse-like strategy, while having minimal effects on preexisting hemostatic clots or extravascular tissue. After intravenous injection, the fibrinolytic activity of RBC-tPA persisted in the bloodstream at least tenfold longer than did that of free tPA. In a model of venous thrombosis induced by intravenously injected fibrin microemboli aggregating in pulmonary vasculature, soluble tPA lysed pulmonary clots lodged before but not after tPA injection, whereas the converse was true for RBC-tPA. Free tPA failed to lyse occlusive carotid thrombosis whether injected before or after vascular trauma, whereas RBC-tPA circulating before, but not injected after, thrombus formation restored blood flow. This RBC-based drug delivery strategy alters the fibrinolytic profile of tPA, permitting prophylactic fibrinolysis.	Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pediat Hematol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Muzykantov, VR (corresponding author), Univ Penn, Inst Environm Med, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021; Atochina-Vasserman, Elena/AAN-2286-2020	Murciano, Juan Carlos/0000-0002-4894-046X; Atochina-Vasserman, Elena N/0000-0001-7950-7004	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169, R01HL066442] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66442, HL-60169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; Anand S, 1996, CIRCULATION, V94, P763, DOI 10.1161/01.CIR.94.4.763; Bax BE, 2000, BRIT J HAEMATOL, V109, P549, DOI 10.1046/j.1365-2141.2000.02059.x; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; BEUTLER E, 1977, P NATL ACAD SCI USA, V74, P4620, DOI 10.1073/pnas.74.10.4620; Blackall DP, 2001, BLOOD, V97, P551, DOI 10.1182/blood.V97.2.551; Brown WR, 2000, STROKE, V31, P707, DOI 10.1161/01.STR.31.3.707; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CAVILL I, 1988, BRIT J HAEMATOL, V70, P491, DOI 10.1111/j.1365-2141.1988.tb02522.x; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; Deklunder G, 1998, STROKE, V29, P1821, DOI 10.1161/01.STR.29.9.1821; Farrehi PM, 1998, CIRCULATION, V97, P1002; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; HEEREMANS JLM, 1995, THROMB HAEMOSTASIS, V73, P488; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HOLVOET P, 1993, CIRCULATION, V87, P1007, DOI 10.1161/01.CIR.87.3.1007; IHLER GM, 1973, P NATL ACAD SCI USA, V70, P2663, DOI 10.1073/pnas.70.9.2663; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KALOFONOS HP, 1990, J NUCL MED, V31, P1791; Krishnamurti C, 1996, BLOOD, V87, P14; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Langer R, 1998, NATURE, V392, P5; MAGNANI M, 1992, P NATL ACAD SCI USA, V89, P6477, DOI 10.1073/pnas.89.14.6477; MAGNANI M, 1992, BIOTECHNOL APPL BIOC, V16, P188; Magnani M, 2002, GENE THER, V9, P749, DOI 10.1038/sj.gt.3301758; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; MUZYKANTOV VR, 1994, ANAL BIOCHEM, V223, P142, DOI 10.1006/abio.1994.1559; MUZYKANTOV VR, 1991, BLOOD, V78, P2611; Muzykantov VR, 1996, ANAL BIOCHEM, V241, P109, DOI 10.1006/abio.1996.0384; Muzykantov VR, 1996, J PHARMACOL EXP THER, V279, P1026; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; PAGANELLI G, 1992, EUR J NUCL MED, V19, P322; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; Rogove AD, 1999, J CELL SCI, V112, P4007; Rossi L, 2001, BIOTECHNOL APPL BIOC, V33, P85, DOI 10.1042/BA20000087; Runge MS, 1996, CIRCULATION, V94, P1412, DOI 10.1161/01.CIR.94.6.1412; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Scott MD, 1997, P NATL ACAD SCI USA, V94, P7566, DOI 10.1073/pnas.94.14.7566; SMIRNOV VN, 1986, P NATL ACAD SCI USA, V83, P6603, DOI 10.1073/pnas.83.17.6603; TAYLOR RP, 1991, P NATL ACAD SCI USA, V88, P3305, DOI 10.1073/pnas.88.8.3305; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; ZALTZMAN AB, 1995, BIOCHEM J, V307, P651, DOI 10.1042/bj3070651	50	143	152	4	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					891	896		10.1038/nbt846	http://dx.doi.org/10.1038/nbt846			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12845330				2022-12-25	WOS:000184484600031
J	Rocha, EPC; Danchin, A				Rocha, EPC; Danchin, A			Essentiality, not expressiveness, drives gene-strand bias in bacteria	NATURE GENETICS			English	Article							ESCHERICHIA-COLI CHROMOSOME; BACILLUS-SUBTILIS; REPLICATION; TRANSCRIPTION; INVERSIONS; GENOMES	Preferential positioning of bacterial genes in the leading strand was thought to result from selection to avoid high head-on collision rates between DNA and RNA polymerases. Here we show, however, that in Bacillus subtilis and Escherichia coli, essentiality (the transcript product), not expressiveness (the collision rate), selectively drives the biased gene distribution.	Inst Pasteur, URA 2171, Unite GGB, F-75015 Paris, France; Univ Paris 06, Atelier Bioinformat, F-75005 Paris, France; HKU Pasteur Res Ctr, Pokfulam, Hong Kong, Peoples R China	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; University of Hong Kong	Rocha, EPC (corresponding author), Inst Pasteur, URA 2171, Unite GGB, 28 Rue Dr Roux, F-75015 Paris, France.		Rocha, Eduardo/B-7009-2009; Shintani, Masaki/A-3219-2012; Rocha, Eduardo/A-4727-2008	Rocha, Eduardo/0000-0001-7704-822X; Shintani, Masaki/0000-0002-6505-9850; Danchin, Antoine/0000-0002-6350-5001				Bremer H, 1996, ESCHERICHIA COLI SAL; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LOUARN JM, 1985, MOL GEN GENET, V201, P467, DOI 10.1007/BF00331341; McLean MJ, 1998, J MOL EVOL, V47, P691, DOI 10.1007/PL00006428; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Rocha EPC, 2002, TRENDS MICROBIOL, V10, P393, DOI 10.1016/S0966-842X(02)02420-4; SEGALL A, 1988, SCIENCE, V241, P1314, DOI 10.1126/science.3045970; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Tao H, 1999, J BACTERIOL, V181, P6425, DOI 10.1128/JB.181.20.6425-6440.1999; Wei Y, 2001, J BACTERIOL, V183, P545, DOI 10.1128/JB.183.2.545-556.2001	15	158	162	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2003	34	4					377	378		10.1038/ng1209	http://dx.doi.org/10.1038/ng1209			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12847524				2022-12-25	WOS:000184470500014
J	Haslberger, AG				Haslberger, AG			Codex guidelines for GM foods include the analysis of unintended effects	NATURE BIOTECHNOLOGY			English	Editorial Material							FIELD PERFORMANCE; TRANSGENE; BARLEY; PLANTS		Univ Vienna, A-1010 Vienna, Austria; WHO, FOS Program Food Safety, CH-1211 Geneva, Switzerland	University of Vienna; World Health Organization	Haslberger, AG (corresponding author), Univ Vienna, A-1010 Vienna, Austria.	haslbergera@who.int	Kesim, Haydar K/B-4662-2010; Haslberger, Alexander G/B-9120-2013	Haslberger, Alexander/0000-0001-9699-537X				Al-Kaff NS, 2000, NAT BIOTECHNOL, V18, P995, DOI 10.1038/79501; ALVAREZMORALES A, 2002, 7 INT S BIOS GEN MOD; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; Bailey-Serres J, 1999, TRENDS PLANT SCI, V4, P142, DOI 10.1016/S1360-1385(99)01386-2; Baker SJ, 1998, PLANT PATHOL, V47, P401, DOI 10.1046/j.1365-3059.1998.00261.x; BARTH R, 2002, GENETIC ENG ORGANIC; Birch ANE, 2002, ANN APPL BIOL, V140, P143, DOI 10.1111/j.1744-7348.2002.tb00166.x; *BT CORN GEN FLOW, 2002, AG BIOT INF; Codex Alimentarius Commission, 2003, JOINT FAO WHO FOOD S; CONNER AJ, 1994, NEW ZEAL J CROP HORT, V22, P361, DOI 10.1080/01140671.1994.9513847; Corvalan C, 2000, DECISION-MAKING IN ENVIRONMENTAL HEALTH, P1; Courtial B, 2001, MOL GENET GENOMICS, V265, P32, DOI 10.1007/s004380000387; *EUR COMM, 2003, GMOS COMM ADDR GM CR; Fehr R, 1999, EPIDEMIOLOGY, V10, P618, DOI 10.1097/00001648-199909000-00031; Haslberger A, 2001, NAT BIOTECHNOL, V19, P613, DOI 10.1038/90201; Horvath H, 2001, THEOR APPL GENET, V102, P1, DOI 10.1007/s001220051612; Jank B, 2000, TRENDS BIOTECHNOL, V18, P326, DOI 10.1016/S0167-7799(00)01470-0; KIRSCHMAN JC, 1989, FOOD CHEM TOXICOL, V27, P555, DOI 10.1016/0278-6915(89)90058-6; Koprek T, 2001, PLANT PHYSIOL, V125, P1354, DOI 10.1104/pp.125.3.1354; Kumpatla SP, 1997, PLANT PHYSIOL, V115, P361, DOI 10.1104/pp.115.2.361; Matzke Marjori A, 2002, Adv Genet, V46, P235; Mauricio R, 2001, NAT REV GENET, V2, P370, DOI 10.1038/35072085; Meyer P, 1999, IN VITRO CELL DEV-PL, V35, P29, DOI 10.1007/s11627-999-0006-0; Meza TJ, 2001, TRANSGENIC RES, V10, P53, DOI 10.1023/A:1008903026579; Momma K, 1999, BIOSCI BIOTECH BIOCH, V63, P314, DOI 10.1271/bbb.63.314; Novak WK, 2000, FOOD CHEM TOXICOL, V38, P473, DOI 10.1016/S0278-6915(00)00040-5; Prakash CS, 2001, PLANT PHYSIOL, V126, P8, DOI 10.1104/pp.126.1.8; SANCHEZGONZALEZ J, 2002, 7 INT S BIOS GEN MOD; Saxena D, 2001, AM J BOT, V88, P1704, DOI 10.2307/3558416; Shewmaker CK, 1999, PLANT J, V20, P401, DOI 10.1046/j.1365-313x.1999.00611.x; Stokes TL, 2002, GENE DEV, V16, P171, DOI 10.1101/gad.952102; *WHO, 2000, WHO EUROANPA SEM WHO; *WHO FOOD AGR ORG, 2001, SAF ASS FOODS DEV GE; *WHO FOOD AGR ORG, 2002, SAF ASP GEN MOD FOOD; World Commission on Environment and Development Our Common Future, 1987, BRUNDTL REP; 2002, EDO NEWS         MAR, V8	36	43	47	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					739	741		10.1038/nbt0703-739	http://dx.doi.org/10.1038/nbt0703-739			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12833088				2022-12-25	WOS:000183886000018
J	Parviz, F; Matullo, C; Garrison, WD; Savatski, L; Adamson, JW; Ning, G; Kaestner, KH; Rossi, JM; Zaret, KS; Duncan, SA				Parviz, F; Matullo, C; Garrison, WD; Savatski, L; Adamson, JW; Ning, G; Kaestner, KH; Rossi, JM; Zaret, KS; Duncan, SA			Hepatocyte nuclear factor 4 alpha controls the development of a hepatic epithelium and liver morphogenesis	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR HNF-4; RAT-LIVER; GENE-TRANSCRIPTION; VISCERAL ENDODERM; EXPRESSION; DIFFERENTIATION; CELLS; FETAL; EMBRYOGENESIS; GASTRULATION	Although advances have been made in understanding cell differentiation, only rudimentary knowledge exists concerning how differentiated cells form tissues and organs. We studied liver organogenesis because the cell and tissue architecture of this organ is well defined. Approximately 60% of the adult liver consists of hepatocytes that are arranged as single-cell anastomosing plates extending from the portal region of the liver lobule toward the central vein(1). The basal surface of the hepatocytes is separated from adjacent sinusoidal endothelial cells by the space of Disse, where the exchange of substances between serum and hepatocytes takes place. The hepatocytes apical surface forms bile canaliculi that transport bile to the hepatic ducts. Proper liver architecture is crucial for hepatic function(2) and is commonly disrupted in disease states, including cirrhosis and hepatitis(3). Here we report that hepatocyte nuclear factor 4alpha (Hnf4alpha) is essential for morphological and functional differentiation of hepatocytes(4), accumulation of hepatic glycogen stores and generation of a hepatic epithelium. We show that Hnf4alpha is a dominant regulator of the epithelial phenotype because its ectopic expression in fibroblasts induces a mesenchymal-to-epithelial transition. Most importantly, the morphogenetic parameters controlled by Hnf4alpha in hepatocytes are essential for normal liver architecture, including the organization of the sinusoidal endothelium.	Med Coll Wisconsin, Dept Anat Cell Biol & Neurobiol, Milwaukee, WI 53226 USA; Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA; Blood Ctr SE, Blood Res Inst, Milwaukee, WI 53226 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	Medical College of Wisconsin; Fox Chase Cancer Center; Versiti Blood Center of Wisconsin; University of Pennsylvania	Duncan, SA (corresponding author), Med Coll Wisconsin, Dept Anat Cell Biol & Neurobiol, Milwaukee, WI 53226 USA.			Matullo, Christine/0000-0003-1598-7007; Duncan, Stephen/0000-0002-2507-7827				BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DEWOLFPEETERS C, 1974, EXP MOL PATHOL, V21, P339, DOI 10.1016/0014-4800(74)90100-2; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Duncan SA, 1997, DEVELOPMENT, V124, P279; Enzan H, 1997, MICROSC RES TECHNIQ, V39, P336, DOI 10.1002/(SICI)1097-0029(19971115)39:4<336::AID-JEMT4>3.0.CO;2-F; FERACCI H, 1987, DEV BIOL, V123, P73, DOI 10.1016/0012-1606(87)90429-5; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; Li JX, 2000, GENE DEV, V14, P464; MEDLOCK ES, 1983, ANAT REC, V207, P31, DOI 10.1002/ar.1092070105; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SHERLOCK S, 1909, DIS LIVER BILIARY SY, P371; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; VASSY J, 1988, CELL DIFFER DEV, V24, P9, DOI 10.1016/0045-6039(88)90082-6; WOOD RL, 1965, ANAT RECORD, V151, P507, DOI 10.1002/ar.1091510403	26	433	458	0	24	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					292	296		10.1038/ng1175	http://dx.doi.org/10.1038/ng1175			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12808453				2022-12-25	WOS:000183815300016
J	Menashe, I; Man, O; Lancet, D; Gilad, Y				Menashe, I; Man, O; Lancet, D; Gilad, Y			Different noses for different people	NATURE GENETICS			English	Article							MHC	Of more than 1,000 human olfactory receptor genes, more than half seem to be pseudogenes. We investigated whether the most recent of these disruptions might still segregate with the intact form by genotyping 51 candidate genes in 189 ethnically diverse humans. The results show an unprecedented prevalence of segregating pseudogenes, identifying one of the most pronounced cases of functional population diversity in the human genome.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Crown Human Genome Ctr, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lancet, D (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Menashe, Idan/AAC-8670-2020; Menashe, Idan/W-6214-2019	Menashe, Idan/0000-0003-1961-1461; 				AMOORE JE, 1974, ANN NY ACAD SCI, V237, P137, DOI 10.1111/j.1749-6632.1974.tb49850.x; BARRON KS, 1994, HUM IMMUNOL, V40, P17, DOI 10.1016/0198-8859(94)90016-7; Ehlers A, 2000, GENOME RES, V10, P1968, DOI 10.1101/gr.10.12.1968; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Gilad Y, 2003, MOL BIOL EVOL, V20, P307, DOI 10.1093/molbev/msg013; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Menashe I, 2002, HUM MOL GENET, V11, P1381, DOI 10.1093/hmg/11.12.1381; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; WHISSELLBUECHY D, 1973, NATURE, V242, P271, DOI 10.1038/242271a0; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; Yeager M, 1999, IMMUNOL REV, V167, P45, DOI 10.1111/j.1600-065X.1999.tb01381.x; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	14	170	196	0	25	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					143	144		10.1038/ng1160	http://dx.doi.org/10.1038/ng1160			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12730696				2022-12-25	WOS:000183200500016
J	Green, P; Ewing, B; Miller, W; Thomas, PJ; Green, ED				Green, P; Ewing, B; Miller, W; Thomas, PJ; Green, ED		NISC Comparative Sequencing Progr	Transcription-associated mutational asymmetry in mammalian evolution	NATURE GENETICS			English	Article							COUPLED REPAIR; SUBSTITUTION PATTERNS; BASE-COMPOSITION; STRAND SYMMETRY; DNA; RATES; GENES; REPLICATION; SEQUENCE; PSEUDOGENES	Although mutation is commonly thought of as a random process, evolutionary studies show that different types of nucleoticle substitution occur with widely varying rates that presumably reflect biases intrinsic to mutation and repair mechanisms(1-4). A strand asymmetry(5,6), the occurrence of particular substitution types at higher rates than their complementary types, that is associated with DNA replication has been found in bacteria(7) and mitochondria(8). A strand asymmetry that is associated with transcription and attributable to higher rates of cytosine deamination on the coding strand has been observed in enterobacteria(9-11). Here, we describe a qualitatively different transcription-associated strand asymmetry in mammals, which may be a byproduct of transcription-coupled repair(12) in germline cells. This mutational asymmetry has acted over long periods of time to produce a compositional asymmetry, an excess of G+T over A+C on the coding strand, in most genes. The mutational and compositional asymmetries can be used to detect the orientations and approximate extents of transcribed regions.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20892 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, P (corresponding author), Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Beletskii A, 1998, BIOL CHEM, V379, P549; BULMER M, 1991, J MOL EVOL, V33, P305, DOI 10.1007/BF02102861; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Francino MP, 2001, MOL BIOL EVOL, V18, P1147, DOI 10.1093/oxfordjournals.molbev.a003888; Francino MP, 1996, SCIENCE, V272, P107, DOI 10.1126/science.272.5258.107; Francino MP, 1997, TRENDS GENET, V13, P240, DOI 10.1016/S0168-9525(97)01118-9; Francino MP, 2000, MOL BIOL EVOL, V17, P416; Frank AC, 1999, GENE, V238, P65, DOI 10.1016/S0378-1119(99)00297-8; GOJOBORI T, 1982, J MOL EVOL, V18, P360, DOI 10.1007/BF01733904; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HESS ST, 1994, J MOL BIOL, V236, P1022, DOI 10.1016/0022-2836(94)90009-4; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Krawczak M, 1998, AM J HUM GENET, V63, P474, DOI 10.1086/301965; Leadon SA, 1997, CANCER RES, V57, P3784; Li W. H, 1997, MOL EVOLUTION; LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; SUEOKA N, 1995, J MOL EVOL, V40, P318, DOI 10.1007/BF00163236; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; TANAKA M, 1994, GENOMICS, V22, P327, DOI 10.1006/geno.1994.1391; Thomas JW, 2002, GENOME RES, V12, P1277, DOI 10.1101/gr.283202; Tillier ERM, 2000, J MOL EVOL, V50, P249, DOI 10.1007/s002399910029; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0	30	211	220	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					514	517		10.1038/ng1103	http://dx.doi.org/10.1038/ng1103			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12612582	Bronze			2022-12-25	WOS:000181928600024
J	Fujikawa, A; Shirasaka, D; Yamamoto, S; Ota, H; Yahiro, K; Fukada, M; Shintani, T; Wada, A; Aoyama, N; Hirayama, T; Fukamachi, H; Noda, M				Fujikawa, A; Shirasaka, D; Yamamoto, S; Ota, H; Yahiro, K; Fukada, M; Shintani, T; Wada, A; Aoyama, N; Hirayama, T; Fukamachi, H; Noda, M			Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori	NATURE GENETICS			English	Article							ZETA RPTP-BETA; VACUOLATING CYTOTOXIN; EPITHELIAL-CELLS; ZETA/RPTP-BETA; BINDING; MIGRATION; TOXIN; MOLECULE; COMPLEX; GENE	The vacuolating cytotoxin VacA produced by Helicobacter pylori causes massive cellular vacuolation in vitro(1-3) and gastric tissue damage in vivo, leading to gastric ulcers, when administered intragastrically(4). Here we report that mice deficient in protein tyrosine phosphatase receptor type Z (Ptprz, also called PTP-xi or RPTP-beta, encoded by Ptprz) do not show mucosal damage by VacA, although VacA is incorporated into the gastric epithelial cells to the same extent as in wild-type mice. Primary cultures of gastric epithelial cells from Ptprz(+/+) and Ptprz(-/-) mice also showed similar incorporation of VacA, cellular vacuolation and reduction in cellular proliferation, but only Ptprz(+/+) cells showed marked detachment from a reconstituted basement membrane 24 h after treatment with VacA. VacA bound to Ptprz, and the levels of tyrosine phosphorylation of the G protein-coupled receptor kinase-interactor 1 (Git1), a Ptprz substrate, were higher after treatment with VacA, indicating that VacA behaves as a ligand for Ptprz. Furthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz(+/+) mice when administered orally. Taken together, these data indicate that erroneous Ptprz signaling induces gastric ulcers.	Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Kobe Univ, Dept Endoscopy, Sch Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med, Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan; Shinshu Univ, Dept Biomed Lab Sci, Sch Hlth Sci, Sch Med, Matsumoto, Nagano 3908621, Japan; Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 8528523, Japan; Univ Tokyo, Dept Sci Biol, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kobe University; Kobe University; Shionogi & Company Limited; Shinshu University; Nagasaki University; University of Tokyo	Noda, M (corresponding author), Natl Inst Basic Biol, Div Mol Neurobiol, 38 Nishigonaka,Myodaiji Cho, Okazaki, Aichi 4448585, Japan.	madon@nibb.ac.jp	Noda, Masaharu/D-7146-2016; Fujikawa, Akihiro/K-9805-2015	Noda, Masaharu/0000-0002-3796-524X; Fujikawa, Akihiro/0000-0002-3950-0550; Shintani, Takafumi/0000-0002-6165-2307; Yahiro, Kinnosuke/0000-0002-9813-0780				Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; COVER TL, 1992, J BIOL CHEM, V267, P10570; FUKAMACHI H, 1994, DIFFERENTIATION, V56, P83, DOI 10.1046/j.1432-0436.1994.56120083.x; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; GLAVIN GB, 1992, FASEB J, V6, P825, DOI 10.1096/fasebj.6.3.1740232; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Manabe R, 2002, J CELL SCI, V115, P1497; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Pai R, 1999, BIOCHEM BIOPH RES CO, V262, P245, DOI 10.1006/bbrc.1999.1194; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Ricci V, 1996, INFECT IMMUN, V64, P2829, DOI 10.1128/IAI.64.7.2829-2833.1996; Ricci V, 1997, J PATHOL, V183, P453; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; Shintani T, 1998, NEUROSCI LETT, V247, P135, DOI 10.1016/S0304-3940(98)00295-X; TEE W, 1995, J CLIN MICROBIOL, V33, P1203, DOI 10.1128/JCM.33.5.1203-1205.1995; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tominaga K, 1997, DIGESTION, V58, P120, DOI 10.1159/000201434; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WARREN JR, 1983, LANCET, V1, P1273; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Zarrilli R, 1999, CELL MICROBIOL, V1, P93, DOI 10.1046/j.1462-5822.1999.00018.x; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	29	198	206	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2003	33	3					375	381		10.1038/ng1112	http://dx.doi.org/10.1038/ng1112			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12598897				2022-12-25	WOS:000181312700014
J	Hammes, HP; Du, XL; Edelstein, D; Taguchi, T; Matsumura, T; Ju, QD; Lin, JH; Bierhaus, A; Nawroth, P; Hannak, D; Neumaier, M; Bergfeld, R; Giardino, I; Brownlee, M				Hammes, HP; Du, XL; Edelstein, D; Taguchi, T; Matsumura, T; Ju, QD; Lin, JH; Bierhaus, A; Nawroth, P; Hannak, D; Neumaier, M; Bergfeld, R; Giardino, I; Brownlee, M			Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy	NATURE MEDICINE			English	Article							CULTURED ENDOTHELIAL-CELLS; PKC-BETA INHIBITOR; FACTOR-KAPPA-B; ADVANCED GLYCATION; MESANGIAL EXPANSION; GLUCOSE-TRANSPORT; THIAMINE; RATS; ACTIVATION; AMINOGUANIDINE	Three of the major biochemical pathways implicated in the pathogenesis of hyperglycemia induced vascular damage (the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)-protein kinase C (PKC) pathway) are activated by increased availability of the glycolytic metabolites glyceraldehyde-3-phosphate and fructose-6-phosphate. We have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit these three pathways, as well as hyperglycemia-associated NF-kappaB activation, by activating the pentose phosphate pathway enzyme transketolase, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-kappaB activation by activating transketolase, and also prevented experimental diabetic retinopathy. The ability of benfotiamine to inhibit three major pathways simultaneously might be clinically useful in preventing the development and progression of diabetic complications.	Albert Einstein Coll Med, Ctr Diabet Res, Bronx, NY 10467 USA; Sch Clin Med, Med Clin V, Mannheim, Germany; Univ Heidelberg, Dept Internal Med 1, Heidelberg, Germany; Sch Clin Med, Inst Clin Chem, Mannheim, Germany; Univ Giessen, Dept Med 3, Giessen, Germany	Yeshiva University; Albert Einstein College of Medicine; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen	Brownlee, M (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res, Bronx, NY 10467 USA.		Hammes, Hans-Peter/S-3719-2019					Ascher E, 2001, SURGERY, V130, P851, DOI 10.1067/msy.2001.117194; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BITSCH R, 1991, ANN NUTR METAB, V35, P292, DOI 10.1159/000177659; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Hammes HP, 1997, DIABETOLOGIA, V40, P629, DOI 10.1007/s001250050726; Hammes HP, 1996, DIABETOLOGIA, V39, P251; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LaSelva M, 1996, DIABETOLOGIA, V39, P1263; Loew D, 1996, INT J CLIN PHARM TH, V34, P47; LUKIENKO PI, 2000, B EXP BIOL MED, V9, P303; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; SAITO N, 1987, J NUTR SCI VITAMINOL, V33, P421, DOI 10.3177/jnsv.33.421; Schenk G, 1998, INT J BIOCHEM CELL B, V30, P1297, DOI 10.1016/S1357-2725(98)00095-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Stepuro II, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1409; STEVENS VJ, 1977, J BIOL CHEM, V252, P2998; Stracke H, 2001, EXP CLIN ENDOCR DIAB, V109, P330, DOI 10.1055/s-2001-17399; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167	31	603	642	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					294	299		10.1038/nm834	http://dx.doi.org/10.1038/nm834			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592403				2022-12-25	WOS:000181312300029
J	Brown, KD; Rathi, A; Kamath, R; Beardsley, DI; Zhan, QM; Mannino, JL; Baskaran, R				Brown, KD; Rathi, A; Kamath, R; Beardsley, DI; Zhan, QM; Mannino, JL; Baskaran, R			The mismatch repair system is required for S-phase checkpoint activation	NATURE GENETICS			English	Article							RADIORESISTANT DNA-SYNTHESIS; ATAXIA-TELANGIECTASIA GENE; NIJMEGEN BREAKAGE SYNDROME; IONIZING-RADIATION; TUMOR-CELLS; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; KINASE; HMLH1; PHOSPHORYLATION; DEFICIENT	Defective S-phase checkpoint activation results in an inability to downregulate DNA replication following genotoxic insult such as exposure to ionizing radiation. This 'radioresistant DNA synthesis' (RDS) is a phenotypic hallmark of ataxia-telangiectasia(1), a cancer-prone disorder caused by mutations in ATM(2). The mismatch repair system principally corrects nucleotide mismatches that arise during replication(3). Here we show that the mismatch repair system is required for activation of the S-phase checkpoint in response to ionizing radiation. Cells deficient in mismatch repair proteins showed RDS, and restoration of mismatch repair function restored normal S-phase checkpoint function. Catalytic activation of ATM and ATM-mediated phosphorylation of the protein NBS1 (also called nibrin) occurred independently of mismatch repair. However, ATM-dependent phosphorylation and activation of the checkpoint kinase CHK2 and subsequent degradation of its downstream target, CDC25A, was abrogated in cells lacking mismatch repair. In vitro and in vivo approaches both show that MSH2 binds to CHK2 and that MLH1 associates with ATM. These findings indicate that the mismatch repair complex formed at the sites of DNA damage facilitates the phosphorylation of CHK2 by ATM, and that defects in this mechanism form the molecular basis for the RDS observed in cells deficient in mismatch repair.	Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, E 1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.							Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Buermeyer AB, 1999, CANCER RES, V59, P538; Chen SK, 2001, RADIAT RES, V155, P832, DOI 10.1667/0033-7587(2001)155[0832:DOOIIC]2.0.CO;2; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fritzell JA, 1997, CANCER RES, V57, P5143; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nehme A, 1997, CANCER RES, V57, P3253; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Umar A, 1997, CANCER RES, V57, P3949; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wang Y, 2000, GENE DEV, V14, P927; Yan T, 2001, CANCER RES, V61, P8290; Zhang H, 1999, CANCER RES, V59, P3021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	30	166	170	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					80	84		10.1038/ng1052	http://dx.doi.org/10.1038/ng1052			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12447371				2022-12-25	WOS:000180136100022
J	Economides, AN; Carpenter, LR; Rudge, JS; Wong, V; Koehler-Stec, EM; Hartnett, C; Pyles, EA; Xu, XB; Daly, TJ; Young, MR; Fandl, JP; Lee, F; Carver, S; McNnay, J; Bailey, K; Ramakanth, S; Hutabarat, R; Huang, TT; Radziejewski, C; Yancopoulos, GD; Stahl, N				Economides, AN; Carpenter, LR; Rudge, JS; Wong, V; Koehler-Stec, EM; Hartnett, C; Pyles, EA; Xu, XB; Daly, TJ; Young, MR; Fandl, JP; Lee, F; Carver, S; McNnay, J; Bailey, K; Ramakanth, S; Hutabarat, R; Huang, TT; Radziejewski, C; Yancopoulos, GD; Stahl, N			Cytokine traps: multi-component, high-affinity blockers of cytokine action	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; IL-4; ALPHA; MODEL	Cytokines can initiate and perpetuate human diseases, and are among the best-validated of therapeutic targets. Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for cytokines such as interleukin (IL)-1, IL-4, IL-6 and IL-13 that use multi-component receptor systems is limited because monomeric soluble receptors generally exhibit low affinity or function as agonists. We describe here a generally applicable method to create very high-affinity blockers called 'cytokine traps' consisting of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components involved in binding the cytokine. Traps potently block cytokines in vitro and in vivo and represent a substantial advance in creating novel therapeutic candidates for cytokine-driven diseases.	Regeneron Pharmaceut Inc, Dept Biomol Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Preclin Pharmacol, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Chem Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Express Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Preclin Mfg & Proc Dev, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Pharmacokinet, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Biochem, Tarrytown, NY 10591 USA	Regeneron; Regeneron; Regeneron; Regeneron; Regeneron; Regeneron; Regeneron	Stahl, N (corresponding author), Regeneron Pharmaceut Inc, Dept Biomol Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	neil.stahl@regeneron.com		Economides, Aris/0000-0002-6508-8942				BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Bresnihan B, 2001, BIODRUGS, V15, P87, DOI 10.2165/00063030-200115020-00003; Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704; Carpenter LR, 1999, ADV PROTEIN CHEM, V52, P109; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Cohen S, 1999, ARTHRITIS RHEUM, V42, pS273; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guler HP, 2001, ARTHRITIS RHEUM, V44, pS370; Gundel R, 1996, CLIN EXP ALLERGY, V26, P719; Haddad E, 2001, BLOOD, V97, P1590, DOI 10.1182/blood.V97.6.1590; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; JOOSTEN LAB, 1994, CLIN EXP IMMUNOL, V97, P204; Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; LEGOUFFE E, 1994, CLIN EXP IMMUNOL, V98, P323; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Nuki George, 1997, Arthritis and Rheumatism, V40, pS224; Reimers JI, 1998, DAN MED BULL, V45, P157; Richard-Miceli C, 2001, BIODRUGS, V15, P251, DOI 10.2165/00063030-200115040-00005; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; van den Berg WB, 1998, SPRINGER SEMIN IMMUN, V20, P149, DOI 10.1007/BF00832004; van Deventer SJH, 1999, ANN RHEUM DIS, V58, P114; VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915	37	293	356	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					47	52		10.1038/nm811	http://dx.doi.org/10.1038/nm811			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483208				2022-12-25	WOS:000180209900021
J	Orive, G; Hernandez, RM; Gascon, AR; Calafiore, R; Chang, TMS; De Vos, P; Hortelano, G; Hunkeler, D; Lacik, I; Shapiro, AMJ; Pedraz, JL				Orive, Gorka; Maria Hernandez, Rosa; Gascon, Alicia R.; Calafiore, Riccardo; Chang, Thomas M. S.; De Vos, Paul; Hortelano, Gonzalo; Hunkeler, David; Lacik, Igor; Shapiro, A. M. James; Luis Pedraz, Jose			Cell encapsulation: Promise and progress	NATURE MEDICINE			English	Article								In cell encapsulation, transplanted cells are protected from immune rejection by an artificial, semipermeable membrane, potentially allowing transplantation (allo-or xenotransplantation) without the need for immunosuppression. Yet, despite some promising results in animal studies, the field has not lived up to expectations, and clinical products based on encapsulated cell technology continue to elude the scientific community. This commentary discusses the reasons for this, summarizes recent progress in the field and outlines what is needed to bring this technology closer to clinical application.	[Orive, Gorka; Maria Hernandez, Rosa; Gascon, Alicia R.; Luis Pedraz, Jose] Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria, Spain; [Calafiore, Riccardo] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy; [Chang, Thomas M. S.] McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Montreal, PQ, Canada; [De Vos, Paul] Dept Pathol & Lab Med, Groningen, Netherlands; [Hortelano, Gonzalo] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Hortelano, Gonzalo] Canadian Blood Serv, Hamilton, ON, Canada; [Hunkeler, David] AQUA TECH Specialties SA, Geneva, Switzerland; [Lacik, Igor] Slovak Acad Sci, Inst Polymer, Dept Special Polymers & Biopolymers, Bratislava, Slovakia; [Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada	University of Basque Country; University of Perugia; McGill University; McMaster University; Canadian Blood Services; Slovak Academy of Sciences; University of Alberta	Pedraz, JL (corresponding author), Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria, Spain.	knppemuj@vc.ehu.es	de Vos, Paul/A-3170-2013; Hernandez, Rosa Maria/S-6332-2017; Hernández, Rosa/GRF-5998-2022; Pedraz, Jose Luis/AAR-1338-2021	Hernandez, Rosa Maria/0000-0002-3947-409X; ORIVE, GORKA/0000-0002-0773-300X; Lacik, Igor/0000-0001-6037-3747; PEDRAZ MUNOZ, JOSE LUIS/0000-0002-3938-2267; Rodriguez-Gascon, Alicia/0000-0002-3195-6385; de vos, paul/0000-0001-9618-2408				Aebischer P, 1999, NAT MED, V5, P852, DOI 10.1038/11271; Anilkumar AV, 2001, BIOTECHNOL BIOENG, V75, P581, DOI 10.1002/bit.10077; Bach FH, 1998, NATURE, V391, P326, DOI 10.1038/34766; Calafiore R, 1999, ANN NY ACAD SCI, V875, P219, DOI 10.1111/j.1749-6632.1999.tb08506.x; Calafiore R, 2001, ANN NY ACAD SCI, V944, P240; CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524; Check E, 2002, NATURE, V419, P5, DOI 10.1038/419005b; Cirone P, 2002, HUM GENE THER, V13, P1157, DOI 10.1089/104303402320138943; de Vos P, 2002, TRENDS MOL MED, V8, P363, DOI 10.1016/S1471-4914(02)02381-X; de Vos P, 2003, BIOMATERIALS, V24, P305, DOI 10.1016/S0142-9612(02)00319-8; de Vos P, 2002, DIABETOLOGIA, V45, P159, DOI 10.1007/s00125-001-0729-x; Desai TA, 2002, EXPERT OPIN BIOL TH, V2, P633, DOI 10.1517/14712598.2.6.633; Dove A, 2002, NAT BIOTECHNOL, V20, P339, DOI 10.1038/nbt0402-339; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Gunzburg WH, 2000, MOL MED TODAY, V6, P199, DOI 10.1016/S1357-4310(00)01708-1; Hasse C, 1997, LANCET, V350, P1296, DOI 10.1016/S0140-6736(05)62473-7; Hortelano G, 1996, BLOOD, V87, P5095, DOI 10.1182/blood.V87.12.5095.bloodjournal87125095; Hunkeler D, 2001, ANN NY ACAD SCI, V944, P456; Hunkeler D, 1999, NAT BIOTECHNOL, V17, P1045, DOI 10.1038/14989; Hunkeler D, ANN NY ACAD SCI, V944, P1; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; King A., J BIOMED MA IN PRESS; Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Lohr M, 2001, LANCET, V357, P1591, DOI 10.1016/S0140-6736(00)04749-8; Mares-Guia M., 2001, US Patent, Patent No. [6281341, 6,281,341]; Murphy FA, 1996, SCIENCE, V273, P746, DOI 10.1126/science.273.5276.746; Orive G, 2002, TRENDS BIOTECHNOL, V20, P382, DOI 10.1016/S0167-7799(02)02037-1; Pelegrin M, 1998, GENE THER, V5, P828, DOI 10.1038/sj.gt.3300632; Prakash S, 1996, NAT MED, V2, P883, DOI 10.1038/nm0896-883; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; Strand BL, 2001, CELL TRANSPLANT, V10, P263, DOI 10.3727/000000001783986800; Sun YL, 1996, J CLIN INVEST, V98, P1417, DOI 10.1172/JCI118929; Thomas LL, 2002, FASEB J, V16, pA1238, DOI 10.1096/fj.01-0590fje; US Pharmacopeia and National Formulary (Rockville Maryland), 2002, US PHARMACOPEIA NATL, V1046, P2762; Wang T, 1997, NAT BIOTECHNOL, V15, P358, DOI 10.1038/nbt0497-358	38	463	511	1	104	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					104	107		10.1038/nm0103-104	http://dx.doi.org/10.1038/nm0103-104			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514721	Green Published			2022-12-25	WOS:000208640400003
J	Roetto, A; Papanikolaou, G; Politou, M; Alberti, F; Girelli, D; Christakis, J; Loukopoulos, D; Camaschella, C				Roetto, A; Papanikolaou, G; Politou, M; Alberti, F; Girelli, D; Christakis, J; Loukopoulos, D; Camaschella, C			Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis	NATURE GENETICS			English	Article							AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; IRON OVERLOAD; GENE; MUTATION; SLC11A3; LIVER	Animal models indicate that the antimicrobial peptide hepcidin (HAMP; OMIM 606464) is probably a key regulator of iron absorption in mammals. Here we report the identification of two mutations (93delG and 166C-->T) in HAMP on 19q13 in two families with a new type of juvenile hemochromatosis.	Univ Turin, Dept Clin & Biol Sci, Azienda Osped San Luigi, I-10043 Orbassano, Italy; Univ Athens, Sch Med, Dept Med 1, Laikon Hosp, GR-11527 Athens, Greece; Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy; Theagenio Canc Ctr, Dept Hematol, Thessaloniki, Greece	University of Turin; Athens Medical School; Laiko General Hospital; National & Kapodistrian University of Athens; University of Verona	Camaschella, C (corresponding author), Univ Turin, Dept Clin & Biol Sci, Azienda Osped San Luigi, I-10043 Orbassano, Italy.		PAPANIKOLAOU, GEORGE/AAL-9017-2021; Roetto, Antonella/K-4731-2016; Camaschella, Clara/A-3289-2015; Girelli, Domenico/B-1183-2008	PAPANIKOLAOU, GEORGE/0000-0002-6755-3633; Girelli, Domenico/0000-0001-9684-1899; ROETTO, Antonella/0000-0003-1188-7375	Telethon [GP0255Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Papanikolaou G, 2002, BLOOD CELL MOL DIS, V29, P168, DOI 10.1006/bcmd.2002.0553; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260	15	663	711	1	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					21	22		10.1038/ng1053	http://dx.doi.org/10.1038/ng1053			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12469120				2022-12-25	WOS:000180136100011
J	Beck, S; Le Good, JA; Guzman, M; Ben Haim, N; Roy, K; Beermann, F; Constam, DB				Beck, S; Le Good, JA; Guzman, M; Ben Haim, N; Roy, K; Beermann, F; Constam, DB			Extraembryonic proteases regulate Nodal signalling during gastrulation	NATURE CELL BIOLOGY			English	Article							MOUSE EMBRYO; AXIAL MESODERM; PRIMITIVE ENDODERM; EXPRESSION; CRIPTO; POPULATION; INDUCTION; EPIBLAST; PROTEINS; MOVEMENT	During gastrulation, a cascade of inductive tissue interactions converts pre-existing polarity in the mammalian embryo into antero-posterior pattern. This process is triggered by Nodal, a protein related to transforming growth factor-beta (TFG-beta) that is expressed in the epiblast and visceral endoderm, and its co-receptor Cripto, which is induced downstream of Nodal. Here we show that the proprotein convertases Spc1 and Spc4 (also known as Furin and Pace4, respectively) are expressed in adjacent extraembryonic ectoderm. They stimulate Nodal maturation after its secretion and are required in vivo for Nodal signalling. Embryo explants deprived of extraembryonic ectoderm phenocopy Spc1(-/-); Spc4(-/-) double mutants in that endogenous Nodal fails to induce Cripto. But recombinant mature Nodal, unlike uncleaved precursor, can efficiently rescue Cripto expression. Cripto is also expressed in explants treated with bone morphogenetic protein 4 (BMP4). This indicates that Nodal may induce Cripto through both a signalling pathway in the embryo and induction of Bmp4 in the extraembryonic ectoderm. A lack of Spc1 and Spc4 affects both pathways because these proteases also stimulate induction of Bmp4.	Swiss Inst Expt Canc Res, Dev Biol Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Beck, S (corresponding author), Swiss Inst Expt Canc Res, Dev Biol Grp, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.			Constam, Daniel B./0000-0002-6256-3891; Le Good, Jessie/0000-0002-6332-9239				Ang SL, 1996, DEVELOPMENT, V122, P243; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Constam DB, 2000, DEVELOPMENT, V127, P245; Constam DB, 2000, GENE DEV, V14, P1146; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; de Souza FSJ, 2000, CELL TISSUE RES, V300, P207, DOI 10.1007/s004410000204; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835; Kinder SJ, 2001, DEVELOPMENT, V128, P3623; LAWSON KA, 1987, DEVELOPMENT, V101, P627; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Perea-Gomez A, 2001, DEVELOPMENT, V128, P753; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Skromne I, 2001, DEVELOPMENT, V128, P2915; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Varlet I, 1997, DEVELOPMENT, V124, P1033; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Wei Y, 2000, DEVELOPMENT, V127, P87; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0	27	171	190	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					981	985		10.1038/ncb890	http://dx.doi.org/10.1038/ncb890			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447384				2022-12-25	WOS:000179571800019
J	Jamin, SP; Arango, NA; Mishina, Y; Hanks, MC; Behringer, RR				Jamin, SP; Arango, NA; Mishina, Y; Hanks, MC; Behringer, RR			Requirement of Bmpr1a for Mullerian duct regression during male sexual development	NATURE GENETICS			English	Article							IBMP RECEPTOR BMPRIB; MOUSE EMBRYOGENESIS; II RECEPTOR; EXPRESSION; HORMONE; GASTRULATION; PATHWAY; ALK2; FAMILY; LIMB	Elimination of the developing female reproductive tract in male fetuses is an essential step in mammalian sexual differentiation(1). In males, the fetal testis produces the transforming growth factor beta (TGF-beta) family member anti-Mullerian hormone (Amh, also known as Mullerian-inhibiting substance (Mis)), which causes regression of the Mullerian ducts, the primordia of the oviducts, uterus and upper vagina(2). Amh induces regression by binding to a specific type II receptor (Amhr2) expressed in the mesenchyme surrounding the ductal epithelium(3-7). Mutations in AMH or AMHR2 in humans and mice disrupt signaling, producing male pseudohermaphrodites that possess oviducts and uteri(8-10). The type I receptor and Smad proteins that are required in vivo for Mullerian duct regression have not yet been identified(11-14). Here we show that targeted disruption of the widely expressed type I bone morphogenetic protein (BMP) receptor Bmpr1a (also known as Alk3) in the mesenchymal cells of the Mullerian ducts leads to retention of oviducts and uteri in males. These results identify Bmpr1a as a type I receptor for Amh-induced regression of Mullerian ducts. Because Bmpr1a is evolutionarily conserved, these findings indicate that a component of the BMP signaling pathway has been co-opted during evolution for male sexual development in amniotes.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Procter & Gamble Co, Hlth Care Res Ctr, Mason, OH USA	University of Texas System; UTMD Anderson Cancer Center; Procter & Gamble	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Jamin, Soazik P./K-1507-2019; Jamin, Soazik/F-6796-2015	Jamin, Soazik P./0000-0002-1688-0167; 				Ahn K, 2001, DEVELOPMENT, V128, P4449; Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Allard S, 2000, DEVELOPMENT, V127, P3349; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Belville C, 1999, AM J MED GENET, V89, P218, DOI 10.1002/(SICI)1096-8628(19991229)89:4<218::AID-AJMG6>3.0.CO;2-E; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Gu ZY, 1999, DEVELOPMENT, V126, P2551; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mishina Y, 1999, DEV BIOL, V213, P314, DOI 10.1006/dbio.1999.9378; Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Newfeld SJ, 1999, GENETICS, V152, P783; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Roberts LM, 1999, DEV BIOL, V208, P110, DOI 10.1006/dbio.1998.9190; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; Yi SE, 2000, DEVELOPMENT, V127, P621; Yi SE, 2001, P NATL ACAD SCI USA, V98, P7994, DOI 10.1073/pnas.141002798	30	297	309	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					408	410		10.1038/ng1003	http://dx.doi.org/10.1038/ng1003			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12368913				2022-12-25	WOS:000179034800017
J	Mota, MM; Hafalla, JCR; Rodriguez, A				Mota, MM; Hafalla, JCR; Rodriguez, A			Migration through host cells activates Plasmodium sporozoites for infection	NATURE MEDICINE			English	Article							TOXOPLASMA-GONDII; GLIDING MOTILITY; INVASION; PROTEINS; ANTIBODIES; SECRETION; BERGHEI; HEPATOCYTES; MEROZOITES; MICROSCOPY	Plasmodium sporozoites, the infective stage of the malaria parasite transmitted by mosquitoes, migrate through several hepatocytes before infecting a final one. Migration through hepatocytes occurs by breaching their plasma membranes, and final infection takes place with the formation of a vacuole around the sporozoite(1). Once in the liver, sporozoites have already reached their target cells, making migration through hepatocytes prior to infection seem unnecessary. Here we show that this migration is required for infection of hepatocytes. Migration through host cells, but not passive contact with hepatocytes, induces the exocytosis of sporozoite apical organelles, a prerequisite for infection with formation of a vacuole. Sporozoite activation induced by migration through host cells is an essential step of Plasmodium life cycle.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10012 USA; NYU, Sch Med, Dept Pathol, New York, NY USA	New York University; New York University	Rodriguez, A (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10012 USA.		Mota, Maria/AAF-2048-2019	Mota, Maria Manuel/0000-0002-2858-1041; Rodriguez, Ana/0000-0002-0060-3405	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049432] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 49432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANNISTER LH, 1989, J PROTOZOOL, V36, P362, DOI 10.1111/j.1550-7408.1989.tb05527.x; Blanco ARA, 1999, MOL BIOCHEM PARASIT, V98, P163, DOI 10.1016/S0166-6851(98)00162-5; Briones MRS, 1996, MOL BIOCHEM PARASIT, V77, P7, DOI 10.1016/0166-6851(96)02574-1; Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X; Bumstead J, 2000, MOL BIOCHEM PARASIT, V110, P311, DOI 10.1016/S0166-6851(00)00280-2; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; CHOBOTAR B, 1993, PARASITOL RES, V79, P15, DOI 10.1007/BF00931212; Coppens I, 1999, EUR J CELL BIOL, V78, P463, DOI 10.1016/S0171-9335(99)80073-9; DANFORTH HD, 1992, PARASITOL RES, V78, P570, DOI 10.1007/BF00936454; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Howard RF, 1998, MOL BIOCHEM PARASIT, V92, P111, DOI 10.1016/S0166-6851(97)00238-7; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Matuschewski K, 2001, MOL BIOCHEM PARASIT, V112, P157, DOI 10.1016/S0166-6851(00)00360-1; MCNEIL PL, 1999, CURRENT PROTOCOLS S2, V2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mota MM, 2001, MICROBES INFECT, V3, P1123, DOI 10.1016/S1286-4579(01)01473-3; Mota MM, 2000, EXP PARASITOL, V96, P257, DOI 10.1006/expr.2000.4570; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Speer CA, 1997, J PARASITOL, V83, P565, DOI 10.2307/3284226; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	24	139	146	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1318	1322		10.1038/nm785	http://dx.doi.org/10.1038/nm785			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379848				2022-12-25	WOS:000179221200040
J	Perretti, M; Chiang, N; La, M; Fierro, IM; Marullo, S; Getting, SJ; Solito, E; Serhan, CN				Perretti, M; Chiang, N; La, M; Fierro, IM; Marullo, S; Getting, SJ; Solito, E; Serhan, CN			Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A(4) receptor	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR; NONPHLOGISTIC PHAGOCYTOSIS; HUMAN-LEUKOCYTES; LEUKOTRIENE B-4; ANNEXIN I; NEUTROPHILS; INHIBITION; DEXAMETHASONE; INFLAMMATION; MECHANISMS	Aspirin (ASA) and dexamethasone (DEX) are widely used anti-inflammatory agents yet their mechanism(s) for blocking polymorphonuclear neutrophil (PMN) accumulation at sites of inflammation remains unclear. Here, we report that inhibition of PMN infiltration by ASA and DEX is a property shared by aspirin-triggered lipoxins (ATL) and the glucocorticoid-induced annexin 1 (ANXA1)-derived peptides that are both generated in vivo and act at the lipoxin A(4) receptor (ALXR/FPRL1) to halt PMN diapedesis. These structurally diverse ligands specifically interact directly with recombinant human ALXR demonstrated by specific radioligand binding and function as well as immunoprecipitation of PMN receptors. In addition, the combination of both ATL and ANXA1-derived peptides limited PMN infiltration and reduced production of inflammatory mediators (that is, prostaglandins and chemokines) in vivo. Together, these results indicate functional redundancies in endogenous lipid and peptide anti-inflammatory circuits that are spatially and temporally separate, where both ATL and specific ANXA1-derived peptides act in concert at ALXR to downregulate PMN recruitment to inflammatory loci.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Dept Biochem Pharmacol, London, England; Harvard Univ, Sch Med, Boston, MA USA; ICGM, Dept Cell Biol, Paris, France; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Neuroendocrinol, London, England	Harvard University; Brigham & Women's Hospital; University of London; Queen Mary University London; Harvard University; Harvard Medical School; Universite de Montpellier; Imperial College London	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Marullo, Stefano/C-6142-2008; Fierro, Iolanda/AAJ-2705-2021; Chiang, Nan/ABA-4924-2021	Marullo, Stefano/0000-0001-9604-9973; Chiang, Nan/0000-0003-1963-1585; Solito, Egle/0000-0001-5279-0049	Arthritis Research UK [15755] Funding Source: Medline; NIDCR NIH HHS [P01 DE013499, P01-DE13499] Funding Source: Medline; NIGMS NIH HHS [R37 GM038765, R01 GM038765, GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	Arthritis Research UK(Versus Arthritis); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ariel A, 1998, J IMMUNOL, V161, P2465; Barnes CJ, 1997, DIGEST DIS SCI, V42, P920, DOI 10.1023/A:1018812430512; BOUMPAS DT, 2001, ARTHRITIS ALLIED CON, P827; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Cotran R.S., 1999, INFLAMMATION BASIC P, P5; Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1; CRONSTEIN BN, 1995, ANNU REV PHARMACOL, V35, P449, DOI 10.1146/annurev.pa.35.040195.002313; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; JICK H, 1965, LANCET, V2, P1203; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LINKE RP, 1991, BIOCHEM BIOPH RES CO, V176, P1100, DOI 10.1016/0006-291X(91)90397-P; Liu YQ, 1999, J IMMUNOL, V162, P3639; MARCUS AJ, 1995, NEW ENGL J MED, V333, P656, DOI 10.1056/NEJM199509073331011; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; Papayianni A, 1996, J IMMUNOL, V156, P2264; PATRONO C, 2001, AM J MED, V110, P625; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; Serhan CN, 2000, AM J RESP CRIT CARE, V161, pS95, DOI 10.1164/ajrccm.161.supplement_1.ltta-19; SIN YM, 1986, ANN RHEUM DIS, V45, P873, DOI 10.1136/ard.45.10.873; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	38	364	383	5	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1296	1302		10.1038/nm786	http://dx.doi.org/10.1038/nm786			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368905	Green Accepted			2022-12-25	WOS:000179221200037
J	Yu, BJ; Sung, BH; Koob, MD; Lee, CH; Lee, JH; Lee, WS; Kim, MS; Kim, SC				Yu, BJ; Sung, BH; Koob, MD; Lee, CH; Lee, JH; Lee, WS; Kim, MS; Kim, SC			Minimization of the Escherichia coli genome using a Tn5-targeted Cre/loxP excision system	NATURE BIOTECHNOLOGY			English	Article							GENETIC-ANALYSIS; LARGE SEGMENTS; ELECTROPORATION; AMPLIFICATION; MUTANTS; K-12; LIFE	An increasing number of microbial genomes have been completely sequenced, and functional analyses of these genomic sequences are under way. To facilitate these analyses, we have developed a genome-engineering tool for determining essential genes and minimizing bacterial genomes. We made two large pools of independent transposon mutants in Escherichia coli using modified Tn5 transposons with two different selection markers and precisely mapped the chromosomal location of 800 of these transposons. By combining a mapped transposon mutation from each of the mutant pools into the same chromosome using phage P1 transduction and then excising the flanked genomic segment by Cre-mediated loxP recombination, we obtained E. coli strains in which large genomic fragments (59-117 kilobases) were deleted. Some of these individual deletions were then combined into a single "cumulative deletion strain" that lacked 287 open reading frames (313.1 kilobases) but that nevertheless exhibited normal growth under standard laboratory conditions.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Korea Inst Energy Res, Biomass Team, Taejon 305343, South Korea	Korea Advanced Institute of Science & Technology (KAIST); University of Minnesota System; University of Minnesota Twin Cities; Korea Institute of Energy Research (KIER)	Kim, SC (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Kim, Sun/GSN-4867-2022; Kim, Sun Chang/C-2026-2011	Sung, Bong Hyun/0000-0002-8992-1118				Akerley BJ, 2002, P NATL ACAD SCI USA, V99, P966, DOI 10.1073/pnas.012602299; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Goryshin IY, 2000, NAT BIOTECHNOL, V18, P97, DOI 10.1038/72017; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HASAN N, 1994, GENE, V150, P51, DOI 10.1016/0378-1119(94)90856-7; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; Kolisnychenko V, 2002, GENOME RES, V12, P640, DOI 10.1101/gr.217202; KOOB MD, 1994, ANN NY ACAD SCI, V745, P1; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; POSFAI G, 1994, NUCLEIC ACIDS RES, V22, P2392, DOI 10.1093/nar/22.12.2392; Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SCHMID MB, 1989, GENETICS, V123, P625; SZYBALSKI W, 1993, GENE, V135, P279, DOI 10.1016/0378-1119(93)90078-H; Tao H, 1999, J BACTERIOL, V181, P6425, DOI 10.1128/JB.181.20.6425-6440.1999; Thompson JR, 1998, YEAST, V14, P565, DOI 10.1002/(SICI)1097-0061(19980430)14:6<565::AID-YEA251>3.0.CO;2-B; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yoon YG, 1998, GENET ANAL-BIOMOL E, V14, P89, DOI 10.1016/S1050-3862(97)10005-5	24	108	132	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					1018	1023		10.1038/nbt740	http://dx.doi.org/10.1038/nbt740			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12244329				2022-12-25	WOS:000178313100019
J	Towers, GJ; Hatziioannou, T; Cowan, S; Goff, SP; Luban, J; Bieniasz, PD				Towers, GJ; Hatziioannou, T; Cowan, S; Goff, SP; Luban, J; Bieniasz, PD			Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOSPORINE-A; RETROVIRUS RESTRICTION; REVERSE TRANSCRIPTION; SIMIAN CELLS; REPLICATION; PROTEIN; BLOCK; GENE; INFECTIVITY	Many mammalian species express restriction factors that confer host resistance to retroviral infection. Here we show that HIV-1 sensitivity to restriction factors is modulated by cyclophilin A (CypA), a host cell protein that binds the HIV-1 capsid protein (CA). In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased >100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding. Conversely, disruption of CA-CypA interaction in human cells reveals that CypA protects HIV-1 from the Ref-1 restriction factor. These findings suggest that HIV-1 has co-opted a host cell protein to counteract restriction factors expressed by human cells and that this adaptation can confer sensitivity to restriction in unnatural hosts. Manipulation of HIV-1 CA recognition by restriction factors promises to advance animal models and new therapeutic strategies for HIV-1 and AIDS.	Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; UCL, Windeyer Inst, Dept Immunol & Mol Pathol, Wohl Virion Ctr, London W1T 4JF, England; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Rockefeller University; Columbia University; University of London; University College London; Columbia University; Howard Hughes Medical Institute; Columbia University	Bieniasz, PD (corresponding author), Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	pbienias@adarc.org	Goff, Stephen P/K-6337-2014; Towers, Greg J/H-8892-2012	Goff, Stephen P/0000-0003-0693-5547; Towers, Gregory/0000-0002-7707-0264; Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199, R01AI050111] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI36199, R01AI50111, R01 AI036199] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bukovsky AA, 1997, P NATL ACAD SCI USA, V94, P10943, DOI 10.1073/pnas.94.20.10943; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Goff SP, 1996, CELL, V86, P691, DOI 10.1016/S0092-8674(00)80141-5; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Kozak CA, 1996, VIROLOGY, V225, P300, DOI 10.1006/viro.1996.0604; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Stoye JP, 2002, P NATL ACAD SCI USA, V99, P11549, DOI 10.1073/pnas.192449399; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Towers G, 2002, J VIROL, V76, P2548, DOI 10.1128/JVI.76.5.2548-2550.2002; Towers G, 2000, P NATL ACAD SCI USA, V97, P12295, DOI 10.1073/pnas.200286297; Wiegers K, 2002, VIROLOGY, V294, P289, DOI 10.1006/viro.2001.1347; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051	27	315	326	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1138	1143		10.1038/nm910	http://dx.doi.org/10.1038/nm910			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12897779				2022-12-25	WOS:000185061600025
J	Deane, R; Yan, SD; Submamaryan, RK; LaRue, B; Jovanovic, S; Hogg, E; Welch, D; Manness, L; Lin, C; Yu, J; Zhu, H; Ghiso, J; Frangione, B; Stern, A; Schmidt, AM; Armstrong, DL; Arnold, B; Liliensiek, B; Nawroth, P; Hofman, F; Kindy, M; Stern, D; Zlokovic, B				Deane, R; Yan, SD; Submamaryan, RK; LaRue, B; Jovanovic, S; Hogg, E; Welch, D; Manness, L; Lin, C; Yu, J; Zhu, H; Ghiso, J; Frangione, B; Stern, A; Schmidt, AM; Armstrong, DL; Arnold, B; Liliensiek, B; Nawroth, P; Hofman, F; Kindy, M; Stern, D; Zlokovic, B			RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TRANSGENIC MICE; MOUSE MODEL; PRECURSOR PROTEIN; SQUIRREL-MONKEY; IN-VIVO; RECEPTOR; CLEARANCE; FLOW	Amyloid-beta peptide (Abeta) interacts with the vasculature to influence Abeta levels in the brain and cerebral blood flow, providing a means of amplifying the Abeta-induced cellular stress underlying neuronal dysfunction and dementia. Systemic Abeta infusion and studies in genetically manipulated mice show that Abeta interaction with receptor for advanced glycation end products (RAGE)-bearing cells in the vessel wall results in transport of Abeta across the blood-brain barrier (BBB) and expression of proinflammatory cytokines and endothelin-1 (ET-1), the latter mediating Abeta-induced vasoconstriction. Inhibition of RAGE-ligand interaction suppresses accumulation of Abeta in brain parenchyma in a mouse transgenic model. These findings suggest that vascular RAGE is a target for inhibiting pathogenic consequences of Abeta-vascular interactions, including development of cerebral amyloidosis.	Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Labs Neurosurg, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Div Neurovasc Biol, Rochester, NY 14642 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Univ So Calif, Sch Med, Dept Neurosurg, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ Kentucky, Sch Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; Heidelberg Univ, Dept Internal Med, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Canc Res, D-69117 Heidelberg, Germany; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA	University of Rochester; University of Rochester; Columbia University; Columbia University; University of Southern California; University of Southern California; University of Kentucky; New York University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University System of Georgia; Augusta University	Zlokovic, B (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Labs Neurosurg, Rochester, NY 14642 USA.	Berislav_Zlokovic@urmc.rochester.edu		Armstrong, Don/0000-0002-4904-638X	NIA NIH HHS [AG16223] Funding Source: Medline; NINDS NIH HHS [NS34467] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034467, R01NS034467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG016223] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bading JR, 2002, J DRUG TARGET, V10, P359, DOI 10.1080/10611860290031831; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; DEMATTOS RB, 2003, ABETA METABOLISM ALZ, P123; ESTRADA C, 1995, J CEREBR BLOOD F MET, V15, P920, DOI 10.1038/jcbfm.1995.117; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Ghilardi JR, 1996, NEUROREPORT, V7, P2607, DOI 10.1097/00001756-199611040-00040; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Khalil Z, 1996, BRAIN RES, V736, P206; Mackic JB, 2002, VASC PHARMACOL, V38, P303, DOI 10.1016/S1537-1891(02)00198-2; Mackic JB, 1998, J NEUROCHEM, V70, P210; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; MANESS LM, 1994, LIFE SCI, V55, P1643, DOI 10.1016/0024-3205(94)00331-9; Martel CL, 1996, NEUROSCI LETT, V206, P157, DOI 10.1016/S0304-3940(96)12462-9; Martel CL, 1997, J NEUROCHEM, V69, P1995; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; Niwa K, 2002, NEUROBIOL DIS, V9, P61, DOI 10.1006/nbdi.2001.0460; Niwa K, 2000, P NATL ACAD SCI USA, V97, P9735, DOI 10.1073/pnas.97.17.9735; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; Wengenack TM, 2000, NAT BIOTECHNOL, V18, P868, DOI 10.1038/78482; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Zlokovic BV, 2000, NAT MED, V6, P718, DOI 10.1038/77397; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	45	1068	1151	1	102	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					907	913		10.1038/nm890	http://dx.doi.org/10.1038/nm890			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808450				2022-12-25	WOS:000183979300032
J	Hess, D; Li, L; Martin, M; Sakano, S; Hill, D; Strutt, B; Thyssen, S; Gray, DA; Bhatia, M				Hess, D; Li, L; Martin, M; Sakano, S; Hill, D; Strutt, B; Thyssen, S; Gray, DA; Bhatia, M			Bone marrow-derived stem cells initiate pancreatic regeneration	NATURE BIOTECHNOLOGY			English	Article							MICE LACKING; DIFFERENTIATION; PLASTICITY; ENDOCRINE; GROWTH; BRAIN; LIVER; PDX-1; VIVO	We show that transplantation of adult bone marrow-derived cells expressing c-kit reduces hyperglycemia in mice with streptozotocin- induced pancreatic damage. Although quantitative analysis of the pancreas revealed a low frequency of donor insulin-positive cells, these cells were not present at the onset of blood glucose reduction. Instead, the majority of transplanted cells were localized to ductal and islet structures, and their presence was accompanied by a proliferation of recipient pancreatic cells that resulted in insulin production. The capacity of transplanted bone marrow-derived stem cells to initiate endogenous pancreatic tissue regeneration represents a previously unrecognized means by which these cells can contribute to the restoration of organ function.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, London, ON N6A 4B8, Canada; Asahi Kasei Corp, Cent R&D & Cent Res Lab, Shizuoka 4168501, Japan; Lawson Hlth Res Inst, London, ON N6A 4V2, Canada; Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Asahi Kasei Corporation; Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute	Bhatia, M (corresponding author), John P Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	mbhatia@robarts.ca	Hess, David A/M-2828-2013; Hill, David J/G-3302-2011; Sakano, Seiji/AAG-1640-2019; /U-3554-2018	Hill, David J/0000-0002-2490-5678; /0000-0002-8634-4984				Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Elliott JI, 1997, CLIN EXP IMMUNOL, V109, P116, DOI 10.1046/j.1365-2249.1997.4241319.x; GERLING IC, 1994, DIABETES, V43, P433, DOI 10.2337/diabetes.43.3.433; Haluzik M, 2000, PHYSIOL RES, V49, pS37; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lammert E, 2003, MECH DEVELOP, V120, P59, DOI 10.1016/S0925-4773(02)00332-5; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; Offield MF, 1996, DEVELOPMENT, V122, P983; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ortiz M, 1999, IMMUNITY, V10, P173, DOI 10.1016/S1074-7613(00)80018-7; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Peters J, 2000, VIRCHOWS ARCH, V436, P527, DOI 10.1007/s004280000208; Pittenger MF, 2000, CURR TOP MICROBIOL, V251, P3; QUESENBERRY P, 1985, EXP HEMATOL, V13, P43; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rajagopal J, 2003, SCIENCE, V299, P363; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Springer ML, 2001, J CLIN INVEST, V107, P1355, DOI 10.1172/JCI13248; Tsai RYL, 2002, DEV CELL, V2, P707, DOI 10.1016/S1534-5807(02)00195-8; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521; ZYSSET T, 1986, EXPERIENTIA, V42, P560, DOI 10.1007/BF01946703	38	482	591	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					763	770		10.1038/nbt841	http://dx.doi.org/10.1038/nbt841			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12819790				2022-12-25	WOS:000183886000028
J	Carlton, VEH; Harris, BZ; Puffenberger, EG; Batta, AK; Knisely, AS; Robinson, DL; Strauss, KA; Schneider, BL; Lim, WA; Salen, G; Morton, DH; Bull, LN				Carlton, VEH; Harris, BZ; Puffenberger, EG; Batta, AK; Knisely, AS; Robinson, DL; Strauss, KA; Schneider, BL; Lim, WA; Salen, G; Morton, DH; Bull, LN			Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT	NATURE GENETICS			English	Article							TIGHT JUNCTIONS; EXTRAHEPATIC CHOLESTASIS; PDZ DOMAINS; HUMAN LIVER; EXPRESSION; TRANSPORT; PROTEINS; ZO-2	Familial hypercholanemia (FHC) is characterized by elevated serum bile acid concentrations, itching, and fat malabsorption(1,2). We show here that FHC in Amish individuals is associated with mutations in tight junction protein 2 (encoded by TJP2, also known as ZO-2) and bile acid Coenzyme A: amino acid N-acyltransferase (encoded by BAAT). The mutation of TJP2, which occurs in the first PDZ domain, reduces domain stability and ligand binding in vitro. We noted a morphological change in hepatic tight junctions. The mutation of BAAT, a bile acid-conjugating enzyme(3), abrogates enzyme activity; serum of individuals homozygous with respect to this mutation contains only unconjugated bile acids. Mutations in both TJP2 and BAAT may disrupt bile acid transport and circulation. Inheritance seems to be oligogenic, with genotype at BAAT modifying penetrance in individuals homozygous with respect to the mutation in TJP2.	Univ Calif San Francisco, San Francisco Gen Hosp, Liver Ctr Lab, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA; Clin Special Children, Strasburg, PA 17579 USA; Vet Affairs Med Ctr, E Orange, NJ 07018 USA; Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England; Mt Sinai Sch Med, Dept Pediat, Div Pediat Hematol, New York, NY 10029 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center	Bull, LN (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Liver Ctr Lab, San Francisco, CA 94110 USA.	lbull@medsfgh.ucsf.edu		Puffenberger, Erik/0000-0002-6388-9148				Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Chen JH, 1996, J FOOD DRUG ANAL, V4, P57; Colas JF, 2001, DEV DYNAM, V221, P117, DOI 10.1002/dvdy.1144; DAWSON PA, 2002, GASTROINTESTINAL LIV, P1051; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hostetler John, 1993, AMISH SOC, DOI 10.2307/539066; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KOGA A, 1978, CELL TISSUE RES, V195, P267; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Mahapatra AK, 2002, PEDIATR NEUROSURG, V36, P113, DOI 10.1159/000048365; McCarthy KM, 2000, J CELL SCI, V113, P3387; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Morton DH, 2000, GASTROENTEROLOGY, V119, P188, DOI 10.1053/gast.2000.8547; Noe J, 2002, GASTROENTEROLOGY, V123, P1659, DOI 10.1053/gast.2002.36587; Rahner C, 1996, GASTROENTEROLOGY, V110, P1564, DOI 10.1053/gast.1996.v110.pm8613064; RONCHI G, 1973, BEITR PATHOL, V150, P316; Setchell KDR, 2001, LIVER DIS CHILDREN, P701; Shneider BL, 1997, HEPATOLOGY, V25, P1176, DOI 10.1002/hep.510250521; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088	25	208	219	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					91	96		10.1038/ng1147	http://dx.doi.org/10.1038/ng1147			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12704386				2022-12-25	WOS:000182667900023
J	Chen, LW; Egan, L; Li, ZW; Greten, FR; Kagnoff, MF; Karin, M				Chen, LW; Egan, L; Li, ZW; Greten, FR; Kagnoff, MF; Karin, M			The two faces of IKK and NF-kappa B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; MICE LACKING; ACTIVATION; KINASE; ALPHA; SEPSIS; APOPTOSIS; RECEPTOR; DISEASE; SUBUNIT	We studied the role of NF-kappaB in acute inflammation caused by gut ischemia-reperfusion through selective ablation of IkappaB kinase (IKK)-beta, the catalytic subunit of IKK that is essential for NF-kappaB activation. Ablation of IKK-beta in enterocytes prevented the systemic inflammatory response, which culminates in multiple organ dysfunction syndrome (MODS) that is normally triggered by gut ischemia-reperfusion. IKK-beta removal from enterocytes, however, also resulted in severe apoptotic damage to the reperfused intestinal mucosa. These results show the dual function of the NF-kappaB system, which is responsible for both tissue protection and systemic inflammation, and underscore the caution that should be exerted in using NF-kappaB and IKK inhibitors.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, Lab Mucosal Immun, San Diego, CA 92103 USA; Natl Yang Ming Med Univ, Kaohsiung Vet Gen Hosp, Dept Surg, Taipei, Taiwan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, San Diego, CA 92103 USA.		Greten, Florian R/AAF-5196-2020	Greten, Florian R/0000-0002-3928-6080				Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Balk RA, 2000, CRIT CARE CLIN, V16, P337, DOI 10.1016/S0749-0704(05)70113-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CATY MG, 1990, ANN SURG, V212, P694, DOI 10.1097/00000658-199012000-00007; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fukatsu K, 2001, ANN SURG, V233, P660, DOI 10.1097/00000658-200105000-00010; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lewis Susan E., 1996, Methods (Orlando), V10, P301, DOI 10.1006/meth.1996.0107; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LI ZW, IN PRESS J IMMUNOL; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pennington C, 2000, AM SURGEON, V66, P914; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; SCHMELING DJ, 1989, SURGERY, V106, P201; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677	29	403	423	1	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					575	581		10.1038/nm849	http://dx.doi.org/10.1038/nm849			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692538				2022-12-25	WOS:000182610600039
J	Sasaki, A; Taketomi, T; Kato, R; Saeki, K; Nonami, A; Sasaki, M; Kuriyama, M; Saito, N; Shibuya, M; Yoshimura, A				Sasaki, A; Taketomi, T; Kato, R; Saeki, K; Nonami, A; Sasaki, M; Kuriyama, M; Saito, N; Shibuya, M; Yoshimura, A			Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1	NATURE CELL BIOLOGY			English	Article							KINASE-ACTIVITY; GROWTH; RECEPTOR; PATHWAY; ANTAGONIST; FGF; IDENTIFICATION; EXPRESSION; INHIBITOR; PROTEINS	The signalling cascade including Raf, mitogen-activated protein kinase (MAPK) kinase and extracellular-signal-regulated kinase (ERK) is important in many facets of cellular regulation(1-3). Raf is activated through both Ras-dependent and Ras-independent mechanisms(4-6), but the regulatory mechanisms of Raf activation remain unclear(7-9). Two families of membrane-bound molecules, Sprouty and Sprouty-related EVH1-domain-containing protein (Spred) have been identified(10-13) and characterized as negative regulators of growth-factor-induced ERK activation(14-25). But the molecular functions of mammalian Sproutys have not been clarified. Here we show that mammalian Sprouty4 suppresses vascular epithelial growth factor (VEGF)-induced, Ras-independent activation of Raf1 but does not affect epidermal growth factor (EGF)-induced, Ras-dependent activation of Raf1. Sprouty4 binds to Raf1 through its carboxy-terminal cysteine-rich domain, and this binding is necessary for the inhibitory activity of Sprouty4. In addition, Sprouty4 mutants of the amino-terminal region containing the conserved tyrosine residue, which is necessary for suppressing fibroblast growth factor signalling(19,25), still inhibit the VEGF-induced ERK pathway. Our results show that receptor tyrosine kinases use distinct pathways for Raf and ERK activation and that Sprouty4 differentially regulates these pathways.	Kyushu Univ, Div Mol & Cellular Immunol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Kobe Univ, Mol Pharmacol Lab, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Univ Tokyo, Div Genet, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	Kyushu University; Kobe University; University of Tokyo	Yoshimura, A (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Div Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Sasaki, Atsuo/0000-0003-2963-4501				Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Minowada G, 1999, DEVELOPMENT, V126, P4465; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Reich A, 1999, DEVELOPMENT, V126, P4139; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	30	204	212	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					427	432		10.1038/ncb978	http://dx.doi.org/10.1038/ncb978			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717443				2022-12-25	WOS:000182691400016
J	Cooper, MK; Wassif, CA; Krakowiak, PA; Taipale, J; Gong, RY; Kelley, RI; Porter, FD; Beachy, PA				Cooper, MK; Wassif, CA; Krakowiak, PA; Taipale, J; Gong, RY; Kelley, RI; Porter, FD; Beachy, PA			A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis	NATURE GENETICS			English	Article							LEMLI-OPITZ-SYNDROME; A REDUCTASE-ACTIVITY; FLOOR PLATE; INHIBITION; FIBROBLASTS; CYCLOPAMINE; BINDING; CYCLODEXTRINS; INDUCTION; PROTEINS	Smith-Lemli-Opitz syndrome (SLOS), desmosterolosis and lathosterolosis are human syndromes caused by defects in the final stages of cholesterol biosynthesis. Many of the developmental malformations in these syndromes occur in tissues and structures whose embryonic patterning depends on signaling by the Hedgehog (Hh) family of secreted proteins. Here we report that response to the Hh signal is compromised in mutant cells from mouse models of SLOS and lathosterolosis and in normal cells pharmacologically depleted of sterols. We show that decreasing levels of cellular sterols correlate with diminishing responsiveness to the Hh signal. This diminished response occurs at sterol levels sufficient for normal autoprocessing of Hh protein, which requires cholesterol as cofactor and covalent adduct. We further find that sterol depletion affects the activity of Smoothened (Smo), an essential component of the Hh signal transduction apparatus.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Howard Hughes Med Inst, Baltimore, MD 21205 USA; NICHHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Kennedy Krieger Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kennedy Krieger Institute	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.			Wassif, Christopher/0000-0002-2524-1420	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000139] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000139] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; BITTMAN R, 1972, P NATL ACAD SCI USA, V69, P3795, DOI 10.1073/pnas.69.12.3795; BROWN MS, 1978, J BIOL CHEM, V253, P1121; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Clayton P, 1996, LANCET, V348, P404, DOI 10.1016/S0140-6736(05)65020-9; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DONNAI D, 1987, AM J MED GENET, V28, P741, DOI 10.1002/ajmg.1320280323; GIBSON KM, 1990, J LIPID RES, V31, P515; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guy RK, 2000, P NATL ACAD SCI USA, V97, P7307, DOI 10.1073/pnas.97.13.7307; Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775; Ingham PW, 2001, SCIENCE, V294, P1879, DOI 10.1126/science.1064115; Kelley R I, 2000, Adv Pediatr, V47, P1; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; MATSUNAGA E, 1977, TERATOLOGY, V16, P261, DOI 10.1002/tera.1420160304; Nowaczyk MJM, 2001, AM J MED GENET, V102, P18, DOI 10.1002/1096-8628(20010722)102:1<18::AID-AJMG1376>3.0.CO;2-E; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; PARNES S, 1990, AM J MED GENET, V35, P397, DOI 10.1002/ajmg.1320350317; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wassink TH, 2001, PSYCHIAT GENET, V11, P57, DOI 10.1097/00041444-200106000-00001	30	298	307	1	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					508	513		10.1038/ng1134	http://dx.doi.org/10.1038/ng1134			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12652302	Bronze			2022-12-25	WOS:000181928600023
J	Drenth, JPH; Morsche, RHMT; Smink, R; Bonifacino, JS; Jansen, JBMJ				Drenth, JPH; Morsche, RHMT; Smink, R; Bonifacino, JS; Jansen, JBMJ			Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease	NATURE GENETICS			English	Article							PROTEIN-KINASE-C; KIDNEY-DISEASE; GENE; ENCODES; IDENTIFICATION; RECEPTORS; CELLS	Polycystic liver disease (PCLD, OMIM 174050) is a dominantly inherited condition characterized by the presence of multiple liver cysts of biliary epithelial origin. Fine mapping established linkage to marker D19S581 (Z(max)=9.65; theta=0.01) in four large Dutch families with PCLD. We identified a splice-acceptor site mutation (1138-2A-->G) in PRKCSH in three families, and a splice-donor site mutation (292+1G-->C) in PRKCSH segregated completely with PCLD in another family. The protein encoded by PRKCSH, here named hepatocystin, is predicted to localize to the endoplasmic reticulum. These findings establish germline mutations in PRKCSH as the probable cause of PCLD.	Univ Med Ctr St Radboud, Dept Med, Div Gastroenterol & Hepatol, Nijmegen, Netherlands; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	Radboud University Nijmegen; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Drenth, JPH (corresponding author), Univ Med Ctr St Radboud, Dept Med, Div Gastroenterol & Hepatol, Nijmegen, Netherlands.		te Morsche, R/P-9143-2015; Drenth, J.P.H./H-8025-2014; Drenth, Joost/V-7436-2019	Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Curto M, 1998, BIOCHEM BIOPH RES CO, V243, P555, DOI 10.1006/bbrc.1997.7982; HIRAI M, 1990, BIOCHEM J, V270, P583, DOI 10.1042/bj2700583; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; Qian Q, 2003, HEPATOLOGY, V37, P164, DOI 10.1053/jhep.2003.50006; Reynolds DM, 2000, AM J HUM GENET, V67, P1598, DOI 10.1086/316904; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Trombetta ES, 2001, BIOCHEMISTRY-US, V40, P10717, DOI 10.1021/bi010629u; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; WARD CJ, 1994, CELL, V77, P881; Xiong HQ, 2002, GENOMICS, V80, P96, DOI 10.1006/geno.2002.6802	13	163	172	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					345	347		10.1038/ng1104	http://dx.doi.org/10.1038/ng1104			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12577059				2022-12-25	WOS:000181312700010
J	Takeuchi, A; Mishina, Y; Miyaishi, O; Kojima, E; Hasegawa, T; Isobe, K				Takeuchi, A; Mishina, Y; Miyaishi, O; Kojima, E; Hasegawa, T; Isobe, K			Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR; BINDING PROTEIN; P53 PROTEIN; MICE; DISRUPTION; ZBP-89; GENE; EXPRESSION; DEFICIENT	Zfp148 belongs to a large family of C2H2-type zinc-finger transcription factors. Zfp148 is expressed in fetal germ cells in 13.5-d-old (E13.5) mouse embryos. Germ-line transmission of mutations were not observed in chimeric Zfp148(+/-) mice, and some of these mice completely lacked spermatogonia. The number of primordial germ cells in Zfp148(+/-) tetraploid embryos was normal until E11.5, but declined from E11.5 to E13.5 and continued to decline until few germ cells were present at E18.5. This phenotype was not rescued by wild-type Sertoli or stromal cells, and is therefore a cell-autonomous phenotype. These results indicate that two functional alleles of Zfp148 are required for the normal development of fetal germ cells. Recent studies have shown that Zfp148 activates p53, which has an important role in cell-cycle regulation(1). Primordial germ cells stop proliferating at approximately E13.5, which correlates with induction of phosphorylation of p53 and its translocation to the nucleus. Phosphorylation of p53 is impaired in Zfp(148+/-) embryonic stem cells and in fetal germ cells from chimeric Zfp148(+/-) embryos. Thus, Zfp148 may be required for regulating p53 in the development of germ cells.	Natl Inst Longev Sci, Dept Basic Gerontol, Obu, Aichi 4748522, Japan; Natl Inst Environm Hlth Studies, Mol Dev Biol Grp, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo,Morioka Cho, Obu, Aichi 4748522, Japan.		Takeuchi, Akihide/AAT-4675-2020; isobe, ken-ichi/A-6685-2011	Takeuchi, Akihide/0000-0002-2781-0180; isobe, ken-ichi/0000-0002-8150-2496	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BUEHR M, 1993, METHOD ENZYMOL, V225, P58; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HOGAN B, 1994, MANIPULATING MOUSE E, P373; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAGY A, 1990, DEVELOPMENT, V110, P815; ROSAI J, 1996, ACKERMANS SURG PATHO, P1260; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wang ZQ, 1997, MECH DEVELOP, V62, P137, DOI 10.1016/S0925-4773(97)00655-2; WONG TW, 1973, ARCH PATHOL, V95, P151; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YOSHINAGA K, 1991, DIFFERENTIATION, V48, P75, DOI 10.1111/j.1432-0436.1991.tb00245.x; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	25	79	96	1	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					172	176		10.1038/ng1072	http://dx.doi.org/10.1038/ng1072			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12524542				2022-12-25	WOS:000180773700015
J	Kathuria, S; Gaetani, S; Fegley, D; Valino, F; Duranti, A; Tontini, A; Mor, M; Tarzia, G; La Rana, G; Calignano, A; Giustino, A; Tattoli, M; Palmery, M; Cuomo, V; Piomelli, D				Kathuria, S; Gaetani, S; Fegley, D; Valino, F; Duranti, A; Tontini, A; Mor, M; Tarzia, G; La Rana, G; Calignano, A; Giustino, A; Tattoli, M; Palmery, M; Cuomo, V; Piomelli, D			Modulation of anxiety through blockade of anandamide hydrolysis	NATURE MEDICINE			English	Article							ACID AMIDE HYDROLASE; CB1 CANNABINOID RECEPTORS; ELEVATED ZERO-MAZE; ENDOGENOUS CANNABINOIDS; BRAIN; ANTAGONIST; INHIBITORS; LOCALIZATION; ANXIOLYTICS; ACTIVATION	The psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Delta(9)-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA; Univ Urbino, Inst Med Chem, I-61029 Urbino, Italy; Univ Parma, Dept Pharmaceut, I-43100 Parma, Italy; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy; Univ Roma La Sapienza, Dept Pharmacol & Gen Physiol, Rome, Italy	University of California System; University of California Irvine; University of Urbino; University of Parma; University of Naples Federico II; Universita degli Studi di Bari Aldo Moro; Sapienza University Rome	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA.	piomelli@uci.edu	Gaetani, Silvana/D-3455-2009; cuomo, vincenzo/J-6777-2012; Cuomo, Vincenzo/D-2772-2009; Mor, Marco/D-2394-2009	Mor, Marco/0000-0003-0199-1849; giustino, arcangela/0000-0002-7962-9797; CALIGNANO, Antonio/0000-0002-1742-3179; TATTOLI, MARIA/0000-0002-4970-264X				Ali MM, 2000, NEUROSCI LETT, V284, P57, DOI 10.1016/S0304-3940(00)00958-7; Arevalo C, 2001, PHARMACOL BIOCHEM BE, V70, P123, DOI 10.1016/S0091-3057(01)00578-0; Beinfeld MC, 2001, NEUROSCI LETT, V301, P69, DOI 10.1016/S0304-3940(01)01591-9; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Beltramo M, 1997, FEBS LETT, V403, P263, DOI 10.1016/S0014-5793(97)00061-6; BICKERDIKE MJ, 1994, EUR J PHARMACOL, V271, P403, DOI 10.1016/0014-2999(94)90800-1; Boger DL, 2000, P NATL ACAD SCI USA, V97, P5044, DOI 10.1073/pnas.97.10.5044; Cahill L, 1998, TRENDS NEUROSCI, V21, P294, DOI 10.1016/S0166-2236(97)01214-9; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Chaperon F, 1999, CRIT REV NEUROBIOL, V13, P243, DOI 10.1615/CritRevNeurobiol.v13.i3.20; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CUOMO V, 1987, NEUROPHARMACOLOGY, V26, P701, DOI 10.1016/0028-3908(87)90230-9; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; Deutsch DG, 1997, BIOCHEM BIOPH RES CO, V231, P217, DOI 10.1006/bbrc.1997.6072; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Fink H, 1998, EXP BRAIN RES, V123, P77, DOI 10.1007/s002210050546; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; HALLER J, IN PRESS EUR J NEURO; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; INSEL TR, 1986, PHARMACOL BIOCHEM BE, V24, P1263, DOI 10.1016/0091-3057(86)90182-6; Iversen L, 2002, CURR OPIN PHARMACOL, V2, P50, DOI 10.1016/S1471-4892(01)00120-5; Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Martin M, 2002, PSYCHOPHARMACOLOGY, V159, P379, DOI 10.1007/s00213-001-0946-5; McDonald AJ, 2001, NEUROSCIENCE, V107, P641, DOI 10.1016/S0306-4522(01)00380-3; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MICZEK KA, 1995, PSYCHOPHARMACOLOGY, V121, P38, DOI 10.1007/BF02245590; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Robson P, 2001, BRIT J PSYCHIAT, V178, P107, DOI 10.1192/bjp.178.2.107; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Tseng AH, 2001, EUR J PHARMACOL, V430, P41, DOI 10.1016/S0014-2999(01)01267-5; Wedzony K, 2000, NEUROPSYCHOPHARMACOL, V23, P547, DOI 10.1016/S0893-133X(00)00150-0; WINSLOW JT, 1991, PROG NEURO-PSYCHOPH, V15, P745, DOI 10.1016/0278-5846(91)90003-J	45	1174	1232	2	84	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					76	81		10.1038/nm803	http://dx.doi.org/10.1038/nm803			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12461523	Green Submitted			2022-12-25	WOS:000180209900025
J	Romisch, K; Matheson, T				Romisch, K; Matheson, T			Cell biology in the Antarctic: studying life in the freezer	NATURE CELL BIOLOGY			English	Article							ANTIFREEZE PROTEINS; COLD-ADAPTATION; NOTOTHENIOID FISH; EVOLUTION; ENZYMES; PHYSIOLOGY; EXPRESSION; BINDING; YEAST; GENE		Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge; University of Cambridge; University of Cambridge	Romisch, K (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.			Matheson, Thomas/0000-0002-6061-9038				Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Bargelloni L, 1998, P NATL ACAD SCI USA, V95, P8670, DOI 10.1073/pnas.95.15.8670; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Carpenter EJ, 2000, APPL ENVIRON MICROB, V66, P4514, DOI 10.1128/AEM.66.10.4514-4517.2000; Chapelle G, 1999, NATURE, V399, P114, DOI 10.1038/20099; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; Cheng CHC, 1998, CURR OPIN GENET DEV, V8, P715, DOI 10.1016/S0959-437X(98)80042-7; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; Detrich HW, 2000, J BIOL CHEM, V275, P37038, DOI 10.1074/jbc.M005699200; DEVRIES AL, 1988, COMP BIOCHEM PHYS B, V90, P611, DOI 10.1016/0305-0491(88)90302-1; Dudley R, 2000, ANNU REV PHYSIOL, V62, P135, DOI 10.1146/annurev.physiol.62.1.135; EASTMAN JT, 1993, ANTARCTIC FISH BIOL, P220; Egginton S, 2002, J EXP BIOL, V205, P769; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Gianese G, 2001, PROTEIN ENG, V14, P141, DOI 10.1093/protein/14.3.141; Graether SP, 1999, J BIOL CHEM, V274, P11842, DOI 10.1074/jbc.274.17.11842; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; HEMMINGSEN EA, 1991, BIOL ANTARCTIC, P101; Hofmann GE, 2000, J EXP BIOL, V203, P2331; HUNT BM, IN PRESS ANTARCTIC S; Johnston IA, 1998, J EXP BIOL, V201, P1; Leinala EK, 2002, STRUCTURE, V10, P619, DOI 10.1016/S0969-2126(02)00745-1; Leiros HKS, 2000, EUR J BIOCHEM, V267, P1039; MACDONALD JA, 1987, ADV MAR BIOL, V24, P321; Marsh AG, 2001, SCIENCE, V291, P1950, DOI 10.1126/science.1056341; O'Brien KM, 2000, J EXP BIOL, V203, P1287; Petrescu I, 2000, EXTREMOPHILES, V4, P137, DOI 10.1007/s007920070028; Portner HO, 2002, J EXP BIOL, V205, P2217; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; SOMERO GN, 1967, SCIENCE, V156, P257, DOI 10.1126/science.156.3772.257; Tomczak MM, 2002, BIOPHYS J, V82, P874, DOI 10.1016/S0006-3495(02)75449-0; Verdier JM, 1996, EUR J BIOCHEM, V241, P740, DOI 10.1111/j.1432-1033.1996.00740.x; Wu Y, 2001, Biochim Biophys Acta, V1524, P11	38	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					3	6		10.1038/ncb0103-3	http://dx.doi.org/10.1038/ncb0103-3			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12511880				2022-12-25	WOS:000180223700002
J	Carter, D; Chakalova, L; Osborne, CS; Dai, YF; Fraser, P				Carter, D; Chakalova, L; Osborne, CS; Dai, YF; Fraser, P			Long-range chromatin regulatory interactions in vivo	NATURE GENETICS			English	Article							BETA-GLOBIN LOCUS; DNASEI HYPERSENSITIVE SITES; CONTROL REGION; GENE-EXPRESSION; DEVELOPMENTAL REGULATION; IN-VIVO; TRANSCRIPTION; ACTIVATION; UPSTREAM; ENHANCER	Communication between distal chromosomal elements is essential for control of many nuclear processes. For example, genes in higher eukaryotes often require distant enhancer sequences for high-level expression. The mechanisms proposed for long-range enhancer action fall into two basic categories. Non-contact models propose that enhancers act at a distance to create a favorable environment for gene transcription(1-3), or act as entry sites(4) or nucleation points(5) for factors that ultimately communicate with the gene. Contact models propose that communication occurs through direct interaction between the distant enhancer and the gene by various mechanisms that 'loop out' the intervening sequences(6-13). Although much attention has focused on contact models, the existence and nature of long-range interactions is still controversial and speculative, as there is no direct evidence that distant sequences physically interact in vivo(14). Here, we report the development of a widely applicable in situ technique to tag and recover chromatin in the immediate vicinity of an actively transcribed gene. We show that the classical enhancer element, HS2 of the prototypical locus control region (LCR) of the beta-globin gene cluster, is in close physical proximity to an actively transcribed HBB (beta-globin) gene located over 50 kb away in vivo, suggesting a direct regulatory interaction. The results give unprecedented insight into the in vivo structure of the LCR-gene interface and provide the first direct evidence of long-range enhancer communication.	Babraham Inst, Dev Genet Programme, Lab Chromat & Gene Express, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Fraser, P (corresponding author), Babraham Inst, Dev Genet Programme, Lab Chromat & Gene Express, Cambridge CB2 4AT, England.	peter.fraser@bbsrc.ac.uk	Osborne, Cameron/N-1398-2017; Fraser, Peter/B-7549-2009; Chakalova, Lyubomira/C-6810-2012	Osborne, Cameron/0000-0003-4126-2499; dai, dai yan feng/0000-0001-7147-1748; Fraser, Peter/0000-0002-0041-1227				Bender MA, 2000, BLOOD, V95, P3600, DOI 10.1182/blood.V95.11.3600.011k42_3600_3604; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bender MA, 2001, BLOOD, V98, P2022, DOI 10.1182/blood.V98.7.2022; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; Farrell CM, 2000, P NATL ACAD SCI USA, V97, P14554, DOI 10.1073/pnas.97.26.14554; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Iborra FJ, 1996, J CELL SCI, V109, P1427; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	24	474	497	2	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2002	32	4					623	626		10.1038/ng1051	http://dx.doi.org/10.1038/ng1051			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12426570				2022-12-25	WOS:000179593000014
J	Nakanishi, K; Taniguchi, T; Ranganathan, V; New, HV; Moreau, LA; Stotsky, M; Mathew, CG; Kastan, MB; Weaver, DT; D'Andrea, AD				Nakanishi, K; Taniguchi, T; Ranganathan, V; New, HV; Moreau, LA; Stotsky, M; Mathew, CG; Kastan, MB; Weaver, DT; D'Andrea, AD			Interaction of FANCD2 and NBS1 in the DNA damage response	NATURE CELL BIOLOGY			English	Article							NIJMEGEN BREAKAGE SYNDROME; FANCONI-ANEMIA PROTEINS; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; S-PHASE; NUCLEAR-LOCALIZATION; COMPLEX; REPAIR; BRCA1; ATM	Fanconi anaemia (FA) and Nijmegen breakage syndrome (NBS) are autosomal recessive chromosome instability syndromes with distinct clinical phenotypes. Cells from individuals affected with FA are hypersensitive to mitomycin C (MMC), and cells from those with NBS are hypersensitive to ionizing radiation. Here we report that both NBS cell lines and individuals with NBS are hypersensitive to MMC, indicating that there may be functional linkage between FA and NBS. In wild-type cells, MMC activates the colocalization of the FA subtype D2 protein (FANCD2) and NBS1 protein in subnuclear foci. Ionizing radiation activates the ataxia telangiectasia kinase (ATM)-dependent and NBS1-dependent phosphorylation of FANCD2, resulting in an S-phase checkpoint. NBS1 and FANCD2 therefore cooperate in two distinct cellular functions, one involved in the DNA crosslink response and one involved in the S-phase checkpoint response.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Great Ormond St Hosp Sick Children, Dept Haematol, London WC1N 3JH, England; Guys Kings & St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; King's College London; St Jude Children's Research Hospital	Nakanishi, K (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	alan_dandrea@dfci.harvard.edu	Taniguchi, Toshiyasu/ADD-8489-2022; Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Taniguchi, Toshiyasu/0000-0002-7746-3658				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KHANNA KK, 1998, CELLULAR RESPONSES D; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Naf D, 1998, MOL CELL BIOL, V18, P5952; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Resnick IB, 2002, J PEDIATR-US, V140, P355, DOI 10.1067/mpd.2002.122724; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Weemaes C M, 1993, Immunodeficiency, V4, P109; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wu X, 2000, Science, V289, P11; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	38	202	209	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					913	920		10.1038/ncb879	http://dx.doi.org/10.1038/ncb879			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447395				2022-12-25	WOS:000179571800010
J	Yang, ST; Kuo, C; Bisi, JE; Kim, MK				Yang, ST; Kuo, C; Bisi, JE; Kim, MK			PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2	NATURE CELL BIOLOGY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID; RAR-ALPHA; SUPPRESSES GROWTH; CANCER CELLS; CHK2; PROTEIN; PATHWAY; P53; EXPRESSION	The promyelocytic leukaemia (PML) gene is translocated in most acute promyelocytic leukaemias and encodes a tumour suppressor protein. PML is involved in multiple apoptotic pathways and is thought to be pivotal in gamma irradiation-induced apoptosis. The DNA damage checkpoint kinase hCds1/Chk2 is necessary for p53-dependent apoptosis after gamma irradiation. In addition, gamma irradiation-induced apoptosis also occurs through p53-independent mechanisms, although the molecular mechanism remains largely unknown. Here, we report that hCds1/Chk2 mediates gamma irradiation-induced apoptosis in a p53-independent manner through an ataxia telangiectasia-mutated (ATM)-hCds1/Chk2-PML pathway. Our results provide the first evidence of a functional relationship between PML and a checkpoint kinase in gamma irradiation-induced apoptosis.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; GlaxoSmithKline Inc, Dept Cellular Genom, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); GlaxoSmithKline	Yang, ST (corresponding author), NHLBI, Lab Biochem Genet, NIH, Bldg 10, Bethesda, MD 20892 USA.	KimM@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Chehab NH, 2000, GENE DEV, V14, P278; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Guidarelli A, 2001, EXP CELL RES, V270, P56, DOI 10.1006/excr.2001.5323; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He DL, 1997, CANCER RES, V57, P1868; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lukas C, 2001, CANCER RES, V61, P4990; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; ORENGO G, 1992, JPN J CANCER RES, V83, P1132, DOI 10.1111/j.1349-7006.1992.tb02735.x; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ruiter GA, 1999, CANCER RES, V59, P2457; Shieh SY, 2000, GENE DEV, V14, P750; Shieh SY, 2000, GENE DEV, V14, P289; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	41	191	200	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					865	870		10.1038/ncb869	http://dx.doi.org/10.1038/ncb869			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402044				2022-12-25	WOS:000179137700015
J	Carrasquillo, MM; McCallion, AS; Puffenberger, EG; Kashuk, CS; Nouri, N; Chakravarti, A				Carrasquillo, MM; McCallion, AS; Puffenberger, EG; Kashuk, CS; Nouri, N; Chakravarti, A			Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease	NATURE GENETICS			English	Article							ENDOTHELIN-B RECEPTOR; ENDOCRINE NEOPLASIA TYPE-2A; PROTEIN-COUPLED RECEPTORS; PHENOTYPIC-EXPRESSION; MISSENSE MUTATION; GROWTH-FACTOR; PROTOONCOGENE; LOCUS; CELLS; GENE	Genetic studies of Hirschsprung disease, a common congenital malformation, have identified eight genes with mutations that can be associated with this condition. Mutations at individual loci are, however, neither necessary nor sufficient to cause clinical disease. We conducted a genome-wide association study in 43 Mennonite family trios using 2,083 microsatellites and single-nucleotide polymorphisms and a new multipoint linkage disequilibrium method that searches for association arising from common ancestry. We identified susceptibility loci at 10q11, 13q22 and 16q23; the gene at 13q22 is EDNRB, encoding a G protein-coupled receptor (GPCR) and the gene at 10q11 is RET, encoding a receptor tyrosine kinase (RTK). Statistically significant joint transmission of RET and EDNRB alleles in affected individuals and non-complementation of aganglionosis in mouse intercrosses between Ret null and the Ednrb hypomorphic piebald allele are suggestive of epistasis between EDNRB and RET. Thus, genetic interaction between mutations in RET and EDNRB is an underlying mechanism for this complex disorder.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Clin Special Children, Strasburg, PA USA; Affymetrix Inc, Santa Clara, CA USA	Case Western Reserve University; Johns Hopkins University; Affymetrix	Chakravarti, A (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, 600 N Wolfe St,Jefferson St Bldg 2-109, Baltimore, MD 21287 USA.			Puffenberger, Erik/0000-0002-6388-9148				Amiel J, 2001, AM J HUM GENET, V69, P1370, DOI 10.1086/324342; Andrew SD, 2000, GENE, V256, P283, DOI 10.1016/S0378-1119(00)00302-4; Auricchio A, 1999, AM J HUM GENET, V64, P1216, DOI 10.1086/302329; BADNER JA, 1990, AM J HUM GENET, V46, P568; Bergey LL, 1992, PA MENNON HERIT, V15, P9; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Borrego S, 1999, J MED GENET, V36, P771, DOI 10.1136/jmg.36.10.771; Borrego S, 2000, J MED GENET, V37, P572, DOI 10.1136/jmg.37.8.572; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; Chakravarti A, 1996, HUM MOL GENET, V5, P303; CHAKRAVARTI A, 2001, METABOLIC MOL BASES, P6231; Fitze G, 1999, AM J HUM GENET, V65, P1469, DOI 10.1086/302618; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LANE PW, 1966, J HERED, V57, P181; Leibl MA, 1999, GUT, V44, P246, DOI 10.1136/gut.44.2.246; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nataf V, 1996, P NATL ACAD SCI USA, V93, P9645, DOI 10.1073/pnas.93.18.9645; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; PUFFETT D, 1994, MUSIC ANAL, V13, P3; Rhim H, 2000, GENOME RES, V10, P17; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; VAN BT, 1995, NATURE, V376, P781; WEBSTER W, 1974, ARCH PATHOL, V97, P111; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	37	209	217	1	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					237	244		10.1038/ng998	http://dx.doi.org/10.1038/ng998			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355085				2022-12-25	WOS:000178311100011
J	Otto, EA; Schermer, B; Obara, T; O'Toole, JF; Hiller, KS; Mueller, AM; Ruf, RG; Hoefele, J; Beekmann, F; Landau, D; Foreman, JW; Goodship, JA; Strachan, T; Kispert, A; Wolf, MT; Gagnadoux, MF; Nivet, H; Antignac, C; Walz, G; Drummond, IA; Benzing, T; Hildebrandt, F				Otto, EA; Schermer, B; Obara, T; O'Toole, JF; Hiller, KS; Mueller, AM; Ruf, RG; Hoefele, J; Beekmann, F; Landau, D; Foreman, JW; Goodship, JA; Strachan, T; Kispert, A; Wolf, MT; Gagnadoux, MF; Nivet, H; Antignac, C; Walz, G; Drummond, IA; Benzing, T; Hildebrandt, F			Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; ADOLESCENT NEPHRONOPHTHISIS; CANDIDATE GENE; SITUS-INVERSUS; PROTEIN; INTERACTS; NEPHROCYSTIN; IDENTIFICATION; PROGRESSION; PATHWAY	Nephronophthisis (NPHP), an autosomal recessive cystic kidney disease, leads to chronic renal failure in children. The genes mutated in NPHP1 and NPHP4 have been identified, and a gene locus associated with infantile nephronophthisis (NPHP2) was mapped. The kidney phenotype of NPHP2 combines clinical features of NPHP and polycystic kidney disease (PKD). Here, we identify inversin (INVS) as the gene mutated in NPHP2 with and without situs inversus. We show molecular interaction of inversin with nephrocystin, the product of the gene mutated in NPHP1 and interaction of nephrocystin with beta-tubulin, a main component of primary cilia. We show that nephrocystin, inversin and beta-tubulin colocalize to primary cilia of renal tubular cells. Furthermore, we produce a PKD-like renal cystic phenotype and randomization of heart looping by knockdown of invs expression in zebrafish. The interaction and colocalization in cilia of inversin, nephrocystin and beta-tubulin connect pathogenetic aspects of NPHP to PKD, to primary cilia function and to left-right axis determination.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Hosp Freiburg, Div Renal, Freiburg, Germany; Univ Hosp Freiburg, Clin Res Ctr, Freiburg, Germany; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Soroka Med Ctr, Dept Pediat, IL-84101 Beer Sheva, Israel; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Newcastle Univ, Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Hannover Med Sch, Inst Mol Biol, Hannover, Germany; Univ Paris 05, Necker Hosp, Dept Pediat Nephrol, Paris, France; Univ Paris 05, Necker Hosp, INSERM, U574, Paris, France; CHU Tours, Chambray Les Tours, France; Inst Reg Sante, Chambray Les Tours, France; Univ Paris 05, Necker Hosp, Dept Genet, Paris, France; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Freiburg; University of Freiburg; Harvard University; Massachusetts General Hospital; Harvard University; Ben Gurion University; Soroka Medical Center; Duke University; Newcastle University - UK; Hannover Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Michigan System; University of Michigan	Hildebrandt, F (corresponding author), Univ Michigan, Dept Pediat, 8220C MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	fhilde@umich.edu	Hoefele, Julia/AAB-6448-2020; Schermer, Bernhard/E-9972-2014; Benzing, Thomas/X-5476-2019; ANTIGNAC, Corinne/H-8945-2017	Hoefele, Julia/0000-0002-7917-7129; Schermer, Bernhard/0000-0002-5194-9000; Otto, Edgar/0000-0002-2387-9973; ANTIGNAC, Corinne/0000-0002-9934-4940	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK069604, R01DK078209] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK069604, R01 DK078209] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Benzing T, 2000, J BIOL CHEM, V275, P28167; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Calvet JP, 2003, NAT GENET, V33, P113, DOI 10.1038/ng1078; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Donaldson JC, 2002, J BIOL CHEM, V277, P29028, DOI 10.1074/jbc.M111697200; Drummond IA, 1998, DEVELOPMENT, V125, P4655; FANCONI G, 1951, Helv Paediatr Acta, V6, P1; GAGNADOUX MF, 1989, PEDIATR NEPHROL, V3, P50, DOI 10.1007/BF00859626; Haider NB, 1998, AM J HUM GENET, V63, P1404, DOI 10.1086/302108; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; HIDLEBRANDT F, 1999, PEDIAT NEPHROLOGY; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Kuida S, 2000, GENOME RES, V10, P49; McQuinn TC, 2001, ANAT RECORD, V263, P62, DOI 10.1002/ar.1077; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Morgan D, 2002, HUM MOL GENET, V11, P3345, DOI 10.1093/hmg/11.26.3345; Morgan D, 2002, HUM GENET, V110, P377, DOI 10.1007/s00439-002-0696-4; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nurnberger J, 2002, MOL BIOL CELL, V13, P3096, DOI 10.1091/mbc.E02-04-0195; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Omran H, 2000, AM J HUM GENET, V66, P118, DOI 10.1086/302705; Omran H, 2001, J AM SOC NEPHROL, V12, P107, DOI 10.1681/ASN.V121107; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Otto E, 2002, AM J HUM GENET, V71, P1161, DOI 10.1086/344395; Otto E, 2000, J AM SOC NEPHROL, V11, P270, DOI 10.1681/ASN.V112270; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; SMITH CH, 1945, AM J DIS CHILD, V69, P369; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; WALDHERR R, 1982, VIRCHOWS ARCH A, V394, P235, DOI 10.1007/BF00430668; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; Woo DDL, 1997, KIDNEY INT, V51, P1613, DOI 10.1038/ki.1997.222; Woo DDL, 1997, J CLIN INVEST, V100, P1934, DOI 10.1172/JCI119724; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Zeisberg M, 2001, CURR OPIN NEPHROL HY, V10, P315, DOI 10.1097/00041552-200105000-00004	49	460	479	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					413	420		10.1038/ng1217	http://dx.doi.org/10.1038/ng1217			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12872123	Green Accepted			2022-12-25	WOS:000184470500019
J	Conant, GC; Wagner, A				Conant, GC; Wagner, A			Convergent evolution of gene circuits	NATURE GENETICS			English	Article							EXPRESSION PATTERNS; ADAPTIVE EVOLUTION; DUPLICATE GENES; NETWORK MOTIFS; YEAST	Convergent evolution is a potent indicator of optimal design. We show here that convergent evolution occurs in genetic networks. Specifically, we show that multiple types of transcriptional regulation circuitry in Escherichia coli and the yeast Saccharomyces cerevisiae have evolved independently and not by duplication of one or a few ancestral circuits.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	University of New Mexico	Wagner, A (corresponding author), Univ New Mexico, Dept Biol, 167 Castetter Hall, Albuquerque, NM 87131 USA.		Conant, Gavin/R-7022-2019; Yang, Chen/G-1379-2010	Conant, Gavin/0000-0002-8677-4933; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; Dermitzakis ET, 2002, MOL BIOL EVOL, V19, P1114, DOI 10.1093/oxfordjournals.molbev.a004169; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Futuyma D. J., 1998, EVOLUTIONARY BIOL; Gould S. J., 1989, WONDERFUL LIFE BURGE; KORNEGAY JR, 1994, MOL BIOL EVOL, V11, P921; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; Stone JR, 2001, MOL BIOL EVOL, V18, P1764, DOI 10.1093/oxfordjournals.molbev.a003964; Wagner A, 2000, P NATL ACAD SCI USA, V97, P6579, DOI 10.1073/pnas.110147097; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913	15	131	137	3	20	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					264	266		10.1038/ng1181	http://dx.doi.org/10.1038/ng1181			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12819781				2022-12-25	WOS:000183815300012
J	Cui, Y; Kelleher, E; Straley, E; Fuchs, E; Gorski, K; Levitsky, H; Borrello, I; Civin, CI; Schoenberger, SP; Cheng, LZ; Pardoll, DM; Whartenby, KA				Cui, Y; Kelleher, E; Straley, E; Fuchs, E; Gorski, K; Levitsky, H; Borrello, I; Civin, CI; Schoenberger, SP; Cheng, LZ; Pardoll, DM; Whartenby, KA			Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells	NATURE MEDICINE			English	Article							PULSED DENDRITIC CELLS; IN-VIVO; ANTITUMOR IMMUNITY; T-CELLS; VACCINATION; INDUCTION; LIGAND; RESPONSES; MELANOMA; VACCINES	A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo-generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Immunol & Hematopoiesis Div, Baltimore, MD 21231 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, La Jolla, CA 92024 USA	Johns Hopkins University; Johns Hopkins Medicine; La Jolla Institute for Immunology	Whartenby, KA (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Immunol & Hematopoiesis Div, Baltimore, MD 21231 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Cui, Yan/0000-0002-2800-6039	NCI NIH HHS [CA96888-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA096888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson LD, 2000, BLOOD, V95, P2426, DOI 10.1182/blood.V95.7.2426.007k28_2426_2433; Asavaroengchai W, 2002, P NATL ACAD SCI USA, V99, P931, DOI 10.1073/pnas.022634999; Banchereau J, 2001, CANCER RES, V61, P6451; Borges L, 1999, J IMMUNOL, V163, P1289; Borrello I, 2000, BLOOD, V95, P3011; Borrello Ivan M, 2002, Cancer Control, V9, P138; Cayeux S, 1999, EUR J IMMUNOL, V29, P225, DOI 10.1002/(SICI)1521-4141(199901)29:01<225::AID-IMMU225>3.0.CO;2-W; Chang AE, 2002, CLIN CANCER RES, V8, P1021; Cui Y, 2002, BLOOD, V99, P399, DOI 10.1182/blood.V99.2.399; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Eggert AAO, 1999, CANCER RES, V59, P3340; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lynch DH, 1998, CRIT REV IMMUNOL, V18, P99, DOI 10.1615/CritRevImmunol.v18.i1-2.110; Mackall CL, 1996, J IMMUNOL, V156, P4609; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Merad M, 2002, BLOOD, V99, P1676, DOI 10.1182/blood.V99.5.1676; Murphy GP, 1999, PROSTATE, V39, P54, DOI 10.1002/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U; Nair SK, 2002, ANN SURG, V235, P540, DOI 10.1097/00000658-200204000-00013; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Teshima T, 2001, CANCER RES, V61, P162; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Whartenby KA, 2002, BLOOD, V100, P3147, DOI 10.1182/blood-2002-01-0118; Woods NB, 2002, LEUKEMIA, V16, P563, DOI 10.1038/sj.leu.2402447	28	46	46	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					952	958		10.1038/nm882	http://dx.doi.org/10.1038/nm882			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12778137				2022-12-25	WOS:000183979300038
J	Kinderlerer, J				Kinderlerer, J			The WTO complaint - why now?	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Sheffield, Sheffield Inst Biotechnol Law & Eth, Dept Law, Sheffield S10 1FL, S Yorkshire, England	University of Sheffield	Kinderlerer, J (corresponding author), Univ Sheffield, Sheffield Inst Biotechnol Law & Eth, Dept Law, Conduit Rd, Sheffield S10 1FL, S Yorkshire, England.							*COD COMM FOOD LAB, 2002, 30 COD COMM FOOD LAB; *EU US BIOT CONS F, 2000, FIN REP; *EUR COMM, 2002, COM200227 EC; *UK ROYAL SOC, 2002, 402 UK ROYAL SOC	4	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					735	736		10.1038/nbt0703-735	http://dx.doi.org/10.1038/nbt0703-735			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12833086				2022-12-25	WOS:000183886000016
J	Lee, SW; Kim, WJ; Choi, YK; Song, HS; Son, MJ; Gelman, IH; Kim, YJ; Kim, KW				Lee, SW; Kim, WJ; Choi, YK; Song, HS; Son, MJ; Gelman, IH; Kim, YJ; Kim, KW			SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; KINASE-C SUBSTRATE; TUMOR-SUPPRESSOR ACTIVITY; CYTOSKELETAL ARCHITECTURE; IN-VIVO; EXPRESSION; GENE; HYPOXIA; ANGIOPOIETIN-1; CELLS	The blood-brain barrier (BBB) is essential for maintaining brain homeostasis and low permeability. BBB maintenance is important in the central nervous system (CNS) because disruption of the BBB may contribute to many brain disorders, including Alzheimer disease and ischemic stroke. The molecular mechanisms of BBB development remain ill-defined, however. Here we report that src-suppressed C-kinase substrate (SSeCKS) decreases the expression of vascular endothelial growth factor (VEGF) through AP-1 reduction and stimulates expression of angiopoietin-1 (Ang-1), an anti permeability factor in astrocytes. Conditioned media from SSeCKS-overexpressing astrocytes (SSeCKS-CM) blocked angiogenesis in vivo and in vitro. Moreover, SSeCKS-CM increased tight junction proteins in endothelial cells, consequently decreasing [H-3]sucrose permeability. Furthermore, immunoreactivity to SSeCKS gradually increased during the BBB maturation period, and SSeCKS-expressing astrocytes closely interacted with zonula occludens (ZO)-1-expressing blood vessels in vivo. Collectively, our results suggest that SSeCKS regulates BBB differentiation by modulating both brain angiogenesis and tight junction formation.	Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Div Infect Dis, New York, NY 10029 USA	Seoul National University (SNU); Pusan National University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.		Choi, Yoon Kyung/AGX-0481-2022	Choi, Yoon Kyung/0000-0003-0242-9612				Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; BREIER G, 1992, DEVELOPMENT, V114, P521; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Gelman IH, 2000, HISTOCHEM J, V32, P13, DOI 10.1023/A:1003950027529; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Krikun G, 2002, AM J PATHOL, V161, P979, DOI 10.1016/S0002-9440(10)64258-7; Lee MS, 2001, CANCER RES, V61, P3290; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Liebner S, 2000, ACTA NEUROPATHOL, V100, P323, DOI 10.1007/s004010000180; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Maltepe E, 1998, J MOL MED-JMM, V76, P391, DOI 10.1007/s001090050231; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Nico B, 1999, DEV BRAIN RES, V114, P161, DOI 10.1016/S0165-3806(99)00008-5; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petty MA, 2001, BRAIN RES REV, V36, P23, DOI 10.1016/S0165-0173(01)00062-5; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Prat A, 2001, GLIA, V36, P145, DOI 10.1002/glia.1104; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Song HS, 2002, BIOCHEM BIOPH RES CO, V290, P325, DOI 10.1006/bbrc.2001.6205; Staddon JM, 1996, CURR OPIN NEUROBIOL, V6, P622, DOI 10.1016/S0959-4388(96)80094-8; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Xia W, 2001, CANCER RES, V61, P5644; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	45	352	368	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					900	906		10.1038/nm889	http://dx.doi.org/10.1038/nm889			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808449				2022-12-25	WOS:000183979300031
J	Trachtenberg, E; Korber, B; Sollars, C; Kepler, TB; Hraber, PT; Hayes, E; Funkhouser, R; Fugate, M; Theiler, J; Hsu, YS; Kunstman, K; Wu, S; Phair, J; Erlich, H; Wolinsky, S				Trachtenberg, E; Korber, B; Sollars, C; Kepler, TB; Hraber, PT; Hayes, E; Funkhouser, R; Fugate, M; Theiler, J; Hsu, YS; Kunstman, K; Wu, S; Phair, J; Erlich, H; Wolinsky, S			Advantage of rare HLA supertype in HIV disease progression	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE RESPONSES; CLASS-I; POLYMORPHISM; DIVERSITY; SELECTION; EPITOPES; PATTERNS; ALLELES; CTL	The highly polymorphic human leukocyte antigen (HLA) class I molecules help to determine the specificity and repertoire of the immune response. The great diversity of these antigen-binding molecules confers differential advantages in responding to pathogens, but presents a major obstacle to distinguishing HLA allele-specific effects. HLA class I supertypes provide a functional classification for the many different HLA alleles that overlap in their peptide-binding specificities. We analyzed the association of these discrete HLA supertypes with HIV disease progression rates in a population of HIV-infected men. We found that HLA supertypes alone and in combination conferred a strong differential advantage in responding to HIV infection, independent of the contribution of single HLA alleles that associate with progression of the disease. The correlation of the frequency of the HLA supertypes with viral load suggests that HIV adapts to the most frequent alleles in the population, providing a selective advantage for those individuals who express rare alleles.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Duke Univ, Med Ctr, Durham, NC 27708 USA; Roche Mol Syst, Alameda, CA 94501 USA	Northwestern University; Feinberg School of Medicine; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; Duke University; Roche Holding	Wolinsky, S (corresponding author), Northwestern Univ, Feinberg Sch Med, 676 N St Clair St, Chicago, IL 60611 USA.	s-wolinsky@northwestern.edu	Wolinsky, Steven/B-2893-2012	Hraber, Peter/0000-0002-2920-4897; Korber, Bette/0000-0002-2026-5757; Kepler, Thomas/0000-0002-1383-6865; Wolinsky, Steven/0000-0002-9625-6697	NCI NIH HHS [P30-CA79458] Funding Source: Medline; NIAID NIH HHS [U01-AI-35039] Funding Source: Medline; NICHD NIH HHS [R01-HD37356] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037356] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA079458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld MA, 2001, J VIROL, V75, P1301, DOI 10.1128/JVI.75.3.1301-1311.2001; Anastos K, 2000, J ACQ IMMUN DEF SYND, V24, P218; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; Bertoni R, 1997, J CLIN INVEST, V100, P503, DOI 10.1172/JCI119559; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; Boon ACM, 2002, J VIROL, V76, P582, DOI 10.1128/JVI.76.2.582-590.2002; BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235; BUGAWAN TL, 1991, IMMUNOGENETICS, V34, P413, DOI 10.1007/BF01787493; BUGAWAN TL, 1994, TISSUE ANTIGENS, V44, P137, DOI 10.1111/j.1399-0039.1994.tb02371.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; Cao K, 2001, HUM IMMUNOL, V62, P1009, DOI 10.1016/S0198-8859(01)00298-1; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Clark B., 1976, Symposia Br Soc Parasit, V14, P87; de Groot NG, 2002, P NATL ACAD SCI USA, V99, P11748, DOI 10.1073/pnas.182420799; ERLICH HA, 2001, MOL EPIDEMIOLOGY PRA, V181; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hendel H, 1999, J IMMUNOL, V162, P6942; HILL A, 1993, IMMUNOGENETICS, V37, P95; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOPE ACA, 1968, J ROY STAT SOC B, V30, P582; Howard J.C., 1987, P397; HUGHES AL, 1990, MOL BIOL EVOL, V7, P515; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Keet IPM, 1999, J INFECT DIS, V180, P299, DOI 10.1086/314862; LI M, 1993, INTRO KOLMOGOROV COM, V546; Little A M, 1999, Rev Immunogenet, V1, P105; MacDonald KS, 2001, IMMUNOL LETT, V79, P151, DOI 10.1016/S0165-2478(01)00277-2; MARSH SGE, 2002, HLA FACTSBOOK, V398; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Nelson GW, 1997, P NATL ACAD SCI USA, V94, P9802, DOI 10.1073/pnas.94.18.9802; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Propato A, 2001, HUM IMMUNOL, V62, P561, DOI 10.1016/S0198-8859(01)00245-2; Rissanen J, 1999, COMPUT J, V42, P260, DOI 10.1093/comjnl/42.4.260; RISSANEN J, 1989, STOCHASTIC COMPLEXIT, V171; Roger M, 1998, FASEB J, V12, P625, DOI 10.1096/fasebj.12.9.625; SAAH AJ, 1992, AM J EPIDEMIOL, V135, P1147, DOI 10.1093/oxfordjournals.aje.a116215; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Slatkin M, 2000, GENETICS, V156, P2119; Tomiyama H, 2000, EUR J IMMUNOL, V30, P2521, DOI 10.1002/1521-4141(200009)30:9<2521::AID-IMMU2521>3.0.CO;2-Q; Trachtenberg E. A., 2001, HIV MOL IMMUNOLOGY D, P1; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; vanderBurg SH, 1997, J IMMUNOL, V159, P3648; VENABLES WN, 1999, MODERN APPL STAT S P, V501; Williams A, 2002, TISSUE ANTIGENS, V59, P3, DOI 10.1034/j.1399-0039.2002.590103.x; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	49	266	274	0	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					928	935		10.1038/nm893	http://dx.doi.org/10.1038/nm893			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819779				2022-12-25	WOS:000183979300035
J	Wikonkal, NM; Remenyik, E; Knezevic, D; Zhang, WG; Liu, M; Zhao, HY; Berton, TR; Johnson, DG; Brash, DE				Wikonkal, NM; Remenyik, E; Knezevic, D; Zhang, WG; Liu, M; Zhao, HY; Berton, TR; Johnson, DG; Brash, DE			Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE; TRANSCRIPTION FACTOR; P53-DEFICIENT MICE; SUNBURN CELL; SKIN-CANCER; IN-VIVO; P53; PROLIFERATION; TUMORIGENESIS; INDUCTION	The E2f1 transcription factor, which regulates genes required for S-phase entry(1-4), also induces apoptosis by transcriptional and post-translational mechanisms(5-8). As E2f1 is inducible by DNA damage(9,10) we investigated its importance in vivo in ultraviolet (UV)-induced apoptosis, a protective mechanism that prevents the epidermis from accumulating UV-induced mutations(11,12). Contrary to expectation, E2f1(-/-) mice demonstrated enhanced keratinocyte apoptosis after UVB exposure, whereas apoptosis was suppressed by epidermis-specific overexpression of human E2F1. Apoptosis induced by gamma-radiation was also repressed by E2f1. E2f1(-/-); Trp53(-/-) double knockout mice exhibited the elevated UVB-induced apoptosis of E2f1(-/-) alone, rather than the profound apoptosis defect seen in Trp53(-/-) mice, indicating that Trp53 (p53) lies functionally upstream of E2f1. Transfecting E2F1 into E2f1(-/-); Trp53(-/-) primary fibroblasts suppressed UVB-induced apoptosis and this suppression was relieved by Trp53. The double knockout also reverted the abnormal sex ratio and early-onset tumours of Trp53(-/-) mice. These results imply that E2f1 functions as a suppressor of an apoptosis pathway that is initiated by DNA photoproducts and perhaps genetic abnormalities; p53 relieves this suppression.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA; Univ Debrecen, Dept Dermatol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; Univ Texas, Dept Carcinogenesis, Div Sci Pk Res, MD Anderson Canc Ctr, Smithville, TX 78957 USA	Yale University; Yale University; Yale University; Yale University; University of Debrecen; University of Texas System; UTMD Anderson Cancer Center	Brash, DE (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.	douglas.brash@yale.edu		Johnson, David/0000-0002-6223-1790; Zhang, Wengeng/0000-0002-1000-4692	NCI NIH HHS [CA079648, CA55737] Funding Source: Medline; NIGMS NIH HHS [GM59507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055737, R01CA079648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Brash DE, 2001, J INVEST DERMATOL, V117, P1234, DOI 10.1046/j.0022-202x.2001.01554.x; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hager B, 1999, J INVEST DERMATOL, V112, P971, DOI 10.1046/j.1523-1747.1999.00605.x; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1999, BBA-REV CANCER, V1423, pM9, DOI 10.1016/S0304-419X(99)00003-7; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	30	72	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					655	660		10.1038/ncb1001	http://dx.doi.org/10.1038/ncb1001			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12833065				2022-12-25	WOS:000183911600016
J	Siliciano, JD; Kajdas, J; Finzi, D; Quinn, TC; Chadwick, K; Margolick, JB; Kovacs, C; Gange, SJ; Siliciano, RF				Siliciano, JD; Kajdas, J; Finzi, D; Quinn, TC; Chadwick, K; Margolick, JB; Kovacs, C; Gange, SJ; Siliciano, RF			Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS INFECTION; COMBINATION THERAPY; VIRAL LOAD; REPLICATION; PERSISTENCE; INDINAVIR; PLASMA; ADULTS; DECAY	Latent HIV-1 persists in resting memory CD4(+) T cells, even in patients receiving highly active antiretroviral therapy (HAART). It has been unclear how stable this latent reservoir is and whether its persistence reflects replenishment by low-level viremia. Here we show that even in treated patients who have had no detectable viremia for as long as 7 years, the reservoir decays so slowly (t(1/2) = 44 months) that eradication is unlikely.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Toronto, Dept Med, Toronto, ON M5B 1L6, Canada; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Toronto; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.		Gange, Stephen/AGY-5004-2022; Abrams, William R/A-5782-2008; Quinn, Thomas/A-2494-2010	Gange, Stephen/0000-0001-7842-512X; 	NIAID NIH HHS [AI43222] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000361, R01AI043222] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	15	1211	1249	1	44	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					727	728		10.1038/nm880	http://dx.doi.org/10.1038/nm880			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754504				2022-12-25	WOS:000183444100027
J	Cao, RH; Brakenhielm, E; Pawliuk, R; Wariaro, D; Post, MJ; Wahlberg, E; Leboulch, P; Cao, YH				Cao, RH; Brakenhielm, E; Pawliuk, R; Wariaro, D; Post, MJ; Wahlberg, E; Leboulch, P; Cao, YH			Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CORONARY-ARTERY DISEASE; CLINICAL-APPLICATIONS; GENE-THERAPY; RECEPTOR; DELIVERY; MICE	The establishment of functional and stable vascular networks is essential for angiogenic therapy. Here we report that a combination of two angiogenic factors, platelet-derived growth factor (PDGF)-BB and fibroblast growth factor (FGF)-2, synergistically induces vascular networks, which remain stable for more than a year even after depletion of angiogenic factors. In both rat and rabbit ischemic hind limb models, PDGF-BB and FGF-2 together markedly stimulated collateral arteriogenesis after ligation of the femoral artery, with a significant increase in vascularization and improvement in paw blood flow. A possible mechanism of angiogenic synergism between PDGF-BB and FGF-2 involves upregulation of the expression of PDGF receptor (PDGFR)-alpha and PDGFR-beta by FGF-2 in newly formed blood vessels. Our data show that a specific combination of angiogenic factors establishes functional and stable vascular networks, and provides guidance for the ongoing clinical trials of angiogenic factors for the treatment of ischemic diseases.	Karolinska Inst, Lab Angiogenesis Res, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Genetix Pharmaceut Inc, Cambridge, MA USA; Karolinska Hosp, Dept Vasc Surg, S-10401 Stockholm, Sweden; Dartmouth Coll Sch Med, Dept Med, Lebanon, NH USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Hop St Louis, INSERM EMI 0111, Paris, France	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Dartmouth College; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cao, YH (corresponding author), Karolinska Inst, Lab Angiogenesis Res, Ctr Microbiol & Tumor Biol, Stockholm, Sweden.		Brakenhielm, Ebba/E-9758-2011	Brakenhielm, Ebba/0000-0003-3378-8300				Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 2001, NAT BIOTECHNOL, V19, P1019, DOI 10.1038/nbt1101-1019; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; ESSEX TJH, 1991, J BIOMED ENG, V13, P189, DOI 10.1016/0141-5425(91)90125-Q; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Freedman SB, 2002, ANN INTERN MED, V136, P54, DOI 10.7326/0003-4819-136-1-200201010-00011; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Lee RJ, 2000, CIRCULATION, V102, P898; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PASSANITI A, 1992, INT J CANCER, V51, P318, DOI 10.1002/ijc.2910510224; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; SEIFERT FC, 1985, J CARDIOVASC SURG, V26, P502; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407; Waltenberger J, 1997, CIRCULATION, V96, P4083; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zetter BR, 2001, J CELL BIOL, V152, pF35, DOI 10.1083/jcb.152.6.F35	30	563	612	3	56	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					604	613		10.1038/nm848	http://dx.doi.org/10.1038/nm848			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669032				2022-12-25	WOS:000182610600043
J	Jones, B; Jones, EL; Bonney, SA; Patel, HN; Mensenkamp, AR; Eichenbaum-Voline, S; Rudling, M; Myrdal, U; Annesi, G; Naik, S; Meadovvs, N; Quattrone, A; Islam, SA; Naoumova, RP; Angelin, B; Infante, R; Levy, E; Roy, CC; Freemont, PS; Scott, J; Shoulders, CC				Jones, B; Jones, EL; Bonney, SA; Patel, HN; Mensenkamp, AR; Eichenbaum-Voline, S; Rudling, M; Myrdal, U; Annesi, G; Naik, S; Meadovvs, N; Quattrone, A; Islam, SA; Naoumova, RP; Angelin, B; Infante, R; Levy, E; Roy, CC; Freemont, PS; Scott, J; Shoulders, CC			Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders	NATURE GENETICS			English	Article							CHYLOMICRON RETENTION DISEASE; ENDOPLASMIC-RETICULUM; ANDERSONS-DISEASE; APOPROTEIN-B; TRANSPORT; PROTEINS; COAT; BINDING; EXPORT	Dietary fat is an important source of nutrition. Here we identify eight mutations in SARA2 that are associated with three severe disorders of fat malabsorption. The Sar1 family of proteins initiates the intracellular transport of proteins in COPII (coat protein)-coated vesicles. Our data suggest that chylomicrons, which vastly exceed the size of typical COPII vesicles, are selectively recruited by the COPII machinery for transport through the secretory pathways of the cell.	Univ London Imperial Coll Sci Technol & Med, Genom & Mol Med Grp, MRC, Ctr Clin Sci, London, England; Huddinge Univ Hosp, Ctr Metab & Endocrinol, Karolinska Inst, Stockholm, Sweden; Huddinge Univ Hosp, Ctr Nutr & Toxicol, Karolinska Inst, Stockholm, Sweden; Cent Hosp Vasteras, Dept Paediat, Vasteras, Sweden; CNR, Inst Neurol Sci, Piano Lago Of Mangone, Consenza, Italy; Barts & London, Dept Adult & Paediat Gastroenterol, Queen Marys Sch Med & Dent, London, England; Univ London Imperial Coll Sci Technol & Med, Struct Bioinformat Grp, London, England; INSERM, Ctr Rech, Paris 12, France; Univ Montreal, Ctr Rech, Hop St Justine, Montreal, PQ H3C 3J7, Canada; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Sci Biol, London, England; Univ London Imperial Coll Sci Technol & Med, Genet & Genom Res Inst, London, England	Imperial College London; Karolinska Institutet; Karolinska Institutet; Vasteras Central Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Neurologiche (ISN-CNR); University of London; Queen Mary University London; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; Imperial College London; University of London; Institute of Cancer Research - UK; Imperial College London	Scott, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Genom & Mol Med Grp, MRC, Ctr Clin Sci, London, England.		Mensenkamp, Arjen/L-4520-2015; Annesi, Grazia/AAX-5732-2020; QUATTRONE, Aldo/A-6734-2016	Mensenkamp, Arjen/0000-0003-3805-877X; Freemont, Paul/0000-0002-5658-8486; QUATTRONE, Aldo/0000-0003-2001-957X				Aguglia U, 2000, ANN NEUROL, V47, P260, DOI 10.1002/1531-8249(200002)47:2<260::AID-ANA21>3.0.CO;2-V; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; BOUMA ME, 1986, J CLIN INVEST, V78, P398, DOI 10.1172/JCI112590; Dannoura AH, 1999, ARTERIOSCL THROM VAS, V19, P2494, DOI 10.1161/01.ATV.19.10.2494; Huang MD, 2001, J CELL BIOL, V155, P937, DOI 10.1083/jcb.200106039; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; NEMETH A, 1995, EUR J CLIN INVEST, V25, P271, DOI 10.1111/j.1365-2362.1995.tb01559.x; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROY CC, 1987, GASTROENTEROLOGY, V92, P390, DOI 10.1016/0016-5085(87)90133-8; Saito Y, 1998, J BIOCHEM-TOKYO, V124, P816, DOI 10.1093/oxfordjournals.jbchem.a022185; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153	15	260	266	2	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					29	31		10.1038/ng1145	http://dx.doi.org/10.1038/ng1145			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12692552				2022-12-25	WOS:000182667900012
J	Kojima, H; Fujimiya, M; Matsumura, K; Younan, P; Imaeda, H; Maeda, M; Chan, L				Kojima, H; Fujimiya, M; Matsumura, K; Younan, P; Imaeda, H; Maeda, M; Chan, L			NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice	NATURE MEDICINE			English	Article							DEPENDENT ADENOVIRAL VECTOR; HEPATIC STEM-CELLS; LUMINAL RELEASE; INSULIN; EXPRESSION; TRANSPLANTATION; ALPHA(1)-ANTITRYPSIN; DIFFERENTIATION; TOXICITY	To explore induced islet neogenesis in the liver as a strategy for the treatment of diabetes, we used helper-dependent adenovirus (HDAD) to deliver the pancreatic duodenal homeobox-1 gene (Ipf1; also known as Pdx-1) to streptozotocin (STZ)-treated diabetic mice. HDAD is relatively nontoxic as it is devoid of genes encoding viral protein. Mice treated with HDAD-Ipf1 developed fulminant hepatitis, however, because of the exocrine-differentiating activity of Ipf1. The diabetes of STZ mice was partially reversed by HDAD-mediated transfer of NeuroD (Neurod), a factor downstream of Ipf1, and completely reversed by a combination of Neurod and betacellulin (Btc), without producing hepatitis. Treated mice were healthy and normoglycemic for the duration of the experiment (>120 d). We detected in the liver insulin and other islet-specific transcripts, including proinsulin-processing enzymes, beta-cell-specific glucokinase and sulfonylurea receptor. Immunocytochemistry detected the presence of insulin, glucagon, pancreatic polypeptide and somatostatin-producing cells organized into islet clusters; immunoelectron microscopy showed typical insulin-containing granules. Our data suggest that Neurod-Btc gene therapy is a promising regimen to induce islet neogenesis for the treatment of insulin-dependent diabetes.	Baylor Coll Med, Dept Med, Sect Diabet Endocrinol & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 52021, Japan	Baylor College of Medicine; Baylor College of Medicine; Shiga University of Medical Science	Chan, L (corresponding author), Baylor Coll Med, Dept Med, Sect Diabet Endocrinol & Metab, Houston, TX 77030 USA.		Imaeda, Hirotsugu/B-9907-2016	Imaeda, Hirotsugu/0000-0002-5516-8527	NHLBI NIH HHS [HL-51586, HL-16512, HL-59314] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059314, R37HL016512, R01HL016512, P01HL059314] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Auricchio A, 2002, GENE THER, V9, P963, DOI 10.1038/sj.gt.3301746; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; Dong HJ, 2001, TRENDS ENDOCRIN MET, V12, P441, DOI 10.1016/S1043-2760(01)00491-X; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Fujimiya M, 1997, HISTOCHEM CELL BIOL, V108, P105, DOI 10.1007/s004180050151; FUJIMIYA M, 1992, NEUROSCI LETT, V145, P229, DOI 10.1016/0304-3940(92)90029-7; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Halban PA, 2001, DIABETES, V50, P2181, DOI 10.2337/diabetes.50.10.2181; Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; KOJIMA H, 1986, FEBS LETT, V201, P271, DOI 10.1016/0014-5793(86)80622-6; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; O'Neal WK, 1998, HUM GENE THER, V9, P1587, DOI 10.1089/hum.1998.9.11-1587; Oka K, 2001, CIRCULATION, V103, P1274; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Paty BW, 2002, DIABETES, V51, P3428, DOI 10.2337/diabetes.51.12.3428; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHING Y, 1993, SCIENCE, V259, P2681; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WATARI N, 1975, ENDOCRINE GUT PANCRA, P179; Yang LJ, 2002, P NATL ACAD SCI USA, V99, P8078, DOI 10.1073/pnas.122210699; Yoon JW, 2002, TRENDS MOL MED, V8, P62, DOI 10.1016/S1471-4914(02)02279-7	32	353	382	0	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					596	603		10.1038/nm867	http://dx.doi.org/10.1038/nm867			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704384				2022-12-25	WOS:000182610600042
J	Miller, HI				Miller, HI			Will we reap what biopharming sows?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	6	6	1	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2003	21	5					480	481		10.1038/nbt0503-480	http://dx.doi.org/10.1038/nbt0503-480			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	674WN	12721561				2022-12-25	WOS:000182660300007
J	Mager, J; Montgomery, ND; de Villena, FPM; Magnuson, T				Mager, J; Montgomery, ND; de Villena, FPM; Magnuson, T			Genome imprinting regulated by the mouse Polycomb group protein Eed	NATURE GENETICS			English	Article							HISTONE H3 METHYLTRANSFERASE; BECKWITH-WIEDEMANN-SYNDROME; DNA METHYLATION; CHROMATIN; DROSOPHILA; MICE; GENE; ASSOCIATION; REPRESSION; COMPLEXES	Epigenetic regulation is essential for temporal, tissue-specific and parent-of-origin-dependent gene expression. It has recently been found that the mouse Polycomb group (PcG) gene Eed (embryonic ectoderm development) acts to maintain repression of the imprinted X chromosome. Here, we investigated whether Eed is also required for regulation of autosomal imprinted loci. Expression analyses showed that transcripts from the silent alleles of a subset of paternally repressed genes were present in Eed(-/-) embryos. Parent-of-origin methylation was preserved in these embryos, but we observed changes in the methylation status of specific CpGs in differentially methylated regions (DMRs) at affected but not at unaffected loci. These data identify Eed as a member of a new class of trans-acting factors that regulate parent-of-origin expression at imprinted loci.	Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Magnuson, T (corresponding author), Univ N Carolina, Dept Genet, 103 Mason Farm Rd, Chapel Hill, NC 27599 USA.			Montgomery, Nathan/0000-0003-1765-6623				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; FAUST C, 1995, DEVELOPMENT, V121, P273; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strichman-Almashanu LZ, 2002, GENOME RES, V12, P543, DOI 10.1101/gr.224102; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	30	205	211	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					502	507		10.1038/ng1125	http://dx.doi.org/10.1038/ng1125			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12627233	Bronze			2022-12-25	WOS:000181928600022
J	Qi, JH; Ebrahem, Q; Moore, N; Murphy, G; Claesson-Welsh, L; Bond, M; Baker, A; Anand-Apte, B				Qi, JH; Ebrahem, Q; Moore, N; Murphy, G; Claesson-Welsh, L; Bond, M; Baker, A; Anand-Apte, B			A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SORSBYS-FUNDUS-DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MESSENGER-RNA EXPRESSION; TYROSINE KINASE; VASCULAR ENDOTHELIUM; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; CELL-DEATH; GENE	Tissue inhibitor of metalloproteinases-3 (TIMP3) is one of four members of a family of proteins that were originally classified according to their ability to inhibit matrix metalloproteinases (MMP). TIMP3, which encodes a potent angiogenesis inhibitor, is mutated in Sorsby fundus dystrophy, a macular degenerative disease with submacular choroidal neovascularization. In this study we demonstrate the ability of TIMP3 to inhibit vascular endothelial factor (VEGF)-mediated angiogenesis and identify the potential mechanism by which this occurs: TIMP3 blocks the binding of VEGF to VEGF receptor-2 and inhibits downstream signaling and angiogenesis. This property seems to be independent of its MMP-inhibitory activity, indicating a new function for this molecule.	Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA; Univ Cambridge, Inst Med Res, Dept Oncol, Cambridge, England; Uppsala Univ, Dept Genet, Vasc Biol Unit, Rudbeck Lab, Uppsala, Sweden; Uppsala Univ, Dept Pathol, Vasc Biol Unit, Rudbeck Lab, Uppsala, Sweden; Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England; Univ Glasgow, Dept Med & Therapeut, Glasgow, Lanark, Scotland; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University of Cambridge; Uppsala University; Uppsala University; Bristol Royal Infirmary; University of Bristol; University of Glasgow; Cleveland Clinic Foundation	Anand-Apte, B (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Baker, Andy/AAO-5250-2021; Bond, Mark/AAG-9293-2019	Baker, Andy/0000-0003-1441-5576; 	NCI NIH HHS [R01 CA106415] Funding Source: Medline; NEI NIH HHS [1 R29 EY12109-01, R29 EY012109, R01 EY016490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY012109, R01EY016490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1998, J HISTOCHEM CYTOCHEM, V46, P437, DOI 10.1177/002215549804600403; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; BYRNE JA, 1995, MOL MED, V1, P418, DOI 10.1007/BF03401579; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Itoh T, 1998, CANCER RES, V58, P1048; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; McElligott Anthony M., 1997, Biochemical Society Transactions, V25, p147S; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RUIZ A, 1996, INVEST OPHTH VIS SCI, V37, pS1143; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; URIA JA, 1994, CANCER RES, V54, P2091; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Zeng ZS, 2001, DIS COLON RECTUM, V44, P1290, DOI 10.1007/BF02234786	46	504	524	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					407	415		10.1038/nm846	http://dx.doi.org/10.1038/nm846			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652295				2022-12-25	WOS:000181987400030
J	Cheung, VG; Conlin, LK; Weber, TM; Arcaro, M; Jen, KY; Morley, M; Spielman, RS				Cheung, VG; Conlin, LK; Weber, TM; Arcaro, M; Jen, KY; Morley, M; Spielman, RS			Natural variation in human gene expression assessed in lymphoblastoid cells	NATURE GENETICS			English	Article							LOCUS; MAP	The sequencing of the human genome has resulted in greater attention to genetic variation among individuals, and variation at the DNA sequence level is now being extensively studied. At the same time, it has become possible to study variation at the level of gene expression by various methods. At present, it is largely unknown how widespread this variation in transcript levels is over the entire genome and to what extent individual differences in expression level are genetically determined. In the present study, we used lymphoblastoid cells to examine variation in gene expression and identified genes whose transcript levels differed greatly among unrelated individuals. We also found evidence for familial aggregation of expression phenotype by comparing variation among unrelated individuals, among siblings within families and between monozygotic twins. These observations suggest that there is a genetic contribution to polymorphic variation in the level of gene expression.	Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cheung, VG (corresponding author), Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.	vcheung@mail.med.upenn.edu	Cheung, Vivian G./AAT-3115-2020; Jen, Kuang-Yu/AAM-5429-2020; Jen, Kuang-Yu/AAM-5722-2020	Jen, Kuang-Yu/0000-0003-2815-5912; Morley, Michael/0000-0002-0958-7376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081930] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM081930, R01 GM081930-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; HARRIS H, 1972, ANN HUM GENET, V36, P9, DOI 10.1111/j.1469-1809.1972.tb00578.x; Oleksiak MF, 2002, NAT GENET, V32, P261, DOI 10.1038/ng983; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; Watts JA, 2002, AM J HUM GENET, V71, P791, DOI 10.1086/342974; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545	13	436	578	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2003	33	3					422	425		10.1038/ng1094	http://dx.doi.org/10.1038/ng1094			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12567189				2022-12-25	WOS:000181312700023
J	Fiscella, M; Perry, JW; Teng, BQ; Bloom, M; Zhang, C; Leung, K; Pukac, L; Florence, K; Concepcion, A; Liu, BJ; Meng, Y; Chen, C; Kanakaraj, P; Kaufmann, TE; Porter, J; Cibotti, R; Mei, Y; Zhou, J; Chen, GX; Roschke, V; Komatsoulis, G; Mansfield, B; Ruben, S; Sanyal, I; Migone, TS				Fiscella, M; Perry, JW; Teng, BQ; Bloom, M; Zhang, C; Leung, K; Pukac, L; Florence, K; Concepcion, A; Liu, BJ; Meng, Y; Chen, C; Kanakaraj, P; Kaufmann, TE; Porter, J; Cibotti, R; Mei, Y; Zhou, J; Chen, GX; Roschke, V; Komatsoulis, G; Mansfield, B; Ruben, S; Sanyal, I; Migone, TS			TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model	NATURE BIOTECHNOLOGY			English	Article							GAMMA	A coordinated effort combining bioinformatic tools with high-throughput cell-based screening assays was implemented to identify novel factors involved in T-cell biology. We generated a unique library of cDNAs encoding predicted secreted and transmembrane domain-containing proteins generated by analyzing the Human Genome Sciences cDNA database with a combination of two algorithms that predict signal peptides. Supernatants from mammalian cells transiently transfected with this library were incubated with primary T cells and T-cell lines in several high-throughput assays. Here we describe the discovery of a T cell factor, TIP (T cell immunomodulatory protein), which does not show any homology to proteins with known function. Treatment of primary human and murine T cells with TIP in vitro resulted in the secretion of IFN-, TNF-, and IL-10, whereas in vivo TIP had a protective effect in a mouse acute graft-versus-host disease (GVHD) model. Therefore, combining functional genomics with high-throughput cell-based screening is a valuable and efficient approach to identifying immunomodulatory activities for novel proteins.	Human Genome Sci Inc, Dept Preclin Dev, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Preclin Discovery, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Lead Dev & Characterizat, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Prot Dev, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Antibody Dev, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Informat Technol, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc	Migone, TS (corresponding author), Human Genome Sci Inc, Dept Preclin Dev, Rockville, MD 20850 USA.	T.Migone@genesis.co.nz		Mansfield, Brian/0000-0002-8533-2789; Komatsoulis, George/0000-0001-6967-7085				Barash S, 2002, BIOCHEM BIOPH RES CO, V294, P835, DOI 10.1016/S0006-291X(02)00566-1; Brok HPM, 1998, BONE MARROW TRANSPL, V22, P1005, DOI 10.1038/sj.bmt.1701478; Chen MQ, 2001, CHINESE J ORG CHEM, V21, P294; Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Forrer P, 1998, BIOL CHEM, V379, P1101, DOI 10.1515/bchm.1998.379.8-9.1101; Fox S, 1999, J BIOMOL SCREEN, V4, P183, DOI 10.1177/108705719900400405; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; GLEICHMANN E, 1984, IMMUNOL TODAY, V5, P324, DOI 10.1016/0167-5699(84)90126-9; Gurlo T, 1998, CYTOKINE, V10, P265, DOI 10.1006/cyto.1997.0288; Hertzberg RP, 2000, CURR OPIN CHEM BIOL, V4, P445, DOI 10.1016/S1367-5931(00)00110-1; Holler E, 2000, BONE MARROW TRANSPL, V25, P237, DOI 10.1038/sj.bmt.1702126; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LaFleur DW, 2001, J BIOL CHEM, V276, P39765, DOI 10.1074/jbc.M102502200; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Miraglia S, 1999, J BIOMOL SCREEN, V4, P193, DOI 10.1177/108705719900400407; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Yang YG, 1998, J CLIN INVEST, V102, P2126, DOI 10.1172/JCI4992	19	34	41	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					302	307		10.1038/nbt797	http://dx.doi.org/10.1038/nbt797			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12598909				2022-12-25	WOS:000181312500027
J	Nicolas, M; Wolfer, A; Raj, K; Kummer, JA; Mill, P; van Noort, M; Hui, CC; Clevers, H; Dotto, GP; Radtke, F				Nicolas, M; Wolfer, A; Raj, K; Kummer, JA; Mill, P; van Noort, M; Hui, CC; Clevers, H; Dotto, GP; Radtke, F			Notch1 functions as a tumor suppressor in mouse skin	NATURE GENETICS			English	Article							NEOPLASTIC TRANSFORMATION; KERATINOCYTE GROWTH; MICE; DIFFERENTIATION; GENE; DETERMINANT; EXPRESSION; HOMOLOG; MAMMARY; GLI	Notch proteins are important in binary cell-fate decisions and inhibiting differentiation in many developmental systems(1), and aberrant Notch signaling is associated with tumorigenesis(2-5). The role of Notch signaling in mammalian skin is less well characterized and is mainly based on in vitro studies, which suggest that Notch signaling induces differentiation in mammalian skin(6,7). Conventional gene targeting is not applicable to establishing the role of Notch receptors or ligands in the skin because Notch1(-/-) embryos die during gestation(8-12). Therefore, we used a tissue-specific inducible gene-targeting approach to study the physiological role of the Notch1 receptor in the mouse epidermis and the corneal epithelium of adult mice. Unexpectedly, ablation of Notch1 results in epidermal and corneal hyperplasia followed by the development of skin tumors and facilitated chemical-induced skin carcinogenesis. Notch1 deficiency in skin and in primary keratinocytes results in increased and sustained expression of Gli2, causing the development of basal-cell carcinoma-like tumors. Furthermore, Notch1 inactivation in the epidermis results in derepressed beta-catenin signaling in cells that should normally undergo differentiation. Enhanced beta-catenin signaling can be reversed by re-introduction of a dominant active form of the Notch1 receptor. This leads to a reduction in the signaling-competent pool of beta-catenin, indicating that Notch1 can inhibit beta-catenin-mediated signaling. Our results indicate that Notch1 functions as a tumor-suppressor gene in mammalian skin.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Univ Med Ctr Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; Harvard Med Sch, Charlestown, MA USA	Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute Experimental Cancer Research; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Harvard University; Massachusetts General Hospital	Radtke, F (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland.	Freddy.Radtke@isrec.unil.ch	Radtke, Freddy/Q-3198-2017; Wolfer, Anita/AAK-1720-2021; Mill, Pleasantine/AAE-4718-2019	Radtke, Freddy/0000-0003-4315-4045; Mill, Pleasantine/0000-0001-5218-134X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Dahmane N, 2001, DEVELOPMENT, V128, P5201; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hamada Y, 1999, DEVELOPMENT, V126, P3415; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Polakis P, 2000, GENE DEV, V14, P1837; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Weinberg WC, 1999, CANCER RES, V59, P2050; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	30	788	849	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2003	33	3					416	421		10.1038/ng1099	http://dx.doi.org/10.1038/ng1099			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12590261				2022-12-25	WOS:000181312700022
J	Singh, N; Ebrahimi, FAW; Gimelbrant, AA; Ensminger, AW; Tackett, MR; Qi, PM; Gribnau, J; Chess, A				Singh, N; Ebrahimi, FAW; Gimelbrant, AA; Ensminger, AW; Tackett, MR; Qi, PM; Gribnau, J; Chess, A			Coordination of the random asynchronous replication of autosomal loci	NATURE GENETICS			English	Article							ALLELIC EXCLUSION; EXPRESSION; SYSTEM; GENES; INTERLEUKIN-2; PATTERNS; MOUSE	Random monoallelic expression and asynchronous replication define an unusual class of autosomal mammalian genes. We show that every cell has randomly chosen either the maternal or paternal copy of each given autosome pair, such that alleles of these genes scattered across the chosen chromosome replicate earlier than the alleles on the homologous chromosome. Thus, chromosome-pair non-equivalence, rather than being limited to X-chromosome inactivation, is a fundamental property of mouse chromosomes.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Chess, A (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Ebrahimi, Farzad/Q-8829-2016	Ebrahimi, Farzad/0000-0001-9091-4647; Gimelbrant, Alexander/0000-0001-6986-0285; Ensminger, Alexander/0000-0003-0824-3704				CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Ebrahimi FAW, 2000, DEV DYNAM, V217, P225, DOI 10.1002/(SICI)1097-0177(200002)217:2<225::AID-DVDY9>3.0.CO;2-3; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	15	85	86	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					339	341		10.1038/ng1102	http://dx.doi.org/10.1038/ng1102			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12577058				2022-12-25	WOS:000181312700008
J	Snyder, JE; Bowers, WJ; Livingstone, AM; Lee, FEH; Federoff, HJ; Mosmann, TR				Snyder, JE; Bowers, WJ; Livingstone, AM; Lee, FEH; Federoff, HJ; Mosmann, TR			Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing	NATURE MEDICINE			English	Article							MEMORY CELLS; PROLIFERATION; INFECTION; EFFECTOR; IMMUNITY; VIRUS	Antigen-specific T cells demonstrate several potent effector functions during immune responses. Direct killing of infected cells is crucial for clearing viruses and other intracellular pathogens, but it has been difficult to measure the frequency of cytolytic cells. We have now developed a single-cell assay to measure the number of cytotoxic cells in a population, using a herpes simplex virus amplicon vector to express Escherichia coli beta-galactosidase in mouse or human target cells, and an Elispot to detect release of beta-galactosidase from killed target cells. This antigen-specific, perforin-dependent Lysispot assay has been combined with a cytokine Elispot in a two-color assay to confirm that cytotoxicity and interferon-gamma secretion are regulated independently. The simultaneous enumeration of cytokine-secreting and cytotoxic cells should be invaluable for ex vivo analysis of immune responses during infection and autoimmunity.	Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Mosmann, TR (corresponding author), Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA.			Snyder-Cappione, Jennifer/0000-0002-0941-5582	NIAID NIH HHS [R01 AI48414] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048414] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; Federoff Howard J., 1995, P109, DOI 10.1016/B978-012397570-6/50009-5; Foxwell AR, 2001, INFECT IMMUN, V69, P2636, DOI 10.1128/IAI.69.4.2636-2642.2001; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Karulin AY, 2000, J IMMUNOL, V164, P1862, DOI 10.4049/jimmunol.164.4.1862; Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214; MALEY DT, 1990, J IMMUNOL METHODS, V134, P61, DOI 10.1016/0022-1759(90)90112-9; Marten NW, 2001, VIRAL IMMUNOL, V14, P1, DOI 10.1089/08828240151061329; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Rininsland FH, 2000, J IMMUNOL METHODS, V240, P143, DOI 10.1016/S0022-1759(00)00191-5; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; Topham DJ, 1997, J IMMUNOL, V159, P5197; Vizler C, 2000, J IMMUNOL, V165, P6314, DOI 10.4049/jimmunol.165.11.6314	20	70	75	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					231	235		10.1038/nm821	http://dx.doi.org/10.1038/nm821			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539041				2022-12-25	WOS:000180801900029
J	Bilder, D; Schober, M; Perrimon, N				Bilder, D; Schober, M; Perrimon, N			Integrated activity of PDZ protein complexes regulates epithelial polarity	NATURE CELL BIOLOGY			English	Article							ZONULA ADHERENS FORMATION; CELL-POLARITY; CAENORHABDITIS-ELEGANS; DROSOPHILA STARDUST; HUMAN HOMOLOG; KINASE-C; CRUMBS; NEUROBLASTS; JUNCTIONS; BAZOOKA	Polarized cells contain numerous membrane domains, but it is unclear how the formation of these domains is coordinated to create a single integrated cell architecture. Genetic screens of Drosophila melanogaster embryos have identified three complexes, each containing one of the PDZ domain proteins-Stardust (Sdt), Bazooka (Baz) and Scribble (Scrib)-that control epithelial polarity and formation of zonula adherens. We find that these complexes can be ordered into a single regulatory hierarchy that is initiated by cell adhesion-dependent recruitment of the Baz complex to the zonula adherens. The Scrib complex represses apical identity along basolateral surfaces by antagonizing Baz-initiated apical polarity. The Sdt-containing Crb complex is recruited apically by the Baz complex to counter antagonistic Scrib activity. Thus, a finely tuned balance between Scrib and Crb complex activity sets the limits of the apical and basolateral membrane domains and positions cell junctions. Our data suggest a model in which the maturation of epithelial cell polarity is driven by integration of the sequential activities of PDZ-based protein complexes.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Bilder, D (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	bilder@socrates.berkeley.edu		Perrimon, Norbert/0000-0001-7542-472X; Bilder, David/0000-0002-1842-4966				Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Grawe F, 1996, DEVELOPMENT, V122, P951; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; MCDONALD KL, 2000, DROSOPHILA LAB MANUA, P245; McMahon L, 2001, J CELL SCI, V114, P2265; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	35	337	340	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					53	58		10.1038/ncb897	http://dx.doi.org/10.1038/ncb897			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510194				2022-12-25	WOS:000180223700013
J	Lu, W; Wu, XX; Lu, YZ; Guo, WZ; Andrieu, JM				Lu, W; Wu, XX; Lu, YZ; Guo, WZ; Andrieu, JM			Therapeutic dendritic-cell vaccine for simian AIDS	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; SUSTAINED VIRAL SUPPRESSION; HIV-INFECTED PATIENTS; IN-VITRO; IMMUNODEFICIENCY; LYMPHOCYTES; RESPONSES; MEMORY; HAART	An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication. Here, we show in SIV-infected rhesus monkeys that an effective and durable SIV-specific cellular and humoral immunity is elicited by a vaccination with chemically inactivated SIV-pulsed dendritic cells. After three immunizations made at two-week intervals, the animals exhibited a 50-fold decrease of SIV DNA and a 1,000-fold decrease of SIV RNA in peripheral blood. Such reduced viral load levels were maintained over the remaining 34 weeks of the study. Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses. Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immunodeficiency viruses.	Inst Rech Vaccins & Immunotherapie Canc & Sida, Paris, France; Univ Paris 05, Ctr Biomed St Peres, Lab Oncol & Virol Mol, Paris, France; Inst Trop Med, Lab Pathol & Virol, Guangzhou, Peoples R China	UDICE-French Research Universities; Universite Paris Cite	Lu, W (corresponding author), Inst Rech Vaccins & Immunotherapie Canc & Sida, Paris, France.	louis.wei-lu@biomedicale.univ-paris5.fr						ANDRIEU JM, 1995, IMMUNOL TODAY, V16, P5, DOI 10.1016/0167-5699(95)80062-X; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chougnet C, 1999, J IMMUNOL, V163, P1666; Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574; Feldman S, 2001, CLIN IMMUNOL, V101, P201, DOI 10.1006/clim.2001.5111; Fenyo EM, 1996, IMMUNOL LETT, V51, P95, DOI 10.1016/0165-2478(96)02561-8; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004; Gray CM, 1999, J IMMUNOL, V162, P1780; Hatano H, 2000, AIDS, V14, P1357, DOI 10.1097/00002030-200007070-00008; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; Hirsch V M, 2000, Adv Pharmacol, V49, P437; Jin X, 2000, MOL MED, V6, P803, DOI 10.1007/BF03402195; Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; Lieberman J, 2001, BLOOD, V98, P1667, DOI 10.1182/blood.V98.6.1667; Lu W, 2000, BLOOD, V96, P250, DOI 10.1182/blood.V96.1.250.013k28_250_258; Lu W, 1999, NAT MED, V5, P1081, DOI 10.1038/12520; Lu W, 2001, J IMMUNOL, V167, P2929, DOI 10.4049/jimmunol.167.5.2929; LU W, 1995, ADV EXP MED BIOL, V374, P235; Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001; Ludewig B, 1999, J IMMUNOL, V163, P1839; McIlroy D, 1998, AIDS RES HUM RETROV, V14, P505, DOI 10.1089/aid.1998.14.505; Mehlhop E, 2002, J IMMUNOL METHODS, V260, P219, DOI 10.1016/S0022-1759(01)00544-0; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Salerno-Goncalves R, 2000, J VIROL, V74, P6648, DOI 10.1128/JVI.74.14.6648-6651.2000; Sapp M, 1999, IMMUNOL LETT, V66, P121, DOI 10.1016/S0165-2478(98)00169-2; Zimmer MI, 2002, BLOOD, V99, P2859, DOI 10.1182/blood.V99.8.2859	37	192	215	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					27	32		10.1038/nm806	http://dx.doi.org/10.1038/nm806			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496959				2022-12-25	WOS:000180209900018
J	Borrebaeck, CAK; Ohlin, M				Borrebaeck, CAK; Ohlin, M			Antibody evolution beyond Nature	NATURE BIOTECHNOLOGY			English	Editorial Material							LIBRARIES; THERAPY		Lund Univ, Dept Immunotechnol, SE-22007 Lund, Sweden	Lund University	Borrebaeck, CAK (corresponding author), Lund Univ, Dept Immunotechnol, POB 7031, SE-22007 Lund, Sweden.		Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938				Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; Jirholt P, 2002, J MOL BIOL, V318, P407, DOI 10.1016/S0022-2836(02)00087-6; Johnson TA, 2000, ANN HEMATOL, V79, P175, DOI 10.1007/s002770050576; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Sblattero D, 2000, NAT BIOTECHNOL, V18, P75, DOI 10.1038/71958; Soderlind E, 2001, COMB CHEM HIGH T SCR, V4, P409; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458	9	29	43	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1189	1190		10.1038/nbt1202-1189	http://dx.doi.org/10.1038/nbt1202-1189			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12454662				2022-12-25	WOS:000179552600024
J	Carpten, JD; Robbins, CM; Villablanca, A; Forsberg, L; Presciuttini, S; Bailey-Wilson, J; Simonds, WF; Gillanders, EM; Kennedy, AM; Chen, JD; Agarwal, SK; Sood, R; Jones, MP; Moses, TY; Haven, C; Petillo, D; Leotlela, PD; Harding, B; Cameron, D; Pannett, AA; Hoog, A; Heath, H; James-Newton, LA; Robinson, B; Zarbo, RJ; Cavaco, BM; Wassif, W; Perrier, ND; Rosen, IB; Kristoffersson, U; Turnpenny, PD; Farnebo, LO; Besser, GM; Jackson, CE; Morreau, H; Trent, JM; Thakker, RV; Marx, SJ; Teh, BT; Larsson, C; Hobbs, MR				Carpten, JD; Robbins, CM; Villablanca, A; Forsberg, L; Presciuttini, S; Bailey-Wilson, J; Simonds, WF; Gillanders, EM; Kennedy, AM; Chen, JD; Agarwal, SK; Sood, R; Jones, MP; Moses, TY; Haven, C; Petillo, D; Leotlela, PD; Harding, B; Cameron, D; Pannett, AA; Hoog, A; Heath, H; James-Newton, LA; Robinson, B; Zarbo, RJ; Cavaco, BM; Wassif, W; Perrier, ND; Rosen, IB; Kristoffersson, U; Turnpenny, PD; Farnebo, LO; Besser, GM; Jackson, CE; Morreau, H; Trent, JM; Thakker, RV; Marx, SJ; Teh, BT; Larsson, C; Hobbs, MR			HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome	NATURE GENETICS			English	Article							HEREDITARY HYPERPARATHYROIDISM; FAMILIAL HYPERPARATHYROIDISM; PARATHYROID TUMORS; GENE; REGION; LOCUS; CHROMOSOME-11; DISTINCT; 1Q21-Q32; LINKAGE	We report here the identification of a gene associated with the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. A single locus associated with HPT-JT (HRPT2) was previously mapped to chromosomal region 1q25-q32. We refined this region to a critical interval of 12 cM by genotyping in 26 affected kindreds. Using a positional candidate approach, we identified thirteen different heterozygous, germline, inactivating mutations in a single gene in fourteen families with HPT-JT. The proposed role of HRPT2 as a tumor suppressor was supported by mutation screening in 48 parathyroid adenomas with cystic features, which identified three somatic inactivating mutations, all located in exon 1. None of these mutations were detected in normal controls, and all were predicted to cause deficient or impaired protein function. HRPT2 is a ubiquitously expressed, evolutionarily conserved gene encoding a predicted protein of 531 amino acids, for which we propose the name parafibromin. Our findings suggest that HRPT2 is a tumor-suppressor gene, the inactivation of which is directly involved in predisposition to HPT-JT and in development of some sporadic parathyroid tumors.	Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Pathol & Oncol, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Surg Sci, S-10401 Stockholm, Sweden; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Inherited Dis Res Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Metab Dis Branch, Bethesda, MD 20892 USA; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Mol Endocrinol Grp, Oxford OX3 9DU, England; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI USA; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Princess Alexandra Hosp, Dept Endocrinol & Diabet, Brisbane, Qld 4102, Australia; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Sydney, NSW 2006, Australia; Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA; Inst Portugues Oncol Francisco Gentil, Ctr Invest Patobiol Mol, Lisbon, Portugal; Kings Coll London, Sch Med & Dent, Dept Clin Biochem, London, England; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Royal Devon & Exeter Hosp Wonford, Dept Clin Genet, Exeter, Devon, England; St Bartholomews Hosp, Dept Endocrinol, London, England; Henry Ford Hosp, Dept Med Genet, Detroit, MI 48202 USA; Univ Utah, Div Endocrinol, Salt Lake City, UT USA; Univ Utah, Dept Infect Dis, Salt Lake City, UT USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Oxford; Van Andel Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eli Lilly; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Henry Ford Health System; Henry Ford Hospital; Portuguese Institute of Oncology; University of London; King's College London; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lund University; Skane University Hospital; University of Exeter; University of London; Queen Mary University London; Henry Ford Health System; Henry Ford Hospital; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Carpten, JD (corresponding author), Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden.	jdc@nhgri.nih.gov; Catharina.Larsson@cmm.ki.se	Caligo, Adelaide Maria/K-4289-2018; Agarwal, Sunita K/D-1428-2016; Perrier, Nancy/T-7474-2019	Caligo, Adelaide Maria/0000-0003-0589-1829; Agarwal, Sunita K/0000-0002-7557-3191; Perrier, Nancy/0000-0001-5933-1005; Bailey-Wilson, Joan/0000-0002-9153-2920; Thakker, Rajesh/0000-0002-1438-3220; Cavaco, Branca/0000-0001-8946-8635; Kennedy, Ann/0000-0003-0290-396X; Teh, Bin Tean/0000-0003-1514-1124	NATIONAL CANCER INSTITUTE [R01CA075177] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043009, Z01DK043012, Z01DK043006] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; DINNEN JS, 1977, J CLIN PATHOL, V30, P966, DOI 10.1136/jcp.30.10.966; EVERSOLE LR, 1985, ORAL SURG ORAL MED O, V60, P505, DOI 10.1016/0030-4220(85)90239-7; FRIEDMAN E, 1992, CANCER RES, V52, P6804; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hobbs MR, 1999, AM J HUM GENET, V64, P518, DOI 10.1086/302259; Hobbs MR, 2002, AM J HUM GENET, V70, P1376, DOI 10.1086/340093; JACKSON CE, 1967, AM J MED, V43, P727, DOI 10.1016/0002-9343(67)90114-3; JACKSON CE, 1990, SURGERY, V108, P1006; KENNETT S, 1971, ORAL SURG ORAL MED O, V31, P502, DOI 10.1016/0030-4220(71)90347-1; Kerkmann K, 2001, CURR GENET, V39, P284, DOI 10.1007/s002940100229; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Shi XM, 1997, MOL CELL BIOL, V17, P1160, DOI 10.1128/MCB.17.3.1160; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; Sood R, 2001, GENOMICS, V73, P211, DOI 10.1006/geno.2001.6500; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2114, DOI 10.1210/jc.83.6.2114; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; Villablanca A, 2002, CLIN ENDOCRINOL, V56, P259; Wassif WS, 1999, CLIN ENDOCRINOL, V50, P191, DOI 10.1046/j.1365-2265.1999.00633.x; Williamson C, 1999, J BONE MINER RES, V14, P230, DOI 10.1359/jbmr.1999.14.2.230	25	503	524	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2002	32	4					676	680		10.1038/ng1048	http://dx.doi.org/10.1038/ng1048			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12434154				2022-12-25	WOS:000179593000024
J	Colognato, H; Baron, W; Avellana-Adalid, V; Relvas, JB; Baron-Van Evercooren, A; Georges-Labouesse, E; ffrench-Constant, C				Colognato, H; Baron, W; Avellana-Adalid, V; Relvas, JB; Baron-Van Evercooren, A; Georges-Labouesse, E; ffrench-Constant, C			CNS integrins switch growth factor signalling to promote target-dependent survival	NATURE CELL BIOLOGY			English	Article							OLIGODENDROCYTE PROGENITOR CELLS; RAT OPTIC-NERVE; IN-VITRO; SIGNALING PATHWAYS; SCHWANN-CELLS; GLIAL-CELLS; DIFFERENTIATION; NEUREGULIN; PROLIFERATION; SYSTEM	Depending on the stage of development, a growth factor can mediate cell proliferation, survival or differentiation. The interaction of cell-surface integrins with extracellular matrix ligands can regulate growth factor responses and thus may influence the effect mediated by the growth factor. Here we show, by using mice lacking the alpha(6) integrin receptor for laminins, that myelin-forming oligodendrocytes activate an integrin-regulated switch in survival signalling when they contact axonal laminins. This switch alters survival signalling mediated by neuregulin from dependence on the phosphatidylinositol-3-OH kinase (PI(3)K) pathway to dependence on the mitogen-activated kinase pathway. The consequent enhanced survival provides a mechanism for target-dependent selection during development of the central nervous system. This integrin-regulated switch reverses the capacity of neuregulin to inhibit the differentiation of precursors, thereby explaining how neuregulin subsequently promotes differentiation and survival in myelinating oligodendrocytes. Our results provide a general mechanism by which growth factors can exert apparently contradictory effects at different stages of development in individual cell lineages.	Univ Cambridge, Dept Med Genet, Cambridge CB2 2PY, England; Univ Cambridge, Dept Pathol, Cambridge CB2 2PY, England; Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; INSERM, CJF 97 11, Lab Pathol Myeline, F-75634 Paris 13, France; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU De Strasbour, France	University of Cambridge; University of Cambridge; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Colognato, H (corresponding author), Univ Cambridge, Dept Med Genet, Cambridge CB2 2PY, England.		Messier, Claude/A-2322-2008; Relvas, Joao B/A-1142-2008; Evercooren, Anne S Baron-Van/G-3632-2013	Messier, Claude/0000-0002-4791-1763; Relvas, Joao B/0000-0001-7636-0924; Baron-Van Evercooren, Anne/0000-0002-4150-2205				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Blaschuk KL, 2000, DEVELOPMENT, V127, P1961; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burne JF, 1996, J NEUROSCI, V16, P2064; Calaora V, 2001, J NEUROSCI, V21, P4740, DOI 10.1523/JNEUROSCI.21-13-04740.2001; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Canoll PD, 1999, MOL CELL NEUROSCI, V13, P79, DOI 10.1006/mcne.1998.0733; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; Corley SM, 2001, GLIA, V36, P281, DOI 10.1002/glia.1116; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; Ebner S, 2000, J NEUROSCI RES, V62, P336; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Flores AI, 2000, J NEUROSCI, V20, P7622; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frost EE, 1999, CURR BIOL, V9, P1251, DOI 10.1016/S0960-9822(99)80506-5; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Lallier TE, 1996, DEVELOPMENT, V122, P2539; McGowan KA, 2000, MICROSC RES TECHNIQ, V51, P262, DOI 10.1002/1097-0029(20001101)51:3<262::AID-JEMT6>3.0.CO;2-V; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Milner R, 1997, GLIA, V21, P350; Milner R, 1996, J NEUROSCI, V16, P7240; MILNER R, 1994, DEVELOPMENT, V120, P3497; Morissette N, 1995, J NEUROSCI, V15, P8067; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Osterhout DJ, 2002, J NEUROSCI RES, V69, P24, DOI 10.1002/jnr.10230; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; Powell SK, 1998, J NEUROSCI RES, V54, P233, DOI 10.1002/(SICI)1097-4547(19981015)54:2<233::AID-JNR11>3.0.CO;2-5; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; Relvas JB, 2001, CURR BIOL, V11, P1039, DOI 10.1016/S0960-9822(01)00292-5; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sperber BR, 2001, J NEUROSCI, V21, P2039, DOI 10.1523/JNEUROSCI.21-06-02039.2001; Stariha RL, 1997, J NEUROCHEM, V68, P945; Tian M, 1997, BRAIN RES, V764, P28, DOI 10.1016/S0006-8993(97)00420-4; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; Vitry S, 1999, J NEUROSCI RES, V58, P735; Zhang ZQ, 1998, J NEUROSCI, V18, P6928	48	200	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					833	841		10.1038/ncb865	http://dx.doi.org/10.1038/ncb865			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12379866				2022-12-25	WOS:000179137700011
J	Nahle, Z; Polakoff, J; Davuluri, RV; McCurrach, ME; Jacobson, MD; Narita, M; Zhang, MQ; Lazebnik, Y; Bar-Sagi, D; Lowe, SW				Nahle, Z; Polakoff, J; Davuluri, RV; McCurrach, ME; Jacobson, MD; Narita, M; Zhang, MQ; Lazebnik, Y; Bar-Sagi, D; Lowe, SW			Direct coupling of the cell cycle and cell death machinery by E2F	NATURE CELL BIOLOGY			English	Article							IN-VIVO; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL TARGET; TUMOR SUPPRESSION; S-PHASE; P53; PROTEINS; EXPRESSION; ACTIVATION; CASPASE-9	Unrestrained E2F activity forces S phase entry and promotes apoptosis through p53-dependent and -independent mechanisms. Here, we show that deregulation of E2F by adenovirus E1A, loss of Rb or enforced E2F-1 expression results in the accumulation of caspase proenzymes through a direct transcriptional mechanism. Increased caspase levels seem to potentiate cell death in the presence of p53-generated signals that trigger caspase activation. Our results demonstrate that mitogenic oncogenes engage a tumour suppressor network that functions at multiple levels to efficiently induce cell death. The data also underscore how cell cycle progression can be coupled to the apoptotic machinery.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Nahle, Z (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Davuluri, Ramana/D-7348-2011	Narita, Masashi/0000-0001-7764-577X; Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [P01CA013106, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106, P30 CA008748] Funding Source: Medline; NHGRI NIH HHS [HG01696] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Robles AI, 2001, CANCER RES, V61, P6660; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	36	349	356	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					859	864		10.1038/ncb868	http://dx.doi.org/10.1038/ncb868			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12389032				2022-12-25	WOS:000179137700014
J	Sax, JK; Fei, PW; Murphy, ME; Bernhard, E; Korsmeyer, SJ; El-Deiry, WS				Sax, JK; Fei, PW; Murphy, ME; Bernhard, E; Korsmeyer, SJ; El-Deiry, WS			BID regulation by p53 contributes to chemosensitivity	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CYTOCHROME-C RELEASE; APOPTOSIS IN-VIVO; P53-DEPENDENT APOPTOSIS; POTENTIAL MEDIATOR; DEATH RECEPTOR; CANCER-CELLS; BINDING-SITE; BCL-2 FAMILY; GENE	The role of the p53 protein (encoded by TP53) in tumour suppression relies partly on the ability of p53 to regulate the transcription of genes that are important in cell-cycle arrest and in apoptosis. But the apoptotic pathway mediated by p53 is not fully understood. Here we show that BID, a member of the pro-apoptotic Bcl-2 family of proteins, is regulated by p53. BID mRNA is increased in a p53-dependent manner in vitro and in vivo, with strong expression in the splenic red pulp and colonic epithelium of gamma-irradiated mice. Both the human and the mouse BID genomic loci contain p53-binding DNA response elements that bind p53 and mediate p53-dependent transactivation of a reporter gene. In addition, BID-null mouse embryonic fibroblasts are more resistant than are wild-type fibroblasts to the DNA damaging agent adriamycin and the nucleotide analogue 5-fluorouracil, both of which stabilize endogenous p53. Our results indicate that BID is a p53-responsive 'chemosensitivity gene' that may enhance the cell death response to chemotherapy.	Univ Penn, Sch Med, Dept Med,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Howard Hughes Med Inst,Lab Mol Oncol & Cell Cycle, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Howard Hughes Med Inst,Lab Mol Oncol & Cell Cycle, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol,Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Howard Hughes Med Inst, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Fox Chase Cancer Center; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Sax, JK (corresponding author), Univ Penn, Sch Med, Dept Med,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Murphy, Maureen/0000-0001-7644-7296				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Attardi LD, 2000, GENE DEV, V14, P704; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; KADKOL S, 2003, TUMOR SUPPRESSOR GEN, V2; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, GENOMICS, V53, P235, DOI 10.1006/geno.1998.5489; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1996, ONCOGENE, V12, P1557; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	50	320	329	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					842	849		10.1038/ncb866	http://dx.doi.org/10.1038/ncb866			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402042				2022-12-25	WOS:000179137700012
J	Daizadeh, I; Miller, D; Glowalla, A; Leamer, M; Nandi, R; Numark, CI				Daizadeh, I; Miller, D; Glowalla, A; Leamer, M; Nandi, R; Numark, CI			A general approach for determining when to patent, publish, or protect information as a trade secret	NATURE BIOTECHNOLOGY			English	Editorial Material									OMelveny Consulting, Los Angeles, CA 90067 USA		Daizadeh, I (corresponding author), OMelveny Consulting, 1999 Ave Stars,9th Floor, Los Angeles, CA 90067 USA.							AMJAD HM, 2002, BUSINESS J      0201; Barrett B, 2002, NAT BIOTECHNOL, V20, P191, DOI 10.1038/nbt0202-191	2	8	9	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					1053	1054		10.1038/nbt1002-1053	http://dx.doi.org/10.1038/nbt1002-1053			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12355117				2022-12-25	WOS:000178313100026
J	Plusa, B; Grabarek, JB; Piotrowska, K; Glover, DM; Zernicka-Goetz, M				Plusa, B; Grabarek, JB; Piotrowska, K; Glover, DM; Zernicka-Goetz, M			Site of the previous meiotic division defines cleavage orientation in the mouse embryo	NATURE CELL BIOLOGY			English	Article							VEGETAL POLES; IMPLANTATION; DYNACTIN; POLARITY; DYNEIN	The conservation of early cleavage patterns in organisms as diverse as echinoderms and mammals suggests that even in highly regulative embryos such as the mouse, division patterns might be important for development(1-4). Indeed, the first cleavage divides the fertilized mouse egg into two cells: one cell that contributes predominantly to the embryonic part of the blastocyst, and one that contributes to the abembryonic part(5,6). Here we show, by removing, transplanting or duplicating the animal or vegetal poles of the mouse egg, that a spatial cue at the animal pole orients the plane of this initial division. Embryos with duplicated animal, but not vegetal, poles show abnormalities in chromosome segregation that compromise their development. Our results show that localized factors in the mammalian egg orient the spindle and so define the initial cleavage plane. In increased dosage, however, these factors are detrimental to the correct execution of division.	Wellcome Trust Canc Res UK Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Canc Res UK Cell Cycle Genet Res Grp, Cambridge CB2 3EH, England; Polish Acad Sci, Dept Expt Embryol, PL-0555 Jastrzebiec, Poland	University of Cambridge; Polish Academy of Sciences	Plusa, B (corresponding author), Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.		Grabarek, Joanna/AAH-4253-2020	Plusa, Berenika/0000-0003-2214-5940; Glover, David/0000-0003-0956-0103; Zernicka-Goetz, Magdalena/0000-0002-7004-2471	Wellcome Trust [064421] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Antczak M, 1997, MOL HUM REPROD, V3, P1067, DOI 10.1093/molehr/3.12.1067; BLOOM, 2001, CURR BIOL, V11, pR326; Brunet S, 1998, CURR BIOL, V8, P1231, DOI 10.1016/S0960-9822(07)00516-7; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Ciemerych MA, 2000, DEVELOPMENT, V127, P3467; Davies TJ, 2002, HUM REPROD, V17, P2368, DOI 10.1093/humrep/17.9.2368; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; GRAHAM CF, 1978, J EMBRYOL EXP MORPH, V48, P53; GULYAS BJ, 1975, J EXP ZOOL, V193, P235, DOI 10.1002/jez.1401930212; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; Piotrowska K, 2001, DEVELOPMENT, V128, P3739; Piotrowska K, 2001, NATURE, V409, P517, DOI 10.1038/35054069; Plusa B, 2002, GENESIS, V32, P193, DOI 10.1002/gene.10027; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; Zernicka-Goetz M, 2002, DEVELOPMENT, V129, P815; Zernicka-Goetz M, 1998, DEVELOPMENT, V125, P4803; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133	20	57	62	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					811	815		10.1038/ncb860	http://dx.doi.org/10.1038/ncb860			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360292				2022-12-25	WOS:000178316500019
J	Ewart-Toland, A; Briassouli, P; de Koning, JP; Mao, JH; Yuan, JW; Chan, F; MacCarthy-Morrogh, L; Ponder, BAJ; Nagase, H; Burn, J; Ball, S; Almeida, M; Linardopoulos, S; Balmain, A				Ewart-Toland, A; Briassouli, P; de Koning, JP; Mao, JH; Yuan, JW; Chan, F; MacCarthy-Morrogh, L; Ponder, BAJ; Nagase, H; Burn, J; Ball, S; Almeida, M; Linardopoulos, S; Balmain, A			Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; CENTROSOME AMPLIFICATION; COLORECTAL CANCERS; BREAST-CANCER; SKIN TUMORS; KINASE; LOCUS; ASSOCIATION; MICE	Linkage analysis and haplotype mapping in interspecific mouse crosses (Mus musculus x Mus spretus) identified the gene encoding Aurora2 (Stk6 in mouse and STK15 in human) as a candidate skin tumor susceptibility gene. The Stk6 allele inherited from the susceptible M. musculus parent was overexpressed in normal cells and preferentially amplified in tumor cells from F 1 hybrid mice. We identified a common genetic variant in STK15 ( resulting in the amino acid substitution F31I) that is preferentially amplified and associated with the degree of aneuploidy in human colon tumors. The Ile31 variant transforms rat1 cells more potently than the more common Phe31 variant. The E2 ubiquitin-conjugating enzyme UBE2N was a preferential binding partner of the weak STK15 Phe31 variant form in yeast two-hybrid screens and in human cells. This interaction results in colocalization of UBE2N with STK15 at the centrosomes during mitosis. These results are consistent with an important role for the Ile31 variant of STK15 in human cancer susceptibility.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Inst Canc Res, Haddows Labs, Ctr Canc Therapeut, Canc Res UK, Sutton SM2 5NG, Surrey, England; Strangeways Res Labs, Univ Dept Oncol, Human Canc Genet Grp, Canc Res UK, Cambridge CB1 8RN, England; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Inst Human Genet, Newcastle Upon Tyne NE1 3B2, Tyne & Wear, England; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Roswell Park Cancer Institute; University of California System; University of California San Francisco	Linardopoulos, S (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA.	spiros@icr.ac.uk; abalmain@cc.ucsf.edu	Toland, Amanda Ewart/E-4202-2011; Mao, Jian-Hua/EIZ-8595-2022; Almeida, Maria Rosário/C-4385-2018	Mao, Jian-Hua/0000-0001-9320-6021; Almeida, Maria Rosário/0000-0002-1889-5469; Linardopoulos, Spiros/0000-0002-6600-400X; Toland, Amanda/0000-0002-0271-1792; Burn, John/0000-0002-9823-2322				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Berry R, 2000, AM J HUM GENET, V67, P82, DOI 10.1086/302994; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; Giet R, 1999, J CELL SCI, V112, P3591; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KEMP CJ, 1993, CANCER RES, V53, P6022; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SEGRAVES R, 2002, DNA ARRAYS LAB MANUA, P380; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	39	280	295	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					403	412		10.1038/ng1220	http://dx.doi.org/10.1038/ng1220			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12881723				2022-12-25	WOS:000184470500018
J	Gibbons, RJ; Pellagatti, A; Garrick, D; Wood, WG; Malik, N; Ayyub, H; Langford, C; Boultwood, J; Wainscoat, JS; Higgs, DR				Gibbons, RJ; Pellagatti, A; Garrick, D; Wood, WG; Malik, N; Ayyub, H; Langford, C; Boultwood, J; Wainscoat, JS; Higgs, DR			Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS)	NATURE GENETICS			English	Article							PIG-A GENE; MENTAL-RETARDATION; MOLECULAR ANALYSIS; CLINICAL-FEATURES; GLOBIN; SPECTRUM	Inherited mutations of specific genes have elucidated the normal roles of the proteins they encode by relating specific mutations to particular phenotypes. But many potentially informative mutations in such genes are lethal early in development. Consequently, inherited mutations may not reflect all the functional roles of such proteins. Acquired, somatic defects should reflect a wider spectrum of mutations because they are not prone to negative selection in development. It has been difficult to identify such mutations so far, but microarray analysis provides a new opportunity to do so. Using this approach, we have shown that in individuals with myelodysplasia associated with alpha-thalassemia (ATMDS), somatic mutations of the gene encoding the chromatin remodeling factor ATRX cause an unexpectedly severe hematological phenotype compared with the wide spectrum of inherited mutations affecting this gene. These findings cast new light on this pleiotropic cofactor, which appears to be an essential component rather than a mere facilitator of globin gene expression.	John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England; John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, LRF Mol Haematol Unit, Oxford OX3 9DS, England; Sanger Ctr, Cambridge, England	University of Oxford; University of Oxford; Wellcome Trust Sanger Institute	Higgs, DR (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England.	drhiggs@molbiol.ox.ac.uk	Garrick, David/F-1728-2017; GARRICK, David/O-5734-2019; Gibbons, Richard/E-6937-2011	Garrick, David/0000-0001-7422-7986; GARRICK, David/0000-0001-7422-7986; Boultwood, Jacqueline/0000-0002-4330-2928; Gibbons, Richard/0000-0002-7680-9311; Pellagatti, Andrea/0000-0002-6122-0221				Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; CRADDOCK CF, 1995, EMBO J, V14, P1718, DOI 10.1002/j.1460-2075.1995.tb07161.x; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 2000, AM J MED GENET, V97, P204, DOI 10.1002/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X; HAPPLE R, 1986, CLIN GENET, V29, P321; Higgs D., 2001, DISORDERS HEMOGLOBIN, P431; HIGGS DR, 1983, AM J MED, V75, P181, DOI 10.1016/0002-9343(83)91189-0; HIGGS DR, 1989, BLOOD, V73, P1081; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Nafa K, 1998, BLOOD CELL MOL DIS, V24, P370, DOI 10.1006/bcmd.1998.0203; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Wada T, 2003, CONTEMPORARY CLIN NE, P309; WEATHERALL DJ, 1978, BRIT J HAEMATOL, V38, P305, DOI 10.1111/j.1365-2141.1978.tb01049.x; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127	16	105	108	3	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					446	449		10.1038/ng1213	http://dx.doi.org/10.1038/ng1213			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12858175				2022-12-25	WOS:000184470500024
J	Allan, LA; Morrice, N; Brady, S; Magee, G; Pathak, S; Clarke, PR				Allan, LA; Morrice, N; Brady, S; Magee, G; Pathak, S; Clarke, PR			Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; PROTEIN-KINASE; APOPTOSIS; ACTIVATION; APAF-1; SURVIVAL; PATHWAYS; PROCASPASE-9; MITOCHONDRIA	Many pro-apoptotic signals activate caspase-9, an initiator protease that activates caspase-3 and downstream caspases to initiate cellular destruction(1). However, survival signals can impinge on this pathway and suppress apoptosis. Activation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase ( MAPK) pathway is associated with protection of cells from apoptosis and inhibition of caspase-3 activation(2-5), although the targets are unknown. Here, we show that the ERK MAPK pathway inhibits caspase-9 activity by direct phosphorylation. In mammalian cell extracts, cytochrome c-induced activation of caspases-9 and -3 requires okadaic-acid-sensitive protein phosphatase activity. The opposing protein kinase activity is overcome by treatment with the broad-specificity kinase inhibitor staurosporine or with inhibitors of MEK1/2. Caspase-9 is phosphorylated at Thr 125, a conserved MAPK consensus site targeted by ERK2 in vitro, in a MEK-dependent manner in cells stimulated with epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol-13-acetate (TPA). Phosphorylation at Thr 125 is sufficient to block caspase-9 processing and subsequent caspase-3 activation. We suggest that phosphorylation and inhibition of caspase-9 by ERK promotes cell survival during development and tissue homeostasis. This mechanism may also contribute to tumorigenesis when the ERK MAPK pathway is constitutively activated.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.		Clarke, Paul/B-1684-2009; Clarke, Paul R./AAA-6803-2020	Clarke, Paul/0000-0003-3525-2622; 				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CLARKE PR, 2002, APOPTOSIS MOL BIOL P, P176; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	368	384	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					647	U45		10.1038/ncb1005	http://dx.doi.org/10.1038/ncb1005			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12792650				2022-12-25	WOS:000183911600015
J	Lisby, M; Mortensen, UH; Rothstein, R				Lisby, M; Mortensen, UH; Rothstein, R			Colocalization of multiple DNA double-strand breaks at a single Rad52 repair centre	NATURE CELL BIOLOGY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL TRANSLOCATIONS; FLUORESCENT PROTEIN; RECOMBINATION; YEAST; DYNAMICS; DAMAGE; CHECKPOINT; COMPLEXES	DNA double-strand break repair (DSBR) is an essential process for preserving genomic integrity in all organisms. To investigate this process at the cellular level, we engineered a system of fluorescently marked DNA double-strand breaks (DSBs) in the yeast Saccharomyces cerevisiae to visualize in vivo DSBR in single cells. Using this system, we demonstrate for the first time that Rad52 DNA repair foci and DSBs colocalize. Time-lapse microscopy reveals that the relocalization of Rad52 protein into a focal assembly is a rapid and reversible process. In addition, analysis of DNA damage checkpoint-deficient cells provides direct evidence for coordination between DNA repair and subsequent release from checkpoint arrest. Finally, analyses of cells experiencing multiple DSBs demonstrate that Rad52 foci are centres of DNA repair capable of simultaneously recruiting more than one DSB.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Tech Univ Denmark, Ctr Proc Biotechnol, Biocentrum, DK-2800 Lyngby, Denmark	Columbia University; Technical University of Denmark	Rothstein, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.	rothstein@cancercenter.columbia.edu	Lisby, Michael/K-9814-2014; Mortensen, Uffe/AAQ-1150-2021	Lisby, Michael/0000-0002-4830-5247; Rothstein, Rodney/0000-0002-4107-9654				Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Haber JE, 1996, P NATL ACAD SCI USA, V93, P13949, DOI 10.1073/pnas.93.24.13949; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Melo JA, 2001, GENE DEV, V15, P2809; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; PLESSIS A, 1992, GENETICS, V130, P451; Ranatunga W, 2001, J BIOL CHEM, V276, P15876, DOI 10.1074/jbc.M011747200; Reid RJD, 2002, METHOD ENZYMOL, V350, P258; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Smith KN, 1998, CURR OPIN GENET DEV, V8, P200, DOI 10.1016/S0959-437X(98)80142-1; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9	30	330	335	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					572	577		10.1038/ncb997	http://dx.doi.org/10.1038/ncb997			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12766777				2022-12-25	WOS:000183202800020
J	Sans, N; Prybylowski, K; Petralia, RS; Chang, K; Wang, YX; Racca, C; Vicini, S; Wenthold, RJ				Sans, N; Prybylowski, K; Petralia, RS; Chang, K; Wang, YX; Racca, C; Vicini, S; Wenthold, RJ			NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex	NATURE CELL BIOLOGY			English	Article							ER RETENTION SIGNAL; SEC6/8 COMPLEX; PLASMA-MEMBRANE; AMPA RECEPTORS; BIOCHEMICAL-EVIDENCE; GLUTAMATE RECEPTORS; SUBUNIT COMPOSITION; SURFACE EXPRESSION; SYNAPSES; DOMAINS	NMDA (N-methyl-D-aspartate) receptors (NMDARs) are targeted to dendrites and anchored at the post-synaptic density (PSD) through interactions with PDZ proteins. However, little is known about how these receptors are sorted from the endoplasmic reticulum and Golgi apparatus to the synapse. Here, we find that synapse-associated protein 102 (SAP102) interacts with the PDZ-binding domain of Sec8, a member of the exocyst complex. Our results show that interactions between SAP102 and Sec8 are involved in the delivery of NMDARs to the cell surface in heterologous cells and neurons. Furthermore, they suggest that an exocyst-SAP102-NMDAR complex is an important component of NMDAR trafficking.	Natl Inst Deafness & Other Commun Disorders, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Dept Physiol & Biophys, Med Ctr, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Georgetown University	Sans, N (corresponding author), Natl Inst Deafness & Other Commun Disorders, Neurochem Lab, NIH, Bldg 50,Room 4146,50 South Dr, Bethesda, MD 20892 USA.	sansn@nidcd.nih.gov	Sans, Nathalie/N-7008-2017	Sans, Nathalie/0000-0001-7658-2471; Vicini, Stefano/0000-0001-8671-5194	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, Z01DC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; Chazot PL, 1997, J NEUROCHEM, V68, P507; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Harris BZ, 2001, J CELL SCI, V114, P3219; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Kittler JT, 2001, TRAFFIC, V2, P437, DOI 10.1034/j.1600-0854.2001.20702.x; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Losi G, 2002, J NEUROPHYSIOL, V87, P1263, DOI 10.1152/jn.00633.2001; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Mori H, 1998, NEURON, V21, P571, DOI 10.1016/S0896-6273(00)80567-X; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Okabe S, 1999, J NEUROSCI, V19, P7781; Petralia RS, 2000, HAND CHEM N, V18, P145; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088	47	243	257	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					520	530		10.1038/ncb990	http://dx.doi.org/10.1038/ncb990			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12738960				2022-12-25	WOS:000183202800012
J	Taniguchi, T; Tischkowitz, M; Ameziane, N; Hodgson, SV; Mathew, CG; Joenje, H; Mok, SC; D'Andrea, AD				Taniguchi, T; Tischkowitz, M; Ameziane, N; Hodgson, SV; Mathew, CG; Joenje, H; Mok, SC; D'Andrea, AD			Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors	NATURE MEDICINE			English	Article							CANCER CELL-LINES; CARCINOMA CELLS; DRUG-RESISTANCE; BREAST-CANCER; FUNCTIONAL-ACTIVITY; HMLH1 EXPRESSION; NUCLEAR-COMPLEX; GENE-EXPRESSION; PROTEINS; INACTIVATION	Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.	Guys Kings & St Thomas Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, London, England; Guys Kings & St Thomas Sch Med, Div Genet & Dev, London, England; Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, Amsterdam, Netherlands; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA	University of London; King's College London; University of London; King's College London; Vrije Universiteit Amsterdam; Harvard University; Brigham & Women's Hospital; Harvard Medical School	D'Andrea, AD (corresponding author), Guys Kings & St Thomas Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, London, England.		Tischkowitz, Marc/O-4452-2018; Taniguchi, Toshiyasu/ADD-8489-2022; 高, 雨莉/HGU-8187-2022; Mathew, Christopher G/G-3434-2015	Tischkowitz, Marc/0000-0002-7880-0628; Mathew, Christopher G/0000-0003-4178-1838; Taniguchi, Toshiyasu/0000-0002-7746-3658	NHLBI NIH HHS [R01HL52725, P01HL54785] Funding Source: Medline; NIDDK NIH HHS [R01 DK43889] Funding Source: Medline; PHS HHS [P0150654] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052725, P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043889] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PA, 1992, CANCER RES, V52, P1895; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61; HAMILTON TC, 1983, CANCER RES, V43, P5379; Harper P, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.33525; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HILLS CA, 1989, BRIT J CANCER, V59, P527, DOI 10.1038/bjc.1989.108; Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Husain A, 1998, GYNECOL ONCOL, V70, P17, DOI 10.1006/gyno.1998.4972; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Kiguchi K, 1998, JPN J CANCER RES, V89, P923, DOI 10.1111/j.1349-7006.1998.tb00650.x; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Kuang Y, 2000, BLOOD, V96, P1625, DOI 10.1182/blood.V96.5.1625.h8001625a_1625_1632; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEWIS AD, 1988, CARCINOGENESIS, V9, P1283, DOI 10.1093/carcin/9.7.1283; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Naf D, 1998, MOL CELL BIOL, V18, P5952; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Plumb JA, 2000, CANCER RES, V60, P6039; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; Shimamura A, 2002, BLOOD, V100, P4649, DOI 10.1182/blood-2002-05-1399; Siddique MA, 2001, EXP HEMATOL, V29, P1448, DOI 10.1016/S0301-472X(01)00754-8; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; WILSON AP, 1984, J NATL CANCER I, V72, P513; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435	45	444	479	1	38	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					568	574		10.1038/nm852	http://dx.doi.org/10.1038/nm852			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692539				2022-12-25	WOS:000182610600038
J	Slager, RE; Lynn, T; Newton, TL; Vlangos, CN; Finucane, B; Elsea, SH				Slager, RE; Lynn, T; Newton, TL; Vlangos, CN; Finucane, B; Elsea, SH			Mutations in RAI1 associated with Smith-Magenis syndrome	NATURE GENETICS			English	Article							CRITICAL INTERVAL; GENE; 17P11.2; DELETION; MOUSE	Smith-Magenis syndrome (SMS) is a mental retardation syndrome associated with deletions involving chromosome 17p11.2. Persons with SMS have characteristic behavioral abnormalities, including self-injurious behaviors and sleep disturbance, and distinct craniofacial and skeletal anomalies. We identified dominant frameshift mutations leading to protein truncation in RAI1 in three individuals who have phenotypic features consistent with SMS but do not have 17p11.2 deletions detectable by standard fluorescence in situ hybridization techniques.	Michigan State Univ, Grad Program Genet, E Lansing, MI 48823 USA; Michigan State Univ, Dept Zool, E Lansing, MI 48823 USA; Michigan State Univ, Dept Pediat Human Dev, E Lansing, MI 48823 USA; Elwyn Training & Res Inst, Elwyn, PA 19063 USA	Michigan State University; Michigan State University; Michigan State University	Elsea, SH (corresponding author), Michigan State Univ, Grad Program Genet, S-320 Plant Biol Bldg, E Lansing, MI 48823 USA.			Elsea, Sarah/0000-0002-1400-8519; Finucane, Brenda/0000-0003-4841-669X				Bi WM, 2002, GENOME RES, V12, P713, DOI 10.1101/gr.73702; Elsea SH, 1997, CYTOGENET CELL GENET, V79, P276, DOI 10.1159/000134742; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; Greenberg F, 1996, AM J MED GENET, V62, P247, DOI 10.1002/(SICI)1096-8628(19960329)62:3<247::AID-AJMG9>3.3.CO;2-9; IMAI Y, 1995, MOL BRAIN RES, V31, P1, DOI 10.1016/0169-328X(95)00020-S; Juyal RC, 1996, AM J HUM GENET, V58, P998; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Lucas RE, 2001, EUR J HUM GENET, V9, P892, DOI 10.1038/sj.ejhg.5200734; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Rekdal C, 2000, J BIOL CHEM, V275, P40288, DOI 10.1074/jbc.M006978200; Seranski P, 2001, GENE, V270, P69, DOI 10.1016/S0378-1119(01)00415-2; Smith ACM, 1998, AM J MED GENET, V81, P179, DOI 10.1002/(SICI)1096-8628(19980328)81:2<179::AID-AJMG10>3.0.CO;2-E; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; VLANGOS CN, IN PRESS MOL GENET M	15	230	240	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					466	468		10.1038/ng1126	http://dx.doi.org/10.1038/ng1126			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12652298	Bronze			2022-12-25	WOS:000181928600016
J	Gonda, K; Fowler, J; Katoku-Kikyo, N; Haroldson, J; Wudel, J; Kikyo, N				Gonda, K; Fowler, J; Katoku-Kikyo, N; Haroldson, J; Wudel, J; Kikyo, N			Reversible disassembly of somatic nucleoli by the germ cell proteins FRGY2a and FRGY2b	NATURE CELL BIOLOGY			English	Article							COLD-SHOCK DOMAIN; POLYMERASE-I TRANSCRIPTION; RNA-BINDING-PROTEINS; Y-BOX PROTEINS; MESSENGER-RNA; XENOPUS-LAEVIS; OOCYTES; ULTRASTRUCTURE; TRANSPLANTATION; RECOGNITION	Egg cytoplasm has the capability to reprogramme differentiated somatic nuclei, as shown by nuclear transplantation in animal cloning(1,2). The nucleoli of donor nuclei are rapidly disassembled on injection into interphase eggs and are correctly reassembled when donor transcription initiates in the early embryos of frogs and mammals, recapitulating the physiological nucleolar dynamics of early embryogenesis(3-6). This is one of the most remarkable structural reorganizations of somatic nuclei in nuclear cloning. Despite the long history of nuclear cloning, almost nothing is known about the molecular mechanism of nucleolar disassembly in egg cytoplasm. Here we show that the Xenopus germ cell proteins FRGY2a and FRGY2b(7-9) reversibly disassemble somatic nucleoli in egg cytoplasm, independently of continuing ribosomal RNA transcription. The carboxy-terminal domain of FRGY2a, which localizes to the nucleoli, is sufficient for nucleolar disassembly in transfected cells. Our results show that a single protein fragment can trigger reversible disassembly of the complex nucleolar structure.	Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kikyo, N (corresponding author), Univ Minnesota, Stem Cell Inst, Mayo Mail Code 716,420 Delaware St, Minneapolis, MN 55455 USA.	kikyo001@tc.umn.edu						BOUVET P, 1995, J BIOL CHEM, V270, P28297; CAIRNS C, 1995, NUCLEIC ACIDS RES, V23, P4583, DOI 10.1093/nar/23.22.4583; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Darzynkiewicz Z, 1990, Methods Cell Biol, V33, P285; GOESSENS G, 1984, INT REV CYTOL, V87, P107, DOI 10.1016/S0074-7696(08)62441-9; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; GURDON JB, 1965, J MOL BIOL, V12, P27, DOI 10.1016/S0022-2836(65)80279-0; GURDON JB, 1968, J EMBRYOL EXP MORPH, V20, P401; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Kanka J, 1999, MOL REPROD DEV, V52, P253, DOI 10.1002/(SICI)1098-2795(199903)52:3&lt;253::AID-MRD2&gt;3.0.CO;2-N; Kanka J, 1996, MOL REPROD DEV, V43, P135, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;135::AID-MRD1&gt;3.0.CO;2-S; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; Ochs RL, 1998, METHOD CELL BIOL, V53, P303; Ouhibi N, 1996, MOL REPROD DEV, V44, P533, DOI 10.1002/(SICI)1098-2795(199608)44:4&lt;533::AID-MRD13&gt;3.0.CO;2-Z; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Sambrook J, 2001, MOL CLONING LAB MANU; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; Simard R, 1970, Int Rev Cytol, V28, P169, DOI 10.1016/S0074-7696(08)62543-7; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; SPECTOR DL, 1997, CELLS LAB MANUAL; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; Verheggen C, 1998, J CELL BIOL, V142, P1167, DOI 10.1083/jcb.142.5.1167; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yurkova MS, 1997, J BIOL CHEM, V272, P10870	30	69	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					205	U4		10.1038/ncb939	http://dx.doi.org/10.1038/ncb939			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12589397				2022-12-25	WOS:000181322500012
J	Brancaccio, M; Fratta, L; Notte, A; Hirsch, E; Poulet, R; Guazzone, S; De Acetis, M; Vecchione, C; Marino, G; Altruda, F; Silengo, L; Tarone, G; Lembo, G				Brancaccio, M; Fratta, L; Notte, A; Hirsch, E; Poulet, R; Guazzone, S; De Acetis, M; Vecchione, C; Marino, G; Altruda, F; Silengo, L; Tarone, G; Lembo, G			Melusin, a muscle-specific integrin beta(1)-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload	NATURE MEDICINE			English	Article							SYNTHASE KINASE 3-BETA; IN-VIVO; HEART-FAILURE; HYPERTROPHY; MECHANISMS; STRESS; PATHWAYS; TRANSCRIPTION; ACTIVATION; INTEGRINS	Cardiac hypertrophy is an adaptive response to a variety of mechanical and hormonal stimuli, and represents an early event in the clinical course leading to heart failure. By gene inactivation, we demonstrate here a crucial role of melusin, a muscle-specific protein that interacts with the integrin 1 cytoplasmic domain, in the hypertrophic response to mechanical overload. Melusin-null mice showed normal cardiac structure and function in physiological conditions, but when subjected to pressure overload-a condition that induces a hypertrophic response in wild-type controls-they developed an abnormal cardiac remodeling that evolved into dilated cardiomyopathy and contractile dysfunction. In contrast, the hypertrophic response was identical in wildtype and melusin-null mice after chronic administration of angiotensin II or phenylephrine at doses that do not increase blood pressure-that is, in the absence of cardiac biomechanical stress. Analysis of intracellular signaling events induced by pressure overload indicated that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was specifically blunted in melusin-null hearts. Thus, melusin prevents cardiac dilation during chronic pressure overload by specifically sensing mechanical stress.	Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; IRCCS Neuromed, Dept Angiocardioneurol, I-86077 Pozzilli, IS, Italy; San Giovanni Battista Hosp, Expt Med Res Ctr, I-10126 Turin, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	University of Turin; IRCCS Neuromed; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Sapienza University Rome	Tarone, G (corresponding author), Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy.	guido.tarone@unito.it; lembo@neuromed.it	Hirsch, Emilio/F-4848-2013; Vecchione, Carmine/K-2175-2018; Lembo, Giuseppe/AAE-8096-2020	Hirsch, Emilio/0000-0002-9073-6024; Lembo, Giuseppe/0000-0002-3510-223X; Vecchione, Carmine/0000-0002-2473-4565; Tarone, Guido/0000-0003-4805-086X; maffei, angelo/0000-0002-7491-0344	Telethon [1327] Funding Source: Medline	Telethon(Fondazione Telethon)		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Brancaccio M, 1999, J BIOL CHEM, V274, P29282, DOI 10.1074/jbc.274.41.29282; Brancaccio M, 1998, CELL ADHES COMMUN, V5, P193, DOI 10.3109/15419069809040291; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Fassler R, 1996, J CELL SCI, V109, P2989; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Keller RS, 2001, AM J PATHOL, V158, P1079, DOI 10.1016/S0002-9440(10)64055-2; Lembo G, 1996, J CLIN INVEST, V98, P2648, DOI 10.1172/JCI119086; MacLellan WR, 2000, CURR OPIN CARDIOL, V15, P128, DOI 10.1097/00001573-200005000-00002; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Norton GR, 2002, J AM COLL CARDIOL, V39, P664, DOI 10.1016/S0735-1097(01)01792-2; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Schultz JEJ, 2002, J CLIN INVEST, V109, P787, DOI 10.1172/JCI200214190; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221	42	223	234	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					68	75		10.1038/nm805	http://dx.doi.org/10.1038/nm805			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496958				2022-12-25	WOS:000180209900024
J	Chang, P; Giddings, TH; Winey, M; Stearns, T				Chang, P; Giddings, TH; Winey, M; Stearns, T			epsilon-tubulin is required for centriole duplication and microtubule organization	NATURE CELL BIOLOGY			English	Article							DELTA-TUBULIN; IN-VITRO; CENTROSOME; IDENTIFICATION; CYCLES; CELLS	Centrosomes nucleate microtubules and serve as poles of the mitotic spindle. Centrioles are a core component of centrosomes and duplicate once per cell cycle. We previously identified epsilon-tubulin as a new member of the tubulin superfamily that localizes asymmetrically to the two centrosomes after duplication. We show that recruitment of epsilon-tubulin to the new centrosome can only occur after exit from S phase and that epsilon-tubulin is associated with the sub-distal appendages of mature centrioles. Xenopus laevis epsilon-tubulin was cloned and shown to be similar to human epsilon-tubulin in both sequence and localization. Depletion of epsilon-tubulin from Xenopus egg extracts blocks centriole duplication in S phase and formation of organized centrosome-independent microtubule asters in M phase. We conclude that E-tubulin is a component of the sub-distal appendages of the centriole, explaining its asymmetric localization to old and new centrosomes, and that epsilon-tubulin is required for centriole duplication and organization of the pericentriolar material.	Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; University of Colorado System; University of Colorado Boulder; Stanford University	Stearns, T (corresponding author), Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA.	stearns@stanford.edu		Stearns, Tim/0000-0002-0671-6582	NIGMS NIH HHS [GM52022, GM 51312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brohmann H, 1997, J BIOL CHEM, V272, P10327, DOI 10.1074/jbc.272.15.10327; Callaini G, 1997, EXP CELL RES, V234, P183, DOI 10.1006/excr.1997.3618; Chang P, 2000, NAT CELL BIOL, V2, P30, DOI 10.1038/71350; de Loubresse NG, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-4; Dupuis-Williams P, 2002, J CELL BIOL, V158, P1183, DOI 10.1083/jcb.200205028; Dutcher SK, 1998, MOL BIOL CELL, V9, P1293, DOI 10.1091/mbc.9.6.1293; DUTCHER SK, IN PRESS MOL BIOL CE; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; INDAN YF, 2001, J CELL SCI, V114, P413; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; MARIANI BD, 1981, P NATL ACAD SCI-BIOL, V78, P4985, DOI 10.1073/pnas.78.8.4985; Mogensen MM, 2000, J CELL SCI, V113, P3013; Moritz M, 2001, CURR OPIN STRUC BIOL, V11, P174, DOI 10.1016/S0959-440X(00)00187-1; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687; Paoletti A, 1996, J CELL SCI, V109, P3089; RIEDER CL, 1982, BIOL CELL, V44, P117; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Vaughan S, 2000, CURR BIOL, V10, pR258, DOI 10.1016/S0960-9822(00)00414-0; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VOROBJEV IA, 1982, J CELL BIOL, V93, P938, DOI 10.1083/jcb.93.3.938; WOLF N, 1978, J ULTRA MOL STRUCT R, V63, P155, DOI 10.1016/S0022-5320(78)80071-9	27	89	94	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					71	76		10.1038/ncb900	http://dx.doi.org/10.1038/ncb900			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510196				2022-12-25	WOS:000180223700016
J	Bufe, B; Hofmann, T; Krautwurst, D; Raguse, JD; Meyerhof, W				Bufe, B; Hofmann, T; Krautwurst, D; Raguse, JD; Meyerhof, W			The human TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides	NATURE GENETICS			English	Article							ADAPTATION; IDENTIFICATION; TRANSDUCTION; EXPRESSION; FAMILY; CELLS	Bitter taste generally causes aversion, which protects humans from ingesting toxic substances. But bitter flavors also contribute to the palatability of food and beverages, thereby influencing nutritional habits in humans(1). Although many studies have examined bitter taste(2-6), the underlying receptor mechanisms remain poorly understood. Anatomical, functional and genetic data from rodents suggest the existence of a family of receptors that are responsive to bitter compounds(7-9). Here we report that a human member of this family, TAS2R16, is present in taste receptor cells on the tongue and is activated by bitter beta-glucopyranosides. Responses to these phytonutrients show a similar concentration dependence and desensitization in transfected cells and in experiments assessing taste perception in humans. Bitter compounds consisting of a hydrophobic residue attached to glucose by a beta-glycosidic bond activate TAS2R16. Thus, TAS2R16 links the recognition of a specific chemical structure to the perception of bitter taste. If the ability of TAS2R16 to detect substances with common molecular properties is typical of the bitter receptor family, it may explain how a few receptors permit the perception of numerous bitter substances.	German Inst Human Nutr, Dept Mol Genet, D-14558 Potsdam, Germany; German Res Ctr Food Chem, Garching, Germany; Clin & Policlin Oral & Maxillofacial Surg & Plast, Charite, Berlin, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Leibniz-Institute for Food Systems Biology at the Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Meyerhof, W (corresponding author), German Inst Human Nutr, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Potsdam, Germany.	meyerhof@mail.dife.de	Krautwurst, Dietmar/AAD-5579-2019; Bufe, Bernd/N-6685-2018	Krautwurst, Dietmar/0000-0002-3350-8682; Bufe, Bernd/0000-0003-1610-0658				Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Ammon C, 2001, ARCH PHYSIOL BIOCHEM, V110, P137; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Caicedo A, 2001, SCIENCE, V291, P1557, DOI 10.1126/science.1056670; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Drewnowski A, 2001, NUTR REV, V59, P163, DOI 10.1111/j.1753-4887.2001.tb07007.x; Drewnowski A, 2000, AM J CLIN NUTR, V72, P1424; Dulac C, 2000, CELL, V100, P607, DOI 10.1016/S0092-8674(00)80697-2; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Frank O, 2001, J AGR FOOD CHEM, V49, P231, DOI 10.1021/jf0010073; Keast RSJ, 2002, CHEM SENSES, V27, P123, DOI 10.1093/chemse/27.2.123; Kinnamon SC, 2000, NEURON, V25, P507, DOI 10.1016/S0896-6273(00)81054-5; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; KUBO I, 1994, PHYSIOL BEHAV, V56, P1203, DOI 10.1016/0031-9384(94)90367-0; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; MAILGAARD M, 1999, SENSORY EVALUATION T, P122; Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Torre V, 1995, J NEUROSCI, V15, P7757; Vane JR, 2000, J PHYSIOL PHARMACOL, V51, P573; VONLEIBIG J, 1844, CHEM BRIEFE; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999	26	323	363	8	92	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2002	32	3					397	401		10.1038/ng1014	http://dx.doi.org/10.1038/ng1014			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12379855				2022-12-25	WOS:000179034800015
J	Enserink, JM; Christensen, AE; de Rooij, J; van Triest, M; Schwede, F; Genieser, HG; Doskeland, SO; Blank, JL; Bos, JL				Enserink, JM; Christensen, AE; de Rooij, J; van Triest, M; Schwede, F; Genieser, HG; Doskeland, SO; Blank, JL; Bos, JL			A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RAS-DEPENDENT ACTIVATION; PROTEIN-KINASE-A; GENE-TRANSCRIPTION; CYCLIC-AMP; MAP KINASE; BINDING; PHOSPHORYLATION; RAF-1; DOMAIN	cAMP is involved in a wide variety of cellular processes that were thought to be mediated by protein kinase A (PKA)(1). However, cAMP also directly regulates Epac1 and Epac2, guanine nucleotide-exchange factors (GEFs) for the small GTPases Rap1 and Rap2 (refs 2,3). Unfortunately, there is an absence of tools to discriminate between PKA- and Epac-mediated effects. Therefore, through rational drug design we have developed a novel cAMP analogue, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8CPT-2Me-cAMP), which activates Epac, but not PKA, both in vitro and in vivo. Using this analogue, we tested the widespread model that Rap1 mediates cAMP-induced regulation of the extracellular signal-regulated kinase (ERK)(4,5). However, both in cell lines in which cAMP inhibits growth-factor-induced ERK activation and in which cAMP activates ERK, 8CPT-2Me-cAMP did not affect ERK activity. Moreover, in cell lines in which cAMP activates ERK, inhibition of PKA and Ras, but not Rap1, abolished cAMP-mediated ERK activation. We conclude that cAMP-induced regulation of ERK and activation of Rap1 are independent processes.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Semaia Pharmaceut, NL-3971 JD Driebergen, Netherlands; BIOLOG Life Sci Inst, D-28071 Bremen, Germany; Univ Leicester, Sch Med, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Bergen; University of Leicester	Enserink, JM (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		de rooij, johan/C-1325-2019; Enserink, Jorrit/E-5383-2010	Enserink, Jorrit/0000-0002-2394-5387; Doskeland, Stein Ove/0000-0002-4009-4756; de rooij, johan/0000-0001-6101-7875; Genieser, Hans-Gottfried/0000-0002-4904-5790				Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; KATAOKA S, 1990, CHEM PHARM BULL, V38, P1596; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kopperud R, 2002, J BIOL CHEM, V277, P13443, DOI 10.1074/jbc.M109869200; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	30	597	610	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					901	906		10.1038/ncb874	http://dx.doi.org/10.1038/ncb874			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402047				2022-12-25	WOS:000179137700020
J	Hanafusa, H; Torii, S; Yasunaga, T; Nishida, E				Hanafusa, H; Torii, S; Yasunaga, T; Nishida, E			Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway	NATURE CELL BIOLOGY			English	Article							RECEPTOR TYROSINE KINASES; DROSOPHILA EGF RECEPTOR; SIGNALING PATHWAYS; FEEDBACK LOOP; CELL-GROWTH; FGF; ACTIVATION; ANTAGONIST; IDENTIFICATION; INHIBITOR	Sprouty (Spry) inhibits signalling by receptor tyrosine kinases; however, the molecular mechanism underlying this function has not been defined. Here we show that after stimulation by growth factors Spry1 and Spry2 translocate to the plasma membrane and become phosphorylated on a conserved tyrosine. Next, they bind to the adaptor protein Grb2 and inhibit the recruitment of the Grb2-Sos complex either to the fibroblast growth factor receptor (FGFR) docking adaptor protein FRS2 or to Shp2. Membrane translocation of Spry is necessary for its phosphorylation, which is essential for its inhibitor activity. A tyrosine-phosphorylated octapeptide derived from mouse Spry2 inhibits Grb2 from binding FRS2, Shp2 or mouse Spry2 in vitro and blocks activation of the extracellular-signal-regulated kinase (ERK) in cells stimulated by growth factor. A non-phosphorylated Spry mutant cannot bind Grb2 and acts as a dominant negative, inducing prolonged activation of ERK in response to FGF and promoting the FGF-induced outgrowth of neurites in PC12 cells. Our findings suggest that Spry functions in a negative feedback mechanism in which its inhibitor activity is controlled rapidly and reversibly by post-translational mechanisms.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Hanafusa, H (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.			Torii, Satoru/0000-0003-4841-7131				Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Golembo M, 1996, DEVELOPMENT, V122, P223; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hanafusa H, 2000, EMBO REP, V1, P32, DOI 10.1093/embo-reports/kvd008; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minowada G, 1999, DEVELOPMENT, V126, P4465; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Reich A, 1999, DEVELOPMENT, V126, P4139; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCOTT SG, 1992, NATURE, V356, P340; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	42	437	445	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					850	858		10.1038/ncb867	http://dx.doi.org/10.1038/ncb867			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402043				2022-12-25	WOS:000179137700013
J	Huang, M; Qian, F; Hu, YY; Ang, CG; Li, Z; Wen, ZL				Huang, M; Qian, F; Hu, YY; Ang, CG; Li, Z; Wen, ZL			Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes	NATURE CELL BIOLOGY			English	Article							MAMMALIAN SWI/SNF COMPLEXES; SWI-SNF COMPLEX; GLUCOCORTICOID RECEPTOR; SERINE PHOSPHORYLATION; NUCLEOSOME DISRUPTION; RESPONSE ELEMENT; BAF COMPLEX; IFN-GAMMA; BINDING; EXPRESSION	Brahma-related gene 1 (BRG1) is a key component of the ATP-dependent chromatin-remodelling SWI2-SNF2 complex and has been implicated in regulating gene expression, cell-cycle control and tumorigenesis. Here we report that BRG1 interacts with signal transducer and activator of transcription 2 (STAT2)-a transcription factor that regulates gene expression mediated by interferon-alpha (IFN-alpha). BRG1 enhances the IFN-alpha-induced expression of 9-27 and IFI27 but not that of four other target genes tested, showing that the activation of different target genes by STAT2 may involve alternative chromatin modifiers. Our results also suggest that the recruitment and activation of BRG1 may require other cis-acting and trans-acting elements in addition to STAT2. Our study links the SWI2-SNF2 complex to the regulation of cytokine-induced gene expression and may identify a molecular mechanism of BRG1-mediated gene activation and tumorigenesis.	Inst Mol & Cell Biol, Lab Mol & Dev Immunol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wen, ZL (corresponding author), Inst Mol & Cell Biol, Lab Mol & Dev Immunol, 30 Med Dr, Singapore 117609, Singapore.			Hu, Yuanyu/0000-0001-5457-4331				Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wong AKC, 2000, CANCER RES, V60, P6171; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	42	116	118	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					774	781		10.1038/ncb855	http://dx.doi.org/10.1038/ncb855			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12244326				2022-12-25	WOS:000178316500014
J	Nishiyama, M; Higuchi, H; Yanagida, T				Nishiyama, M; Higuchi, H; Yanagida, T			Chemomechanical coupling of the forward and backward steps of single kinesin molecules	NATURE CELL BIOLOGY			English	Article							ATP HYDROLYSIS; DIMERIC KINESIN; MOTOR PROTEIN; 8-NM STEP; MYOSIN-V; K-LOOP; FORCE; MOTILITY; MICROTUBULES; PROCESSIVITY	The molecular motor kinesin travels processively along a microtubule in a stepwise manner. Here we have studied the chemomechanical coupling of the hydrolysis of ATP to the mechanical work of kinesin by analysing the individual stepwise movements according to the directionality of the movements. Kinesin molecules move primarily in the forward direction and only occasionally in the backward direction. The hydrolysis of a single ATP molecule is coupled to either the forward or the backward movement. This bidirectional movement is well described by a model of Brownian motion assuming an asymmetric potential of activation energy. Thus, the stepwise movement along the microtubule is most probably due to Brownian motion that is biased towards the forward direction by chemical energy stored in ATP molecules.	Osaka Univ, Dept Biophys Engn, Osaka 5608531, Japan; Tohoku Univ, Grad Sch Engn, Dept Met, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Sendai, Miyagi 9808579, Japan; Osaka Univ, Grad Sch Med, Dept Physiol & Biosignaling, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Nanobiol, Suita, Osaka 5650871, Japan; JST, ICORP, Single Mol Proc Project, Osaka 5620035, Japan	Osaka University; Tohoku University; Tohoku University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Nishiyama, M (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Kyoto 6068502, Japan.	higuchi@material.tohoku.ac.jp	Nishiyama, Masayoshi/F-8857-2012; Yanagida, Toshio/D-1919-2009; Nishiyama, Masayoshi/AAI-4579-2021	Nishiyama, Masayoshi/0000-0002-0525-3766				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; FEYNMAN RP, 1963, FEYNMAN LECT PHYSICS, V1; Fisher ME, 2001, P NATL ACAD SCI USA, V98, P7748, DOI 10.1073/pnas.141080498; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; Hirakawa E, 2000, P NATL ACAD SCI USA, V97, P2533, DOI 10.1073/pnas.050585297; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J., 2001, MECH MOTOR PROTEINS; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Inoue Y, 2001, BIOPHYS J, V81, P2838, DOI 10.1016/S0006-3495(01)75925-5; Kawaguchi K, 2000, BIOCHEM BIOPH RES CO, V272, P895, DOI 10.1006/bbrc.2000.2856; Kawaguchi K, 2001, SCIENCE, V291, P667, DOI 10.1126/science.291.5504.667; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; KOJIMA H, IN PRESS J BIOL PHYS; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; OOSAWA F, 1989, Jikeikai Medical Journal, V36, P219; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rogers KR, 2001, EMBO J, V20, P5101, DOI 10.1093/emboj/20.18.5101; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Tucker C, 1997, J BIOL CHEM, V272, P9481; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, P167	46	246	251	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					790	797		10.1038/ncb857	http://dx.doi.org/10.1038/ncb857			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360289				2022-12-25	WOS:000178316500016
J	Draper, N; Walker, EA; Bujalska, IJ; Tomlinson, JW; Chalder, SM; Arlt, W; Lavery, GG; Bedendo, O; Ray, DW; Laing, I; Malunowicz, E; White, PC; Hewison, M; Mason, PJ; Connell, JM; Shackleton, CHL; Stewart, PM				Draper, N; Walker, EA; Bujalska, IJ; Tomlinson, JW; Chalder, SM; Arlt, W; Lavery, GG; Bedendo, O; Ray, DW; Laing, I; Malunowicz, E; White, PC; Hewison, M; Mason, PJ; Connell, JM; Shackleton, CHL; Stewart, PM			Mutations in the genes encoding 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency	NATURE GENETICS			English	Article							APPARENT MINERALOCORTICOID EXCESS; MICROSOMAL ELECTRON-TRANSPORT; POLYCYSTIC-OVARY-SYNDROME; EXPRESSION; OBESITY; HYPERCORTISOLISM; INHERITANCE; DISEASE; STRESS; MICE	In cortisone reductase deficiency (CRD), activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2). This suggests a defect in the gene HSD11B1 encoding 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), a primary regulator of tissue-specific glucocorticoid bioavailability(3). We identified intronic mutations in HSD11B1 that resulted in reduced gene transcription in three individuals with CRD. In vivo, 11beta-HSD1 catalyzes the reduction of cortisone to cortisol(4) whereas purified enzyme acts as a dehydrogenase converting cortisol to cortisone(5). Oxo-reductase activity can be regained using a NADPH-regeneration system and the cytosolic enzyme glucose-6-phosphate dehydrogenase(4,5). But the catalytic domain of 11beta-HSD1 faces into the lumen of the endoplasmic reticulum ( ER; ref. 6). We hypothesized that endolumenal hexose-6-phosphate dehydrogenase ( H6PDH) regenerates NADPH in the ER7, thereby influencing directionality of 11beta-HSD1 activity. Mutations in exon 5 of H6PD in individuals with CRD attenuated or abolished H6PDH activity. These individuals have mutations in both HSD11B1 and H6PD in a triallelic digenic model of inheritance, resulting in low 11beta-HSD1 expression and ER NADPH generation with loss of 11beta-HSD1 oxoreductase activity. CRD defines a new ER-specific redox potential and establishes H6PDH as a potential factor in the pathogenesis of PCOS.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Manchester, Endocrine Sci Res Grp, Manchester, Lancs, England; Manchester Royal Infirm, Dept Clin Biochem, Manchester M13 9WL, Lancs, England; Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England; Univ Glasgow, MRC, Blood Pressure Unit, Glasgow, Lanark, Scotland; Childrens Hosp Med Ctr, Steroid Lab, Oakland, CA USA	University of Birmingham; University of Manchester; University of Manchester; Children's Memorial Health Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Imperial College London; University of Glasgow	Stewart, PM (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.		Lavery, Gareth/F-9346-2010; Mason, Philip J/B-1087-2008; Arlt, Wiebke/B-6310-2009	Arlt, Wiebke/0000-0001-5106-9719; Tomlinson, Jeremy/0000-0002-3170-8533; Ray, David/0000-0002-4739-6773				AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Agarwal AK, 2001, ENDOCR RES, V27, P1, DOI 10.1081/ERC-100107163; Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Biason-Lauber A, 2000, HORM RES, V53, P260, DOI 10.1159/000023577; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; CARL S, 1996, P DYNAMIC SYSTEMS AP, V2, P91; Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979; Filling C, 2001, MOL CELL ENDOCRINOL, V171, P99, DOI 10.1016/S0303-7207(00)00419-6; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Fraser R, 1999, HYPERTENSION, V33, P1364, DOI 10.1161/01.HYP.33.6.1364; Jamieson A, 1999, J CLIN ENDOCR METAB, V84, P3570, DOI 10.1210/jc.84.10.3570; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; KIMURA K, 1979, J BIOCHEM-TOKYO, V85, P319, DOI 10.1093/oxfordjournals.jbchem.a132336; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; NIKKILA H, 1993, J CLIN ENDOCR METAB, V77, P687, DOI 10.1210/jc.77.3.687; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Phillipov G, 1996, J CLIN ENDOCR METAB, V81, P3855, DOI 10.1210/jc.81.11.3855; RODIN A, 1994, NEW ENGL J MED, V330, P460, DOI 10.1056/NEJM199402173300703; Savage DB, 2002, NAT GENET, V31, P379, DOI 10.1038/ng926; STEGEMAN JJ, 1979, BIOCHEM BIOPH RES CO, V87, P410, DOI 10.1016/0006-291X(79)91811-4; Stewart PM, 1999, VITAM HORM, V57, P249; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; White PC, 2000, ENDOCR REV, V21, P245, DOI 10.1210/er.21.3.245	30	239	257	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2003	34	4					434	439		10.1038/ng1214	http://dx.doi.org/10.1038/ng1214			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12858176				2022-12-25	WOS:000184470500022
J	Hallahan, AR; Pritchard, JI; Chandraratna, RAS; Ellenbogen, RG; Geyer, JR; Overland, RP; Strand, AD; Tapscott, SJ; Olson, JM				Hallahan, AR; Pritchard, JI; Chandraratna, RAS; Ellenbogen, RG; Geyer, JR; Overland, RP; Strand, AD; Tapscott, SJ; Olson, JM			BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect	NATURE MEDICINE			English	Article							BONE MORPHOGENETIC PROTEINS; ATHYMIC NUDE-MICE; SPEMANN ORGANIZER; PROGENITOR CELLS; GENE-EXPRESSION; NERVOUS-SYSTEM; GROWTH-FACTOR; ACID; RECEPTOR; DIFFERENTIATION	The mechanisms of retinoid activity in tumors remain largely unknown. Here we establish that retinoids cause extensive apoptosis of medulloblastoma cells. In a xenograft model, retinoids largely abrogated tumor growth. Using receptor-specific retinoid agonists, we defined a subset of mRNAs that were induced by all active retinoids in retinoid-sensitive cell lines. We also identified bone morphogenetic protein-2 (BMP-2) as a candidate mediator of retinoid activity. BMP-2 protein induced medulloblastoma cell apoptosis, whereas the BMP-2 antagonist noggin blocked both retinoid and BMP-2-induced apoptosis. BMP-2 also induced p38 mitogen-activated protein kinase (MAPK), which is necessary for BMP-2- and retinoid-induced apoptosis. Retinoid-resistant medulloblastoma cells underwent apoptosis when treated with BMP-2 or when cultured with retinoid-sensitive medulloblastoma cells. Retinoid-induced expression of BMP-2 is thus necessary and sufficient for apoptosis of retinoid-responsive cells, and expression of BMP-2 by retinoid-sensitive cells is sufficient to induce apoptosis in surrounding retinoid-resistant cells.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Childrens Hosp, Div Pediat Oncol, Seattle, WA 98105 USA; Allergan Pharmaceut Inc, Retinoid Res, Irvine, CA 92623 USA; Univ Washington, Childrens Hosp, Dept Neurosurg, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Seattle Children's Hospital; University of Washington; University of Washington Seattle; AbbVie; Allergan; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.		Hallahan, Andrew R/F-1757-2010	Tapscott, Stephen/0000-0002-0319-0968				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Caricasole A, 2000, INT J DEV BIOL, V44, P443; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chandraratna RAS, 1996, BRIT J DERMATOL, V135, P18, DOI 10.1111/j.1365-2133.1996.tb15662.x; Conley BA, 1999, CANCER CHEMOTH PHARM, V43, P183, DOI 10.1007/s002800050883; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Evans AE, 1999, CLIN CANCER RES, V5, P3594; Farah MH, 2000, DEVELOPMENT, V127, P693; Ghatpande S, 2002, BLOOD, V99, P2379, DOI 10.1182/blood.V99.7.2379; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Johnson AT, 1999, BIOORGAN MED CHEM, V7, P1321, DOI 10.1016/S0968-0896(99)00055-3; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; KELES GE, 1993, NEUROSURGERY, V32, P274, DOI 10.1227/00006123-199302000-00017; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu J, 2000, ANTICANCER RES, V20, P2659; MARIA BL, 1989, J NEURO-ONCOL, V7, P329, DOI 10.1007/BF02147090; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Olson JM, 2001, DEV BIOL, V234, P174, DOI 10.1006/dbio.2001.0245; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rostomily RC, 1997, CANCER RES, V57, P3526; SHALINSKY DR, 1995, CANCER RES, V55, P3183; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Song QB, 1998, DEV BIOL, V196, P119, DOI 10.1006/dbio.1998.8847; Strand AD, 2002, HUM MOL GENET, V11, P2207, DOI 10.1093/hmg/11.19.2207; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang Q, 2001, BREAST CANCER RES TR, V67, P157, DOI 10.1023/A:1010643323268; Yamamoto M, 1996, DEV BRAIN RES, V93, P182, DOI 10.1016/0165-3806(96)00038-7; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhu GF, 1999, DEV BIOL, V215, P118, DOI 10.1006/dbio.1999.9431; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	150	155	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1033	1038		10.1038/nm904	http://dx.doi.org/10.1038/nm904			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872164				2022-12-25	WOS:000184484900027
J	Tan, TC; Valova, VA; Malladi, CS; Graham, ME; Berven, LA; Jupp, OJ; Hansra, G; McClure, SJ; Sarcevic, B; Boadle, RA; Larsen, MR; Cousin, MA; Robinson, PJ				Tan, TC; Valova, VA; Malladi, CS; Graham, ME; Berven, LA; Jupp, OJ; Hansra, G; McClure, SJ; Sarcevic, B; Boadle, RA; Larsen, MR; Cousin, MA; Robinson, PJ			Cdk5 is essential for synaptic vesicle endocytosis	NATURE CELL BIOLOGY			English	Article							CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; DYNAMIN-I; NERVE-TERMINALS; SH3 DOMAIN; TRANSMITTER RELEASE; INTACT SYNAPTOSOMES; GTPASE ACTIVITY; HIGH-AFFINITY; PHOSPHORYLATION	Synaptic vesicle endocytosis (SVE) is triggered by calcineurin-mediated dephosphorylation of the dephosphin proteins. SVE is maintained by the subsequent rephosphorylation of the dephosphins by unidentified protein kinases. Here, we show that cyclin-dependent kinase 5 (Cdk5) phosphorylates dynamin I on Ser 774 and Ser 778 in vitro, which are identical to its endogenous phosphorylation sites in vivo. Cdk5 antagonists and expression of dominant-negative Cdk5 block phosphorylation of dynamin 1, but not of amphiphysin or AP180, in nerve terminals and inhibit SVE. Thus Cdk5 has an essential role in SVE and is the first dephosphin kinase identified in nerve terminals.	Childrens Med Res Inst, Cell Signalling Unit, Wentworthville, NSW 2145, Australia; Royal Hosp Women, Randwick, NSW 2031, Australia; Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Westmead Hosp, Inst Clin Pathol & Med Res, Electron Microscope Lab, Westmead, NSW 2145, Australia; Macquarie Univ, Australian Proteom Anal Facil, N Ryde, NSW 2109, Australia; Univ Edinburgh, Div Biomed Sci, Membrane Biol Grp, Edinburgh EH8 9XD, Midlothian, Scotland	Children's Medical Research Institute - Australia; Garvan Institute of Medical Research; University of Sydney; Macquarie University; University of Edinburgh	Robinson, PJ (corresponding author), Childrens Med Res Inst, Cell Signalling Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.		Graham, Mark E/A-6480-2014; Robinson, Phillip J/G-4008-2011; Larsen, Martin Rossel/F-1411-2015	Graham, Mark E/0000-0002-7290-1217; Robinson, Phillip J/0000-0002-7878-0313; Malladi, Chandra/0000-0002-5882-8228; Sarcevic, Boris/0000-0002-8063-1050; Larsen, Martin Rossel/0000-0001-6203-0123; Cousin, Michael/0000-0002-1762-160X; Tan, Timothy/0000-0003-4449-1457				Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Chen-Hwang MC, 2002, J BIOL CHEM, V277, P17597, DOI 10.1074/jbc.M111101200; Cousin MA, 2000, J NEUROSCI, V20, P949, DOI 10.1523/JNEUROSCI.20-03-00949.2000; Cousin MA, 2000, MOL NEUROBIOL, V22, P115, DOI 10.1385/MN:22:1-3:115; Cousin MA, 2001, J NEUROCHEM, V76, P105, DOI 10.1046/j.1471-4159.2001.00049.x; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; COUSIN MA, 2003, J BIOL CHEM     0516; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HOSOYA H, 1994, BIOCHEM BIOPH RES CO, V202, P1127, DOI 10.1006/bbrc.1994.2045; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Negash S, 2002, J CELL SCI, V115, P2109; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Song XD, 1996, IEEE T IMAGE PROCESS, V5, P16, DOI 10.1109/83.481667; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; TSAI LH, 1993, DEVELOPMENT, V119, P1029; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Yan Z, 2002, J PHYSIOL-LONDON, V540, P761; Zhou W, 2000, J AM SOC MASS SPECTR, V11, P273, DOI 10.1016/S1044-0305(00)00100-8	50	241	258	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					701	710		10.1038/ncb1020	http://dx.doi.org/10.1038/ncb1020			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12855954	Green Published			2022-12-25	WOS:000184687300011
J	Brown, E; McKee, T; diTomaso, E; Pluen, A; Seed, B; Boucher, Y; Jain, RK				Brown, E; McKee, T; diTomaso, E; Pluen, A; Seed, B; Boucher, Y; Jain, RK			Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation	NATURE MEDICINE			English	Article							2ND-HARMONIC GENERATION; MICROSCOPY; RELAXIN; TRANSPORT; DIFFUSION; TISSUE	The content and structure of collagen is essential in governing the delivery of therapeutic molecules in tumors. Thus, simple histological staining of tumor tissue biopsies for collagen could be used to assess the accessibility of molecular therapeutics in tumors. Here we show that it is possible to optically image fibrillar collagen in tumors growing in mice using second-harmonic generation (SHG). Using this noninvasive technique, we estimated relative diffusive hindrance, quantified the dynamics of collagen modification after pharmacologic intervention and provided mechanistic insight into improved diffusive transport induced by the hormone relaxin. This technology could offer basic scientists and clinicians an enhanced ability to estimate the relative penetrabilities of molecular therapeutics.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); University of Manchester	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.		McKee, Trevor David/N-4308-2019; Jain, Rakesh K/I-1384-2017; Pluen, Alain/F-5300-2015	McKee, Trevor David/0000-0002-2195-6146; Jain, Rakesh K/0000-0001-7571-3548; Pluen, Alain/0000-0002-5953-8011	NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA80124] Funding Source: Medline; NIGMS NIH HHS [T32GM08334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal A, 2001, TISSUE ENG, V7, P191, DOI 10.1089/107632701300062813; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; BYLANDER JE, 1987, P SOC EXP BIOL MED, V185, P76; Campagnola PJ, 2002, BIOPHYS J, V82, P493, DOI 10.1016/S0006-3495(02)75414-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fleischmajer R, 1998, ANN NY ACAD SCI, V857, P212, DOI 10.1111/j.1749-6632.1998.tb10118.x; FREUND I, 1986, BIOPHYS J, V50, P693, DOI 10.1016/S0006-3495(86)83510-X; FRIEDEN EH, 1985, P SOC EXP BIOL MED, V180, P39; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Helmchen F, 2001, NEURON, V31, P903, DOI 10.1016/S0896-6273(01)00421-4; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Moreaux L, 2000, J OPT SOC AM B, V17, P1685, DOI 10.1364/JOSAB.17.001685; Netti PA, 2000, CANCER RES, V60, P2497; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Stoller P, 2002, BIOPHYS J, V82, P3330, DOI 10.1016/S0006-3495(02)75673-7; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Williams RM, 2001, CURR OPIN CHEM BIOL, V5, P603, DOI 10.1016/S1367-5931(00)00241-6; Zoumi A, 2002, P NATL ACAD SCI USA, V99, P11014, DOI 10.1073/pnas.172368799	20	701	716	1	136	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					796	800		10.1038/nm879	http://dx.doi.org/10.1038/nm879			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754503				2022-12-25	WOS:000183444100038
J	Tomaru, U; Yamano, Y; Nagai, M; Maric, D; Kaumaya, PTP; Biddison, W; Jacobson, S				Tomaru, U; Yamano, Y; Nagai, M; Maric, D; Kaumaya, PTP; Biddison, W; Jacobson, S			Detection of virus-specific T cells and CD8(+) T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections	NATURE MEDICINE			English	Article							NEUROLOGICAL DISEASE; LYMPHOCYTES; MEMORY; HTLV-1; MYELOPATHY; HAM/TSP; LOAD	Antigen-specific CD8(+) T cells acquire peptide-major histocompatibility complex (MHC) clusters through T-cell receptor (TCR)-mediated endocytosis after specific antigen stimulation. We generated an antigen-presenting cell (APC) expressing human leukocyte antigen (HLA)-A*201 coupled to the enhanced green fluorescent protein (GFP), which delivered GFP to an antigen-specific T cell when pulsed with antigenic peptide. We quantitatively identified human T-cell lymphotropic virus type I ( HTLV-I) Tax(11-19) peptide-specific T-cell populations in peripheral blood mononuclear cells (PBMCs) from patients with HTLV-I-associated neurologic disease and defined a new CD8(+) T-cell epitope in the HTLV-I envelope region. Acquisition of peptide-HLA-GFP complexes by antigen-specific T cells could distinguish, with respect to phenotype and perforin production, T cells from the chronic viral infections cytomegalovirus and HTLV-I. This approach will be a powerful tool in understanding the role of antigen-specific T-cell responses in health and disease.	NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 890, Japan; NINDS, Neurophysiol Lab, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University System of Ohio; Ohio State University	Jacobson, S (corresponding author), NINDS, Neuroimmunol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.		Yamano, Yoshihisa/AAG-3955-2020; Kaumaya, Pravin T. P/E-3354-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002817, Z01NS002817, Z01NS002603] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Frangione-Beebe M, 2000, VACCINE, V19, P1068, DOI 10.1016/S0264-410X(00)00340-6; GESSAIN A, 1985, LANCET, V2, P407; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Kubota R, 2000, J IMMUNOL, V164, P5192, DOI 10.4049/jimmunol.164.10.5192; Mendez E, 1997, J VIROL, V71, P9143; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668; OSAME M, 1986, LANCET, V1, P1031; OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191; PARKER KC, 1994, J IMMUNOL, V152, P163; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; WINTER CC, 1991, J IMMUNOL, V146, P3508; Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88	21	45	51	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					469	475		10.1038/nm845	http://dx.doi.org/10.1038/nm845			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652294				2022-12-25	WOS:000181987400039
J	Errington, J				Errington, J			Dynamic proteins and a cytoskeleton in bacteria	NATURE CELL BIOLOGY			English	Article							BACILLUS-SUBTILIS DEPENDS; CELL-DIVISION; ESCHERICHIA-COLI; POLAR LOCALIZATION; SPATIAL REGULATION; PROPER PLACEMENT; DNA SEGREGATION; FACTORY MODEL; TRANSCRIPTION; REPLICATION	The application of modern fluorescence microscopic methods to bacteria has revolutionized our view of their subcellular organization. Many proteins are now known to be targeted with exquisite precision to specific locations in the cell, or to undergo rapid directed changes in localization. Structural and functional homologues of tubulin (FtsZ) and actin (MreB) are now indisputably present in bacteria, overturning the textbook view that the cytoskeleton is unique to eukaryotes. These advances are stimulating a radical rethink about how various fundamental processes are organised in bacteria.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Errington, J (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	jeff.errington@path.ox.ac.uk	Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388				BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Chen JC, 2001, MOL MICROBIOL, V42, P395, DOI 10.1046/j.1365-2958.2001.02640.x; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; ERRINGTON J, 2001, BACILLUS SUBTILIS IT, P97; Fu XL, 2001, P NATL ACAD SCI USA, V98, P980, DOI 10.1073/pnas.031549298; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 2000, ANNU REV MICROBIOL, V54, P681, DOI 10.1146/annurev.micro.54.1.681; Hale CA, 2001, EMBO J, V20, P1563, DOI 10.1093/emboj/20.7.1563; HOWARD M, 2001, PHYS REV LETT, V87; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jensen RB, 2002, NAT REV MOL CELL BIO, V3, P167, DOI 10.1038/nrm758; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Kruse K, 2002, BIOPHYS J, V82, P618, DOI 10.1016/S0006-3495(02)75426-X; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lewis PJ, 2000, EMBO J, V19, P710, DOI 10.1093/emboj/19.4.710; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Margolin W, 2000, FEMS MICROBIOL REV, V24, P531, DOI 10.1016/S0168-6445(00)00038-3; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; Marston AL, 1999, MOL CELL, V4, P673, DOI 10.1016/S1097-2765(00)80378-0; Mascarenhas J, 2001, EMBO REP, V2, P685, DOI 10.1093/embo-reports/kve160; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; MOLLERJENSEN J, 2002, EMBO J; Quisel JD, 1999, MOL CELL, V4, P665, DOI 10.1016/S1097-2765(00)80377-9; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Scheffers DJ, 2001, FEBS LETT, V506, P6, DOI 10.1016/S0014-5793(01)02855-1; Shapiro L, 2000, CELL, V100, P89, DOI 10.1016/S0092-8674(00)81686-4; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Weber MHW, 2001, J BACTERIOL, V183, P6435, DOI 10.1128/JB.183.21.6435-6443.2001; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000	42	61	63	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					175	178		10.1038/ncb0303-175	http://dx.doi.org/10.1038/ncb0303-175			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12646867				2022-12-25	WOS:000181322500002
J	Yan, SS; Wu, ZY; Zhang, HP; Furtado, G; Chen, X; Yan, SF; Schmidt, AM; Brown, C; Stern, A; LaFaille, J; Chess, L; Stern, DM; Jiang, H				Yan, SS; Wu, ZY; Zhang, HP; Furtado, G; Chen, X; Yan, SF; Schmidt, AM; Brown, C; Stern, A; LaFaille, J; Chess, L; Stern, DM; Jiang, H			Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; ALPHA-4 INTEGRIN; BRAIN PARENCHYMA; TRANSGENIC MICE; RECEPTOR; EXPRESSION; RAGE; INFLAMMATION; MECHANISMS	Multiple sclerosis (MS) is a devastating neuroinflammatory disorder of the central nervous system (CNS) in which T cells that are reactive with major components of myelin sheaths have a central role. The receptor for advanced glycation end products (RAGE) is present on T cells, mononuclear phagocytes and endothelium. Its pro-inflammatory ligands, S100-calgranulins, are upregulated in MS and in the related rodent model, experimental autoimmune encephalomyelitis (EAE). Blockade of RAGE suppressed EAE when disease was induced by myelin basic protein (MBP) peptide or encephalitogenic T cells, or when EAE occurred spontaneously in T-cell receptor (TCR)-transgenic mice devoid of endogenous TCR- and TCR-chains. Inhibition of RAGE markedly decreased infiltration of the CNS by immune and inflammatory cells. Transgenic mice with targeted overexpression of dominant-negative RAGE in CD4(+) T cells were resistant to MBP-induced EAE. These data reinforce the importance of RAGE-ligand interactions in modulating properties of CD4(+) T cells that infiltrate the CNS.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Fujian Med Univ, Dept Neurol, Affiliated Hosp 1, Fujian, Peoples R China; NYU, Skirball Inst Biomed Sci, New York, NY USA; NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; Med Coll Georgia, Sch Med, Augusta, GA 30912 USA	Columbia University; Columbia University; Columbia University; Columbia University; Fujian Medical University; New York University; New York University; University System of Georgia; Augusta University	Yan, SS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	sdy1@columbia.edu			NIAID NIH HHS [AI44927, AI46132] Funding Source: Medline; NINDS NIH HHS [NS42855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI046132, R01AI044927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adlam M, 1997, INT IMMUNOL, V9, P877, DOI 10.1093/intimm/9.6.877; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Bauer J, 2001, GLIA, V36, P235, DOI 10.1002/glia.1112; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; CARLOS TM, 1990, BLOOD, V76, P965; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Girvin AR, 2000, J IMMUNOL, V164, P136, DOI 10.4049/jimmunol.164.1.136; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; HAFLER DA, 1995, IMMUNOL REV, V144, P75, DOI 10.1111/j.1600-065X.1995.tb00066.x; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hohlfeld R, 2001, CURR OPIN NEUROL, V14, P299, DOI 10.1097/00019052-200106000-00006; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Jiang H, 2001, P NATL ACAD SCI USA, V98, P6301, DOI 10.1073/pnas.101123098; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Karpus WJ, 1998, J IMMUNOL, V161, P2667; KOBAYASHI Y, 1995, CELL IMMUNOL, V164, P295, DOI 10.1006/cimm.1995.1173; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Neuhaus O, 2001, NEUROLOGY, V56, P702, DOI 10.1212/WNL.56.6.702; Nygardas PT, 2000, EUR J IMMUNOL, V30, P1911, DOI 10.1002/1521-4141(200007)30:7<1911::AID-IMMU1911>3.0.CO;2-E; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Owens T, 2001, NAT MED, V7, P161, DOI 10.1038/84603; Pahan K, 2000, NEUROSCI LETT, V287, P17, DOI 10.1016/S0304-3940(00)01167-8; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wong FS, 1999, IMMUNOL REV, V169, P93, DOI 10.1111/j.1600-065X.1999.tb01309.x; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	38	152	172	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					287	293		10.1038/nm831	http://dx.doi.org/10.1038/nm831			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12598893				2022-12-25	WOS:000181312300028
J	Ramaswamy, S; Ross, KN; Lander, ES; Golub, TR				Ramaswamy, S; Ross, KN; Lander, ES; Golub, TR			A molecular signature of metastasis in primary solid tumors	NATURE GENETICS			English	Article							EXPRESSION; CANCER; BREAST; CELLS; GENE; CLASSIFICATION; CARCINOMA; REVEALS	Metastasis is the principal event leading to death in individuals with cancer, yet its molecular basis is poorly understood(1). To explore the molecular differences between human primary tumors and metastases, we compared the gene-expression profiles of adenocarcinoma metastases of multiple tumor types to unmatched primary adenocarcinomas. We found a gene-expression signature that distinguished primary from metastatic adenocarcinomas. More notably, we found that a subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature. We confirmed this finding by applying the expression signature to data on 279 primary solid tumors of diverse types. We found that solid tumors carrying the gene-expression signature were most likely to be associated with metastasis and poor clinical outcome (P < 0.03). These results suggest that the metastatic potential of human tumors is encoded in the bulk of a primary tumor, thus challenging the notion that metastases arise from rare cells within a primary tumor that have the ability to metastasize(2).	MIT, Ctr Genome Res, Whitehead Inst, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Ramaswamy, S (corresponding author), MIT, Ctr Genome Res, Whitehead Inst, 1 Kendall Sq,Bldg 300, Cambridge, MA 02139 USA.							Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HAINSWORTH JD, 1993, NEW ENGL J MED, V329, P257; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hellman S., 2001, CANC PRINCIPLES PRAC; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jensen BV, 2002, INT J CANCER, V98, P582, DOI 10.1002/ijc.10187; Olumi AF, 1999, CANCER RES, V59, P5002; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	29	1828	1944	2	123	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					49	54		10.1038/ng1060	http://dx.doi.org/10.1038/ng1060			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12469122				2022-12-25	WOS:000180136100016
J	Santoro, R; Li, JW; Grummt, I				Santoro, R; Li, JW; Grummt, I			The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription	NATURE GENETICS			English	Article							POLYMERASE I TRANSCRIPTION; HISTONE METHYLATION; DNA METHYLATION; CHROMATIN; ISWI; TEMPLATES; SUBUNIT; HDAC1; FORM	Epigenetic control mechanisms silence about half of the ribosomal RNA (rRNA) genes in metabolically active cells. In exploring the mechanism by which the active or silent state of rRNA genes is inherited, we found that NoRC, a nucleolar remodeling complex containing Snf2h (also called Smarca5, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily a, member 5), represses rDNA transcription. NoRC mediates rDNA silencing by recruiting DNA methyltransferase and histone deacetylase activity to the rDNA promoter, thus establishing structural characteristics of heterochromatin such as DNA methylation, histone hypoacetylation and methylation of the Lys9 residue of histone H3. These results indicate that active and inactive rRNA genes can be demarcated by their associated proteins, and link chromatin remodeling to DNA methylation and specific histone modifications.	German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Grummt, I (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany.	I.Grummt@DKFZ-Heidelberg.de	Santoro, Raffaella/L-2637-2013					Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; GOODMARK JP, 2000, CELL, V103, P423; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460	26	323	332	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2002	32	3					393	396		10.1038/ng1010	http://dx.doi.org/10.1038/ng1010			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12368916				2022-12-25	WOS:000179034800014
J	Griffin, KJP; Kimelman, D				Griffin, KJP; Kimelman, D			One-Eyed Pinhead and Spadetail are essential for heart and somite formation	NATURE CELL BIOLOGY			English	Article							NO TAIL; ENDODERM FORMATION; ZEBRAFISH HOMOLOG; GENE; EXPRESSION; PROTEIN; MESODERM; EMBRYO; DIFFERENTIATION; MORPHOGENESIS	Mutant analysis in the zebrafish Danio rerio has demonstrated distinct developmental roles for the T-box transcription factor Spadetail (Spt)(1) and the Nodal-receptor cofactor One-Eyed Pinhead (Oep)(2) in the formation of mesoderm and endoderm. Here, we show that spt and oep genetically interact and are together essential for the formation of cardiac and somitic mesoderm. These two mesodermal defects are dependent on different effectors of Nodal signalling; cardiac mesoderm formation involves the mix-like transcription factor Bonnie and Clyde (Bon)(3), whereas somitogenesis is dependent on a different pathway. Analysis of the somite defect in Zoep; spt embryos has provided insights into the control of somitic mesoderm formation by Spt, which was previously implicated in the regulation of cell adhesion and motility(4,5). We show that the failure to form somites in Zoep; spt embryos is independent of this and that Spt must have an additional function. We propose that the major role of Spt in somitogenesis is to promote the differentiation of presomitic mesoderm from tailbud progenitors by antagonizing progenitor-type gene expression and behaviour.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.							Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Kanki JP, 1997, DEVELOPMENT, V124, P881; KELLY GM, 1995, DEVELOPMENT, V121, P1787; Kikuchi Y, 2000, GENE DEV, V14, P1279; Kikuchi Y, 2001, GENE DEV, V15, P1493, DOI 10.1101/gad.892301; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; Liao W, 1997, DEVELOPMENT, V124, P381; Lun K, 1998, DEVELOPMENT, V125, P3049; Mathis L, 2001, NAT CELL BIOL, V3, P559, DOI 10.1038/35078535; Muller M, 1996, DEVELOPMENT, V122, P2071; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Pogoda HM, 2000, CURR BIOL, V10, P1041, DOI 10.1016/S0960-9822(00)00669-2; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Reiter JF, 2001, DEV BIOL, V234, P330, DOI 10.1006/dbio.2001.0259; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schier AF, 1997, DEVELOPMENT, V124, P327; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHIMIZU T, 1985, J CELL BIOL, V101, P1115, DOI 10.1083/jcb.101.3.1115; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Yamamoto A, 1998, DEVELOPMENT, V125, P3389; YAN YL, 1995, DEV DYNAM, V203, P363, DOI 10.1002/aja.1002030308; Yelon D, 1999, DEV BIOL, V214, P23, DOI 10.1006/dbio.1999.9406; Yelon D, 2001, DEV DYNAM, V222, P552, DOI 10.1002/dvdy.1243; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	30	63	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					821	825		10.1038/ncb862	http://dx.doi.org/10.1038/ncb862			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360294				2022-12-25	WOS:000178316500021
J	Oliferenko, S; Balasubramanian, MK				Oliferenko, S; Balasubramanian, MK			Astral microtubules monitor metaphase spindle alignment in fission yeast	NATURE CELL BIOLOGY			English	Article							SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; MITOTIC SPINDLE	Segregating genetic material along the longest axis of the cell ensures that there is a sufficient distance between daughter chromosomes at the point of cytokinesis. Monitoring the orientation of the mitotic spindle can be subjected to cell cycle controls. In the fission yeast Schizosaccharomyces pombe, the existence of such a cell-cycle checkpoint has been proposed to delay the metaphase to anaphase transition when spindle poles are not properly oriented with respect to the actomyosin ring(1). Here we show, by using a fission yeast mutant compromised in its assembly of astral microtubules, that in the absence of astral microtubules short metaphase spindles are unable to orient themselves with respect to the long axis of the cell and are delayed in spindle elongation. This astral defect engages a spindle orientation checkpoint because deletion of the transcription factor Atf1, which is involved in maintaining this checkpoint, allows misaligned asterless metaphase spindles to elongate. We propose that astral microtubules are involved directly in monitoring orientation of the metaphase spindle and in controlling the timing of elongation in fission yeast.	Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117604, Singapore; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	National University of Singapore; National University of Singapore	Oliferenko, S (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.	snejana@tll.org.sg		Balasubramanian, Mohan/0000-0002-1292-8602; Oliferenko, Snezhana/0000-0002-8138-6851				Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Decottignies A, 2001, J CELL SCI, V114, P2627; Ding DQ, 1998, J CELL SCI, V111, P701; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Hagan IM, 1996, CELL MOTIL CYTOSKEL, V34, P69; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	12	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					816	820		10.1038/ncb861	http://dx.doi.org/10.1038/ncb861			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360293				2022-12-25	WOS:000178316500020
J	Terebiznik, MR; Vieira, OV; Marcus, SL; Slade, A; Yip, CM; Trimble, WS; Meyer, T; Finlay, BB; Grinstein, S				Terebiznik, MR; Vieira, OV; Marcus, SL; Slade, A; Yip, CM; Trimble, WS; Meyer, T; Finlay, BB; Grinstein, S			Elimination of host cell PtdIns(4,5)P-2 by bacterial SigD promotes membrane fission during invasion by Salmonella	NATURE CELL BIOLOGY			English	Article							EPITHELIAL-CELLS; PLASMA-MEMBRANE; LIVING CELLS; ACTIN CYTOSKELETON; PHOSPHOLIPASE-C; KINASE-C; TYPHIMURIUM; PROTEIN; ACTIVATION; EFFECTOR	Salmonella invades mammalian cells by inducing membrane ruffling and macropinocytosis through actin remodelling. Because phosphoinositides are central to actin assembly, we have studied the dynamics of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) in HeLa cells during invasion by Salmonella typhimurium. Here we show that the outermost parts of the ruffles induced by invasion show a modest enrichment in PtdIns(4,5)P-2, but that PtdIns(4,5)P-2 is virtually absent from the invaginating regions. Rapid disappearance of PtdIns(4,5)P-2 requires the expression of the Salmonella phosphatase SigD (also known as SopB). Deletion of SigD markedly delays fission of the invaginating membranes, indicating that elimination of PtdIns(4,5)P-2 may be required for rapid formation of Salmonella-containing vacuoles. Heterologous expression of SigD is sufficient to promote the disappearance of PtdIns(4,5)P-2, to reduce the rigidity of the membrane skeleton, and to induce plasmalemmal invagination and fission. Hydrolysis of PtdIns(4,5)P-2 may be a common and essential feature of membrane fission during several internalization processes including invasion, phagocytosis and possibly endocytosis.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 3G9, Canada; Univ Toronto, Dept Chem Engn, Toronto, ON M5S 3G9, Canada; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of Toronto; University of Toronto; Stanford University	Terebiznik, MR (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca	Vieira, Otilia V/O-8660-2017; Vieira, O V/C-4860-2013	Vieira, Otilia V/0000-0003-4924-1780; Meyer, Tobias/0000-0003-4339-3804				A-Hassan E, 1998, BIOPHYS J, V74, P1564, DOI 10.1016/S0006-3495(98)77868-3; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Criss AK, 2001, J CELL SCI, V114, P1331; Dworkin MS, 2001, CLIN INFECT DIS, V33, P1010, DOI 10.1086/322644; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; Friebel A, 2001, J BIOL CHEM, V276, P34035, DOI 10.1074/jbc.M100609200; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jepson MA, 2001, CELL MICROBIOL, V3, P417, DOI 10.1046/j.1462-5822.2001.00124.x; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Parker C, 2001, FEMS MICROBIOL LETT, V195, P73, DOI 10.1111/j.1574-6968.2001.tb10500.x; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Sechi AS, 2000, J CELL SCI, V113, P3685; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stebbins CE, 2000, MOL CELL, V6, P1449, DOI 10.1016/S1097-2765(00)00141-6; Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Teruel MN, 1999, J NEUROSCI METH, V93, P37, DOI 10.1016/S0165-0270(99)00112-0; Tolias K, 2000, METHOD ENZYMOL, V325, P190; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	41	219	227	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					766	773		10.1038/ncb854	http://dx.doi.org/10.1038/ncb854			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360287				2022-12-25	WOS:000178316500013
J	Xu, JF; Zheng, SL; Komiya, A; Mychaleckyj, JC; Isaacs, SD; Hu, JJ; Sterling, D; Lange, EM; Hawkins, GA; Turner, A; Ewing, CM; Faith, DA; Johnson, JR; Suzuki, H; Bujnovszky, P; Wiley, KE; DeMarzo, AM; Bova, GS; Chang, BL; Hall, MC; McCullough, DL; Partin, AW; Kassabian, VS; Carpten, JD; Bailey-Wilson, JE; Trent, JM; Ohar, J; Bleecker, ER; Walsh, PC; Isaacs, WB; Meyers, DA				Xu, JF; Zheng, SL; Komiya, A; Mychaleckyj, JC; Isaacs, SD; Hu, JJ; Sterling, D; Lange, EM; Hawkins, GA; Turner, A; Ewing, CM; Faith, DA; Johnson, JR; Suzuki, H; Bujnovszky, P; Wiley, KE; DeMarzo, AM; Bova, GS; Chang, BL; Hall, MC; McCullough, DL; Partin, AW; Kassabian, VS; Carpten, JD; Bailey-Wilson, JE; Trent, JM; Ohar, J; Bleecker, ER; Walsh, PC; Isaacs, WB; Meyers, DA			Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk	NATURE GENETICS			English	Article							TUMOR-ASSOCIATED MACROPHAGES; LINKAGE ANALYSIS; SUSCEPTIBILITY; CHROMOSOME-1; EXPRESSION; INFECTION; TOPOLOGY; BINDING; MODEL	Deletions on human chromosome 8p22-23 in prostate cancer cells 1 and linkage studies in families affected with hereditary prostate cancer (HPC)(2-4) have implicated this region in the development of prostate cancer. The macrophage scavenger receptor 1 gene (MSR1, also known as SR-A) is located at 8p22 and functions in several processes proposed to be relevant to prostate carcinogenesis (5-10). Here we report the results of genetic analyses that indicate that mutations in MSR1 may be associated with risk of prostate cancer. Among families affected with HPC, we identified six rare missense mutations and one nonsense mutation in MSR1. A family-based linkage and association test indicated that these mutations co-segregate with prostate cancer (P = 0.0007). In addition, among men of European descent, MSR1 mutations were detected in 4.4% of individuals affected with non-HPC as compared with 0.8% of unaffected men (P = 0.009). Among African American men, these values were 12.5% and 1.8%, respectively (P = 0.01). These results show that MSR1 may be important in susceptibility to prostate cancer in men of both African American and European descent.	Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genet, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; St Louis Univ, Dept Med, St Louis, MO 63103 USA; Georgia Urol, Atlanta, GA USA; NHGRI, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Isaacs, WB (corresponding author), Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.		Sterling, David/H-6738-2019	Bailey-Wilson, Joan/0000-0002-9153-2920; Bova, George/0000-0003-1639-3104	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000107] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ACTON S, 1993, J BIOL CHEM, V268, P3530; BOVA GS, 1993, CANCER RES, V53, P3869; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; DEJAGER S, 1993, J CLIN INVEST, V92, P894, DOI 10.1172/JCI116664; EMI M, 1993, J BIOL CHEM, V268, P2120; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Gibbs M, 2000, AM J HUM GENET, V67, P100, DOI 10.1086/302969; Goddard KAB, 2001, AM J HUM GENET, V68, P1197, DOI 10.1086/320103; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Latil A, 1998, VIRCHOWS ARCH, V432, P389, DOI 10.1007/s004280050183; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; Nelson WG, 2001, UROLOGY, V57, P39, DOI 10.1016/S0090-4295(00)00939-0; OTT J, 1998, ANAL HUMAN GENETIC L; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Shimura S, 2000, CANCER RES, V60, P5857; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Strickler HD, 2001, EPIDEMIOL REV, V23, P144, DOI 10.1093/oxfordjournals.epirev.a000781; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; WADA Y, 1995, ANN NY ACAD SCI, V748, P226; Weir BS., 1996, GENETIC DATA ANAL; WHITTEMORE AS, 1994, BIOMETRICS, V50, P109, DOI 10.2307/2533201; Xu JF, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; Xu JF, 2002, CANCER EPIDEM BIOMAR, V11, P664	30	247	263	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					321	325		10.1038/ng994	http://dx.doi.org/10.1038/ng994			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244320				2022-12-25	WOS:000178311100025
J	Chao, HJ; Mansfield, SG; Bartel, RC; Hiriyanna, S; Mitchell, LG; Garcia-Blanco, M; Walsh, CE				Chao, HJ; Mansfield, SG; Bartel, RC; Hiriyanna, S; Mitchell, LG; Garcia-Blanco, M; Walsh, CE			Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing	NATURE MEDICINE			English	Article							PRE-MESSENGER-RNA; HUMAN-FACTOR VIII; GENE-THERAPY; REPAIR; RESTORATION; EXPRESSION; PROTEIN; VECTOR	Conventional gene therapy of hemophilia A relies on the transfer of factor VIII (FVIII; encoded by the F8 gene) cDNA. We carried out spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutant FVIII mRNA. A pre-trans-splicing molecule (PTM) corrected endogenous FVIII mRNA in F8 knockout mice with the hemophilia A phenotype, producing sufficient functional FVIII to correct the hemophilia A phenotype. This is the first description of phenotypic correction of a genetic defect by RNA repair in a knockout animal model. Our results indicate the feasibility of using SMaRT to repair RNA for the treatment of genetic diseases.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Intronn Inc, Gaithersburg, MD 20878 USA	Icahn School of Medicine at Mount Sinai	Walsh, CE (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.				PHS HHS [R01-68215] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bi L, 1996, BLOOD, V88, P3446, DOI 10.1182/blood.V88.9.3446.bloodjournal8893446; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Budker V, 1996, GENE THER, V3, P593; Chao HJ, 2000, BLOOD, V95, P1594, DOI 10.1182/blood.V95.5.1594.005k34_1594_1599; Chao HJ, 2001, MOL THER, V4, P217, DOI 10.1006/mthe.2001.0449; Gorman L, 2000, J BIOL CHEM, V275, P35914, DOI 10.1074/jbc.M006259200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herweijer H, 2001, J GENE MED, V3, P280, DOI 10.1002/jgm.178; KARPATI G, 1994, CLIN INVEST MED, V17, P499; KAUFMAN R, 2000, HEMATOLOGY BASIC PRI, V8, P1850; Kikumori T, 2001, HUM GENE THER, V12, P1429, DOI 10.1089/104303401750298580; Koehler DR, 2001, MOL THER, V4, P84, DOI 10.1006/mthe.2001.0435; Lillicrap David, 2000, Haematologica, V85, P108; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; Roy S, 1999, HAEMOPHILIA, V5, P340; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Sullenger BA, 1999, GENE THER, V6, P461, DOI 10.1038/sj.gt.3300903; Watanabe T, 2000, ADV DRUG DELIVER REV, V44, P109, DOI 10.1016/S0169-409X(00)00089-2; Yenchitsomanus P, 2001, HAEMOPHILIA, V7, P335, DOI 10.1046/j.1365-2516.2001.00507.x	22	127	140	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1015	1019		10.1038/nm900	http://dx.doi.org/10.1038/nm900			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847523				2022-12-25	WOS:000184484900024
J	Rutsch, F; Ruf, N; Vaingankar, S; Toliat, MR; Suk, A; Hohne, W; Schauer, G; Lehmann, M; Roscioli, T; Schnabel, D; Epplen, JT; Knisely, A; Superti-Furga, A; McGill, J; Filippone, M; Sinaiko, AR; Vallance, H; Hinrichs, B; Smith, W; Ferre, M; Terkeltaub, R; Nurnberg, P				Rutsch, F; Ruf, N; Vaingankar, S; Toliat, MR; Suk, A; Hohne, W; Schauer, G; Lehmann, M; Roscioli, T; Schnabel, D; Epplen, JT; Knisely, A; Superti-Furga, A; McGill, J; Filippone, M; Sinaiko, AR; Vallance, H; Hinrichs, B; Smith, W; Ferre, M; Terkeltaub, R; Nurnberg, P			Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification	NATURE GENETICS			English	Article							NONSENSE; PC-1	Idiopathic infantile arterial calcification (IIAC; OMIM 208000) is characterized by calcification of the internal elastic lamina of muscular arteries and stenosis due to myointimal proliferation. We analyzed affected individuals from 11 unrelated kindreds and found that IIAC was associated with mutations that inactivated ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). This cell surface enzyme generates inorganic pyrophosphate (PPi), a solute that regulates cell differentiation and serves as an essential physiologic inhibitor of calcification.	Univ Calif San Diego, Vet Affairs Med Ctr, Dept Med, La Jolla, CA 92161 USA; Humboldt Univ, Charite Univ Hosp, Inst Med Genet, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Charite Univ Hosp, Inst Biochem, Berlin, Germany; Childrens Hosp & Clin, Dept Pathol, Minneapolis, MN USA; Royal Prince Alfred Hosp, Dept Clin & Mol Genet, Sydney, NSW, Australia; Humboldt Univ, Charite Univ Hosp, Dept Pediat, Berlin, Germany; Ruhr Univ Bochum, Dept Human Genet, D-4630 Bochum, Germany; Kings Coll Hosp London, Inst Liver Studies, London SE5 8RX, England; Univ Childrens Hosp, Div Metab & Mol Dis, Zurich, Switzerland; Royal Childrens Hosp, Dept Metab Med, Brisbane, Qld, Australia; Univ Padua, Sch Med, Dept Pediat, Padua, Italy; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Biochem Dis Lab, Vancouver, BC, Canada; Eppendorf Univ Hosp, Dept Neonatol, Hamburg, Germany; Barbara Bush Childrens Hosp, Maine Med Ctr, Div Genet, Portland, OR USA; Prenatal Diagnost Ctr, Roanoke, VA USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Children's Hospitals & Clinics of Minnesota; University of Sydney; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruhr University Bochum; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University Children's Hospital Zurich; Royal Children's Hospital Brisbane; University of Padua; University of Minnesota System; University of Minnesota Twin Cities; BC Women's Hospital & Health Centre; University of Hamburg; University Medical Center Hamburg-Eppendorf	Terkeltaub, R (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, Dept Med, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	rterkeltaub@ucsd.edu	superti-furga, andrea/E-9162-2015	superti-furga, andrea/0000-0002-3543-7531; Schnabel, Dirk/0000-0002-7944-7790; Epplen, Joerg T./0000-0002-6087-3327; Vallance, Hilary/0000-0003-1734-1445				Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Hosoda Y, 1981, Ryumachi, V21 Suppl, P157; Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; MAQUAT LE, 2000, TRANSLATIONAL CONTRO; MENTEN ML, 1948, AM J CLIN PATHOL, V18, P805; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Rutsch F, 2003, CURR OPIN RHEUMATOL, V15, P302, DOI 10.1097/00002281-200305000-00019; Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002-9440(10)63996-X; Saxena A, 2003, PEDIATR CARDIOL, V24, P80, DOI 10.1007/s00246-001-0067-2; VERA J, 1990, PEDIATR RADIOL, V20, P585, DOI 10.1007/BF02129060; Wax JR, 2001, AM J OBSTET GYNECOL, V185, P1267, DOI 10.1067/mob.2001.117186	15	425	446	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2003	34	4					379	381		10.1038/ng1221	http://dx.doi.org/10.1038/ng1221			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12881724				2022-12-25	WOS:000184470500015
J	Suzuki, A; Yamada, R; Chang, XT; Tokuhiro, S; Sawada, T; Suzuki, M; Nagasaki, M; Nakayama-Hamada, M; Kawaida, R; Ono, M; Ohtsuki, M; Furukawa, H; Yoshino, S; Yukioka, M; Tohma, S; Matsubara, T; Wakitani, S; Teshima, R; Nishioka, Y; Sekine, A; Iida, A; Takahashi, A; Tsunoda, T; Nakamura, Y; Yamamoto, K				Suzuki, A; Yamada, R; Chang, XT; Tokuhiro, S; Sawada, T; Suzuki, M; Nagasaki, M; Nakayama-Hamada, M; Kawaida, R; Ono, M; Ohtsuki, M; Furukawa, H; Yoshino, S; Yukioka, M; Tohma, S; Matsubara, T; Wakitani, S; Teshima, R; Nishioka, Y; Sekine, A; Iida, A; Takahashi, A; Tsunoda, T; Nakamura, Y; Yamamoto, K			Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis	NATURE GENETICS			English	Article							SHARED EPITOPE HYPOTHESIS; ANTIFILAGGRIN AUTOANTIBODIES; IMMUNOBLOTTING DETECTION; ANTIKERATIN ANTIBODIES; MESSENGER-RNA; SUSCEPTIBILITY; LINKAGE; POLYMORPHISMS; DIAGNOSIS; FILAGGRIN	Individuals with rheumatoid arthritis frequently have autoantibodies to citrullinated peptides, suggesting the involvement of the peptidylarginine deiminases citrullinating enzymes (encoded by PADI genes) in rheumatoid arthritis. Previous linkage studies have shown that a susceptibility locus for rheumatoid arthritis includes four PADI genes but did not establish which PADI gene confers susceptibility to rheumatoid arthritis. We used a case-control linkage disequilibrium study to show that PADI type 4 is a susceptibility locus for rheumatoid arthritis (P = 0.000008). PADI4 was expressed in hematological and rheumatoid arthritis synovial tissues. We also identified a haplotype of PADI4 associated with susceptibility to rheumatoid arthritis that affected stability of transcripts and was associated with levels of antibody to citrullinated peptide in sera from individuals with rheumatoid arthritis. Our results imply that the PADI4 haplotype associated with susceptibility to rheumatoid arthritis increases production of citrullinated peptides acting as autoantigens, resulting in heightened risk of developing the disease.	Inst Phys & Chem Res, SNP Res Ctr, Lab Rheumat Dis, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Sankyo Co Ltd, Tokyo 140, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan; Nippon Med Coll, Dept Joint Dis & Rheumatism, Tokyo 113, Japan; Yukioka Hosp, Osaka, Japan; Natl Sagamihara Hosp, Kanagawa, Japan; Matsubara Mayflower Hosp, Hyogo, Japan; Osaka Minami Natl Hosp, Osaka, Japan; Tottori Univ, Dept Orthoped Surg, Tottori 680, Japan; Yamanashi Prefectural Cent Hosp, Yamanashi, Japan; Inst Phys & Chem Res, SNP Res Ctr, Lab Genotyping, Kanagawa, Japan; Inst Phys & Chem Res, SNP Res Ctr, Lab Med Informat, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan	RIKEN; Daiichi Sankyo Company Limited; University of Tokyo; Nippon Medical School; Tottori University; RIKEN; RIKEN; University of Tokyo	Yamada, R (corresponding author), Inst Phys & Chem Res, SNP Res Ctr, Lab Rheumat Dis, Tsurumi Ku, 1-7-22 Suehirocho, Yokohama, Kanagawa 2300045, Japan.		Iida, Aritoshi/CAA-1373-2022; Tsunoda, Tatsuhiko/K-2061-2014; Yamamoto, Kazuhiko/N-5096-2015; Sawed, Tetsuji/GRX-6582-2022; Suzuki, Akari/N-5389-2015; Peng, Bo/A-6920-2009	Iida, Aritoshi/0000-0001-7538-1651; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Peng, Bo/0000-0001-8225-2284; Yamada, Ryo/0000-0002-1587-630X				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Asaga H, 2001, J LEUKOCYTE BIOL, V70, P46; Baeten D, 2001, ARTHRITIS RHEUM, V44, P2255, DOI 10.1002/1529-0131(200110)44:10<2255::AID-ART388>3.0.CO;2-#; Cornelis F, 1998, P NATL ACAD SCI USA, V95, P10746, DOI 10.1073/pnas.95.18.10746; Cuadrado A, 2002, NUCLEIC ACIDS RES, V30, P2202, DOI 10.1093/nar/30.10.2202; de Vries N, 2002, ARTHRITIS RHEUM-US, V46, P921, DOI 10.1002/art.10210; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P236, DOI 10.1186/ar93; GOMESDAUDRIX V, 1994, ANN RHEUM DIS, V53, P735, DOI 10.1136/ard.53.11.735; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Hirakawa M, 2002, NUCLEIC ACIDS RES, V30, P158, DOI 10.1093/nar/30.1.158; Hirano T, 2002, NAT IMMUNOL, V3, P342, DOI 10.1038/ni0402-342; Jansen ALMA, 2002, J RHEUMATOL, V29, P2074; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; MacKay K, 2002, ARTHRITIS RHEUM, V46, P632, DOI 10.1002/art.10147; Masson-Bessiere C, 2001, J IMMUNOL, V166, P4177, DOI 10.4049/jimmunol.166.6.4177; McIntyre LM, 2000, GENET EPIDEMIOL, V19, P18, DOI 10.1002/1098-2272(200007)19:1<18::AID-GEPI2>3.0.CO;2-Y; Menard HA, 2000, ARTHRITIS RES, V2, P429, DOI 10.1186/ar122; Nakashima K, 1999, J BIOL CHEM, V274, P27786, DOI 10.1074/jbc.274.39.27786; Nepom GT, 1998, ADV IMMUNOL, V68, P315, DOI 10.1016/S0065-2776(08)60563-5; Nogueira L, 2001, ANN RHEUM DIS, V60, P882; Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047; OTT J, 1977, ANN HUM GENET, V40, P443, DOI 10.1111/j.1469-1809.1977.tb02031.x; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; Schellekens GA, 2000, ARTHRITIS RHEUM-US, V43, P155, DOI 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3; Schildkraut Joellen M., 1998, P379; Seldin MF, 1999, ARTHRITIS RHEUM, V42, P1071, DOI 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8; Shibue T, 2000, ARTHRITIS RHEUM, V43, P753, DOI 10.1002/1529-0131(200004)43:4<753::AID-ANR5>3.0.CO;2-O; Shiozawa S, 1998, INT IMMUNOL, V10, P1891, DOI 10.1093/intimm/10.12.1891; van Venrooij WJ, 2000, ARTHRITIS RES, V2, P249, DOI 10.1186/ar95; VINCENT C, 1989, ANN RHEUM DIS, V48, P712, DOI 10.1136/ard.48.9.712; Vincent C, 1998, J RHEUMATOL, V25, P838; Vincent C, 2002, ARTHRITIS RHEUM, V46, P2051, DOI 10.1002/art.10436; Weyand CM, 2000, ARTHRITIS RES, V2, P212, DOI 10.1186/ar90; Yang TY, 2003, J BIOL CHEM, V278, P15291, DOI 10.1074/jbc.M300954200; Zhou XD, 2002, ARTHRITIS RHEUM-US, V46, P2990, DOI 10.1002/art.10601; Zhou ZJ, 2002, CURR OPIN RHEUMATOL, V14, P250, DOI 10.1097/00002281-200205000-00010	40	816	894	1	31	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2003	34	4					395	402		10.1038/ng1206	http://dx.doi.org/10.1038/ng1206			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12833157				2022-12-25	WOS:000184470500017
J	Azuara, V; Brown, KE; Williams, RRE; Webb, N; Dillon, N; Festenstein, R; Buckle, V; Merkenschlager, M; Fisher, AG				Azuara, V; Brown, KE; Williams, RRE; Webb, N; Dillon, N; Festenstein, R; Buckle, V; Merkenschlager, M; Fisher, AG			Heritable gene silencing in lymphocytes delays chromatid resolution without affecting the timing of DNA replication	NATURE CELL BIOLOGY			English	Article							LOCUS-CONTROL REGION; CHROMOSOME STRUCTURE; TEMPORAL-ORDER; HETEROCHROMATIN; CELLS; TRANSCRIPTION; ORGANIZATION; ASSOCIATION; ACTIVATION; GENOME	Temporal control of DNA replication has been implicated in epigenetic regulation of gene expression on the basis of observations that certain tissue-specific genes replicate earlier in expressing than non-expressing cells. Here, we show evidence that several leukocyte-specific genes replicate early in lymphocytes regardless of their transcription and also in fibroblasts, where these genes are never normally expressed. Instead, the heritable silencing of some genes (Rag-1, TdT, CD8alpha and lambda5) and their spatial recruitment to heterochromatin domains within the nucleus of lymphocytes resulted in a markedly delayed resolution of sister chromatids into doublet signals discernable by 3D fluorescence in situ hybridization ( FISH). Integration of transgenes within heterochromatin ( in cis) did, however, confer late replication and this was reversed after variegated transgene expression. These findings emphasise that chromosomal location is important for defining the replication timing of genes and show that retarded sister-chromatid resolution is a novel feature of inactive chromatin.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Lymphocyte Dev Grp, London W12 ONN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Gene Regulat & Chromatin Grp, Hammersmith Hosp, London W12 ONN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Gene Control Mech & Dis,MRC Clin Sci Ctr, London W12 ONN, England; John Radcliffe Hosp, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England	Imperial College London; Imperial College London; Imperial College London; University of Oxford	Azuara, V (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Lymphocyte Dev Grp, Du Cane Rd, London W12 ONN, England.			Azuara, Veronique/0000-0003-4608-3713; Merkenschlager, Matthias/0000-0003-2889-3288				Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; GILBERT DM, 1986, P NATL ACAD SCI USA, V83, P2924, DOI 10.1073/pnas.83.9.2924; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; Mileham P, 1996, MAMM GENOME, V7, P253, DOI 10.1007/s003359900077; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Sabbattini P, 1999, MOL CELL BIOL, V19, P671; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; TALJANIDISZ J, 1989, MOL CELL BIOL, V9, P2881, DOI 10.1128/MCB.9.7.2881; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Zhou J, 2002, MOL CELL BIOL, V22, P4876, DOI 10.1128/MCB.22.13.4876-4889.2002	30	86	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					668	U49		10.1038/ncb1006	http://dx.doi.org/10.1038/ncb1006			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12833066				2022-12-25	WOS:000183911600018
J	Cohen, M; Stutz, F; Belgareh, N; Haguenauer-Tsapis, R; Dargemont, C				Cohen, M; Stutz, F; Belgareh, N; Haguenauer-Tsapis, R; Dargemont, C			Ubp3 requires a cofactor, Bre5, to specifically de-ubiquitinate the COPII protein, Sec23	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; DEUBIQUITINATING ENZYMES; SECRETORY PATHWAY; VESICLE FORMATION; COAT; GENE; PROTEASOME; INTERACTS; TRANSPORT; CLONING	Ubiquitination is important for a broad array of cellular functions. Although reversal of this process, de-ubiquitination, most probably represents an important regulatory step contributing to cellular homeostasis, the specificity and properties of de-ubiquitination enzymes remain poorly understood. Here, we show that the Saccharomyces cerevisiae ubiquitin protease Ubp3 requires an additional protein, Bre5, to form an active de-ubiquitination complex that cleaves ubiquitin from specific substrates. In particular, this complex rescues Sec23p, a COPII subunit essential for the transport between the endoplasmic reticulum and the Golgi apparatus, from degradation by the proteasome. This probably contributes to maintaining and adapting a Sec23 expression level that is compatible with an efficient secretion pathway, and consequently with cell growth and viability.	Univ Paris 06, Inst Jacques Monod, Nucleocytoplasm Transport Grp, UMR 7592,CNRS, F-75251 Paris 05, France; Univ Paris 07, F-75251 Paris, France; Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; Univ Paris 06, Inst Jacques Monod, Ubiquitin & Intracellular Trafficking Grp, UMR 7592,CNRS, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Geneva; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Dargemont, C (corresponding author), Univ Paris 06, Inst Jacques Monod, Nucleocytoplasm Transport Grp, UMR 7592,CNRS, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.		Cohen, Mickael/F-4122-2011; Stutz, Françoise C/N-4329-2017; Cohen, Mickael/P-7148-2019; Haguenauer-Tsapis, Rosine/C-5446-2012	Cohen, Mickael/0000-0002-1372-680X; 				Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Avaro S, 2002, YEAST, V19, P351, DOI 10.1002/yea.838; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Brew CT, 2002, GENETICS, V162, P1079; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Dupre S, 2001, CURR BIOL, V11, pR932, DOI 10.1016/S0960-9822(01)00558-9; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Holm Connie, 1993, Methods (Orlando), V5, P102, DOI 10.1006/meth.1993.1014; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kahana A, 1999, MOL CELL BIOL, V19, P6608; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164	32	127	134	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					661	U47		10.1038/ncb1003	http://dx.doi.org/10.1038/ncb1003			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12778054				2022-12-25	WOS:000183911600017
J	Luker, GD; Pica, CM; Song, JL; Luker, KE; Piwnica-Worms, D				Luker, GD; Pica, CM; Song, JL; Luker, KE; Piwnica-Worms, D			Imaging 26S proteasome activity and inhibition in living mice	NATURE MEDICINE			English	Article							DEPENDENT PROTEOLYSIS; UBIQUITIN; PROTEINS; SYSTEM; PS-341	The ubiquitin-proteasome pathway is the central mediator of regulated proteolysis in cells, and defects in this pathway are associated with cancer and neurodegenerative diseases. To assess 26S proteasome function in living animals, we developed a ubiquitin-luciferase reporter for bioluminescence imaging. The reporter was degraded rapidly under steady-state conditions and stabilized in a dose- and time-dependent manner in response to proteasome inhibitors. Using bioluminescence imaging after one dose of the chemotherapeutic proteasome inhibitor bortezomib (PS-341), proteasome function in tumor xenografts was blocked within 30 min and returned to nearly baseline by 46 h. After a 2-week regimen of bortezomib, however, imaging of target tumors showed significantly enhanced proteasome inhibition that no longer returned to baseline. The ubiquitin-luciferase reporter enables repetitive tissue-specific analysis of 26S proteasome activity in vivo and should facilitate development and validation of proteasome inhibitors in mouse models, as well as investigations of the ubiquitin-proteasome pathway in disease pathogenesis.	Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA.	piwnica-wormsd@mir.wustl.edu		Luker, Kathryn/0000-0001-8314-3370; luker, gary/0000-0001-6832-2581	NCI NIH HHS [P50 CA94056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Deroo BJ, 2002, J BIOL CHEM, V277, P20120, DOI 10.1074/jbc.C200173200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; LeBlanc R, 2002, CANCER RES, V62, P4996; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lightcap ES, 2000, CLIN CHEM, V46, P673; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Pye J, 2003, AM J PHYSIOL-HEART C, V284, pH919, DOI 10.1152/ajpheart.00851.2002; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Stack JH, 2000, NAT BIOTECHNOL, V18, P1298, DOI 10.1038/82422; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Welsh S, 1997, CURR OPIN BIOTECH, V8, P617, DOI 10.1016/S0958-1669(97)80038-9; Zhang L, 2001, STROKE, V32, P2926, DOI 10.1161/hs1201.100207	22	156	163	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					969	973		10.1038/nm894	http://dx.doi.org/10.1038/nm894			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819780				2022-12-25	WOS:000183979300041
J	Smith, LL; Coller, HA; Roberts, JM				Smith, LL; Coller, HA; Roberts, JM			Telomerase modulates expression of growth-controlling genes and enhances cell proliferation	NATURE CELL BIOLOGY			English	Article							MAMMARY EPITHELIAL-CELLS; CATALYTIC SUBUNIT; CANCER-CELLS; TUMORIGENESIS; SENESCENCE; MICE; INHIBITION	Most somatic cells do not express sufficient amounts of telomerase to maintain a constant telomere length during cycles of chromosome replication. Consequently, there is a limit to the number of doublings somatic cells can undergo before telomere shortening triggers an irreversible state of cellular senescence(1,2). Ectopic expression of telomerase overcomes this limitation, and in conjunction with specific oncogenes can transform cells to a tumorigenic phenotype(3). However, recent studies have questioned whether the stabilization of chromosome ends entirely explains the ability of telomerase to promote tumorigenesis and have resulted in the hypothesis that telomerase has a second function that also supports cell division(4-11). Here we show that ectopic expression of telomerase in human mammary epithelial cells (HMECs) results in a diminished requirement for exogenous mitogens and that this correlates with telomerase-dependent induction of genes that promote cell growth. Furthermore, we show that inhibiting expression of one of these genes, the epidermal growth factor receptor (EGFR), reverses the enhanced proliferation caused by telomerase. We conclude that telomerase may affect proliferation of epithelial cells not only by stabilizing telomeres, but also by affecting the expression of growth-promoting genes.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Roberts, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA.				NCI NIH HHS [1 F32 CA83311-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA083311] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Chang S, 2002, P NATL ACAD SCI USA, V99, P12520, DOI 10.1073/pnas.212514699; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Ishiguro T, 2000, ONCOL RES, V12, P181; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Luparello C, 2001, J BONE MINER RES, V16, P2173, DOI 10.1359/jbmr.2001.16.12.2173; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Ornitz D.M., 2001, GENOME BIOL, V2; Reimold AM, 2000, GENE DEV, V14, P152; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; [No title captured]	31	369	387	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					474	479		10.1038/ncb985	http://dx.doi.org/10.1038/ncb985			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717449				2022-12-25	WOS:000182691400023
J	Nunes, MC; Roy, NS; Keyoung, HM; Goodman, RR; McKhann, G; Jiang, L; Kang, J; Nedergaard, M; Goldman, SA				Nunes, MC; Roy, NS; Keyoung, HM; Goodman, RR; McKhann, G; Jiang, L; Kang, J; Nedergaard, M; Goldman, SA			Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; FETAL HUMAN BRAIN; CNS STEM-CELLS; IN-VITRO; OLIGODENDROCYTE DEVELOPMENT; SUBVENTRICULAR ZONE; SUBEPENDYMAL CELLS; PRECURSOR CELL; GROWTH-FACTOR; FOREBRAIN	The subcortical white matter of the adult human brain harbors a pool of glial progenitor cells. These cells can be isolated by fluorescence-activated cell sorting (FACS) after either transfection with green fluorescent protein (GFP) under the control of the CNP2 promoter, or A2B5-targeted immunotagging. Although these cells give rise largely to oligodendrocytes, in low-density culture we observed that some also generated neurons. We thus asked whether these nominally glial progenitors might include multipotential progenitor cells capable of neurogenesis. We found that adult human white-matter progenitor cells (WMPCs) could be passaged as neurospheres in vitro and that these cells generated functionally competent neurons and glia both in vitro and after xenograft to the fetal rat brain. WMPCs were able to produce neurons after their initial isolation and did not require in vitro expansion or reprogramming to do so. These experiments indicate that an abundant pool of mitotically competent neurogenic progenitor cells resides in the adult human white matter.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; New York Med Coll, Dept Anat & Cell Biol, Valhalla, NY 10595 USA	Cornell University; Columbia University; New York Medical College	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Nunes, Marta/0000-0003-3788-878X; Goldman, Steven/0000-0002-5498-4303	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039559, R01NS033106, R37NS029813] Funding Source: NIH RePORTER; NINDS NIH HHS [R37/R01NS29813, R01NS39559, R01NS33106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gravel M, 1998, J NEUROSCI RES, V53, P393; Han JJ, 1999, HUM GENE THER, V10, P1867, DOI 10.1089/10430349950017545; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Mason JL, 2002, MOL CELL NEUROSCI, V20, P30, DOI 10.1006/mcne.2002.1114; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; TSE FW, 1992, J NEUROSCI, V12, P1781; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yashima K, 1998, CELL GROWTH DIFFER, V9, P805; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	41	568	605	1	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					439	447		10.1038/nm837	http://dx.doi.org/10.1038/nm837			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627226				2022-12-25	WOS:000181987400034
J	Gasman, S; Kalaidzidis, Y; Zerial, M				Gasman, S; Kalaidzidis, Y; Zerial, M			RhoD regulates endosome dynamics through Diaphanous-related Formin and Src tyrosine kinase	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SMALL GTPASE; ACTIN CYTOSKELETON; MAMMALIAN-CELLS; FAMILY KINASES; MDCK CELLS; PROTEINS; MEMBRANE; MICROTUBULES; LYSOSOMES	Early endosomes move bidirectionally between the cell periphery and the interior through a mechanism regulated by the low molecular weight GTPase RhoD. Here, we identify a novel splice variant of human Diaphanous, hDia2C, which specifically binds to RhoD and is recruited onto early endosomes. Expression of RhoD and hDia2C induces a striking alignment of early endosomes along actin filaments and reduces their motility. This activity depends on the membrane recruitment and activation of c-Src kinase, thus uncovering a new role in endosome function. Our results define a novel signal transduction pathway, in which hDia2C and c-Src are sequentially activated by RhoD to regulate the motility of early endosomes through interactions with the actin cytoskeleton.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; CNRS, UPR Neurotransmiss & Secret Neuroendocrine 2356, F-67084 Strasbourg, France; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Lomonosov Moscow State University	Zerial, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.		Kalaidzidis, Yannis/H-3094-2016; Gasman, Stephane/D-5113-2017; stéphane, gasman/Q-1145-2019	Kalaidzidis, Yannis/0000-0002-6137-1193; Gasman, Stephane/0000-0001-8415-1276; stéphane, gasman/0000-0001-8415-1276				Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Bergeland T, 2001, CURR BIOL, V11, P644, DOI 10.1016/S0960-9822(01)00177-4; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Chetverikov D, 1999, COMPUTING, V62, P321, DOI 10.1007/s006070050027; CHISTOFORIDIS S, 1999, NATURE, V397, P621; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Durrbach A, 1996, J CELL SCI, V109, P457; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kalaidzidis Y. L., 1997, PROGRAMMIROVANIE, V4, P38; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kato T, 2001, J CELL SCI, V114, P775; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Krebs A, 2001, J CELL SCI, V114, P3663; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Murphy C, 2001, EUR J CELL BIOL, V80, P391, DOI 10.1078/0171-9335-00173; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Uetz P, 1996, J BIOL CHEM, V271, P33525, DOI 10.1074/jbc.271.52.33525; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volberg T, 2001, J CELL SCI, V114, P2279; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	54	164	169	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					195	U3		10.1038/ncb935	http://dx.doi.org/10.1038/ncb935			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12577064				2022-12-25	WOS:000181322500011
J	Marculescu, R; Vanura, K; Le, T; Simon, P; Jager, U; Nadel, B				Marculescu, R; Vanura, K; Le, T; Simon, P; Jager, U; Nadel, B			Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and individuals with T-ALL	NATURE GENETICS			English	Article							CELL ACUTE-LEUKEMIA; TCR-BETA LOCUS; CHROMOSOMAL TRANSLOCATIONS; TAL2; RECOMBINATION; LCK; DNA	After V(D) J-mediated translocations, signal joints are retained on one of the derivative chromosomes. We report here that such signal joints are highly reactive and constitute unstable genomic elements with potential oncogenic properties.	Univ Vienna, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria; Austrian Acad Sci, Ctr Mol Med, A-1010 Vienna, Austria; Univ Vienna, Dept Surg, Vienna, Austria; Parc Sci Luminy, Ctr Immunol, CNRS INSERM Marseille Luminy, F-13288 Marseille, France	University of Vienna; Austrian Academy of Sciences; University of Vienna; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Nadel, B (corresponding author), Univ Vienna, Dept Lab Med, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Nadel, Bertrand/J-2197-2014; Vanura, Katrina/AAG-1236-2021	Vanura, Katrina/0000-0002-2217-4998; Simon, Paul/0000-0002-2932-5074				BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BURNETT RC, 1994, BLOOD, V84, P1232; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	15	24	24	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					342	344		10.1038/ng1092	http://dx.doi.org/10.1038/ng1092			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12567187				2022-12-25	WOS:000181312700009
J	Taylor, SW; Fahy, E; Zhang, B; Glenn, GM; Warnock, DE; Wiley, S; Murphy, AN; Gaucher, SP; Capaldi, RA; Gibson, BW; Ghosh, SS				Taylor, SW; Fahy, E; Zhang, B; Glenn, GM; Warnock, DE; Wiley, S; Murphy, AN; Gaucher, SP; Capaldi, RA; Gibson, BW; Ghosh, SS			Characterization of the human heart mitochondrial proteome	NATURE BIOTECHNOLOGY			English	Article							MASS-SPECTROMETRIC IDENTIFICATION; RIBOSOMAL-PROTEINS PRESENT; 2-DIMENSIONAL ELECTROPHORESIS; SYSTEMATIC IDENTIFICATION; IMPORT RECEPTORS; CULTURED-CELLS; TOM COMPLEX; DATABASE; SUBUNIT; FRACTIONATION	To gain a better understanding of the critical role of mitochondria in cell function, we have compiled an extensive catalogue of the mitochondrial proteome using highly purified mitochondria from normal human heart tissue. Sucrose gradient centrifugation was employed to partially resolve protein complexes whose individual protein components were separated by one-dimensional PAGE. Total in-gel processing and subsequent detection by mass spectrometry and rigorous bioinformatic analysis yielded a total of 615 distinct protein identifications. All protein pI values, molecular weight ranges, and hydrophobicities were represented. The coverage of the known subunits of the oxidative phosphorylation machinery within the inner mitochondrial membrane was >90%. A significant proportion of identified proteins are involved in signaling, RNA, DNA, and protein synthesis, ion transport, and lipid metabolism. The biochemical roles of 19% of the identified proteins have not been defined. This database of proteins provides a comprehensive resource for the discovery of novel mitochondrial functions and pathways.	MitoKor, San Diego, CA 92121 USA; Buck Inst Age Res, Novato, CA 94945 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Buck Institute for Research on Aging; University of Oregon	Taylor, SW (corresponding author), MitoKor, 11494 Sorrento Valley Rd, San Diego, CA 92121 USA.	taylors@mitokor.com	Murphy, Anne N/H-3217-2016	Murphy, Anne N/0000-0002-5222-9902				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Bardel J, 2002, PROTEOMICS, V2, P880, DOI 10.1002/1615-9861(200207)2:7<880::AID-PROT880>3.0.CO;2-0; Caggese C, 1999, MOL GEN GENET, V261, P64, DOI 10.1007/s004380050942; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Chinnery PF, 1999, J MED GENET, V36, P425; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Murray J, 2002, FEBS LETT, V529, P173, DOI 10.1016/S0014-5793(02)03278-7; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PARRY DM, 1984, J BIOL CHEM, V259, P8917; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Pflieger D, 2002, ANAL CHEM, V74, P2400, DOI 10.1021/ac011295h; Rabilloud T, 2001, PROTEOMICS, V1, P1105, DOI 10.1002/1615-9861(200109)1:9<1105::AID-PROT1105>3.0.CO;2-M; Rabilloud T, 1998, ELECTROPHORESIS, V19, P1006, DOI 10.1002/elps.1150190616; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; Scheffler NK, 2001, MITOCHONDRION, V1, P161, DOI 10.1016/S1567-7249(01)00007-1; Schwartz R, 2001, GENOME RES, V11, P703, DOI 10.1101/gr.GR-1587R; Simpson PB, 1997, BIOCHEM J, V325, P239, DOI 10.1042/bj3250239; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; Terkeltaub R, 2002, MITOCHONDRION, V1, P301, DOI 10.1016/S1567-7249(01)00037-X; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	51	542	584	1	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					281	286		10.1038/nbt793	http://dx.doi.org/10.1038/nbt793			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12592411				2022-12-25	WOS:000181312500024
J	Izmailova, E; Bertley, FMN; Huang, Q; Makori, N; Miller, CJ; Young, RA; Aldovini, A				Izmailova, E; Bertley, FMN; Huang, Q; Makori, N; Miller, CJ; Young, RA; Aldovini, A			HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; APOPTOSIS-INDUCING LIGAND; RECOMBINANT ADENOVIRUS; GENE-EXPRESSION; RESPONSE GENE; PROTEIN; INFECTION; TYPE-1; CHEMOKINE; TRANSCRIPTION	Immature dendritic cells are among the first cells infected by retroviruses after mucosal exposure. We explored the effects of human immunodeficiency virus-1 (HIV-1) and its Tat transactivator on these primary antigen-presenting cells using DNA microarray analysis and functional assays. We found that HIV-1 infection or Tat expression induces interferon (IFN)-responsive gene expression in immature human dendritic cells without inducing maturation. Among the induced gene products are chemokines that recruit activated T cells and macrophages, the ultimate target cells for the virus. Dendritic cells in the lymph nodes of macaques infected with simian immunodeficiency virus (SIV) have elevated levels of monocyte chemoattractant protein 2 (MCP-2), demonstrating that chemokine induction also occurs during retroviral infection in vivo. These results show that HIV-1 Tat reprograms host dendritic cell gene expression to facilitate expansion of HIV-1 infection.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Pathol Microbiol & Immunol, Sch Vet Med, Davis, CA 95616 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; MIT, Dept Biol, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Massachusetts Institute of Technology (MIT)	Aldovini, A (corresponding author), Childrens Hosp, Dept Med, Boston, MA 02115 USA.	anna.aldovini@tch.harvard.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Izmailova, Elena/0000-0002-7150-1748	NCRR NIH HHS [RR14555, RR00169] Funding Source: Medline; NIAID NIH HHS [AI41365, AI44476] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014555, P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041365, R01AI044476, R01AI041365] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini C, 2000, AM J RESP CRIT CARE, V162, P1466, DOI 10.1164/ajrccm.162.4.2003130; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Engelmayer J, 1999, J IMMUNOL, V163, P6762; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fujii N, 1999, VIRUS RES, V65, P175, DOI 10.1016/S0168-1702(99)00114-8; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Marzio G, 1999, GENETICA, V106, P125, DOI 10.1023/A:1003797332379; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Miura Y, 2001, J EXP MED, V193, P651, DOI 10.1084/jem.193.5.651; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Smith SG, 2001, IMMUNOL LETT, V76, P79, DOI 10.1016/S0165-2478(00)00324-2; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Xiao WH, 1998, P NATL ACAD SCI USA, V95, P1085, DOI 10.1073/pnas.95.3.1085; Zhang XT, 2001, CHINESE J CATAL+, V22, P95; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	45	173	180	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					191	197		10.1038/nm822	http://dx.doi.org/10.1038/nm822			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539042				2022-12-25	WOS:000180801900023
J	Cenci, G; Siriaco, G; Raffa, GD; Kellum, R; Gatti, M				Cenci, G; Siriaco, G; Raffa, GD; Kellum, R; Gatti, M			The Drosophila HOAP protein is required for telomere capping	NATURE CELL BIOLOGY			English	Article							RECOGNITION COMPLEX; HETEROCHROMATIN; HP1; GENES	HOAP (HP1/ORC-associated protein) has recently been isolated(1) from Drosophila melanogaster embryos as part of a cytoplasmic complex that contains heterochromatin protein 1 (HP1) and the origin recognition complex subunit 2 (ORC2). Here, we show that caravaggio, a mutation in the HOAP-encoding gene, causes extensive telomere-telomere fusions in larval brain cells, indicating that HOAP is required for telomere capping. Our analyses indicate that HOAP is specifically enriched at mitotic chromosome telomeres, and strongly suggest that HP1 and HOAP form a telomere-capping complex that does not contain ORC2.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, I-00185 Rome, Italy; Univ Kentucky, Lexington, KY 40506 USA	Sapienza University Rome; University of Kentucky	Gatti, M (corresponding author), Univ Lecce, Dipartimento Sci & Tecnol Biol Ambientali, I-73100 Lecce, Italy.		Gatti, Maurizio/J-9703-2013; Gatti, Maurizio/S-2877-2019	Gatti, Maurizio/0000-0003-3777-300X; Cenci, Giovanni/0000-0002-9628-1411; raffa, grazia daniela/0000-0002-5072-5240				Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pardue ML, 1995, TELOMERES, P339; Schmid KJ, 1997, P NATL ACAD SCI USA, V94, P9746, DOI 10.1073/pnas.94.18.9746; Shareef MM, 2001, MOL BIOL CELL, V12, P1671, DOI 10.1091/mbc.12.6.1671; Siriaco GM, 2002, GENETICS, V160, P235; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759	15	138	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					82	84		10.1038/ncb902	http://dx.doi.org/10.1038/ncb902			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510197				2022-12-25	WOS:000180223700018
J	Le, WD; Xu, PY; Jankovic, J; Jiang, H; Appel, SH; Smith, RG; Vassilatis, DK				Le, WD; Xu, PY; Jankovic, J; Jiang, H; Appel, SH; Smith, RG; Vassilatis, DK			Mutations in NR4A2 associated with familial Parkinson disease	NATURE GENETICS			English	Article							RECEPTOR NURR1 GENE; NURR1-DEFICIENT MICE; NEURONS; IDENTIFICATION; TRANSCRIPTION; ORGANIZATION; LOCALIZATION; EXPRESSION; PROMOTER; AGENESIS	NR4A2, encoding a member of nuclear receptor superfamily 1, is essential for the differentiation of the nigral dopaminergic neurons(2-4). To determine whether NR4A2 is a susceptibility gene for Parkinson disease, we carried out genetic analyses in 201 individuals affected with Parkinson disease and 221 age-matched unaffected controls. We identified two mutations in NR4A2 associated with Parkinson disease (-291Tdel and -245T-->G), which map to the first exon of NR4A2 and affect one allele in 10 of 107 individuals with familial Parkinson disease but not in any individuals with sporadic Parkinson disease (n = 94) or in unaffected controls (n = 221). The age at onset of disease and clinical features of these ten individuals were not different from those of individuals with typical Parkinson disease. The mutations resulted in a marked decrease in NR4A2 mRNA levels in transfected cell lines and in lymphocytes of affected individuals. Additionally, mutations in NR4A2 affect transcription of the gene encoding tyrosine hydroxylase. These data suggest that mutations in NR4A2 can cause dopaminergic dysfunction, associated with Parkinson disease.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Le, WD (corresponding author), Baylor Coll Med, Dept Neurol, 1 Baylor Plaza, Houston, TX 77030 USA.	Weidongl@bcm.tmc.edu						Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castillo SO, 1997, GENOMICS, V41, P250, DOI 10.1006/geno.1997.4677; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Chen YH, 2001, AM J MED GENET, V105, P753, DOI 10.1002/ajmg.10036; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Healy DG, 2002, MOVEMENT DISORD, V17, pS34; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Ichinose H, 1999, GENE, V230, P233, DOI 10.1016/S0378-1119(99)00065-7; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Le W, 1999, J NEUROCHEM, V73, P2218; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; MARTIN ED, 2001, JAMA-J AM MED ASSOC, V286, P2239; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SaucedoCardenas O, 1996, J MOL NEUROSCI, V7, P51, DOI 10.1007/BF02736848; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; Torii T, 1999, GENE, V230, P225, DOI 10.1016/S0378-1119(99)00064-5; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	30	353	381	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2003	33	1					85	89		10.1038/ng1066	http://dx.doi.org/10.1038/ng1066			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12496759				2022-12-25	WOS:000180136100023
J	Leitner, WW; Hwang, LN; deVeer, MJ; Zhou, AM; Silverman, RH; Williams, BRG; Dubensky, TW; Ying, H; Restifo, NP				Leitner, WW; Hwang, LN; deVeer, MJ; Zhou, AM; Silverman, RH; Williams, BRG; Dubensky, TW; Ying, H; Restifo, NP			Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; ANTIGEN-PRESENTING CELLS; SEMLIKI-FOREST-VIRUS; NF-KAPPA-B; SINDBIS-VIRUS; DENDRITIC CELLS; IMMUNE-RESPONSES; INTERFERON ACTION; REPLICON VECTORS; GENE-EXPRESSION	Cancer vaccines targeting 'self' antigens that are expressed at consistently high levels by tumor cells are potentially useful in immunotherapy, but immunological tolerance may block their function. Here, we describe a novel, naked DNA vaccine encoding an alphavirus replicon (self-replicating mRNA) and the self/tumor antigen tyrosinase-related protein-1. Unlike conventional DNA vaccines, this vaccine can break tolerance and provide immunity to melanoma. The vaccine mediates production of double-stranded RNA, as evidenced by the autophosphorylation of dsRNA-dependent protein kinase R (PKR). Double-stranded RNA is critical to vaccine function because both the immunogenicity and the anti-tumor activity of the vaccine are blocked in mice deficient for the RNase L enzyme, a key component of the 2',5-linked oligoadenylate synthetase antiviral pathway involved in double-stranded RNA recognition. This study shows for the first time that alphaviral replicon-encoding DNA vaccines activate innate immune pathways known to drive antiviral immune responses, and points the way to strategies for improving the efficacy of immunization with naked DNA.	NCI, NIH, Bethesda, MD 20892 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Clin Chem Program, Cleveland, OH 44115 USA; Chiron Corp, Ctr Gene Therapy, Emeryville, CA 94608 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Novartis	Leitner, WW (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.		Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/M-6549-2019; Williams, Bryan R. G./A-5021-2009; Restifo, Nicholas Phillip/Z-1614-2019; Leitner, Wolfgang W/F-5741-2011	Williams, Bryan R. G./0000-0002-4969-1151; Leitner, Wolfgang W/0000-0003-3125-5922; Restifo, Nicholas P./0000-0003-4229-4580	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline; NCI NIH HHS [CA44059, R01 CA044059] Funding Source: Medline; NIAID NIH HHS [R01 AI034039, R01-AI34039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562; Blum JS, 1997, CRIT REV IMMUNOL, V17, P411; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Chattergoon MA, 2000, NAT BIOTECHNOL, V18, P974, DOI 10.1038/79470; Chen Z, 2001, INT J CANCER, V93, P539, DOI 10.1002/ijc.1365; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; HERWEIJER H, 1995, HUM GENE THER, V6, P1161, DOI 10.1089/hum.1995.6.9-1161; ITO S, 1983, J INVEST DERMATOL, V80, P268, DOI 10.1111/1523-1747.ep12534616; JOHANNING FW, 1995, NUCLEIC ACIDS RES, V23, P1495, DOI 10.1093/nar/23.9.1495; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Leitner WW, 2000, CANCER RES, V60, P51; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Leitner WW, 2001, CURR PHARM DESIGN, V7, P1641, DOI 10.2174/1381612013397249; LEITNER WW, 1997, J IMMUNOL, V157, P6119; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Perri S, 2000, J VIROL, V74, P9802, DOI 10.1128/JVI.74.20.9802-9807.2000; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Restifo NP, 2001, NAT BIOTECHNOL, V19, P527, DOI 10.1038/89255; Revilla Y, 1997, VIROLOGY, V228, P400, DOI 10.1006/viro.1996.8395; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; Sasaki S, 2001, NAT BIOTECHNOL, V19, P543, DOI 10.1038/89289; SCHLESINGER RW, 1980, TOGAVIRUSES, P459; Schlesinger S, 2001, EXPERT OPIN BIOL TH, V1, P177, DOI 10.1517/14712598.1.2.177; Shaif-Muthana M, 2000, CANCER RES, V60, P6441; Surman DR, 1998, J IMMUNOL METHODS, V214, P51, DOI 10.1016/S0022-1759(98)00036-2; Terenzi F, 1999, NUCLEIC ACIDS RES, V27, P4369, DOI 10.1093/nar/27.22.4369; Touloukian CE, 2002, CANCER RES, V62, P5144; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	46	223	260	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					33	39		10.1038/nm813	http://dx.doi.org/10.1038/nm813			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496961	Green Accepted			2022-12-25	WOS:000180209900019
J	Olivares, EC; Hollis, RP; Chalberg, TW; Meuse, L; Kay, MA; Calos, MP				Olivares, EC; Hollis, RP; Chalberg, TW; Meuse, L; Kay, MA; Calos, MP			Site-specific genomic integration produces therapeutic Factor IX levels in mice	NATURE BIOTECHNOLOGY			English	Article							LONG-TERM EXPRESSION; PLASMID DNA; TRANSGENE EXPRESSION; GENE-EXPRESSION; MOUSE-LIVER; IN-VITRO; ALPHA(1)-ANTITRYPSIN; RECOMBINASE; CELLS; VIVO	We used the integrase from phage phiC31 to integrate the human Factor IX (hFIX) gene permanently into specific sites in the mouse genome. A plasmid containing attB and an expression cassette for hFIX was delivered to the livers of mice by using high-pressure tail vein injection. When an integrase expression plasmid was co-injected, hFIX serum levels increased more than tenfold to similar to4 mug/ml, similar to normal FIX levels, and remained stable throughout the more than eight months of the experiment. hFIX levels persisted after partial hepatectomy, suggesting genomic integration of the vector. Site-specific integration was proven by characterizing and quantifying genomic integration in the liver at the DNA level. Integration was documented at two pseudo-attP sites, native sequences with partial identity to attP, with one site highly predominant. This study demonstrates in vivo gene transfer in an animal by site-specific genomic integration.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Stanford University; Stanford University	Calos, MP (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.		Wilson, Matthew H/K-3193-2013	Kay, Mark/0000-0002-2799-2615	NHLBI NIH HHS [HL68112] Funding Source: Medline; NIDDK NIH HHS [DK49022] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068112, R56HL068112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen ZY, 2001, MOL THER, V3, P403, DOI 10.1006/mthe.2001.0278; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KUHSTOSS S, 1991, J MOL BIOL, V222, P897, DOI 10.1016/0022-2836(91)90584-S; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Miao CH, 2000, MOL THER, V1, P522, DOI 10.1006/mthe.2000.0075; Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709; RAUSCH H, 1991, NUCLEIC ACIDS RES, V19, P5187, DOI 10.1093/nar/19.19.5187; Sclimenti CR, 2001, NUCLEIC ACIDS RES, V29, P5044, DOI 10.1093/nar/29.24.5044; Stoll SM, 2001, MOL THER, V4, P122, DOI 10.1006/mthe.2001.0429; Thorpe HM, 1998, P NATL ACAD SCI USA, V95, P5505, DOI 10.1073/pnas.95.10.5505; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Tsui LV, 2002, NAT BIOTECHNOL, V20, P53, DOI 10.1038/nbt0102-53; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang G, 2000, GENE THER, V7, P1344, DOI 10.1038/sj.gt.3301229; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang GF, 2001, HUM GENE THER, V12, P427, DOI 10.1089/10430340150504046	18	232	258	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2002	20	11					1124	1128		10.1038/nbt753	http://dx.doi.org/10.1038/nbt753			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	611WV	12379870				2022-12-25	WOS:000179041500023
J	Zardo, G; Tiirikainen, MI; Hong, CB; Misra, A; Feuerstein, BG; Volik, S; Collins, CC; Lamborn, KR; Bollen, A; Pinkel, D; Albertson, DG; Costello, JF				Zardo, G; Tiirikainen, MI; Hong, CB; Misra, A; Feuerstein, BG; Volik, S; Collins, CC; Lamborn, KR; Bollen, A; Pinkel, D; Albertson, DG; Costello, JF			Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors	NATURE GENETICS			English	Article							DNA COPY NUMBER; GLIOBLASTOMA-MULTIFORME; METHYLATION; CANCER; LOCI; HYPERMETHYLATION; CHROMOSOME-10; CARCINOMA; PATTERNS; LUNG	Aberrant methylation of CpG islands and genomic deletion are two predominant mechanisms of gene inactivation in tumorigenesis, but the extent to which they interact is largely unknown. The lack of an integrated approach to study these mechanisms has limited the understanding of tumor genomes and cancer genes. Restriction landmark genomic scanning (RLGS; ref. 1) is useful for global analysis of aberrant methylation of CpG islands, but has not been amenable to alignment with deletion maps because the identity of most RLGS fragments is unknown. Here, we determined the nucleotide sequence and exact chromosomal position of RLGS fragments throughout the genome using the whole chromosome of origin of the fragments 2 and in silico restriction digestion of the human genome sequence. To study the interaction of these gene-inactivation mechanisms in primary brain tumors, we integrated RLGS-based methylation analysis with high-resolution deletion maps from microarray-based comparative genomic hybridization (array CGH; ref. 3). Certain subsets of gene-associated CpG islands were preferentially affected by convergent methylation and deletion, including genes that exhibit tumor-suppressor activity, such as CISH1 (encoding SOCS1; ref. 4), as well as genes such as COE3 that have been missed by traditional non-integrated approaches. Our results show that most aberrant methylation events are focal and independent of deletions, and the rare convergence of these mechanisms can pinpoint biallelic gene inactivation without the use of positional cloning.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Costello, JF (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA.		Tirikainen, M/B-6954-2012; Feuerstein, Burt G/A-5186-2015	Tirikainen, M/0000-0002-8124-3818; Feuerstein, Burt G/0000-0001-7276-8842				Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dubois L, 2001, MECH DEVELOP, V108, P3, DOI 10.1016/S0925-4773(01)00486-5; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; Ginzinger DG, 2000, CANCER RES, V60, P5405; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KARLBOM AE, 1993, HUM GENET, V92, P169; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; Rouillard JM, 2001, GENOME RES, V11, P1453, DOI 10.1101/gr.181601; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005	21	127	140	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					453	458		10.1038/ng1007	http://dx.doi.org/10.1038/ng1007			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12355068				2022-12-25	WOS:000179034800026
J	Bernal, JA; Luna, R; Espina, A; Lazaro, I; Ramos-Morales, F; Romero, F; Arias, C; Silva, A; Tortolero, M; Pintor-Toro, JA				Bernal, JA; Luna, R; Espina, A; Lazaro, I; Ramos-Morales, F; Romero, F; Arias, C; Silva, A; Tortolero, M; Pintor-Toro, JA			Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis	NATURE GENETICS			English	Article							TUMOR-TRANSFORMING GENE; EXPRESSION; HPTTG; PROGRESSION; INHIBITOR; DIVISION; PROTEIN; CANCER; GROWTH; CELLS	The gene PTTG1 (encoding the pituitary tumor-transforming 1 protein) is overexpressed in several different tumor types, is tumorigenic in vivo and shows transcriptional activity(1-4). The PTTG1 protein is cell-cycle regulated and was identified as the human securin (a category of proteins involved in the regulation of sister-chromatid separation) on the basis of biochemical similarities with the Pds1p protein of budding yeast and the Cut2p protein of fission yeast(5,6). To unravel the function of human securin in oncogenesis, we carried out a phage-display screening to identify proteins that interact with securin. Notably, we isolated the p53 tumor suppressor. Pull-down and coimmunoprecipitation assays demonstrated that p53 interacts specifically with securin both in vitro and in vivo. This interaction blocks the specific binding of p53 to DNA and inhibits its transcriptional activity. Securin also inhibits the ability of p53 to induce cell death. Moreover, we observed that transfection of H1299 cells with securin induced an accumulation of G2 cells that compensated for the loss of G2 cells caused by transfection with p53. We demonstrated the physiological relevance of this interaction in PTTG1-deficient human tumor cells (PTTG1(-/-)): both apoptotic and transactivating functions of p53 were potentiated in these cells compared to parental cells. We propose that the oncogenic effect of increased expression of securin may result from modulation of p53 functions.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; CSIC, Ctr Invest Biol, Madrid, Spain; Univ Sevilla, Dept Genet, Seville, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Sevilla; University of Sevilla	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Espina Zambrano, Águeda Gema/AAB-2657-2021; Ramos-Morales, Francisco/C-5734-2008; LUNA, ROSA/F-3974-2016; Romero, Francisco/K-2101-2014; Tortolero, Maria/K-5744-2014; Bernal, Juan A/N-4544-2014; Pintor-Toro, Jose/L-4737-2014	Espina Zambrano, Águeda Gema/0000-0003-1962-0990; Ramos-Morales, Francisco/0000-0002-1151-4547; LUNA, ROSA/0000-0002-6131-6610; Romero, Francisco/0000-0002-9588-6881; Tortolero, Maria/0000-0003-1797-9940; Bernal, Juan A/0000-0002-9933-5550; Pintor-Toro, Jose/0000-0002-9060-5243				BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOEB LA, 1991, CANCER RES, V51, P3075; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Schmitt CA, 1999, J PATHOL, V187, P127; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	30	162	173	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					306	311		10.1038/ng997	http://dx.doi.org/10.1038/ng997			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355087				2022-12-25	WOS:000178311100022
J	O'Sullivan, JN; Bronner, MP; Brentnall, TA; Finley, JC; Shen, WT; Emerson, S; Emond, MJ; Gollahon, KA; Moskovitz, AH; Crispin, DA; Potter, JD; Rabinovitch, PS				O'Sullivan, JN; Bronner, MP; Brentnall, TA; Finley, JC; Shen, WT; Emerson, S; Emond, MJ; Gollahon, KA; Moskovitz, AH; Crispin, DA; Potter, JD; Rabinovitch, PS			Chromosomal instability in ulcerative colitis is related to telomere shortening	NATURE GENETICS			English	Article							LENGTH DYNAMICS; DYSFUNCTION; CANCER; MICE; EVOLUTION; DYSPLASIA; SEQUENCE; TUMORS; CELLS; P53	Ulcerative colitis, a chronic inflammatory disease of the colon, is associated with a high risk of colorectal carcinoma(1) that is thought to develop through genomic instability(2). We considered that the rapid cell turnover and oxidative injury observed in ulcerative colitis might accelerate telomere shortening(3), thereby increasing the potential of chromosomal ends to fuse(4), resulting in cycles of chromatin bridge breakage and fusion(5,6) and chromosomal instability associated with tumor cell progression(7,8). Here we have used quantitative fluorescence in situ hybridization to compare chromosomal aberrations and telomere shortening in non-dysplastic mucosa taken from individuals affected by ulcerative colitis, either with (UC progressors) or without (UC non-progressors) dysplasia or cancer. Losses, but not gains, of chromosomal arms and centromeres are highly correlated with telomere shortening. Chromosomal losses are greater and telomeres are shorter in biopsy samples from UC progressors than in those from UC non-progressors or control individuals without ulcerative colitis. A mechanistic link between telomere shortening and chromosomal instability is supported by a higher frequency of anaphase bridges-an intermediate in the breakage and fusion of chromatin bridges(9)-in UC progressors than in UC non-progressors or control individuals. Our study shows that telomere length is correlated with chromosomal instability in a precursor of human cancer.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Rabinovitch, PS (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	petersr@u.washington.edu		Potter, John/0000-0001-5439-1500; O'Sullivan, Jacintha/0000-0001-8622-9858				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRENTNALL TA, 1994, GASTROENTEROLOGY, V107, P369, DOI 10.1016/0016-5085(94)90161-9; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Day JP, 1998, CARCINOGENESIS, V19, P259, DOI 10.1093/carcin/19.2.259; DELANGE T, 1995, TELOMERES, P265; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Kilburn AE, 2001, MOL CELL BIOL, V21, P126, DOI 10.1128/MCB.21.1.126-135.2001; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Loeb KR, 1999, AM J PATHOL, V154, P1621, DOI 10.1016/S0002-9440(10)65415-6; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; McClintock B, 1941, GENETICS, V26, P234; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; Oexle K, 1998, J THEOR BIOL, V190, P369, DOI 10.1006/jtbi.1997.0559; Rabinovitch PS, 1999, CANCER RES, V59, P5148; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; RUBIN CE, 1992, GASTROENTEROLOGY, V103, P1611, DOI 10.1016/0016-5085(92)91185-7; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Whitehead CM, 1999, J CELL BIOCHEM, P192; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592	29	269	279	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					280	284		10.1038/ng989	http://dx.doi.org/10.1038/ng989			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355086				2022-12-25	WOS:000178311100017
J	DeLamarter, J				DeLamarter, J			Biotechnology partnerships - medicine for an ailing industry?	NATURE BIOTECHNOLOGY			English	Editorial Material									Serono, Geneva, Switzerland		DeLamarter, J (corresponding author), Serono, Geneva, Switzerland.							EDMUNDS RC, 2001, SPLICING COST SQUEEZ; FOREMSKI T, 2002, FINANCIAL TIMES 0910; OGG M, 2000, CMR INT NEWS, V18, P1; Tollman PA, 2001, REVOLUTION R D; 2003, INT HERALD TRIB 0212, P6	5	4	4	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					847	848		10.1038/nbt0803-847	http://dx.doi.org/10.1038/nbt0803-847			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12894192				2022-12-25	WOS:000184484600014
J	Johnson, MD; Kenney, N; Stoica, A; Hilakivi-Clarke, L; Singh, B; Chepko, G; Clarke, R; Sholler, PF; Lirio, AA; Foss, C; Reiter, R; Trock, B; Paik, S; Martin, MB				Johnson, MD; Kenney, N; Stoica, A; Hilakivi-Clarke, L; Singh, B; Chepko, G; Clarke, R; Sholler, PF; Lirio, AA; Foss, C; Reiter, R; Trock, B; Paik, S; Martin, MB			Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland	NATURE MEDICINE			English	Article							TOTAL DIET SAMPLES; EXPOSURE; PESTICIDES; CHEMICALS; ELEMENTS; GERMANY; ADULTS; ALPHA	It has been suggested that environmental contaminants that mimic the effects of estrogen contribute to disruption of the reproductive systems of animals in the wild, and to the high incidence of hormone-related cancers and diseases in Western populations. Previous studies have shown that functionally, cadmium acts like steroidal estrogens in breast cancer cells as a result of its ability to form a high-affinity complex with the hormone binding domain of the estrogen receptor(1,2). The results of the present study show that cadmium also has potent estrogen-like activity in vivo. Exposure to cadmium increased uterine wet weight, promoted growth and development of the mammary glands and induced hormone-regulated genes in ovariectomized animals. In the uterus, the increase in wet weight was accompanied by proliferation of the endometrium and induction of progesterone receptor (PgR) and complement component C3. In the mammary gland, cadmium promoted an increase in the formation of side branches and alveolar buds and the induction of casein, whey acidic protein, PgR and C3. In utero exposure to the metal also mimicked the effects of estrogens. Female offspring experienced an earlier onset of puberty and an increase in the epithelial area and the number of terminal end buds in the mammary gland.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Hampton Univ, Dept Biol, Hampton, VA 23668 USA; Georgetown Univ, Dept Chem, Washington, DC 20007 USA; Univ Pittsburgh, Pittsburgh, PA 15238 USA	Georgetown University; Hampton University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Martin, MB (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA.	martinmb@georgetown.edu	Chepko, Gloria/B-2235-2010; Clarke, Robert/A-6485-2008	Chepko, Gloria/0000-0002-4691-9894; Clarke, Robert/0000-0002-9278-0854; johnson, Michael/0000-0001-6260-7586	NCI NIH HHS [P30-CA51008, P50-CA58185, CA70708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008, R01CA070708, R03CA070708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antila E, 1996, SCI TOTAL ENVIRON, V186, P251, DOI 10.1016/0048-9697(96)05119-4; CANTOR KP, 1994, J OCCUP MED; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GARTRELL MJ, 1986, J ASSOC OFF ANA CHEM, V69, P146; GARTRELL MJ, 1986, J ASSOC OFF ANA CHEM, V69, P123; HEINEMAN WR, 1984, LAB TECHNIQUES ELECT; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; HilakiviClarke L, 1997, J CELL PHYSIOL, V170, P279, DOI 10.1002/(SICI)1097-4652(199703)170:3<279::AID-JCP9>3.0.CO;2-L; *INT AG RES CANC, 1976, IARC MON EV CARC RIS, P48; International Agency for Research on Cancer, 1993, BER CADM MERC EXP GL, P119; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; Martin MB, 2003, ENDOCRINOLOGY, V144, P2425, DOI 10.1210/en.2002-221054; Moschandreas DJ, 2002, J EXPO ANAL ENV EPID, V12, P233, DOI 10.1038/sj.jea.7500230; Muller M, 1998, FOOD ADDIT CONTAM, V15, P135, DOI 10.1080/02652039809374622; ROTHSCHILD TC, 1988, EXP MOL PATHOL, V48, P59, DOI 10.1016/0014-4800(88)90046-9; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; TOMOOKA Y, 1982, J NATL CANCER I, V69, P1347; *US EPA, 1981, EPA600881 OFF RES DE; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; WHO (World Health Organization), 2001, WHO TECHN REP SER, V901; Wilhelm M, 2002, SCI TOTAL ENVIRON, V285, P11, DOI 10.1016/S0048-9697(01)01123-8; Ysart G, 2000, FOOD ADDIT CONTAM, V17, P775, DOI 10.1080/026520300415327	25	408	428	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1081	1084		10.1038/nm902	http://dx.doi.org/10.1038/nm902			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858169				2022-12-25	WOS:000184484900034
J	Muller, I; Wagner, W; Volker, A; Schellmann, S; Nacry, P; Kuttner, F; Schwarz-Sommer, Z; Mayer, U; Jurgens, G				Muller, I; Wagner, W; Volker, A; Schellmann, S; Nacry, P; Kuttner, F; Schwarz-Sommer, Z; Mayer, U; Jurgens, G			Syntaxin specificity of cytokinesis in Arabidopsis	NATURE CELL BIOLOGY			English	Article							MEMBRANE-FUSION; CELL PLATE; PROTEIN; KNOLLE; EMBRYO; EXPRESSION; TRANSPORT; SNARES; PLANTS	Syntaxins interact with other SNAREs (soluble NSF-attachment protein receptors) to form structurally related complexes(1) that mediate membrane fusion in diverse intracellular trafficking pathways(2-5). The original SNARE hypothesis(6) postulated that each type of transport vesicle has its own distinct vesicle-SNARE that pairs up with a unique target-SNARE, or syntaxin, on the target membrane. However, recent evidence suggests that small G-proteins of the Rab family and their effectors mediate the initial contact between donor and acceptor membranes(7), providing complementary specificity to SNARE pairing at a later step towards membrane fusion(3-5). To assess the role of syntaxin specificity in membrane recognition requires a biological assay in which one syntaxin is replaced by other family members that do not normally function in that trafficking pathway. Here, we examine whether membrane fusion in Arabidopsis thaliana cytokinesis, which involves a plant-specific syntaxin, the cell-cycle-regulated KNOLLE (KN) protein(8,9), can be mediated by other syntaxins if expressed under the control of KN cis-regulatory sequences. Only a non-essential syntaxin was targeted to the plane of cell division and sufficiently related to KN to perform its function, thus revealing syntaxin specificity of cytokinesis.	Univ Tubingen, ZMBP, Entwicklungsgenet, D-72076 Tubingen, Germany; Max Planck Inst Zuchtungsforsch, D-50289 Cologne, Germany; CSIRO Plant Ind, Glen Osmond, SA 5064, Australia; Lab Biochim & Physiol Mol Plantes, UMR 5004, F-34060 Montpellier, France; Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Agro; Montpellier SupAgro; Universite de Montpellier; Max Planck Society	Jurgens, G (corresponding author), Univ Tubingen, ZMBP, Entwicklungsgenet, Morgenstelle 3, D-72076 Tubingen, Germany.		Nacry, Philippe/AAK-4361-2020	Nacry, Philippe/0000-0001-7766-4989				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Bednarek SY, 2002, TRAFFIC, V3, P621, DOI 10.1034/j.1600-0854.2002.30904.x; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Conceicao ADS, 1997, PLANT CELL, V9, P571, DOI 10.2307/3870508; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Grebe M, 2000, PLANT CELL, V12, P343, DOI 10.1105/tpc.12.3.343; Hamann T, 2002, GENE DEV, V16, P1610, DOI 10.1101/gad.229402; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Leyman B, 2000, PLANT J, V24, P369, DOI 10.1046/j.1365-313x.2000.00886.x; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sanderfoot AA, 2000, PLANT PHYSIOL, V124, P1558, DOI 10.1104/pp.124.4.1558; Sanderfoot AA, 2001, PLANT CELL, V13, P659, DOI 10.1105/tpc.13.3.659; Staehlin LA, 1996, CELL, V84, P821, DOI 10.1016/S0092-8674(00)81060-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Volker A, 2001, J CELL SCI, V114, P3001; Waizenegger I, 2000, CURR BIOL, V10, P1371, DOI 10.1016/S0960-9822(00)00775-2; Yokoyama R, 2001, PLANT CELL PHYSIOL, V42, P292, DOI 10.1093/pcp/pce034; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zuo JR, 2000, PLANT CELL, V12, P1137, DOI 10.1105/tpc.12.7.1137	27	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					531	534		10.1038/ncb991	http://dx.doi.org/10.1038/ncb991			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12738961				2022-12-25	WOS:000183202800013
J	Vrontou, S; Petrou, P; Meyer, BI; Galanopoulos, VK; Imai, K; Yanagi, M; Chowdhury, K; Scambler, PJ; Chalepakis, G				Vrontou, S; Petrou, P; Meyer, BI; Galanopoulos, VK; Imai, K; Yanagi, M; Chowdhury, K; Scambler, PJ; Chalepakis, G			Fras1 deficiency results in cryptophthalmos, renal agenesis and blebbed phenotype in mice	NATURE GENETICS			English	Article							MEMBRANE-SPANNING PROTEOGLYCAN; DROSOPHILA-MELANOGASTER; EXTRACELLULAR-MATRIX; KIDNEY MORPHOGENESIS; EXPRESSION; DISEASE; MUTANTS; MODEL; NG2	Loss of tight association between epidermis and dermis underlies several blistering disorders and is frequently caused by impaired function of extracellular matrix (ECM) proteins(1,2). Here we describe a new protein in mouse, Fras1, that is specifically detected in a linear fashion underlying the epidermis and the basal surface of other epithelia in embryos. Loss of Fras1 function results in the formation of subepidermal hemorrhagic blisters as well as unilateral or bilateral renal agenesis during mouse embryogenesis. Postnatally, homozygous Fras1 mutants have fusion of the eyelids and digits and unilateral renal agenesis or dysplasia. The defects observed in Fras1(-/-) mice phenocopy those of the existing bl (blebbed) mouse mutants(3,4), which have been considered a model for the human genetic disorder Fraser syndrome(5,6). We show that bl/bl homozygous embryos are devoid of Fras1 protein, consistent with the finding that Fras1 is mutated in these mice(6). In sum, our data suggest that perturbations in the composition of the extracellular space underlying epithelia could account for the onset of the blebbed phenotype in mouse and Fraser syndrome manifestation in human.	FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Dev Genet, Neuherberg, Germany; Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England	Foundation for Research & Technology - Hellas (FORTH); University of Crete; Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of London; University College London	Chalepakis, G (corresponding author), FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece.		Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628				Arin MJ, 2001, TRENDS MOL MED, V7, P422, DOI 10.1016/S1471-4914(01)02095-0; Bruckner-Tuderman L, 1998, J MOL MED-JMM, V76, P226, DOI 10.1007/s001090050213; Darling S, 1994, Clin Dysmorphol, V3, P91; Gustafsson E, 2000, EXP CELL RES, V261, P52, DOI 10.1006/excr.2000.5042; Hodor PG, 2000, DEV BIOL, V222, P181, DOI 10.1006/dbio.2000.9696; Kuure S, 2000, MECH DEVELOP, V92, P31, DOI 10.1016/S0925-4773(99)00323-8; LYON MF, 1996, GENETIC VARIANTS STR; McGowan KA, 2000, MICROSC RES TECHNIQ, V51, P262, DOI 10.1002/1097-0029(20001101)51:3<262::AID-JEMT6>3.0.CO;2-V; MCGREGOR L, 2003, NAT GENET, V34; MOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Slavotinek AM, 2002, J MED GENET, V39, P623, DOI 10.1136/jmg.39.9.623; SNYDER PB, 1986, P NATL ACAD SCI USA, V83, P3341, DOI 10.1073/pnas.83.10.3341; Spirito F, 2001, J BIOL CHEM, V276, P18828, DOI 10.1074/jbc.M100381200; Tillet E, 1997, J BIOL CHEM, V272, P10769; Willem M, 2002, DEVELOPMENT, V129, P2711; WINTER RM, 1990, CLIN GENET, V37, P494	21	93	95	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					209	214		10.1038/ng1168	http://dx.doi.org/10.1038/ng1168			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12766770	Green Published			2022-12-25	WOS:000183200500029
J	Echevarria, W; Leite, MF; Guerra, MT; Zipfel, WR; Nathanson, MH				Echevarria, W; Leite, MF; Guerra, MT; Zipfel, WR; Nathanson, MH			Regulation of calcium signals in the nucleus by a nucleoplasmic reticulum	NATURE CELL BIOLOGY			English	Article							RAT-LIVER NUCLEI; PROTEIN-KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; TRANSCRIPTION FACTOR; CYTOPLASMIC CALCIUM; CA2+ STORE; CELL-TYPES; RECEPTOR; MICROSCOPY; ACTIVATION	Calcium is a second messenger in virtually all cells and tissues(1). Calcium signals in the nucleus have effects on gene transcription and cell growth that are distinct from those of cytosolic calcium signals; however, it is unknown how nuclear calcium signals are regulated. Here we identify a reticular network of nuclear calcium stores that is continuous with the endoplasmic reticulum and the nuclear envelope. This network expresses inositol 1,4,5-trisphosphate (InsP(3)) receptors, and the nuclear component of InsP(3)-mediated calcium signals begins in its locality. Stimulation of these receptors with a little InsP(3) results in small calcium signals that are initiated in this region of the nucleus. Localized release of calcium in the nucleus causes nuclear protein kinase C (PKC) to translocate to the region of the nuclear envelope, whereas release of calcium in the cytosol induces translocation of cytosolic PKC to the plasma membrane. Our findings show that the nucleus contains a nucleoplasmic reticulum with the capacity to regulate calcium signals in localized subnuclear regions. The presence of such machinery provides a potential mechanism by which calcium can simultaneously regulate many independent processes in the nucleus.	Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pediat, Sch Med, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil; Cornell Univ, Dept Appl & Engn Phys, Ithaca, NY 14853 USA	Yale University; Yale University; Yale University; Universidade Federal de Minas Gerais; Cornell University	Nathanson, MH (corresponding author), Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	de Fatima Leite, Maria/AAK-2555-2021; Zipfel, Warren/B-4059-2016	Zipfel, Warren/0000-0003-2640-329X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747, R01DK045710] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR004224-150063] Funding Source: Medline; NIDDK NIH HHS [R01 DK045710, R01 DK045710-06A2, R01 DK061747] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; Dobi A, 1998, P NATL ACAD SCI USA, V95, P5981, DOI 10.1073/pnas.95.11.5981; Fox JL, 1997, BIOCHEM J, V326, P491, DOI 10.1042/bj3260491; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; GEE KR, 1994, J AM CHEM SOC, V116, P8366, DOI 10.1021/ja00097a054; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; Leite MF, 2002, J BIOL CHEM, V277, P16313, DOI 10.1074/jbc.M109207200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Lui PPY, 1998, BIOCHEM BIOPH RES CO, V247, P88, DOI 10.1006/bbrc.1998.8649; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Teruel MN, 2002, SCIENCE, V295, P1910, DOI 10.1126/science.1065028; Wamhoff BR, 2002, J VASC RES, V39, P208, DOI 10.1159/000063686; Williams RM, 2001, CURR OPIN CHEM BIOL, V5, P603, DOI 10.1016/S1367-5931(00)00241-6; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; ZHU QQ, 1987, J PHOTOCHEM, V39, P317, DOI 10.1016/0047-2670(87)80041-2	40	299	304	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					440	446		10.1038/ncb980	http://dx.doi.org/10.1038/ncb980			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717445	Green Accepted			2022-12-25	WOS:000182691400018
J	Muckenthaler, M; Roy, CN; Custodio, AO; Minana, B; deGraaf, J; Montross, LK; Andrews, NC; Hentze, MW				Muckenthaler, M; Roy, CN; Custodio, AO; Minana, B; deGraaf, J; Montross, LK; Andrews, NC; Hentze, MW			Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis	NATURE GENETICS			English	Article							IRON TRANSPORTER; HEREDITARY HEMOCHROMATOSIS; ANTIMICROBIAL PEPTIDE; DUODENAL EXPRESSION; MESSENGER-RNAS; C/EBP-ALPHA; GENE; DEFICIENCY; ABSORPTION; OVERLOAD	Individuals with hereditary hemochromatosis suffer from systemic iron overload due to duodenal hyperabsorption(1,2). Most cases arise from a founder mutation in HFE (845G-->)A; ref. 2) that results in the amino-acid substitution C282Y and prevents the association of FIFE with beta2-microglobulin. Mice homozygous with respect to a null allele of We (Hfe(-/-)) or homozygous with respect to the orthologous 882G-->A mutation (Hfe(845A/845A)) develop iron overload that recapitulates hereditary hemochromatosis in humans, confirming that hereditary hemochromatosis arises from loss of FIFE function(3). Much work has focused on an exclusive role for the intestine in hereditary hemochromatosis. HFE deficiency in intestinal crypt cells is thought to cause intestinal iron deficiency and greater expression of iron transporters such as SLC11A2 (also called DMT1, DCT1 and NRAMP2) and SLC11A3 (also called IREG1, ferroportin and MTP1; ref. 3). Published data on the expression of these transporters in the duodenum of HFE-deficient mice and humans are contradictory(4-8). in this report, we used a custom microarray to assay changes in duodenal and hepatic gene expression in Hfe-deficient mice. We found unexpected alterations in the expression of Slc39a1 (mouse ortholog of SLC11A3) and Cybrd1, which encode key iron transport proteins, and Hamp (hepcidin antimicrobial peptide), a hepatic regulator of iron transport. We propose that inappropriate regulatory cues from the liver underlie greater duodenal iron absorption, possibly involving the ferric reductase Cybrd1.	Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; European Molecular Biology Laboratory (EMBL)	Hentze, MW (corresponding author), Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA.	hentze@embl.de	Hentze, Matthias W/V-3980-2017; minana, belen/K-5530-2015	Hentze, Matthias W/0000-0002-4023-7876; minana, belen/0000-0001-7676-5788; Andrews, Nancy/0000-0003-0243-4462; Custodio, Angel Omar/0000-0003-0916-2826; Muckenthaler, Martina/0000-0002-3778-510X				Ahmad KA, 2002, BLOOD CELL MOL DIS, V29, P361, DOI 10.1006/bcmd.2002.0575; Ajioka RS, 2002, BLOOD, V100, P1465, DOI 10.1182/blood-2001-11-0037; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Canonne-Hergaux F, 2001, BLOOD, V97, P1138, DOI 10.1182/blood.V97.4.1138; Courselaud B, 2002, J BIOL CHEM, V277, P41163, DOI 10.1074/jbc.M202653200; Dupic F, 2002, GASTROENTEROLOGY, V122, P745, DOI 10.1053/gast.2002.31877; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Fleming RE, 2002, ANNU REV PHYSIOL, V64, P663, DOI 10.1146/annurev.physiol.64.081501.155838; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Levy JE, 1999, BLOOD, V94, P9, DOI 10.1182/blood.V94.1.9.413a43_9_11; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Richter A, 2002, BIOTECHNIQUES, V33, P620, DOI 10.2144/02333rr05_11834a; Rolfs A, 2002, AM J PHYSIOL-GASTR L, V282, pG598, DOI 10.1152/ajpgi.00371.2001; Simpson RJ, 2003, GUT, V52, P510, DOI 10.1136/gut.52.4.510; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Trinder D, 2002, P NATL ACAD SCI USA, V99, P5622, DOI 10.1073/pnas.082112299; Trinder D, 2000, GUT, V46, P270, DOI 10.1136/gut.46.2.270; Yang FM, 2002, J BIOL CHEM, V277, P39786, DOI 10.1074/jbc.M201485200; Yoshida T, 2000, J INORG BIOCHEM, V82, P33, DOI 10.1016/S0162-0134(00)00156-2; Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033	30	247	251	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2003	34	1					102	107		10.1038/ng1152	http://dx.doi.org/10.1038/ng1152			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12704390				2022-12-25	WOS:000182667900025
J	Dode, C; Levilliers, J; Dupont, JM; De Paepe, A; Le Du, N; Soussi-Yanicostas, N; Coimbra, RS; Delmaghani, S; Compain-Nouaille, S; Baverel, F; Pecheux, C; Le Tessier, D; Cruaud, C; Delpech, M; Speleman, F; Vermeulen, S; Amalfitano, A; Bachelot, Y; Bouchard, P; Cabrol, S; Carel, JC; Delemarre-van de Waal, H; Goulet-Salmon, B; Kottler, ML; Richard, O; Sanchez-Franco, F; Saura, R; Young, J; Petit, C; Hardelin, JP				Dode, C; Levilliers, J; Dupont, JM; De Paepe, A; Le Du, N; Soussi-Yanicostas, N; Coimbra, RS; Delmaghani, S; Compain-Nouaille, S; Baverel, F; Pecheux, C; Le Tessier, D; Cruaud, C; Delpech, M; Speleman, F; Vermeulen, S; Amalfitano, A; Bachelot, Y; Bouchard, P; Cabrol, S; Carel, JC; Delemarre-van de Waal, H; Goulet-Salmon, B; Kottler, ML; Richard, O; Sanchez-Franco, F; Saura, R; Young, J; Petit, C; Hardelin, JP			Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome	NATURE GENETICS			English	Article							HEPARAN-SULFATE; ANOSMIN-1; GENE	We took advantage of overlapping interstitial deletions at chromosome 8p11-p12 in two individuals with contiguous gene syndromes and defined an interval of roughly 540 kb associated with a dominant form of Kallmann syndrome, KAL2. We establish here that loss-of-function mutations in FGFR1 underlie KAL2 whereas a gain-of-function mutation in FGFR1 has been shown to cause a form of craniosynostosis. Moreover, we suggest that the KAL1 gene product, the extracellular matrix protein anosmin-1, is involved in FGF signaling and propose that the gender difference in anosmin-1 dosage (because KAL1 partially escapes X inactivation) explains the higher prevalence of the disease in males.	Inst Pasteur, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Hop Cochin, Lab Biochim & Genet Mol, F-75014 Paris, France; Inst Cochin Genet Mol, F-75014 Paris, France; Hop Cochin, Lab Cytogenet, F-75674 Paris, France; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; Genoscope, Evry, France; Duke Univ, Med Ctr, Durham, NC 27706 USA; Hop A Michallon, Grenoble, France; Hop St Antoine, Serv Endocrinol, F-75571 Paris, France; Hop Armand Trousseau, Serv Physiol, Paris, France; Hop St Vincent de Paul, Serv Physiol, F-75674 Paris, France; Hop St Vincent de Paul, Serv Physiol, F-75674 Paris, France; Hop St Vincent de Paul, Serv Endocrinol Pediat, F-75674 Paris, France; Vrije Univ Amsterdam, Med Ctr, Dept Pediat, Amsterdam, Netherlands; Ctr Hosp Alencon, Alencon, France; Hop Clemenceau, Dept Genet & Reprod, Caen, France; Hop Nord St Etienne, Serv Pediat & Genet, St Etienne, France; Inst Salud Carlos III, Madrid, Spain; Hop Pellegrin, Serv Genet Med, F-33076 Bordeaux, France; Hop Bicetre, Serv Endocrinol, Le Kremlin Bicetre, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Ghent University; Ghent University Hospital; Duke University; CHU Grenoble Alpes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Vrije Universiteit Amsterdam; CHU de Caen NORMANDIE; CHU de St Etienne; Instituto de Salud Carlos III; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Hardelin, JP (corresponding author), Inst Pasteur, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France.	hardelin@pasteur.fr	Soussi-Yanicostas, Nadia/GPF-8264-2022; Young, Jacques/N-5251-2019; speleman, frank/AAR-5184-2020; Young, Jacques/T-2976-2018; Coimbra, Roney/ABA-0586-2022; Carel, Jean-Claude/AAZ-7691-2020; Soussi-Yanicostas, Nadia/U-6339-2018	Soussi-Yanicostas, Nadia/0000-0001-7734-9401; Young, Jacques/0000-0001-9286-5631; speleman, frank/0000-0002-6628-8559; Young, Jacques/0000-0001-9286-5631; Carel, Jean-Claude/0000-0002-0424-6767; Delmaghani, Sedigheh/0000-0003-2092-5097; Vermeulen, Stefan/0000-0003-3710-800X; Cruaud, Corinne/0000-0002-4752-7278; DUPONT, Jean-Michel/0000-0002-9680-3662; Petit, Christine/0000-0002-9069-002X; Coimbra, Roney/0000-0002-9204-0573				Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Bulow HE, 2002, P NATL ACAD SCI USA, V99, P6346, DOI 10.1073/pnas.092128099; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Hardelin JP, 2001, MOL CELL ENDOCRINOL, V179, P75, DOI 10.1016/S0303-7207(01)00462-2; Hardelin JP, 1999, DEV DYNAM, V215, P26, DOI 10.1002/(SICI)1097-0177(199905)215:1<26::AID-DVDY4>3.3.CO;2-4; Hebert JM, 2003, DEVELOPMENT, V130, P1101, DOI 10.1242/dev.00334; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Oliveira LMB, 2001, J CLIN ENDOCR METAB, V86, P1532, DOI 10.1210/jc.86.4.1532; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; Soussi-Yanicostas N, 2002, CELL, V109, P217, DOI 10.1016/S0092-8674(02)00713-4; SoussiYanicostas N, 1996, J CELL SCI, V109, P1749; Vermeulen S, 2002, AM J MED GENET, V108, P315, DOI 10.1002/ajmg.10295; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307	15	546	565	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2003	33	4					463	465		10.1038/ng1122	http://dx.doi.org/10.1038/ng1122			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12627230	Bronze			2022-12-25	WOS:000181928600015
J	Puls, I; Jonnakuty, C; LaMonte, BH; Holzbaur, ELF; Tokito, M; Mann, E; Floeter, MK; Bidus, K; Drayna, D; Oh, SJ; Brown, RH; Ludlow, CL; Fischbeck, KH				Puls, I; Jonnakuty, C; LaMonte, BH; Holzbaur, ELF; Tokito, M; Mann, E; Floeter, MK; Bidus, K; Drayna, D; Oh, SJ; Brown, RH; Ludlow, CL; Fischbeck, KH			Mutant dynactin in motor neuron disease	NATURE GENETICS			English	Article							FAST AXONAL-TRANSPORT; DROSOPHILA-MELANOGASTER; P150(GLUED) COMPONENT; CYTOPLASMIC DYNEIN; SWISS-MODEL; COMPLEX	Impaired axonal transport in motor neurons has been proposed as a mechanism for neuronal degeneration in motor neuron disease. Here we show linkage of a lower m neuron disease to a region of 4 Mb at chromosome 2p13. Mutation analysis of a gene this interval that encodes the largest subunit of the axonal transport protein dynactin showed a single base-pair change resulting in an amino-acid substitution that is p dicted to distort the folding of dynactin's microtubule-binding domain. Binding assays show decreased binding of the mutant protein to microtubules. Our results show the dysfunction of dynactin-mediated transport can lead to human motor neuron disease.	NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; NINDS, Laryngeal & Speech Sect, NIH, Bethesda, MD 20892 USA; NINDS, Electromyography Sect, NIH, Bethesda, MD 20892 USA; NIDCD, Sect Syst Biol Commun Disorders, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Massachusetts Gen Hosp, Day Neuromuscular Res Lab, Charlestown, MA 02129 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Alabama System; University of Alabama Birmingham; Harvard University; Massachusetts General Hospital	Puls, I (corresponding author), NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA.			Ludlow, Christy/0000-0002-2015-6171	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002976, Z01NS002976, ZIANS002980, Z01NS002980, ZIANS002974, Z01NS002974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000046, ZIADC000046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Dupuis L, 2000, NEUROBIOL DIS, V7, P274, DOI 10.1006/nbdi.2000.0292; Gepner J, 1996, GENETICS, V142, P865; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARTE PJ, 1983, DEV BIOL, V99, P88, DOI 10.1016/0012-1606(83)90256-7; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Li SL, 2002, J BIOL CHEM, V277, P48596, DOI 10.1074/jbc.M208512200; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	15	714	737	1	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					455	456		10.1038/ng1123	http://dx.doi.org/10.1038/ng1123			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12627231	Bronze			2022-12-25	WOS:000181928600011
J	Ray, A; Hector, RE; Roy, N; Song, JH; Berkner, KL; Runge, KW				Ray, A; Hector, RE; Roy, N; Song, JH; Berkner, KL; Runge, KW			Sir3p phosphorylation by the Slt2p pathway effects redistribution of silencing function and shortened lifespan	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CALORIC RESTRICTION; RIBOSOMAL DNA; YEAST; SPAN; GENE; MECHANISMS; LONGEVITY; STRENGTH; SYSTEM	An organism's lifespan is modulated by environmental conditions. When nutrients are abundant, the metabolism of many organisms shifts to growth or reproduction at the expense of longer lifespan, whereas a scarcity of nutrients reverses this shift(1-3). These correlations suggest that organisms respond to environmental changes by altering their metabolism to promote either reproduction and growth or long life. The only previously reported signaling mechanism involved in this response is the nutrient-responsive insulin/insulin-like growth factor-1 receptor pathway(1). Here we report another pathway that controls the length of yeast lifespan. Commitment to cell growth activates the Slt2p MAP kinase pathway, which phosphorylates the transcriptional silencing protein Sir3p, resulting in a shorter lifespan. Elimination of the Sir3p phosphorylation site at Ser275 extended lifespan by 38%. Lifespan extension occurs by a mechanism that is independent of suppressing rDNA recombination. Thus, Slt2p is an enzymatic regulator of silencing function that couples commitment to cell growth and shorter lifespan.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Runge, KW (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.		Runge, Kurt/AAW-9308-2021; Roy, Nilanjan/I-5113-2014	Runge, Kurt/0000-0001-8492-0530; Roy, Nilanjan/0000-0002-4888-2079; Berkner, Kathleen/0000-0001-8054-8081; Roy, Nilanjan/0000-0001-8788-7350	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081093, R01HL055666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019960] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019960] Funding Source: Medline; NIGMS NIH HHS [R01 GM050752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai WD, 2002, MOL CELL, V10, P1295, DOI 10.1016/S1097-2765(02)00695-0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; de Nobel H, 2000, TRENDS MICROBIOL, V8, P344, DOI 10.1016/S0966-842X(00)01805-9; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; Park PU, 2002, METHOD ENZYMOL, V351, P468; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Roy N, 2000, CURR BIOL, V10, P111, DOI 10.1016/S0960-9822(00)00298-0; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stone EM, 1996, J CELL BIOL, V135, P571, DOI 10.1083/jcb.135.3.571; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638	29	44	44	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					522	526		10.1038/ng1132	http://dx.doi.org/10.1038/ng1132			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12640455	Bronze			2022-12-25	WOS:000181928600026
J	Winrow, CJ; Hemming, ML; Allen, DM; Quistad, GB; Casida, JE; Barlow, C				Winrow, CJ; Hemming, ML; Allen, DM; Quistad, GB; Casida, JE; Barlow, C			Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity	NATURE GENETICS			English	Article							GULF-WAR; CATALYTIC DOMAIN; INHIBITION; NERVE; BRAIN; NEURODEGENERATION; FAMILY; AGENTS; ATAXIA; HENS	Neuropathy target esterase (NTE) is involved in neural development and is the target for neurodegeneration induced by selected organophosphorus pesticides and chemical warfare agents. We generated mice with disruptions in Nte, the gene encoding NTE. Nte(-/-) mice die after embryonic day 8, and Nte(+/-) mice have lower activity of Nte in the brain and higher mortality when exposed to the Nte-inhibiting compound ethyl octylphosphonofluoridate (EOPF) than do wild-type mice. Nte(+/-) and wild-type mice treated with 1 mg per kg of body weight of EOPF have elevated motor activity, showing that even minor reduction of Nte activity leads to hyperactivity. These studies show that genetic or chemical reduction of Nte activity results in a neurological phenotype of hyperactivity in mammals and indicate that EOPF toxicity occurs directly through inhibition of Nte without the requirement for Nte gain of function or aging.	Univ Calif Berkeley, Dept Environm Sci Policy & Management, Environm Chem & Toxicol Lab, Berkeley, CA 94720 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	University of California System; University of California Berkeley; Salk Institute	Barlow, C (corresponding author), Merck Res Labs, 3535 Gen Atom Court, San Diego, CA 92121 USA.	carrolee_barlow@merck.com	Winrow, Christopher/K-1864-2014	Winrow, Christopher/0000-0001-8248-4157; Hemming, Mathew/0000-0003-4674-7778				Akbarsha M. A., 1998, Indian Journal of Experimental Biology, V36, P34; Atkins J, 2000, J BIOL CHEM, V275, P24477, DOI 10.1074/jbc.M002921200; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Burgess JR, 2000, AM J CLIN NUTR, V71, p327S, DOI 10.1093/ajcn/71.1.327S; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cavanagh J B, 1973, CRC Crit Rev Toxicol, V2, P365, DOI 10.3109/10408447309082021; DEBLEECKER JL, 1992, CLIN NEUROL NEUROSUR, V94, P93, DOI 10.1016/0303-8467(92)90065-B; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; EHRICH M, 1993, CHEM-BIOL INTERACT, V87, P431, DOI 10.1016/0009-2797(93)90071-6; EHRICH M, 2001, HDB PESTICIDE TOXICO, V2, P987; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Enserink M, 2001, SCIENCE, V291, P812, DOI 10.1126/science.291.5505.812; Escudero MA, 1997, J NEUROCHEM, V68, P2170; Forshaw PJ, 2001, J NEUROCHEM, V79, P400, DOI 10.1046/j.1471-4159.2001.00562.x; Glynn P, 1999, BIOCHEM J, V344, P625, DOI 10.1042/0264-6021:3440625; Glynn P, 2000, PROG NEUROBIOL, V61, P61, DOI 10.1016/S0301-0082(99)00043-X; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P223, DOI 10.1001/jama.277.3.223; Hamm JT, 1998, NEUROTOXICOLOGY, V19, P853; Hardell L, 2002, ENVIRON RES, V88, P141, DOI 10.1006/enrs.2002.4337; Hitt E, 2002, NAT MED, V8, P198, DOI 10.1038/nm0302-198a; HUSAIN K, 1993, J APPL TOXICOL, V13, P143, DOI 10.1002/jat.2550130212; Ishimatsu M, 2002, J NEUROPHYSIOL, V87, P1206, DOI 10.1152/jn.00463.2001; Jamal GA, 1998, ADVERSE DRUG REACT T, V17, P1; Jamal GA, 1997, ADVERSE DRUG REACT T, V16, P133; JOHNSON MK, 1977, ARCH TOXICOL, V37, P113, DOI 10.1007/BF00293860; JOHNSON MK, 1974, J NEUROCHEM, V23, P785, DOI 10.1111/j.1471-4159.1974.tb04404.x; Johnson MK., 2001, HDB PESTICIDE TOXICO, P953, DOI 10.1016/B978-012426260-7.50050-1; KARCZMAR AG, 1984, FUND APPL TOXICOL, V4, pS1, DOI 10.1016/0272-0590(84)90133-7; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Lotti M, 2002, MUSCLE NERVE, V25, P492, DOI 10.1002/mus.10086; Lush MJ, 1998, BIOCHEM J, V332, P1; MEREDITH C, 1988, J NEUROCHEM, V51, P1097, DOI 10.1111/j.1471-4159.1988.tb03073.x; MIGNERY GA, 1988, GENE, V62, P27, DOI 10.1016/0378-1119(88)90577-X; Moretto A, 2002, ARCH TOXICOL, V76, P367, DOI 10.1007/s00204-002-0352-8; Moser M, 2000, MECH DEVELOP, V90, P279, DOI 10.1016/S0925-4773(99)00239-7; Randall JC, 1997, J TOXICOL ENV HEALTH, V51, P571, DOI 10.1080/009841097159845; Ray DE, 2001, TOXICOL LETT, V120, P343, DOI 10.1016/S0378-4274(01)00266-1; Ried Thomas, 1992, Human Molecular Genetics, V1, P307, DOI 10.1093/hmg/1.5.307; Ross CA, 1999, PHILOS T ROY SOC B, V354, P1005, DOI 10.1098/rstb.1999.0452; Schettler T, 2001, ENVIRON HEALTH PERSP, V109, P813, DOI 10.2307/3454643; Solberg Y, 1997, TRENDS PHARMACOL SCI, V18, P183, DOI 10.1016/S0165-6147(97)89540-5; TORMO N, 1993, J NEUROCHEM, V61, P2164, DOI 10.1111/j.1471-4159.1993.tb07455.x; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Veronesi B, 1997, NEUROTOXICOLOGY, V18, P283; VILANOVA E, 1993, CHEM-BIOL INTERACT, V87, P369, DOI 10.1016/0009-2797(93)90065-7; Wilson BW, 2002, DRUG CHEM TOXICOL, V25, P131, DOI 10.1081/DCT-120003255; WU SY, 1995, CHEM RES TOXICOL, V8, P1070, DOI 10.1021/tx00050a011; Wu SY, 1996, TOXICOL APPL PHARM, V139, P195, DOI 10.1006/taap.1996.0158; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481	50	132	140	2	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2003	33	4					477	485		10.1038/ng1131	http://dx.doi.org/10.1038/ng1131			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12640454	Bronze			2022-12-25	WOS:000181928600018
J	Mira, MT; Alcais, A; Van Thuc, N; Thai, VH; Huong, NT; Ba, NN; Verner, A; Hudson, TJ; Abel, L; Schurr, E				Mira, MT; Alcais, A; Van Thuc, N; Thai, VH; Huong, NT; Ba, NN; Verner, A; Hudson, TJ; Abel, L; Schurr, E			Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population	NATURE GENETICS			English	Article							GENETIC EPIDEMIOLOGY; TUBERCULOID LEPROSY; LINKAGE ANALYSIS; ASSOCIATION; POLYMORPHISM; SEGREGATION; GENOTYPE	Leprosy, a chronic infectious disease caused by Mycobacterium leprae, affects an estimated 700,000 persons each year(1). Clinically, leprosy can be categorized as paucibacillary or multibacillary disease(2). These clinical forms develop in persons that are intrinsically susceptible to leprosy per se, that is, leprosy independent of its specific clinical manifestation(3). We report here on a genome-wide search for loci controlling susceptibility to leprosy per se in a panel of 86 families including 205 siblings affected with leprosy from Southern Vietnam. Using model-free linkage analysis, we found significant evidence for a susceptibility gene on chromosome region 6q25 (maximum likelihood binomial (MLB) lod score 4.31; P=5x10(-6)). We confirmed this by family-based association analysis in an independent panel of 208 Vietnamese leprosy simplex families. Of seven microsatellite markers underlying the linkage peak, alleles of two markers (D6S1035 and D6S305) showed strong evidence for association with leprosy (P=6.7x10(-4) and P=5.9x10(-5), respectively).	McGill Univ, McGill Ctr Study Host Resistance, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Univ Paris 05, Inst Natl Sante & Rech Med, U550, Unite Human Genet Infect Dis,Necker Med Sch, Paris, France; Hosp Dermato Venereol, Ho Chi Minh City, Vietnam; McGill Univ, Montreal Genome Ctr, Ctr Hlth, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McGill University	Schurr, E (corresponding author), McGill Univ, McGill Ctr Study Host Resistance, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	erwin@igloo.epi.mcgill.ca	Mira, Marcelo T/B-5046-2010; Alcais, Alexandre/J-5882-2017; Abel, Laurent/H-8888-2017	Mira, Marcelo T/0000-0002-8087-9400; Alcais, Alexandre/0000-0002-1012-2226; Abel, Laurent/0000-0001-7016-6493				Abel L, 1998, AM J HUM GENET, V63, P638, DOI 10.1086/301958; Abel L, 1998, GENET EPIDEMIOL, V15, P371, DOI 10.1002/(SICI)1098-2272(1998)15:4<371::AID-GEPI4>3.0.CO;2-5; Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830; ABEL L, 1988, AM J HUM GENET, V42, P256; ABEL L, 1995, GENET EPIDEMIOL, V12, P63, DOI 10.1002/gepi.1370120107; Chakravartti MR, 1973, TOPICS HUMAN GENETIC, P1; FEITOSA MF, 1995, AM J HUM GENET, V56, P1179; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Jacobson RR, 1999, LANCET, V353, P655, DOI 10.1016/S0140-6736(98)06322-3; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Meisner SJ, 2001, AM J TROP MED HYG, V65, P733, DOI 10.4269/ajtmh.2001.65.733; Rajalingam R, 1997, TISSUE ANTIGENS, V49, P168, DOI 10.1111/j.1399-0039.1997.tb02731.x; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; RISCH N, 1987, AM J HUM GENET, V40, P1; Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282; Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536; Shaw MA, 2001, GENES IMMUN, V2, P196, DOI 10.1038/sj.gene.6363754; SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930; Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958; VANEDEN W, 1980, J INFECT DIS, V141, P693, DOI 10.1093/infdis/141.6.693; VANEDEN W, 1985, J INFECT DIS, V151, P9, DOI 10.1093/infdis/151.1.9; *WHO, 2002, WKLY EPIDEMIOL REC, V77, P1	24	138	147	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2003	33	3					412	415		10.1038/ng1096	http://dx.doi.org/10.1038/ng1096			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12577057				2022-12-25	WOS:000181312700021
J	Tanner, SM; Aminoff, M; Wright, FA; Liyanarachchi, S; Kuronen, M; Saarinen, A; Massika, O; Mandel, H; Broch, H; de la Chapelle, A				Tanner, SM; Aminoff, M; Wright, FA; Liyanarachchi, S; Kuronen, M; Saarinen, A; Massika, O; Mandel, H; Broch, H; de la Chapelle, A			Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia	NATURE GENETICS			English	Article							HUMAN GENOME; GENE; CUBILIN; PROTEIN; IDENTIFICATION; EXPRESSION; MUTATIONS; PROMOTERS; RECEPTOR; MEGALIN	The amnionless gene, Amn, on mouse chromosome 12 encodes a type I transmembrane protein that is expressed in the extraembryonic visceral layer during gastrulation(1). Mice homozygous with respect to the amn mutation generated by a transgene insertion have no amnion(2,3). The embryos are severely compromised, surviving to the tenth day of gestation but seem to lack the mesodermal layers that normally produce the trunk(4). The Amn protein has one transmembrane domain separating a larger, N-terminal extracellular region and a smaller, C-terminal cytoplasmic region. The extracellular region harbors a cysteine-rich domain resembling those occurring in Chordin, found in Xenopus laevis embryos, and Sog, found in Drosophila melanogaster. As these cysteine-rich domains bind bone morphogenetic proteins (Bmps), it has been speculated that the cysteine-rich domain in Amn also binds Bmps(4). We show that homozygous mutations affecting exons 1-4 of human AMN lead to selective malabsorption of vitamin B-12 (a phenotype associated with megaloblastic anemia 1, MGA1; OMIM 261100; refs. 5,6) in otherwise normal individuals, suggesting that the 5' end of AMN is dispensable for embryonic development but necessary for absorption of vitamin B-12. When the 5 end of AMN is truncated by mutations, translation is initiated from alternative downstream start codons.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Folkhalsan Inst Genet, Helsinki, Finland; Rambam Med Ctr, Dept Pediat, Metab Unit, Haifa, Israel; Vestfold Cent Hosp, Dept Pediat, Tonsberg, Norway	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Helsinki; Rambam Health Care Campus; Technion Israel Institute of Technology	de la Chapelle, A (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA.			Seitsonen, Anne/0000-0001-5488-0291				Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; BROCH H, 1984, ACTA PAEDIATR SCAND, V73, P248, DOI 10.1111/j.1651-2227.1984.tb09937.x; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Dunn NR, 2001, NAT GENET, V27, P351, DOI 10.1038/86829; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Genschel J, 2000, HUM MUTAT, V16, P451, DOI 10.1002/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; IMERSLUND O, 1960, ACTA PAEDIATR SCAND, P1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Kalantry S, 2001, NAT GENET, V27, P412, DOI 10.1038/86912; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Tomihara-Newberger C, 1998, DEV BIOL, V204, P34, DOI 10.1006/dbio.1998.9034; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; Wang X, 1996, DEV BIOL, V177, P274, DOI 10.1006/dbio.1996.0162; WRIGHT FA, 2001, GENOME BIOL, V2; Xu DB, 1999, BLOOD, V94, P3604, DOI 10.1182/blood.V94.10.3604.422k22_3604_3606; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424; Zhang MQ, 1998, GENOME RES, V8, P319, DOI 10.1101/gr.8.3.319	23	103	105	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					426	429		10.1038/ng1098	http://dx.doi.org/10.1038/ng1098			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12590260				2022-12-25	WOS:000181312700024
J	Otterbein, LE; Zuckerbraun, BS; Haga, M; Liu, F; Song, RP; Usheva, A; Stachulak, C; Bodyak, N; Smith, RN; Csizmadia, E; Tyagi, S; Akamatsu, Y; Flavell, RJ; Billiar, TR; Tzeng, E; Bach, FH; Choi, AMK; Soares, MP				Otterbein, LE; Zuckerbraun, BS; Haga, M; Liu, F; Song, RP; Usheva, A; Stachulak, C; Bodyak, N; Smith, RN; Csizmadia, E; Tyagi, S; Akamatsu, Y; Flavell, RJ; Billiar, TR; Tzeng, E; Bach, FH; Choi, AMK; Soares, MP			Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITOR; MUSCLE CELL-PROLIFERATION; HEME OXYGENASE-1; PROTEIN; EXPRESSION; GROWTH; ATHEROSCLEROSIS; INDUCTION; MODEL; P21	Carbon monoxide (CO), one of the products of heme oxygenase action on heme, prevents arteriosclerotic lesions that occur following aorta transplantation; pre-exposure to 250 parts per million of CO for 1 hour before injury suppresses stenosis after carotid balloon injury in rats as well as in mice. The protective effect of CO is associated with a profound inhibition of graft leukocyte infiltration/activation as well as with inhibition of smooth muscle cell proliferation. The anti-proliferative effect of CO in vitro requires the activation of guanylate cyclase, the generation of cGMP, the activation of p38 mitogen-activated protein kinases and the expression of the cell cycle inhibitor p21(Cip1). These findings demonstrate a protective role for CO in vascular injury and support its use as a therapeutic agent.	Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Univ Pittsburgh, Sch Med, Montefiore Univ Hosp, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Surg, Montefiore Univ Hosp, Pittsburgh, PA USA; Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Inst Gulbenkian Ciencias, Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yale University; Howard Hughes Medical Institute; Yale University; Instituto Gulbenkian de Ciencia	Bach, FH (corresponding author), Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	fritzhbach@aol.com; choiam@msx.upmc.edu		Soares, Miguel/0000-0002-9314-4833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057854, R29HL057854, R01HL060234, R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53458, HL5785405, R01 HL057854, HL67040, HL58688, HL60234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; COCEANI F, 1993, SCIENCE, V260, P739, DOI 10.1126/science.8484109; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; INDOLFI C, 1995, CIRCULATION, V92, P1230, DOI 10.1161/01.CIR.92.5.1230; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; LINDNER V, 1993, CIRC RES, V73, P792, DOI 10.1161/01.RES.73.5.792; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; NASEEM KM, 1997, BIOCHEM SOC T, V3, pS396; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PLISSONNIER D, 1995, TRANSPLANTATION, V60, P414, DOI 10.1097/00007890-199509000-00003; REIDY MA, 1992, CIRCULATION, V86, P43; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yutani C, 1999, PATHOL INT, V49, P273, DOI 10.1046/j.1440-1827.1999.00861.x	41	434	472	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					183	190		10.1038/nm817	http://dx.doi.org/10.1038/nm817			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539038				2022-12-25	WOS:000180801900022
J	Robert, MF; Morin, S; Beaulieu, N; Gauthier, F; Chute, IC; Barsalou, A; MacLeod, AR				Robert, MF; Morin, S; Beaulieu, N; Gauthier, F; Chute, IC; Barsalou, A; MacLeod, AR			DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells	NATURE GENETICS			English	Article							DNA METHYLATION; METHYLTRANSFERASES; EXPRESSION; 5-AZADEOXYCYTIDINE; P16(INK4A); NEOPLASIA; TISSUES; ISLANDS; TUMORS; HMLH1	Transcriptional silencing by CpG island methylation is a prevalent mechanism of tumor-suppressor gene suppression in cancers(1-4). Genetic experiments have defined the importance of the DNA methyltransferase Dnmt1 for the maintenance of methylation in mouse cells(5) and its role in neoplasia(6). In human bladder cancer cells, selective depletion of DNMT1 with antisense inhibitors has been shown to induce demethylation and reactivation of the silenced tumor-suppressor gene CDKN2A(7). In contrast, targeted disruption of DNMT1 alleles in HCT116 human colon cancer cells produced clones that retained CpG island methylation and associated tumor-suppressor gene silencing 8, whereas HCT116 clones with inactivation of both DNMT1 and DNMT3B showed much lower levels of DNA methylation, suggesting that the two enzymes are highly cooperative(9). We used a combination of genetic (antisense and siRNA) and pharmacologic (5-aza-2'-deoxycytidine) inhibitors of DNA methyl transferases to study the contribution of the DNMT isotypes to cancer-cell methylation. Selective depletion of DNMT1 using either antisense or siRNA resulted in lower cellular maintenance methyltransferase activity, global and gene-specific demethylation and re-expression of tumor-suppressor genes in human cancer cells. Specific depletion of DNMT1 but not DNMT3A or DNMT3B markedly potentiated the ability of 5-aza-2'-deoxycytidine to reactivate silenced tumor-suppressor genes, indicating that inhibition of DNMT1 function is the principal means by which 5-aza-2'-deoxycytidine reactivates genes. These results indicate that DNMT1 is necessary and sufficient to maintain global methylation and aberrant CpG island methylation in human cancer cells.	MethylGene, Dept Mol Biol, Montreal, PQ H4S 2A1, Canada		MacLeod, AR (corresponding author), MethylGene, Dept Mol Biol, 7220 Frederick Banting, Montreal, PQ H4S 2A1, Canada.							Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; CHRISTMAN JK, 1985, J BIOL CHEM, V260, P4059; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HAAF T, 1989, CHROMOSOMA, V98, P93, DOI 10.1007/BF00291043; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; JUTTERMAN R, 1994, P NATL ACAD SCI USA, V981, P11797; Kane MF, 1997, CANCER RES, V57, P808; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Leung SY, 1999, CANCER RES, V59, P159; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Margot JB, 2001, J CELL BIOCHEM, V83, P373, DOI 10.1002/jcb.1236; MERLO A, 1995, NAT MED, V1, P633; Myohanen SK, 1998, CANCER RES, V58, P591; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	30	486	525	1	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					61	65		10.1038/ng1068	http://dx.doi.org/10.1038/ng1068			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12496760				2022-12-25	WOS:000180136100018
J	Leader, B; Lim, H; Carabatsos, MJ; Harrington, A; Ecsedy, J; Pellman, D; Maas, R; Leder, P				Leader, B; Lim, H; Carabatsos, MJ; Harrington, A; Ecsedy, J; Pellman, D; Maas, R; Leder, P			Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes	NATURE CELL BIOLOGY			English	Article							MITOTIC SPINDLE; DROSOPHILA; GENE; MATURATION; CAPPUCCINO; POLARITY; HOMOLOG; MICE; EGGS; REORGANIZATION	Successful reproduction in mammals requires a competent egg, which is formed during meiosis through two assymetrical cell divisions. Here, we show that a recently identified formin homology (FH) gene, formin-2 (Fmn2), is a maternal-effect gene that is expressed in oocytes and is required for progression through metaphase of meiosis I. Fmn2(-/-) oocytes cannot correctly position the metaphase spindle during meiosis I and form the first polar body. We demonstrate that Fmn2 is required for microtubule-independent chromatin positioning during metaphase I. Fertilization of Fmn2(-/-) oocytes results in polyploid embryo formation, recurrent pregnancy loss and sub-fertility in Fmn2(-/-) females. Injection of Fmn2 mRNA into Fmn2-deficient oocytes rescues the metaphase I block. Given that errors in meiotic maturation result in severe birth defects and are the most common cause of chromosomal aneuploidy and pregnancy loss in humans, studies of Fmn2 may provide a better understanding of infertility and birth defects.	Harvard Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Genet, Brigham & Womens Hosp, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Washington University (WUSTL)	Leader, B (corresponding author), Harvard Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.	leder@rascal.med.harvard.edu	Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X				Afshar K, 2000, DEVELOPMENT, V127, P1887; Albertini DF, 1998, J MOL MED, V76, P795, DOI 10.1007/s001090050283; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Brunet S, 1999, J CELL BIOL, V146, P1, DOI 10.1083/jcb.146.1.1; Carabatsos MJ, 2000, MICROSC RES TECHNIQ, V49, P435, DOI 10.1002/(SICI)1097-0029(20000601)49:5<435::AID-JEMT5>3.0.CO;2-H; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; DAS SK, 1994, DEVELOPMENT, V120, P1071; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; deVantery C, 1997, DEV BIOL, V187, P43, DOI 10.1006/dbio.1997.8599; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EPPIG JJ, 1994, DEV BIOL, V164, P1, DOI 10.1006/dbio.1994.1175; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Gardner RL, 1997, DEVELOPMENT, V124, P289; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Heil-Chapdelaine RA, 1999, J CELL BIOL, V144, P809, DOI 10.1083/jcb.144.5.809; Hill JA, 2000, J REPROD FERTIL, P91; HOGAN B, 1994, MANIPULATING MOUSE E, P185; Jackson SM, 1999, GENETICS, V153, P289; Kato T, 2001, J CELL SCI, V114, P775; KAUFMAN MH, 1987, DEVELOPMENT, V101, P383; Leader B, 2000, MECH DEVELOP, V93, P221, DOI 10.1016/S0925-4773(00)00276-8; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LONGO FJ, 1985, DEV BIOL, V107, P382, DOI 10.1016/0012-1606(85)90320-3; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Magie CR, 1999, DEVELOPMENT, V126, P5353; MARO B, 1990, International Journal of Developmental Biology, V34, P127; MARO B, 1986, J EMBRYOL EXP MORPH, V92, P11; Matova N, 2001, DEV BIOL, V231, P291, DOI 10.1006/dbio.2000.0120; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Sawin KE, 2002, CURR BIOL, V12, pR6, DOI 10.1016/S0960-9822(01)00637-6; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4152, DOI 10.1073/pnas.82.12.4152; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Wassarman Paul M., 1994, P79; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Weiss RS, 2000, GENE DEV, V14, P1886; Yarm F, 2001, CURR OPIN MICROBIOL, V4, P696, DOI 10.1016/S1369-5274(01)00271-5; Zeller R, 1999, CELL TISSUE RES, V296, P85, DOI 10.1007/s004410051269; Zernicka-Goetz M, 1998, DEVELOPMENT, V125, P4803	44	253	262	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					921	928		10.1038/ncb880	http://dx.doi.org/10.1038/ncb880			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447394				2022-12-25	WOS:000179571800011
J	Matanis, T; Akhmanova, A; Wulf, P; Del Nery, E; Weide, T; Stepanova, T; Galjart, N; Grosveld, F; Goud, B; De Zeeuw, CI; Barnekow, A; Hoogenraad, CC				Matanis, T; Akhmanova, A; Wulf, P; Del Nery, E; Weide, T; Stepanova, T; Galjart, N; Grosveld, F; Goud, B; De Zeeuw, CI; Barnekow, A; Hoogenraad, CC			Bicaudal-D regulates COPI-independent Golgi-ER transport by recruiting the dynein-dynactin motor complex	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; SHIGA TOXIN; RAB6; PROTEINS; CELLS; CLIP-115; PATHWAY; BINDING; GENE	The small GTPase Rab6a is involved in the regulation of membrane traffic from the Golgi apparatus towards the endoplasmic reticulum (ER) in a coat complex coatomer protein I (COPI)-independent pathway(1-6). Here, we used a yeast two-hybrid approach to identify binding partners of Rab6a. In particular, we identified the dynein-dynactin-binding protein Bicaudal-D1 (BICD1), one of the two mammalian homologues of Drosophila Bicaudal-D7-10. BICD1 and BICD2 colocalize with Rab6a on the trans-Golgi network (TGN) and on cytoplasmic vesicles, and associate with Golgi membranes in a Rab6-dependent manner. Overexpression of BICD1 enhances the recruitment of dynein-dynactin to Rab6a-containing vesicles. Conversely, overexpression of the carboxy-terminal domain of BICD, which can interact with Rab6a but not with cytoplasmic dynein, inhibits microtubule minus-end-directed movement of green fluorescent protein (GFP)-Rab6a vesicles and induces an accumulation of Rab6a and COPI-independent ER cargo in peripheral structures. These data suggest that coordinated action between Rab6a, BICD and the dynein-dynactin complex controls COPI-independent Golgi-ER transport.	Univ Munster, Dept Expt Tumorbiol, D-48149 Munster, Germany; Erasmus Univ, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	University of Munster; Erasmus University Rotterdam; Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Matanis, T (corresponding author), MIT, Picower Ctr Learning & Memory, 77 Massachusetts Ave E18-215, Cambridge, MA 02139 USA.		Akhmanova, Anna S/B-8896-2011; Hoogenraad, Casper/B-8866-2011; Galjart, Niels/D-1146-2010; Goud, Bruno/GWC-4807-2022	Akhmanova, Anna S/0000-0002-9048-8614; Hoogenraad, Casper/0000-0002-2666-0758; Galjart, Niels/0000-0003-1964-3607; DEL NERY, Elaine/0000-0002-9654-5202				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Baens M, 1997, GENOMICS, V45, P601, DOI 10.1006/geno.1997.4971; Bullock SL, 2001, NATURE, V414, P611, DOI 10.1038/414611a; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Gross SP, 2002, J CELL BIOL, V156, P715, DOI 10.1083/jcb.200109047; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Purcell K, 1999, J CELL BIOL, V146, P731, DOI 10.1083/jcb.146.4.731; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; Storrie B, 2000, TRENDS CELL BIOL, V10, P385, DOI 10.1016/S0962-8924(00)01818-3; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	24	298	313	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					986	992		10.1038/ncb891	http://dx.doi.org/10.1038/ncb891			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447383				2022-12-25	WOS:000179571800020
J	Bevis, BJ; Hammond, AT; Reinke, CA; Glick, BS				Bevis, BJ; Hammond, AT; Reinke, CA; Glick, BS			De novo formation of transitional ER sites and Golgi structures in Pichia pastoris	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ORGANIZATION; PROTEIN-TRANSPORT; MATRIX PROTEINS; APPARATUS; YEAST; COPII; DYNAMICS; HOMOLOG	Transitional ER (tER) sites are ER subdomains that are functionally, biochemically and morphologically distinct from the surrounding rough ER. Here we have used confocal video microscopy to study the dynamics of tER sites and Golgi structures in the budding yeast Pichia pastoris. The biogenesis of tER sites is tightly linked to the biogenesis of Golgi, and both compartments can apparently form de novo. tER sites often fuse with one another, but they maintain a consistent average size through shrinkage after fusion and growth after de novo formation. Golgi dynamics are similar, although late Golgi elements often move away from tER sites towards regions of polarized growth. Our results can be explained by assuming that tER sites give rise to Golgi cisternae that continually mature.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Glick, BS (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.	bsglick@midway.uchicago.edu						Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barr FA, 2002, TRENDS CELL BIOL, V12, P101, DOI 10.1016/S0962-8924(01)02240-1; Becker B, 1996, MICROBIOL REV, V60, P697, DOI 10.1128/MMBR.60.4.697-721.1996; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bracker CE, 1996, PROTOPLASMA, V194, P250, DOI 10.1007/BF01882032; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; Glick BS, 2002, NAT REV MOL CELL BIO, V3, P615, DOI 10.1038/nrm877; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; Hager KM, 1999, J CELL SCI, V112, P2631; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Hammond AT, 2000, TRAFFIC, V1, P935, DOI 10.1034/j.1600-0854.2000.011203.x; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Lowe M, 2002, CURR BIOL, V12, pR166, DOI 10.1016/S0960-9822(02)00732-7; Marshall WF, 2001, J CELL BIOL, V155, P405, DOI 10.1083/jcb.200106141; McNew JA, 1998, FEBS LETT, V435, P89, DOI 10.1016/S0014-5793(98)01044-8; Miles S, 2001, J CELL BIOL, V155, P543, DOI 10.1083/jcb.200103104; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Mollenhauer H H, 1978, Subcell Biochem, V5, P327; Morin-Ganet MN, 2000, TRAFFIC, V1, P56, DOI 10.1034/j.1600-0854.2000.010109.x; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Payne WE, 2000, YEAST, V16, P979; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Rossanese OW, 2001, TRAFFIC, V2, P589, DOI 10.1034/j.1600-0854.2001.20901.x; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; Russ J. C., 2006, IMAGE PROCESSING HDB; Sears IB, 1998, YEAST, V14, P783, DOI 10.1002/(SICI)1097-0061(19980615)14:8<783::AID-YEA272>3.0.CO;2-Y; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Soderholm J, 2001, BIOTECHNIQUES, V31, P306, DOI 10.2144/01312st01; STAEHELIN LA, 1995, ANNU REV PLANT PHYS, V46, P261, DOI 10.1146/annurev.pp.46.060195.001401; Stephens DJ, 2000, J CELL SCI, V113, P2177; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667	45	182	185	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					750	756		10.1038/ncb852	http://dx.doi.org/10.1038/ncb852			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360285				2022-12-25	WOS:000178316500011
J	Lemmers, RJLF; de Kievit, P; Sandkuijl, L; Padberg, GW; van Ommen, GJB; Frants, RR; van der Maarel, SM				Lemmers, RJLF; de Kievit, P; Sandkuijl, L; Padberg, GW; van Ommen, GJB; Frants, RR; van der Maarel, SM			Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere	NATURE GENETICS			English	Article							GENE; REARRANGEMENTS; IDENTIFICATION; FAMILY; REGION	Contractions in the polymorphic D4Z4 repeat array of subtelomere 4qter cause autosomal dominant facioscapulohumeral muscular dystrophy in humans. A polymorphic segment of 10 kb directly distal to D4Z4 exists in two allelic forms, 4qA and 4qB. Although both alleles are equally common in the general population, we now report that FSHD is associated solely with the 4qA allele.	Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; Univ Med Ctr Nijmegen, Dept Neurol, Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.		van der Maarel, Silvere/X-3631-2018; Padberg, G.W.A.M./H-8079-2014	van der Maarel, Silvere/0000-0001-8103-711X; 				AGRESTI A, 1989, J MOL BIOL, V205, P625, DOI 10.1016/0022-2836(89)90308-2; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Gabriels J, 1999, GENE, V236, P25, DOI 10.1016/S0378-1119(99)00267-X; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Mefford HC, 2002, NAT REV GENET, V3, P91, DOI 10.1038/nrg727; Trask BJ, 1998, HUM MOL GENET, V7, P13, DOI 10.1093/hmg/7.1.13; van Geel M, 2002, GENOMICS, V79, P210, DOI 10.1006/geno.2002.6690; van Geel M, 2000, CYTOGENET CELL GENET, V88, P316, DOI 10.1159/000015518; van Overveld PGM, 2000, HUM MOL GENET, V9, P2879; vanDeutekom JCT, 1996, HUM MOL GENET, V5, P581, DOI 10.1093/hmg/5.5.581; WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26	12	191	204	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					235	236		10.1038/ng999	http://dx.doi.org/10.1038/ng999			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355084				2022-12-25	WOS:000178311100010
J	Khokha, MK; Hsu, D; Brunet, LJ; Dionne, MS; Harland, RM				Khokha, MK; Hsu, D; Brunet, LJ; Dionne, MS; Harland, RM			Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; VERTEBRATE LIMB; FEEDBACK LOOP; DEFORMITY GENE; GROWTH; OUTGROWTH; INDUCTION; PROTEINS; FAMILY	During limb outgrowth, signaling by bone morphogenetic proteins (BMPs) must be moderated to maintain the signaling loop between the zone of polarizing activity (ZPA) and the apical ectodermal ridge (AER). Gremlin, an extracellular BMP antagonist, has been proposed to fulfill this function and therefore be important in limb patterning. We tested this model directly by mutating the mouse gene encoding gremlin (Cktsf1b1, herein called gremlin). In the mutant limb, the feedback loop between the ZPA and the AER is interrupted, resulting in abnormal skeletal pattern. We also show that the gremlin mutation is allelic to the limb deformity mutation (ld). Although BMPs and their antagonists have multiple roles in limb development, these experiments show that gremlin is the principal BMP antagonist required for early limb outgrowth and patterning.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of California System; University of California Berkeley; Stanford University	Harland, RM (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	harland@socrates.berkeley.edu	Dionne, Marc/J-2572-2013	Dionne, Marc/0000-0002-8283-1750				Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Dionne MS, 2001, MOL CELL BIOL, V21, P636, DOI 10.1128/MCB.21.2.636-643.2001; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; Kuhlman J, 1997, DEVELOPMENT, V124, P133; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Marigo V, 1996, DEVELOPMENT, V122, P1225; Merino R, 1999, DEVELOPMENT, V126, P2161; Merino R, 1999, DEVELOPMENT, V126, P5515; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Pizette S, 1999, DEVELOPMENT, V126, P883; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; VOGT TF, 1992, MAMM GENOME, V3, P431, DOI 10.1007/BF00356152; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	30	284	298	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2003	34	3					303	307		10.1038/ng1178	http://dx.doi.org/10.1038/ng1178			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12808456				2022-12-25	WOS:000183815300018
J	Kirvan, CA; Swedo, SE; Heuser, JS; Cunningham, MW				Kirvan, CA; Swedo, SE; Heuser, JS; Cunningham, MW			Mimicry and auto antibody-mediated neuronal cell signaling in Sydenham chorea	NATURE MEDICINE			English	Article							GUILLAIN-BARRE-SYNDROME; STREPTOCOCCAL-M-PROTEINS; BETA-D-GLUCOSAMINE; KINASE-II; MONOCLONAL-ANTIBODIES; RHEUMATIC CARDITIS; GANGLIOSIDES; RECOGNIZES; LIPOPOLYSACCHARIDES; LYSOSPHINGOLIPIDS	Streptococcus pyogenes-induced acute rheumatic fever (ARF) is one of the best examples of postinfectious autoimmunity due to molecular mimicry between host and pathogen. Sydenham chorea is the major neurological manifestation of ARF but its pathogenesis has remained elusive, with no candidate autoantigen or mechanism of pathogenesis described. Chorea monoclonal antibodies showed specificity for mammalian lysoganglioside and N-acetyl-beta-D-glucosamine (GlcNAc), the dominant epitope of the group A streptococcal (GAS) carbohydrate. Chorea antibodies targeted the surface of human neuronal cells, with specific induction of calcium/calmodulin-dependent protein (CaM) kinase II activity by monoclonal antibody 24.3.1 and sera from active chorea. Convalescent sera and sera from other streptococcal diseases in the absence of chorea did not activate the kinase. The new evidence implicates anti body-mediated neuronal cell signaling in the immunopathogenesis of Sydenham chorea and will lead to a better understanding of other antibody-mediated neurological disorders.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; NIMH, Pediat & Dev Neuropsychiat Branch, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Cunningham, MW (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA.	madeleine-cunningham@ouhsc.edu		Cunningham, Madeleine/0000-0001-8122-728X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035280, R37HL035280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002666] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35280] Funding Source: Medline; NIAID NIH HHS [T32 AI007633, 1T32-AI07633-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ang CW, 2001, INFECT IMMUN, V69, P2462, DOI 10.1128/IAI.69.4.2462-2469.2001; Antone SM, 1997, J IMMUNOL, V159, P5422; BRONZE MS, 1993, J IMMUNOL, V151, P2820; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Cunningham MW, 2000, EFFECTS OF MICROBES ON THE IMMUNE SYSTEM, P123; Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132; Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8; Giedd JN, 1995, NEUROLOGY, V45, P2199, DOI 10.1212/WNL.45.12.2199; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kantor L, 1999, J NEUROSCI, V19, P3801; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kotani M, 1997, BRAIN RES PROTOC, V1, P152, DOI 10.1016/S1385-299X(96)00025-6; Marques-Dias MJ, 1997, PSYCHIAT CLIN N AM, V20, P809, DOI 10.1016/S0193-953X(05)70346-4; NAUSIEDA PA, 1983, NEUROLOGY, V33, P750, DOI 10.1212/WNL.33.6.750; O'Hanlon GM, 2001, BRAIN, V124, P893, DOI 10.1093/brain/124.5.893; Paparounas K, 1999, BRAIN, V122, P807, DOI 10.1093/brain/122.5.807; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Quattrini A, 2001, J NEUROIMMUNOL, V114, P213, DOI 10.1016/S0165-5728(00)00452-5; Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001; Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076; Schulman H, 1995, PROG BRAIN RES, V105, P95; SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Stollerman GH, 2001, CLIN INFECT DIS, V33, P806, DOI 10.1086/322665; Sueyoshi N, 2001, J LIPID RES, V42, P1197; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; SWEDO SE, 1994, JAMA-J AM MED ASSOC, V272, P1788, DOI 10.1001/jama.272.22.1788; SWEDO SE, 1993, PEDIATRICS, V91, P706; Takigawa T, 2000, INTERNAL MED, V39, P123, DOI 10.2169/internalmedicine.39.123; TARANTA A, 1959, NEW ENGL J MED, V260, P1204, DOI 10.1056/NEJM195906112602402; TARANTA A, 1956, AM J MED, V20, P170, DOI 10.1016/0002-9343(56)90186-3; VEASY LG, 1994, J PEDIATR-US, V124, P9, DOI 10.1016/S0022-3476(94)70247-0; Weber F, 2000, MUSCLE NERVE, V23, P1414, DOI 10.1002/1097-4598(200009)23:9<1414::AID-MUS13>3.0.CO;2-0; WENG NP, 1992, J IMMUNOL, V149, P2518; Yuki N, 1997, J INFECT DIS, V176, pS150, DOI 10.1086/513800; Zhao WQ, 1999, J NEUROSCI RES, V55, P557, DOI 10.1002/(SICI)1097-4547(19990301)55:5<557::AID-JNR3>3.3.CO;2-G	44	292	300	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					914	920		10.1038/nm892	http://dx.doi.org/10.1038/nm892			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819778				2022-12-25	WOS:000183979300033
J	Katsuno, M; Adachi, H; Doyu, M; Minamiyama, M; Sang, C; Kobayashi, Y; Inukai, A; Sobue, G				Katsuno, M; Adachi, H; Doyu, M; Minamiyama, M; Sang, C; Kobayashi, Y; Inukai, A; Sobue, G			Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy	NATURE MEDICINE			English	Article							RECESSIVE BULBOSPINAL NEURONOPATHY; ANDROGEN RECEPTOR PROTEIN; HUNTINGTONS-DISEASE; CAG-REPEAT; HETEROZYGOUS FEMALES; NUCLEAR INCLUSIONS; EXPRESSION; NEURODEGENERATION; NEUROPATHOLOGY; DYSFUNCTION	Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motor neuron disease that affects males. It is caused by the expansion of a polyglutamine (polyQ) tract in androgen receptors. Female carriers are usually asymptomatic. No specific treatment has been established. Our transgenic mouse model carrying a full-length human androgen receptor with expanded polyQ has considerable gender-related motor impairment. This phenotype was abrogated by castration, which prevented nuclear translocation of mutant androgen receptors. We examined the effect of androgen-blockade drugs on our mouse model. Leuprorelin, a lutenizing hormone-releasing hormone (LHRH) agonist that reduces testosterone release from the testis, rescued motor dysfunction and nuclear accumulation of mutant androgen receptors in male transgenic mice. Moreover, leuprorelin treatment reversed the behavioral and histopathological phenotypes that were once caused by transient increases in serum testosterone. Flutamide, an androgen antagonist promoting nuclear translocation of androgen receptors, yielded no therapeutic effect. Leuprorelin thus seems to be a promising candidate for the treatment of SBMA.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	Adachi, Hiroaki/AAM-7812-2020; KATSUNO, MASAHISA/I-7502-2014	Adachi, Hiroaki/0000-0002-9302-4663; KATSUNO, MASAHISA/0000-0001-9453-9311				Adachi H, 2003, J NEUROSCI, V23, P2203; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517; Fischbeck KH, 1999, PHILOS T R SOC B, V354, P1075, DOI 10.1098/rstb.1999.0461; Gottlieb B, 1999, AM J MED GENET, V89, P210, DOI 10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Huggins C, 1941, CANCER RES, V1, P293; IGARASHI S, 1992, NEUROLOGY, V42, P2300, DOI 10.1212/WNL.42.12.2300; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kobayashi Y, 1998, BIOCHEM BIOPH RES CO, V252, P145, DOI 10.1006/bbrc.1998.9624; LABRIE F, 1993, CANCER-AM CANCER SOC, V72, P3816, DOI 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lu SF, 1999, J NEUROBIOL, V41, P505, DOI 10.1002/(SICI)1097-4695(199912)41:4<505::AID-NEU6>3.0.CO;2-N; Luo SQ, 1997, UROLOGY, V50, P913, DOI 10.1016/S0090-4295(97)00393-2; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; Mariotti C, 2000, NEUROMUSCULAR DISORD, V10, P391, DOI 10.1016/S0960-8966(99)00132-7; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770; SOBUE G, 1993, J NEUROL SCI, V117, P74, DOI 10.1016/0022-510X(93)90157-T; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Tanaka F, 1996, HUM MOL GENET, V5, P1253, DOI 10.1093/hmg/5.9.1253; Taylor JP, 2002, TRENDS MOL MED, V8, P195, DOI 10.1016/S1471-4914(02)02332-8; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Walcott JL, 2002, J BIOL CHEM, V277, P50855, DOI 10.1074/jbc.M209466200; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	39	211	231	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					768	773		10.1038/nm878	http://dx.doi.org/10.1038/nm878			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754502				2022-12-25	WOS:000183444100034
J	Zhang, B; Cunningham, MA; Nichols, WC; Bernat, JA; Seligsohn, U; Pipe, SW; McVey, JH; Schulte-Overberg, U; de Bosch, NB; Ruiz-Saez, A; White, GC; Tuddenham, EGD; Kaufman, RJ; Ginsburg, D				Zhang, B; Cunningham, MA; Nichols, WC; Bernat, JA; Seligsohn, U; Pipe, SW; McVey, JH; Schulte-Overberg, U; de Bosch, NB; Ruiz-Saez, A; White, GC; Tuddenham, EGD; Kaufman, RJ; Ginsburg, D			Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex	NATURE GENETICS			English	Article							COAGULATION-FACTOR-VIII; COMBINED FACTOR-V; SOLUBLE SECRETORY PROTEINS; ENDOPLASMIC-RETICULUM; INTERMEDIATE COMPARTMENT; RECESSIVE TRAITS; ERGIC-53 GENE; DEFICIENCY; VESICLES; FAMILIES	Mutations in LMAN1 (also called ERGIC-53) result in combined deficiency of factor V and factor VIII ( F5F8D), an autosomal recessive bleeding disorder characterized by coordinate reduction of both clotting proteins(1). LMAN1 is a mannose-binding type 1 transmembrane protein localized to the endoplasmic reticulum Golgi intermediate compartment (ERGIC; refs. 2,3), suggesting that F5F8D could result from a defect in secretion of factor V and factor VIII (ref. 4). Correctly folded proteins destined for secretion are packaged in the ER into COPII-coated vesicles(5), which subsequently fuse to form the ERGIC. Secretion of certain abundant proteins suggests a default pathway requiring no export signals (bulk flow; refs. 6,7). An alternative mechanism involves selective packaging of secreted proteins with the help of specific cargo receptors(8-13). The latter model would be consistent with mutations in LMAN1 causing a selective block to export of factor V and factor VIII. But similar to30% of individuals with F5F8D have normal levels of LMAN1, suggesting that mutations in another gene may also be associated with F5F8D(14,15). Here we show that inactivating mutations in MCFD2 cause F5F8D with a phenotype indistinguishable from that caused by mutations in LMAN1. MCFD2 is localized to the ERGIC through a direct, calcium-dependent interaction with LMAN1. These findings suggest that the MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, London W12 0NN, England; Humboldt Univ, Charite Med Ctr, Berlin, Germany; Ctr Nacl Hemofilia, Banco Municipal Sangre, Caracas, Venezuela; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cincinnati Children's Hospital Medical Center; University of Michigan System; University of Michigan; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Michigan System; University of Michigan; Imperial College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Ginsburg, D (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu	Tuddenham, Edward/AAS-6196-2020; Pipe, Steven W./ABC-3843-2020; Zhang, Bin/B-8102-2012	Tuddenham, Edward/0000-0001-8955-2909; Pipe, Steven W./0000-0003-2558-2089; Bernat, John/0000-0003-2033-6129; Ruiz-Saez, Arlette/0000-0002-4341-1294; McVey, John/0000-0002-7416-533X	MRC [MC_U120074259] Funding Source: UKRI; Medical Research Council [MC_U120074259] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; DEKA N, 1988, GENE, V71, P123, DOI 10.1016/0378-1119(88)90084-4; Fiedler K, 1996, J CELL SCI, V109, P271; GINSBURG D, 2002, EMERY RIMOINS PRINCI, V2, P1926; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nichols WC, 1997, J CLIN INVEST, V99, P596, DOI 10.1172/JCI119201; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nichols WC, 1999, BLOOD, V93, P2261; OERI J, 1954, MED PROBL PAEDIAT, V1, P575; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	30	200	208	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					220	225		10.1038/ng1153	http://dx.doi.org/10.1038/ng1153			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12717434				2022-12-25	WOS:000183200500031
J	Dyer, MA; Livesey, FJ; Cepko, CL; Oliver, G				Dyer, MA; Livesey, FJ; Cepko, CL; Oliver, G			Prox1 function controls progenitor cell proliferation and horizontal, cell genesis in the mammalian retina	NATURE GENETICS			English	Article							RAT RETINA; AMACRINE CELLS; GANGLION-CELL; HOMEOBOX; MATH5; DIFFERENTIATION; ANTIBODIES	Retinal progenitor cells regulate their proliferation during development so that the correct number of each cell type is made at the appropriate time. We found that the homeodomain protein Prox1 regulates the exit of progenitor cells from the cell cycle in the embryonic mouse retina. Cells lacking Prox1 are less likely to stop dividing, and ectopic expression of Prox1 forces progenitor cells to exit the cell cycle. During retinogenesis, Prox1 can be detected in differentiating horizontal, bipolar and All amacrine cells. Horizontal cells are absent in retinae of. Prox1(-/-) mice and misexpression of Prox1 in postnatal progenitor cells promotes horizontal-cell formation. Thus, Prox1 activity is both necessary and sufficient for progenitor-cell proliferation and cell-fate determination in the vertebrate retina.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Cambridge	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.	cepko@rascal.med.harvard.edu; guillermo.oliver@stjude.org	Dyer, Michael/N-8134-2018	Livesey, Rick/0000-0001-6128-3372				Alexiades MR, 1996, DEV DYNAM, V205, P293, DOI 10.1002/(SICI)1097-0177(199603)205:3<293::AID-AJA9>3.0.CO;2-D; Brown NL, 1998, DEVELOPMENT, V125, P4821; Brown NL, 2001, DEVELOPMENT, V128, P2497; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; DELEEUW AM, 1990, J NEUROCYTOL, V19, P253, DOI 10.1007/BF01217303; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Dyer MA, 2001, J COMP NEUROL, V429, P601; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Morrow EM, 1998, J NEUROSCI, V18, P3738; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang SW, 2001, GENE DEV, V15, P24, DOI 10.1101/gad.855301; WASSLE H, 1993, J COMP NEUROL, V332, P407; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844	22	306	316	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					53	58		10.1038/ng1144	http://dx.doi.org/10.1038/ng1144			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12692551				2022-12-25	WOS:000182667900016
J	Gaide, O; Schneider, P				Gaide, O; Schneider, P			Permanent correction of an inherited ectodermal dysplasia with recombinant EDA	NATURE MEDICINE			English	Article							ECTODYSPLASIN-A; HAIR-FOLLICLES; TABBY MICE; GENE; MUTATIONS; MOUSE; MORPHOGENESIS; HOMOLOG; REVEALS; LIGANDS	X-linked hypohidrotic ectodermal dysplasia (XLHED; OMIM 305100) is a genetic disorder characterized by absence or deficient function of hair, teeth and sweat glands(1). Affected children may experience life-threatening high fever resulting from reduced ability to sweat(2). Mice with the Tabby phenotype share many symptoms with human XLHED patients because both phenotypes are caused by mutations of the syntenic ectodysplasin A gene (Eda) on the X chromosome(3,4). Two main splice variants of Eda, encoding EDA1 and EDA2, engage the tumor necrosis factor (TNF) family receptors EDAR and XEDAR, respectively(5). The EDA1 protein, acting through EDAR, is essential for proper formation of skin appendages; the functions of EDA2 and XEDAR are not known. EDA1 must be proteolytically processed to a soluble form to be active(6-9). Here, we show that treatment of pregnant Tabby mice with a recombinant form of EDA1, engineered to cross the placental barrier, permanently rescues the Tabby phenotype in the offspring. Notably, sweat glands can also be induced by EDA1 after birth. This is the first example of a developmental genetic defect that can be permanently corrected by short-term treatment with a recombinant protein.	Univ Lausanne, Inst Biochem, BIL, Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Lausanne	Schneider, P (corresponding author), Univ Lausanne, Inst Biochem, BIL, Biomed Res Ctr, CH-1066 Epalinges, Switzerland.	pascal.schneider@ib.unil.ch		Schneider, Pascal/0000-0003-0677-9409				CLARKE A, 1987, ARCH DIS CHILD, V62, P989, DOI 10.1136/adc.62.10.989; Colcher D, 1998, Q J NUCL MED, V42, P225; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ersch J, 1999, OBSTET GYNECOL, V94, P753, DOI 10.1016/S0029-7844(99)00379-8; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Jauniaux E, 1995, HUM REPROD, V10, P3297, DOI 10.1093/oxfordjournals.humrep.a135906; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kristenova-Cermakova P, 2002, CONNECT TISSUE RES, V43, P283, DOI 10.1080/03008200290000727; Laurikkala J, 2002, DEVELOPMENT, V129, P2541; Lesot H, 1996, INT J DEV BIOL, V40, P1017; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Montonen O, 1998, J HISTOCHEM CYTOCHEM, V46, P281, DOI 10.1177/002215549804600301; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; PINHEIRO M, 1994, AM J MED GENET, V53, P153, DOI 10.1002/ajmg.1320530207; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schneider P, 2001, J BIOL CHEM, V276, P18819, DOI 10.1074/jbc.M101280200; Srivastava AK, 2001, HUM MOL GENET, V10, P2973, DOI 10.1093/hmg/10.26.2973; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; THESLEFF I, 2002, SCI STKE, V131; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	25	151	160	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					614	618		10.1038/nm861	http://dx.doi.org/10.1038/nm861			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692542	Green Published			2022-12-25	WOS:000182610600044
J	Nielsen, KM				Nielsen, KM			Transgenic organisms - time for conceptual diversification?	NATURE BIOTECHNOLOGY			English	Editorial Material							PROTEIN; BIOTECHNOLOGY		Univ Tromso, Dept Pharm, Fac Med, N-9037 Tromso, Norway; Norwegian Inst Gene Ecol, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Nielsen, KM (corresponding author), Univ Tromso, Dept Pharm, Fac Med, N-9037 Tromso, Norway.	knielsen@farmasi.uit.no	Nielsen, Kaare Magne/G-8107-2018	Nielsen, Kaare Magne/0000-0002-7217-2114				Bailey JE, 2001, NAT BIOTECHNOL, V19, P503, DOI 10.1038/89204; Betton JM, 1997, NAT BIOTECHNOL, V15, P1276, DOI 10.1038/nbt1197-1276; Bohorova N, 2001, THEOR APPL GENET, V103, P817, DOI 10.1007/s001220100686; Etterson JR, 2001, SCIENCE, V294, P151, DOI 10.1126/science.1063656; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Friedt W, 1996, ADV LIF SCI, P163; Gaskell G, 1999, SCIENCE, V285, P384, DOI 10.1126/science.285.5426.384; Greenspan RJ, 2001, NAT REV GENET, V2, P383, DOI 10.1038/35072018; Hall BG, 1999, FEMS MICROBIOL LETT, V178, P1; Huang S, 2000, NAT BIOTECHNOL, V18, P471, DOI 10.1038/75235; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Madsen KH, 2002, J AGR ENVIRON ETHIC, V15, P267, DOI 10.1023/A:1015729011895; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; PALUMBI SR, 2001, CHRON HIGH ED   0413, pB7; Pascal G, 2001, CELL MOL BIOL, V47, P1329; Sagar A, 2000, NAT BIOTECHNOL, V18, P2, DOI 10.1038/71861; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; Venes D., 2001, TABERS CYCLOPEDIC ME; Wolfenbarger LL, 2000, SCIENCE, V290, P2088, DOI 10.1126/science.290.5499.2088; Wynne B, 2001, Sci Cult (Lond), V10, P445, DOI 10.1080/09505430120093586	21	78	86	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					227	228		10.1038/nbt0303-227	http://dx.doi.org/10.1038/nbt0303-227			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610561				2022-12-25	WOS:000181312500010
J	Boocock, GRB; Morrison, JA; Popovic, M; Richards, N; Ellis, L; Durie, PR; Rommens, JM				Boocock, GRB; Morrison, JA; Popovic, M; Richards, N; Ellis, L; Durie, PR; Rommens, JM			Mutations in SBDS are associated with Shwachman-Diamond syndrome	NATURE GENETICS			English	Article							SPINAL MUSCULAR-ATROPHY; GENE; PSEUDOGENE; DELETION; DNA	Shwachman-Diamond syndrome (SDS; OMIM 260400) is an autosomal recessive disorder with clinical features that include pancreatic exocrine insufficiency, hematological dysfunction and skeletal abnormalities(1-4). Here, we report identification of disease-associated mutations in an uncharacterized gene, SBDS, in the interval of 1.9 cM at 7q11 previously shown to be associated with the disease(5,6). We report that SBDS has a 1.6-kb transcript and encodes a predicted protein of 250 amino acids. A pseudogene copy (SBDSP) with 97% nucleotide sequence identity resides in a locally duplicated genomic segment of 305 kb. We found recurring mutations resulting from gene conversion in 89% of unrelated individuals with SDS (141 of 158), with 60% (95 of 158) carrying two converted alleles. Converted segments consistently included at least one of two pseudogene-like sequence changes that result in protein truncation. SDBS is a member of a highly conserved protein family of unknown function with putative orthologs in diverse species including archaea and eukaryotes. Archaeal orthologs are located within highly conserved operons that include homologs of RNA-processing genes(7), suggesting that SDS may be caused by a deficiency in an aspect of RNA metabolism that is essential for development of the exocrine pancreas, hematopoiesis and chrondrogenesis.	Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Gastroenterol & Nutr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Program Integrat Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Rommens, JM (corresponding author), Hosp Sick Children, Program Genet & Genome Biol, 555 Univ Ave,Room 11-109A,Elm Wing Annex, Toronto, ON M5G 1X8, Canada.	johanna@genet.sickkids.on.ca	Rommens, Johanna/AAT-7465-2021					Antonarakis S. E., 2001, METABOLIC MOL BASES, P343; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; Bunge S, 1998, EUR J HUM GENET, V6, P492, DOI 10.1038/sj.ejhg.5200213; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Cai L, 2001, J MOL MED, V79, P536, DOI 10.1007/s001090100275; Chen JM, 2000, J MED GENET, V37, P67, DOI 10.1136/jmg.37.1.67; Chen JM, 2000, EUR J HUM GENET, V8, P473, DOI 10.1038/sj.ejhg.5200492; Ginzberg H, 1999, J PEDIATR-US, V135, P81, DOI 10.1016/S0022-3476(99)70332-X; Ginzberg H, 2000, AM J HUM GENET, V66, P1413, DOI 10.1086/302856; Goobie S, 2001, AM J HUM GENET, V68, P1048, DOI 10.1086/319505; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Ip WF, 2002, J PEDIATR-US, V141, P259, DOI 10.1067/mpd.2002.125849; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Popovic M, 2002, EUR J HUM GENET, V10, P250, DOI 10.1038/sj.ejhg.5200798; Roesler J, 2000, BLOOD, V95, P2150, DOI 10.1182/blood.V95.6.2150; Rozen S, 2000, BIOINFORMATICS METHO; Sambrook J., 2001, MOL CLONING; SCHWACHMAN H, 1964, J PEDIATR-US, V65, P645; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; STRACHAN T, 1994, J INHERIT METAB DIS, V17, P430, DOI 10.1007/BF00711358; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	29	486	513	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2003	33	1					97	101		10.1038/ng1062	http://dx.doi.org/10.1038/ng1062			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12496757				2022-12-25	WOS:000180136100025
J	Gitler, AD; Zhu, Y; Ismat, FA; Lu, MM; Yamauchi, Y; Parada, LF; Epstein, JA				Gitler, AD; Zhu, Y; Ismat, FA; Lu, MM; Yamauchi, Y; Parada, LF; Epstein, JA			Nf1 has an essential role in endothelial cells	NATURE GENETICS			English	Article							NEURAL CREST; NEUROFIBROMATOSIS TYPE-1; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; CARDIAC DEVELOPMENT; TRANSGENIC MICE; MODEL; TRANSFORMATION; ABNORMALITIES; MORPHOGENESIS	Neurofibromatosis type 1 (NF1) or von Recklinghausen neurofibromatosis is a genetic disorder that occurs in 1 of 4000 births and is characterized by benign and malignant tumors. Cardiovascular defects also contribute to NF1, though the pathogenesis is still unclear. Deficiency in neurofibromin (encoded by Nf1) in mice results in mid-embryonic lethality owing to cardiac abnormalities previously thought to be secondary to cardiac neural-crest defects. Using tissue-specific gene inactivation, we show that endothelial-specific inactivation of Nf1 recapitulates key aspects of the complete null phenotype, including multiple cardiovascular abnormalities involving the endocardial cushions and myocardium. This phenotype is associated with an elevated level of ras signaling in Nf1(-/-) endothelial cells and greater nuclear localization of the transcription factor Nfatc1. Inactivation of Nf1 in the neural crest does not cause cardiac defects but results in tumors of neural-crest origin resembling those seen in humans with NF1. These results establish a new and essential role for Nf1 in endothelial cells and confirm the requirement for neurofibromin in the neural crest.	Univ Penn Hlth Syst, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Dev & Cell Biol, Philadelphia, PA 19104 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Cardiol, Philadelphia, PA 19104 USA; Kumamoto Univ, Sch Med, Dept Dev Genet, Kumamoto 860, Japan	University of Pennsylvania; University of Pennsylvania; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Kumamoto University	Epstein, JA (corresponding author), Univ Penn Hlth Syst, Dept Med, Div Cardiol, 954 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Zhu, Yuan/ABF-8405-2020; Ismat, Fraz Ahmed/AAG-7470-2019; Parada, luis F/B-9400-2014	Gitler, Aaron/0000-0001-8603-1526; Ismat, Fraz/0000-0002-2172-146X; Epstein, Jonathan/0000-0001-8637-4465	NINDS NIH HHS [R01 NS034296, R01 NS034296-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Epstein JA, 1996, TRENDS CARDIOVAS MED, V6, P255, DOI 10.1016/S1050-1738(96)00110-7; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Feiner L, 2001, DEVELOPMENT, V128, P3061; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Ichida M, 2001, J BIOL CHEM, V276, P3524, DOI 10.1074/jbc.M004275200; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jiang XB, 2000, DEVELOPMENT, V127, P1607; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Li J, 2000, GENESIS, V26, P162, DOI 10.1002/(SICI)1526-968X(200002)26:2<162::AID-GENE21>3.0.CO;2-R; Lin AE, 2000, AM J MED GENET, V95, P108, DOI 10.1002/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; RICCI A, 1984, AM J SURG PATHOL, V8, P19, DOI 10.1097/00000478-198401000-00002; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Ya J, 1998, CIRC RES, V83, P986, DOI 10.1161/01.RES.83.10.986; Yamauchi Y, 1999, DEV BIOL, V212, P191, DOI 10.1006/dbio.1999.9323; YANG JT, 1995, DEVELOPMENT, V121, P549; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	30	126	128	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					75	79		10.1038/ng1059	http://dx.doi.org/10.1038/ng1059			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12469121	Green Accepted			2022-12-25	WOS:000180136100021
J	Carro, E; Trejo, JL; Gomez-Isla, T; LeRoith, D; Torres-Aleman, I				Carro, E; Trejo, JL; Gomez-Isla, T; LeRoith, D; Torres-Aleman, I			Serum insulin-like growth factor I regulates brain amyloid-levels	NATURE MEDICINE			English	Article							CHOROID-PLEXUS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; BETA-PEPTIDE; CEREBROSPINAL-FLUID; BINDING-PROTEINS; MESSENGER-RNA; RECEPTOR; PLASMA; NEURODEGENERATION	Levels of insulin-like growth factor I (IGF-I), a neuroprotective hormone, decrease in serum during aging, whereas amyloid-beta(Abeta), which is involved in the pathogenesis of Alzheimer disease, accumulates in the brain. High brain Abeta levels are found at an early age in mutant mice with low circulating IGF-I, and Abeta burden can be reduced in aging rats by increasing serum IGF-I. This opposing relationship between serum IGF-I and brain Abeta levels reflects the ability of IGF-I to induce clearance of brain Abeta, probably by enhancing transport of Abeta carrier proteins such as albumin and transthyretin into the brain. This effect is antagonized by tumor necrosis factor-alpha, a proinflammatory cytokine putatively involved in dementia and aging. Because IGF-I treatment of mice overexpressing mutant amyloid markedly reduces their brain Abeta burden, we consider that circulating IGF-I is a physiological regulator of brain amyloid levels with therapeutic potential.	CSIC, Inst Cajal, Neuroendocrinol Lab, E-28002 Madrid, Spain; Univ Navarra, Univ Navarra Clin, E-31080 Pamplona, Spain; NIH, Clin Endocrinol Branch, Bethesda, MD USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); University of Navarra; National Institutes of Health (NIH) - USA	Torres-Aleman, I (corresponding author), CSIC, Inst Cajal, Neuroendocrinol Lab, E-28002 Madrid, Spain.	torres@cajal.csic.es	Trejo, Jose Luis/F-5518-2016; Torres-Aleman, Ignacio/A-1613-2008; Carro, Eva/D-6240-2018	Torres-Aleman, Ignacio/0000-0001-8107-7947; Carro, Eva/0000-0002-6504-4579				Aberg MAI, 2000, J NEUROSCI, V20, P2896; AMADUCCI L, 1994, CURR OPIN NEUROL, V7, P283, DOI 10.1097/00019052-199408000-00001; Arvat E, 2000, DRUG AGING, V16, P29, DOI 10.2165/00002512-200016010-00003; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; Busiguina S, 2000, NEUROBIOL DIS, V7, P657, DOI 10.1006/nbdi.2000.0311; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Carro E, 2000, J NEUROSCI, V20, P2926; CHANOINE JP, 1992, ENDOCRINOLOGY, V130, P933, DOI 10.1210/en.130.2.933; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Chun JT, 1999, EXP NEUROL, V157, P194, DOI 10.1006/exnr.1999.7052; Craft S, 2000, ANN NY ACAD SCI, V903, P222, DOI 10.1111/j.1749-6632.2000.tb06371.x; DICKSON PW, 1986, J BIOL CHEM, V261, P3475; Dickstein JB, 2000, AM J PHYSIOL-REG I, V279, pR148, DOI 10.1152/ajpregu.2000.279.1.R148; ELOVAARA I, 1986, ACTA NEUROL SCAND, V74, P245, DOI 10.1111/j.1600-0404.1986.tb07863.x; Fernandez AM, 1998, P NATL ACAD SCI USA, V95, P1253, DOI 10.1073/pnas.95.3.1253; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kozyraki R, 2001, J MOL MED, V79, P161, DOI 10.1007/s001090100193; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2; Mustafa A, 1999, DEMENT GERIATR COGN, V10, P446, DOI 10.1159/000017188; Niikura T, 2001, J NEUROSCI, V21, P1902, DOI 10.1523/JNEUROSCI.21-06-01902.2001; Paxinos G., 2004, J CHEM INF MODEL, V5th; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Pratico D, 2000, NEUROBIOL AGING, V21, P441, DOI 10.1016/S0197-4580(00)00141-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Strazielle N, 1999, J NEUROSCI, V19, P6275; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THAM A, 1993, J NEURAL TRANSM-PARK, V5, P165, DOI 10.1007/BF02257671; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Vaucher E, 2001, J CHEM NEUROANAT, V21, P323, DOI 10.1016/S0891-0618(01)00120-X; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	45	425	469	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1390	1397		10.1038/nm793	http://dx.doi.org/10.1038/nm793			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415260				2022-12-25	WOS:000179552000035
J	Kagan, JC; Roy, CR				Kagan, JC; Roy, CR			Legionella phagosomes intercept vesicular traffic from endoplasmic reticulum exit sites	NATURE CELL BIOLOGY			English	Article							SECRETORY PATHWAY; INTERMEDIATE COMPARTMENT; INTRACELLULAR GROWTH; MEMBRANE-PROTEIN; GOLGI TRANSPORT; IN-VIVO; PNEUMOPHILA; COPII; ER; GIANTIN	It is unknown how Legionella pneumophila cells escape the degradative lysosomal pathway after phagocytosis by macrophages and replicate in an organelle derived from the endoplasmic reticulum. Here we show that, after internalization, L. pneumophila-containing phagosomes recruit early secretory vesicles. Once L. pneumophila phagosomes have intercepted early secretory vesicles they begin to acquire proteins residing in transitional and rough endoplasmic reticulum. The functions of Sar1 and ADP-ribosylation factor-1 are important for biogenesis of the L. pneumophila replicative organelle. These data indicate that L. pneumophila intercepts vesicular traffic from endoplasmic-reticulum exit sites to create an organelle that permits intracellular replication and prevents destruction by the host cell.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbiol Pathogenesis, New Haven, CT 06536 USA	Yale University	Kagan, JC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbiol Pathogenesis, 295 Congress Ave, New Haven, CT 06536 USA.			Roy, Craig/0000-0003-4490-440X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041699, R01AI041699] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41699] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AbuKwaik Y, 1996, APPL ENVIRON MICROB, V62, P2022, DOI 10.1128/AEM.62.6.2022-2028.1996; Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Blum R, 1999, J CELL SCI, V112, P537; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Coers J, 1999, NAT CELL BIOL, V1, P451, DOI 10.1038/15687; Coers J, 2000, MOL MICROBIOL, V38, P719, DOI 10.1046/j.1365-2958.2000.02176.x; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hauri HP, 2000, J CELL SCI, V113, P587; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; KATZ SM, 1982, LAB INVEST, V46, P24; Khelef N, 2001, INFECT IMMUN, V69, P5157, DOI 10.1128/IAI.69.8.5157-5161.2001; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lord JM, 1998, J CELL BIOL, V140, P733; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ramachandra L, 2000, J IMMUNOL, V164, P5103, DOI 10.4049/jimmunol.164.10.5103; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Roy CR, 1998, MOL MICROBIOL, V28, P663, DOI 10.1046/j.1365-2958.1998.00841.x; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Shugrue CA, 1999, J CELL SCI, V112, P4547; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Tilney LG, 2001, J CELL SCI, V114, P4637; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Wiater LA, 1998, INFECT IMMUN, V66, P4450	38	345	356	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					945	954		10.1038/ncb883	http://dx.doi.org/10.1038/ncb883			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447391				2022-12-25	WOS:000179571800014
J	Ness, JE; Kim, S; Gottman, A; Pak, R; Krebber, A; Borchert, TV; Govindarajan, S; Mundorff, EC; Minshull, J				Ness, JE; Kim, S; Gottman, A; Pak, R; Krebber, A; Borchert, TV; Govindarajan, S; Mundorff, EC; Minshull, J			Synthetic shuffling expands functional protein diversity by allowing amino acids to recombine independently	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO SELECTION; FAMILY; EVOLUTION; GENERATION; LIBRARIES; PLASMID; GENES	We describe synthetic shuffling, an evolutionary protein engineering technology in which every amino acid from a set of parents is allowed to recombine independently of every other amino acid. With the use of degenerate oligonucleotides, synthetic shuffling provides a direct route from database sequence information to functional libraries. Physical starting genes are unnecessary, and additional design criteria such as optimal codon usage or known beneficial mutations can also be incorporated. We performed synthetic shuffling of 15 subtilisin genes and obtained active and highly chimeric enzymes with desirable combinations of properties that we did not obtain by other directed-evolution methods.	Maxygen, Redwood City, CA 94063 USA; Novozymes, Prot Design, DK-2880 Bagsvaerd, Denmark	Novozymes	Ness, JE (corresponding author), Maxygen, 515 Galveston Dr, Redwood City, CA 94063 USA.							Bott R, 1996, ADV EXP MED BIOL, V379, P277; BRYAN P N, 1986, Proteins Structure Function and Genetics, V1, P326; Bryan PN, 2000, BBA-PROTEIN STRUCT M, V1543, P203, DOI 10.1016/S0167-4838(00)00235-1; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; Coco WM, 2001, NAT BIOTECHNOL, V19, P354, DOI 10.1038/86744; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Gibbs MD, 2001, GENE, V271, P13, DOI 10.1016/S0378-1119(01)00506-6; Gilliland GL, 1996, ADV EXP MED BIOL, V379, P159; Graycar T, 1999, J MOL BIOL, V292, P97, DOI 10.1006/jmbi.1999.3033; Gupta R, 2002, APPL MICROBIOL BIOT, V59, P15, DOI 10.1007/s00253-002-0975-y; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Kikuchi M, 1999, GENE, V236, P159, DOI 10.1016/S0378-1119(99)00240-1; Kikuchi M, 2000, GENE, V243, P133, DOI 10.1016/S0378-1119(99)00547-8; Moore GL, 2001, P NATL ACAD SCI USA, V98, P3226, DOI 10.1073/pnas.051631498; Ness JE, 1999, NAT BIOTECHNOL, V17, P893, DOI 10.1038/12884; Ness JE, 2001, ADV PROTEIN CHEM, V55, P261, DOI 10.1016/S0065-3233(01)55006-8; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; Raillard S, 2001, CHEM BIOL, V8, P891, DOI 10.1016/S1074-5521(01)00061-8; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; Rice J., 1995, MATH STAT DATA ANAL; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Shafikhani S, 1997, BIOTECHNIQUES, V23, P304, DOI 10.2144/97232rr01; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Sun FZ, 1999, J COMPUT BIOL, V6, P77, DOI 10.1089/cmb.1999.6.77; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Wilson DS, 2001, P NATL ACAD SCI USA, V98, P3750, DOI 10.1073/pnas.061028198	30	145	240	5	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1251	1255		10.1038/nbt754	http://dx.doi.org/10.1038/nbt754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12426575				2022-12-25	WOS:000179552600046
J	Soderling, SH; Binns, KL; Wayman, GA; Davee, SM; Ong, SH; Pawson, T; Scott, JD				Soderling, SH; Binns, KL; Wayman, GA; Davee, SM; Ong, SH; Pawson, T; Scott, JD			The WRP component of the WAVE-1 complex attenuates Rac-mediated signalling	NATURE CELL BIOLOGY			English	Article							ALDRICH-SYNDROME PROTEIN; ARP2/3 COMPLEX; ACTIN CYTOSKELETON; SH3 DOMAIN; WASP; GTPASES; GROWTH; SRC	WAVE-1, which is also known as Scar, is a scaffolding protein that directs actin reorganization by relaying signals from the GTPase Rac to the Arp2/3 complex. Although the molecular details of WAVE activation by Rac have been described, the mechanisms by which these signals are terminated remain unknown. Here we have used tandem mass spectrometry to identify previously unknown components of the WAVE signalling network including WRP, a Rac-selective GTPase-activating protein. WRP binds directly to WAVE-1 through its Src homology domain 3 and specifically inhibits Rac function in vivo. Thus, we propose that WRP is a binding partner of WAVE-1 that functions as a signal termination factor for Rac.	Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Soderling, SH (corresponding author), Vollum Inst, Howard Hughes Med Inst, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.		Pawson, Tony J/E-4578-2013					ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Frank R, 1996, Methods Mol Biol, V66, P149; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Luo LQ, 1996, PERSPECT DEV NEUROBI, V4, P199; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Muller WA, 1996, TRENDS GENET, V12, P91, DOI 10.1016/0168-9525(96)81419-3; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stradal T, 2001, CURR BIOL, V11, P891, DOI 10.1016/S0960-9822(01)00239-1; Takenawa T, 2001, J CELL SCI, V114, P1801; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589	25	153	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					970	975		10.1038/ncb886	http://dx.doi.org/10.1038/ncb886			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447388				2022-12-25	WOS:000179571800017
J	Kurose, K; Gilley, K; Matsumoto, S; Watson, PH; Zhou, XP; Eng, C				Kurose, K; Gilley, K; Matsumoto, S; Watson, PH; Zhou, XP; Eng, C			Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas	NATURE GENETICS			English	Article							EXPRESSION; CANCERS	We have recently shown that loss of heterozygosity of specific markers, including those at 10q23, 17p13-p15 and 16q24, can occur in the stromal and epithelial compartments of primary invasive breast carcinomas. Here, we demonstrate high frequencies of somatic mutations in TP53 (encoding tumor protein p53) and PTEN (encoding phosphate and tensin homolog) in breast neoplastic epithelium and stroma. Mutations in TP53 and PTEN are mutually exclusive in either compartment. In contrast, mutations in WFDC1 (16q24, encoding WAP four-disulfide core domain 1) occur with low frequency in the stroma.	Ohio State Univ, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Div Human Genet, Dept Internal Med, Columbus, OH 43210 USA; Univ Manitoba, Dept Pathol, Winnipeg, MB R3T 2N2, Canada; Univ Cambridge, Human Canc Genet Res Grp, Canc Res UK, Cambridge CB2 2XZ, England	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Manitoba; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA.			Eng, Charis/0000-0002-3693-5145; Watson, Peter/0000-0002-1642-0638				ENG C, 2001, METABOLIC MOL BASES, V1, P979; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Larsen M, 2000, MAMM GENOME, V11, P767, DOI 10.1007/s003350010135; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; Wernert N, 2001, ANTICANCER RES, V21, P2259	8	339	358	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					355	357		10.1038/ng1013	http://dx.doi.org/10.1038/ng1013			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12379854				2022-12-25	WOS:000179034800009
J	Sano, M; Abdellatif, M; Oh, H; Xie, M; Bagella, L; Giordano, A; Michael, LH; DeMayo, FJ; Schneider, MD				Sano, M; Abdellatif, M; Oh, H; Xie, M; Bagella, L; Giordano, A; Michael, LH; DeMayo, FJ; Schneider, MD			Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy	NATURE MEDICINE			English	Article							RNA-POLYMERASE-II; P-TEFB; TRANSGENIC MICE; TERMINAL DOMAIN; HEART-FAILURE; IN-VIVO; PATHWAY; TAT; PHOSPHORYLATION; INHIBITION	Hypertrophic growth is a risk factor for mortality in heart diseases. Mechanisms are lacking for this global increase in RNA and protein per cell, which underlies hypertrophy. Hypertrophic signals cause phosphorylation of the RNA polymerase II C-terminal domain, required for transcript elongation. RNA polymerase II kinases include cyclin-dependent kinases-7 (Cdk7) and Cdk9, components of two basal transcription factors. We report activation of Cdk7 and -9 in hypertrophy triggered by signaling proteins (Galphaq, calcineurin) or chronic mechanical stress. Only Cdk9 was activated by acute load or, in culture, by endothelin. A preferential role for Cdk9 was shown in RNA polymerase II phosphorylation and growth induced by endothelin, using pharmacological and dominant-negative inhibitors. All four hypertrophic signals dissociated 7SK small nuclear RNA, an endogenous inhibitor, from cyclin T-Cdk9. Cdk9 was limiting for cardiac growth, shown by suppressing its inhibitor (7SK) in culture and preventing downregulation of its activator (cyclin T1) in mouse myocardium.	Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Mol Med, Newark, NJ 07103 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Schneider, MD (corresponding author), Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA.		Sano, Motoaki/L-3405-2013; Xie, Min/AAY-3426-2020; Giordano, Antonio/F-1927-2010; DeMayo, Francesco/C-6255-2019	Xie, Min/0000-0002-2967-3490; Giordano, Antonio/0000-0002-5959-016X; DeMayo, Francesco/0000-0002-9480-7336; BAGELLA, Luigi/0000-0003-2815-037X; Schneider, Michael/0000-0001-9645-1938	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; De Luca A, 2001, J HISTOCHEM CYTOCHEM, V49, P693, DOI 10.1177/002215540104900603; Doi T, 1999, BIOCHEMISTRY-US, V38, P3090, DOI 10.1021/bi981919m; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann CH, 2001, J CELL SCI, V114, P1491; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Majello B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1358, DOI 10.2741/Majello; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sano M, 2002, CIRCULATION, V105, P8, DOI 10.1161/circ.105.1.8; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Verdecchia P, 2001, J AM COLL CARDIOL, V38, P1829, DOI 10.1016/S0735-1097(01)01663-1; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	45	201	215	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1310	1317		10.1038/nm778	http://dx.doi.org/10.1038/nm778			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368904				2022-12-25	WOS:000179221200039
J	Suka, N; Luo, KH; Grunstein, M				Suka, N; Luo, KH; Grunstein, M			Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin	NATURE GENETICS			English	Article							SILENT MATING LOCI; TELOMERIC HETEROCHROMATIN; SACCHAROMYCES-CEREVISIAE; DOSAGE COMPENSATION; MOLECULAR-MODEL; MSL COMPLEX; H3; METHYLATION; DROSOPHILA; PROTEINS	The Sir3 protein helps form telomeric heterochromatin by interacting with hypoacetylated histone H4 lysine 16 (H4-Lys16). The molecular nature of the heterochromatin boundary is still unknown. Here we show that the MYST-like acetyltransferase Sas2p is required for the acetylation (Ac) of H4-Lys16 in euchromatin. In a sas2Delta strain or a phenocopy Lys16Arg mutant, Sir3p spreads from roughly 3 kb to roughly 15 kb, causing hypoacetylation and repression of adjacent chromatin. We also found that disruption of Sir3p binding in a deacetylase-deficient sir2Delta strain can be suppressed by sas2Delta. These data indicate that opposing effects of Sir2p and Sas2p on acetylation of H4-Lys16 maintain the boundary at telomeric heterochromatin.	Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Grunstein, M (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Boyer Hall, Los Angeles, CA 90095 USA.							Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brown AJP, 1998, METHOD MICROBIOL, V26, P119; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Gu WG, 2000, EMBO J, V19, P5202, DOI 10.1093/emboj/19.19.5202; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIMURA A, 2002, NAT GENET, V32; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wach A, 1998, METHOD MICROBIOL, V26, P67	33	335	345	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					378	383		10.1038/ng1017	http://dx.doi.org/10.1038/ng1017			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12379856				2022-12-25	WOS:000179034800012
J	Sokac, AM; Co, C; Taunton, J; Bement, W				Sokac, AM; Co, C; Taunton, J; Bement, W			Cdc42-dependent actin polymerization during compensatory endocytosis in Xenopus eggs	NATURE CELL BIOLOGY			English	Article							DIRECT MEMBRANE RETRIEVAL; ARP2/3 COMPLEX; ANIMAL-CELLS; RECRUITMENT; EXOCYTOSIS; VESICLES; DYNAMIN; ACTIVATION; MOVEMENT; BINDING	The actin filament (F-actin) cytoskeleton associates dynamically with the plasma membrane and is thus ideally positioned to participate in endocytosis. Indeed, a wealth of genetic and biochemical evidence has confirmed that actin interacts with components of the endocytic machinery(1), although its precise function in endocytosis remains unclear. Here, we use 4D microscopy to visualize the contribution of actin during compensatory endocytosis in Xenopus laevis eggs. We show that the actin cytoskeleton maintains exocytosing cortical granules as discrete invaginated compartments, such that when actin is disrupted, they collapse into the plasma membrane. Invaginated, exocytosing cortical granule compartments are directly retrieved from the plasma membrane by F-actin coats that assemble on their surface. These dynamic F-actin coats seem to drive closure of the exocytic fusion pores and ultimately compress the cortical granule compartments. Active Cdc42 and N-WASP are recruited to exocytosing cortical granule membranes before F-actin coat assembly and coats assemble by Cdc42-dependent, de novo actin polymerization. Thus, F-actin may power fusion pore resealing and function in two novel endocytic capacities: the maintenance of invaginated compartments and the processing of endosomes.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94107 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	Sokac, AM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	amsokac@wisc.edu	Bement, William/AAA-5444-2021					Becker KA, 1999, J CELL SCI, V112, P97; Bement WM, 2000, J EXP ZOOL, V286, P767, DOI 10.1002/(SICI)1097-010X(20000601)286:7<767::AID-JEZ11>3.0.CO;2-L; Bernheim-Groswasser A, 2002, NATURE, V417, P308, DOI 10.1038/417308a; Canman JC, 1997, J CELL SCI, V110, P1907; CAO LG, 1990, J CELL BIOL, V110, P1089, DOI 10.1083/jcb.110.4.1089; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Geli MI, 1998, J CELL SCI, V111, P1031; Giardini PA, 2003, P NATL ACAD SCI USA, V100, P6493, DOI 10.1073/pnas.1031670100; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Kaksonen M, 2000, J CELL SCI, V113, P4421; KLINE D, 1985, DEV BIOL, V111, P471, DOI 10.1016/0012-1606(85)90499-3; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lee E, 2002, TRAFFIC, V3, P186, DOI 10.1034/j.1600-0854.2002.030304.x; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Ma L, 1998, J CELL BIOL, V140, P1125; Mandato CA, 2001, J CELL BIOL, V154, P785, DOI 10.1083/jcb.200103105; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schafer DA, 2000, TRAFFIC, V1, P892; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Terasaki M, 2001, MOL BIOL CELL, V12, P1103, DOI 10.1091/mbc.12.4.1103; UPDADHYAYA A, 2003, P NATL ACAD SCI USA, V100, P4521; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; WHALLEY T, 1995, J CELL BIOL, V131, P1183, DOI 10.1083/jcb.131.5.1183	32	111	113	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					727	732		10.1038/ncb1025	http://dx.doi.org/10.1038/ncb1025			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12872130				2022-12-25	WOS:000184687300014
J	Vasil, IK				Vasil, IK			The science and politics of plant biotechnology - a personal perspective	NATURE BIOTECHNOLOGY			English	Editorial Material							GENETICALLY-MODIFIED CROPS; RICE PLANTS; ENVIRONMENT; RELEASE; YIELD; GENES		Univ Florida, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Vasil, IK (corresponding author), Univ Florida, Box 110690, Gainesville, FL 32611 USA.							Conner AJ, 2003, PLANT J, V33, P19, DOI 10.1046/j.0960-7412.2002.001607.x; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Hedden P, 2003, TRENDS GENET, V19, P5, DOI 10.1016/S0168-9525(02)00009-4; Herman EM, 2003, PLANT PHYSIOL, V132, P36, DOI 10.1104/pp.103.021865; Horvath H, 2003, P NATL ACAD SCI USA, V100, P364, DOI 10.1073/pnas.0136911100; Jenner HL, 2003, TRENDS BIOTECHNOL, V21, P190, DOI 10.1016/S0167-7799(03)00086-6; Ku MSB, 1999, NAT BIOTECHNOL, V17, P76, DOI 10.1038/5256; Ku MSB, 2001, NOVART FDN SYMP, V236, P100; Kuiper HA, 2001, PLANT J, V27, P503, DOI 10.1046/j.1365-313X.2001.01119.x; Li XY, 2003, NATURE, V422, P618, DOI 10.1038/nature01518; Nap JP, 2003, PLANT J, V33, P1, DOI 10.1046/j.0960-7412.2003.01602.x; Oerke EC., 1994, CROP PRODUCTION CROP; Qaim M, 2003, SCIENCE, V299, P900, DOI 10.1126/science.1080609; *UN, 2002, VIT WAT GRAPH WAT US; VASIL IK, 2003, PLANT BIOTECHNOLOGY	15	40	44	0	30	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					849	851		10.1038/nbt0803-849	http://dx.doi.org/10.1038/nbt0803-849			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12894193				2022-12-25	WOS:000184484600015
J	Simske, JS; Koppen, M; Sims, P; Hodgkin, J; Yonkof, A; Hardin, J				Simske, JS; Koppen, M; Sims, P; Hodgkin, J; Yonkof, A; Hardin, J			The cell junction protein VAB-9 regulates adhesion and epidermal morphology in C-elegans	NATURE CELL BIOLOGY			English	Article							PERIPHERAL MYELIN PROTEIN-22; CAENORHABDITIS-ELEGANS; INTERCELLULAR-JUNCTIONS; EPITHELIAL-CELLS; TIGHT JUNCTIONS; EMBRYO; DLG-1; MORPHOGENESIS; HYPODERMIS; CLAUDIN-1	Epithelial cell junctions are essential for cell polarity, adhesion and morphogenesis. We have analysed VAB-9, a cell junction protein in Caenorhabditis elegans. VAB-9 is a predicted four-pass integral membrane protein that has greatest similarity to BCMP1 ( brain cell membrane protein 1, a member of the PMP22/EMP/Claudin family of cell junction proteins) and localizes to the adherens junction domain of C. elegans apical junctions(1-4). Here, we show that VAB-9 requires HMR1/ cadherin for localization to the cell membrane, and both HMP-1/alpha-catenin and HMP-2/beta-catenin for maintaining its distribution at the cell junction. In vab-9 mutants, morphological defects correlate with disorganization of F-actin at the adherens junction; however, localization of the cadherin-catenin complex and epithelial polarity is normal. These results suggest that VAB-9 regulates interactions between the cytoskeleton and the adherens junction downstream of or parallel to alpha-catenin and/or beta-catenin. Mutations in vab-9 enhance adhesion defects through functional loss of the cell junction genes apical junction molecule 1 (ajm-1) and discs large 1 (dlg-1), suggesting that VAB-9 is involved in cell adhesion. Thus, VAB-9 represents the first characterized tetraspan adherens junction protein in C. elegans and defines a new family of such proteins in higher eukaryotes.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA	University of Wisconsin System; University of Wisconsin Madison; University of Oxford; MetroHealth System	Simske, JS (corresponding author), Univ Wisconsin, Dept Zool, 1117 W Johnson St, Madison, WI 53706 USA.				NIGMS NIH HHS [GM58038] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; BRENNER S, 1974, GENETICS, V77, P71; Christophe-Hobertus C, 2001, BMC Genomics, V2, P3, DOI 10.1186/1471-2164-2-3; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; HERMAN RK, 1980, NEMATODES BIOL MODEL, V1, P227; HODGKIN J, 1983, GENETICS, V103, P43; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Karabinos A, 2001, P NATL ACAD SCI USA, V98, P7863, DOI 10.1073/pnas.121169998; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Koppen M, 2001, NAT CELL BIOL, V3, P983, DOI 10.1038/ncb1101-983; Lamb RS, 1998, MOL BIOL CELL, V9, P3505, DOI 10.1091/mbc.9.12.3505; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; McMahon L, 2001, J CELL SCI, V114, P2265; Mohler WA, 1998, BIOTECHNIQUES, V24, P1006; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Notterpek L, 2001, P NATL ACAD SCI USA, V98, P14404, DOI 10.1073/pnas.251548398; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; Raich WB, 1999, CURR BIOL, V9, P1139, DOI 10.1016/S0960-9822(00)80015-9; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; WILLIAMS BD, 1992, GENETICS, V131, P609; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	32	66	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					619	U2		10.1038/ncb1002	http://dx.doi.org/10.1038/ncb1002			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12819787				2022-12-25	WOS:000183911600011
J	Ishida, S; Yamashiro, K; Usui, T; Kaji, Y; Ogura, Y; Hida, T; Honda, Y; Oguchi, Y; Adamis, AP				Ishida, S; Yamashiro, K; Usui, T; Kaji, Y; Ogura, Y; Hida, T; Honda, Y; Oguchi, Y; Adamis, AP			Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELL APOPTOSIS; OXIDIZED LDL; IN-VIVO; GROWTH; NEOVASCULARIZATION; EXPRESSION; VEGF; INHIBITOR; SYSTEM; DEATH	Retinal ischemia can cause vision-threatening pathological neovascularization. The mechanisms of retinal ischemia are not fully understood, however. Here we have shown that leukocytes prune the retinal vasculature during normal development and obliterate it in disease. Beginning at postnatal day 5 (P5) in the normal rat, vascular pruning began centrally and extended peripherally, leaving behind a less dense, smaller-caliber vasculature. The pruning was correlated with retinal vascular expression of intercellular adhesion molecule-1 (ICAM-1) and coincided with an outward-moving wave of adherent leukocytes composed in part of cytotoxic T lymphocytes. The leukocytes adhered to the vasculature through CD18 and remodeled it through Fas ligand (FasL)-mediated endothelial cell apoptosis. In a model of oxygen-induced ischemic retinopathy, this process was exaggerated. Leukocytes used CD18 and FasL to obliterate the retinal vasculature, leaving behind large areas of ischemic retina. In vitro, T lymphocytes isolated from oxygen-exposed neonates induced a FasL-mediated apoptosis of hyperoxygenated endothelial cells. Targeting these pathways may prove useful in the treatment of retinal ischemia, a leading cause of vision loss and blindness.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Retina Res Lab, Boston, MA 02114 USA; Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan; Univ Tokyo, Fac Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan; Nagoya City Univ, Med Univ, Dept Ophthalmol, Mizuho Ku, Aichi 4678601, Japan; Kyorin Eye Ctr, Tokyo 1818611, Japan; Eyetech Res Ctr, Woburn, MA 01801 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Keio University; Kyoto University; University of Tokyo; Nagoya City University	Adamis, AP (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Retina Res Lab, 325 Cambridge St, Boston, MA 02114 USA.		ISHIDA, SUSUMU/D-7067-2012	Yamashiro, Kenji/0000-0001-9354-8558	NATIONAL EYE INSTITUTE [R01EY011627, R01EY012611] Funding Source: NIH RePORTER; NEI NIH HHS [EY12611, EY11627] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Aoki T, 1997, ADV EXP MED BIOL, V411, P503; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; DiezRoux G, 1997, DEVELOPMENT, V124, P3633; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HIRAHARA H, 1995, TRANSPLANTATION, V59, P85, DOI 10.1097/00007890-199501150-00015; Hughes S, 2000, MICROCIRCULATION, V7, P317, DOI 10.1038/sj.mn.7300119; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nishio K, 1998, AM J RESP CRIT CARE, V157, P599, DOI 10.1164/ajrccm.157.2.9704102; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Wigginton JM, 2001, J CLIN INVEST, V108, P51; Willam C, 1999, AM J PHYSIOL-HEART C, V276, pH2044, DOI 10.1152/ajpheart.1999.276.6.H2044; WILSON RW, 1993, J IMMUNOL, V151, P1571; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624	25	189	195	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					781	788		10.1038/nm877	http://dx.doi.org/10.1038/nm877			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12730690				2022-12-25	WOS:000183444100036
J	Kabashima, K; Sakata, D; Nagamachi, M; Miyachi, Y; Inaba, K; Narumiya, S				Kabashima, K; Sakata, D; Nagamachi, M; Miyachi, Y; Inaba, K; Narumiya, S			Prostaglandin E-2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells	NATURE MEDICINE			English	Article							IMMUNOSTIMULATORY DENDRITIC CELLS; CONTACT HYPERSENSITIVITY; IL-12 PRODUCTION; HUMAN KERATINOCYTES; DOWN-REGULATION; UP-REGULATION; MICE LACKING; LYMPH-NODES; RECEPTOR; EXPRESSION	Antigen-specific immune responses in the skin are initiated by antigen uptake into Langerhans cells and the subsequent migration of these cells to draining lymph nodes. Although prostaglandin E-2 (PGE(2)) is produced substantially in skin exposed to antigen, its role remains unclear. Here we show that although Langerhans cells express all four PGE receptor subtypes, their migration to regional lymph nodes was decreased only in EP4-deficient (Ptger4(-/-)) mice and in wild-type mice treated with an EP4 antagonist. An EP4 agonist promoted the migration of Langerhans cells, increased their expression of costimulatory molecules and enhanced their ability to stimulate T cells in the mixed lymphocyte reaction in vitro. Contact hypersensitivity to antigen was impaired in Ptger4(-/-) mice and in wild-type mice treated with the EP4 antagonist during sensitization. PGE(2)-EP4 signaling thus facilitates initiation of skin immune responses by promoting the migration and maturation of Langerhans cells.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Dept Dermatol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Anim Dev & Physiol, Kyoto 6068502, Japan	Kyoto University; Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan.		Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554				Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Daugschies A, 1998, INT J PARASITOL, V28, P355, DOI 10.1016/S0020-7519(97)00153-7; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Eberhard J, 2002, CLIN DIAGN LAB IMMUN, V9, P132, DOI 10.1128/CDLI.9.1.132-137.2002; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GRABBE S, 1995, J IMMUNOL, V155, P4207; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; INABA K, 1986, J EXP MED, V164, P605, DOI 10.1084/jem.164.2.605; JAFFER S, 1995, AM J NEPHROL, V15, P300, DOI 10.1159/000168853; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kimber I, 2000, BRIT J DERMATOL, V142, P401, DOI 10.1046/j.1365-2133.2000.03349.x; KURIMOTO I, 1993, J INVEST DERMATOL, V101, P132, DOI 10.1111/1523-1747.ep12363616; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; Luft T, 2002, BLOOD, V100, P1362, DOI 10.1182/blood-2001-12-0360; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ortner U, 1996, J IMMUNOL METHODS, V193, P71, DOI 10.1016/0022-1759(96)00058-0; RAO TS, 1993, INFLAMMATION, V17, P723, DOI 10.1007/BF00920477; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; RUZICKA T, 1982, INT ARCH ALLER A IMM, V69, P347, DOI 10.1159/000233198; Rys-Sikora KE, 2000, AM J PHYSIOL-CELL PH, V278, pC822, DOI 10.1152/ajpcell.2000.278.4.C822; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shinomiya S, 2001, BIOCHEM PHARMACOL, V61, P1153, DOI 10.1016/S0006-2952(01)00586-X; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101; Weinlich G, 1998, J INVEST DERMATOL, V110, P441, DOI 10.1046/j.1523-1747.1998.00161.x; Whittaker DS, 2000, J IMMUNOL, V165, P4298, DOI 10.4049/jimmunol.165.8.4298	42	244	257	1	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					744	749		10.1038/nm872	http://dx.doi.org/10.1038/nm872			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740571				2022-12-25	WOS:000183444100030
J	Akbari, O; Stock, P; Meyer, E; Kronenberg, M; Sidobre, S; Nakayama, T; Taniguchi, M; Grusby, MJ; DeKruyff, RH; Umetsu, DT				Akbari, O; Stock, P; Meyer, E; Kronenberg, M; Sidobre, S; Nakayama, T; Taniguchi, M; Grusby, MJ; DeKruyff, RH; Umetsu, DT			Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity	NATURE MEDICINE			English	Article							KILLER T-CELLS; NONOBESE DIABETIC MICE; ALPHA-GALACTOSYLCERAMIDE; INTERLEUKIN (IL)-4; INTERFERON-GAMMA; ASTHMA; RESPONSES; HYPERRESPONSIVENESS; INFLAMMATION; ASSOCIATION	Using natural killer T (NKT) cell-deficient mice, we show here that allergen-induced airway hyperreactivity (AHR), a cardinal feature of asthma, does not develop in the absence of V(alpha)14i NKT cells. The failure of NKT cell-deficient mice to develop AHR is not due to an inability of these mice to produce type 2 T-helper (Th2) responses because NKT cell-deficient mice that are immunized subcutaneously at non-mucosal sites produce normal Th2-biased responses. The failure to develop AHR can be reversed by the adoptive transfer of tetramer-purified NKT cells producing interleukin (IL)-4 and IL-13 to Ja281(-/-) mice, which lack the invariant T-cell receptor (TCR) of NKT cells, or by the administration to Cd1d(-/-) mice of recombinant IL-13, which directly affects airway smooth muscle cells. Thus, pulmonary V(alpha)14i NKT cells crucially regulate the development of asthma and Th2-biased respiratory immunity against nominal exogenous antigens. Therapies that target V(alpha)14i NKT cells may be clinically effective in limiting the development of AHR and asthma.	Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA USA; Chiba Univ, Grad Sch Med, Chiba, Japan; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Stanford University; La Jolla Institute for Immunology; Chiba University; Harvard University; Harvard T.H. Chan School of Public Health	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA.		Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007	NATIONAL CANCER INSTITUTE [R01CA052511] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, T32AI007290, R01AI026322, R01AI040171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52511] Funding Source: Medline; NHLBI NIH HHS [R01 HL62348] Funding Source: Medline; NIAID NIH HHS [T32AI07290, AI40171, R01 AI26322] Funding Source: Medline; NIGMS NIH HHS [GM62135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Carnaud C, 1999, J IMMUNOL, V163, P4647; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Haczku A, 2001, AM J RESP CELL MOL, V25, P45, DOI 10.1165/ajrcmb.25.1.4391; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee PT, 2002, J CLIN INVEST, V110, P793, DOI 10.1172/JCI200215832; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; Leishman AJ, 2002, IMMUNITY, V16, P355, DOI 10.1016/S1074-7613(02)00284-4; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Matsuda JL, 2002, NAT IMMUNOL, V3, P966, DOI 10.1038/ni837; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; SANDER B, 1991, SCAND J IMMUNOL, V33, P287, DOI 10.1111/j.1365-3083.1991.tb01774.x; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang B, 2001, J EXP MED, V194, P313, DOI 10.1084/jem.194.3.313; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; 1998, MORB MORTAL WKLY REP, V47, P1022	46	552	596	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					582	588		10.1038/nm851	http://dx.doi.org/10.1038/nm851			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669034				2022-12-25	WOS:000182610600040
J	Cheok, MH; Yang, WL; Pui, CH; Downing, JR; Cheng, C; Naeve, CW; Relling, MV; Evans, WE				Cheok, MH; Yang, WL; Pui, CH; Downing, JR; Cheng, C; Naeve, CW; Relling, MV; Evans, WE			Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells	NATURE GENETICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA STRAND BREAKS; NONPOLYPOSIS COLORECTAL-CANCER; TYROSINE KINASE; METHOTREXATE; ACCUMULATION; DAMAGE; PHARMACOGENOMICS; CLASSIFICATION; CHEMOTHERAPY	To elucidate the genomics of cellular responses to cancer treatment, we analyzed the expression of over 9,600 human genes in acute lymphoblastic leukemia cells before and after in vivo treatment with methotrexate and mercaptopurine given alone or in combination. Based on changes in gene expression, we identified 124 genes that accurately discriminated among the four treatments. Discriminating genes included those involved in apoptosis, mismatch repair, cell cycle control and stress response. Only 14% of genes that changed when these medications were given as single agents also changed when they were given together. These data indicate that lymphoid leukemia cells of different molecular subtypes share common pathways of genomic response to the same treatment, that changes in gene expression are treatment-specific and that gene expression can illuminate differences in cellular response to drug combinations versus single agents.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Hematol Malignancies Program, Memphis, TN 38105 USA; Univ Bonn, D-5300 Bonn, Germany; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Bonn; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Hematol Malignancies Program, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Downing, James R./N-8102-2018; Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018; Cheok, Meyling h/C-3822-2014; Evans, William E./C-2069-2012; Cheng, Cheng/N-8075-2018; Cheok, Meyling/AFS-4025-2022	Pui, Ching-Hon/0000-0003-0303-5658; Cheok, Meyling h/0000-0002-7820-8026; Evans, William E./0000-0002-9333-5322; Cheok, Meyling/0000-0002-7820-8026				Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BOKKERINK JPM, 1993, BIOCHEM PHARMACOL, V45, P1455, DOI 10.1016/0006-2952(93)90045-X; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gong JG, 1999, NATURE, V399, P806; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; LI JC, 1984, P NATL ACAD SCI-BIOL, V81, P5694, DOI 10.1073/pnas.81.18.5694; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LORICO A, 1988, CANCER RES, V48, P2036; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Palmirotta R, 1998, EUR J CANCER, V34, P927, DOI 10.1016/S0959-8049(98)00031-8; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; Wijnen J, 1996, AM J HUM GENET, V58, P300; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	29	196	215	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					85	90		10.1038/ng1151	http://dx.doi.org/10.1038/ng1151			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12704389				2022-12-25	WOS:000182667900022
J	Matsumoto, N; Tamura, S; Fujiki, Y				Matsumoto, N; Tamura, S; Fujiki, Y			The pathogenic peroxin Pex26p recruits the Pex1p-Pex6p AAA ATPase complexes to peroxisomes	NATURE CELL BIOLOGY			English	Article							MATRIX PROTEIN IMPORT; INTEGRAL MEMBRANE-PROTEIN; DEFICIENT ZELLWEGER-SYNDROME; TARGETING SIGNAL RECEPTOR; MAMMALIAN-CELL MUTANT; BIOGENESIS DISORDERS; FUNCTIONAL COMPLEMENTATION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CDNA CLONING	Peroxisomes are ubiquitous organelles with a single membrane that contain over 50 different enzymes that catalyse various metabolic pathways, including beta-oxidation and lipid synthesis(1). Peroxisome biogenesis disorders (PBDs), such as Zellweger syndrome and neonatal adrenoleukodystrophy, are fatal genetic diseases that are autosomal recessive(2,3). Among the PBDs of the 12 complementation groups (CGs)(4), 11 associated PEX genes have been isolated(4-7). Accordingly, only the PBD pathogenic gene for CG8 (also called CG-A) remains unidentified. Here we have isolated human PEX26 encoding a type II peroxisomal membrane protein of relative molecular mass 34,000 (M-r 34K) by using ZP167 cells, a Chinese hamster ovary (CHO) mutant cell line(5,8). Expression of PEX26 restores peroxisomal protein import in the fibroblasts of an individual with PBD of CG8. This individual possesses a homozygous, inactivating pathogenic point mutation, Arg98Trp, in Pex26. Pex6 and Pex1 of the AAA ATPase family co-immunoprecipitate with Pex26. Epitope-tagged Pex6 and Pex1 are discernible as puncta in normal CHO-K1 cells, but not in PEX26-defective cells. PEX26 expression in ZP167 cells re-establishes colocalization of Pex6 and Pex1 with Pex26, in a Pex6-dependent manner. Thus, Pex26 recruits Pex6-Pex1 complexes to peroxisomes.	Kyushu Univ, Fac Sci, Dept Biol, Grad Sch, Fukuoka 812, Japan; Japan Sci & Technol Corp, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Grad Sch, Fukuoka 812, Japan.		Matsumoto, Naomi/AFL-4833-2022; Matsumoto, Naomi/AAD-3468-2022					Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Geisbrecht BV, 1998, P NATL ACAD SCI USA, V95, P8630, DOI 10.1073/pnas.95.15.8630; Ghaedi K, 2000, AM J HUM GENET, V67, P976, DOI 10.1086/303086; Ghaedi K, 1999, EXP CELL RES, V248, P482, DOI 10.1006/excr.1999.4412; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hashiguchi N, 2002, MOL BIOL CELL, V13, P711, DOI 10.1091/mbc.01-10-0479; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; LAZAROW PB, 1995, METABOLIC BASIS INHE, V7, P2287; Matsumoto N, 2001, J HUM GENET, V46, P273, DOI 10.1007/s100380170078; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tamura S, 2001, BIOCHEM J, V357, P417, DOI 10.1042/0264-6021:3570417; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	39	136	145	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					454	460		10.1038/ncb982	http://dx.doi.org/10.1038/ncb982			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717447				2022-12-25	WOS:000182691400020
J	Tamaru, H; Zhang, X; McMillen, D; Singh, PB; Nakayama, J; Grewal, SI; Allis, CD; Cheng, XD; Selker, EU				Tamaru, H; Zhang, X; McMillen, D; Singh, PB; Nakayama, J; Grewal, SI; Allis, CD; Cheng, XD; Selker, EU			Trimethylated lysine 9 of histone H3 is a mark for DNA methylation in Neurospora crassa	NATURE GENETICS			English	Article							INDUCED POINT MUTATION; METHYLTRANSFERASE ACTIVITY; PROTEIN; DOMAIN; PATTERNS; HP1; HETEROCHROMATIN; CHROMOSOME; ENHANCER; GENES	Besides serving to package nuclear DNA, histones carry information in the form of a diverse array of post-translational modifications. Methylation of histones H3 and H4 has been implicated in long-term epigenetic 'memory'(1). Dimethylation or trimethylation of Lys4 of histone H3 (H3 Lys4) has been found in expressible euchromatin of yeasts and mammals(2-4). In contrast, methylation of Lys9 of histone H3 (H3 Lys9) has been implicated in establishing and maintaining the largely quiescent heterochromatin of mammals, yeasts, Drosophila melanogaster and plants". we have previously shown that a DNA methylation mutant of Neurospora crassa, dim-5 (defective in methylation), has a nonsense mutation in the SET domain of an H3-specific histone methyltransferase and that substitutions of H3 Lys9 cause gross hypomethylation of DNA(10). Similarly, the KRYPTONITE histone methyltransferase is required for full DNA methylation in Arabidopsis thaliana(11). We used biochemical, genetic and immunological methods to investigate the specific mark for DNA methylation in N. crassa. Here we show that trimethylated H3 Lys9, but not dimethylated H3 Lys9, marks chromatin regions for cytosine methylation and that DIM-5 specifically creates this mark.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Roslin Inst, Div Gene Express & Dev, Nuc Reprogramming Lab, Roslin EH25 9PS, Midlothian, Scotland; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Oregon; Emory University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Cold Spring Harbor Laboratory; University of Virginia	Selker, EU (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.		Nakayama, Jun-ichi/C-6003-2011; Singh, Prim/G-1088-2014	Nakayama, Jun-ichi/0000-0002-5597-8239; Singh, Prim/0000-0002-9571-0974				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Hays SM, 2002, GENETICS, V160, P961; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Margolin BS, 1998, GENETICS, V149, P1787; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, IN PRESS NATURE; SINGER MJ, 1995, MOL CELL BIOL, V15, P5586; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6	30	299	314	1	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					75	79		10.1038/ng1143	http://dx.doi.org/10.1038/ng1143			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12679815				2022-12-25	WOS:000182667900020
J	Gratton, JP; Yu, J; Griffith, JW; Babbitt, RW; Scotland, RS; Hickey, R; Giordano, FJ; Sessa, WC				Gratton, JP; Yu, J; Griffith, JW; Babbitt, RW; Scotland, RS; Hickey, R; Giordano, FJ; Sessa, WC			Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo	NATURE MEDICINE			English	Article							PROTEIN TRANSDUCTION DOMAIN; INTRACELLULAR DELIVERY; ANGIOGENESIS; PENETRATIN; RETROVIRUS; MOUSE	Small polybasic peptides derived from the transduction domains of certain proteins, such as the third alpha-helix of the Antennapedia (Antp) homeodomain, can cross the cell membrane through a receptor-independent mechanism. These cell-permeable molecules have been used as 'Trojan horses' to introduce biologically active cargo molecules such as DNA, peptides or proteins into cells. Using these cell-permeable peptides, we have developed an efficient and simple method to increase virally mediated gene delivery and protein expression in vitro and in vivo. Here, we show that cell-permeable peptides increase viral cell entry, improve gene expression at reduced titers of virus and improve efficacy of therapeutically relevant genes in vivo.	Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cardiovasc Med,Boyer Ctr Mol Med, Vasc Cell Signaling & Therapeut Program, New Haven, CT 06510 USA	Yale University; Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06510 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R37HL061371, R01HL064793, R01HL061371] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57665, HL64793, HL61371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baek S, 1998, CIRC RES, V82, P295, DOI 10.1161/01.RES.82.3.295; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cullen BR, 2001, CELL, V105, P697, DOI 10.1016/S0092-8674(01)00392-0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; Sharma S, 2000, J VIROL, V74, P10790, DOI 10.1128/JVI.74.22.10790-10795.2000; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	17	157	177	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					357	362		10.1038/nm835	http://dx.doi.org/10.1038/nm835			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12598894				2022-12-25	WOS:000181312300039
J	Taylor, CF; Paton, NW; Garwood, KL; Kirby, PD; Stead, DA; Yin, ZK; Deutsch, EW; Selway, L; Walker, J; Riba-Garcia, I; Mohammed, S; Deery, MJ; Howard, JA; Dunkley, T; Aebersold, R; Kell, DB; Lilley, KS; Roepstorff, P; Yates, JR; Brass, A; Brown, AJP; Cash, P; Gaskell, SJ; Hubbard, SJ; Oliver, SG				Taylor, CF; Paton, NW; Garwood, KL; Kirby, PD; Stead, DA; Yin, ZK; Deutsch, EW; Selway, L; Walker, J; Riba-Garcia, I; Mohammed, S; Deery, MJ; Howard, JA; Dunkley, T; Aebersold, R; Kell, DB; Lilley, KS; Roepstorff, P; Yates, JR; Brass, A; Brown, AJP; Cash, P; Gaskell, SJ; Hubbard, SJ; Oliver, SG			A systematic approach to modeling, capturing, and disseminating proteomics experimental data	NATURE BIOTECHNOLOGY			English	Article							PROTEIN	Both the generation and the analysis of proteome data are becoming increasingly widespread, and the field of proteomics is moving incrementally toward high-throughput approaches. Techniques are also increasing in complexity as the relevant technologies evolve. A standard representation of both the methods used and the data generated in proteomics experiments, analogous to that of the MIAME (minimum information about a microarray experiment) guidelines for transcriptomics, and the associated MAGE (microarray gene expression) object model and XML (extensible markup language) implementation, has yet to emerge. This hinders the handling, exchange, and dissemination of proteomics data. Here, we present a UML (unified modeling language) approach to proteomics experimental data, describe XML and SQL (structured query language) implementations of that model, and discuss capture, storage, and dissemination strategies. These make explicit what data might be most usefully captured about proteomics experiments and provide complementary routes toward the implementation of a proteome repository.	Univ Manchester, Sch Biol Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Dept Comp Sci, Manchester M13 9PL, Lancs, England; Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZF, Scotland; Inst Syst Biol, Seattle, WA 98103 USA; Univ Manchester, Inst Sci & Technol, Dept Chem, Manchester M60 1QD, Lancs, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Inpharmatica Ltd, London, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Manchester; University of Manchester; University of Aberdeen; Institute for Systems Biology (ISB); University of Manchester; University of Manchester; University of Cambridge; University of Southern Denmark; Scripps Research Institute	Oliver, SG (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.		Deutsch, Eric/AAF-5912-2020; Hubbard, Simon J/B-9006-2009; Lilley, Kathryn/ABF-5787-2020; Mohammed, Shabaz/AAY-6313-2020; Brown, Alistair J.P./B-6627-2014; Kell, Douglas/E-8318-2011; Oliver, Stephen/AAQ-5992-2021; Mohammed, Shabaz/D-1042-2010	Lilley, Kathryn/0000-0003-0594-6543; Mohammed, Shabaz/0000-0003-2640-9560; Kell, Douglas/0000-0001-5838-7963; Oliver, Stephen/0000-0003-3410-6439; Mohammed, Shabaz/0000-0003-2640-9560; Taylor, Christopher/0000-0002-9666-798X; Hubbard, Simon/0000-0002-8601-9524; Deutsch, Eric/0000-0001-8732-0928; Brown, Alistair JP/0000-0003-1406-4251; Stead, David/0000-0001-9268-5868; Brass, Andrew/0000-0002-0389-7058; Paton, Norman/0000-0003-2008-6617	Biotechnology and Biological Sciences Research Council [E19354] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Attwood TK, 2000, INT J BIOCHEM CELL B, V32, P139, DOI 10.1016/S1357-2725(99)00106-5; BOOCH G, 1997, UNIFIED MODELLING LA; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hoogland C, 2000, NUCLEIC ACIDS RES, V28, P286, DOI 10.1093/nar/28.1.286; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; PENNINGTON SR, 2001, PROTEOMICS; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Sanchez JC, 2001, PROTEOMICS, V1, P136; Sidhu KS, 2001, PROTEOMICS, V1, P1368, DOI 10.1002/1615-9861(200111)1:11<1368::AID-PROT1368>3.0.CO;2-U; SPELLMAN PT, 2002, GENOME BIOL, V3; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Wilkins M. R., 1997, PROTEOME RES NEW FRO	16	196	210	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					247	254		10.1038/nbt0303-247	http://dx.doi.org/10.1038/nbt0303-247			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610571				2022-12-25	WOS:000181312500019
J	Bergamaschi, D; Samuels, Y; O'Neil, NJ; Trigiante, G; Crook, T; Hsieh, JK; O'Connor, DJ; Zhong, S; Campargue, I; Tomlinson, ML; Kuwabara, PE; Lu, X				Bergamaschi, D; Samuels, Y; O'Neil, NJ; Trigiante, G; Crook, T; Hsieh, JK; O'Connor, DJ; Zhong, S; Campargue, I; Tomlinson, ML; Kuwabara, PE; Lu, X			iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR; CAENORHABDITIS-ELEGANS; DROSOPHILA P53; APOPTOSIS; HOMOLOG	We have previously shown that ASPP1 and ASPP2 are specific activators of p53; one mechanism by which wild-type p53 is tolerated in human breast carcinomas is through loss of ASPP activity. We have further shown that 53BP2, which corresponds to a C-terminal fragment of ASPP2, acts as a dominant negative inhibitor of p53 (ref. 1). Hence, an inhibitory form of ASPP resembling 53BP2 could allow cells to bypass the tumor-suppressor functions of p53 and the ASPP proteins. Here, we characterize such a protein, iASPP (inhibitory member of the ASPP family), encoded by PPP1R13L in humans and ape-1 in Caenorhabditis elegans. iASPP is an evolutionarily conserved inhibitor of p53; inhibition of iASPP by RNA-mediated interference or antisense RNA in C elegans or human cells, respectively, induces p53-dependent apoptosis. Moreover, iASPP is an oncoprotein that cooperates with Ras, E1A and E7, but not mutant p53, to transform cells in vitro. Increased expression of iASPP also confers resistance to ultraviolet radiation and to cisplatin-induced apoptosis. iASPP expression is upregulated in human breast carcinomas expressing wild-type p53 and normal levels of ASPP. Inhibition of iASPP could provide an important new strategy for treating tumors expressing wild-type p53.	Univ London Imperial Coll Sci & Technol, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Wellcome Trust Sanger Inst, Cambridge, England	Imperial College London; Ludwig Institute for Cancer Research; Wellcome Trust Sanger Institute	Lu, X (corresponding author), Univ London Imperial Coll Sci & Technol, Sch Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		O'Neil, Nigel/J-4012-2014	O'Neil, Nigel/0000-0002-1992-6976; Lu, Xin/0000-0002-6587-1152; Samuels, Yardena/0000-0002-3349-7266; Bergamaschi, Daniele/0000-0002-3955-1091; Kuwabara, Patricia/0000-0002-1108-7776				Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662	12	297	354	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					162	167		10.1038/ng1070	http://dx.doi.org/10.1038/ng1070			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12524540				2022-12-25	WOS:000180773700013
J	Ghoreschi, K; Thomas, P; Breit, S; Dugas, M; Mailhammer, R; van Eden, W; van der Zee, R; Biedermann, T; Prinz, J; Mack, M; Mrowietz, U; Christophers, E; Schlondorff, D; Plewig, G; Sander, CA; Rocken, M				Ghoreschi, K; Thomas, P; Breit, S; Dugas, M; Mailhammer, R; van Eden, W; van der Zee, R; Biedermann, T; Prinz, J; Mack, M; Mrowietz, U; Christophers, E; Schlondorff, D; Plewig, G; Sander, CA; Rocken, M			Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN INTERLEUKIN-4; CYTOTOXIC T-LYMPHOCYTE; TUMOR-NECROSIS-FACTOR; PHASE-II; HYPERSENSITIVITY REACTIONS; MULTIPLE-SCLEROSIS; IMMUNE DEVIATION; DENDRITIC CELLS; IN-VITRO; ANTIGEN	Selective skewing of autoreactive interferon-gamma (IFN-gamma)-producing T helper cells (Th1) toward an interleukin-4 (IL-4)-producing (Th2) phenotype can in experimental animals alleviate autoimmune disease without inducing general immunosuppression. In a prospective dose escalation study, we assessed treatment with human IL-4 (rhuIL-4) in 20 patients with severe psoriasis. The therapy was well tolerated, and within six weeks all patients showed decreased clinical scores and 15 improved more than 68%. Stable reduction of clinical scores was significantly better at 0.2-0.5 mug rhuIL-4 than at less than or equal to0.1 mug rhuIL-4 (P = 0.009). In psoriatic lesions, treatment with 0.2-0.5 mug/kg rhuIL-4 reduced the concentrations of IL-8 and IL-19, two cytokines directly involved in psoriasis; the number of chemokine receptor CCR5(+) Th1 cells; and the IFN-gamma/IL-4 ratio. In the circulation, 0.2-0.5 mug/kg rhuIL-4 increased the number of IL-4(+)CD4(+) T cells two- to three-fold. Thus, IL-4 therapy can induce Th2 differentiation in human CD4(+) T cells and has promise as a potential treatment for psoriasis, a prototypic Th1-associated autoimmune disease.	Univ Munich, Dept Dermatol & Allergol, Munich, Germany; Univ Munich, Inst Biometr, Munich, Germany; Univ Munich, Dept Internal Med, Munich, Germany; GSF Munich, Forschungszentrum, Munich, Germany; Univ Utrecht, Fac Vet Med, Inst Infect Dis & Immunol, NL-3508 TC Utrecht, Netherlands; Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; Univ Tubingen, Dept Dermatol, Tubingen, Germany	University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Utrecht University; University of Kiel; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Rocken, M (corresponding author), Univ Munich, Dept Dermatol & Allergol, Munich, Germany.	mrocken@med.uni-tuebingen.de	Dugas, Susanne/G-6201-2011; Mrowietz, U/B-1645-2010; Prinz, Jörg/AAP-9472-2021; van der Zee, Ruurd/O-5256-2015; Dugas, Martin/F-5454-2011	Mrowietz, U/0000-0002-9539-0712; van der Zee, Ruurd/0000-0002-4331-2755; Rocken, Martin/0000-0003-3795-7001; Biedermann, Tilo/0000-0002-5352-5105; Ghoreschi, Kamran/0000-0002-5526-7517; van Eden, Willem/0000-0003-1272-704X				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; [Anonymous], 1996, Arch Dermatol, V132, P419; Asadullah K, 2001, J INVEST DERMATOL, V116, P721, DOI 10.1046/j.0022-202x.2001.01317.x; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Biedermann T, 2001, EUR J IMMUNOL, V31, P1582, DOI 10.1002/1521-4141(200105)31:5<1582::AID-IMMU1582>3.0.CO;2-M; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Breit S, 1996, EUR J IMMUNOL, V26, P1860, DOI 10.1002/eji.1830260829; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Christophers E., 1999, PSORIASIS EPIDERMIS, V5th, P495; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Granstein RD, 2001, NEW ENGL J MED, V345, P284, DOI 10.1056/NEJM200107263450410; Kalinski P, 2000, J IMMUNOL, V165, P1877, DOI 10.4049/jimmunol.165.4.1877; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Koch AE, 2001, ARTHRITIS RHEUM-US, V44, P31, DOI 10.1002/1529-0131(200101)44:1<31::AID-ANR5>3.0.CO;2-4; Krueger G, 2001, ARCH DERMATOL, V137, P280; Leach MW, 1997, CLIN IMMUNOL IMMUNOP, V83, P12, DOI 10.1006/clin.1997.4304; Lebwohl M, 1998, J AM ACAD DERMATOL, V39, P464, DOI 10.1016/S0190-9622(98)70325-1; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Luftl M, 1997, ARCH DERMATOL, V133, P1597, DOI 10.1001/archderm.133.12.1597; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NESTLE FO, 1994, J CLIN INVEST, V94, P202, DOI 10.1172/JCI117308; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Prinz JC, 1999, EUR J IMMUNOL, V29, P3360, DOI 10.1002/(SICI)1521-4141(199910)29:10<3360::AID-IMMU3360>3.0.CO;2-G; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Reich K, 2001, J INVEST DERMATOL, V116, P319, DOI 10.1046/j.1523-1747.2001.01248.x; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; ROCKEN M, 1994, J EXP MED, V179, P1885, DOI 10.1084/jem.179.6.1885; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; Trepicchio WL, 1999, J CLIN INVEST, V104, P1527, DOI 10.1172/JCI6910; Vokes EE, 1998, CANCER J SCI AM, V4, P46; Whitehead RP, 1998, J IMMUNOTHER, V21, P440, DOI 10.1097/00002371-199811000-00006; WONG HL, 1993, J EXP MED, V177, P775, DOI 10.1084/jem.177.3.775	46	323	344	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					40	46		10.1038/nm804	http://dx.doi.org/10.1038/nm804			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12461524				2022-12-25	WOS:000180209900020
J	Mor-Vaknin, N; Punturieri, A; Sitwala, K; Markovitz, DM				Mor-Vaknin, N; Punturieri, A; Sitwala, K; Markovitz, DM			Vimentin is secreted by activated macrophages	NATURE CELL BIOLOGY			English	Article							INTERMEDIATE-FILAMENTS; PROTEIN; BINDING; DIFFERENTIATION; INTERLEUKIN-10; EXPRESSION; EXPORT; IGG	Vimentin is a widely expressed intermediate filament protein thought to be involved mainly in structural processes, such as wound healing(1). We now demonstrate that activated human macrophages secrete vimentin into the extracellular space. The maturation of blood-derived monocytes into macrophages involves several signalling pathways(2,3). We show that secretion of vimentin, which is phosphorylated at serine and threonine residues, is enhanced by the phosphatase inhibitor okadaic acid and blocked by the specific protein kinase C inhibitor GO6983. These findings are consistent with previous observations that phosphorylation of vimentin affects its intracellular localization and that vimentin is a substrate for protein kinase C (PKC)(4,5). We also show that the anti-inflammatory cytokine interleukin-10 (IL-10), which inhibits PKC activity, blocks secretion of vimentin. In contrast, the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) can trigger secretion of vimentin. Finally, we found that extracellular vimentin is involved in bacterial killing and the generation of oxidative metabolites, two important functions of activated macrophages. These data establish that vimentin is secreted by macrophages in response to pro-inflammatory signalling pathways and is probably involved in immune function.	Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Res Sect, Ann Arbor, MI 48105 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu		Duncan, Mara/0000-0002-2383-0109	NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NIAMS NIH HHS [P30 AR48310-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bhattacharyya S, 2001, INFECT IMMUN, V69, P1499, DOI 10.1128/IAI.69.3.1499-1507.2001; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CAIN H, 1982, PATHOL RES PRACT, V175, P162, DOI 10.1016/S0344-0338(82)80106-4; CAIN H, 1983, VIRCHOWS ARCH B, V42, P65, DOI 10.1007/BF02890371; Cheng TJ, 1998, J CELL BIOCHEM, V71, P169; CHRISTIAN J L, 1990, New Biologist, V2, P700; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; FRANCESCHI C, 1989, AGING, V1, P1; Gao YS, 2001, J CELL BIOL, V152, P877, DOI 10.1083/jcb.152.5.877; HANSSON GK, 1987, EXP CELL RES, V170, P338, DOI 10.1016/0014-4827(87)90311-9; HANSSON GK, 1984, P NATL ACAD SCI-BIOL, V81, P3103, DOI 10.1073/pnas.81.10.3103; Lo CJ, 1998, J SURG RES, V79, P179, DOI 10.1006/jsre.1998.5418; Matsukawa A, 2000, J IMMUNOL, V164, P5362, DOI 10.4049/jimmunol.164.10.5362; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; PERIDES G, 1987, J BIOL CHEM, V262, P13742; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; RIUS C, 1992, J CELL SCI, V101, P395; SANCHEZ A, 1990, J RHEUMATOL, V17, P205; Schlosser-Silverman E, 2000, J BACTERIOL, V182, P5225, DOI 10.1128/JB.182.18.5225-5230.2000; SENECAL JL, 1988, ARTHRITIS RHEUM, V31, P864, DOI 10.1002/art.1780310707; TERASAKI M, 1992, J CELL SCI, V101, P315; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; [No title captured]	29	395	415	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					59	63		10.1038/ncb898	http://dx.doi.org/10.1038/ncb898			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12483219				2022-12-25	WOS:000180223700014
J	Baonza, A; Murawsky, CM; Travers, AA; Freeman, M				Baonza, A; Murawsky, CM; Travers, AA; Freeman, M			Pointed and Tramtrack69 establish an EGFR-dependent transcriptional switch to regulate mitosis	NATURE CELL BIOLOGY			English	Article							DEVELOPING DROSOPHILA EYE; CELL-CYCLE PROGRESSION; ETS DOMAIN PROTEIN; FISSION YEAST; REPRESSOR TRAMTRACK; MITOTIC CONTROL; GENE; KINASE; DIFFERENTIATION; PROLIFERATION	Cell division in animals must be regulated; during development, for example, proliferation often occurs in spatially and temporally restricted patterns(1-3), and loss of mitotic control underlies cancer(4). The epidermal growth factor receptor (EGFR) has been implicated extensively in the control of cell proliferation in metazoans(5-7); in addition, hyperactivity of the EGFR and its three relatives, ErbB2-ErbB4, are implicated in many cancers(8). But little is known about how these receptor tyrosine kinases regulate the cell cycle. In the developing Drosophila melanogaster imaginal eye disc, there is a single patterned mitosis that sweeps across the eye disc epithelium in the third larval instar(9). This 'second mitotic wave' is triggered by EGFR signalling 5 and depends on expression of String, the Drosophila homologue of Cdc25 phosphatase, the ultimate regulator of mitosis in all eukaryotic cells(10-12). Here we show that two antagonistic transcriptional regulators, Pointed, an activator, and Tramtrack69, a repressor, directly regulate the transcription of string. The activity of at least one of these regulators, Pointed, is controlled by EGFR signalling. This establishes a molecular mechanism for how intercellular signalling can control string expression, and thereby cell proliferation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Baonza, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Freeman, Matthew/0000-0003-0410-5451; Murawsky, Christopher/0000-0002-9698-052X; Baonza, Antonio/0000-0003-3252-0038				Badenhorst P, 2002, MECH DEVELOP, V117, P87, DOI 10.1016/S0925-4773(02)00183-1; Badenhorst P, 2001, DEVELOPMENT, V128, P4093; Baker NE, 2001, CELL, V104, P699, DOI 10.1016/S0092-8674(02)06076-2; BROWN JL, 1993, DEVELOPMENT, V117, P45; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1989, DEVELOPMENT, V107, P1; Gabay L, 1996, DEVELOPMENT, V122, P3355; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Lehman DA, 1999, DEVELOPMENT, V126, P1793; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	37	64	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					976	980		10.1038/ncb887	http://dx.doi.org/10.1038/ncb887			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447387				2022-12-25	WOS:000179571800018
J	DiTullio, RA; Mochan, TA; Venere, M; Bartkova, J; Sehested, M; Bartek, J; Halazonetis, TD				DiTullio, RA; Mochan, TA; Venere, M; Bartkova, J; Sehested, M; Bartek, J; Halazonetis, TD			53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE; PHOSPHORYLATION; PROTEIN; RAD9; KINASE; CHK2; SITES; YEAST; SMC1	53BP1 is a conserved nuclear protein that is implicated in the DNA damage response. After irradiation, 53BP1 localizes rapidly to nuclear foci, which represent sites of DNA double strand breaks(1-4), but its precise function is unclear. Using small interference RNA (siRNA), we demonstrate that 53BP1 functions as a DNA damage checkpoint protein. 53BP1 is required for at least a subset of ataxia telangiectasia-mutated (ATM)-dependent phosphorylation events at sites of DNA breaks and for cell cycle arrest at the G2-M interphase after exposure to irradiation. Interestingly, in cancer cell lines expressing mutant p53, 53BP1 was localized to distinct nuclear foci and ATM-dependent phosphorylation of Chk2 at Thr 68 was detected, even in the absence of irradiation. In addition, more than 50% of Chk2 was phosphorylated at Thr 68 in surgically resected lung and breast tumour specimens from otherwise untreated patients. We conclude that the constitutive activation of the DNA damage checkpoint pathway may be linked to the high frequency of p53 mutations in human cancer, as p53 is a downstream target of Chk2 and ATM.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Hosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Danish Cancer Society; The Wistar Institute; University of Pennsylvania; University of Pennsylvania	DiTullio, RA (corresponding author), Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk; halazonetis@wistar.upenn.edu	Halazonetis, Thanos/D-7923-2011; Bartek, Jiri/G-5870-2014		NATIONAL CANCER INSTITUTE [P01CA025874, R01CA076367, T32CA009171] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA25874, CA76367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; BARTKOVA J, 1995, CANCER RES, V55, P949; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lukas C, 2001, CANCER RES, V61, P4990; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG B, 2002, SCI ONLINE      1003, DOI DOI 10.1126/SCIENCE.1076182; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	27	343	354	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					998	1002		10.1038/ncb892	http://dx.doi.org/10.1038/ncb892			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447382				2022-12-25	WOS:000179571800022
J	Fernandez-Capetillo, O; Chen, HT; Celeste, A; Ward, I; Romanienko, PJ; Morales, JC; Naka, K; Xia, ZF; Camerini-Otero, RD; Motoyama, N; Carpenter, PB; Bonner, WM; Chen, JJ; Nussenzweig, A				Fernandez-Capetillo, O; Chen, HT; Celeste, A; Ward, I; Romanienko, PJ; Morales, JC; Naka, K; Xia, ZF; Camerini-Otero, RD; Motoyama, N; Carpenter, PB; Bonner, WM; Chen, JJ; Nussenzweig, A			DNA damage-induced G(2)-M checkpoint activation by histone H2AX and 53BP1	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; NUCLEAR FOCI; ATM; PHOSPHORYLATION; KINASE; BRCA1; P53	Activation of the ataxia telangiectasia mutated (ATM) kinase triggers diverse cellular responses to ionizing radiation (IR), including the initiation of cell cycle checkpoints(1). Histone H2AX, p53 binding-protein 1 (53BP1) and Chk2 are targets of ATM-mediated phosphorylation(2-5), but little is known about their roles in signalling the presence of DNA damage. Here, we show that mice lacking either H2AX or 53BP1, but not Chk2, manifest a G2-M checkpoint defect close to that observed in ATM(-/-) cells after exposure to low, but not high, doses of IR. Moreover, H2AX regulates the ability of 53BP1 to efficiently accumulate into IR-induced foci. We propose that at threshold levels of DNA damage, H2AX-mediated concentration of 53BP1 at double-strand breaks is essential for the amplification of signals that might otherwise be insufficient to prevent entry of damaged cells into mitosis.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; NILS, Dept Geriatr Res, Aichi 4748522, Japan; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fernandez-Capetillo, O (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	andre_nussenzweig@nih.gov	Fernandez-Capetillo, Oscar/H-3508-2015; Naka, Kazuhito/X-3756-2019	Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Naka, Kazuhito/0000-0001-6646-6004; Morales, Julio/0000-0002-0854-7866	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Antoccia A, 1997, INT J RADIAT BIOL, V71, P41, DOI 10.1080/095530097144409; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; WANG B, 2002, SCI ONLINE      1003, DOI DOI 10.1126/SCIENCE.1076182; WARD I, UNPUB MOL CELL BIOL; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	28	544	564	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					993	997		10.1038/ncb884	http://dx.doi.org/10.1038/ncb884			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447390				2022-12-25	WOS:000179571800021
J	Reiter, CD; Wang, XD; Tanus-Santos, JE; Hogg, N; Cannon, RO; Schechter, AN; Gladwin, MT				Reiter, CD; Wang, XD; Tanus-Santos, JE; Hogg, N; Cannon, RO; Schechter, AN; Gladwin, MT			Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease	NATURE MEDICINE			English	Article							REGIONAL BLOOD-FLOW; PULMONARY-HYPERTENSION; MEDIATED VASODILATION; ERYTHROCYTES; ERYTHROPOIETIN; AUTOXIDATION; INSTABILITY; CONSUMPTION; ENDOTHELIUM; DETERMINES	Although the deleterious vasoconstrictive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic effects of chronic hemolysis on nitric oxide bioavailability have not been considered or quantified. Central to this investigation is the understanding that nitric oxide reacts at least 1,000 times more rapidly with free hemoglobin solutions than with erythrocytes. We hypothesized that decompartmentalization of hemoglobin into plasma would divert nitric oxide from homeostatic vascular function. We demonstrate here that plasma from patients with sickle-cell disease contains cell-free ferrous hemoglobin, which stoichiometrically consumes micromolar quantities of nitric oxide and abrogates forearm blood flow responses to nitric oxide donor infusions. Therapies that inactivate plasma hemoglobin by oxidation or nitric oxide ligation restore nitric oxide bioavailability. Decompartmentalization of hemoglobin and subsequent dioxygenation of nitric oxide may explain the vascular complications shared by acute and chronic hemolytic disorders.	NIDDK, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Medical College of Wisconsin; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Gladwin, MT (corresponding author), NIDDK, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA.		Tanus-Santos, Jose/A-4451-2008	Schechter, Alan N/0000-0002-5235-9408	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Belhassen L, 2001, BLOOD, V97, P1584, DOI 10.1182/blood.V97.6.1584; BENSINGER TA, 1974, ARCH INTERN MED, V133, P624, DOI 10.1001/archinte.133.4.624; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COIN JT, 1979, J BIOL CHEM, V254, P1178; DE CR, 1995, J CLIN INVEST, V96, P60; deFigueiredo LFP, 1997, J TRAUMA, V42, P847; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Han TH, 2002, P NATL ACAD SCI USA, V99, P7763, DOI 10.1073/pnas.122118299; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kaul DK, 2000, AM J PHYSIOL-HEART C, V278, pH1799, DOI 10.1152/ajpheart.2000.278.6.H1799; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; Nath KA, 2000, AM J PHYSIOL-REG I, V279, pR1949, DOI 10.1152/ajpregu.2000.279.6.R1949; NAUMANN HN, 1971, AM J CLIN PATHOL, V56, P137; POHL U, 1991, BASIC RES CARDIOL, V86, P97; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Ulatowski JA, 1996, CRIT CARE MED, V24, P558, DOI 10.1097/00003246-199604000-00003; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; VOGEL W, 1986, AM J PHYSIOL, V251, P413	48	948	981	2	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1383	1389		10.1038/nm799	http://dx.doi.org/10.1038/nm799			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426562				2022-12-25	WOS:000179552000034
J	Valderrama-Carvajal, H; Cocolakis, E; Lacerte, A; Lee, EH; Krystal, G; Ali, S; Lebrun, JJ				Valderrama-Carvajal, H; Cocolakis, E; Lacerte, A; Lee, EH; Krystal, G; Ali, S; Lebrun, JJ			Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; INOSITOL 5-PHOSPHATASE SHIP; A-INDUCED APOPTOSIS; TARGETED DISRUPTION; B-CELLS; BONE-MARROW; ACTIVATION; PROTEIN; PHOSPHORYLATION; RECEPTOR	Members of the transforming growth factor beta (TGF-beta) family regulate fundamental physiological processes, such as cell growth, differentiation and apoptosis, in almost all cell types(1). As a result, defects in TGF-beta signalling pathways have been linked to uncontrolled cellular proliferation and carcinogenesis(1). Here, we explored the signal transduction mechanisms downstream of the activin/TGF-beta receptors that result in cell growth arrest and apoptosis. We show that in haematopoietic cells, TGF-beta family members regulate apoptosis through expression of the inositol phosphatase SHIP (Src homology 2 (SH2) domain-containing 5' inositol phosphatase), a central regulator of phospholipid metabolism(2). We also demonstrated that the Smad pathway is required in the transcriptional regulation of the SHIP gene. Activin/TGF-beta-induced expression of SHIP results in intracellular changes in the pool of phospholipids, as well as in inhibition of both Akt/PKB (protein kinase B) phosphorylation and cell survival. Our results link phospholipid metabolism to activin/TGF-beta-mediated apoptosis and define TGF-beta family members as potent inducers of SHIP expression.	McGill Univ, Royal Victoria Hosp, Dept Med, Mol Endocrinol Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Div Hematol, Montreal, PQ H3A 1A1, Canada; British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; British Columbia Cancer Agency	Valderrama-Carvajal, H (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Mol Endocrinol Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Lebrun, Jean-Jacques/GNP-5222-2022	Krystal, Gerald/0000-0002-1961-6281				Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Bourgin C, 2002, MOL CELL BIOL, V22, P3744, DOI 10.1128/MCB.22.11.3744-3756.2002; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Horn S, 2001, LEUKEMIA, V15, P112, DOI 10.1038/sj.leu.2401990; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; Krystal G, 1999, INT J BIOCHEM CELL B, V31, P1007, DOI 10.1016/S1357-2725(99)00072-2; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Li DM, 1997, CANCER RES, V57, P2124; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rohrschneider LR, 2000, GENE DEV, V14, P505; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Wolf I, 2000, GENOMICS, V69, P104, DOI 10.1006/geno.2000.6324	29	135	145	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					963	969		10.1038/ncb885	http://dx.doi.org/10.1038/ncb885			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447389				2022-12-25	WOS:000179571800016
J	Cowles, CR; Hirschhorn, JN; Altshuler, D; Lander, ES				Cowles, CR; Hirschhorn, JN; Altshuler, D; Lander, ES			Detection of regulatory variation in mouse genes	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; GILBERTS-SYNDROME; CANDIDATE GENES; EXPRESSION; DNA; DIVERSITY; REGIONS; ASSAY	Functional polymorphism in genes can be classified as coding variation, altering the amino-acid sequence of the encoded protein, or regulatory variation, affecting the level or pattern of expression of the gene. Coding variation can be recognized directly from DNA sequence, and consequently its frequency and characteristics have been extensively described. By contrast, virtually nothing is known about the extent to which gene regulation varies in populations. Yet it is likely that regulatory variants are important in modulating gene function: alterations in gene regulation have been proposed to influence disease susceptibility and to have been the primary substrate for the evolution of species(1). Here, we report a systematic study to assess the extent of cis-acting regulatory variation in 69 genes across four inbred mouse strains. We find that at least four of these genes show allelic differences in expression level of 1.5-fold or greater, and that some of these differences are tissue specific. The results show that the impact of regulatory variants can be detected at a significant frequency in a genomic survey and suggest that such variation may have important consequences for organismal phenotype and evolution. The results indicate that larger-scale surveys in both mouse and human could identify a substantial number of genes with common regulatory variation.	Whitehead Inst, Cambridge, MA 02142 USA; MIT, Ctr Genome Res, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lander@wi.mit.edu	Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107; Hirschhorn, Joel/0000-0002-1650-7901				BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Cambien F, 1999, AM J HUM GENET, V65, P183, DOI 10.1086/302448; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; Grabe Niels, 2002, In Silico Biology, V2, pS1; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KOBAYASHI M, 1995, MOL CELL PROBE, V9, P175, DOI 10.1006/mcpr.1995.0027; Landegren U, 1998, GENOME RES, V8, P769, DOI 10.1101/gr.8.8.769; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; LI WH, 1991, GENETICS, V129, P513; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RaveHarel N, 1997, AM J HUM GENET, V60, P87; SINGERSAM J, 1994, PCR METH APPL, V3, pS48; SYVANEN AC, 1990, GENOMICS, V8, P684, DOI 10.1016/0888-7543(90)90255-S; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097	23	295	307	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2002	32	3					432	437		10.1038/ng992	http://dx.doi.org/10.1038/ng992			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12410233				2022-12-25	WOS:000179034800022
J	Goklany, IM				Goklany, IM			From precautionary principle to risk-risk analysis	NATURE BIOTECHNOLOGY			English	Editorial Material									US Dept Interior, Off Policy Anal, Washington, DC 20240 USA	United States Department of the Interior	Goklany, IM (corresponding author), US Dept Interior, Off Policy Anal, Washington, DC 20240 USA.							Goklany I., 2001, PRECAUTIONARY PRINCI; Miller H, 2000, NAT BIOTECHNOL, V18, P697; POLLAN M, 2001, NY TIMES SUNDAY 0509, V92, P94; Raffensperger C, 1999, PROTECTING PUBLIC HL, P8	4	19	21	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2002	20	11					1075	1075		10.1038/nbt1102-1075	http://dx.doi.org/10.1038/nbt1102-1075			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	611WV	12410243	Bronze			2022-12-25	WOS:000179041500007
J	Covic, L; Misra, M; Badar, J; Singh, C; Kuliopulos, A				Covic, L; Misra, M; Badar, J; Singh, C; Kuliopulos, A			Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation	NATURE MEDICINE			English	Article							CRYSTAL-STRUCTURE; ANTAGONIST; AGGREGATION; REVEALS; PATIENT; CLONING	Transmembrane signaling through G protein-coupled receptors (GPCRs) controls a diverse array of cellular processes including metabolism, growth, motility, adhesion, neuronal signaling and blood coagulation. The numerous GPCRs and their key roles in both normal physiology and disease have made them the target for more than 50% of all prescribed drugs. GPCR agonists and antagonists act on the extracellular side of the receptors, whereas the intracellular surface has not yet been exploited for development of new therapeutic agents. Here, we demonstrate the utility of novel cell-penetrating peptides, termed 'pepducins', that act as intracellular inhibitors of signal transference from receptors to G proteins(1). Attachment of a palmitate lipid to peptides based on the third intracellular loop of protease-activated receptor 1 (PAR1)(2) or PAR4 (refs. 3-5) yielded potent inhibitors of thrombin-mediated aggregation of human platelets. Infusion of the anti-PAR4 pepducin into mice extended bleeding time and protected against systemic platelet activation, consistent with the phenotype of PAR4-deficient mice. We show that pepducins might be used to ascertain the physiological roles of GPCRs and rapidly determine the potential therapeutic value of blockade of a particular signaling pathway.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Div Hematol Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Div Hematol Oncol, 750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu			NHLBI NIH HHS [R01HL57905, R01HL64701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057905, R01HL064701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade-Gordon P, 2001, J PHARMACOL EXP THER, V298, P34; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, THROMB HAEMOSTASIS, V87, P722, DOI 10.1055/s-0037-1613071; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Ma L, 2001, BRIT J PHARMACOL, V134, P701, DOI 10.1038/sj.bjp.0704312; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Seiler SM, 1996, MOL PHARMACOL, V49, P190; Smyth SS, 2001, BLOOD, V98, P1055, DOI 10.1182/blood.V98.4.1055; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	24	215	240	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1161	1165		10.1038/nm760	http://dx.doi.org/10.1038/nm760			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357249				2022-12-25	WOS:000178311000044
J	Dove, A				Dove, A			Seeking sweet relief for diabetes	NATURE BIOTECHNOLOGY			English	Article								Diabetes is a modern-day epidemic in the making, but drug developers are still undecided over the best strategy for its treatment.										Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; FLETCHER L, 2002, NAT BIOTECHNOL, V20, P645; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Ray NF, 1998, DIABETES CARE, V21, P296; Sesti G., 2002, Pharmacogenomics Journal, V2, P25, DOI 10.1038/sj.tpj.6500078; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000	7	6	7	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					977	981		10.1038/nbt1002-977	http://dx.doi.org/10.1038/nbt1002-977			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12355109				2022-12-25	WOS:000178313100010
J	Haendeler, J; Hoffmann, J; Tischler, V; Berk, BC; Zeiher, AM; Dimmeler, S				Haendeler, J; Hoffmann, J; Tischler, V; Berk, BC; Zeiher, AM; Dimmeler, S			Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69	NATURE CELL BIOLOGY			English	Article							NITRIC-OXIDE; MAMMALIAN THIOREDOXIN; ANGIOTENSIN-II; SIGNAL; NO; ANTIOXIDANTS; SUPPRESSION; MODULATION; ACTIVATION; INHIBITOR	Thioredoxin 1 (Trx) is a known redox regulator that is implicated in the redox control of cell growth and apoptosis inhibition. Here we show that Trx is essential for maintaining the content of S-nitrosylated molecules in endothelial cells. Trx itself is S-nitrosylated at cysteine 69 under basal conditions, and this S-nitrosylation is required for scavenging reactive oxygen species and for preserving the redox regulatory activity of Trx. S-nitrosylation of Trx also contributes to the anti-apoptotic function of Trx. Thus, Trx can exert its complete redox regulatory and anti-apoptotic functions in endothelial cells only when cysteine 69 is S-nitrosylated.	Goethe Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	Goethe University Frankfurt; University of Rochester	Haendeler, J (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Tischler, Verena/Q-7263-2017	Tischler, Verena/0000-0002-6673-8329; Berk, Bradford/0000-0002-2767-4115; Haendeler, Judith/0000-0001-8507-4540; Dimmeler, Stefanie/0000-0002-1045-2436				ABELLO PA, 1994, SHOCK, V2, P79, DOI 10.1097/00024382-199408000-00001; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Baker A, 1997, CANCER RES, V57, P5162; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, CIRCULATION, V95, P1760; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 2000, REGUL PEPTIDES, V90, P19, DOI 10.1016/S0167-0115(00)00105-1; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Haendeler J, 2000, CIRC RES, V86, P729, DOI 10.1161/01.RES.86.7.729; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Tsao PS, 1998, J CARDIOVASC PHARM, V32, pS48	43	320	334	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					743	749		10.1038/ncb851	http://dx.doi.org/10.1038/ncb851			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12244325				2022-12-25	WOS:000178316500010
J	Schubert, D				Schubert, D			A different perspective on GM food	NATURE BIOTECHNOLOGY			English	Editorial Material							PROTEOGLYCAN; DISEASE		Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Schubert, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schubert@salk.edu						Atkinson RG, 2002, PLANT PHYSIOL, V129, P122, DOI 10.1104/pp.010986; Gronemeyer H, 2001, CELL MOL BIOL LETT, V6, P3; Kilbourne EM, 1996, J RHEUMATOL, V23, P81; Lappe M., 1999, J MED FOOD, V1, P241, DOI [10.1089/jmf.1998.1.241, DOI 10.1089/JMF.1998.1.241]; Middleton E, 2000, PHARMACOL REV, V52, P673; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; Srivastava M, 1999, MOL MED, V5, P753, DOI 10.1007/BF03402099	8	37	38	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					969	969		10.1038/nbt1002-969	http://dx.doi.org/10.1038/nbt1002-969			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12355105	Bronze			2022-12-25	WOS:000178313100007
J	Bres, V; Kiernan, RE; Linares, LK; Chable-Bessia, C; Plechakova, O; Treand, C; Emiliani, S; Peloponese, JM; Jeang, KT; Coux, O; Scheffner, M; Benkirane, M				Bres, V; Kiernan, RE; Linares, LK; Chable-Bessia, C; Plechakova, O; Treand, C; Emiliani, S; Peloponese, JM; Jeang, KT; Coux, O; Scheffner, M; Benkirane, M			A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter	NATURE CELL BIOLOGY			English	Article							REGULATORY PARTICLE; CYCLIN T1; DEGRADATION; PROTEASOME; MDM2; PROTEIN; IDENTIFICATION; COACTIVATORS; SUBCOMPLEX; ACTIVATION	The human immunodeficiency virus type 1 (HIV-1) encodes a potent transactivator, Tat, which functions through binding to a short leader RNA, called transactivation responsive element (TAR). Recent studies suggest that Tat activates the HIV-1 long terminal repeat (LTR), mainly by adapting co-activator complexes, such as p300, PCAF and the positive transcription elongation factor P-TEFb, to the promoter. Here, we show that the proto-oncoprotein Hdm2 interacts with Tat and mediates its ubiquitination in vitro and in vivo. In addition, Hdm2 is a positive regulator of Tat-mediated transactivation, indicating that the transcriptional properties of Tat are stimulated by ubiquitination. Fusion of ubiquitin to Tat bypasses the requirement of Hdm2 for efficient transactivation, supporting the notion that ubiquitin has a non-proteolytic function in Tat-mediated transactivation.	Inst Human Genet, Mol Virol Lab, CNRS, UPR 1142, Montpellier, France; Univ Cologne, Zentrum Biochem, D-50931 Cologne, Germany; Ctr Rech Biochim Macromol, UPR 1086, Montpellier, France; Inst Cochin Genet Mol, Dept Malad Infect, F-75014 Paris, France; NIAID, Mol Virol Lab, NIH, Bethesda, MD 20892 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Cologne; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Benkirane, M (corresponding author), Inst Human Genet, Mol Virol Lab, CNRS, UPR 1142, Montpellier, France.	bmonsef@igh.cnrs.fr	Jeang, Kuan-Teh/A-2424-2008; Scheffner, Martin/K-2940-2012; Coux, Olivier/P-6847-2019; Kiernan, Rosemary/GXV-8695-2022; Linares, Laetitia LKL/F-9901-2018; Coux, Olivier/B-3406-2010	Scheffner, Martin/0000-0003-2229-0128; Coux, Olivier/0000-0001-8455-3849; Linares, Laetitia LKL/0000-0003-1661-2119; Coux, Olivier/0000-0001-8455-3849; Peloponese, Jean-Marie/0000-0002-9677-9703; Kiernan, Rosemary/0000-0001-6645-0686	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270	32	147	155	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					754	761		10.1038/ncb1023	http://dx.doi.org/10.1038/ncb1023			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12883554				2022-12-25	WOS:000184687300018
J	Zhou, JY; Payen, JF; Wilson, DA; Traystman, RJ; van Zijl, PCM				Zhou, JY; Payen, JF; Wilson, DA; Traystman, RJ; van Zijl, PCM			Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI	NATURE MEDICINE			English	Article							SATURATION-TRANSFER CEST; MAGNETIZATION-TRANSFER; WATER-CONTENT; CONTRAST AGENTS; EXCHANGE; BRAIN; RESONANCE; RAT; SPECTROSCOPY; INVIVO	In the past decade, it has become possible to use the nuclear (proton, H-1) signal of the hydrogen atoms in water for noninvasive assessment of functional and physiological parameters with magnetic resonance imaging (MRI). Here we show that it is possible to produce pH-sensitive MRI contrast by exploiting the exchange between the hydrogen atoms of water and the amide hydrogen atoms of endogenous mobile cellular proteins and peptides. Although amide proton concentrations are in the millimolar range, we achieved a detection sensitivity of several percent on the water signal (molar concentration). The pH dependence of the signal was calibrated in situ, using phosphorus spectroscopy to determine pH, and proton exchange spectroscopy to measure the amide proton transfer rate. To show the potential of amide proton transfer (APT) contrast for detecting acute stroke, pH effects were noninvasively imaged in ischemic rat brain. This observation opens the possibility of using intrinsic pH contrast, as well as protein- and/or peptide-content contrast, as diagnostic tools in clinical imaging.	Johns Hopkins Univ, Sch Med, Dept Radiol, Div MRI Res, Baltimore, MD 21205 USA; Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA; Grenoble Univ, Sch Med, Dept Anesthesiol, F-38000 Grenoble, France; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Johns Hopkins University; Kennedy Krieger Institute; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite de Franche-Comte; Johns Hopkins University	Zhou, JY (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, Div MRI Res, 217 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Van Zijl, Peter C/ABF-3732-2020; Payen, Jean-Francois/L-6667-2014; van Zijl, Peter C/B-8680-2008		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031490] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41 EB015909] Funding Source: Medline; NINDS NIH HHS [NS31490] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aime S, 2002, MAGN RESON MED, V47, P639, DOI 10.1002/mrm.10106; BEHAR KL, 1993, MAGNET RESON MED, V30, P38, DOI 10.1002/mrm.1910300107; COVINGTON AK, 1966, J PHYS CHEM-US, V70, P3820, DOI 10.1021/j100884a011; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; Ewing JR, 1999, MAGN RESON MED, V41, P696, DOI 10.1002/(SICI)1522-2594(199904)41:4<696::AID-MRM7>3.0.CO;2-5; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; Goffeney N, 2001, J AM CHEM SOC, V123, P8628, DOI 10.1021/ja0158455; Hakumaki JM, 2000, TRENDS BIOCHEM SCI, V25, P357, DOI 10.1016/S0968-0004(00)01614-5; HELPERN JA, 1987, MAGNET RESON MED, V5, P302, DOI 10.1002/mrm.1910050313; Henkelman RM, 2001, NMR BIOMED, V14, P57, DOI 10.1002/nbm.683; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; Liepinsh E, 1996, MAGNET RESON MED, V35, P30, DOI 10.1002/mrm.1910350106; Lin WL, 2000, J CEREBR BLOOD F MET, V20, P37, DOI 10.1097/00004647-200001000-00007; Makela HI, 2002, J CEREBR BLOOD F MET, V22, P547; MOON RB, 1973, J BIOL CHEM, V248, P7276; Mori S, 1998, MAGNET RESON MED, V40, P36, DOI 10.1002/mrm.1910400105; Mori S, 1997, J AM CHEM SOC, V119, P6844, DOI 10.1021/ja963351f; Pekar J, 1996, MAGNET RESON MED, V35, P70, DOI 10.1002/mrm.1910350110; SCHOLZ TD, 1993, MAGNET RESON MED, V29, P352, DOI 10.1002/mrm.1910290311; TORACK RM, 1976, J NEUROPATH EXP NEUR, V35, P385, DOI 10.1097/00005072-197607000-00001; Ward KM, 2000, MAGN RESON MED, V44, P799, DOI 10.1002/1522-2594(200011)44:5<799::AID-MRM18>3.0.CO;2-S; Ward KM, 2000, J MAGN RESON, V143, P79, DOI 10.1006/jmre.1999.1956; WOLFF SD, 1990, J MAGN RESON, V86, P164, DOI 10.1016/0022-2364(90)90220-4; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang SR, 2001, J AM CHEM SOC, V123, P1517, DOI 10.1021/ja005820q; Zhou JY, 1998, MAGNET RESON MED, V40, P712, DOI 10.1002/mrm.1910400511	27	815	876	13	158	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1085	1090		10.1038/nm907	http://dx.doi.org/10.1038/nm907			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872167				2022-12-25	WOS:000184484900035
J	Kim, MJ; Park, BJ; Kang, YS; Kim, HJ; Park, JH; Kang, JW; Lee, SW; Han, JM; Lee, HW; Kim, S				Kim, MJ; Park, BJ; Kang, YS; Kim, HJ; Park, JH; Kang, JW; Lee, SW; Han, JM; Lee, HW; Kim, S			Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation	NATURE GENETICS			English	Article							FAR UPSTREAM ELEMENT; SURFACTANT; MICE; GENE; IDENTIFICATION; TRANSCRIPTION; PROLIFERATION; DEFECTS; COMPLEX; GROWTH	p38 is associated with a macromolecular tRNA synthetase complex(1). It has an essential role as a scaffold for the complex, and genetic disruption of p38 in mice causes neonatal lethality(2). Here we investigated the molecular mechanisms underlying lethality of p38-mutant mice. p38-deficient mice showed defects in lung differentiation and respiratory distress syndrome. p38 was found to interact with FUSE-binding protein (FBP), a transcriptional activator of c-myc(3). Binding of p38 stimulated ubiquitination and degradation of FBP, leading to downregulation of c-myc, which is required for differentiation of functional alveolar type II cells. Transforming growth factor-beta (TGF-beta) induced p38 expression and promoted its translocation to nuclei for the regulation of FBP and c-myc. Thus, this work identified a new activity of p38 as a mediator of TGF-beta signaling and its functional importance in the control of c-myc during lung differentiation.	Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Biotechnol Incubat Ctr, Seoul 151742, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Suwon 440746, South Korea	Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU)	Kim, S (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020	Han, Jung Min/0000-0003-3372-7575				Ben-Izhak O, 2002, HISTOPATHOLOGY, V41, P519, DOI 10.1046/j.1365-2559.2002.01444.x; Chinoy MR, 2001, PEDIATR PULM, V32, P129, DOI 10.1002/ppul.1099.abs; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Ehrhardt A, 2001, BRIT J CANCER, V84, P813, DOI 10.1054/bjoc.2000.1676; Griese M, 1999, EUR RESPIR J, V13, P1455, DOI 10.1183/09031936.99.13614779; Guo QM, 2000, CANCER RES, V60, P5922; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; Kang J, 2000, J BIOL CHEM, V275, P31682, DOI 10.1074/jbc.M909965199; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SUGAHARA K, 1994, AM J RESP CELL MOL, V11, P397, DOI 10.1165/ajrcmb.11.4.7917308; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang XJ, 1998, NEUROSCI LETT, V252, P191, DOI 10.1016/S0304-3940(98)00598-9; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	29	141	160	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					330	336		10.1038/ng1182	http://dx.doi.org/10.1038/ng1182			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12819782				2022-12-25	WOS:000183815300023
J	Zeisberg, M; Hanai, J; Sugimoto, H; Mammoto, T; Charytan, D; Strutz, F; Kalluri, R				Zeisberg, M; Hanai, J; Sugimoto, H; Mammoto, T; Charytan, D; Strutz, F; Kalluri, R			BMP-7 counteracts TGF-beta 1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury	NATURE MEDICINE			English	Article							TGF-BETA SUPERFAMILY; E-CADHERIN; SIGNAL-TRANSDUCTION; SMAD PROTEINS; FIBROSIS; PROMOTER; EXPRESSION; INHIBITOR; ELEMENT; CELLS	Bone morphogenic protein (BMP)-7 is a 35-kDa homodimeric protein and a member of the transforming growth factor (TGF)-beta superfamily(1). BMP-7 expression is highest in the kidney, and its genetic deletion in mice leads to severe impairment of eye, skeletal and kidney development(2). Here we report that BMP-7 reverses TGF-beta1-induced epithelial-to-mesenchymal transition (EMT) by reinduction of E-cadherin, a key epithelial cell adhesion molecule(3). Additionally, we provide molecular evidence for Smad-dependent reversal of TGF-beta1-induced EMT by BMP-7 in renal tubular epithelial cells and mammary ductal epithelial cells. In the kidney, EMT-induced accumulation of myofibroblasts and subsequent tubular atrophy are considered key determinants of renal fibrosis during chronic renal injury. We therefore tested the potential of BMP-7 to reverse TGF-beta1-induced de novo EMT in a mouse model of chronic renal injury(4). Our results show that systemic administration of recombinant human BMP-7 leads to repair of severely damaged renal tubular epithelial cells, in association with reversal of chronic renal injury. Collectively, these results provide evidence of cross talk between BMP-7 and TGF-beta1 in the regulation of EMT in health and disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Ctr Matrix Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Ctr Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Ctr Matrix Biol, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; charytan, david/0000-0002-7695-3583	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007199, R01DK051711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55001, T32 DK07199-25, DK 51711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9	28	1108	1199	0	97	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					964	968		10.1038/nm888	http://dx.doi.org/10.1038/nm888			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808448				2022-12-25	WOS:000183979300040
J	Reboul, J; Vaglio, P; Rual, JF; Lamesch, P; Martinez, M; Armstrong, CM; Li, SM; Jacotot, L; Bertin, N; Janky, R; Moore, T; Hudson, JR; Hartley, JL; Brasch, MA; Vandenhaute, J; Boulton, S; Endress, GA; Jenna, S; Chevet, E; Papasotiropoulos, V; Tolias, PP; Ptacek, J; Snyder, M; Huang, R; Chance, MR; Lee, HM; Doucette-Stamm, L; Hill, DE; Vidal, M				Reboul, J; Vaglio, P; Rual, JF; Lamesch, P; Martinez, M; Armstrong, CM; Li, SM; Jacotot, L; Bertin, N; Janky, R; Moore, T; Hudson, JR; Hartley, JL; Brasch, MA; Vandenhaute, J; Boulton, S; Endress, GA; Jenna, S; Chevet, E; Papasotiropoulos, V; Tolias, PP; Ptacek, J; Snyder, M; Huang, R; Chance, MR; Lee, HM; Doucette-Stamm, L; Hill, DE; Vidal, M			C-elegans ORFeome version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression	NATURE GENETICS			English	Article							GENES; IDENTIFICATION; MICROARRAYS; CLONING	To verify the genome annotation and to create a resource to functionally characterize the proteome, we attempted to Gateway-clone all predicted protein-encoding open reading frames (ORFs), or the 'ORFeome,' of Caenorhabditis elegans. We successfully cloned approximately 12,000 ORFs (ORFeome 1.1), of which roughly 4,000 correspond to genes that are untouched by any cDNA or expressed-sequence tag (EST). More than 50% of predicted genes needed corrections in their intron-exon structures. Notably, approximately 11,000 C. elegans proteins can now be expressed under many conditions and characterized using various high-throughput strategies, including large-scale interactome mapping. We suggest that similar ORFeome projects will be valuable for other organisms, including humans.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Fac Univ Notre Dame Paix, Unite Rech Biol Mol, B-5000 Namur, Belgium; Res Genet Invitrogen, Huntsville, AL USA; Life Technol Invitrogen, Rockville, MD USA; Protedyne Crop, Windsor, CT 06095 USA; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; Publ Hlth Res Inst, Ctr Appl Genom, Newark, NJ 07103 USA; Yale Univ, New Haven, CT 06520 USA; Albert Einstein Coll Med, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Genome Therapeut, Waltham, MA 02453 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Namur; Thermo Fisher Scientific; McGill University; Yale University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	marc_vidal@dfci.harvard.edu	Bertin, Nicolas/O-9602-2019; Hill, David E/B-6617-2011; chevet, eric/E-4992-2016; Reboul, Jerome/P-9103-2016; Bertin, Nicolas/C-3025-2008	chevet, eric/0000-0001-5855-4522; Reboul, Jerome/0000-0002-5513-4546; Huang, Raymond/0000-0001-7661-797X; Vaglio, Philippe/0000-0003-2900-5596; Papasotiropoulos, Vasileios/0000-0002-0292-6793; Rual, Jean-Francois/0000-0003-4465-8819; Bertin, Nicolas/0000-0002-9835-9606; Janky, Rekin's/0000-0001-5135-2469				Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Gera JF, 2002, METHOD ENZYMOL, V350, P499, DOI 10.1016/S0076-6879(02)50981-2; Hammarstrom M, 2002, PROTEIN SCI, V11, P313, DOI 10.1110/ps.22102; Harrison PM, 2001, NUCLEIC ACIDS RES, V29, P818, DOI 10.1093/nar/29.3.818; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Hazbun TR, 2001, P NATL ACAD SCI USA, V98, P4277, DOI 10.1073/pnas.091096398; Hillier L, 1991, PCR Methods Appl, V1, P124; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MacBeath G, 2000, SCIENCE, V289, P1760; Mardis E, 2002, GENOME RES, V12, P669, DOI 10.1101/gr.032102; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Oshiro G, 2002, GENOME RES, V12, P1210, DOI 10.1101/gr.226802; Reboul J, 2001, NAT GENET, V27, P332, DOI 10.1038/85913; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Vaglio P, 2003, NUCLEIC ACIDS RES, V31, P237, DOI 10.1093/nar/gkg092; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	30	284	314	0	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2003	34	1					35	41		10.1038/ng1140	http://dx.doi.org/10.1038/ng1140			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12679813				2022-12-25	WOS:000182667900014
J	Reynolds, AR; Tischer, C; Verveer, PJ; Rocks, O; Bastiaens, PIH				Reynolds, AR; Tischer, C; Verveer, PJ; Rocks, O; Bastiaens, PIH			EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation	NATURE CELL BIOLOGY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR; SELF-PHOSPHORYLATION; HYDROGEN-PEROXIDE; KINASE-ACTIVITY; MODEL; AUTOPHOSPHORYLATION; DIMERIZATION; INACTIVATION; TRANSDUCTION	The epidermal growth factor receptor (EGFR) belongs to the receptor tyrosine kinase (RTK) superfamily and is involved in regulating cell proliferation, differentiation and motility(1). Growth factor binding induces receptor oligomerization at the plasma membrane(2-5), which leads to activation of the intrinsic RTK activity and trans-phosphorylation of tyrosine residues in the intracellular part of the receptor(6,7). These residues are docking sites for proteins containing Src homology domain 2 and phosphotyrosine-binding domains that relay the signal inside the cell(8-10). In response to EGF attached to beads, lateral propagation of EGFR phosphorylation occurs at the plasma membrane(11), representing an early amplification step in EGFR signalling. Here we have investigated an underlying reaction network that couples RTK activity to protein tyrosine phosphatase (PTP) inhibition by reactive oxygen species. Mathematical analysis of the chemical kinetic equations of the minimal reaction network detects general properties of this system that can be observed experimentally by imaging EGFR phosphorylation in cells. The existence of a bistable state in this reaction network explains a threshold response and how a high proportion of phosphorylated receptors can be maintained in plasma membrane regions that are not exposed to ligand.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Lincolns Inn Fields Labs, Cell Biophys Lab, Canc Res UK London Res Inst, London WC2A 3PX, England; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	European Molecular Biology Laboratory (EMBL); Cancer Research UK; Max Planck Society	Bastiaens, PIH (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Rocks, Oliver/AFI-7418-2022; Rocks, Oliver/ABG-3341-2020	Rocks, Oliver/0000-0001-6349-9193				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; COCHET C, 1988, J BIOL CHEM, V263, P3290; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HSU CYJ, 1991, J BIOL CHEM, V266, P603; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Murray JD.., 2003, MATH BIOL, DOI DOI 10.1007/B98869; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; PAWSON T, 1988, ONCOGENE, V3, P491; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Verveer PJ, 2000, BIOPHYS J, V78, P2127, DOI 10.1016/S0006-3495(00)76759-2; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	27	170	170	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					447	453		10.1038/ncb981	http://dx.doi.org/10.1038/ncb981			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717446				2022-12-25	WOS:000182691400019
J	Bogdanov, VY; Balasubramanian, V; Hathcock, J; Vele, O; Lieb, M; Nemerson, Y				Bogdanov, VY; Balasubramanian, V; Hathcock, J; Vele, O; Lieb, M; Nemerson, Y			Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein	NATURE MEDICINE			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; SHED MEMBRANE MICROPARTICLES; FACTOR PATHWAY; FACTOR-VIIA; BLOOD; THROMBOSIS; LOCALIZATION; COAGULATION; ANTIBODIES; ACTIVATION	Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVIIa and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation(1). TF is found in adventitia of blood vessels(2) and the lipid core of atherosclerotic plaques(3). In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood(4,5). Biologically active TF has been detected in vessel walls and circulating blood(6). Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease(7-10). It is unclear how TF circulates, although it may be present in pro-coagulant microparticles(11,12). We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.	CUNY Mt Sinai Sch Med, Dept Med, Div Thrombosis Res, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nemerson, Y (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Thrombosis Res, New York, NY 10029 USA.			Bogdanov, Vladimir/0000-0003-4968-1129; Vele, Oana/0000-0002-4132-4832				Ambrose JA, 1997, AM J CARDIOL, V79, P559, DOI 10.1016/S0002-9149(96)00815-6; Amengual O, 1998, THROMB HAEMOSTASIS, V79, P276, DOI 10.1055/s-0037-1614977; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BADIMON L, 1986, ARTERIOSCLEROSIS, V6, P312, DOI 10.1161/01.ATV.6.3.312; BAUMGARTNER HR, 1980, J LAB CLIN MED, V95, P208; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; BERG HC, 1993, RANDOM WALKS BIOL, P37; CARSON SD, 1992, BLOOD COAGUL FIBRIN, V3, P779, DOI 10.1097/00001721-199212000-00012; Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRABOWSKI EF, 1990, BLOOD, V75, P390; Guo WM, 2001, CHINESE MED J-PEKING, V114, P30; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Key NS, 1998, BLOOD, V91, P4216, DOI 10.1182/blood.V91.11.4216.411k15_4216_4223; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814; Pawlinski R, 2002, P NATL ACAD SCI USA, V99, P15333, DOI 10.1073/pnas.242501899; Rosseau S, 2000, J IMMUNOL, V164, P427, DOI 10.4049/jimmunol.164.1.427; Suefuji H, 1997, AM HEART J, V134, P253, DOI 10.1016/S0002-8703(97)70132-7; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; Turitto VT, 1998, THROMB RES, V92, pS25, DOI 10.1016/S0049-3848(98)00157-1; Zaman AG, 2000, ATHEROSCLEROSIS, V149, P251, DOI 10.1016/S0021-9150(99)00479-7; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	25	371	387	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					458	462		10.1038/nm841	http://dx.doi.org/10.1038/nm841			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652293				2022-12-25	WOS:000181987400037
J	Stewart, SA; Ben-Porath, I; Carey, VJ; O'Connor, BF; Hahn, WC; Weinberg, RA				Stewart, SA; Ben-Porath, I; Carey, VJ; O'Connor, BF; Hahn, WC; Weinberg, RA			Erosion of the telomeric single-strand overhang at replicative senescence	NATURE GENETICS			English	Article							NORMAL HUMAN-CELLS; HUMAN FIBROBLASTS; LIFE-SPAN; IN-VITRO; HUMAN-CHROMOSOMES; VIVO; END; LOOP	Cultured primary human cells inevitably enter a state of replicative senescence for which the specific molecular trigger is unknown. We show that the single-strand telomeric overhang, a key component of telomere structure, is eroded at senescence. Expression of telomerase prevents overhang loss, suggesting that this enzyme prevents senescence by maintaining proper telomere structure. In contrast, progressive overhang loss occurs in cells that avoid senescence through the inactivation of p53 and Rb, indicating that overhang erosion is the result of continuous cell division and not a consequence of senescence. We thus provide evidence for a specific molecular alteration in telomere structure at senescence and suggest that this change, rather than overall telomere length, serves to trigger this state.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Channing Lab, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Stewart, Sheila A/C-5213-2012					ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1973, AM J MED SCI, V265, P432, DOI 10.1097/00000441-197306000-00001; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; KARSEDER J, 2002, SCIENCE, V295, P2446; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Stansel RM, 2001, EMBO J, V20, P5532; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	28	256	268	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					492	496		10.1038/ng1127	http://dx.doi.org/10.1038/ng1127			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12652299	Bronze			2022-12-25	WOS:000181928600020
J	Ozawa, T; Sako, Y; Sato, M; Kitamura, T; Umezawa, Y				Ozawa, T; Sako, Y; Sato, M; Kitamura, T; Umezawa, Y			A genetic approach to identifying mitochondrial proteins	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; SUBCELLULAR-LOCALIZATION; SYSTEM; PROTEOMICS; CDNAS	The control of intricate networks within eukaryotic cells relies on differential compartmentalization of proteins. We have developed a method that allows rapid identification of novel proteins compartmentalized in mitochondria by screening large-scale cDNA libraries. The principle is based on reconstitution of split-enhanced green fluorescent protein (EGFP) by protein splicing of DnaE derived from Synechocystis sp. PCC6803. The cDNA libraries are expressed in mammalian cells following infection with retrovirus. If a test protein contains a functional mitochondrial targeting signal (MTS), it translocates into the mitochondrial matrix, where EGFP is then formed by protein splicing. The cells harboring this reconstituted EGFP are screened rapidly by fluorescence-activated cell sorting, and the cDNAs are isolated and identified from the cells. The analysis of 258 cDNAs revealed various MTSs, among which we identified new transcripts corresponding to mitochondrial proteins. This method should provide a means to map proteins distributed within intracellular organelles in a broad range of different tissues and disease states.	Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, Tokyo, Japan; Univ Tokyo, Dept Hematopoiet Factors, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Umezawa, Y (corresponding author), Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan.	umezawa@chem.s.u-tokyo.ac.jp	Kitamura, Toshio/AAA-2071-2021; Sato, Moritoshi/O-2735-2018	Sato, Moritoshi/0000-0002-3095-5831				Bejarano LA, 1999, J CELL SCI, V112, P4207; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kruft V, 2001, PLANT PHYSIOL, V127, P1694, DOI 10.1104/pp.010474; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Lopez MF, 2002, CIRC RES, V90, P380, DOI 10.1161/hh0402.105757; Maltman DJ, 2002, ELECTROPHORESIS, V23, P626, DOI 10.1002/1522-2683(200202)23:4&lt;626::AID-ELPS626&gt;3.0.CO;2-#; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Ozawa T, 2002, SUPRAMOL CHEM, V14, P271, DOI 10.1080/10610270290026185; Ozawa T, 2001, ANAL CHEM, V73, P5866, DOI 10.1021/ac010717k; Ozawa T, 2001, CURR OPIN CHEM BIOL, V5, P578, DOI 10.1016/S1367-5931(00)00244-1; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Ueki N, 1998, NAT BIOTECHNOL, V16, P1338, DOI 10.1038/4315; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WIJK K, 2000, TRENDS PLANT SCI, V5, P420	21	104	118	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					287	293		10.1038/nbt791	http://dx.doi.org/10.1038/nbt791			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12577068				2022-12-25	WOS:000181312500025
J	Chan, B; Lanyi, A; Song, HK; Griesbach, J; Simarro-Grande, M; Poy, F; Howie, D; Sumegi, J; Terhorst, C; Eck, MJ				Chan, B; Lanyi, A; Song, HK; Griesbach, J; Simarro-Grande, M; Poy, F; Howie, D; Sumegi, J; Terhorst, C; Eck, MJ			SAP couples Fyn to SLAM immune receptors	NATURE CELL BIOLOGY			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; GENE-PRODUCT SAP; HUMAN B-LYMPHOCYTES; HEMATOPOIETIC-CELLS; CRYSTAL-STRUCTURE; ENCODING GENE; SH3 DOMAIN; ACTIVATION; MUTATIONS; SURFACE	SAP (SLAM-associated protein) is a small lymphocyte-specific signalling molecule that is defective or absent in patients with X-linked lymphoproliferative syndrome (XLP)(1-3). Consistent with its single src homology 2 (SH2) domain architecture and unusually high affinity for SLAM (also called CD150), SAP has been suggested to function by blocking binding of SHP-2 or other SH2-containing signalling proteins to SLAM receptors(1,4). Additionally, SAP has recently been shown to be required for recruitment and activation of the Src-family kinase FynT after SLAM ligation(5). This signalling 'adaptor' function has been difficult to conceptualize, because unlike typical SH2-adaptor proteins, SAP contains only a single SH2 domain and lacks other recognized protein interaction domains or motifs. Here, we show that the SAP SH2 domain binds to the SH3 domain of FynT and directly couples FynT to SLAM. The crystal structure of a ternary SLAM-SAP-Fyn-SH3 complex reveals that SAP binds the FynT SH3 domain through a surface-surface interaction that does not involve canonical SH3 or SH2 binding interactions. The observed mode of binding to the Fyn-SH3 domain is expected to preclude the auto-inhibited conformation of Fyn, thereby promoting activation of the kinase after recruitment. These findings broaden our understanding of the functional repertoire of SH3 and SH2 domains.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center	Eck, MJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.		Song, Hyun Kyu/D-6763-2016; Simarro, Maria/M-3947-2015	Song, Hyun Kyu/0000-0001-5684-4059; Simarro, Maria/0000-0001-8917-7328				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holdorf AD, 2002, NAT IMMUNOL, V3, P259, DOI 10.1038/ni761; Howie D, 2002, BLOOD, V99, P957, DOI 10.1182/blood.V99.3.957; HOWIE D, IN PRESS BLOOD; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Morra M, 2001, J BIOL CHEM, V276, P36809, DOI 10.1074/jbc.M101305200; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nagy N, 2002, IMMUNOL LETT, V82, P141, DOI 10.1016/S0165-2478(02)00029-9; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SIDORENKO SP, 1993, J IMMUNOL, V151, P4614; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Wang N, 2001, IMMUNOGENETICS, V53, P382, DOI 10.1007/s002510100337; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	30	254	266	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					155	160		10.1038/ncb920	http://dx.doi.org/10.1038/ncb920			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545174				2022-12-25	WOS:000180802100016
J	Lower, KM; Turner, G; Kerr, BA; Mathews, KD; Shaw, MA; Gedeon, AK; Schelley, S; Hoyme, HE; White, SM; Delatycki, MB; Lampe, AK; Clayton-Smith, J; Stewart, H; van Ravenswaay, CMA; de Vries, BBA; Cox, B; Grompe, M; Ross, S; Thomas, P; Mulley, JC; Gecz, J				Lower, KM; Turner, G; Kerr, BA; Mathews, KD; Shaw, MA; Gedeon, AK; Schelley, S; Hoyme, HE; White, SM; Delatycki, MB; Lampe, AK; Clayton-Smith, J; Stewart, H; van Ravenswaay, CMA; de Vries, BBA; Cox, B; Grompe, M; Ross, S; Thomas, P; Mulley, JC; Gecz, J			Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome	NATURE GENETICS			English	Article							LINKED MENTAL-RETARDATION; GENE LOCALIZATION; PROTEINS; FINGER; XLMR; REV	Borjeson-Forssman-Lehmann syndrome (BFLS; OMIM 301900) is characterized by moderate to severe mental retardation, epilepsy, hypogonadism, hypometabolism, obesity with marked gynecomastia, swelling of subcutaneous tissue of the face, narrow palpebral fissure and large but not deformed ears(1). Previously, the gene associated with BFLS was localized to 17 Mb in Xq26-q27 (refs 2-4). We have reduced this interval to roughly 9 Mb containing more than 62 genes. Among these, a novel, widely expressed zinc-finger (plant homeodomain (PHD)-like finger) gene (PHF6) had eight different missense and truncation mutations in seven familial and two sporadic cases of BFLS. Transient transfection studies with PHF6 tagged with green fluorescent protein (GFP) showed diffuse nuclear staining with prominent nucleolar accumulation. Such localization, and the presence of two PHD-like zinc fingers, is suggestive of a role for PHF6 in transcription.	Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA 5001, Australia; Univ Newcastle, Waratah, NSW, Australia; St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England; Univ Iowa Hosp & Clin, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA; Stanford Univ, Sch Med, Dept Pediat, Div Med Genet, Stanford, CA 94305 USA; Royal Childrens Hosp, Genet Hlth Serv, Melbourne, Vic, Australia; Int Ctr Life, Inst Human Genet, Dept Clin Genet, Newcastle Upon Tyne, Tyne & Wear, England; Churchill Hosp, Dept Med Genet, Oxford OX3 7LJ, England; Univ Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Adelaide, Dept Mol Biosci, Adelaide, SA, Australia	Womens & Childrens Hospital Australia; University of Adelaide; University of Newcastle; University of Manchester; University of Iowa; University of Iowa; Stanford University; Royal Children's Hospital Melbourne; Newcastle University - UK; University of Oxford; Radboud University Nijmegen; Oregon Health & Science University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Adelaide	Gecz, J (corresponding author), Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, 72 King William Rd, Adelaide, SA 5006, Australia.		Gedeon, Agi/G-7890-2011; Thomas, Paul Q/K-4497-2012; Delatycki, Martin B/A-5409-2013; Gecz, Jozef/X-3469-2019	Gecz, Jozef/0000-0002-7884-6861; Grompe, Markus/0000-0002-6616-4345; mathews, katherine/0000-0003-4160-0435; Lower, Karen/0000-0003-2196-5234; Hoyme, Harold/0000-0002-1979-693X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BORJESON M, 1962, ACTA MED SCAND, V171, P13; Cabezas DA, 2000, J MED GENET, V37, P663, DOI 10.1136/jmg.37.9.663; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Gecz J, 2000, GENOMICS, V69, P242, DOI 10.1006/geno.2000.6326; Gedeon AK, 1996, AM J MED GENET, V64, P121, DOI 10.1002/(SICI)1096-8628(19960712)64:1<121::AID-AJMG20>3.0.CO;2-O; Gedeon AK, 1996, AM J MED GENET, V64, P63, DOI 10.1002/(SICI)1096-8628(19960712)64:1<63::AID-AJMG9>3.0.CO;2-S; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GUSTAVSON KH, 1993, AM J MED GENET, V45, P654, DOI 10.1002/ajmg.1320450527; Hope TJ, 1999, ARCH BIOCHEM BIOPHYS, V365, P186, DOI 10.1006/abbi.1999.1207; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; MATHEWS KD, 1989, AM J MED GENET, V34, P470, DOI 10.1002/ajmg.1320340403; Meetei AR, 2000, J BIOL CHEM, V275, P38500, DOI 10.1074/jbc.M002734200; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Prives C, 1999, J PATHOL, V187, P112; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SKARE J, 1993, GENOMICS, V16, P254, DOI 10.1006/geno.1993.1169; Stevenson RE, 2000, AM J MED GENET, V97, P174, DOI 10.1002/1096-8628(200023)97:3<174::AID-AJMG1034>3.0.CO;2-4; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; TURNER G, 1989, AM J MED GENET, V34, P463, DOI 10.1002/ajmg.1320340402; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	26	154	158	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					661	665		10.1038/ng1040	http://dx.doi.org/10.1038/ng1040			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12415272				2022-12-25	WOS:000179593000021
J	Palacios, F; Schweitzer, JK; Boshans, RL; D'Souza-Schorey, C				Palacios, F; Schweitzer, JK; Boshans, RL; D'Souza-Schorey, C			ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly	NATURE CELL BIOLOGY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; EPITHELIAL-CELL MIGRATION; TUMOR-METASTASIS; PLASMA-MEMBRANE; MDCK CELLS; E-CADHERIN; RHO; GENE; RAC; TRANSPORT	ARF6-regulated endocytosis of E-cadherin is essential during the disassembly of adherens junctions in epithelial cells. Here, we show that activation of ARF6 promotes clathrin-dependent internalization of E-cadherin and caveolae at the basolateral cell surface. Furthermore, we demonstrate that ARF6-GTP, a constitutively activate form of ARF6, interacts with and recruits Nm23-H1, a nucleoside diphosphate (NDP) kinase that provides a source of GTP for dynamin-dependent fission of coated vesicles during endocytosis. Finally, we show that ARF6-mediated recruitment of Nm-23-H1 to cell junctions is accompanied by a decrease in the cellular levels of Rac1-GTP, consistent with previous findings that Nm23-H1 down-regulates activation of Rac1. These studies provide a molecular basis for ARF6 function in polarized epithelia during adherens junction disassembly.	Univ Notre Dame, Dept Sci Biol, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute	Palacios, F (corresponding author), Univ Notre Dame, Dept Sci Biol, Notre Dame, IN 46556 USA.							Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Benard V, 2002, METHOD ENZYMOL, V345, P349; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Iizuka N, 2001, CANCER LETT, V174, P65, DOI 10.1016/S0304-3835(01)00684-X; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Muller K, 1998, NATO ASI S 4 SCI TEC, V23, P83; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Xiao CZ, 1998, WORLD J GASTROENTERO, V4, P412, DOI 10.3748/wjg.v4.i5.412; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; ZENG ZS, 1994, BRIT J CANCER, V70, P1025, DOI 10.1038/bjc.1994.442	38	257	262	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					929	936		10.1038/ncb881	http://dx.doi.org/10.1038/ncb881			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447393				2022-12-25	WOS:000179571800012
J	John, GR; Shankar, SL; Shafit-Zagardo, B; Massimi, A; Lee, SC; Raine, CS; Brosnan, CF				John, GR; Shankar, SL; Shafit-Zagardo, B; Massimi, A; Lee, SC; Raine, CS; Brosnan, CF			Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation	NATURE MEDICINE			English	Article							NOTCH RECEPTOR; LESIONS; DIFFERENTIATION; ASTROCYTES; MECHANISMS; DISEASE	During mammalian central nervous system (CNS) development, contact-mediated activation of Notch1 receptors on oligodendrocyte precursors by the ligand Jagged1 induces Hes5, which inhibits maturation of these cells. Here we tested whether the Notch pathway is re-expressed in the adult CNS in multiple sclerosis (MS), an inflammatory demyelinating disease in which remyelination is typically limited. We found that transforming growth factor-beta1 (TGF-beta1), a cytokine upregulated in MS, specifically re-induced Jagged1 in primary cultures of human astrocytes. Within and around active MS plaques lacking remyelination, Jagged1 was expressed at high levels by hypertrophic astrocytes, whereas Notch1 and Hes5 localized to cells with an immature oligodendrocyte phenotype, and TGF-beta1 was associated with perivascular extracellular matrix in the same areas. In contrast, there was negligible Jagged1 expression in remyelinated lesions. Experiments in vitro showed that Jagged1 signaling inhibited process outgrowth from primary human oligodendrocytes. These data are the first to implicate the Notch pathway in the limited remyelination in MS. Thus, Notch may represent a potential target for therapeutic intervention in this disease.	Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	John, GR (corresponding author), Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10467 USA.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Massimi, Aldo/0000-0002-1549-386X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038102, R01NS040137, P50NS011920, P01NS011920, R01NS008952] Funding Source: NIH RePORTER; NIMH NIH HHS [MH55477] Funding Source: Medline; NINDS NIH HHS [NS11920, NS38102, NS40137, NS08952] Funding Source: Medline; CSR NIH HHS [RG3020] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CSR NIH HHS		Baranzini SE, 2000, J IMMUNOL, V165, P6576, DOI 10.4049/jimmunol.165.11.6576; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Givogri MI, 2002, J NEUROSCI RES, V67, P309, DOI 10.1002/jnr.10128; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Kondo T, 2000, DEVELOPMENT, V127, P2989; Lassmann H, 1998, J NEUROIMMUNOL, V86, P213, DOI 10.1016/S0165-5728(98)00031-9; LEE SC, 1997, MOL BIOL MULTIPLE SC, P71; Liu J, 1996, J IMMUNOL, V157, P3569; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; MCDONALD WI, 1969, NATURE, V221, P182, DOI 10.1038/221182a0; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Prineas J. W., 1997, GREENFIELDS NEUROPAT, P813; PRINEAS JW, 1990, LAB INVEST, V63, P624; RAINE CS, 1997, TXB NEUROPATHOLOGY, P243; Raine CS, 1997, MULTIPLE SCLEROSIS C, P151; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Stears RL, 2000, PHYSIOL GENOMICS, V3, P93, DOI 10.1152/physiolgenomics.2000.3.2.93; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Wolswijk G, 1998, J NEUROSCI, V18, P601; WU E, 1992, LAB INVEST, V67, P88	31	382	397	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1115	1121		10.1038/nm781	http://dx.doi.org/10.1038/nm781			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357247				2022-12-25	WOS:000178311000038
J	Bernal-Mizrachi, C; Weng, S; Feng, C; Finck, BN; Knutsen, RH; Leone, TC; Coleman, TY; Mecham, RP; Kelly, DP; Semenkovich, CF				Bernal-Mizrachi, C; Weng, S; Feng, C; Finck, BN; Knutsen, RH; Leone, TC; Coleman, TY; Mecham, RP; Kelly, DP; Semenkovich, CF			Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice	NATURE MEDICINE			English	Article							INDUCED INSULIN-RESISTANCE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; RENAL-TRANSPLANT RECIPIENTS; CHAIN FATTY-ACIDS; DEFICIENT MICE; HEPATIC GLUCONEOGENESIS; METABOLIC SYNDROME; COACTIVATOR PGC-1; CUSHINGS-SYNDROME; BLOOD-PRESSURE	Hypertension and diabetes are common side effects of glucocorticoid treatment. To determine whether peroxisome proliferator-activated receptor-alpha (PPAR-alpha) mediates these sequelae, mice deficient in low-density lipoprotein receptor (Ldlr(-/-)), with (Ppara (+/+)) or without (Ppara(-/-)) PPAR-alpha, were treated chronically with dexamethasone. Ppara (+/+), but not Ppara (-/-), mice developed hyperglycemia, hyperinsulinemia and hypertension. Similar effects on glucose metabolism were seen in a different model using C57BL/6 mice. Hepatic gluconeogenic gene expression was increased and insulin-mediated suppression of endogenous glucose production was less effective in dexamethasone-treated Ppara (+/+) mice. Adenoviral reconstitution of PPAR-alpha in the livers of nondiabetic, normotensive, dexamethasone-treated Ppara -/- mice induced hyperglycemia, hyperinsulinemia and increased gluconeogenic gene expression. It also increased blood pressure, renin activity, sympathetic nervous activity and renal sodium retention. Human hepatocytes treated with dexamethasone and the PPAR-alpha agonist Wy14,643 induced PPARA and gluconeogenic gene expression. These results identify hepatic activation of PPAR-alpha as a mechanism underlying glucocorticoid-induced insulin resistance.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.		Kelly, Daniel/ABG-2056-2021	Semenkovich, Clay/0000-0003-1163-1871; Bernal-Mizrachi, Carlos/0000-0002-8991-7522; Finck, Brian/0000-0001-5411-3674	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020091] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG20091] Funding Source: Medline; NIDDK NIH HHS [DK56341, DK20579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrew R, 2002, EXP CLIN ENDOCR DIAB, V110, P284, DOI 10.1055/s-2002-34591; ARNER P, 1983, DIABETES CARE, V6, P23, DOI 10.2337/diacare.6.1.23; Benthem L, 2000, AM J PHYSIOL-ENDOC M, V279, pE1286, DOI 10.1152/ajpendo.2000.279.6.E1286; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernal-Mizrachi C, 2002, ARTERIOSCL THROM VAS, V22, P961, DOI 10.1161/01.ATV.0000019404.65403.71; Dirlewanger M, 2000, CLIN NUTR, V19, P29, DOI 10.1054/clnu.1999.0064; Djurhuus CB, 2002, AM J PHYSIOL-ENDOC M, V283, pE172, DOI 10.1152/ajpendo.00544.2001; Duclos M, 2001, CLIN ENDOCRINOL, V55, P447, DOI 10.1046/j.1365-2265.2001.01384.x; EKSTRAND A, 1992, METABOLISM, V41, P692, DOI 10.1016/0026-0495(92)90306-U; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Goodpaster BH, 1999, DIABETES, V48, P839, DOI 10.2337/diabetes.48.4.839; GREKIN RJ, 1995, HYPERTENSION, V26, P193, DOI 10.1161/01.HYP.26.1.193; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hawkins M, 1999, J BIOL CHEM, V274, P31312, DOI 10.1074/jbc.274.44.31312; Hermanowski-Vosatka A, 2000, BIOCHEM BIOPH RES CO, V279, P330, DOI 10.1006/bbrc.2000.3966; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; HOWLETT TA, 1985, CLIN ENDOCRINOL META, V14, P911, DOI 10.1016/S0300-595X(85)80083-9; HRICIK DE, 1991, TRANSPLANTATION, V51, P374, DOI 10.1097/00007890-199102000-00020; Khani S, 2001, CLIN SCI, V101, P739, DOI 10.1042/cs1010739; Kopf D, 2001, METABOLISM, V50, P929, DOI 10.1053/meta.2001.24928; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Levitt NS, 2000, J CLIN ENDOCR METAB, V85, P4611, DOI 10.1210/jc.85.12.4611; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; ORBACH J, 1973, Q J EXP PHYSIOL CMS, V58, P267, DOI 10.1113/expphysiol.1973.sp002214; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Randich A, 2001, NEUROREPORT, V12, P3101, DOI 10.1097/00001756-200110080-00024; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Schreyer SA, 2002, AM J PHYSIOL-ENDOC M, V282, pE207, DOI 10.1152/ajpendo.2002.282.1.E207; TAPPY L, 1994, J CLIN ENDOCR METAB, V79, P1063, DOI 10.1210/jc.79.4.1063; Tauchmanova L, 2002, J CLIN ENDOCR METAB, V87, P4872, DOI 10.1210/jc.2001-011766; Tordjman K, 2002, J LIPID RES, V43, P936; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; VACCA G, 1994, CARDIOSCIENCE, V5, P261; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Williams LC, 2001, DERMATOL CLIN, V19, P63, DOI 10.1016/S0733-8635(05)70230-8; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	46	163	176	1	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1069	1075		10.1038/nm898	http://dx.doi.org/10.1038/nm898			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847522				2022-12-25	WOS:000184484900032
J	Haberman, RP; Samulski, RJ; McCown, TJ				Haberman, RP; Samulski, RJ; McCown, TJ			Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion	NATURE MEDICINE			English	Article							TERM GENE-EXPRESSION; EPILEPSY; BRAIN; CELLS; STIMULATION	Seizure disorders present an attractive gene therapy target, particularly because viral vectors such as adeno-associated virus (AAV) and lentivirus can stably transduce neurons(1,2,3). When we targeted the N-methyl-D-aspartic acid (NMDA) excitatory amino acid receptor with an AAV-delivered antisense oligonucleotide, however, the promoter determined whether focal seizure sensitivity was significantly attenuated or facilitated(4). One potential means to circumvent this liability would be to express an inhibitory neuroactive peptide and constitutively secrete the peptide from the transduced cell. The neuropeptide galanin can modulate seizure activity in vivo(5,6), and the laminar protein fibronectin is usually secreted through a constitutive pathway(7,8). Initially, inclusion of the fibronectin secretory signal sequence (FIB) 9 in an AAV vector caused significant gene product secretion in vitro. More importantly, the combination of this secretory signal with the coding sequence for the active galanin peptide significantly attenuated in vivo focal seizure sensitivity, even with different promoters, and prevented kainic acid-induced hilar cell death. Thus, neuroactive peptide expression and local secretion provides a new gene therapy platform for the treatment of neurological disorders.	Univ N Carolina, Sch Med, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	McCown, TJ (corresponding author), Univ N Carolina, Sch Med, Gene Therapy Ctr, 7119 Thurston Bowles Bldg,CB 7352, Chapel Hill, NC 27599 USA.				NINDS NIH HHS [NS 35633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BENARI Y, 1990, EUR J NEUROSCI, V2, P62, DOI 10.1111/j.1460-9568.1990.tb00381.x; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Burazin TCD, 2000, EUR J NEUROSCI, V12, P2901, DOI 10.1046/j.1460-9568.2000.00184.x; Crawley JN, 1996, LIFE SCI, V58, P2185, DOI 10.1016/0024-3205(96)00093-8; Criswell HE, 1997, NEUROPHARMACOLOGY, V36, P1641, DOI 10.1016/S0028-3908(97)00169-X; Haberman RP, 2000, J VIROL, V74, P8732, DOI 10.1128/JVI.74.18.8732-8739.2000; Haberman RP, 1998, GENE THER, V5, P1604, DOI 10.1038/sj.gt.3300782; Haberman RP, 2002, MOL THER, V6, P495, DOI 10.1006/mthe.2002.0701; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Hynes RO, 1990, FIBRONECTINS; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Mazarati AM, 1998, J NEUROSCI, V18, P10070; MCCOWN TJ, 1991, BRAIN RES, V567, P25, DOI 10.1016/0006-8993(91)91431-Y; MCCOWN TJ, 1984, EXP NEUROL, V86, P527, DOI 10.1016/0014-4886(84)90087-6; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; NADLER JV, 1981, LIFE SCI, V29, P2031; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Paxinos G, 1988, RAT BRAIN STEREOTAXI; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Sarang SS, 2002, PHYSIOL GENOMICS, V11, P45, DOI 10.1152/physiolgenomics.00064.2002; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zeng G, 1998, BIOTECHNIQUES, V25, P206, DOI 10.2144/98252bm05	26	136	146	1	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1076	1080		10.1038/nm901	http://dx.doi.org/10.1038/nm901			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858168				2022-12-25	WOS:000184484900033
J	Song, WY; Sohn, EJ; Martinoia, E; Lee, YJ; Yang, YY; Jasinski, M; Forestier, C; Hwang, I; Lee, Y				Song, WY; Sohn, EJ; Martinoia, E; Lee, YJ; Yang, YY; Jasinski, M; Forestier, C; Hwang, I; Lee, Y			Engineering tolerance and accumulation of lead and cadmium in transgenic plants	NATURE BIOTECHNOLOGY			English	Article							RESISTANCE-ASSOCIATED PROTEIN; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; INDIAN MUSTARD; YEAST; GLUTATHIONE; TRANSPORT; GENE; PHYTOREMEDIATION; DETOXIFICATION	We have studied the utility of the yeast protein YCF1, which detoxifies cadmium by transporting it into vacuoles, for the remediation of lead and cadmium contamination. We found that the yeast YCF1-deletion mutant DTY167 was hypersensitive to Pb(II) as compared with wild-type yeast. DTY167 cells overexpressing YCF1 were more resistant to Pb( II) and Cd( II) than were wild-type cells, and accumulated more lead and cadmium. Analysis of transgenic Arabidopsis thaliana plants overexpressing YCF1 showed that YCF1 is functionally active and that the plants have enhanced tolerance of Pb( II) and Cd( II) and accumulated greater amounts of these metals. These results suggest that transgenic plants expressing YCF1 may be useful for phytoremediation of lead and cadmium.	POSTECH, Div Mol Life Sci, Natl Res Lab Phytoremediat, Pohang 790784, South Korea; POSTECH, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea; Univ Zurich, Inst Pflanzenbiol, CH-8008 Zurich, Switzerland; CEA Cadarache, DEVM LEMS, CNRS, UMR 163, F-13108 St Paul Les Durance, France	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); University of Zurich; CEA; Centre National de la Recherche Scientifique (CNRS)	Lee, Y (corresponding author), POSTECH, Div Mol Life Sci, Natl Res Lab Phytoremediat, Pohang 790784, South Korea.		FORESTIER, Cyrille/AAX-8921-2021; Martinoia, Enrico/AAH-8712-2021; Jasinski, Michal/AAA-3167-2022; Lee, Youngsook/E-6578-2016; FORESTIER, Cyrille/B-9684-2009	FORESTIER, Cyrille/0000-0003-2141-1303; Lee, Youngsook/0000-0002-5808-9613; Jasinski, Michal/0000-0003-0904-5873				Clemens S, 2002, TRENDS PLANT SCI, V7, P309, DOI 10.1016/S1360-1385(02)02295-1; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Dominguez-Solis JR, 2001, J BIOL CHEM, V276, P9297, DOI 10.1074/jbc.M009574200; Frangne N, 2002, PLANT PHYSIOL, V128, P726, DOI 10.1104/pp.010590; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Lanphear BP, 1998, SCIENCE, V281, P1617, DOI 10.1126/science.281.5383.1617; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; Raskin I., 2000, PHYTOREMEDIATION TOX; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rugh CL, 1996, P NATL ACAD SCI USA, V93, P3182, DOI 10.1073/pnas.93.8.3182; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; Salt DE, 1998, ANNU REV PLANT PHYS, V49, P643, DOI 10.1146/annurev.arplant.49.1.643; SALT DE, 1993, J BIOL CHEM, V268, P12297; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; TOMMASINI R, 1993, Z NATURFORSCH C, V48, P867; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; Zhu YL, 1999, PLANT PHYSIOL, V121, P1169, DOI 10.1104/pp.121.4.1169; Zhu YL, 1999, PLANT PHYSIOL, V119, P73, DOI 10.1104/pp.119.1.73	25	250	290	5	93	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					914	919		10.1038/nbt850	http://dx.doi.org/10.1038/nbt850			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12872132				2022-12-25	WOS:000184484600035
J	Celeste, A; Fernandez-Capetillo, O; Kruhlak, MJ; Pilch, DR; Staudt, DW; Lee, A; Bonner, RF; Bonner, WM; Nussenzweig, A				Celeste, A; Fernandez-Capetillo, O; Kruhlak, MJ; Pilch, DR; Staudt, DW; Lee, A; Bonner, RF; Bonner, WM; Nussenzweig, A			Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; DEPENDENT NUCLEAR-DYNAMICS; MRE11 COMPLEX; GENOMIC INSTABILITY; CELLULAR-RESPONSE; REPAIR; DAMAGE; 53BP1; FOCI; REPLICATION	Histone H2AX is rapidly phosphorylated in the chromatin micro-environment surrounding a DNA double-strand break (DSB). Although H2AX deficiency is not detrimental to life, H2AX is required for the accumulation of numerous essential proteins into irradiation induced foci (IRIF). However, the relationship between IRIF formation, H2AX phosphorylation (gamma-H2AX) and the detection of DNA damage is unclear. Here, we show that the migration of repair and signalling proteins to DSBs is not abrogated in H2AX(-/-) cells, or in H2AX-deficient cells that have been reconstituted with H2AX mutants that eliminate phosphorylation. Despite their initial recruitment to DSBs, numerous factors, including Nbs1, 53BP1 and Brca1, subsequently fail to form IRIF. We propose that gamma-H2AX does not constitute the primary signal required for the redistribution of repair complexes to damaged chromatin, but may function to concentrate proteins in the vicinity of DNA lesions. The differential requirements for factor recruitment to DSBs and sequestration into IRIF may explain why essential regulatory pathways controlling the ability of cells to respond to DNA damage are not abolished in the absence of H2AX.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; NIH, Sect Med Biophys, Lab Integrat & Med Biophys, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.		Fernandez-Capetillo, Oscar/H-3508-2015; Bonner, Robert F/C-6783-2015; Bonner, Robert/GQO-9087-2022	Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Staudt, David/0000-0002-3399-9311	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000265] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000265] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; YAGI H, 1995, J BIOL CHEM, V270, P18759, DOI 10.1074/jbc.270.32.18759; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	27	766	804	0	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					675	U51		10.1038/ncb1004	http://dx.doi.org/10.1038/ncb1004			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12792649				2022-12-25	WOS:000183911600019
J	Miller, HI				Miller, HI			First salvo in transatlantic food fight is far from last word	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	1	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					737	738		10.1038/nbt0703-737	http://dx.doi.org/10.1038/nbt0703-737			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12833087				2022-12-25	WOS:000183886000017
J	Blattman, JN; Grayson, JM; Wherry, EJ; Kaech, SM; Smith, KA; Ahmed, R				Blattman, JN; Grayson, JM; Wherry, EJ; Kaech, SM; Smith, KA; Ahmed, R			Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo	NATURE MEDICINE			English	Article							DIRECT VISUALIZATION; CUTTING EDGE; INTERLEUKIN-2; MEMORY; MICE; LYMPHOCYTES; ACTIVATION; ALPHA; PERSISTENCE; INDUCTION	Interleukin (IL)-2 is currently used to enhance T-cell immunity but can have both positive and negative effects on T cells. To determine whether these opposing results are due to IL-2 acting differently on T cells depending on their stage of differentiation, we examined the effects of IL-2 therapy during the expansion, contraction and memory phases of the T-cell response in lymphocytic choriomeningitis virus (LCMV)-infected mice. IL-2 treatment during the expansion phase was detrimental to the survival of rapidly dividing effector T cells. In contrast, IL-2 therapy was highly beneficial during the death phase, resulting in increased proliferation and survival of virus-specific T cells. IL-2 treatment also increased proliferation of resting memory T cells in mice that controlled the infection. Virus-specific T cells in chronically infected mice also responded to IL-2 resulting in decreased viral burden. Thus, timing of IL-2 administration and differentiation status of the T cell are critical parameters in designing IL-2 therapies.	Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY USA	Emory University; Cornell University	Ahmed, R (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.	ra@microbio.emory.edu	Wherry, John/ABI-1280-2020		NIAID NIH HHS [1F32AI0249-01A1, AI30048] Funding Source: Medline; PHS HHS [A151181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030048, R01AI030048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; COUSENS LP, 1995, J IMMUNOL, V155, P5690; Dai ZH, 2000, J IMMUNOL, V165, P3031, DOI 10.4049/jimmunol.165.6.3031; Davey RT, 2000, JAMA-J AM MED ASSOC, V284, P183, DOI 10.1001/jama.284.2.183; GILLIS S, 1978, J EXP MED, V148, P18, DOI 10.1084/jem.148.1.18; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Grayson JM, 2001, J IMMUNOL, V166, P795, DOI 10.4049/jimmunol.166.2.795; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Jin X, 2000, J INFECT DIS, V181, P165, DOI 10.1086/315201; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Komanduri KV, 2001, VIROLOGY, V279, P459, DOI 10.1006/viro.2000.0697; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Kovacs JA, 2001, EUR J IMMUNOL, V31, P1351, DOI 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Kuroda K, 1996, J IMMUNOL, V157, P1422; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; LOTZE MT, 1985, J IMMUNOL, V135, P2865; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; MIER JW, 1988, J CLIN IMMUNOL, V8, P426, DOI 10.1007/BF00916947; Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Smith K A, 2000, HIV Clin Trials, V1, P16, DOI 10.1310/4VD1-WGAU-VX2L-V3JE; Smith KA, 2001, THERAPEUTIC IMMUNOLOGY, SECOND EDITION, P240; Smith KA, 2001, CURR OPIN IMMUNOL, V13, P617, DOI 10.1016/S0952-7915(00)00270-3; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Whitmire JK, 1999, J IMMUNOL, V163, P3194; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	42	301	327	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					540	547		10.1038/nm866	http://dx.doi.org/10.1038/nm866			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692546				2022-12-25	WOS:000182610600034
J	Ditzel, M; Wilson, R; Tenev, T; Zachariou, A; Paul, A; Deas, E; Meier, P				Ditzel, M; Wilson, R; Tenev, T; Zachariou, A; Paul, A; Deas, E; Meier, P			Degradation of DIAP1 by the N-end rule pathway is essential for regulating apoptosis	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-PROTEIN LIGASE; DROSOPHILA CASPASE DRONC; PROGRAMMED CELL-DEATH; IN-VITRO; INHIBITOR; HID; REAPER; GENE; SURVIVAL; LACKING	Some members of the inhibitor of apoptosis (IAP) protein family block apoptosis by binding to and neutralizing active caspases. We recently demonstrated that a physical association between IAP and caspases alone is insufficient to regulate caspases in vivo and that an additional level of control is provided by IAP-mediated ubiquitination of both itself and the associated caspases(1). Here we show that Drosophila IAP 1 (DIAP1)is degraded by the 'N-end rule' pathway and that this process is indispensable for regulating apoptosis. Caspase-mediated cleavage of DIAP1 at position 20 converts the more stable pro-N-degron of DIAP1 into the highly unstable, Asn-bearing, DIAP1 N-degron of the N-end rule degradation pathway. Thus, DIAP1 represents the first known metazoan substrate of the N-end rule pathway that is targeted for degradation through its amino-terminal Asn residue. We demonstrate that the N-end rule pathway is required for regulation of apoptosis induced by Reaper and Hid expression in the Drosophila melanogaster eye. Our data suggest that DIAP1 instability, mediated through caspase activity and subsequent exposure of the N-end rule pathway, is essential for suppression of apoptosis. We suggest that DIAP1 safeguards cell viability through the coordinated mutual destruction of itself and associated active caspases.	Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Meier, P (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, Mary Jean Mitchell Green Bldg,Fulham Rd, London SW3 6JB, England.		Deas, Emma/A-6755-2010	Tenev, Tencho/0000-0001-8762-1069; Meier, Pascal/0000-0003-2760-6523				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Igaki T, 2002, J BIOL CHEM, V277, P23103, DOI 10.1074/jbc.C200222200; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Lisi S, 2000, GENETICS, V154, P669; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sheng J, 2002, EMBO J, V21, P6061, DOI 10.1093/emboj/cdf626; Sijts AJAM, 1997, J BIOL CHEM, V272, P19261, DOI 10.1074/jbc.272.31.19261; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	39	201	204	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					467	473		10.1038/ncb984	http://dx.doi.org/10.1038/ncb984			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12692559				2022-12-25	WOS:000182691400022
J	Ivaska, J; Bosca, L; Parker, PJ				Ivaska, J; Bosca, L; Parker, PJ			PKC epsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1	NATURE CELL BIOLOGY			English	Letter							PROTEIN PHOSPHATASE 2A; KINASE-C-EPSILON; TYROSINE KINASES; ACTIVATION; PDK1; DEPHOSPHORYLATION; DOMAIN; ALPHA; DELTA; ZETA	The critical dependence of receptor-triggered signals on integrin-mediated cell-substrate. interactions represents a fundamental biological paradigm in health and disease. However, the molecular connections of these permissive inputs, which operate through integrin-matrix interactions, has remained largely obscure. Here we show that the serine-threonine kinase protein kinase C epsilon (PKCepsilon) functions as a signal integrator between cytokine and integrin signalling pathways. Integrins are shown to control PKCepsilon phosphorylation acutely by determining complex formation with protein phosphatase 2A (PP2A) and the upstream kinase PDK1 (phosphoinositide-dependent kinase 1). The PP2A-induced loss of PKCepsilon function results in attenuated interferon gamma (INF-gamma)-induced phosphorylation of STAT1 (signal transducer and activator of transcription 1) downstream of Janus kinase 1/2 (JAK1/2). PKCepsilon function and the IFN-gamma response can be recovered by inhibition of PP2A if PDK1 is associated with PKCepsilon in this complex. More directly, a PP2A-resistant mutant of PKCepsilon is sufficient for restoration of the IFN-gamma response in suspension culture. Thus, PKCepsilon functions as a central point of integration through which integrin engagement exerts a permissive input on IFN-gamma signalling.	Canc Res UK London Res Inst, Prot Phosphorylat Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England; CSIC, Inst Bioquim, UCM, Fac Farm, E-28040 Madrid, Spain	Cancer Research UK; Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Ivaska, J (corresponding author), Canc Res UK London Res Inst, Prot Phosphorylat Lab, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	peter.parker@cancer.org.uk	Parker, Peter j/D-5192-2013; Bosca, Lisardo/A-2059-2008	Bosca, Lisardo/0000-0002-0253-5469; Ivaska, Johanna/0000-0002-6295-6556; parker, peter/0000-0002-6218-2933				Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; CARTRILLO A, 2002, J EXP MED, V194, P1231; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; England K, 2001, J BIOL CHEM, V276, P10437, DOI 10.1074/jbc.M009421200; Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P561, DOI 10.1021/bi010719z; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Saito Y, 2002, J BIOL CHEM, V277, P23216, DOI 10.1074/jbc.M200605200; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Srivastava J, 2002, FEBS LETT, V516, P265, DOI 10.1016/S0014-5793(02)02500-0; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	25	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					363	369		10.1038/ncb957	http://dx.doi.org/10.1038/ncb957			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12640464				2022-12-25	WOS:000182080700022
J	O'Driscoll, M; Ruiz-Perez, VL; Woods, CG; Jeggo, PA; Goodship, JA				O'Driscoll, M; Ruiz-Perez, VL; Woods, CG; Jeggo, PA; Goodship, JA			A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome	NATURE GENETICS			English	Article							DNA-DAMAGE; CELLULAR RADIOSENSITIVITY; HISTONE H2AX; CHECKPOINT; GENE; FIBROBLASTS; SEQUENCE	Seckel syndrome (OMIM 210600) is an autosomal recessive disorder characterized by intrauterine growth retardation, dwarfism, microcephaly and mental retardation. Clinically, Seckel syndrome shares features in common with disorders involving impaired DNA-damage responses, such as Nijmegen breakage syndrome (OMIM 251260) and LIG4 syndrome (OMIM 606593). We previously mapped a locus associated with Seckel syndrome to chromosome 3q22.1-q24 in two consanguineous Pakistani families(1). Further marker analysis in the families, including a recently born unaffected child with a recombination in the critical region, narrowed the region to an interval of 5 Mbp between markers D3S1316 and D3S1S57 (145.29 Mbp and 150.37 Mbp). The gene encoding ataxia-telangiectasia and Rad3-related protein (ATR) maps to this region(2,3). A fibroblast cell line derived from an affected individual displays a defective DNA damage response caused by impaired ATR function. We identified a synonymous mutation in affected individuals that alters ATR splicing. The mutation confers a phenotype including marked microcephaly (head circumference 12 s.d. below the mean) and dwarfism (5 s.d. below the mean). Our analysis shows that UV-induced ATR activation can occur in non-replicating cells following processing by nucleotide excision repair.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Sussex; Saint James's University Hospital; University of Leeds; Newcastle University - UK	Jeggo, PA (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	p.a.jeggo@sussex.ac.uk	Ruiz-Perez, Victor L/K-6066-2014; woods, christopher g/A-1361-2010	Ruiz-Perez, Victor L/0000-0003-0635-3619; O'Driscoll, Mark/0000-0003-2765-316X				ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; ARLETT CF, 1992, MUTAT RES, V273, P127, DOI 10.1016/0921-8777(92)90074-D; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 2000, GENE DEV, V14, P397; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Goodship J, 2000, AM J HUM GENET, V67, P498, DOI 10.1086/303023; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Marcou Y, 2001, RADIOTHER ONCOL, V60, P75, DOI 10.1016/S0167-8140(01)00370-X; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	20	590	601	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2003	33	4					497	501		10.1038/ng1129	http://dx.doi.org/10.1038/ng1129			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12640452	Bronze			2022-12-25	WOS:000181928600021
J	O'Connell, CB; Mooseker, MS				O'Connell, CB; Mooseker, MS			Native Myosin-IXb is a plus-, not a minus-end-directed motor	NATURE CELL BIOLOGY			English	Article							ACTIN-BASED MOTOR; PURIFICATION; ASSAY; VI	Myosin-IXb (Myo9b) is a single-headed, processive motor(1,2) that contains a Rho-GTPase-activating protein (GAP) domain within its tail(3,4). Although tail-less myosin-IXb motor domain moves towards the minus end of the actin filament(2), we show here that full-length myosin-IXb is a plus-end-directed motor. This suggests that the tail domain of myosin-IXb regulates motor directionality.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06511 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Mooseker, MS (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06511 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, P01DK055389, R37DK025387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25387, DK 55389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahler M, 2000, BBA-MOL CELL RES, V1496, P52, DOI 10.1016/S0167-4889(00)00008-2; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Post PL, 1998, J CELL SCI, V111, P941; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	15	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					171	U3		10.1038/ncb924	http://dx.doi.org/10.1038/ncb924			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12563277				2022-12-25	WOS:000180802100019
J	Sohn, JH; Bora, PS; Suk, HJ; Molina, H; Kaplan, HJ; Bora, NS				Sohn, JH; Bora, PS; Suk, HJ; Molina, H; Kaplan, HJ; Bora, NS			Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells	NATURE MEDICINE			English	Article							IMMUNE DEVIATION ACAID; GROWTH-FACTOR-BETA; ANTERIOR-CHAMBER; ACQUIRED-IMMUNITY; AQUEOUS-HUMOR; TGF-BETA; B-CELLS; T-CELLS; INDUCTION; PRIVILEGE	Systemic tolerance can be induced by the introduction of antigen into an immune-privileged site. Here we investigated the role of complement in the induction of tolerance after intraocular injection. We found that the development of antigen-specific tolerance is dependent on a complement activation product. The ligation of the complement C3 activation product iC3b to complement receptor type 3 (the iC3b receptor) on antigen-presenting cells resulted in the sequential production of transforming growth factor-beta2 and interleukin-10, which is essential for the induction of tolerance. These observations may extend to the development of both neonatal tolerance and other forms of acquired tolerance.	Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	University of Louisville; Washington University (WUSTL)	Bora, NS (corresponding author), Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.			Bora, Puran/0000-0003-4781-1217	NATIONAL EYE INSTITUTE [R01EY009730, R01EY010543, R01EY013335] Funding Source: NIH RePORTER; NEI NIH HHS [EY 13335, R01 EY013335, EY10543, EY09730] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARVIEUX J, 1988, IMMUNOLOGY, V65, P229; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201; D'Orazio TJ, 1998, J IMMUNOL, V160, P2089; D'Orazio TJ, 1998, IMMUNOLOGY, V95, P47; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; FORIS G, 1983, IMMUNOL LETT, V6, P7, DOI 10.1016/0165-2478(83)90022-6; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; FRITZINGER DC, 1994, P NATL ACAD SCI USA, V91, P12775, DOI 10.1073/pnas.91.26.12775; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hammerberg C, 1998, J EXP MED, V187, P1133, DOI 10.1084/jem.187.7.1133; Hammerberg C, 1996, J IMMUNOL, V157, P5254; HARA Y, 1993, J IMMUNOL, V151, P5162; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; Kabat EA, 1961, EXPT IMMUNOHISTOCHEM, P133; KALLI KR, 1991, J IMMUNOL, V147, P590; KAPLAN HJ, 1977, J IMMUNOL, V118, P809; KAPLAN HJ, 1978, J IMMUNOL, V120, P689; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kosiewicz MM, 1998, J IMMUNOL, V161, P5382; McQuillen DP, 1999, J INFECT DIS, V179, P124, DOI 10.1086/314545; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROSS GD, 1980, J IMMUNOL METHODS, V37, P197, DOI 10.1016/0022-1759(80)90307-5; ROSS GD, 1993, CLIN EXP IMMUNOL, V92, P181; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; Shankland SJ, 1996, KIDNEY INT, V50, P116, DOI 10.1038/ki.1996.294; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Streilein JW, 1999, SPRINGER SEMIN IMMUN, V21, P95; STREILEIN JW, 1981, J EXP MED, V153, P1058, DOI 10.1084/jem.153.5.1058; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; TAYLOR AW, 1994, J IMMUNOL, V153, P1080; TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545; THOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83; Tsuji RF, 1997, J EXP MED, V186, P1015, DOI 10.1084/jem.186.7.1015; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WILBANKS G A, 1992, Regional Immunology, V4, P130; WILBANKS GA, 1990, IMMUNOLOGY, V71, P383; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Yoshida Y, 1998, J IMMUNOL, V161, P5873	45	146	158	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					206	212		10.1038/nm814	http://dx.doi.org/10.1038/nm814			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12514742	Green Accepted			2022-12-25	WOS:000180801900025
J	Szczebara, FM; Chandelier, C; Villeret, C; Masurel, A; Bourot, S; Duport, C; Blanchard, S; Groisillier, A; Testet, E; Costaglioli, P; Cauet, G; Degryse, E; Balbuena, D; Winter, J; Achstetter, T; Spagnoli, R; Pompon, D; Dumas, B				Szczebara, FM; Chandelier, C; Villeret, C; Masurel, A; Bourot, S; Duport, C; Blanchard, S; Groisillier, A; Testet, E; Costaglioli, P; Cauet, G; Degryse, E; Balbuena, D; Winter, J; Achstetter, T; Spagnoli, R; Pompon, D; Dumas, B			Total biosynthesis of hydrocortisone from a simple carbon source in yeast	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; PROGESTERONE; PREGNENOLONE; RECOMBINATION; VECTORS; PLASMID; CLONING	We report on the production of hydrocortisone, the major adrenal glucocorticoid of mammals and an important intermediate of steroidal drug synthesis, from a simple carbon source by recombinant Saccharomyces cerevisiae strains. An artificial and fully self-sufficient biosynthetic pathway involving 13 engineered genes was assembled and expressed in a single yeast strain. Endogenous sterol biosynthesis was rerouted to produce compatible sterols to serve as substrates for the heterologous part of the pathway. Biosynthesis involves eight mammalian proteins (mature forms of CYP11A1, adrenodoxin (ADX), and adrenodoxin reductase (ADR); mitochondrial forms of ADX and CYP11B1; 3beta-HSD, CYP17A1, and CYP21A1). Optimization involved modulating the two mitochondrial systems and disrupting of unwanted side reactions associated with ATF2, GCY1, and YPR1 gene products. Hydrocortisone was the major steroid produced. This work demonstrates the feasibility of transfering a complex biosynthetic pathway from higher eukaryotes into microorganisms.	Avemtis Pharma, Funct Genom, F-93400 Vitry Sur Seine, France; CNRS, Lab Ingn Prot Membranaires, CGM, F-91198 Gif Sur Yvette, France; Univ Bordeaux 2, Ecole Super Tecnol Biomol Bordeux 2, F-33076 Bordeaux, France; Transgene SA, F-67082 Strasbourg, France; Aventis Pharma, Lead Discovery Technol, F-93235 Romainville, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite de Bordeaux; Transgene SA; Sanofi-Aventis; Sanofi France	Dumas, B (corresponding author), Avemtis Pharma, Funct Genom, 13 Quai J Guesdes, F-93400 Vitry Sur Seine, France.	bruno.dumas@aventis.com		Bourot, Stephane/0000-0002-9069-5787				Angermayr M, 1997, MOL GEN GENET, V256, P682, DOI 10.1007/s004380050616; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BURK D, 2000, METHODS YEAST GENETI; Cauet G, 1999, EUR J BIOCHEM, V261, P317, DOI 10.1046/j.1432-1327.1999.00282.x; Dayem LC, 2002, BIOCHEMISTRY-US, V41, P5193, DOI 10.1021/bi015593k; DEGRYSE E, 1995, YEAST, V11, P629, DOI 10.1002/yea.320110704; Degryse E, 1996, GENE, V170, P45, DOI 10.1016/0378-1119(95)00858-6; Degryse E, 1999, J STEROID BIOCHEM, V71, P239, DOI 10.1016/S0960-0760(99)00137-5; DUMAS B, 1994, CYTOCHROME P450, P527; Dumas B, 1996, EUR J BIOCHEM, V238, P495, DOI 10.1111/j.1432-1033.1996.0495z.x; Duport C, 1998, NAT BIOTECHNOL, V16, P186, DOI 10.1038/nbt0298-186; KAPPELI O, 1985, J GEN MICROBIOL, V131, P1411; Lacour T, 1996, GENE, V174, P289, DOI 10.1016/0378-1119(96)00041-8; Lacour T, 1998, J BIOL CHEM, V273, P23984, DOI 10.1074/jbc.273.37.23984; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Milgrom E, 1990, HORMONES MOL DIS, P387; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; SAKAKI T, 1991, PHARMACOGENETICS, V1, P86, DOI 10.1097/00008571-199111000-00005; Shkumatov VM, 2002, BIOCHEMISTRY-MOSCOW+, V67, P456, DOI 10.1023/A:1015290108071; Slater S, 1999, NAT BIOTECHNOL, V17, P1011, DOI 10.1038/13711; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WOODWARD RB, 1952, J AM CHEM SOC, V74, P4223, DOI 10.1021/ja01137a001; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhang Y, 2000, J MOL ENDOCRINOL, V25, P221, DOI 10.1677/jme.0.0250221	30	221	256	6	97	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2003	21	2					143	149		10.1038/nbt775	http://dx.doi.org/10.1038/nbt775			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	642KE	12514739				2022-12-25	WOS:000180802000026
J	Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB				Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB			The orphan nuclear receptor HNF4 alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4	NATURE MEDICINE			English	Article							PREGNANE-X-RECEPTOR; HUMAN CYP2B6 GENE; TRANSCRIPTIONAL REGULATION; VISCERAL ENDODERM; ACTIVATION; EXPRESSION; HNF-4; GASTRULATION; REQUIRES; EMBRYOS	The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is thought to be involved in the metabolism of nearly 50% of all the drugs currently prescribed. Alteration in the activity or expression of this enzyme seems to be a key predictor of drug responsiveness and toxicity(1). Currently available studies indicate that the ligand-activated nuclear receptors pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3) regulate CYP3A4 expression(2,3). However, in cell-based reporter assays, CYP3A4 promoter activity was most pronounced in liver-derived cells and minimal or modest in non-hepatic cells(2), indicating that a liver-specific factor is required for physiological transcriptional response. Here we show that the orphan nuclear receptor hepatocyte nuclear factor-4alpha (HNF4alpha; HNF4A) is critically involved in the PXR- and CAR-mediated transcriptional activation of CYP3A4. We identified a specific cis-acting element in the CYP3A4 gene enhancer that confers HNF4alpha binding and thereby permits PXR- and CAR-mediated gene activation. Fetal mice with conditional deletion of Hnf4alpha had reduced or absent expression of CYP3A. Furthermore, adult mice with conditional hepatic deletion of Hnf4alpha had reduced basal and inducible expression of CYP3A. These data identify HNF4alpha as an important regulator of coordinate nuclear-receptor-mediated response to xenobiotics.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; NCI, Lab Metab, Div Basic Sci, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA	Vanderbilt University; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Kim, RB (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA.	richard.kim@vanderbilt.edu	Lee, Wooin/K-7789-2012; Inoue, Yusuke/O-6207-2018; Schuetz, Erin/N-8087-2018; Kim, Richard/D-6971-2011; Cline, Cynthia D/F-7065-2012	Lee, Wooin/0000-0001-7805-869X; Inoue, Yusuke/0000-0002-9710-7482; Kim, Richard/0000-0001-8148-1632; Duncan, Stephen/0000-0002-2507-7827	NIEHS NIH HHS [ES08658] Funding Source: Medline; NIGMS NIH HHS [GM60346, GM31304, GM54724] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, R55GM054724, R01GM060346, R01GM054724] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Duncan SA, 1997, DEVELOPMENT, V124, P279; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Huss JM, 1998, J BIOL CHEM, V273, P16155, DOI 10.1074/jbc.273.26.16155; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Li JX, 2000, GENE DEV, V14, P464; Ogino M, 1999, ARCH BIOCHEM BIOPHYS, V362, P32, DOI 10.1006/abbi.1998.1012; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Saito T, 2001, J BIOL CHEM, V276, P38010; Schuetz E, 2002, MOL PHARMACOL, V62, P439, DOI 10.1124/mol.62.3.439; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang J, 2001, PHARMACOGENETICS, V11, P555, DOI 10.1097/00008571-200110000-00003	23	374	381	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					220	224		10.1038/nm815	http://dx.doi.org/10.1038/nm815			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12514743				2022-12-25	WOS:000180801900027
J	Haigis, KM; Dove, WF				Haigis, KM; Dove, WF			A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity	NATURE GENETICS			English	Article							WILD HOUSE MICE; MITOTIC RECOMBINATION; INTESTINAL NEOPLASIA; HOMOLOGOUS RECOMBINATION; MOUSE; ADENOMAS; CHROMOSOMES; CANCER; PREDISPOSITION; MULTIPLICITY	In mammals, loss of APC/Apc gatekeeper function initiates intestinal tumorigenesis. Several different mechanisms have been shown or proposed to mediate functional loss of APC/Apc: mutation in APC/Apc, non-disjunction, homologous somatic recombination and epigenetic silencing. The demonstration that, in the C57BL/6 (B6) Apc(Min/+) mouse model of inherited intestinal cancer, loss of Apc function can occur by loss of heterozygosity (LOH) through somatic recombination between homologs presents an opportunity to search for polymorphisms in the homologous somatic recombination pathway. We report that the Robertsonian translocation Rb(7.18)9Lub (Rb9) suppresses the multiplicity of intestinal adenomas in this mouse model. As the copy number of Rb9 increases, the association with the interphase nucleolus of the rDNA repeats centromeric to the Apc locus on Chromosome 18 is increasingly disrupted. Our analysis shows that homologous somatic recombination is the principal pathway for LOH in adenomas in B6 Apc(Min/+) mice. These studies provide additional evidence that neoplastic growth can initiate in the complete absence of canonical genomic instability.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.							BRASCH JM, 1979, CYTOGENET CELL GENET, V24, P122, DOI 10.1159/000131365; Bridger JM, 1998, J CELL SCI, V111, P1241; Cormier RT, 2000, CANCER RES, V60, P3965; DAVISSON MT, 1987, CYTOGENET CELL GENET, V45, P70, DOI 10.1159/000132432; DAVISSON MT, 1993, GENETICS, V133, P649; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P789, DOI 10.2307/2287160; EPPIG JT, 1988, J HERED, V79, P425, DOI 10.1093/oxfordjournals.jhered.a110545; Falconer D. S, 1996, INTRO QUANTITATIVE G; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Frydman N, 2001, HUM REPROD, V16, P2274, DOI 10.1093/humrep/16.11.2274; GARCIABELLIDO A, 1978, MOL GEN GENET, V161, P317, DOI 10.1007/BF00331007; Gould KA, 1996, GENETICS, V144, P1769; GROPP A, 1982, CYTOGENET CELL GENET, V34, P67, DOI 10.1159/000131794; Hagstrom SA, 1999, P NATL ACAD SCI USA, V96, P2952, DOI 10.1073/pnas.96.6.2952; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; LANE PW, 1985, J HERED, V76, P476, DOI 10.1093/oxfordjournals.jhered.a110152; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; LUONGO C, 1994, CANCER RES, V54, P5947; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; MERRIAM JR, 1972, MOL GEN GENET, V115, P294, DOI 10.1007/BF00333168; Merritt AJ, 1997, P NATL ACAD SCI USA, V94, P13927, DOI 10.1073/pnas.94.25.13927; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; Robertson WRB, 1916, J MORPHOL, V27, P179, DOI 10.1002/jmor.1050270202; Rothstein R, 2000, GENE DEV, V14, P1; Shaffer LG, 2000, ANNU REV GENET, V34, P297, DOI 10.1146/annurev.genet.34.1.297; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; SILVER LM, 1981, NATURE, V290, P68, DOI 10.1038/290068a0; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tucker M, 2000, J NATL CANCER I, V92, P530, DOI 10.1093/jnci/92.7.530; Turker MS, 1999, CANCER RES, V59, P4781; WALLACE BMN, 1992, CYTOGENET CELL GENET, V61, P211, DOI 10.1159/000133410	43	73	75	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					33	39		10.1038/ng1055	http://dx.doi.org/10.1038/ng1055			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12447373				2022-12-25	WOS:000180136100014
J	Kashkush, K; Feldman, M; Levy, AA				Kashkush, K; Feldman, M; Levy, AA			Transcriptional activation of retrotransposons alters the expression of adjacent genes in wheat	NATURE GENETICS			English	Article							LONG-TERMINAL REPEATS; TRANSPOSABLE ELEMENTS; ANTISENSE PROMOTER; L1 RETROTRANSPOSON; GENOME EVOLUTION; MAIZE GENOME; WIS 2-1A; ALLOPOLYPLOIDY; METHYLATION; SEQUENCE	Retrotransposons are a principal component of most eukaryotic genomes, representing roughly 40% of the human genome 1 and 50-80% of some grass genomes(2). They are usually transcriptionally silent but can be activated under certain stresses. Despite their considerable contribution to genome structure, their impact on the expression of adjacent genes is not well understood. The steady-state transcript levels originating from Wis 2-1A retrotransposons are much higher in newly synthesized wheat amphiploids (two or more diverged genomes in the same nucleus). On activation, both Wis 2-1A long terminal repeats drive the readout synthesis of new transcripts from adjacent sequences including the antisense or sense strands of known genes. Here we report that activation of these antisense or sense transcripts is associated with silencing or activation of the corresponding genes, respectively. These data, together with the abundance of retrotransposons in genomes and their ability to be activated by various signals, support the view of transposons as potential controlling elements.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Levy, AA (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.	avi.levy@weizmann.ac.il	KASHKUSH, KHALIL/ABT-5599-2022	KASHKUSH, KHALIL/0000-0001-7861-4959				De Keukeleire P, 2001, MOL GENET GENOMICS, V265, P72, DOI 10.1007/s004380000390; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; Feschotte C, 2002, NAT REV GENET, V3, P329, DOI 10.1038/nrg793; Fu HH, 2001, P NATL ACAD SCI USA, V98, P8903, DOI 10.1073/pnas.141221898; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hirochika H, 1996, P NATL ACAD SCI USA, V93, P7783, DOI 10.1073/pnas.93.15.7783; Kashkush K, 2002, GENETICS, V160, P1651; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUCAS H, 1992, MOL BIOL EVOL, V9, P716; MARTIENSSEN R, 1990, GENE DEV, V4, P331, DOI 10.1101/gad.4.3.331; MASSON P, 1987, GENETICS, V117, P117; Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Muniz LM, 2001, GENOME, V44, P979, DOI 10.1139/gen-44-6-979; Nigumann P, 2002, GENOMICS, V79, P628, DOI 10.1006/geno.2002.6758; Ozkan H, 2001, PLANT CELL, V13, P1735, DOI 10.1105/tpc.13.8.1735; POUTEAU S, 1991, EMBO J, V10, P1911, DOI 10.1002/j.1460-2075.1991.tb07717.x; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; SanMiguel PJ, 2002, FUNCT INTEGR GENOMIC, V2, P70, DOI 10.1007/s10142-002-0056-4; Shaked H, 2001, PLANT CELL, V13, P1749, DOI 10.1105/tpc.13.8.1749; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Vicient CM, 2001, PLANT PHYSIOL, V125, P1283, DOI 10.1104/pp.125.3.1283; Vinogradova T, 2002, MOL GENET GENOMICS, V266, P796, DOI 10.1007/s00438-001-0596-7; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; Wicker T, 2001, PLANT J, V26, P307, DOI 10.1046/j.1365-313X.2001.01028.x	26	522	574	1	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					102	106		10.1038/ng1063	http://dx.doi.org/10.1038/ng1063			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12483211				2022-12-25	WOS:000180136100026
J	Bereshchenko, OR; Gu, W; Dalla-Favera, R				Bereshchenko, OR; Gu, W; Dalla-Favera, R			Acetylation inactivates the transcriptional repressor BCL6	NATURE GENETICS			English	Article							CENTER B-CELLS; GERMINAL-CENTER FORMATION; FINGER ENCODING GENE; SOMATIC HYPERMUTATION; HISTONE DEACETYLASES; POZ DOMAIN; P53; LYMPHOMA; PROTEIN; DIFFERENTIATION	The proto-oncogene BCL6 encodes a BTB/POZ-zinc finger transcriptional repressor that is necessary for germinal-center formation and has been implicated in the pathogenesis of B-cell lymphomas. Here we show that the coactivator p300 binds and acetylates BCL6 in vivo and inhibits its function. Acetylation disrupts the ability of BCL6 to recruit histone deacetylases (HDACs), thereby hindering its capacity to repress transcription and to induce cell transformation. BCL6 is acetylated under physiologic conditions in normal germinal-center B cells and in germinal center-derived B-cell tumors. Treatment with specific inhibitors shows that levels of acetylation of BCL6 are controlled by both HDAC-dependent and SIR2-dependent pathways. Pharmacological inhibition of these pathways leads to the accumulation of the inactive acetylated BCL6 and to cell-cycle arrest and apoptosis in B-cell lymphoma cells. These results identify a new mechanism of regulation of the proto-oncogene BCL6 with potential for therapeutic exploitation. Furthermore, these findings provide a new mechanism by which acetylation can promote transcription not only by modifying histones and activating transcriptional activators, but also by inhibiting transcriptional repressors.	Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Dalla-Favera, R (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.			Bereshchenko, Oxana/0000-0002-2772-6042				Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Artiga MJ, 2002, AM J PATHOL, V160, P1371, DOI 10.1016/S0002-9440(10)62564-3; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, J CELL SCI, V114, P2363; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guarente L, 2000, GENE DEV, V14, P1021; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Moller MB, 1999, CLIN CANCER RES, V5, P1085; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	50	328	342	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					606	613		10.1038/ng1018	http://dx.doi.org/10.1038/ng1018			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12402037				2022-12-25	WOS:000179593000012
J	Brindle, JT; Antti, H; Holmes, E; Tranter, G; Nicholson, JK; Bethell, HWL; Clarke, S; Schofield, PM; McKilligin, E; Mosedale, DE; Grainger, DJ				Brindle, JT; Antti, H; Holmes, E; Tranter, G; Nicholson, JK; Bethell, HWL; Clarke, S; Schofield, PM; McKilligin, E; Mosedale, DE; Grainger, DJ			Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics	NATURE MEDICINE			English	Article							NMR-SPECTROSCOPY; SMOKING; RISK	Although a wide range of risk factors for coronary heart disease have been identified from population studies, these measures, singly or in combination, are insufficiently powerful to provide a reliable, noninvasive diagnosis of the presence of coronary heart disease. Here we show that pattern-recognition techniques applied to proton nuclear magnetic resonance (H-1-NMR) spectra of human serum can correctly diagnose not only the presence, but also the severity, of coronary heart disease. Application of supervised partial least squares-discriminant analysis to orthogonal signal-corrected data sets allows >90% of subjects with stenosis of all three major coronary vessels to be distinguished from subjects with angiographically normal coronary arteries, with a specificity of >90%. Our studies show for the first time a technique capable of providing an accurate, noninvasive and rapid diagnosis of coronary heart disease that can be used clinically, either in population screening or to allow effective targeting of treatments such as statins.	Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London, England; Papworth Hosp, NHS Trust, Dept Cardiol, Cambridge CB3 8RE, England; GlaxoSmithKline, Med Res Ctr, Stevenage, Herts, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Papworth Hospital; GlaxoSmithKline	Grainger, DJ (corresponding author), Addenbrookes Hosp, Dept Med, POB 157, Cambridge CB2 2QQ, England.	djg15@cam.ac.uk	Nicholson, Jeremy K/B-3395-2012; Holmes, Elaine/A-2189-2015; Holmes, Elaine/ABE-6606-2020	Nicholson, Jeremy K/0000-0002-8123-8349; Holmes, Elaine/0000-0002-0556-8389; Tranter, George/0000-0002-2877-1785				AlaKorpela M, 1995, NMR BIOMED, V8, P235, DOI 10.1002/nbm.1940080603; AlaKorpela M, 1995, PROG NUCL MAG RES SP, V27, P475, DOI 10.1016/0079-6565(95)01013-0; Cullen P, 1998, EUR HEART J, V19, pC5; Eriksson L., 1999, INTRO MULTI MEGAVARI; Holmes E, 2000, CHEM RES TOXICOL, V13, P471, DOI 10.1021/tx990210t; Isles CG, 2000, QJM-INT J MED, V93, P567, DOI 10.1093/qjmed/93.9.567; KJELSBERG MO, 1986, PREV MED, V15, P254; Kjelsberg MO, 1997, AM J CLIN NUTR, V65, P191; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; Lindon JC, 2001, PROG NUCL MAG RES SP, V39, P1, DOI 10.1016/S0079-6565(00)00036-4; Lindon JC, 2000, CONCEPT MAGNETIC RES, V12, P289, DOI 10.1002/1099-0534(2000)12:5<289::AID-CMR3>3.0.CO;2-W; MCILVAIN HE, 1992, AM J PREV MED, V8, P165, DOI 10.1016/S0749-3797(18)30826-2; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; NICHOLSON JK, 1995, ANAL CHEM, V67, P793, DOI 10.1021/ac00101a004; NICHOLSON JK, 1989, PROG NUCL MAG RES SP, V21, P449, DOI 10.1016/0079-6565(89)80008-1; OTVOS JD, 1997, HDB LIPOPROTEIN TEST, P497; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Storck T, 2002, CURR OPIN DRUG DISC, V5, P90; Wold S, 1998, CHEMOMETR INTELL LAB, V44, P175, DOI 10.1016/S0169-7439(98)00109-9; 1998, NATL STAT DH1, V31	20	875	987	4	184	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1439	1444		10.1038/nm802	http://dx.doi.org/10.1038/nm802			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12447357				2022-12-25	WOS:000179552000042
J	Kielman, MF; Rindapaa, M; Gaspar, C; van Poppel, N; Breukel, C; van Leeuwen, S; Taketo, MM; Roberts, S; Smits, R; Fodde, R				Kielman, MF; Rindapaa, M; Gaspar, C; van Poppel, N; Breukel, C; van Leeuwen, S; Taketo, MM; Roberts, S; Smits, R; Fodde, R			Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling	NATURE GENETICS			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER; MOUSE MODEL; GENES; MUTATION; TUMORS; MICE; EXPRESSION; REGULATORS; ACTIVATION	The Wnt signal-transduction pathway induces the nuclear translocation of membrane-bound beta-catenin (Catnb) and has a key role in cell-fate determination. Tight somatic regulation of this signal is essential, as uncontrolled nuclear accumulation of beta-catenin can cause developmental defects and tumorigenesis in the adult organism. The adenomatous polyposis coli gene (APC) is a major controller of the Wnt pathway and is essential to prevent tumorigenesis in a variety of tissues and organs. Here, we have investigated the effect of different mutations in Apc on the differentiation potential of mouse embryonic stem (ES) cells. We provide genetic and molecular evidence that the ability and sensitivity of ES cells to differentiate into the three germ layers is inhibited by increased doses of beta-catenin by specific Apc mutations. These range from a severe differentiation blockade in Apc alleles completely deficient in beta-catenin regulation to more specific neuroectodermal, dorsal mesodermal and endodermal defects in more hypomorphic alleles. Accordingly, a targeted oncogenic mutation in Catnb also affects the differentiation potential of ES cells. Expression profiling of wildtype and Apc-mutated teratomas supports the differentiation defects at the molecular level and pinpoints a large number of downstream structural and regulating genes. Chimeric experiments showed that this effect is cell-autonomous. Our results imply that constitutive activation of the Apc/beta-catenin signaling pathway results in differentiation defects in tissue homeostasis, and possibly underlies tumorigenesis in the colon and other self-renewing tissues.	Leiden Univ, Med Ctr, Sylvius Lab, Ctr Human & Clin Genet, NL-2333 RA Leiden, Netherlands; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto, Japan; Rosetta Inpharmat, Kirkland, WA USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Kyoto University; Merck & Company	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Sylvius Lab, Ctr Human & Clin Genet, Wassenaarseweg 72, NL-2333 RA Leiden, Netherlands.		Gaspar, Claudia/I-6402-2013; Fodde, Riccardo/AAW-9394-2021	Gaspar, Claudia/0000-0003-1051-0998; Fodde, Riccardo/0000-0001-9839-4324				Boman BM, 2001, CANCER RES, V61, P8408; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen JR, 2001, MOL CELL ENDOCRINOL, V177, P43, DOI 10.1016/S0303-7207(01)00456-7; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Fodde Riccardo, 1995, Critical Reviews in Oncogenesis, V6, P291; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LAMIUM H, 1999, NAT MED, V5, P1071; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Polakis P, 2000, GENE DEV, V14, P1837; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Stevens L C, 1967, Adv Morphog, V6, P1; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamada M, 2000, DEV BIOL, V228, P95, DOI 10.1006/dbio.2000.9927	36	297	312	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					594	605		10.1038/ng1045	http://dx.doi.org/10.1038/ng1045			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12426568				2022-12-25	WOS:000179593000011
J	Kimura, A; Umehara, T; Horikoshi, M				Kimura, A; Umehara, T; Horikoshi, M			Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; YEAST HETEROCHROMATIN; LYSINE RESIDUES; CORE HISTONES; STRAND BREAKS; ACETYLTRANSFERASE; REPRESSION; H3; COMPLEX; PROTEIN	Genes located in chromosomal regions near telomeres are transcriptionally silent, whereas those located in regions away from telomeres are not. Here we show that there is a gradient of acetylation of histone H4 at lysine 16 (H4-Lys16) along a yeast chromosome; this gradient ranges from a hypoacetylated state in regions near the telomere to a hyperacetylated state in more distant regions. The hyperacetylation is regulated by Sas2p, a member of the MYST-type family of histone acetylases, whereas hypoacetylation is under the control of Sir2p, a histone deacetylase. Loss of hyperacetylation is accompanied by an increase in localization of the telomere protein Sir3p and the inactivation of gene expression in telomere-distal regions. Thus, the Sas2p and Sir2p function in concert to regulate transcription in yeast, by acetylating and deacetylating H4-Lys16 in a mechanism that may be common to all eukaryotes.	Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratoey Res Adv Technol, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Dev Biol Lab, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratoey Res Adv Technol, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.		Umehara, Takashi/N-5683-2015; Umehara, Takashi/AHB-1730-2022	Umehara, Takashi/0000-0003-3464-2960; Umehara, Takashi/0000-0003-3464-2960				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; SUKA N, 2002, NATURE GENET, V32; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VegaPalas MA, 1997, NAT GENET, V15, P232, DOI 10.1038/ng0397-232; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	51	290	296	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					370	377		10.1038/ng993	http://dx.doi.org/10.1038/ng993			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12410229				2022-12-25	WOS:000179034800011
J	Sharp, R; Recio, JA; Jhappan, C; Otsuka, T; Liu, SQ; Yu, YL; Liu, WJ; Anver, M; Navid, F; Helman, LJ; DePinho, RA; Merlino, G				Sharp, R; Recio, JA; Jhappan, C; Otsuka, T; Liu, SQ; Yu, YL; Liu, WJ; Anver, M; Navid, F; Helman, LJ; DePinho, RA; Merlino, G			Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis	NATURE MEDICINE			English	Article							SKELETAL-MUSCLE CELLS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; SCATTER-FACTOR; GENE-EXPRESSION; MET RECEPTOR; PROTEIN; DIFFERENTIATION; INHIBITION; ACTIVATION	Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children, yet molecular events associated with the genesis and progression of this potentially fatal disease are largely unknown. For the molecules and pathways that have been implicated, genetic validation has been impeded by lack of a mouse model of RMS. Here we show that simultaneous loss of Ink4a/Arf function and disruption of c-Met signaling in Ink4a/Arf(-/-) mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. In cultured myoblasts, c-Met activation and Ink4a/Arf loss suppress myogenesis in an additive fashion. Our data indicate that human c-MET and INK4a/ARF, situated at the nexus of pathways regulating myogenic growth and differentiation, represent critical targets in RMS pathogenesis. The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer.	NCI, Mol Biol Lab, Bethesda, MD 20892 USA; Frederick Canc Res & Dev Ctr, SAIC, Pathol Histotechnol Lab, Frederick, MD USA; NCI, Pediat Branch, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Merlino, G (corresponding author), NCI, Mol Biol Lab, Bldg 37, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		DePinho, Ronald/0000-0002-5625-577X; Recio, Juan Angel/0000-0002-7320-3832	NATIONAL CANCER INSTITUTE [U01CA084313, Z01BC008756] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA84313-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Allen RE, 1997, METHOD CELL BIOL, V52, P155, DOI 10.1016/S0091-679X(08)60378-7; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Ferracini R, 1996, ONCOGENE, V12, P1697; FILMUS J, 1994, ONCOGENE, V9, P3627; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; Ginsberg JP, 1998, CANCER RES, V58, P3542; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097-4652(200007)184:1<101::AID-JCP11>3.0.CO;2-D; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Otsuka T, 1998, CANCER RES, V58, P5157; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051	39	127	129	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1276	1280		10.1038/nm787	http://dx.doi.org/10.1038/nm787			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368906				2022-12-25	WOS:000179221200034
J	Guan, HP; Li, Y; Jensen, MV; Newgard, CB; Steppan, CM; Lazar, MA				Guan, HP; Li, Y; Jensen, MV; Newgard, CB; Steppan, CM; Lazar, MA			A futile metabolic cycle activated in adipocytes by antidiabetic agents	NATURE MEDICINE			English	Article							OB GENE-EXPRESSION; PPAR-GAMMA; ADIPOSE-TISSUE; RECEPTOR-GAMMA; FATTY-ACIDS; BODY-WEIGHT; ALPHA; GLUCOSE; THIAZOLIDINEDIONE; DIFFERENTIATION	Thiazolidinediones (TZDs) are effective therapies for type 2 diabetes, which has reached epidemic proportions in industrialized societies. TZD treatment reduces circulating free fatty acids (FFAs), which oppose insulin actions in skeletal muscle and other insulin target tissues. Here we report that TZDs, acting as ligands for the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma, markedly induce adipocyte glycerol kinase (GyK) gene expression. This is surprising, as standard textbooks indicate that adipocytes lack GyK and thereby avoid futile cycles of triglyceride breakdown and resynthesis from glycerol and FFAs. By inducing GyK, TZDs markedly stimulate glycerol incorporation into triglyceride and reduce FFA secretion from adipocytes. The 'futile' fuel cycle resulting from expression of GyK in adipocytes is thus a novel mechanism contributing to reduced FFA levels and perhaps insulin sensitization by antidiabetic therapies.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Sarah Stedman Ctr Nutr Studies, Durham, NC USA; Duke Univ, Med Ctr, Dept Pharmacol, Duke Program Diabet Res, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Duke Program Diabet Res, Durham, NC USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Duke University; Duke University; Duke University	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019	Guan, Hong-Ping/0000-0002-2282-3193	NIDDK NIH HHS [DK49780] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Boden G, 2001, ENDOCRIN METAB CLIN, V30, P801, DOI 10.1016/S0889-8529(05)70216-4; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Felig P, 1995, ENDOCRINOL METAB, P1107; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gaudet D, 2000, AM J HUM GENET, V66, P1558, DOI 10.1086/302903; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Huq AHMM, 1997, HUM MOL GENET, V6, P1803, DOI 10.1093/hmg/6.11.1803; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; Jequier E, 1999, PHYSIOL REV, V79, P451, DOI 10.1152/physrev.1999.79.2.451; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KAPLAN ML, 1981, AM J PHYSIOL, V240, pE101, DOI 10.1152/ajpendo.1981.240.2.E101; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; KRUSYNSKA YT, 1997, TXB DIABETES; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li Y, 2002, MOL ENDOCRINOL, V16, P1040, DOI 10.1210/me.16.5.1040; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Matthews CK, 1996, BIOCHEMISTRY-US, P819; Mauvais-Jarvis F, 2001, DIABETES METAB, V27, P415; Mukherjee R, 2000, MOL ENDOCRINOL, V14, P1425, DOI 10.1210/me.14.9.1425; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; ROSEN ED, IN PRESS GENES DEV; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; STEINBERG D, 1961, J BIOL CHEM, V236, P1631; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Stumvoll M, 2002, ANN MED, V34, P217, DOI 10.1080/713782132; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	46	303	317	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1122	1128		10.1038/nm780	http://dx.doi.org/10.1038/nm780			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357248				2022-12-25	WOS:000178311000039
J	Polesello, C; Delon, I; Valenti, P; Ferrer, P; Payre, F				Polesello, C; Delon, I; Valenti, P; Ferrer, P; Payre, F			Dmoesin controls actin-based cell shape and polarity during Drosophila melanogaster oogenesis	NATURE CELL BIOLOGY			English	Article							OSKAR MESSENGER-RNA; ERM FAMILY MEMBERS; FERM DOMAIN; ANTEROPOSTERIOR POLARITY; PLASMA-MEMBRANE; POSTERIOR POLE; BINDING-SITE; LOCALIZATION; CYTOSKELETON; PROTEINS	Ezrin, Radixin and Moesin (ERM) proteins are thought to constitute a bridge between the actin cytoskeleton and the plasma membrane (PM). Here we report a genetic analysis of Dmoesin, the sole member of the ERM family in Drosophila. We show that Dmoesin is required during oogenesis for anchoring microfilaments to the oocyte cortex. Alteration of the actin cytoskeleton resulting from Dmoesin mutations impairs the localization of maternal determinants, thus disrupting antero-posterior polarity. This study also demonstrates the requirement of Dmoesin for the specific organization of cortical microfilaments in nurse cells and, consequently, mutations in Dmoesin produce severe defects in cell shape.	CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Payre, F (corresponding author), CNRS, UMR 5547, Ctr Dev Biol, Bat4R3,118 route Narbonne, F-31062 Toulouse 4, France.		Cédric, POLESELLO/ABC-3406-2021	PAYRE, Francois/0000-0002-8144-6711; Polesello, Cedric/0000-0001-6859-2960				BAKER NE, 1988, DEVELOPMENT, V103, P289; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Baum B, 2000, CURR BIOL, V10, P964, DOI 10.1016/S0960-9822(00)00640-0; Bourbon HM, 2002, MECH DEVELOP, V110, P71, DOI 10.1016/S0925-4773(01)00566-4; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clark IE, 1997, DEVELOPMENT, V124, P461; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; HAY B, 1990, DEVELOPMENT, V109, P425; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Ishikawa H, 2001, J MOL BIOL, V310, P973, DOI 10.1006/jmbi.2001.4818; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lantz VA, 1999, MECH DEVELOP, V85, P111, DOI 10.1016/S0925-4773(99)00096-9; Lee EY, 2001, BBA-GEN SUBJECTS, V1525, P217, DOI 10.1016/S0304-4165(01)00107-6; MacDougall N, 2001, DEVELOPMENT, V128, P665; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Manseau L, 1996, DEVELOPMENT, V122, P2109; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Robinson DN, 1997, ANNU REV CELL DEV BI, V13, P147, DOI 10.1146/annurev.cellbio.13.1.147; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717	45	109	109	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					782	789		10.1038/ncb856	http://dx.doi.org/10.1038/ncb856			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360288				2022-12-25	WOS:000178316500015
J	Kashima, T; Manley, JL				Kashima, T; Manley, JL			A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy	NATURE GENETICS			English	Article							HNRNP A/B PROTEINS; MOTOR-NEURON SMN; IN-VIVO; SILENCER ELEMENT/; SINGLE NUCLEOTIDE; DETERMINING GENE; BINDING-SITES; SR PROTEINS; A1; ASF/SF2	Spinal muscular atrophy (SMA) is a relatively common neurodegenerative disease caused by homozygous loss of the survival motor neuron 1 (SMN1) gene(1). Humans possess a linked, nearly identical gene, SMN2, which produces a functional SMN protein but at levels insufficient to compensate for loss of SMN1 (refs. 1,2). A C/T transition at position +6 in exon 7 is all that differentiates the two genes, but this is sufficient to prevent efficient exon 7 splicing in SMN2 ( refs. 2,3). Here we show that the C/T transition functions not to disrupt an exonic splicing enhancer (ESE) in SMN1 (ref. 4), as previously suggested, but rather to create an exonic splicing silencer (ESS) in SMN2. We show that this ESS functions as a binding site for a known repressor protein, hnRNP A1, which binds to SMN2 but not SMN1 exon 7 RNA. We establish the physiological importance of these results by using small interfering RNAs to reduce hnRNP A protein levels in living cells and show that this results in efficient SMN2 exon 7 splicing. Our findings not only define a new mechanism underlying the inefficient splicing of SMN2 exon 7 but also illustrate more generally the remarkable sensitivity and precision that characterizes control of mRNA splicing.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459				Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Hofmann Y, 2002, HUM MOL GENET, V11, P2037, DOI 10.1093/hmg/11.17.2037; Hou VC, 2002, EMBO J, V21, P6195, DOI 10.1093/emboj/cdf625; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Tange TO, 2001, EMBO J, V20, P5748; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577	30	417	432	0	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2003	34	4					460	463		10.1038/ng1207	http://dx.doi.org/10.1038/ng1207			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12833158				2022-12-25	WOS:000184470500027
J	Ahmed, A; Thompson, J; Emiliusen, L; Murphy, S; Beauchamp, RD; Suzuki, K; Alemany, R; Harrington, K; Vile, RG				Ahmed, A; Thompson, J; Emiliusen, L; Murphy, S; Beauchamp, RD; Suzuki, K; Alemany, R; Harrington, K; Vile, RG			A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization	NATURE BIOTECHNOLOGY			English	Article							INTESTINAL EPITHELIAL-CELLS; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; GENE-EXPRESSION; PROTEIN-KINASE; SUICIDE GENE; 3'-UNTRANSLATED REGION; COMPETENT ADENOVIRUS; CARCINOMA-CELLS; BINDING-PROTEIN	The expression of various proteins associated with rapid responses to inflammation and/or proliferation can be controlled at the level of mRNA stability. Because tumor cells continually recapitulate intracellular programs of proliferation, we have used tumor cell-selective stabilization of mRNA as a means to control therapeutic gene expression. We describe an adenoviral vector that is conditionally replication competent in which expression of the essential adenoviral early region 1A (E1A) gene is regulated by ligation to the 3 untranslated region (UTR) of PTGS2 (also known as COX2), the gene encoding prostaglandin-endoperoxide synthase 2, allowing activated RAS/P-MAPK-specific stabilization of its mRNA. Induction of activated RAS supports replication, whereas matched cells in which activated RAS/P-MAPK is not expressed are very poor substrates for viral replication both in vitro and in vivo. Further tumor-targeting strategies will also be required to prevent viral replication at extratumoral sites where PTGS2 is normally induced. Many different genes contain 3 UTRs that control selective mRNA stability under different physiological, pathological and tumor-associated conditions. Therefore, generating tumor selectivity at the level of mRNA stability is a strategy with broad potential applicability in vector design.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37235 USA; Inst Catala Oncol, Barcelona, Spain; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Mayo Clinic; Mayo Clinic; Vanderbilt University; Catalan Institute of Oncology; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Vile, RG (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.			Harrington, Kevin/0000-0002-6014-348X; Beauchamp, Robert Daniel/0000-0002-8446-4114				Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Bakhle YS, 2001, BRIT J PHARMACOL, V134, P1137, DOI 10.1038/sj.bjp.0704365; BAUER SR, 1989, ONCOGENE, V4, P615; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackburn RV, 1998, CANCER RES, V58, P1358; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chong H, 2002, MOL THER, V5, P195, DOI 10.1006/mthe.2002.0531; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Derrigo M, 2000, INT J MOL MED, V5, P111; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Doyle GA, 2000, CANCER RES, V60, P2756; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HENDERSON BR, 1992, CANCER RES, V52, P2489; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lee CH, 1998, J CELL PHYSIOL, V177, P1; LI Y, 1989, ONCOGENE, V4, P795; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Maity A, 2000, EXP CELL RES, V255, P250, DOI 10.1006/excr.1999.4804; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Maity A, 1997, CELL GROWTH DIFFER, V8, P311; Montero L, 1999, CANCER RES, V59, P5286; Ramachandra M, 2001, NAT BIOTECHNOL, V19, P1035, DOI 10.1038/nbt1101-1035; Ring CJA, 1996, GENE THER, V3, P1094; Rodriguez R, 1997, CANCER RES, V57, P2559; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 2001, CANCER RES, V61, P2670; Siders WM, 1996, CANCER RES, V56, P5638; SIDRANSKY H, 1978, CANCER RES, V38, P1645; STAUBER C, 1988, NUCLEIC ACIDS RES, V16, P9399, DOI 10.1093/nar/16.20.9399; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vile RG, 2000, GENE THER, V7, P2, DOI 10.1038/sj.gt.3301084; Yamamoto M, 2001, MOL THER, V3, P385, DOI 10.1006/mthe.2001.0275	48	39	41	1	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					771	777		10.1038/nbt835	http://dx.doi.org/10.1038/nbt835			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12794639				2022-12-25	WOS:000183886000029
J	Haq, S; Kilter, H; Michael, A; Tao, J; O'Leary, E; Sun, XM; Walters, B; Bhattacharya, K; Chen, X; Cui, L; Andreucci, M; Rosenzweig, A; Guerrero, JL; Patten, R; Liao, R; Molkentin, J; Picard, M; Bonventre, JV; Force, T				Haq, S; Kilter, H; Michael, A; Tao, J; O'Leary, E; Sun, XM; Walters, B; Bhattacharya, K; Chen, X; Cui, L; Andreucci, M; Rosenzweig, A; Guerrero, JL; Patten, R; Liao, R; Molkentin, J; Picard, M; Bonventre, JV; Force, T			Deletion of cytosolic phospholipase A(2) promotes striated muscle growth	NATURE MEDICINE			English	Article							KINASE-C-ZETA; INSULIN-RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; POSTNATAL-GROWTH; TRANSGENIC MICE; FACTOR-I; CARDIOMYOCYTE HYPERTROPHY; PHOSPHOINOSITIDE 3-KINASE; VENTRICULAR HYPERTROPHY; DIFFERENTIAL ACTIVATION	Generation of arachidonic acid by the ubiquitously expressed cytosolic phospholipase A(2) (PLA(2)) has a fundamental role in the regulation of cellular homeostasis, inflammation and tumorigenesis. Here we report that cytosolic PLA(2) is a negative regulator of growth, specifically of striated muscle. We find that normal growth of skeletal muscle, as well as normal and pathologic stress-induced hypertrophic growth of the heart, are exaggerated in Pla2g4a(-/-) mice, which lack the gene encoding cytosolic PLA(2). The mechanism underlying this phenotype is that cytosolic PLA(2) negatively regulates insulin-like growth factor (IGF)-1 signaling. Absence of cytosolic PLA(2) leads to sustained activation of the IGF-1 pathway, which results from the failure of 3-phosphoinositide-dependent protein kinase (PDK)-1 to recruit and phosphorylate protein kinase C (PKC)-zeta, a negative regulator of IGF-1 signaling. Arachidonic acid restores activation of PKC-zeta, correcting the exaggerated IGF-1 signaling. These results indicate that cytosolic PLA(2) and arachidonic acid regulate striated muscle growth by modulating multiple growth-regulatory pathways.	Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Boston University; Boston University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Haq, S (corresponding author), Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.		Rosenzweig, Anthony/AAD-7893-2019; Picard, Michael/F-1567-2013	Picard, Michael/0000-0002-9264-3243; Force, Thomas/0000-0002-0450-8659; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067371, R01HL061688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK050282, R29DK050282] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67371, HL61688] Funding Source: Medline; NIDDK NIH HHS [DK50282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Cittadini A, 2001, ENDOCRINOLOGY, V142, P332, DOI 10.1210/en.142.1.332; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fazio S, 2000, EUR J ENDOCRINOL, V142, P211, DOI 10.1530/eje.0.1420211; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Haq S, 2001, CIRCULATION, V103, P670; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	45	71	72	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					944	951		10.1038/nm891	http://dx.doi.org/10.1038/nm891			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808451				2022-12-25	WOS:000183979300037
J	Nakai, H; Montini, E; Fuess, S; Storm, TA; Grompe, M; Kay, MA				Nakai, H; Montini, E; Fuess, S; Storm, TA; Grompe, M; Kay, MA			AAV serotype 2 vectors preferentially integrate into active genes in mice	NATURE GENETICS			English	Article							IN-VIVO; RETROVIRAL INTEGRATION; HUMAN GENOME; LEUKEMIA; EXPRESSION; THERAPY; SITES; LIVER; NUCLEOSOMES; JUNCTIONS	Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissues(1). In the liver, although stable transgene expression primarily results from extrachromosomal vector genomes(2), a series of experiments has shown that vector genomes integrate into host chromosomes in hepatocytes(3-5) at a low frequency(2). Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mice(6) and two human subjects(7,8) have raised concerns about the potential for rAAV2-mediated insertional mutagenesis. Here we characterize rAAV2-targeted chromosomal integration sites isolated from selected or non-selected hepatocytes in vector-injected mouse livers. We document frequent chromosomal deletions of up to 2 kb at integration sites (14 of 14 integrations, 100%; most of the deletions were <0.3 kb) and preferred integration into genes (21 of 29 integrations, 72%). In addition, all of the targeted genes analyzed (20 of 20 targeted genes, 100%) were expressed in the liver. This is the first report to our knowledge on host chromosomal effects of rAAV2 integration in animals, and it provides insights into the nature of rAAV2 vector integration into chromosomes in quiescent somatic cells in animals and human subjects.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Stanford University; Stanford University; Oregon Health & Science University; Oregon Health & Science University	Kay, MA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, 300 Pasteur Dr,Rm G305A, Stanford, CA 94305 USA.	markay@stanford.edu	Montini, Eugenio/L-1152-2016	Montini, Eugenio/0000-0003-1771-6067; Kay, Mark/0000-0002-2799-2615; Grompe, Markus/0000-0002-6616-4345				CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Chen SJ, 2000, MOL THER, V1, P414, DOI 10.1006/mthe.2000.0065; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leclercq I, 2000, J VIROL, V74, P2305, DOI 10.1128/JVI.74.5.2305-2312.2000; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; Marshall E, 2002, SCIENCE, V298, P34, DOI 10.1126/science.298.5591.34; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Miller DG, 2002, NAT GENET, V30, P147, DOI 10.1038/ng824; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0; Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yang CC, 1997, J VIROL, V71, P9231, DOI 10.1128/JVI.71.12.9231-9247.1997	29	278	297	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					297	302		10.1038/ng1179	http://dx.doi.org/10.1038/ng1179			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12778174				2022-12-25	WOS:000183815300017
J	Hashimshony, T; Zhang, JM; Keshet, I; Bustin, M; Cedar, H				Hashimshony, T; Zhang, JM; Keshet, I; Bustin, M; Cedar, H			The role of DNA methylation in setting up chromatin structure during development	NATURE GENETICS			English	Article							H3 LYSINE-4 METHYLATION; MOUSE EMBRYO; HISTONE H1; BINDING; TRANSCRIPTION; COMPLEX	DNA methylation inhibits gene expression in animal cells, probably by affecting chromatin structure. Biochemical studies suggest that this process may be mediated by methyl-specific binding proteins that recruit enzymatic machinery capable of locally altering histone modification(1). To test whether DNA methylation actually has a role in the assembly of chromatin during normal development, we used cell transfection and a transgene construct genetically programmed to be either methylated or unmethylated in all cell types of the mouse(2). Chromatin immunoprecipitation (ChIP) analysis shows that the presence of DNA methylation brings about the deacetylation of histone H4 and methylation of Lys9 of histone H3 (H3 Lys9) and prevents methylation of Lys4 of histone H3 (H3 Lys4), thus generating a structure identical to that of methylated sequences in the genome. These results indicate that the methylation pattern established in early embryogenesis is profoundly important in setting up the structural profile of the genome.	Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel; NCI, Prot Sect, Mol Carcinogenesis Lab, Div Basic Sci,NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, POB 12272, IL-91120 Jerusalem, Israel.	cedar@md2.huji.ac.il	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [ZIABC004496, Z01BC004496] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; FUKS F, 2002, J BIOL CHEM; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; MONK M, 1987, DEVELOPMENT, V99, P371; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; RENZ M, 1975, P NATL ACAD SCI USA, V72, P733, DOI 10.1073/pnas.72.2.733; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	24	266	276	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2003	34	2					187	192		10.1038/ng1158	http://dx.doi.org/10.1038/ng1158			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12740577				2022-12-25	WOS:000183200500025
J	Tufarelli, C; Stanley, JAS; Garrick, D; Sharpe, JA; Ayyub, H; Wood, WG; Higgs, DR				Tufarelli, C; Stanley, JAS; Garrick, D; Sharpe, JA; Ayyub, H; Wood, WG; Higgs, DR			Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; HUMAN TELOMERIC REGION; ALPHA-GLOBIN; MOUSE EMBRYOS; CPG ISLAND; EXPRESSION; LOCUS; CELLS; MICE; DIFFERENTIATION	Nearly all human genetic disorders result from a limited repertoire of mutations in an associated gene or its regulatory elements. We recently described an individual with an inherited form of anemia (alpha-thalassemia) who has a deletion that results in a truncated, widely expressed gene (LUC7L) becoming juxtaposed to a structurally normal alpha-globin gene (HBA2). Although it retains all of its local and remote cis-regulatory elements, expression of HBA2 is silenced and its CpG island becomes completely methylated early during development. Here we show that in the affected individual, in a transgenic model and in differentiating embryonic stem cells, transcription of antisense RNA mediates silencing and methylation of the associated CpG island. These findings identify a new mechanism underlying human genetic disease.	Univ Oxford, MRC, Mol Haematol Unit, Weatherall Inst Mol Med,John Radcliffe Hosp, Oxford OX3 9DS, England	University of Oxford	Higgs, DR (corresponding author), Univ Oxford, MRC, Mol Haematol Unit, Weatherall Inst Mol Med,John Radcliffe Hosp, Oxford OX3 9DS, England.		Garrick, David/F-1728-2017; GARRICK, David/O-5734-2019; Tufarelli, Cristina/AAD-3265-2019	Garrick, David/0000-0001-7422-7986; GARRICK, David/0000-0001-7422-7986; Tufarelli, Cristina/0000-0002-1053-4618				Barbour VM, 2000, BLOOD, V96, P800, DOI 10.1182/blood.V96.3.800.015k11a_800_807; Baylin Stephen B., 2000, P293; Bedell MA, 1996, NAT GENET, V12, P229, DOI 10.1038/ng0396-229; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; Brown KE, 2001, NAT CELL BIOL, V3, P602, DOI 10.1038/35078577; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cooper D. N., 1993, HUMAN GENE MUTATION; Daniels R, 1997, HUM REPROD, V12, P2251, DOI 10.1093/humrep/12.10.2251; Ehrlich Melanie, 2000, P273; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; FEI YJ, 1988, BRIT J HAEMATOL, V68, P249, DOI 10.1111/j.1365-2141.1988.tb06197.x; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Hardison R., 2001, DISORDERS HEMOGLOBIN, P95, DOI 10.1017/CBO9780511596582; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; KULOZIK AE, 1988, BLOOD, V71, P467; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; MARTIN GR, 1978, NATURE, V271, P829; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; SPIVAK JL, 1973, BLOOD, V42, P257, DOI 10.1182/blood.V42.2.257.257; Tufarelli C, 2001, GENOMICS, V71, P307, DOI 10.1006/geno.2000.6394; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wroe SF, 2000, P NATL ACAD SCI USA, V97, P3342, DOI 10.1073/pnas.050015397; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	43	428	455	1	28	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					157	165		10.1038/ng1157	http://dx.doi.org/10.1038/ng1157			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12730694				2022-12-25	WOS:000183200500021
J	Joseph, SB; Castrillo, A; Laffitte, BA; Mangelsdorf, DJ; Tontonoz, P				Joseph, SB; Castrillo, A; Laffitte, BA; Mangelsdorf, DJ; Tontonoz, P			Reciprocal regulation of inflammation and lipid metabolism by liver X receptors	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; MACROPHAGE-GENE-EXPRESSION; OXIDE SYNTHASE GENE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); REDUCES ATHEROSCLEROSIS; GLUCOCORTICOID RECEPTOR; DEFICIENT MICE; OXIDIZED LDL	Macrophages have important roles in both lipid metabolism and inflammation and are central to the pathogenesis of atherosclerosis. The liver X receptors (LXRs) are established mediators of lipid-inducible gene expression, but their role in inflammation and immunity is unknown. We demonstrate here that LXRs and their ligands are negative regulators of macrophage inflammatory gene expression. Transcriptional profiling of lipopolysaccharide (LPS)-induced macrophages reveals reciprocal LXR-dependent regulation of genes involved in lipid metabolism and the innate immune response. In vitro, LXR ligands inhibit the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase (COX)-2 and interleukin-6 (IL-6) in response to bacterial infection or LPS stimulation. In vivo, LXR agonists reduce inflammation in a model of contact dermatitis and inhibit inflammatory gene expression in the aortas of atherosclerotic mice. These findings identify LXRs as lipid-dependent regulators of inflammatory gene expression that may serve to link lipid metabolism and immune functions in macrophages.	Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA.	ptontonoz@mednet.ucla.edu		Mangelsdorf, David/0000-0002-4355-0796; Joseph, Sean/0000-0002-2602-8517	NHLBI NIH HHS [HL 660881] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Callejas NA, 2000, GASTROENTEROLOGY, V119, P493, DOI 10.1053/gast.2000.9374; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hansson G K, 1999, Curr Atheroscler Rep, V1, P150, DOI 10.1007/s11883-999-0011-0; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte Bryan A, 2002, Curr Atheroscler Rep, V4, P213; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Liu SX, 1998, ATHEROSCLEROSIS, V136, P43, DOI 10.1016/S0021-9150(97)00185-8; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pasterkamp G, 2000, ATHEROSCLEROSIS, V150, P245, DOI 10.1016/S0021-9150(99)00371-8; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wu ZL, 1998, CELL BIOCHEM FUNCT, V16, P153, DOI 10.1002/(SICI)1099-0844(199809)16:3<153::AID-CBF778>3.0.CO;2-T	40	972	1016	2	77	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					213	219		10.1038/nm820	http://dx.doi.org/10.1038/nm820			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12524534				2022-12-25	WOS:000180801900026
J	Koo, B; Pardey, P; Wright, B				Koo, B; Pardey, P; Wright, B			The price of conserving agricultural biodiversity	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA; Univ Calif Berkeley, Dept Agr & Resource Econ, Berkeley, CA 94720 USA	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Berkeley				Wright, Brian/0000-0002-6440-8596				Alston J.M., 2000, INT FOOD POLICY RES; BRENNAN J, 1995, 195 NEW S WAL DEP AG; HARLAN J R, 1972, Journal of Environmental Quality, V1, P212; Koo B, 2000, AM J AGR ECON, V82, P797, DOI 10.1111/0002-9092.00082; National Research Council Committee on Genetic Vulnerability of Major C, 1972, GEN VULN MAJ CROPS; PARDEY P. G., 1996, HIDDEN HARVEST US BE; Pardey PG, 2001, CROP SCI, V41, P1286, DOI 10.2135/cropsci2001.4141286x; Wright BD, 1997, AUST J AGR RESOUR EC, V41, P81, DOI 10.1111/1467-8489.00005	8	12	12	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2003	21	2					126	128		10.1038/nbt0203-126	http://dx.doi.org/10.1038/nbt0203-126			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	642KE	12560828				2022-12-25	WOS:000180802000008
J	Tanentzapf, G; Tepass, U				Tanentzapf, G; Tepass, U			Interactions between the crumbs, lethal giant larvae and bazooka pathways in epithelial polarization	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR GENE; CELL POLARITY; DROSOPHILA STARDUST; RECESSIVE ONCOGENE; MEMBRANE-SKELETON; ZONULA ADHERENS; APICAL MEMBRANE; PROTEIN; JUNCTIONS; HOMOLOG	Several protein complexes that are involved in epithelial apicobasal polarity have been identified(1). However, the mechanism by which these complexes interact to form an integrated polarized cell morphology remains unclear. Crumbs (Crb) and Lethal giant larvae (Lgl) are components of distinct complexes that regulate epithelial polarization in Drosophila melanogaster, but may not interact directly as they localize to the apical and basolateral membrane, respectively(2-9). Nevertheless, a genetic screen identifies marked functional interactions between crb and lgl. These interactions extend to other genes within the crb (stardust, sdt) and lgl (discs large, dig; scribble, scrib) pathways. Our findings suggest that the crb and lgl pathways function competitively to define apical and basolateral surfaces. They also suggest that in the absence of lgl pathway activity, the crb pathway is not required to maintain epithelial polarity. Moreover, we show that crb and lgl cooperate in zonula adherens formation early in development. At later stages, epithelial cells in these mutants acquire normal polarity, indicating the presence of compensatory mechanisms. We find that bazooka (baz) functions redundantly with crb/sdt to support apical polarity at mid- to late-embryogenesis. Despite regaining cell polarity, however, epithelial cells in crb and lgl pathway mutants fail to re-establish normal overall tissue architecture, indicating that the timely acquisition of polarized cell structure is essential for normal tissue organization.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada	University of Toronto	Tepass, U (corresponding author), Univ Cambridge, Wellcome Trust canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1QR, England.	utepass@zoo.utoronto.ca	Tanentzapf, Guy/C-8864-2012	Tanentzapf, Guy/0000-0002-2443-233X				Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chou TB, 1996, GENETICS, V144, P1673; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; FEHON RG, 1994, DEVELOPMENT, V120, P545; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Grawe F, 1996, DEVELOPMENT, V122, P951; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Medina E, 2002, J CELL BIOL, V158, P941, DOI 10.1083/jcb.200203080; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAVER LH, 1994, MOLEN STRUCTURE DETE, V1, P2; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	40	289	294	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					46	52		10.1038/ncb896	http://dx.doi.org/10.1038/ncb896			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510193				2022-12-25	WOS:000180223700012
J	Borgonovo, B; Cocucci, E; Racchetti, G; Podini, P; Bachi, A; Meldolesi, J				Borgonovo, B; Cocucci, E; Racchetti, G; Podini, P; Bachi, A; Meldolesi, J			Regulated exocytosis: a novel, widely expressed system	NATURE CELL BIOLOGY			English	Article							HUMAN GENE AHNAK; PLASMA-MEMBRANE; PC12 CELLS; SUBCELLULAR-LOCALIZATION; DESMOYOKIN/AHNAK PROTEIN; COMPARTMENT; SECRETION; REPAIR; CA2+; TRANSLOCATION	Electrophysiological studies in some secretory and non-secretory cells have identified an extensive form of calcium-induced exocytosis that is rapid (hundreds of milliseconds), insensitive to tetanus toxin and distinct from regulated secretion. We have now identified a marker of the process, desmoyokin-AHNAK, in a clonal derivative of the neuronal cell line, PC12. In resting cells, desmoyokin-AHNAK is localized within the lumen of specific vesicles, but appears on the cell surface during stimulation. Desmoyokin-AHNAK-positive vesicles exist in a variety of cells and tissues and are distinct from the endoplasmic reticulum, Golgi, trans-Golgi, endosomes and lysosomes, and from Glut4 and constitutive secretion vesicles. They seem to be involved in two models of plasmalemma enlargement: differentiation and membrane repair. We therefore propose that these vesicles should be called 'enlargosomes'.	Vita Salute San Raffaele Univ, Dept Neurosci, I-20132 Milan, Italy; Excellence Ctr Cell Differentiat, I-20132 Milan, Italy; Univ Milan, Dept Pharmacol, I-20132 Milan, Italy; IRCCS San Raffaele, I-20132 Milan, Italy; Vita Salute San Raffaele Univ, Dept Cell Pathol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Borgonovo, B (corresponding author), Vita Salute San Raffaele Univ, Dept Neurosci, Via Olgettina 58, I-20132 Milan, Italy.		bachi, angela/B-3527-2015; racchetti, Gabriella/ABG-7347-2020; podini, paola/AAN-4766-2020	bachi, angela/0000-0003-4842-6556; Cocucci, Emanuele/0000-0002-0088-9845; Racchetti, Gabriella/0000-0003-0062-8300	Telethon [1118] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Banerjee A, 1999, J BIOL CHEM, V274, P26518, DOI 10.1074/jbc.274.37.26518; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; Coco S, 1999, J NEUROSCI, V19, P9803; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; Gatti G, 1997, MOL BIOL CELL, V8, P1789, DOI 10.1091/mbc.8.9.1789; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kaether C, 1997, EUR J CELL BIOL, V74, P133; Kasai H, 1999, P NATL ACAD SCI USA, V96, P945, DOI 10.1073/pnas.96.3.945; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; Leoni C, 1999, MOL BIOL CELL, V10, P2919, DOI 10.1091/mbc.10.9.2919; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Malosio ML, 1999, J PHYSIOL-LONDON, V520, P43, DOI 10.1111/j.1469-7793.1999.t01-1-00043.x; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Mellman I, 2000, J CELL BIOL, V149, P529, DOI 10.1083/jcb.149.3.529; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; Paolucci C, 2000, J BIOL CHEM, V275, P19638, DOI 10.1074/jbc.M000511200; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rupnik M, 2000, P NATL ACAD SCI USA, V97, P5627, DOI 10.1073/pnas.090359097; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Skoldberg F, 2002, BIOCHEM BIOPH RES CO, V291, P951, DOI 10.1006/bbrc.2002.6534; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; Thoidis G, 2001, TRAFFIC, V2, P577, DOI 10.1034/j.1600-0854.2001.20807.x; THOMAS P, IN PRESS J PHYSL LON; Togo T, 1999, J CELL SCI, V112, P719; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	45	144	147	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					955	962		10.1038/ncb888	http://dx.doi.org/10.1038/ncb888			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447386				2022-12-25	WOS:000179571800015
J	Glieder, A; Farinas, ET; Arnold, FH				Glieder, A; Farinas, ET; Arnold, FH			Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase	NATURE BIOTECHNOLOGY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; MOLECULAR-DYNAMICS SIMULATIONS; METHANE MONOOXYGENASE; CYTOCHROME P450BM-3; ESCHERICHIA-COLI; SIEVE CATALYSTS; N-ALKANE; OXIDATION; ENZYME; ACID	We have converted cytochrome P450 BM-3 from Bacillus megaterium (P450 BM-3), a medium- chain (C12-C18) fatty acid monooxygenase, into a highly efficient catalyst for the conversion of alkanes to alcohols. The evolved P450 BM-3 exhibits higher turnover rates than any reported biocatalyst for the selective oxidation of hydrocarbons of small to medium chain length (C3-C8). Unlike naturally occurring alkane hydroxylases, the best known of which are the large complexes of methane monooxygenase (MMO) and membrane-associated non-heme iron alkane monooxygenase (AlkB), the evolved enzyme is monomeric, soluble, and requires no additional proteins for catalysis. The evolved alkane hydroxylase was found to be even more active on fatty acids than wild-type BM-3, which was already one of the most efficient fatty acid monooxgenases known. A broad range of substrates including the gaseous alkane propane induces the low to high spin shift that activates the enzyme. This catalyst for alkane hydroxylation at room temperature opens new opportunities for clean, selective hydrocarbon activation for chemical synthesis and bioremediation.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Graz Tech Univ, Inst Biotechnol, A-8010 Graz, Austria	California Institute of Technology; Graz University of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, MC 210-41, Pasadena, CA 91125 USA.			glieder, anton/0000-0002-5986-9689; Farinas, Edgardo/0000-0002-5514-9115; Arnold, Frances H./0000-0002-4027-364X				Appel D, 2001, J BIOTECHNOL, V88, P167, DOI 10.1016/S0168-1656(01)00249-8; ASHRAF W, 1994, FEMS MICROBIOL LETT, V122, P1, DOI 10.1111/j.1574-6968.1994.tb07134.x; BENSON S, 1979, J BACTERIOL, V140, P754, DOI 10.1128/JB.140.3.754-762.1979; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; Chang YT, 2000, BIOCHEMISTRY-US, V39, P2484, DOI 10.1021/bi991966u; Chen HY, 2000, SCIENCE, V287, P1995, DOI 10.1126/science.287.5460.1995; CIRINO PC, 2002, IN PRESS ADV SYNTH C; Farinas ET, 2001, ADV SYNTH CATAL, V343, P601, DOI 10.1002/1615-4169(200108)343:6/7<601::AID-ADSC601>3.0.CO;2-9; Fisher MB, 1998, BIOCHEM BIOPH RES CO, V248, P352, DOI 10.1006/bbrc.1998.8842; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1990, METHOD ENZYMOL, V188, P191; GREEN J, 1989, J BIOL CHEM, V264, P17698; Groves John T., 1995, P3; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Hartmann M, 2000, ANGEW CHEM INT EDIT, V39, P888, DOI 10.1002/(SICI)1521-3773(20000303)39:5<888::AID-ANIE888>3.0.CO;2-R; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; LEADBETTER ER, 1959, NATURE, V184, P1428, DOI 10.1038/1841428a0; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Mathys RG, 1999, BIOTECHNOL BIOENG, V64, P459, DOI 10.1002/(SICI)1097-0290(19990820)64:4<459::AID-BIT9>3.0.CO;2-C; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MODI S, 1995, BIOCHEMISTRY-US, V34, P8982, DOI 10.1021/bi00028a006; Munro Andrew W., 1993, Biochemical Society Transactions, V21, p412S; Murrell JC, 2000, ARCH MICROBIOL, V173, P325, DOI 10.1007/s002030000158; NARHI LO, 1986, J BIOL CHEM, V261, P7160; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAULSEN MD, 1995, PROTEINS, V21, P237, DOI 10.1002/prot.340210306; Reipa V, 1997, P NATL ACAD SCI USA, V94, P13554, DOI 10.1073/pnas.94.25.13554; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Schwaneberg U, 2001, J BIOMOL SCREEN, V6, P111, DOI 10.1177/108705710100600207; Schwaneberg U, 1999, ANAL BIOCHEM, V269, P359, DOI 10.1006/abio.1999.4047; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; Staijen IE, 2000, EUR J BIOCHEM, V267, P1957, DOI 10.1046/j.1432-1327.2000.01196.x; Stevenson JA, 1996, J AM CHEM SOC, V118, P12846, DOI 10.1021/ja963087q; Thomas JM, 2001, ACCOUNTS CHEM RES, V34, P191, DOI 10.1021/ar970020e; TONGE GM, 1977, BIOCHEM J, V161, P333, DOI 10.1042/bj1610333; Watkinson RJ, 1990, BIODEGRADATION, V1, P79, DOI 10.1007/BF00058828; Yeom HY, 1997, ARCH BIOCHEM BIOPHYS, V337, P209, DOI 10.1006/abbi.1996.9763; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258; Zimmer T, 1996, BIOCHEM BIOPH RES CO, V224, P784, DOI 10.1006/bbrc.1996.1100	41	316	340	4	125	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2002	20	11					1135	1139		10.1038/nbt744	http://dx.doi.org/10.1038/nbt744			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	611WV	12368811				2022-12-25	WOS:000179041500025
J	Heaney, AP; Fernando, M; Yong, WH; Melmed, S				Heaney, AP; Fernando, M; Yong, WH; Melmed, S			Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; CUSHINGS-SYNDROME; IN-VITRO; DIFFERENTIAL-DIAGNOSIS; SERUM CORTISOL; RETINOIC ACID; PEROXISOME; DISEASE; ACTIVATION; LIGANDS	Adrenocorticotrophic hormone (ACTH)-secreting pituitary tumors are associated with high morbidity due to excess glucocorticoid production. No suitable drug therapies are currently available, and surgical excision is not invariably curative. Here we demonstrate immunoreactive expression of the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) exclusively in normal ACTH-secreting human anterior pituitary cells: PPAR-gamma was abundantly expressed in all of six human ACTH-secreting pituitary tumors studied. PPAR-gamma activators induced G(0)/G(1) cell-cycle arrest and apoptosis and suppressed ACTH secretion in human and murine corticotroph tumor cells. Development of murine corticotroph tumors, generated by subcutaneous injection of ACTH-secreting AtT20 cells, was prevented in four of five mice treated with the thiazolidinedione compound rosiglitazone, and ACTH and corticosterone secretion was suppressed in all treated mice. Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Pathol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Heaney, AP (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90024 USA.				NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Findling JW, 2001, ENDOCRIN METAB CLIN, V30, P729, DOI 10.1016/S0889-8529(05)70209-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Goldstein BJ, 2000, INT J CLIN PRACT, V54, P333; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2002, OXFORD TXB ENDOCRINO, P109; Hoybye C, 2001, NEUROSURGERY, V49, P284; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRIEGER DT, 1975, NEW ENGL J MED, V293, P893, DOI 10.1056/NEJM197510302931802; Kubota T, 1998, CANCER RES, V58, P3344; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; Melmed S, 2002, J CLIN ENDOCR METAB, V87, P4054, DOI 10.1210/jc.2002-011841; Motomura W, 2000, CANCER RES, V60, P5558; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS EJ, 1982, LANCET, V2, P646; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shimon I, 1998, ANN INTERN MED, V129, P472, DOI 10.7326/0003-4819-129-6-199809150-00009; Simmons NE, 2001, J NEUROSURG, V95, P1, DOI 10.3171/jns.2001.95.1.0001; SONINO N, 1987, NEW ENGL J MED, V317, P812, DOI 10.1056/NEJM198709243171307; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TRAINER PJ, 1994, ENDOCRIN METAB CLIN, V23, P571, DOI 10.1016/S0889-8529(18)30085-9; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; White A, 1998, CLIN ENDOCRINOL, V48, P251, DOI 10.1046/j.1365-2265.1998.00451.x; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116	41	183	191	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1281	1287		10.1038/nm784	http://dx.doi.org/10.1038/nm784			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379847				2022-12-25	WOS:000179221200035
J	Browning, H; Hackney, DD; Nurse, P				Browning, H; Hackney, DD; Nurse, P			Targeted movement of cell end factors in fission yeast	NATURE CELL BIOLOGY			English	Article							SCHIZOSACCHAROMYCES-POMBE; MICROTUBULAR CYTOSKELETON; POLARIZED GROWTH; PLUS-END; KINESIN; PROTEIN; APC; DYNAMICS; EB1; CAPTURE	Kinesins are microtubule-based motor proteins that transport cargo to specific locations within the cell. However, the mechanisms by which cargoes are directed to specific cellular locations have remained elusive. Here, we investigated the in vivo movement of the Schizosaccharomyces pombe kinesin Tea2 to establish how it is targeted to microtubule tips and cell ends. Tea2 is loaded onto microtubules in the middle of the cell, in close proximity to the nucleus, and then travels using its intrinsic motor activity primarily at the tips of polymerizing microtubules. The microtubule-associated protein Mal3, an EB1 homologue, is required for loading and/or processivity of Tea2 and this function can be substituted by human EB1. In addition, the cell-end marker Tea1 is required to anchor Tea2 to cell ends. Movement of Tea1 and the CLIP170 homologue Tip1 to cell ends is abolished in Tea2 rigor (ATPase) mutants. We propose that microtubule-based transport from the vicinity of the nucleus to cell ends can be precisely regulated, with Mal3 required for loading/processivity, Tea2 for movement and Tea1 for cell-end anchoring.	Canc Res UK, London Res Inst, Cell Cycle Lab, London WC2A 3PX, England; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Cancer Research UK; Carnegie Mellon University	Browning, H (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	browninh@andrew.cmu.edu			NINDS NIH HHS [NS28562] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Bienz M, 2001, NAT CELL BIOL, V3, pE67, DOI 10.1038/35060140; Bloom K, 2000, NAT CELL BIOL, V2, pE96, DOI 10.1038/35014089; Browning H, 2000, J CELL BIOL, V151, P15, DOI 10.1083/jcb.151.1.15; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Chen CR, 2000, MOL BIOL CELL, V11, P4067, DOI 10.1091/mbc.11.12.4067; Drummond DR, 2000, CURR BIOL, V10, P766, DOI 10.1016/S0960-9822(00)00570-4; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Hayles J, 2001, NAT REV MOL CELL BIO, V2, P647, DOI 10.1038/35089520; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Jin H, 2001, MOL BIOL CELL, V12, P1275, DOI 10.1091/mbc.12.5.1275; Kusch J, 2002, GENE DEV, V16, P1627, DOI 10.1101/gad.222602; Maekawa H, 2003, EMBO J, V22, P438, DOI 10.1093/emboj/cdg063; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; Niccoli T, 2002, J CELL SCI, V115, P1651; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; West RR, 2001, MOL BIOL CELL, V12, P3919, DOI 10.1091/mbc.12.12.3919; WOODS A, 1989, J CELL SCI, V93, P491; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	32	97	99	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					812	818		10.1038/ncb1034	http://dx.doi.org/10.1038/ncb1034			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12894167				2022-12-25	WOS:000185059000014
J	Matsunaga, T; Takemoto, N; Sato, T; Takimoto, R; Tanaka, I; Fujimi, A; Akiyama, TH; Kuroda, H; Kawano, Y; Kobune, M; Kato, J; Hirayama, Y; Sakamaki, S; Kohda, K; Miyake, K; Niitsu, Y				Matsunaga, T; Takemoto, N; Sato, T; Takimoto, R; Tanaka, I; Fujimi, A; Akiyama, TH; Kuroda, H; Kawano, Y; Kobune, M; Kato, J; Hirayama, Y; Sakamaki, S; Kohda, K; Miyake, K; Niitsu, Y			Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; MAINTENANCE INTENSIFICATION THERAPY; DRUG-INDUCED APOPTOSIS; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; HEMATOPOIETIC-CELL; LIGAND-BINDING; SCID MICE; ADHESION; INDUCTION	Bone-marrow minimal residual disease (MRD) causes relapse after chemotherapy in patients with acute myelogenous leukemia (AML). We postulate that the drug resistance is induced by the attachment of very late antigen (VLA)-4 on leukemic cells to fibronectin on bone-marrow stromal cells. We found that VLA-4-positive cells acquired resistance to anoikis (loss of anchorage) or drug-induced apoptosis through the phosphatidylinositol-3-kinase (PI-3K)/AKT/Bcl-2 signaling pathway, which is activated by the interaction of VLA-4 and fibronectin. This resistance was negated by VLA-4-specific antibodies. In a mouse model of MRD, we achieved a 100% survival rate by combining VLA-4-specific antibodies and cytosine arabinoside (AraC), whereas AraC alone prolonged survival only slightly. In addition, overall survival at 5 years was 100% for 10 VLA-4-negative patients and 44.4% for 15 VLA-4-positive patients. Thus, the interaction between VLA-4 on leukemic cells and fibronectin on stromal cells may be crucial in bone marrow MRD and AML prognosis.	Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0600061, Japan; Higashi Sapporo Hosp, Dept Internal Med, Shiroishi Ku, Sapporo, Hokkaido 0030003, Japan; Japanese Red Cross Asahikawa Hosp, Dept Internal Med, Asahikawa, Hokkaido 0700061, Japan; Univ Tokyo, Inst Med Sci, Div Infect Genet, Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; University of Tokyo	Niitsu, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0600061, Japan.	niitsu@sapmed.ac.jp						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Almeida-Porada G, 2002, EXP HEMATOL, V30, P1454, DOI 10.1016/S0301-472X(02)00967-0; Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; BENDALL LJ, 1993, BLOOD, V82, P3125; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; DAWANO Y, 2003, BLOOD, V101, P532; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIAMEUNIER P, 1993, MAMM GENOME, V4, P695, DOI 10.1007/BF00357792; GARSON OM, 1989, CANCER GENET CYTOGEN, V40, P187, DOI 10.1016/0165-4608(89)90024-1; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hann IM, 1997, BLOOD, V89, P2311, DOI 10.1182/blood.V89.7.2311; Heinze G, 2003, COMPUT METH PROG BIO, V71, P155, DOI 10.1016/S0169-2607(02)00077-9; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Kawada H, 1999, EXP HEMATOL, V27, P904, DOI 10.1016/S0301-472X(99)00012-0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kobayashi T, 1996, J CLIN ONCOL, V14, P204, DOI 10.1200/JCO.1996.14.1.204; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; OHNO R, 1993, CANCER, V71, P3888, DOI 10.1002/1097-0142(19930615)71:12<3888::AID-CNCR2820711216>3.0.CO;2-G; PREISLER HD, 1989, BRIT J HAEMATOL, V71, P189, DOI 10.1111/j.1365-2141.1989.tb04253.x; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yoshino H, 2000, BONE MARROW TRANSPL, V26, P1211, DOI 10.1038/sj.bmt.1702702; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088	46	418	446	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1158	1165		10.1038/nm909	http://dx.doi.org/10.1038/nm909			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12897778				2022-12-25	WOS:000185061600028
J	Mahnke, K; Qian, YJ; Knop, J; Enk, AH				Mahnke, K; Qian, YJ; Knop, J; Enk, AH			Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo	NATURE BIOTECHNOLOGY			English	Article							IMMATURE; TOLERANCE; CD4(+)	A T-cell receptor mimic peptide (TCRpep) consisting of an 8-amino-acid peptide, homologous to the transmembrane region of the T-cell receptor (TCR) chain, blocks T-cell activation after systemic application. When dendritic cells (DCs) were transduced to secrete the TCRpep and injected into mice, evidence of immunosuppression was observed. In a CD8-driven allergy model, the injection of DCs transduced with the TCRpep reduced inflammation markedly and in a CD4(+) T cell-dependent model of multiple sclerosis (experimental autoimmune encephalitis, EAE), injection of TCRpep-secreting DCs abrogated EAE symptoms and prolonged survival. These effects were antigen specific, because transduced DCs that did not express the respective antigen failed to convey protection in the allergy model as well as in the EAE model. Thus these data show that DCs expressing the TCRpep are able to suppress T-cell activation and might be a useful tool for inducing antigen-specific immune suppression in vivo.	Johannes Gutenberg Univ Mainz, Dept Dermatol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Mahnke, K (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Langenbeckstr 1, D-55101 Mainz, Germany.	mahnke@hautklinik.klinik.uni-mainz.de						Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Gollner GP, 2000, GENE THER, V7, P1000, DOI 10.1038/sj.gt.3301183; Goverman J, 1999, IMMUNOL REV, V169, P147, DOI 10.1111/j.1600-065X.1999.tb01313.x; Grabbe Stephan, 2002, Trends Immunol, V23, P66, DOI 10.1016/S1471-4906(01)02152-4; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Hackstein H, 2001, TRENDS IMMUNOL, V22, P437, DOI 10.1016/S1471-4906(01)01959-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Li ZG, 1998, CELL IMMUNOL, V190, P101, DOI 10.1006/cimm.1998.1383; Mahnke K, 2002, IMMUNOL CELL BIOL, V80, P477, DOI 10.1046/j.1440-1711.2002.01115.x; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Steinbrink K, 1999, BLOOD, V93, P1634, DOI 10.1182/blood.V93.5.1634.405k11_1634_1642; Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Wang XM, 2002, CLIN IMMUNOL, V105, P199, DOI 10.1006/clim.2002.5270	21	15	17	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					903	908		10.1038/nbt842	http://dx.doi.org/10.1038/nbt842			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12833070				2022-12-25	WOS:000184484600033
J	Olbrich, H; Fliegauf, M; Hoefele, J; Kispert, A; Otto, E; Volz, A; Wolf, MT; Sasmaz, G; Trauer, U; Reinhardt, R; Sudbrak, R; Antignac, C; Gretz, N; Walz, G; Schermer, B; Benzing, T; Hildebrandt, F; Omran, H				Olbrich, H; Fliegauf, M; Hoefele, J; Kispert, A; Otto, E; Volz, A; Wolf, MT; Sasmaz, G; Trauer, U; Reinhardt, R; Sudbrak, R; Antignac, C; Gretz, N; Walz, G; Schermer, B; Benzing, T; Hildebrandt, F; Omran, H			Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; SENIOR-LOKEN-SYNDROME; FAMILIAL NEPHROPATHY; PROTEIN; PROGRESSION; INTERACTS; LOCUS; IDENTIFICATION; NEPHROCYSTIN; P130(CAS)	Nephronophthisis (NPHP), a group of autosomal recessive cystic kidney disorders, is the most common genetic cause of progressive renal failure in children and young adults(1). NPHP may be associated with Leber congenital amaurosis, tapetoretinal degeneration, cerebellar ataxia, cone-shaped epiphyses, congenital oculomotor apraxia and hepatic fibrosis(2-6). Loci associated with an infantile type of NPHP on 9q22-q31 (NPHP2), juvenile types of NPHP on chromosomes 2q12-q13 (NPHP1) and 1p36 (NPHP4) and an adolescent type of NPHP on 3q21-q22 (NPHP3) have been mapped(7-10). NPHP1 and NPHP4 have been identified(11-13), and interaction of the respective encoded proteins nephrocystin and nephrocystin-4 has been shown(13). Here we report the identification of NPHP3, encoding a novel 1,330-amino acid protein that interacts with nephrocystin. We describe mutations in NPHP3 in families with isolated NPHP and in families with NPHP with associated hepatic fibrosis or tapeto-retinal degeneration. We show that the mouse ortholog Nphp3 is expressed in the node, kidney tubules, retina, respiratory epithelium, liver, biliary tract and neural tissues. In addition, we show that a homozygous missense mutation in Nphp3 is probably responsible for the polycystic kidney disease (pcy) mouse phenotype(14). Interventional studies in the pcy mouse have shown beneficial effects by modification of protein intake and administration of methylprednisolone(15-17), suggesting therapeutic strategies for treating individuals with NPHP3.	Univ Hosp Freiburg, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Hannover Med Sch, Inst Mol Biol, Hannover, Germany; Max Planck Inst Mol Genet, Berlin, Germany; Univ Paris 05, Necker Hosp, Dept Genet, Paris, France; Heidelberg Univ, Klinikum Mannheim, Med Res Ctr, D-68167 Mannheim, Germany; Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Clin Res Ctr, D-79106 Freiburg, Germany	University of Freiburg; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hannover Medical School; Max Planck Society; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; University of Freiburg; University of Freiburg	Omran, H (corresponding author), Univ Hosp Freiburg, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany.	omran@kikli.ukl.uni-freiburg.de	Volz, Andreas/AAA-6290-2019; Hoefele, Julia/AAB-6448-2020; Schermer, Bernhard/E-9972-2014; Sudbrak, Ralf/HHZ-8821-2022; Benzing, Thomas/X-5476-2019; ANTIGNAC, Corinne/H-8945-2017	Hoefele, Julia/0000-0002-7917-7129; Schermer, Bernhard/0000-0002-5194-9000; Otto, Edgar/0000-0002-2387-9973; Omran, Heymut/0000-0003-0282-6765; ANTIGNAC, Corinne/0000-0002-9934-4940; Reinhardt, Richard/0000-0001-9376-2132				ANTIGNAC C, 1993, NAT GENET, V3, P342, DOI 10.1038/ng0493-342; AUKEMA HM, 1992, KIDNEY INT, V42, P837, DOI 10.1038/ki.1992.358; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Betz R, 2000, J PEDIATR-US, V136, P828, DOI 10.1067/mpd.2000.106225; BOICHIS H, 1973, Q J MED, V42, P221; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Erck C, 2000, NEUROCHEM RES, V25, P5, DOI 10.1023/A:1007523028834; GATTONE VH, 1995, AM J KIDNEY DIS, V25, P302, DOI 10.1016/0272-6386(95)90013-6; Haider NB, 1998, AM J HUM GENET, V63, P1404, DOI 10.1086/302108; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hildebrandt F, 2001, PEDIATR NEPHROL, V16, P168, DOI 10.1007/s004670000518; LOKEN AC, 1961, ACTA PAEDIATR, V50, P177, DOI 10.1111/j.1651-2227.1961.tb08037.x; MAINZER F, 1970, AM J MED, V49, P556, DOI 10.1016/S0002-9343(70)80051-1; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Omran H, 2002, J AM SOC NEPHROL, V13, P75, DOI 10.1681/ASN.V13175; Omran H, 2000, AM J HUM GENET, V66, P118, DOI 10.1086/302705; Omran H, 2001, NEPHROL DIAL TRANSPL, V16, P755, DOI 10.1093/ndt/16.4.755; Omran H, 2001, J AM SOC NEPHROL, V12, P107, DOI 10.1681/ASN.V121107; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Schuermann MJ, 2002, AM J HUM GENET, V70, P1240, DOI 10.1086/340317; SENIOR B, 1961, AM J OPHTHALMOL, V52, P625, DOI 10.1016/0002-9394(61)90147-7; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; Tomobe K, 1998, AM J KIDNEY DIS, V31, P55, DOI 10.1053/ajkd.1998.v31.pm9428452; Volz A, 2002, CYTOGENET GENOME RES, V97, P163, DOI 10.1159/000066617	29	257	271	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					455	459		10.1038/ng1216	http://dx.doi.org/10.1038/ng1216			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12872122				2022-12-25	WOS:000184470500026
J	Autiero, M; Waltenberger, J; Communi, D; Kranz, A; Moons, L; Lambrechts, D; Kroll, J; Plaisance, S; De Mol, M; Bono, F; Kliche, S; Fellbrich, G; Ballmer-Hofer, K; Maglione, D; Mayr-Beyrle, U; Dewerchin, M; Dombrowski, S; Stanimirovic, D; Van Hummelen, P; Dehio, C; Hicklin, DJ; Persico, G; Herbert, JM; Communi, D; Shibuya, M; Collen, D; Conway, EM; Carmeliet, P				Autiero, M; Waltenberger, J; Communi, D; Kranz, A; Moons, L; Lambrechts, D; Kroll, J; Plaisance, S; De Mol, M; Bono, F; Kliche, S; Fellbrich, G; Ballmer-Hofer, K; Maglione, D; Mayr-Beyrle, U; Dewerchin, M; Dombrowski, S; Stanimirovic, D; Van Hummelen, P; Dehio, C; Hicklin, DJ; Persico, G; Herbert, JM; Communi, D; Shibuya, M; Collen, D; Conway, EM; Carmeliet, P			Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; COLLATERAL VESSEL DEVELOPMENT; PHOSPHOLIPASE-C-GAMMA; AUTOPHOSPHORYLATION SITE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL PROLIFERATION; CRYSTAL-STRUCTURE; IN-VIVO; ANGIOGENESIS	Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Here we report that placental growth factor (PGF, also known as PIGF) regulates inter- and intramolecular cross talk between the VEGF RTKs Flt1 and Flk1. Activation of Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through Flk1. Even though VEGF and PGF both bind Flt1, PGF uniquely stimulated the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Furthermore, the VEGF/PGF heterodimer activated intramolecular VEGF receptor cross talk through formation of Flk1/Flt1 heterodimers. The inter- and intramolecular VEGF receptor cross talk is likely to have therapeutic implications, as treatment with VEGF/PGF heterodimer or a combination of VEGF plus PGF increased ischemic myocardial angiogenesis in a mouse model that was refractory to VEGF alone.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Ulm, Med Ctr, Dept Internal Med 2, D-8908 Ulm, Germany; Sanofi Rech, Haemobiol Dept, F-31036 Toulouse, France; Paul Scherrer Inst, Lab Biomol Res Mol Cell Biol, CH-5232 Villigen, Switzerland; Geymonat SpA, I-03012 Anagni, Italy; Natl Res Council Canada, Inst Biol Sci, Cellular Neurobiol Grp, Ottawa, ON K1A 0R6, Canada; Univ Basel, Bioctr, Div Mol Microbiol, CH-4056 Basel, Switzerland; ImClone Syst Inc, New York, NY 10014 USA; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, B-1070 Brussels, Belgium; Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo 1088639, Japan	Flanders Institute for Biotechnology (VIB); KU Leuven; Ulm University; Sanofi-Aventis; Sanofi France; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; National Research Council Canada; University of Basel; Eli Lilly; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Tokyo	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Lambrechts, Diether/AAJ-3167-2020; Plaisance, Stephane/ABI-6307-2020; Carmeliet, Peter/AAQ-5140-2020; Kranz, Andrea/D-3617-2012; Dehio, Christoph/AAD-5572-2019; Verdrengh, Evelien/H-4571-2012; Plaisance, Stephane/B-3488-2009; Dehio, Christoph/R-8277-2016; Waltenberger, Johannes/I-1813-2013	Lambrechts, Diether/0000-0002-3429-302X; Plaisance, Stephane/0000-0002-1651-241X; Carmeliet, Peter/0000-0001-7961-1821; Dehio, Christoph/0000-0001-7288-1052; Plaisance, Stephane/0000-0002-1651-241X; Dehio, Christoph/0000-0001-7288-1052; van hummelen, paul/0000-0002-4801-8600; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Waltenberger, Johannes/0000-0002-2417-9880; Conway, Edward/0000-0003-0081-0305; Ballmer-Hofer, Kurt/0000-0002-3800-9129				Adini A, 2002, CANCER RES, V62, P2749; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gingras D, 2000, BIOCHEM J, V348, P273, DOI 10.1042/0264-6021:3480273; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Huang K, 2001, INT J BIOCHEM CELL B, V33, P315, DOI 10.1016/S1357-2725(01)00019-X; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Ito N, 2001, CELL SIGNAL, V13, P849, DOI 10.1016/S0898-6568(01)00209-1; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Odorisio T, 2002, J CELL SCI, V115, P2559; PARK JE, 1994, J BIOL CHEM, V269, P25646; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Waltenberger J, 2001, CARDIOVASC RES, V49, P554, DOI 10.1016/S0008-6363(00)00228-5; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yu Y, 2001, BIOCHEM J, V358, P465, DOI 10.1042/0264-6021:3580465; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	600	643	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					936	943		10.1038/nm884	http://dx.doi.org/10.1038/nm884			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12796773				2022-12-25	WOS:000183979300036
J	Toyo-oka, K; Shionoya, A; Gambello, MJ; Cardoso, C; Leventer, R; Ward, HL; Ayala, R; Tsai, LH; Dobyns, W; Ledbetter, D; Hirotsune, S; Wynshaw-Boris, A				Toyo-oka, K; Shionoya, A; Gambello, MJ; Cardoso, C; Leventer, R; Ward, HL; Ayala, R; Tsai, LH; Dobyns, W; Ledbetter, D; Hirotsune, S; Wynshaw-Boris, A			14-3-3 epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome	NATURE GENETICS			English	Article							PROTEIN PHOSPHATASE 2A; CYTOPLASMIC DYNEIN; CORTICAL DEVELOPMENT; EMBRYONIC LETHALITY; LISSENCEPHALY GENE; LIS1 GENE; PHOSPHORYLATION; DROSOPHILA; CDK5; MALFORMATION	Heterozygous deletions of 17p13.3 result in the human neuronal migration disorders isolated lissencephaly sequence (ILS) and the more severe Miller Dieker syndrome (MDS). Mutations in PAFAH1B1 (the gene encoding LIS1) are responsible for ILS and contribute to MDS, but the genetic causes of the greater severity of MDS are unknown. Here, we show that the gene encoding 14-3-3epsilon (YWHAE), one of a family of ubiquitous phosphoserine/threonine binding proteins, is always deleted in individuals with MDS. Mice deficient in Ywhae have defects in brain development and neuronal migration, similar to defects observed in mice heterozygous with respect to Pafah1b1. Mice heterozygous with respect to both genes have more severe migration defects than single heterozygotes. 14-3-3epsilon binds to CDK5/p35-phosphorylated NUDEL and this binding maintains NUDEL phosphorylation. Similar to LIS1, deficiency of 14-3-3epsilon results in mislocalization of NUDEL and LIS1, consistent with reduction of cytoplasmic dynein function. These results establish a crucial role for 14-3-3epsilon in neuronal development by sustaining the effects of CDK5 phosphorylation and provide a molecular explanation for the differences in severity of human neuronal migration defects with 17p13.3 deletions.	Univ Calif San Diego, Sch Med, Dept Pediat, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, Ctr Canc, La Jolla, CA 92093 USA; Japan Sci & Technol Corp, Ctr Genome Med Sci, Saitama Med Sch, PRESTO, Hidaka, Saitama 3501241, Japan; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, Boston, MA 02115 USA; Fac Med Timone, INSERM, U491, F-13385 Marseille 05, France; Royal Childrens Hosp, Dept Neurol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of California System; University of California San Diego; University of California System; University of California San Diego; Japan Science & Technology Agency (JST); Saitama Medical University; University of Chicago; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Wynshaw-Boris, A (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat, Ctr Canc, 9500 Gilman Dr,Mailstop 0627, La Jolla, CA 92093 USA.		Dobyns, William Brian/ABC-6525-2021; Toyooka, Kazuhito/AAQ-6928-2020; Cardoso, Carlos/M-2767-2019; Cardoso, Carlos/H-4520-2016; Dobyns, William/AAI-2768-2020; Toyooka, Kazuhito/AAH-7175-2019	Toyooka, Kazuhito/0000-0002-0173-0430; Cardoso, Carlos/0000-0003-1914-9553; Cardoso, Carlos/0000-0003-1914-9553; Dobyns, William/0000-0002-7681-2844; Toyooka, Kazuhito/0000-0002-0173-0430				Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Cahana A, 2001, P NATL ACAD SCI USA, V98, P6429, DOI 10.1073/pnas.101122598; Cardoso C, 2003, AM J HUM GENET, V72, P918, DOI 10.1086/374320; Cardoso C, 2000, HUM MOL GENET, V9, P3019, DOI 10.1093/hmg/9.20.3019; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; DOBYNS WB, 1992, NEUROLOGY, V42, P1375, DOI 10.1212/WNL.42.7.1375; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Fleck MW, 2000, J NEUROSCI, V20, P2439; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gambello MJ, 2003, J NEUROSCI, V23, P1719; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Hirotsune S, 1997, GENOME RES, V7, P625, DOI 10.1101/gr.7.6.625; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; Liu Z, 2000, NAT CELL BIOL, V2, P776, DOI 10.1038/35041011; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; OSHIMA T, 1996, P NATL ACAD SCI USA, V93, P11173; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; VEERANNA, 1995, J NEUROCHEM, V64, P2681; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003	50	309	327	0	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					274	285		10.1038/ng1169	http://dx.doi.org/10.1038/ng1169			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12796778				2022-12-25	WOS:000183815300014
J	Muller-Kuhrt, L				Muller-Kuhrt, L			Putting nature back into drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material							PRODUCTS; PERSPECTIVE; LIBRARIES		AnalytiCon Discovery GmbH, Potsdam, Germany		Muller-Kuhrt, L (corresponding author), AnalytiCon Discovery GmbH, Potsdam, Germany.							Bindseil KU, 2001, DRUG DISCOV TODAY, V6, P840, DOI 10.1016/S1359-6446(01)01856-6; Brohm D, 2002, ANGEW CHEM INT EDIT, V41, P307, DOI 10.1002/1521-3773(20020118)41:2<307::AID-ANIE307>3.0.CO;2-1; Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893; Harvey A, 2000, DRUG DISCOV TODAY, V5, P294, DOI 10.1016/S1359-6446(00)01511-7; Henkel T, 1999, ANGEW CHEM INT EDIT, V38, P643, DOI 10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G; Lee ML, 2001, J COMB CHEM, V3, P284, DOI 10.1021/cc000097l; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Nicolaou KC, 1997, NATURE, V387, P268, DOI 10.1038/387268a0; Oprea TI, 2001, J CHEM INF COMP SCI, V41, P1308, DOI 10.1021/ci010366a; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o	10	20	21	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2003	21	6					602	602		10.1038/nbt0603-602	http://dx.doi.org/10.1038/nbt0603-602			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	684RR	12776140	Bronze			2022-12-25	WOS:000183220800011
J	Basta, M; Van Goor, F; Luccioli, S; Billings, EM; Vortmeyer, AO; Baranyi, L; Szebeni, J; Alving, CR; Carroll, MC; Berkower, I; Stojilkovic, SS; Metcalfe, DD				Basta, M; Van Goor, F; Luccioli, S; Billings, EM; Vortmeyer, AO; Baranyi, L; Szebeni, J; Alving, CR; Carroll, MC; Berkower, I; Stojilkovic, SS; Metcalfe, DD			F(ab)'(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins	NATURE MEDICINE			English	Article							DOSE INTRAVENOUS IMMUNOGLOBULIN; IMMUNE GLOBULIN; COMPLEMENT; RECEPTORS; ASTHMA; PATHOGENESIS; MODULATION; ACTIVATION; COMPONENTS; FRAGMENTS	High-dose intravenous immunoglobulin (IVIG) prevents immune damage by scavenging complement fragments C3b and C4b. We tested the hypothesis that exogenous immunoglobulin molecules also bind anaphylatoxins C3a and C5a, thereby neutralizing their pro-inflammatory effects. Single-cell calcium measurements in HMC-1 human mast cells showed that a rise in intracellular calcium caused by C3a and C5a was inhibited in a concentration-dependent manner by IVIG, F(ab)'(2)-IVIG and irrelevant human monoclonal antibody. C3a- and C5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basophils were also suppressed by exogenous immunoglobulins. In a mouse model of asthma, immunoglobulin treatment reduced cellular migration to the lung. Lethal C5a-mediated circulatory collapse in pigs was prevented by pretreatment with F(ab)'(2)-IVIG. Molecular modeling, surface plasmon resonance (SPR) and western blot analyses suggested a physical association between anaphylatoxins and the constant region of F(ab)'(2). This binding could interfere with the role of C3a and C5a in inflammation.	NINDS, Neuronal Excitabil Sect, NIH, Bethesda, MD 20892 USA; NICHHD, Sect Cellular Signaling, NIH, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NHLBI, Computat Biophys Sect, NIH, Bethesda, MD 20892 USA; NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; US FDA, Immunoregulat Lab, Off Vaccines, Ctr Biol, Bethesda, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Harvard University; Harvard Medical School; US Food & Drug Administration (FDA)	Basta, M (corresponding author), NINDS, Neuronal Excitabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.			Basta, Milan/0000-0001-5958-9241	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000607, ZIAAI000761, Z01AI000761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baranyi L, 1998, PEPTIDES, V19, P211, DOI 10.1016/S0196-9781(97)00370-7; BASTA M, 1991, BLOOD, V77, P376; Basta M, 1996, J NEUROIMMUNOL, V71, P227, DOI 10.1016/S0165-5728(96)00133-6; BASTA M, 1989, BLOOD, V74, P326; Basta M, 1996, CLIN EXP IMMUNOL, V104, P21, DOI 10.1111/cei.1996.104.s1.21; BASTA M, 1991, BLOOD, V78, P700; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; DEBOER JP, 1992, IMMUNOPHARMACOLOGY, V24, P135, DOI 10.1016/0162-3109(92)90019-9; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; FISHER MB, 1996, J IMMUNOL, V157, P549; FRANK MM, 1989, FUNDAMENTAL IMMUNOLO, P686; HARTUNG HP, 1983, J IMMUNOL, V130, P1345; HUGLI TE, 1989, CURR TOP MICROBIOL I, V153, P181; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Kekow J, 1998, LANCET, V351, P184, DOI 10.1016/S0140-6736(05)78212-X; Komura H, 2002, MICROBIOL IMMUNOL, V46, P115, DOI 10.1111/j.1348-0421.2002.tb02667.x; LUCCIOLI S, J ALLERGY CLIN IMMUN, V110, P117; Maizel JV, 1971, METHOD VIROL, V5, P179; MORGAN E L, 1986, Complement, V3, P128; MORGAN EL, 1983, J IMMUNOL, V130, P1257; NEZLIN R, 1993, J IMMUNOL METHODS, V163, P269, DOI 10.1016/0022-1759(93)90131-P; NEZLIN R, 1992, EUR J IMMUNOL, V22, P1955, DOI 10.1002/eji.1830220744; NEZLIN R, 1992, MOL IMMUNOL, V30, P935; Nilsson G, 1996, J IMMUNOL, V157, P1693; OPPERMANN M, 1992, IMMUNOPHARMACOLOGY, V24, P119, DOI 10.1016/0162-3109(92)90018-8; Pauwels RA, 1998, CLIN EXP ALLERGY, V28, P1; PLATT JL, 1991, EUR J IMMUNOL, V21, P2887, DOI 10.1002/eji.1830211135; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302; WEIGLE WO, 1983, SPRINGER SEMIN IMMUN, V6, P173; Zhang T, 1996, PROTEIN SCI, V5, P348	38	182	188	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					431	438		10.1038/nm836	http://dx.doi.org/10.1038/nm836			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12612546				2022-12-25	WOS:000181987400033
J	Maier, THP				Maier, THP			Semisynthetic production of unnatural L-alpha-amino acids by metabolic engineering of the cysteine-biosynthetic pathway	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; ENZYMATIC-SYNTHESIS; EXPRESSION; GENE	There is an increasing demand for peptide-mimicking molecules to modulate the interactions between proteins of pharmaceutical and agrochemical interest and their target polypeptides. Unnatural L-alpha-amino acids differing from the 20 naturally proteinogenic amino acids only in their side chain are ideal for this purpose, but their chemical synthesis is complex. Here we describe a fermentation-based approach for biosynthesis of unnatural amino acids after re-engineering the cysteine-biosynthetic pathway in Escherichia coli. O-acetylation of serine, the committed step of the pathway, was released from feedback inhibition by mutating the serine acetyltransferase gene. Next, the naturally broad substrate specificity of O-acetylserine sulfhydrylase was exploited for the direct in vivo incorporation of an unnatural side chain in a semisynthetic fermentation process comparable to the production of beta-lactams. O-acetyl-L-serine extruded from the cells by way of the O-acetylserine efflux protein was amenable to further biotransformations.	Wacker Chem GMBH, Consortium Elektrochem Ind GMBH, D-81379 Munich, Germany	Wacker Chemie	Maier, THP (corresponding author), Wacker Chem GMBH, Consortium Elektrochem Ind GMBH, Zielstattstr 20, D-81379 Munich, Germany.	thomas.maier@wacker.com						Albrecht M, 2000, NAT BIOTECHNOL, V18, P843, DOI 10.1038/78443; Beiboer SHW, 1996, PROTEIN ENG, V9, P345, DOI 10.1093/protein/9.4.345; Boswell C., 1999, CHEM MARKET REP 0614, V14, P9; BROWN JD, 1998, Patent No. 0968997; Burkovski A, 2002, APPL MICROBIOL BIOT, V58, P265, DOI 10.1007/s00253-001-0869-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Dassler T, 2000, MOL MICROBIOL, V36, P1101, DOI 10.1046/j.1365-2958.2000.01924.x; DENK D, 1987, J GEN MICROBIOL, V133, P515; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Drauz K, 1997, CHIMIA, V51, P310; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GUIBOURDENCHE C, 1993, TETRAHEDRON-ASYMMETR, V4, P2041, DOI 10.1016/S0957-4166(00)82252-1; IKEGAMI F, 1994, PHYTOCHEMISTRY, V35, P1089, DOI 10.1016/S0031-9422(00)94805-2; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098; Keasling JD, 1999, TRENDS BIOTECHNOL, V17, P452, DOI 10.1016/S0167-7799(99)01376-1; Kitabatake M, 2000, J BACTERIOL, V182, P143, DOI 10.1128/JB.182.1.143-145.2000; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; LEINFELDER W, 1996, Patent No. 9715673; MAIER T, 2001, Patent No. 10107002; NAKAMURA T, 1984, J BACTERIOL, V158, P1122, DOI 10.1128/JB.158.3.1122-1127.1984; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; SORENSEN MA, 1991, J BACTERIOL, V173, P5244, DOI 10.1128/jb.173.16.5244-5246.1991; Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; WATKINS KJ, 2001, CHEM ENG NEWS   0108, P11; WOLFE S, 1972, CAN J CHEM, V52, P2412; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	30	75	87	3	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					422	427		10.1038/nbt807	http://dx.doi.org/10.1038/nbt807			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	664VH	12640465				2022-12-25	WOS:000182082400024
J	Reich, DE; Gabriel, SB; Altshuler, D				Reich, DE; Gabriel, SB; Altshuler, D			Quality and completeness of SNP databases	NATURE GENETICS			English	Article								To address the quality and completeness of single-nucleotide polymorphism (SNP) databases, we resequenced 173 kb (spanning 17 loci) in 150 chromosomes of west African and European ancestry. Over 88% of SNPs in the public (TSC and BAC overlap) and Celera databases were confirmed in independent resequencing. Approximately 45% of all human heterozygosity is attributable to SNPs already available from the two databases, and of SNPs with minor-allele frequencies >10%, more than half are represented.	MIT, Program Med & Populat Genet, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Reich, DE (corresponding author), MIT, Program Med & Populat Genet, Whitehead Inst, Ctr Genome Res, 1 Kendall Sq, Cambridge, MA 02139 USA.		Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107					0	145	150	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					457	458		10.1038/ng1133	http://dx.doi.org/10.1038/ng1133			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12652301	Bronze			2022-12-25	WOS:000181928600012
J	Robertson, SP; Twigg, SRF; Sutherland-Smith, AJ; Biancalana, V; Gorlin, RJ; Horn, D; Kenwrick, SJ; Kim, CA; Morava, E; Newbury-Ecob, R; Orstavik, KH; Quarrell, OWJ; Schwartz, CE; Shears, DJ; Suri, M; Kendrick-Jones, J; Wilkie, AOM				Robertson, SP; Twigg, SRF; Sutherland-Smith, AJ; Biancalana, V; Gorlin, RJ; Horn, D; Kenwrick, SJ; Kim, CA; Morava, E; Newbury-Ecob, R; Orstavik, KH; Quarrell, OWJ; Schwartz, CE; Shears, DJ; Suri, M; Kendrick-Jones, J; Wilkie, AOM		OPD-Spectrum Disorders Clinical Co	Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans	NATURE GENETICS			English	Article							MELNICK-NEEDLES-SYNDROME; SYNDROME TYPE-II; PERIVENTRICULAR HETEROTOPIA; DIGITAL SYNDROME; INACTIVATION; MIGRATION; NEURONS; DOMAIN; LOCUS; MALES	Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. Filamin A, encoded by the gene FLNA, is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers(1,2). We identified localized mutations in FLNA that conserve the reading frame and lead to a broad range of congenital malformations, affecting craniofacial structures, skeleton, brain, viscera and urogenital tract, in four X-linked human disorders: otopalatodigital syndrome types 1 (OPD1; OMIM 311300) and 2 (OPD2; OMIM 304120), frontometaphyseal dysplasia (FMD; OMIM 305620) and Melnick-Needles syndrome (MNS; OMIM 309350). Several mutations are recurrent, and all are clustered into four regions of the gene: the actin-binding domain and rod domain repeats 3, 10 and 14/15. Our findings contrast with previous observations that loss of function of FLNA is embryonic lethal in males but manifests in females as a localized neuronal migration disorder, called periventricular nodular heterotopia (PVNH; refs. 3-6). The patterns of mutation, X-chromosome inactivation and phenotypic manifestations in the newly described mutations indicate that they have gain-of-function effects, implicating. filamin A in signaling pathways that mediate organogenesis in multiple systems during embryonic development.	City Hosp, Clin Genet Serv, Nottingham NG5 1PB, England; Inst Child Hlth, Clin & Mol Genet Unit, London, England; Greenwood Genet Ctr, Greenwood, SC 29646 USA; Sheffield Childrens Hosp, N Trent Clin Genet Serv, Sheffield, S Yorkshire, England; Univ Oslo, Inst Grp Clin Med, Oslo, Norway; United Bristol Hosp Trust, Clin Genet Serv, Bristol, Avon, England; Univ Pecs, Dept Med Genet, Pecs, Hungary; Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge, England; Humboldt Univ, Inst Humangenet, Berlin, Germany; Univ Minnesota, Dept Oral Pathol & Genet, Minneapolis, MN USA; CHRU, Strasbourg, France; Fac Med, Lab Diagnost Genet, Strasbourg, France; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Nottingham; University of London; University College London; Greenwood Genetic Center; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Oslo; University of Pecs; Universidade de Sao Paulo; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Humboldt University of Berlin; University of Minnesota System; University of Minnesota Twin Cities; CHU Strasbourg; MRC Laboratory Molecular Biology; University of Oxford	Robertson, SP (corresponding author), Univ Otago, Dept Paediat & Child Hlth, Dunedin, New Zealand.		Sutherland-Smith, Andrew/F-1813-2011; Twigg, Stephen/AAU-1135-2021; Wilkie, Andrew/AAC-3820-2020; Suri, Mohnish/HIK-0223-2022; Biancalana, Valerie/O-2351-2016; VERLOES, Alain/E-7287-2014	Sutherland-Smith, Andrew/0000-0001-9485-1428; Twigg, Stephen/0000-0001-5024-049X; Wilkie, Andrew/0000-0002-2972-5481; Suri, Mohnish/0000-0001-9037-701X; VERLOES, Alain/0000-0003-4819-0264; Kim, Chong/0000-0002-1754-1300; Lacombe, Didier/0000-0002-8956-2207; Robertson, Stephen/0000-0002-5181-7809				ALLEN RC, 1992, AM J HUM GENET, V51, P1229; ANDRE M, 1981, J PEDIATR-US, V98, P747, DOI 10.1016/S0022-3476(81)80835-9; BIANCALANA V, 1991, HUM GENET, V88, P228, DOI 10.1007/BF00206078; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; DONNENFELD AE, 1987, AM J MED GENET, V27, P159, DOI 10.1002/ajmg.1320270117; DUDDING BA, 1967, AM J DIS CHILD, V113, P214, DOI 10.1001/archpedi.1967.02090170078006; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FITCH N, 1983, AM J MED GENET, V15, P655, DOI 10.1002/ajmg.1320150416; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GORLIN RJ, 1969, AM J DIS CHILD, V118, P487, DOI 10.1001/archpedi.1969.02100040489014; Hassoun H, 1997, BLOOD, V90, P398; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kosho T, 2002, J Med Genet, V39, pE7, DOI 10.1136/jmg.39.2.e7; Kristiansen M, 2002, AM J MED GENET, V108, P120, DOI 10.1002/ajmg.10245; LEMAREC B, 1988, ANN GENET-PARIS, V31, P155; McCoy AJ, 1999, NAT STRUCT BIOL, V6, P836; MELNICK JC, 1966, AMER J ROENTGENOL RA, V97, P39, DOI 10.2214/ajr.97.1.39; Moro F, 2002, NEUROLOGY, V58, P916, DOI 10.1212/WNL.58.6.916; Norwood FLM, 2000, STRUCTURE, V8, P481, DOI 10.1016/S0969-2126(00)00132-5; Robertson S, 1997, AM J MED GENET, V71, P341, DOI 10.1002/(SICI)1096-8628(19970822)71:3<341::AID-AJMG16>3.0.CO;2-K; Robertson SP, 2001, AM J HUM GENET, V69, P223, DOI 10.1086/321280; Sheen VL, 2001, HUM MOL GENET, V10, P1775, DOI 10.1093/hmg/10.17.1775; Sheen VL, 2002, HUM MOL GENET, V11, P2845, DOI 10.1093/hmg/11.23.2845; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; STRATTON RF, 1991, AM J MED GENET, V41, P169, DOI 10.1002/ajmg.1320410206; TAYBI H, 1962, AMER J ROENTGENOL RA, V88, P450; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Verloes A, 2000, AM J MED GENET, V90, P407, DOI 10.1002/(SICI)1096-8628(20000228)90:5<407::AID-AJMG11>3.0.CO;2-D	29	304	325	0	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					487	491		10.1038/ng1119	http://dx.doi.org/10.1038/ng1119			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12612583	Bronze			2022-12-25	WOS:000181928600019
J	Lappe-Siefke, C; Goebbels, S; Gravel, M; Nicksch, E; Lee, J; Braun, PE; Griffiths, IR; Nave, KA				Lappe-Siefke, C; Goebbels, S; Gravel, M; Nicksch, E; Lee, J; Braun, PE; Griffiths, IR; Nave, KA			Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination	NATURE GENETICS			English	Article							2',3'-CYCLIC NUCLEOTIDE 3'-PHOSPHODIESTERASE; CENTRAL-NERVOUS-SYSTEM; PROTEOLIPID PROTEIN; SPINAL-CORD; CNS MYELIN; SUBCELLULAR-DISTRIBUTION; MULTIPLE-SCLEROSIS; MESSENGER-RNA; MICE; 3-PHOSPHODIESTERASE	Myelination of axons by oligodendrocytes enables rapid impulse propagation in the central nervous system. But long-term interactions between axons and their myelin sheaths are poorly understood. Here we show that Cnp1, which encodes 2',3'-cyclic nucleotide phosphodiesterase in oligodendrocytes, is essential for axonal survival but not for myelin assembly. In the absence of glial cyclic nucleotide phosphodiesterase, mice developed axonal swellings and neurodegeneration throughout the brain, leading to hydrocephalus and premature death. But, in contrast to previously studied myelin mutants, the ultrastructure, periodicity and physical stability of myelin were not altered in these mice. Genetically, the chief function of glia in supporting axonal integrity can thus be completely uncoupled from its function in maintaining compact myelin. Oligodendrocyte dysfunction, such as that in multiple sclerosis lesions, may suffice to cause secondary axonal loss.	Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Glasgow, Appl Neurobiol Grp, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	Max Planck Society; McGill University; University of Glasgow	Nave, KA (corresponding author), Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany.	nave@em.mpg.de	Nave, Klaus-Armin/C-8883-2011; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				AGRAWAL HC, 1990, J BIOL CHEM, V265, P11849; Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Ballestero RP, 1999, J NEUROCHEM, V72, P1362, DOI 10.1046/j.1471-4159.1999.721362.x; BENNETT SAL, 1995, ACTA NEUROPATHOL, V89, P126; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; BOISON D, 1995, J NEUROSCI, V15, P5502; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BRAUN PE, 1988, J NEUROSCI, V8, P3057; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; DEANGELIS D, 1994, NATO ADV SCI INST SE, V258, P49; DEANGELIS DA, 1994, J NEUROSCI RES, V39, P386, DOI 10.1002/jnr.490390405; Gallyas F, 1979, Neurol Res, V1, P203; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GIULIAN D, 1980, J BIOL CHEM, V255, P5993; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; GRIFFITHS IR, 1981, J NEUROCYTOL, V10, P847, DOI 10.1007/BF01262657; Heaton PA, 1996, NUCLEIC ACIDS RES, V24, P850, DOI 10.1093/nar/24.5.850; HOTCHKISS RD, 1948, ARCH BIOCHEM, V16, P131; Joyner AL, 1993, GENE TARGETING PRACT; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; KURIHARA T, 1967, J NEUROCHEM, V14, P1167, DOI 10.1111/j.1471-4159.1967.tb06164.x; Laezza C, 1997, FEBS LETT, V413, P260, DOI 10.1016/S0014-5793(97)00924-1; Lee J, 2002, J NEUROCHEM, V81, P65; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; McFerran BW, 1997, J CELL SCI, V110, P2979; NAVE KA, 2002, GLIAL CELL DEV; NISHIZAWA Y, 1985, NEUROCHEM RES, V10, P1107, DOI 10.1007/BF00965885; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; ONeill RC, 1997, J NEUROSCI RES, V50, P248; Raine C., 1984, MYELIN, P1, DOI 10.1007/978-1-4757-1830-0_1; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; Rosenbluth J, 1996, J COMP NEUROL, V371, P336, DOI 10.1002/(SICI)1096-9861(19960722)371:2<336::AID-CNE12>3.0.CO;2-Q; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; Sporkel O, 2002, GLIA, V37, P19, DOI 10.1002/glia.10014; SPRINKLE TJ, 1985, NEUROCHEM RES, V10, P919, DOI 10.1007/BF00964629; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; Tsukada Yasuzo, 1992, P449; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4; YU WP, 1994, NEURON, V12, P1353, DOI 10.1016/0896-6273(94)90450-2	48	724	734	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					366	374		10.1038/ng1095	http://dx.doi.org/10.1038/ng1095			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12590258				2022-12-25	WOS:000181312700013
J	Lukas, C; Falck, J; Bartkova, J; Bartek, J; Lukas, J				Lukas, C; Falck, J; Bartkova, J; Bartek, J; Lukas, J			Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage	NATURE CELL BIOLOGY			English	Article							FORKHEAD-ASSOCIATED DOMAIN; S-PHASE CHECKPOINT; TUMOR-SUPPRESSOR; MRE11 COMPLEX; KINASE CHK2; IN-VIVO; PROTEIN; REPAIR; PHOSPHORYLATION; P53	Cell cycle checkpoints are signal transduction pathways activated after DNA damage to protect genomic integrity(1). Dynamic spatiotemporal coordination is a vital, but poorly understood aspect, of these checkpoints. Here, we provide evidence for a strikingly different behaviour of Chk2 versus Nbs1, key mediators of the ataxia-telangiecatesia-mutated (ATM)-controlled checkpoint pathways induced by DNA double-strand breaks (DSBs)(1,2). In live human cells with DSBs restricted to small sub-nuclear areas, Nbs1 was rapidly recruited to the damaged regions and underwent a dynamic exchange in the close vicinity of the DSB sites. In contrast, Chk2 continued to rapidly move throughout the entire nucleus, irrespective of DNA damage and including the DSB-free areas. Although phosphorylation of Chk2 by ATM occurred exclusively at the DSB sites, forced immobilization of Chk2 to spatially restricted, DSB-containing nuclear areas impaired its stimulating effect on p53-dependent transcription. These results unravel a dynamic nature of Nbs1 interaction with DSB lesions and identify Chk2 as a candidate transmitter of the checkpoint signal, allowing for a coordinated pan-nuclear response to focal DNA damage.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Lukas, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Chehab NH, 2000, GENE DEV, V14, P278; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Lukas C, 2001, CANCER RES, V61, P4990; Melo JA, 2001, GENE DEV, V15, P2809; Norris PS, 1997, ONCOGENE, V15, P2241, DOI 10.1038/sj.onc.1201406; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; WARD IM, 2001, J BIOL CHEM, V276, P2971; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	30	385	392	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					255	U12		10.1038/ncb945	http://dx.doi.org/10.1038/ncb945			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598907				2022-12-25	WOS:000181322500020
J	Schoenherr, CJ; Levorse, JM; Tilghman, SM				Schoenherr, CJ; Levorse, JM; Tilghman, SM			CTCF maintains differential methylation at the Igf2/H19 locus	NATURE GENETICS			English	Article							MOUSE H19 GENE; IMPRINTED EXPRESSION; H19/IGF2 LOCUS; CPG ISLAND; REGION; DNA; INSULATOR; UPSTREAM; DELETION	Genomic imprinting relies on establishing and maintaining the parental-specific methylation of DNA elements that control the differential expression of maternal and paternal alleles. Although the essential DNA methyltransferases have been discovered, proteins that regulate the sequence-specific establishment and maintenance of allelic methylation have not been identified. One candidate regulator of methylation, the zinc-finger protein CTCF, binds to the imprinting control region (ICR) of the genes Igf2 (encoding insulin-like growth factor 2) and H19 (fetal liver mRNA; refs. 1,2). The unmethylated maternal ICR is a chromatin boundary that prevents distant enhancers from activating Igf2 (refs. 3-6). In vitro experiments have suggested that CTCF mediates boundary activity of the maternal ICR, and that methylation of the paternal ICR abolishes this activity by preventing CTCF binding(3,4,6). Using mice with point mutations in all four CTCF sites in the ICR, we show that maternally transmitted mutant ICRs in neonatal mice acquire a substantial but heterogeneous degree of methylation. Mutant ICRs in oocytes and blastocysts are not methylated, however, indicating that binding of CTCF is not required to establish the unmethylated ICR during oogenesis. We also show that the mutant ICR lacks enhancer-blocking activity, as the expression of Igf2 is activated on mutant maternal chromosomes. Conversely, maternal H19 expression is reduced, suggesting a positive role for CTCF in the transcription of that gene. This study constitutes the first in vivo demonstration of the multiple functions of CTCF in an ICR.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Howard Hughes Medical Institute; Princeton University; Princeton University; University of Illinois System; University of Illinois Urbana-Champaign	Schoenherr, CJ (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hata K, 2002, DEVELOPMENT, V129, P1983; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Kaffer CR, 2000, GENE DEV, V14, P1908; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Srivastava M, 2000, GENE DEV, V14, P1186; Thorvaldsen JL, 2002, MOL CELL BIOL, V22, P2450, DOI 10.1128/MCB.22.8.2450-2462.2002; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422	25	233	249	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					66	69		10.1038/ng1057	http://dx.doi.org/10.1038/ng1057			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12461525				2022-12-25	WOS:000180136100019
J	Prokunina, L; Castillejo-Lopez, C; Oberg, F; Gunnarsson, I; Berg, L; Magnusson, V; Brookes, AJ; Tentler, D; Kristjansdottir, H; Grondal, G; Bolstad, AI; Svenungsson, E; Lundberg, I; Sturfelt, G; Jonssen, A; Truedsson, L; Lima, G; Alcocer-Varela, J; Jonsson, R; Gyllensten, UB; Harley, JB; Alarcon-Segovia, D; Steinsson, K; Alarcon-Riquelme, ME				Prokunina, L; Castillejo-Lopez, C; Oberg, F; Gunnarsson, I; Berg, L; Magnusson, V; Brookes, AJ; Tentler, D; Kristjansdottir, H; Grondal, G; Bolstad, AI; Svenungsson, E; Lundberg, I; Sturfelt, G; Jonssen, A; Truedsson, L; Lima, G; Alcocer-Varela, J; Jonsson, R; Gyllensten, UB; Harley, JB; Alarcon-Segovia, D; Steinsson, K; Alarcon-Riquelme, ME			A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans	NATURE GENETICS			English	Article							ALLELE-SPECIFIC HYBRIDIZATION; SIB-PAIR FAMILIES; HUMAN PD-1 GENE; AUTOIMMUNE-DISEASES; CROHNS-DISEASE; T-LYMPHOCYTES; EXPRESSION; IMMUNORECEPTOR; TOLERANCE; PEDIGREES	Systemic lupus erythematosus (SLE, OMIM 152700) is a complex autoimmune disease that affects 0.05% of the Western population, predominantly women(1-4). A number of susceptibility loci for SLE have been suggested in different populations, but the nature of the susceptibility genes and mutations is yet to be identified(5-9). We previously reported a susceptibility locus (SLEB2) for Nordic multi-case families(9,10). Within this locus, the programmed cell death 1 gene (PDCD1, also called PD-1) was considered the strongest candidate for association with the disease(11-14). Here, we analyzed 2,510 individuals, including members of five independent sets of families as well as unrelated individuals affected with SLE, for single-nucleotide polymorphisms (SNPs) that we identified in PDCD1. We show that one intronic SNP in PDCD1 is associated with development of SLE in Europeans (found in 12% of affected individuals versus 5% of controls; P=0.00001, r.r. (relative risk)=2.6) and Mexicans (found in 7% of affected individuals versus 2% of controls; P=0.0009, r.r.=3.5). The associated allele of this SNP alters a binding site for the runt-related transcription factor 1 (RUNX1, also called AML1) located in an intronic enhancer, suggesting a mechanism through which it can contribute to the development of SLE in humans.	Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Med Genet Sect, S-75185 Uppsala, Sweden; Everygene AB, Uppsala, Sweden; Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Sect Pathol, S-75185 Uppsala, Sweden; Univ Uppsala, Evolut Biol Ctr, Dept Comparat Physiol, S-75185 Uppsala, Sweden; Karolinska Inst, Rheumatol Unit, Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden; Labdpitalinn, Dept Rheumatol, Reykjavik, Iceland; Labdpitalinn, Ctr Rheumatol Res, Reykjavik, Iceland; Univ Bergen, Broegelmann Res Lab, Bergen, Norway; Haukeland Univ Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway; Univ Lund Hosp, Dept Clin Immunol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden; Inst Nacl Ciencias Med & Nutr Salvador Zubirdan, Dept Immunol & Rheumatol, Mexico City, DF, Mexico; Univ Oklahoma, Dept Med, Arthrit & Immunol Program, Oklahoma Med Res Fdn, Oklahoma City, OK USA; US Dept Vet Affairs, Oklahoma City, OK USA	Uppsala University; Uppsala University; Uppsala University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Bergen; University of Bergen; Haukeland University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs	Alarcon-Riquelme, ME (corresponding author), Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Med Genet Sect, Dag Hammarsjolds Vag 20, S-75185 Uppsala, Sweden.		Tentler, Dmitri/AAE-4519-2019; Alarcón-Riquelme, Marta E./ABF-8163-2020; Höiom, Veronica/F-4153-2012; lima, giuseppina GPPL/C-5995-2012; Prokunina-Olsson, Ludmila/V-7960-2019; Prokunina-Olsson, Ludmila/A-8240-2019	Tentler, Dmitri/0000-0003-3976-1205; Alarcón-Riquelme, Marta E./0000-0002-7632-4154; lima, giuseppina GPPL/0000-0002-1792-2605; Prokunina-Olsson, Ludmila/0000-0002-9622-2091; Prokunina-Olsson, Ludmila/0000-0002-9622-2091; Berg, Louise/0000-0001-6538-2837; Svenungsson, Elisabet/0000-0003-3396-3244				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARNETT FC, 1992, RHEUM DIS CLIN N AM, V18, P865; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Finger LR, 1997, GENE, V197, P177, DOI 10.1016/S0378-1119(97)00260-6; Gaffney PM, 2000, AM J HUM GENET, V66, P547, DOI 10.1086/302767; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; GUDMUNDSSON S, 1990, J RHEUMATOL, V17, P1162; Howell WM, 1999, NAT BIOTECHNOL, V17, P87, DOI 10.1038/5270; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; LATHROP GM, 1983, TISSUE ANTIGENS, V22, P160, DOI 10.1111/j.1399-0039.1983.tb01183.x; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Lindqvist AKB, 2000, J AUTOIMMUN, V14, P169, DOI 10.1006/jaut.1999.0357; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Magnusson V, 2000, GENOMICS, V70, P307, DOI 10.1006/geno.2000.6374; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Prince JA, 2001, GENOME RES, V11, P152, DOI 10.1101/gr.150201; Shai R, 1999, HUM MOL GENET, V8, P639, DOI 10.1093/hmg/8.4.639; SHINOHARA T, 1994, GENOMICS, V23, P704, DOI 10.1006/geno.1994.1562; Stahl-Hallengren C, 2000, J RHEUMATOL, V27, P685; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; THOMSON G, 1995, AM J HUM GENET, V57, P487; Vibhakar R, 1997, EXP CELL RES, V232, P25, DOI 10.1006/excr.1997.3493; Wong HK, 1999, J IMMUNOL, V163, P1682	29	594	652	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					666	669		10.1038/ng1020	http://dx.doi.org/10.1038/ng1020			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12402038				2022-12-25	WOS:000179593000022
J	Auberson-Huang, L				Auberson-Huang, L			The dialogue between precaution and risk	NATURE BIOTECHNOLOGY			English	Editorial Material							GENETICALLY-MODIFIED ORGANISMS											AUBERSONHUANG L, 2001, P 3 C EUR SOC AGR FO, P119; CHRISTOFOROU T, 2000, ENV LAW J, V8, P622; Kappeli O, 1998, CHIMIA, V52, P137; Matthee M, 2000, J AGR ENVIRON ETHIC, V12, P59, DOI 10.1023/A:1009504212205; Stirling A., 1999, SCI PRECAUTION MANAG, V1; WOLT JD, 2000, AGBIOFORUM, V3, P291; 1997, WTDS26RUSA WORLD TRA	7	9	9	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2002	20	11					1076	1078		10.1038/nbt1102-1076	http://dx.doi.org/10.1038/nbt1102-1076			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	611WV	12410244				2022-12-25	WOS:000179041500008
J	Xia, HB; Mao, QW; Paulson, HL; Davidson, BL				Xia, HB; Mao, QW; Paulson, HL; Davidson, BL			siRNA-mediated gene silencing in vitro and in vivo	NATURE BIOTECHNOLOGY			English	Article							DOUBLE-STRANDED-RNA; CENTRAL-NERVOUS-SYSTEM; SMALL INTERFERING RNA; MAMMALIAN-CELLS; LYSOSOMAL STORAGE; PROTEIN-KINASE; ANTISENSE RNA; EXPRESSION; VECTORS; PLANTS	RNA interference is now established as an important biological strategy for gene silencing, but its application to mammalian cells has been limited by nonspecific inhibitory effects of long dsRNA on translation. Here, we describe a viral-mediated delivery mechanism that results in specific silencing of targeted genes through expression of small interfering RNA (siRNA). We establish proof of principle by markedly diminishing expression of exogenous and endogenous genes in vitro and in vivo in brain and liver, and further apply this strategy to a model system of a major class of neurodegenerative disorders, the polyglutamine diseases, to show reduced polyglutamine aggregation in cells. This viral-mediated strategy should prove generally useful in reducing expression of target genes to model biological processes or to provide therapy for dominant human diseases.	Univ Iowa, Coll Med, Program Gene Therapy, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Program Gene Therapy, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Program Gene Therapy, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Davidson, BL (corresponding author), Univ Iowa, Coll Med, Program Gene Therapy, Dept Internal Med, Iowa City, IA 52242 USA.	beverly-davidson@uiowa.edu		Mao, Qinwen/0000-0001-7876-2046; Xia, Haibin/0000-0002-2038-5759	NICHD NIH HHS [HD 44093] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044093] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blomer U, 1997, J VIROL, V71, P6641; Brooks AI, 2002, P NATL ACAD SCI USA, V99, P6216, DOI 10.1073/pnas.082011999; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chai YH, 1999, J NEUROSCI, V19, P10338; COGONI C, 1994, ANTON LEEUW INT J G, V65, P205, DOI 10.1007/BF00871948; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; MINKS MA, 1979, J BIOL CHEM, V254, P180; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Moulder KL, 1999, J NEUROSCI, V19, P705; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ooboshi H, 1997, ARTERIOSCL THROM VAS, V17, P1786, DOI 10.1161/01.ATV.17.9.1786; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Stein CS, 1999, J VIROL, V73, P3424, DOI 10.1128/JVI.73.4.3424-3429.1999; Svoboda P, 2000, DEVELOPMENT, V127, P4147; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	32	719	942	1	154	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					1006	1010		10.1038/nbt739	http://dx.doi.org/10.1038/nbt739			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12244328				2022-12-25	WOS:000178313100017
J	Scheid, OM; Afsar, K; Paszkowski, J				Scheid, OM; Afsar, K; Paszkowski, J			Formation of stable epialleles and their paramutation-like interaction in tetraploid Arabidopsis thaliana	NATURE GENETICS			English	Article							POLYPLOIDS; EVOLUTION; PLANTS; GENES; METHYLATION; EXPRESSION	Polyploidization is found frequently in plants(1,2), and species previously considered to be diploid may show remnants of earlier polyploidization events on closer inspection of their genomes(3). The success of polyploids may lie in increased genetic redundancy supporting subsequent genetic diversification(4-6). Although doubling the genome does not generate diversity per se, recent studies show that rapid genomic rearrangements and changes in DNA modification and gene expression patterns are associated with polyploid formation(7-13). But recessive modifications will not become phenotypically apparent in early polyploid generations. Here we show that epialleles in tetraploid plants (but not in diploids) interact in trans and lead to heritable gene silencing persisting after segregation from the inactivating allele. This mechanism, resembling paramutation, leads to the establishment of functional epigenetic homozygosity and, thus, to conversion of new recessive alleles into traits expressed in early polyploid generations. Such interactions probably contribute to rapid adaptation and evolution of polyploid plant species.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Scheid, OM (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	ortrun@fmi.ch		Mittelsten Scheid, Ortrun/0000-0002-7757-4809				Adams KL, 2003, P NATL ACAD SCI USA, V100, P4649, DOI 10.1073/pnas.0630618100; Amedeo P, 2000, NATURE, V405, P203, DOI 10.1038/35012108; BRINK RA, 1968, SCIENCE, V159, P161, DOI 10.1126/science.159.3811.161; Chandler VL, 2000, PLANT MOL BIOL, V43, P121, DOI 10.1023/A:1006499808317; Comai L, 2000, PLANT CELL, V12, P1551, DOI 10.1105/tpc.12.9.1551; Finnegan EJ, 2002, CURR OPIN PLANT BIOL, V5, P101, DOI 10.1016/S1369-5266(02)00233-9; Hagemann R, 1993, MOL BIOL TOMATO, P75; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; Kashkush K, 2002, GENETICS, V160, P1651; Lee HS, 2001, P NATL ACAD SCI USA, V98, P6753, DOI 10.1073/pnas.121064698; Leitch IJ, 1997, TRENDS PLANT SCI, V2, P470, DOI 10.1016/S1360-1385(97)01154-0; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Martinez-Perez E, 2000, J CELL BIOL, V148, P233, DOI 10.1083/jcb.148.2.233; MASSON J, 1992, PLANT J, V2, P829, DOI 10.1111/j.1365-313X.1992.tb00153.x; Osborn TC, 2003, TRENDS GENET, V19, P141, DOI 10.1016/S0168-9525(03)00015-5; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Paterson AH, 2000, PLANT CELL, V12, P1523, DOI 10.1105/tpc.12.9.1523; Rassoulzadegan M, 2002, EMBO J, V21, P440, DOI 10.1093/emboj/21.3.440; Saze H, 2003, NAT GENET, V34, P65, DOI 10.1038/ng1138; Scheid OM, 1998, P NATL ACAD SCI USA, V95, P632, DOI 10.1073/pnas.95.2.632; Scheid OM, 1996, P NATL ACAD SCI USA, V93, P7114, DOI 10.1073/pnas.93.14.7114; SEUFERT R, 1963, Z VEREBUNGSL, V94, P112, DOI 10.1007/BF00895161; Soltis PS, 2000, P NATL ACAD SCI USA, V97, P7051, DOI 10.1073/pnas.97.13.7051; SONG KM, 1995, P NATL ACAD SCI USA, V92, P7719, DOI 10.1073/pnas.92.17.7719; STEBBINS GL, 1966, SCIENCE, V152, P1463, DOI 10.1126/science.152.3728.1463; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; Weiss H, 2000, HEREDITAS, V133, P255, DOI 10.1111/j.1601-5223.2000.00255.x; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384	28	103	108	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2003	34	4					450	454		10.1038/ng1210	http://dx.doi.org/10.1038/ng1210			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	706TE	12847525				2022-12-25	WOS:000184470500025
J	Vincent, S; Thomas, A; Brasher, B; Benson, JD				Vincent, S; Thomas, A; Brasher, B; Benson, JD			Targeting of proteins to membranes through hedgehog auto-processing	NATURE BIOTECHNOLOGY			English	Article							AUTOPROCESSING DOMAIN; SIGNAL-TRANSDUCTION; LIPID RAFTS; CHOLESTEROL; CELLS; MICRODOMAINS	Hedgehog proteins use an auto-processing strategy to generate cholesterol- conjugated peptide products that act as extracellular ligands in a number of developmental signaling pathways. We describe an approach that takes advantage of the hedgehog auto-processing reaction to carry out intracellular modification of heterologous proteins, resulting in their localization to cell membranes. Such processing occurs spontaneously, without accessory proteins or modification by other enzymes. Using the green fluorescent protein (GFP) and the product of the Hras as model proteins, we demonstrate the use of hedgehog auto-processing to process heterologous N-terminal domains and direct the resulting biologically active products to cell membranes. This system represents a tool for targeting functional peptides and proteins to cell membranes, and may also offer a means of directing peptides or other small molecules to components of cholesterol metabolism or regulation.	Novartis Inst Biomed Res, Cambridge, MA 02139 USA; GenPath Pharmaceut, Cambridge, MA 02139 USA; SelectX Pharmaceut, Lexington, MA 02421 USA	Novartis	Benson, JD (corresponding author), Novartis Inst Biomed Res, 100 Technol Sq, Cambridge, MA 02139 USA.	john.benson@pharma.novartis.com						ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Grand-Perret T, 2001, NAT MED, V7, P1332, DOI 10.1038/nm1201-1332; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Hartmann T, 2001, TRENDS NEUROSCI, V24, pS45, DOI 10.1016/S0166-2236(00)01990-1; Ingham PW, 2001, SCIENCE, V294, P1879, DOI 10.1126/science.1064115; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; ROGERS W, 2002, BIOTECHNIQUES, V5, P1044; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	20	20	29	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					936	940		10.1038/nbt844	http://dx.doi.org/10.1038/nbt844			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12858181				2022-12-25	WOS:000184484600039
J	Jin, YH; Clark, AB; Slebos, RJC; Al-Refai, H; Taylor, JA; Kunkel, TA; Resnick, MA; Gordenin, DA				Jin, YH; Clark, AB; Slebos, RJC; Al-Refai, H; Taylor, JA; Kunkel, TA; Resnick, MA; Gordenin, DA			Cadmium is a mutagen that acts by inhibiting mismatch repair	NATURE GENETICS			English	Article							DNA-POLYMERASES DELTA; REPLICATION; EXONUCLEASES; EPSILON; ERRORS; PCNA; RUNS	Most errors that arise during DNA replication can be corrected by DNA polymerase proofreading or by post-replication mismatch repair (MMR). Inactivation of both mutation-avoidance systems results in extremely high mutability that can lead to error catastrophe(1,2). High mutability and the likelihood of cancer can be caused by mutations and epigenetic changes that reduce MMR3,4. Hypermutability can also be caused by external factors that directly inhibit MMR. Identifying such factors has important implications for understanding the role of the environment in genome stability. We found that chronic exposure of yeast to environmentally relevant concentrations of cadmium, a known human carcinogen(5), can result in extreme hypermutability. The mutation specificity along with responses in proofreading-deficient and MMR-deficient mutants indicate that cadmium reduces the capacity for MMR of small misalignments and base-base mismatches. In extracts of human cells, cadmium inhibited at least one step leading to mismatch removal. Together, our data show that a high level of genetic instability can result from environmental impediment of a mutation-avoidance system.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Gordenin, DA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	gordenin@niehs.nih.gov	Dmitry, Gordenin/C-3907-2018; taylor, jack a/C-7154-2019; resnick, Michael/F-1668-2019; Kunkel, Thomas A./D-5088-2019	Dmitry, Gordenin/0000-0002-8399-1836; taylor, jack a/0000-0001-5303-6398; resnick, Michael/0000-0002-8473-7506; Kunkel, Thomas A./0000-0002-9900-1788	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065073] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Coleman WB, 1999, ANTICANCER RES, V19, P4645; Drotschmann K, 1999, CURR BIOL, V9, P907, DOI 10.1016/S0960-9822(99)80396-0; Elinder C-G, 1985, CADMIUM HLTH TOXICOL, P81; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Gary R, 1999, MOL CELL BIOL, V19, P5373; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Gordenin DA, 1998, MUTAT RES-FUND MOL M, V400, P45, DOI 10.1016/S0027-5107(98)00047-5; Harfe BD, 2000, GENETICS, V156, P571; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hartwig A, 2001, ANTIOXID REDOX SIGN, V3, P625, DOI 10.1089/15230860152542970; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; IARC, 1993, BER CADM MERC EXP GL, V58, P119; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; KHROMOVBORISOV NN, 2002, TECH TIPS ONLINE, V1; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Leach Fredrick S, 2002, Curr Opin Urol, V12, P407, DOI 10.1097/00042307-200209000-00007; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waalkes M.P., 1996, TOXICOLOGY METALS, P231	29	374	400	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2003	34	3					326	329		10.1038/ng1172	http://dx.doi.org/10.1038/ng1172			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12796780	Green Accepted			2022-12-25	WOS:000183815300022
J	Mazurier, F; Doedens, M; Gan, OI; Dick, JE				Mazurier, F; Doedens, M; Gan, OI; Dick, JE			Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells	NATURE MEDICINE			English	Article							HUMAN HEMATOPOIETIC-CELLS; BONE-MARROW; SEEDING EFFICIENCY; LONG-TERM; IN-VITRO; BLOOD; ENGRAFTMENT; EXPANSION; ASSAY	A major problem hampering effective stem cell-based therapies is the absence of a clear understanding of the human hematopoietic stem cell (HSC) pool composition. The severe combined immunodeficiency (SCID) repopulating cell (SRC) xenotransplant assay system provides a powerful tool for characterizing the frequency, cell surface markers, cell cycle status, homing and response to cytokine stimulation of human HSCs1-3. Clonal tracking of retrovirally transduced SRCs and transplantation of specific subpopulations revealed SRC classes with distinct repopulation potentials(4-7). However, all HSC repopulation assays are based on intravenous injection, a complex process that requires circulation through blood, recognition and extravasation through bone marrow vasculature, and migration to a supportive microenvironment(8-11). Thus, some classes of HSCs may remain undetected. By direct intrafemoral injection, we identified rapid SRCs (R-SRCs) within the Lin(-)CD34(+)CD38(lo)CD36(-) subpopulation. R-SRCs rapidly generate high levels of human myeloid and erythroid cells within the injected femur, migrate to the blood and colonize individual bones of non-obese diabetic (NOD)-SCID mice within 2 weeks after transplantation. Lentivector-mediated clonal analysis of individual R-SRCs revealed heterogeneity in their proliferative and migratory properties. The identification of a new HSC class and an effective intrafemoral assay provide the tools required to develop more effective stem cell-based therapies that rely on rapid reconstitution.	Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Mol Genet & Microbiol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dick, JE (corresponding author), Univ Hlth Network, Div Cell & Mol Biol, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jdick@uhnres.utoronto.ca		Mazurier, Frederic/0000-0002-6984-7096; Dick, John/0000-0002-9527-8317				Ando K, 2000, EXP HEMATOL, V28, P690, DOI 10.1016/S0301-472X(00)00154-5; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Bonnet D, 2002, J PATHOL, V197, P430, DOI 10.1002/path.1153; Cashman JD, 2000, BLOOD, V96, P3979, DOI 10.1182/blood.V96.12.3979.h8003979_3979_3981; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; Guenechea G, 2000, MOL THER, V1, P566, DOI 10.1006/mthe.2000.0077; Guenechea G, 2001, NAT IMMUNOL, V2, P75, DOI 10.1038/83199; Hagglund H, 1998, BONE MARROW TRANSPL, V21, P331, DOI 10.1038/sj.bmt.1701116; Hogan CJ, 2002, P NATL ACAD SCI USA, V99, P413, DOI 10.1073/pnas.012336799; Kerre TCC, 2001, J IMMUNOL, V167, P3692, DOI 10.4049/jimmunol.167.7.3692; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lemischka IR, 2001, NAT IMMUNOL, V2, P11, DOI 10.1038/83115; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Quesenberry PJ, 1998, P NATL ACAD SCI USA, V95, P15155, DOI 10.1073/pnas.95.26.15155; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; van Hennik PB, 1999, BLOOD, V94, P3055, DOI 10.1182/blood.V94.9.3055.421k05_3055_3061; WANG JC, 2001, HEMATOPOIESIS DEV AP, P99; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wang JF, 2003, BLOOD, V101, P2924, DOI 10.1182/blood-2002-09-2782; Yahata T, 2003, BLOOD, V101, P2905, DOI 10.1182/blood-2002-07-1995	25	221	239	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					959	963		10.1038/nm886	http://dx.doi.org/10.1038/nm886			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12796774				2022-12-25	WOS:000183979300039
J	Cai, ST; Han, HJ; Kohwi-Shigematsu, T				Cai, ST; Han, HJ; Kohwi-Shigematsu, T			Tissue-specific nuclear architecture and gene expession regulated by SATB1	NATURE GENETICS			English	Article							MATRIX-ATTACHMENT REGION; BINDING PROTEIN SATB1; BETA-GLOBIN LOCUS; CELL-SPECIFIC DEMETHYLATION; HISTONE H3 METHYLATION; C-MYC; CHAIN ENHANCER; IN-VIVO; CHROMATIN; DNA	Eukaryotic chromosomes are packaged in nuclei by many orders of folding. Little is known about how higher-order chromatin packaging might affect gene expression. SATB1 is a cell-type specific nuclear protein that recruits chromatin-remodeling factors and regulates numerous genes during thymocyte differentiation. Here we show that in thymocyte nuclei, SATB1 has a cage-like 'network' distribution circumscribing heterochromatin and selectively tethers specialized DNA sequences onto its network. This was shown by fluorescence in situ hybridization on wild-type and Satb1-null thymocytes using in vivo SATB1-bound sequences as probes. Many gene loci, including that of Myc and a brain-specific gene, are anchored by the SATB1 network at specific genomic sites, and this phenomenon is precisely correlated with proper regulation of distant genes. Histone-modification analyses across a gene-enriched genomic region of 70 kb showed that acetylation of histone H3 at Lys9 and Lys14 peaks at the SATB1-binding site and extends over a region of roughly 10 kb covering genes regulated by SATB1. By contrast, in Satb1-null thymocytes, this site is marked by methylation at H3 Lys9. We propose SATB1 as a new type of gene regulator with a novel nuclear architecture, providing sites for tissue-specific organization of DNA sequences and regulating region-specific histone modification.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kohwi-Shigematsu, T (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd 84-171, Berkeley, CA 94720 USA.							Alvarez JD, 2000, GENE DEV, V14, P521; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Cai ST, 1999, METHODS, V19, P394, DOI 10.1006/meth.1999.0875; Chan HM, 2001, J CELL SCI, V114, P2363; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Douglas NC, 2001, NAT IMMUNOL, V2, P307, DOI 10.1038/86308; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Liu WM, 1999, CANCER RES, V59, P5695; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; Schubeler D, 2000, GENE DEV, V14, P940; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084	50	336	364	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					42	51		10.1038/ng1146	http://dx.doi.org/10.1038/ng1146			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12692553	Green Published			2022-12-25	WOS:000182667900015
J	Liu, ST; Hittle, JC; Jablonski, SA; Campbell, MS; Yoda, K; Yen, TJ				Liu, ST; Hittle, JC; Jablonski, SA; Campbell, MS; Yoda, K; Yen, TJ			Human CENP-I specifies localization of CENP-F, MAD1 and MAD2 to kinetochores and is essential for mitosis	NATURE CELL BIOLOGY			English	Article							MITOTIC CHECKPOINT PROTEINS; MAMMALIAN-CELLS; CHROMOSOME ALIGNMENT; HELA-CELLS; CHROMATIN; SEGREGATION; ATTACHMENT; MONITORS; COMPLEX; HOMOLOG	The kinetochore, a macromolecular complex located at the centromere of chromosomes, provides essential functions for accurate chromosome segregation(1,2). Kinetochores contain checkpoint proteins that monitor attachments between the kinetochore and microtubules to ensure that cells do not exit mitosis in the presence of unaligned chromosomes(3,4). Here we report that human CENP-1, a constitutive protein of the kinetochore that shares limited similarity with Mis6 of Schizosaccharomyces pombe, is required for the localization of CENP-F and the checkpoint proteins MAD1 and MAD2 to kinetochores. Depletion of CENP-1 from kinetochores causes the cell cycle to delay in G2. Although monopolar chromosomes in CENP-1-depleted cells fall to establish bipolar connections, the cells are unable to arrest in mitosis. These cells are transiently delayed in mitosis in a MAD2-dependent manner, even though their kinetochores are depleted of MAD2. The delay is extended considerably when the number of unattached kinetochores is increased. This suggests that no single unattached kinetochore in CENP-1-depleted cells can arrest mitosis. The collective output from many unattached kinetochores is required to reach a threshold signal of 'wait for anaphase' to sustain a prolonged mitotic arrest.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Fox Chase Cancer Center; Nagoya University	Liu, ST (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Liu, Song-Tao/Y-4732-2019	Yen, Tim/0000-0003-2159-0997; Liu, Song-Tao/0000-0002-9623-8579; Jablonski, Sandra/0000-0001-7220-8159	NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM44762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Campbell MS, 2001, J CELL SCI, V114, P953; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Kao GD, 2001, ONCOGENE, V20, P3486, DOI 10.1038/sj.onc.1204445; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Maney T, 2000, INT REV CYTOL, V194, P67; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; Measday V, 2002, GENE DEV, V16, P101, DOI 10.1101/gad.949302; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Roberts RG, 1996, GENOMICS, V37, P122, DOI 10.1006/geno.1996.0528; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Van Hooser AA, 2001, CURR BIOL, V11, pR855, DOI 10.1016/S0960-9822(01)00515-2; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181	27	122	130	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					341	345		10.1038/ncb953	http://dx.doi.org/10.1038/ncb953			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12640463				2022-12-25	WOS:000182080700018
J	Tonon, G; Modi, S; Wu, LZ; Kubo, A; Coxon, AB; Komiya, T; O'Neil, K; Stover, K; El-Naggar, A; Griffin, JD; Kirsch, IR; Kaye, FJ				Tonon, G; Modi, S; Wu, LZ; Kubo, A; Coxon, AB; Komiya, T; O'Neil, K; Stover, K; El-Naggar, A; Griffin, JD; Kirsch, IR; Kaye, FJ			t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway	NATURE GENETICS			English	Article							MINOR SALIVARY-GLAND; NEOPLASTIC TRANSFORMATION; CHROMOSOMAL TRANSLOCATIONS; HUMAN HOMOLOG; GENE; TUMOR; ACTIVATION; EXPRESSION; MASTERMIND; RECEPTORS	Truncation of Notch1 has been shown to cause a subtype of acute leukemia(1), and activation of Notch4 has been associated with mammary and salivary gland carcinomas of mice(2). Here we identify a new mechanism for disrupting Notch signaling in human tumorigenesis, characterized by altered function of a new ortholog of the Drosophila melanogaster Notch co-activator molecule Mastermind. We cloned the t(11;19) translocation that underlies the most common type of human malignant salivary gland tumor. This rearrangement fuses exon 1 from a novel gene of unknown function at 19p13, termed mucoepidermoid carcinoma translocated 1 (MECT1), with exons 2-5 of a novel member of the Mastermind-like gene family (MAML2) at 11q21 (ref. 3). Similar to D. melanogaster Mastermind and MAML1 (refs. 4,5), full-length MAML2 functioned as a CSL (CBF-1, suppressor of hairless and Lag-1)-dependent transcriptional co-activator for ligand-stimulated Notch. In contrast, MECT1-MAML2 activated transcription of the Notch target gene HES1 independently of both Notch ligand and CSL binding sites. MECT1-MAML2 induced foci formation in RK3E epithelial cells, confirming a biological effect for the fusion product. These data suggest a new mechanism to disrupt the function of a Notch co-activator in a common type of malignant salivary gland tumor.	Natl Canc Inst, Genet Branch, Ctr Canc Res, Bethesda, MD 20889 USA; Natl Naval Med Ctr, Bethesda, MD 20889 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Natl Naval Med Ctr, Dept Med, Div Pulm, Bethesda, MD 20889 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Walter Reed National Military Medical Center; University of Texas System; UTMD Anderson Cancer Center	Kaye, FJ (corresponding author), Natl Canc Inst, Genet Branch, Ctr Canc Res, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	Tonon, Giovanni/J-9804-2018; kaye, frederic/E-2437-2011	Tonon, Giovanni/0000-0003-2973-5038; 	NATIONAL CANCER INSTITUTE [Z01SC007256, ZIASC007256] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; DAHLENFORS R, 1995, CANCER GENET CYTOGEN, V79, P188, DOI 10.1016/0165-4608(94)00121-Q; DAHLENFORS R, 1994, HEREDITAS, V120, P287, DOI 10.1111/j.1601-5223.1994.00287.x; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ElNaggar AK, 1996, CANCER GENET CYTOGEN, V87, P29, DOI 10.1016/0165-4608(95)00266-9; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HORSMAN DE, 1995, CANCER GENET CYTOGEN, V80, P165, DOI 10.1016/0165-4608(94)00187-G; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JOHANSSON M, 1995, CANCER GENET CYTOGEN, V80, P85, DOI 10.1016/0165-4608(94)00160-D; Kojika S, 2001, EXP HEMATOL, V29, P1041, DOI 10.1016/S0301-472X(01)00676-2; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tonon G, 2000, GENE CHROMOSOME CANC, V27, P418, DOI 10.1002/(SICI)1098-2264(200004)27:4<418::AID-GCC12>3.0.CO;2-O; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; Wolfe MS, 2001, J MOL NEUROSCI, V17, P199, DOI 10.1385/JMN:17:2:199; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464	30	373	399	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2003	33	2					208	213		10.1038/ng1083	http://dx.doi.org/10.1038/ng1083			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12539049	Green Published			2022-12-25	WOS:000180773700022
J	Kotb, M; Norrby-Teglund, A; McGeer, A; El-Sherbini, H; Dorak, MT; Khurshid, A; Green, K; Peeples, J; Wade, J; Thomson, G; Schwartz, B; Low, DE				Kotb, M; Norrby-Teglund, A; McGeer, A; El-Sherbini, H; Dorak, MT; Khurshid, A; Green, K; Peeples, J; Wade, J; Thomson, G; Schwartz, B; Low, DE			An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections	NATURE MEDICINE			English	Article							TOXIC-SHOCK-SYNDROME; T-CELLS; DISEASE; SUPERANTIGENS; RESPONSES	The role of host genetic factors in conferring predisposition or protection in infectious diseases has become evident. Infection with group A streptococci causes a wide spectrum of disease ranging from pharyngitis to streptococcal toxic shock syndrome. The release of inflammatory cytokines triggered by streptococcal superantigens has a pivotal role in invasive streptococcal disease. However, individuals infected with the same strain can develop very different manifestations. We report here that the immunogenetics of the host influence the outcome of invasive streptococcal infection, and demonstrate the underlying mechanism for these genetic associations. Specific human leukocyte antigen class II haplotypes conferred strong protection from severe systemic disease, whereas others increased the risk of severe disease. Patients with the DRB1*1501/DQB1*0602 haplotype mounted significantly reduced responses and were less likely to develop severe systemic disease (P<0.0001). We propose that human leukocyte antigen class II allelic variation contributes to differences in severity of invasive streptococcal infections through their ability to regulate cytokine responses triggered by streptococcal superantigens.	Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA; Univ Tennessee, Dept Surg & Mol Sci, Memphis, TN USA; Huddinge Univ Hosp, Ctr Infect Dis, Karolinska Inst, Stockholm, Sweden; Univ Toronto, Toronto, ON, Canada; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA	Kotb, M (corresponding author), Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA.		Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040198] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40198] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basma H, 1999, INFECT IMMUN, V67, P1871; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; Doraiswamy PM, 2001, J CLIN PSYCHIAT, V62, P30; Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; Hill AVS, 1999, BRIT MED BULL, V55, P401, DOI 10.1258/0007142991902457; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; Kaul R, 1999, CLIN INFECT DIS, V28, P800, DOI 10.1086/515199; Kaul R, 1997, AM J MED, V103, P18, DOI 10.1016/S0002-9343(97)00160-5; KOTB M, 1995, CLIN MICROBIOL REV, V8, P411, DOI 10.1128/CMR.8.3.411; LOW DE, 1998, EMERGING PATHOGENS, V7; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Newton DW, 1996, J IMMUNOL, V157, P3988; Norrby-Teglund A, 2001, J INFECT DIS, V184, P853, DOI 10.1086/323443; Norrby-Teglund A, 2000, EUR J IMMUNOL, V30, P3247, DOI 10.1002/1521-4141(200011)30:11<3247::AID-IMMU3247>3.0.CO;2-D; NorrbyTeglund A, 1997, INFECT IMMUN, V65, P5209, DOI 10.1128/IAI.65.12.5209-5215.1997; OHNISHI H, 1995, J IMMUNOL, V154, P3180; OLERUP O, 1992, TISSUE ANTIGENS, V39, P2253; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; WADE J, 1998, HLA 1998; WATANABEOHNISHI R, 1995, J INFECT DIS, V171, P74, DOI 10.1093/infdis/171.1.74	23	277	289	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1398	1404		10.1038/nm800	http://dx.doi.org/10.1038/nm800			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12436116				2022-12-25	WOS:000179552000036
J	Mallet, VO; Mitchell, C; Guidotti, JE; Jaffray, P; Fabre, M; Spencer, D; Arnoult, D; Kahn, A; Gilgenkrantz, H				Mallet, VO; Mitchell, C; Guidotti, JE; Jaffray, P; Fabre, M; Spencer, D; Arnoult, D; Kahn, A; Gilgenkrantz, H			Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice	NATURE BIOTECHNOLOGY			English	Article							FULMINANT HEPATIC-FAILURE; ACUTE LIVER-FAILURE; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; IN-VIVO; LINEAGE ABLATION; DEATH; EXPRESSION; DISEASE; HEPATOCYTES	Studying the effects of the loss of a specific cell type is a powerful approach in biology. Here we present a method based on the controlled activation of the apoptotic machinery. We expressed a modified caspase-3-containing chemical inducer of dimerization (CID)-binding sites in the livers of transgenic mice. In the absence of CID, no liver injury was detectable, underlining the absence of leakage in our system. In contrast, injection of the CID produced activation of the chimeric caspase-3, which led to a dose-dependent pure hepatocyte ablation with subsequent regeneration. This method is effective in both growing and nongrowing cells, and is therefore applicable to a wide range of cells and tissues. Moreover, because apoptosis has been described in numerous pathological circumstances, this system is useful for generating mouse models of human disorders as well as for studying the recovery or regeneration of tissues after cell loss.	Cochin Inst, Dept Genet Dev & Mol Pathol, F-75014 Paris, France; Cochin Inst, Biochem Lab, F-75014 Paris, France; Hop Bicetre, Pathol Lab, F-94275 Le Kremlin Bicetre, France; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Hop Bichat Claude Bernard, INSERM, U9922, EMI, F-75877 Paris 18, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Baylor College of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gilgenkrantz, H (corresponding author), Cochin Inst, Dept Genet Dev & Mol Pathol, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	gilgenkrantz@cochin.inserm.fr	Gilgenkrantz, Helene/G-5534-2017; Guidotti, Jacques-Emmanuel/M-9014-2018; Mallet, Vincent/G-4623-2011	guidotti, jacques-emmanuel/0000-0001-9285-8167; gilgenkrantz, helene/0000-0001-6770-4561; Mallet, Vincent/0000-0003-2219-9201				BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; Braun KM, 2000, NAT MED, V6, P320; CARACENI P, 1995, LANCET, V345, P163, DOI 10.1016/S0140-6736(95)90171-X; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FINGEROTE RJ, 1993, AM J GASTROENTEROL, V88, P1000; Fox CK, 2001, LIVER, V21, P272, DOI 10.1034/j.1600-0676.2001.021004272.x; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hecht N, 2001, MOL THER, V3, P683, DOI 10.1006/mthe.2001.0313; Janin A, 2002, BLOOD, V99, P2940, DOI 10.1182/blood.V99.8.2940; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; KOBAYASHI K, 1995, P NATL ACAD SCI USA, V92, P1132, DOI 10.1073/pnas.92.4.1132; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kosai K, 1999, HEPATOLOGY, V30, P151, DOI 10.1002/hep.510300102; Krajewska M, 1997, CANCER RES, V57, P1605; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; MATTHEWS T, 1988, REV INFECT DIS, V10, pS490; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Nanji AA, 1998, SEMIN LIVER DIS, V18, P187, DOI 10.1055/s-2007-1007154; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Newsome PN, 2000, LIVER TRANSPLANT, V6, P21, DOI 10.1016/S1527-6465(00)80029-5; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; Rudiger HA, 2002, GASTROENTEROLOGY, V122, P202, DOI 10.1053/gast.2002.30304; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Woo M, 1999, J IMMUNOL, V163, P4909; Xie XM, 2001, CANCER RES, V61, P6795; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yoon JW, 2001, ANN NY ACAD SCI, V928, P200; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	39	52	62	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1234	1239		10.1038/nbt762	http://dx.doi.org/10.1038/nbt762			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12434157				2022-12-25	WOS:000179552600043
J	Cook, PR				Cook, PR			Predicting three-dimensional genome structure from transcriptional activity	NATURE GENETICS			English	Editorial Material							RNA-POLYMERASE; INTERPHASE CHROMOSOMES; BACILLUS-SUBTILIS; SELF-ORGANIZATION; NUCLEAR MATRIX; LIVING CELLS; MODEL; GENES; DNA; SITES	We would like to be able to predict how genomes are folded in the cell from the primary DNA sequence. A model for the three-dimensional structure of all genomes is presented; it is based on the structure of the bacterial nucleoid, where RNA polymerases cluster and loop the DNA. Loops appear and disappear as polymerases initiate and terminate, but the microscopic structure is 'self-organizing' and, to some extent, predictable. At the macroscopic level, transcriptional activity drives pairing between homologous sequences, inactivity allows genome compaction, and the segregation machinery orients whole chromosomes.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Cook, PR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	peter.cook@path.ox.ac.uk		Cook, Peter/0000-0002-6639-188X				Abranches R, 1998, J CELL BIOL, V143, P5, DOI 10.1083/jcb.143.1.5; Bremer H, 1996, ESCHERICHIA COLI SAL; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Chubb JR, 2002, CURR BIOL, V12, P439, DOI 10.1016/S0960-9822(02)00695-4; Cook PR, 1997, J CELL SCI, V110, P1033; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; COOK PR, 1995, J CELL SCI, V108, P2927; Cook PR, 2001, PRINCIPLES NUCL STRU; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Frey MR, 1999, CURR BIOL, V9, P126, DOI 10.1016/S0960-9822(99)80066-9; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Gustafsson MGL, 1999, CURR OPIN STRUC BIOL, V9, P627, DOI 10.1016/S0959-440X(99)00016-0; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Ishihama A, 1981, Adv Biophys, V14, P1; Jackson DA, 1996, NUCLEIC ACIDS RES, V24, P1212, DOI 10.1093/nar/24.7.1212; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1984, J CELL SCI, P59; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kurz A, 1996, J CELL BIOL, V135, P1195, DOI 10.1083/jcb.135.5.1195; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Levsky JM, 2002, SCIENCE, V297, P836, DOI 10.1126/science.1072241; Lewis PJ, 2000, EMBO J, V19, P710, DOI 10.1093/emboj/19.4.710; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Manders EMM, 1999, J CELL BIOL, V144, P813, DOI 10.1083/jcb.144.5.813; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Mascarenhas J, 2001, EMBO REP, V2, P685, DOI 10.1093/embo-reports/kve160; MCKEE BD, 1992, GENETICS, V132, P529; MCMANUS J, 1994, J CELL SCI, V107, P469; Minsky A, 2002, NAT REV MOL CELL BIO, V3, P50, DOI 10.1038/nrm700; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Nickerson JA, 2001, J CELL SCI, V114, P463; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pettijohn D.E., 1996, ESCHERICHIA COLI SAL, P158; Pombo A, 1998, EMBO J, V17, P1768, DOI 10.1093/emboj/17.6.1768; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SAITOH Y, 1978, COLD SPRING HARB SYM, V58, P755; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sudbrak R, 2001, HUM MOL GENET, V10, P77, DOI 10.1093/hmg/10.1.77; Sugaya K, 2000, J CELL SCI, V113, P2679	52	123	128	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2002	32	3					347	352		10.1038/ng1102-347	http://dx.doi.org/10.1038/ng1102-347			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12410231				2022-12-25	WOS:000179034800007
J	Parvari, R; Hershkovitz, E; Grossman, N; Gorodischer, R; Loeys, B; Zecic, A; Mortier, G; Gregory, S; Sharony, R; Kambouris, M; Sakati, N; Meyer, BF; Al Aqeel, AI; Al Humaidan, AK; Al Zanhrani, F; Al Swaid, A; Al Othman, J; Diaz, GA; Weiner, R; Khan, KTS; Gordon, R; Gelb, BD				Parvari, R; Hershkovitz, E; Grossman, N; Gorodischer, R; Loeys, B; Zecic, A; Mortier, G; Gregory, S; Sharony, R; Kambouris, M; Sakati, N; Meyer, BF; Al Aqeel, AI; Al Humaidan, AK; Al Zanhrani, F; Al Swaid, A; Al Othman, J; Diaz, GA; Weiner, R; Khan, KTS; Gordon, R; Gelb, BD		HRD Autosomal Recessive Kenny-Caffey	Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome	NATURE GENETICS			English	Article							MICROTUBULE-ORGANIZING CENTER; CONGENITAL HYPOPARATHYROIDISM; MENTAL-RETARDATION; GOLGI-APPARATUS; GENE; GROWTH; POLARIZATION; REPEATS; PROTEIN; TUBULIN	The syndrome of congenital hypoparathyroidism, mental retardation, facial dysmorphism and extreme growth failure (HRD or Sanjad-Sakati syndrome; OMIM 241410) is an autosomal recessive disorder reported almost exclusively in Middle Eastern populations(1-3). A similar syndrome with the additional features of osteosclerosis and recurrent bacterial infections has been classified as autosomal recessive Kenny-Caffey syndrome(4) (AR-KCS; OMIM 244460). Both traits have previously been mapped to chromosome 1q43-44 (refs 5,6) and, despite the observed clinical variability, share an ancestral haplotype, suggesting a common founder mutation 7. We describe refinement of the critical region to an interval of roughly 230 kb and identification of deletion and truncation mutations of TBCE in affected individuals. The gene TBCE encodes one of several chaperone proteins required for the proper folding of alpha-tubulin subunits and the formation of alpha-beta-tubulin heterodimers. Analysis of diseased fibroblasts and lymphoblastoid cells showed lower microtubule density at the microtubule-organizing center (MTOC) and perturbed microtubule polarity in diseased cells. Immunofluorescence and ultrastructural studies showed disturbances in subcellular organelles that require microtubules for membrane trafficking, such as the Golgi and late endosomal compartments. These findings demonstrate that HRD and AR-KCS are chaperone diseases caused by a genetic defect in the tubulin assembly pathway, and establish a potential connection between tubulin physiology and the development of the parathyroid.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Ben Gurion Univ Negev, Dept Dev Mol Genet, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Pediat, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Skin Bank, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Invest Dermatol Lab, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Microbiol & Immunol, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel; Ghent Univ Hosp, Dept Med Genet, Ghent, Belgium; Ghent Univ Hosp, Dept Neonatol, Ghent, Belgium; Wellcome Trust Res Labs, Sanger Inst, Cambridge, England; Tel Aviv Univ, Sapir Med Ctr, Genet Inst, Meir Hosp,Sackler Sch Med, IL-69978 Tel Aviv, Israel; King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Al Jahra Hosp, Dept Pediat, Safat, Kuwait; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Wellcome Trust Sanger Institute; Tel Aviv University; Sackler Faculty of Medicine; King Faisal Specialist Hospital & Research Center; Prince Sultan Military Medical City; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Jahra Hosptial; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Diaz, GA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, 1 Gustave Levy Pl, New York, NY 10029 USA.		Loeys, Bart/B-3236-2017; Mortier, Geert/D-2542-2012; Gorodischer, Rafael/AAQ-8132-2020; Diaz, George/AAF-6199-2021; Herskowitz, eli/F-1922-2012	Loeys, Bart/0000-0003-3703-9518; Mortier, Geert/0000-0001-9871-4578; Herskowitz, eli/0000-0003-1624-1960; Gregory, Simon/0000-0002-7805-1743; Gorodischer, Rafael/0000-0002-7649-3353; Meyer, Brian/0000-0002-0388-9568				BARTOLINI F, 2002, J BIOL CHEM, V14, P14; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; des Portes V, 1998, CELL, V92, P51; Diaz GA, 1999, AM J MED GENET, V85, P48, DOI 10.1002/(SICI)1096-8628(19990702)85:1<48::AID-AJMG9>3.0.CO;2-Y; Diaz GA, 1998, GENOMICS, V54, P13, DOI 10.1006/geno.1998.5530; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HERSHKOVITZ E, 1995, ISRAEL J MED SCI, V31, P293; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Khan KTS, 1997, AM J MED GENET, V69, P126; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KUPFER A, 1983, P NATL ACAD SCI-BIOL, V80, P7224, DOI 10.1073/pnas.80.23.7224; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Martin N, 2002, NAT GENET, V32, P443, DOI 10.1038/ng1016; MERESSE S, 1995, J CELL SCI, V108, P3349; Parvari R, 1998, AM J HUM GENET, V63, P163, DOI 10.1086/301915; PIERRE P, 1994, J CELL SCI, V107, P1909; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RICHARDSON RJ, 1990, ARCH DIS CHILD, V65, P1113, DOI 10.1136/adc.65.10.1113; SANJAD SA, 1991, ARCH DIS CHILD, V66, P193, DOI 10.1136/adc.66.2.193; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	30	154	160	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					448	452		10.1038/ng1012	http://dx.doi.org/10.1038/ng1012			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12389028				2022-12-25	WOS:000179034800025
J	Rhee, J; Mahfooz, NS; Arregui, C; Lilien, J; Balsamo, J; VanBerkum, MFA				Rhee, J; Mahfooz, NS; Arregui, C; Lilien, J; Balsamo, J; VanBerkum, MFA			Activation of the repulsive receptor Roundabout inhibits N-cadherin-mediated cell adhesion	NATURE CELL BIOLOGY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; NEURONAL PROCESS OUTGROWTH; CENTRAL-NERVOUS-SYSTEM; AXON GUIDANCE; TYROSINE KINASE; NEURITE OUTGROWTH; SLIT; MIDLINE; ROLES; DROSOPHILA	The formation of axon trajectories requires integration of local adhesive interactions with directional information from attractive and repulsive cues. Here, we show that these two types of information are functionally integrated; activation of the transmembrane receptor Roundabout (Robo) by its ligand, the secreted repulsive guidance cue Slit, inactivates N-cadherin-mediated adhesion. Loss of N-cadherin-mediated adhesion is accompanied by tyrosine phosphorylation of beta-catenin and its loss from the N-cadherin complex, concomitant with the formation of a supramolecular complex containing Robo, Abelson (Abl) kinase and N-cadherin. Local formation of such a receptor complex is an ideal mechanism to steer the growth cone while still allowing adhesion and growth in other directions.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA; Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	University of Iowa; Wayne State University	Rhee, J (corresponding author), Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA.			Arregui, Carlos/0000-0003-0704-3321				Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; Bagri A, 2002, NEURON, V33, P233, DOI 10.1016/S0896-6273(02)00561-5; BALSAMO J, 1991, J CELL BIOL, V113, P429, DOI 10.1083/jcb.113.2.429; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 2001, J CELL BIOL, V155, P1117, DOI 10.1083/jcb.200110077; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BIXBY JL, 1988, J CELL BIOL, V107, P353, DOI 10.1083/jcb.107.1.353; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Erskine L, 2000, J NEUROSCI, V20, P4975; Fricke C, 2001, SCIENCE, V292, P507, DOI 10.1126/science.1059496; Fritz JL, 2000, DEVELOPMENT, V127, P1991; GAYAGONZALEZ L, 1991, J NEUROSCI RES, V29, P474, DOI 10.1002/jnr.490290407; Grevengoed EE, 2001, J CELL BIOL, V155, P1185, DOI 10.1083/jcb.200105102; Grunwald GB, 1996, PROG RETIN EYE RES, V15, P363, DOI 10.1016/1350-9462(96)00008-0; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Hutson LD, 2002, NEURON, V33, P205, DOI 10.1016/S0896-6273(01)00579-7; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Lambert M, 2000, J CELL SCI, V113, P2207; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Li HD, 2000, J CELL BIOL, V149, P1275, DOI 10.1083/jcb.149.6.1275; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Loureiro J, 1998, CURR BIOL, V8, P622, DOI 10.1016/S0960-9822(98)70249-0; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Murray MJ, 1999, J NEUROSCI, V19, P7901; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1117; Niclou SP, 2000, J NEUROSCI, V20, P4962; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5; Ranscht B, 2000, INT J DEV NEUROSCI, V18, P643, DOI 10.1016/S0736-5748(00)00030-7; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; Ringstedt T, 2000, J NEUROSCI, V20, P4983; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	50	153	156	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					798	805		10.1038/ncb858	http://dx.doi.org/10.1038/ncb858			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360290				2022-12-25	WOS:000178316500017
J	Hrachovinova, I; Cambien, B; Hafezi-Moghadam, A; Kappelmayer, J; Camphausen, RT; Widom, A; Xia, LJ; Kazazian, HH; Schaub, RG; McEver, RP; Wagner, DD				Hrachovinova, I; Cambien, B; Hafezi-Moghadam, A; Kappelmayer, J; Camphausen, RT; Widom, A; Xia, LJ; Kazazian, HH; Schaub, RG; McEver, RP; Wagner, DD			Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A	NATURE MEDICINE			English	Article							TISSUE FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; GLYCOPROTEIN LIGAND-1; VENOUS THROMBOSIS; SOLUBLE FORM; FACTOR-VIII; EXPRESSION; PLATELETS; ADHESION	High plasma levels of soluble P-selectin are associated with thrombotic disorders and may predict future cardiovascular events. Mice with high levels of soluble P-selectin have more microparticles in their plasma than do normal mice. Here we show that chimeras of P-selectin and immunoglobulin (P-sel-Ig) induced formation of procoagulant microparticles in human blood through P-selectin glycoprotein ligand-1 (PSGL-1; encoded by the Psgl1 gene, officially known as Selpl). In addition, Psgl1(-/-) mice produced fewer microparticles after P-sel-Ig infusion and did not spontaneously increase their microparticle count in old age as do wild-type mice. Injected microparticles specifically bound to thrombi and thus could be involved in thrombin generation at sites of injury. Infusion of P-sel-Ig into hemophilia A mice produced a 20-fold increase over control immunoglobulin in microparticles containing tissue factor. This significantly improved the kinetics of fibrin formation in the hemophilia A mice and normalized their tail-bleeding time. P-sel-Ig treatment could become a new approach to sustained control of bleeding in hemophilia.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Wyeth Res, Cambridge, MA 02140 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Pfizer; University of Pennsylvania; University of Pennsylvania	Wagner, DD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	wagner@cbr.med.harvard.edu	Cambien, Béatrice/AAD-8973-2021	Cambien, Béatrice/0000-0002-6914-0525; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502, R01HL053756, P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54502, R01 HL053756, P01 HL056949, HL56949] Funding Source: Medline; PHS HHS [53756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Barkalow FJ, 2000, BLOOD, V96, P3070; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHONG BH, 1994, BLOOD, V83, P1535; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DiMichele DM, 2000, HAEMOPHILIA, V6, P38; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Hillis GS, 2002, AM HEART J, V143, P235, DOI 10.1067/mhj.2002.120303; IKEDA H, 1995, CIRCULATION, V92, P1693, DOI 10.1161/01.CIR.92.7.1693; ISHIWATA N, 1994, J BIOL CHEM, V269, P23708; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; Lacroix-Desmazes S, 2002, HAEMOPHILIA, V8, P273, DOI 10.1046/j.1365-2516.2002.00624.x; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, THROMB HAEMOSTASIS, V87, P364; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Michelson AD, 2001, CIRCULATION, V104, P1533, DOI 10.1161/hc3801.095588; Muchitsch EM, 1999, THROMB HAEMOSTASIS, V82, P1371; Myers D, 2002, THROMB HAEMOSTASIS, V87, P374, DOI 10.1055/s-0037-1613014; NEMERSON Y, 1988, BLOOD, V71, P1; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; Parker C, 2001, ATHEROSCLEROSIS, V156, P417, DOI 10.1016/S0021-9150(00)00672-9; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; Prorock AJ, 2003, AM J PHYSIOL-HEART C, V284, pH133, DOI 10.1152/ajpheart.00957.2001; Rauch U, 2000, BLOOD, V96, P170, DOI 10.1182/blood.V96.1.170.013k42_170_175; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; TOOMBS CF, 1995, J PHARMACOL EXP THER, V275, P941; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Wakefield TW, 1996, J SURG RES, V64, P26, DOI 10.1006/jsre.1996.0301; Xia LJ, 2002, J CLIN INVEST, V109, P939	45	247	257	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1020	1025		10.1038/nm899	http://dx.doi.org/10.1038/nm899			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858167				2022-12-25	WOS:000184484900025
J	Taylor, MR				Taylor, MR			Rethinking US leadership in food biotechnology	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					852	854		10.1038/nbt0803-852	http://dx.doi.org/10.1038/nbt0803-852			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12894194				2022-12-25	WOS:000184484600016
J	Vasilakis, N; Falvey, D; Gangolli, SS; Coleman, J; Kowalski, J; Udem, SA; Zamb, TJ; Kovacs, GR				Vasilakis, N; Falvey, D; Gangolli, SS; Coleman, J; Kowalski, J; Udem, SA; Zamb, TJ; Kovacs, GR			Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors	NATURE BIOTECHNOLOGY			English	Article							EQUINE ENCEPHALITIS-VIRUS; SINDBIS VIRUS; RNA; VACCINATION; SYSTEM; GENES; VACCINES	This report describes a transfection-independent system for packaging alphavirus replicon vectors using modified vaccinia virus Ankara (MVA) vectors to express all of the RNA components necessary for the production of Venezuelan equine encephalitis (VEE) virus replicon particles (VRP). Infection of mammalian cells with these recombinant MVA vectors resulted in robust expression of VEE structural genes, replication of the alphavirus vector and high titers of VRP. In addition, VRP packaging was achieved in a cell type (fetal rhesus lung) that has been approved for the manufacturing of vaccines destined for human use.	Wyeth Vaccines Res, Viral Vaccine Discovery, Pearl River, NY 10965 USA	Pfizer	Kovacs, GR (corresponding author), Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA.							BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; Davis NL, 2002, IUBMB LIFE, V53, P209, DOI 10.1080/15216540212657; Davis NL, 2000, J VIROL, V74, P371, DOI 10.1128/JVI.74.1.371-378.2000; Davis NL, 1996, J VIROL, V70, P3781, DOI 10.1128/JVI.70.6.3781-3787.1996; DAVIS NL, 1991, VIROLOGY, V183, P20, DOI 10.1016/0042-6822(91)90114-Q; Driver DA, 1995, ANN NY ACAD SCI, V772, P261, DOI 10.1111/j.1749-6632.1995.tb44754.x; Dubensky TW, 2000, GENE THERAPY, P109; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Kovacs GR, 2003, J VIROL METHODS, V111, P29, DOI 10.1016/S0166-0934(03)00132-0; MONROE SS, 1983, P NATL ACAD SCI-BIOL, V80, P3279, DOI 10.1073/pnas.80.11.3279; Polo JM, 1999, P NATL ACAD SCI USA, V96, P4598, DOI 10.1073/pnas.96.8.4598; Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878; Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360; Smerdou C, 1999, J VIROL, V73, P1092, DOI 10.1128/JVI.73.2.1092-1098.1999; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; Velders MP, 2001, CANCER RES, V61, P7861; WEISS BG, 1991, J VIROL, V65, P4017, DOI 10.1128/JVI.65.8.4017-4025.1991	20	12	16	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					932	935		10.1038/nbt845	http://dx.doi.org/10.1038/nbt845			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12845329				2022-12-25	WOS:000184484600038
J	Nakada, C; Ritchie, K; Oba, Y; Nakamura, M; Hotta, Y; Iino, R; Kasai, RS; Yamaguchi, K; Fujiwara, T; Kusumi, A				Nakada, C; Ritchie, K; Oba, Y; Nakamura, M; Hotta, Y; Iino, R; Kasai, RS; Yamaguchi, K; Fujiwara, T; Kusumi, A			Accumulation of anchored proteins forms membrane diffusion barriers during neuronal polarization	NATURE CELL BIOLOGY			English	Article							SINGLE-PARTICLE TRACKING; FREE-CELL SURFACE; PLASMA-MEMBRANE; LATERAL DIFFUSION; HIPPOCAMPAL-NEURONS; HYDRODYNAMIC INTERACTIONS; HOP DIFFUSION; MONTE-CARLO; E-CADHERIN; SKELETON	The formation and maintenance of polarized distributions of membrane proteins in the cell membrane are key to the function of polarized cells. In polarized neurons, various membrane proteins are localized to the somatodendritic domain or the axon. Neurons control polarized delivery of membrane proteins to each domain, and in addition, they must also block diffusional mixing of proteins between these domains. However, the presence of a diffusion barrier in the cell membrane of the axonal initial segment (IS), which separates these two domains, has been controversial: it is difficult to conceive barrier mechanisms by which an even diffusion of phospholipids could be blocked. Here, by observing the dynamics of individual phospholipid molecules in the plasma membrane of developing hippocampal neurons in culture, we found that their diffusion was blocked in the IS membrane. We also found that the diffusion barrier is formed in neurons 7 - 10 days after birth through the accumulation of various transmembrane proteins that are anchored to the dense actin-based membrane skeleton meshes being formed under the IS membrane. We conclude that various membrane proteins anchored to the dense membrane skeleton function as rows of pickets, which even stop the overall diffusion of phospholipids, and may represent a universal mechanism for formation of diffusion barriers in the cell membrane.	ERATO, Kusumi Membrane Organizer Project, Nagoya, Aichi 4600012, Japan; Nagoya Univ, Dept Biol Sci, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; RIKEN, Lab Memory & Learning, Brain Sci Inst, Wako, Saitama 3510198, Japan; JST, Yoshida ATP Syst Project, ERATO, Midori Ku, Yokohama, Kanagawa 2260026, Japan	Japan Science & Technology Agency (JST); Nagoya University; Nagoya University; Nagoya University; RIKEN; Japan Science & Technology Agency (JST)	Kusumi, A (corresponding author), ERATO, Kusumi Membrane Organizer Project, Nagoya, Aichi 4600012, Japan.		Nakamura, Mitsuhiro/I-1969-2014; Iino, Ryota/B-7746-2011; Fujiwara, Takahiro/G-2755-2012; Kasai, Rinshi S./ABA-7656-2021	Nakamura, Mitsuhiro/0000-0002-8679-2381; Iino, Ryota/0000-0003-0110-5704; Fujiwara, Takahiro/0000-0001-5576-759X; Kasai, Rinshi S./0000-0002-9234-3283				Akashi K, 1996, BIOPHYS J, V71, P3242, DOI 10.1016/S0006-3495(96)79517-6; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P7198, DOI 10.1021/bi00146a024; BARTLES JR, 1995, TRENDS CELL BIOL, V5, P400, DOI 10.1016/S0962-8924(00)89089-3; BUSSELL SJ, 1995, BIOPHYS J, V68, P1836, DOI 10.1016/S0006-3495(95)80360-7; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DODD TL, 1995, J FLUID MECH, V293, P147, DOI 10.1017/S0022112095001674; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; FUTERMAN AH, 1993, NATURE, V362, P119, DOI 10.1038/362119a0; Iino R, 2001, BIOPHYS J, V80, P2667, DOI 10.1016/S0006-3495(01)76236-4; Iino R, 2001, J FLUORESC, V11, P187, DOI 10.1023/A:1012297000742; JACOBSON K, 1981, BIOCHEMISTRY-US, V20, P5268, DOI 10.1021/bi00521a027; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; Konno K, 2000, NEUROSCI LETT, V285, P29, DOI 10.1016/S0304-3940(00)01017-X; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Kusumi A, 1998, METHOD CELL BIOL, V55, P173; Offenhausser A, 1997, NEUROSCI LETT, V223, P9, DOI 10.1016/S0304-3940(97)13372-9; PASENKIEWICZGIERULA M, 1991, BIOCHIMIE, V73, P1311, DOI 10.1016/0300-9084(91)90094-H; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; Ritchie K, 2003, METHOD ENZYMOL, V360, P618; Sahara Y, 2000, EUR J NEUROSCI, V12, P1961, DOI 10.1046/j.1460-9568.2000.00084.x; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; Saxton MJ, 1997, BIOPHYS J, V72, P1744, DOI 10.1016/S0006-3495(97)78820-9; SAXTON MJ, 1994, BIOPHYS J, V66, P394, DOI 10.1016/S0006-3495(94)80789-1; SPEROTTO MM, 1991, BIOPHYS J, V59, P261, DOI 10.1016/S0006-3495(91)82219-6; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tomishige M, 1998, J CELL BIOL, V142, P989, DOI 10.1083/jcb.142.4.989; Tomishige M, 1999, MOL BIOL CELL, V10, P2475, DOI 10.1091/mbc.10.8.2475; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17789; Winckler B, 1996, NATURE, V379, P213, DOI 10.1038/379213a0; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	33	275	281	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					626	U3		10.1038/ncb1009	http://dx.doi.org/10.1038/ncb1009			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12819789				2022-12-25	WOS:000183911600012
J	Seitz, H; Youngson, N; Lin, SP; Dalbert, S; Paulsen, M; Bachellerie, JP; Ferguson-Smith, AC; Cavaille, J				Seitz, H; Youngson, N; Lin, SP; Dalbert, S; Paulsen, M; Bachellerie, JP; Ferguson-Smith, AC; Cavaille, J			Imprinted microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon-like gene	NATURE GENETICS			English	Article							IDENTIFICATION; DOMAIN; RNA; METHYLATION; TARGETS; AIR	MicroRNAs (miRNAs) are an abundant class of RNAs that are similar to21-25 nucleotides (nt) long, interact with mRNAs and trigger either translation repression or RNA cleavage (RNA interference, RNAi) depending on the degree of complementarity with their targets. Here we show that the imprinted mouse distal chromosome 12 locus encodes two miRNA genes expressed from the maternally inherited chromosome and antisense to a retrotransposon-like gene (Rtl1) expressed only from the paternal allele.	Univ Toulouse 3, LBME, CNRS UMR 5099, IFR 109, F-31062 Toulouse, France; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Saarland, FR Genet, Postfach 151150, D-66041 Saarbrucken, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Cambridge; Saarland University	Cavaille, J (corresponding author), Univ Toulouse 3, LBME, CNRS UMR 5099, IFR 109, 118 Route Narbonne, F-31062 Toulouse, France.		Ferguson-Smith, Anne C/G-7534-2011; cavaille, jerome/AAM-8047-2020; Paulsen, Martina/G-2262-2010; Seitz, Hervé/AAE-6487-2019; Youngson, Neil/AAB-7389-2019	Seitz, Hervé/0000-0001-8172-5393; Youngson, Neil/0000-0003-0690-4580; CAVAILLE, Jerome/0000-0003-2833-6836; Lin, Shau-Ping/0000-0003-3423-991X; Ferguson-Smith, Anne/0000-0002-7608-5894				Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527; Charlier C, 2001, GENOME RES, V11, P850, DOI 10.1101/gr.172701; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rougeulle C, 2002, TRENDS GENET, V18, P434, DOI 10.1016/S0168-9525(02)02749-X; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	13	284	313	1	15	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					261	262		10.1038/ng1171	http://dx.doi.org/10.1038/ng1171			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12796779				2022-12-25	WOS:000183815300010
J	Bachtrog, D				Bachtrog, D			Adaptation shapes patterns of genome evolution on sexual and asexual chromosomes in Drosophila	NATURE GENETICS			English	Article							NEO-Y CHROMOSOME; DEGENERATION; HYPOTHESIS; MIRANDA	What advantage might sexual recombination confer? Population genetics theory predicts that asexual genomes are less efficient at eliminating deleterious mutations and incorporating beneficial alleles(1,2). Here, I compare patterns of genome evolution in a 40-kb gene-rich region on homologous neo-sex chromosomes of Drosophila miranda(3). Genes on the non-recombining neo-Y show various signs of degeneration, including transposable-element insertions, frameshift mutations and a higher rate of amino-acid substitution. In contrast, loci on the recombining neo-X show intact open reading frames and generally low rates of amino-acid substitution. One exceptional gene on the neo-X shows evidence for adaptive protein evolution, affecting patterns of variability at neighboring regions along the chromosome. These findings illustrate the limits to natural selection in an asexual genome. Deleterious mutations, including repetitive DNA, accumulate on a non-recombining chromosome, whereas rapid protein evolution due to positive selection is confined to the recombining homolog.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Bachtrog, D (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	Doris.Bachtrog@ed.ac.uk						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bachtrog D, 2000, CURR BIOL, V10, P1025, DOI 10.1016/S0960-9822(00)00656-4; Bachtrog D, 2003, MOL BIOL EVOL, V20, P173, DOI 10.1093/molbev/msg035; Bachtrog D, 2002, NATURE, V416, P323, DOI 10.1038/416323a; BACHTROG D, IN PRESS GENETICS; Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Bell G., 1982, MASTERPIECE NATURE; Bull J. J., 1983, EVOLUTION SEX DETERM; Carvalho AB, 2002, CURR OPIN GENET DEV, V12, P664, DOI 10.1016/S0959-437X(02)00356-8; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; FELSENSTEIN J, 1974, GENETICS, V78, P737; HUDSON RR, 1987, GENETICS, V116, P153; Kimura MA, 1985, NEUTRAL THEORY MOL E; Li W. H, 1997, MOL EVOLUTION; Macknight RH, 1939, GENETICS, V24, P180; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Ohno S., 1970, EVOLUTION GENE DUPLI; Orr HA, 1998, GENETICS, V150, P1693; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Rice WR, 2001, SCIENCE, V294, P555, DOI 10.1126/science.1061380; Rice WR, 2002, NAT REV GENET, V3, P241, DOI 10.1038/nrg760; RICE WR, 1994, SCIENCE, V263, P230, DOI 10.1126/science.8284674; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SMITH JM, 1978, EVOLUTION SEX; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Steinemann M, 1998, GENETICA, V102-3, P409, DOI 10.1023/A:1017058119760; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; TAJIMA F, 1989, GENETICS, V123, P585	28	79	83	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2003	34	2					215	219		10.1038/ng1164	http://dx.doi.org/10.1038/ng1164			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12754509				2022-12-25	WOS:000183200500030
J	Barozzi, P; Luppi, M; Facchetti, F; Mecucci, C; Alu, M; Sarid, R; Rasini, V; Ravazzini, L; Rossi, E; Festa, S; Crescenzi, B; Wolf, DG; Schulz, TF; Torelli, G				Barozzi, P; Luppi, M; Facchetti, F; Mecucci, C; Alu, M; Sarid, R; Rasini, V; Ravazzini, L; Rossi, E; Festa, S; Crescenzi, B; Wolf, DG; Schulz, TF; Torelli, G			Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors	NATURE MEDICINE			English	Article							HUMAN-HERPESVIRUS-8 INFECTION; HISTOLOGICAL SECTIONS; SPINDLE CELLS; TRANSMISSION; HERPESVIRUS; RECIPIENTS; BLOOD; IDENTIFICATION; MICROCHIMERISM; PRECURSORS	Kaposi sarcoma (KS) is a vascular tumor that can develop in recipients of solid tissue transplants as a result of either primary infection or reactivation of a gammaherpesvirus, the KS-associated herpesvirus, also known as human herpesvirus-8 (HHV-8). We studied whether HHV-8 and the elusive KS progenitor cells could be transmitted from the donor through the grafts. We used a variety of molecular, cytogenetic, immunohistochemical and immunofluorescence methods to show that the HHV-8-infected neoplastic cells in post-transplant KS from five of eight renal transplant patients harbored either genetic or antigenic markers of their matched donors. These data suggest the use of donor-derived HHV-8-specific T cells for the control of post-transplant KS.	Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy; Univ Brescia, Dept Pathol, Brescia, Italy; Univ Perugia, Dept Clin & Expt Med, Sect Hematol & Clin Immunol, I-06100 Perugia, Italy; Univ Modena & Reggio Emilia, Dept Morphol Sci & Forens Med, Sect Forens Med, Modena, Italy; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Hadassah Univ Hosp, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel; Hannover Med Sch, Dept Virol, D-3000 Hannover, Germany	Universita di Modena e Reggio Emilia; University of Brescia; University of Perugia; Universita di Modena e Reggio Emilia; Bar Ilan University; Hebrew University of Jerusalem; Hannover Medical School	Luppi, M (corresponding author), Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy.		Rossi, Elisa/AAO-8202-2020; Comoli, Patrizia/K-2732-2018; Facchetti, Fabio/E-7190-2010; Rossi, Elisa/D-6387-2014; Luppi, Mario/J-3668-2016; Barozzi, Patrizia/Q-2638-2016; Schulz, Thomas/AAA-1634-2019	Rossi, Elisa/0000-0002-0570-6104; Comoli, Patrizia/0000-0001-5964-0553; Facchetti, Fabio/0000-0003-4975-2388; Rossi, Elisa/0000-0002-0570-6104; Luppi, Mario/0000-0002-0373-1154; Barozzi, Patrizia/0000-0002-8936-1114; Schulz, Thomas/0000-0001-8792-5345				Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Bodo I, 1999, NEW ENGL J MED, V341, P807, DOI 10.1056/NEJM199909093411105; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DICTOR M, 1988, AM J PATHOL, V130, P411; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Kanzler H, 2000, BLOOD, V95, P1023, DOI 10.1182/blood.V95.3.1023.003k07_1023_1031; KOKOVA M, 1993, LANCET, V342, P140; Kruskall MS, 2001, BLOOD, V98, P272, DOI 10.1182/blood.V98.2.272; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lee TH, 1999, BLOOD, V93, P3127; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Luppi M, 2000, NEW ENGL J MED, V343, P1378, DOI 10.1056/NEJM200011093431905; Luppi M, 2000, BLOOD, V96, P3279; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Masood S, 1998, ANN CLIN LAB SCI, V28, P215; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Parravicini C, 1997, BLOOD, V90, P2826; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Qian JQ, 1996, AM J PATHOL, V149, P1193; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; Rao AS, 1996, CLIN IMMUNOL IMMUNOP, V80, pS46, DOI 10.1006/clin.1996.0141; Regamey N, 1998, NEW ENGL J MED, V339, P1358, DOI 10.1056/NEJM199811053391903; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Sarid R, 2001, CLIN INFECT DIS, V32, P1502, DOI 10.1086/320153	26	148	163	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					554	561		10.1038/nm862	http://dx.doi.org/10.1038/nm862			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692543				2022-12-25	WOS:000182610600036
J	Edbauer, D; Winkler, E; Regula, JT; Pesold, B; Steiner, H; Haass, C				Edbauer, D; Winkler, E; Regula, JT; Pesold, B; Steiner, H; Haass, C			Reconstitution of gamma-secretase activity	NATURE CELL BIOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP; PRESENILIN; NICASTRIN; APH-1; ENDOPROTEOLYSIS; CLEAVAGE; PATHWAY; PEN-2	gamma-Secretase is a membrane protein complex with an unusual aspartyl protease activity that catalyses the regulated intramembranous cleavage of the beta-amyloid precursor protein (APP) to release the Alzheimer's disease (AD)-associated amyloid beta-peptide (Abeta) and the APP intracellular domain (AICD)(1). Here we show the reconstitution of gamma-secretase activity in the yeast Saccharomyces cerevisiae, which lacks endogenous gamma-secretase activity. Reconstituted gamma-secretase activity depends on the presence of four complex components including presenilin (PS)(1), nicastrin (Nct)(2), APH-1 (refs 3-6) and PEN-2 (refs 4, 7), is associated with endoproteolysis of PS8, and produces Abeta and AICD in vitro. Thus, the biological activity of gamma-secretase is reconstituted by the co-expression of human PS, Nct, APH-1 and PEN-2 in yeast.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, Protein Anal Unit, D-80336 Munich, Germany	University of Munich; University of Munich	Steiner, H (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany.	hsteiner@pbm.med.uni-muenchen.de	Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653; Regula, Joerg Thomas/0000-0002-7343-1077				Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, FEBS LETT, V463, P245, DOI 10.1016/S0014-5793(99)01627-0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	15	743	775	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					486	488		10.1038/ncb960	http://dx.doi.org/10.1038/ncb960			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12679784				2022-12-25	WOS:000182691400025
J	Haglund, K; Sigismund, S; Polo, S; Szymkiewicz, I; Di Fiore, PP; Dikic, I				Haglund, K; Sigismund, S; Polo, S; Szymkiewicz, I; Di Fiore, PP; Dikic, I			Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation	NATURE CELL BIOLOGY			English	Article							EPIDERMAL GROWTH-FACTOR; UBIQUITIN-INTERACTING MOTIF; RECEPTOR TYROSINE KINASES; PLASMA-MEMBRANE; DOWN-REGULATION; EGF RECEPTOR; MEDIATED ENDOCYTOSIS; CBL; PROTEINS; PATHWAY	Many cellular proteins are post-translationally modified by the addition of a single ubiquitin or a polyubiquitin chain(1). Among these are receptor tyrosine kinases (RTKs), which undergo ligand-dependent ubiquitination(2). The ubiquitination of RTKs has become recognized as an important signal for their endocytosis and degradation in the lysosome(3); however, it is not clear whether ubiquitination itself is sufficient for this process or simply participates in its regulation. The issue is further complicated by the fact that RTKs are thought to be polyubiquitinated-a modification that is linked to protein degradation by the proteasome(4). By contrast, monoubiquitination has been associated with diverse proteasome-independent cellular functions including intracellular protein movement(5). Here we show that the epidermal growth factor and platelet-derived growth factor receptors are not polyubiquitinated but rather are monoubiquitinated at multiple sites after their ligand-induced activation. By using different biochemical and molecular genetics approaches, we show that a single ubiquitin is sufficient for both receptor internalization and degradation. Thus, monoubiquitination is the principal signal responsible for the movement of RTKs from the plasma membrane to the lysosome.	European Inst Oncol, I-20141 Milan, Italy; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; FIRC Inst Mol Oncol, IFOM, I-20122 Milan, Italy; Univ Milan, I-20122 Milan, Italy; Univ Frankfurt, Inst Biochem 2, Sch Med, D-60590 Frankfurt, Germany	IRCCS European Institute of Oncology (IEO); Ludwig Institute for Cancer Research; IFOM - FIRC Institute of Molecular Oncology; University of Milan; Goethe University Frankfurt	Di Fiore, PP (corresponding author), European Inst Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Sigismund, Sara/H-3687-2017; Haglund, Kaisa/B-3927-2017; Dikic, Ivan/O-4650-2015; Di Fiore, Pier Paolo/K-2130-2012; Pilecka, Iwona/AAT-9114-2021	Sigismund, Sara/0000-0002-1396-4453; Haglund, Kaisa/0000-0002-7946-3299; Dikic, Ivan/0000-0001-8156-9511; Di Fiore, Pier Paolo/0000-0002-2252-0950; Pilecka, Iwona/0000-0002-5057-346X; Polo, Simona/0000-0001-5536-9399	Telethon [D.090] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; de Melker AA, 2001, J CELL SCI, V114, P2167; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033	30	628	641	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					461	466		10.1038/ncb983	http://dx.doi.org/10.1038/ncb983			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717448				2022-12-25	WOS:000182691400021
J	Fujimuro, M; Wu, FY; ApRhys, C; Kajumbula, H; Young, DB; Hayward, GS; Hayward, SD				Fujimuro, M; Wu, FY; ApRhys, C; Kajumbula, H; Young, DB; Hayward, GS; Hayward, SD			A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; NUCLEAR ANTIGEN; GENE-EXPRESSION; DNA-SEQUENCES; COLON-CARCINOMA; BOX PROTEIN; CYCLIN D1; CELLS; HUMAN-HERPESVIRUS-8	The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) is expressed in all KSHV-associated tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). We found that beta-catenin is overexpressed in both PEL cells and KS tissue. Introduction of anti-LANA small interfering RNA (siRNA) into PEL cells eliminated beta-catenin accumulation; LANA itself upregulated expression of beta-catenin in transfected cells. LANA stabilizes beta-catenin by binding to the negative regulator GSK-3beta causing a cell cycle-dependent nuclear accumulation of GSK-3beta. The LANA C terminus contains sequences similar to the GSK-3beta-binding domain of Axin. Disruption of this region resulted in a mutant LANA that failed to re-localize GSK-3beta or stabilize beta-catenin. The importance of this pathway to KSHV-driven cell proliferation was highlighted by the observation that LANA, but not mutant LANA, stimulates entry into S phase. Redistribution of GSK-3beta can therefore be a source of beta-catenin dysregulation in human cancers.	Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Hayward, SD (corresponding author), Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.		Fujimuro, Masahiro/AAC-4727-2020	Kajumbula, Henry/0000-0002-2075-0007; Fujimuro, Masahiro/0000-0002-5165-0789	NATIONAL CANCER INSTITUTE [R01CA085151, P01CA081400] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85151, P01 CA81400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barker N, 2000, ADV CANCER RES, V77, P1; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hu JH, 2002, J VIROL, V76, P11677, DOI 10.1128/JVI.76.22.11677-11687.2002; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Olsen SJ, 2000, J INFECT DIS, V182, P306, DOI 10.1086/315689; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Polakis P, 2000, GENE DEV, V14, P1837; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001	38	250	267	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					300	306		10.1038/nm829	http://dx.doi.org/10.1038/nm829			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592400				2022-12-25	WOS:000181312300030
J	Siekhaus, DE; Drubin, DG				Siekhaus, DE; Drubin, DG			Spontaneous receptor-independent heterotrimeric G-protein signalling in an RGS mutant	NATURE CELL BIOLOGY			English	Article							GTPASE-ACTIVATING PROTEINS; SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; A-FACTOR; ALPHA; EXPRESSION; GENE; PURIFICATION; INHIBITION; MUTATIONS	Tripartite G-protein-coupled receptors (GPCRs) represent one of the largest groups of signal transducers, transmitting signals from hormones, neuropeptides, odorants, food and light(1,2). Ligand-bound receptors catalyse GDP/GTP exchange on the G-protein alpha-subunit (Galpha), leading to alpha-GTP separation from the betagamma subunits and pathway activation. Activating mutations in the receptors or G proteins underlie many human diseases, including some cancers, dwarfism and premature puberty. Regulators of G-protein signalling (RGS proteins) are known to modulate the level and duration of ligand-induced signalling by accelerating the intrinsic GTPase activity of the Galpha subunit, and thus reformation of the inactive GDP-bound Galpha(3-5). Here we find that even in the absence of receptor, mutation of the RGS family member Sst2 (refs 6-9) permits spontaneous activation of the G-protein-coupled mating pathway in Saccharomyces cerevisiae at levels normally seen only in the presence of ligand. Our work demonstrates the occurence of spontaneous tripartite G-protein signalling in vivo and identifies a requirement for RGS proteins in preventing such receptor-independent activation.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	drubin@uclink4.berkeley.edu	Siekhaus, Daria/AAN-1779-2020	Siekhaus, Daria/0000-0001-8323-8353	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20291, GM50399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Mateus C, 2000, YEAST, V16, P1313, DOI 10.1002/1097-0061(200010)16:14<1313::AID-YEA626>3.0.CO;2-O; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Pauwels PJ, 1998, MOL NEUROBIOL, V17, P109, DOI 10.1007/BF02802027; PERLMAN R, 1993, P NATL ACAD SCI USA, V90, P5474, DOI 10.1073/pnas.90.12.5474; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STONE DE, 1990, MOL CELL BIOL, V10, P4439, DOI 10.1128/MCB.10.9.4439; Weiner OD, 2000, FR MOLEC B, V28, P201; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	30	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					231	U6		10.1038/ncb941	http://dx.doi.org/10.1038/ncb941			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598904				2022-12-25	WOS:000181322500016
J	Tunaru, S; Kero, J; Schaub, A; Wufka, C; Blaukat, A; Pfeffer, K; Offermanns, S				Tunaru, S; Kero, J; Schaub, A; Wufka, C; Blaukat, A; Pfeffer, K; Offermanns, S			PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR; MACROPHAGES; INHIBITION	Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug(1,2). The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet(3,4). Its primary action is to decrease lipolysis in adipose tissue by inhibiting hormone-sensitive triglyceride lipase(5). This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipose tissue(6) through a G(i)-protein-mediated inhibition of adenylyl cyclase(7-9). A G-protein-coupled receptor for nicotinic acid has been proposed in adipocytes(10,11). Here, we show that the orphan G-protein-coupled receptor, 'protein upregulated in macrophages by interferon-gamma' (mouse PUMA-G, human HM74)(12,13), is highly expressed in adipose tissue and is a nicotinic acid receptor. Binding of nicotinic acid to PUMA-G or HM74 results in a G(i)-mediated decrease in cAMP levels. In mice lacking PUMA-G, the nicotinic acid-induced decrease in free fatty acid (FFA) and triglyceride plasma levels was abrogated, indicating that PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid in vivo. The identification of the nicotinic acid receptor may be useful in the development of new drugs to treat dyslipidemia.	Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Univ Dusseldorf, Inst Med Microbiol, D-4000 Dusseldorf, Germany	Ruprecht Karls University Heidelberg; Technical University of Munich; Heinrich Heine University Dusseldorf	Pfeffer, K (corresponding author), Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany.		kero, jukka/G-3448-2014; Tunaru, Sorin/G-8516-2011; Offermanns, Stefan/L-3313-2017	kero, jukka/0000-0001-8767-7222; Tunaru, Sorin/0000-0002-6005-1737; Offermanns, Stefan/0000-0001-8676-6805; Pfeffer, Klaus/0000-0002-5652-6330				AKTORIES K, 1982, N-S ARCH PHARMACOL, V321, P247, DOI 10.1007/BF00498508; AKTORIES K, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1525; AKTORIES K, 1980, FEBS LETT, V115, P11, DOI 10.1016/0014-5793(80)80715-0; AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; BUTCHER RW, 1968, J BIOL CHEM, V243, P17005; CARLSON L A, 1968, Acta Medica Scandinavica, V183, P457; CARLSON LA, 1963, ACTA MED SCAND, V173, P719; FREDHOLM BB, 1981, INT J OBESITY, V5, P643; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; HOTZ W, 1983, ADV LIPID RES, V20, P195; KATHER H, 1983, FEBS LETT, V161, P149, DOI 10.1016/0014-5793(83)80749-2; Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707; LENTNER C, 1984, GEIGY SCI TABLES, V3, P129; Lorenzen A, 2002, BIOCHEM PHARMACOL, V64, P645, DOI 10.1016/S0006-2952(02)01220-0; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Olsson AG, 1994, HDB EXPT PHARM, V109, P349; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; Schaub A, 2001, EUR J IMMUNOL, V31, P3714, DOI 10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1; SVEDMYR N, 1969, CLIN PHARMACOL THER, V10, P559; Szapary Philippe O., 2001, Current Opinion in Pharmacology, V1, P113, DOI 10.1016/S1471-4892(01)00028-5; Yousefi S, 2000, BIOCHEM BIOPH RES CO, V277, P401, DOI 10.1006/bbrc.2000.3678	25	604	647	2	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					352	355		10.1038/nm824	http://dx.doi.org/10.1038/nm824			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563315				2022-12-25	WOS:000181312300038
J	Blazquez, MA; Ahn, JH; Weigel, D				Blazquez, MA; Ahn, JH; Weigel, D			A thermosensory pathway controlling flowering time in Arabidopsis thaliana	NATURE GENETICS			English	Article							MADS DOMAIN PROTEIN; CIRCADIAN CLOCK; PHYTOCHROME-B; MUTANTS; GENE; VERNALIZATION; ENCODES; LIGHT; PHENOTYPE; REPRESSOR	Onset of flowering is controlled by environmental signals such as light and temperature. Molecular-genetic studies in Arabidopsis thaliana have focused on daily light duration, or photoperiod, and transient exposure to winter-like temperatures, or vernalizationl. Yet ambient growth temperature, which is strongly affected by current changes in global climate(2), has been largely ignored. Here, we show that genes of the autonomous pathway, previously thought only to act independently of the environment as regulators of the floral repressor FLC (ref. 1), are centrally involved in mediating the effects of ambient temperature. In contrast to wild-type plants and those mutant in other pathways, autonomous-pathway mutants flower at the same time regardless of ambient temperature. In contrast, the exaggerated temperature response of cryptochrome-2 mutants is caused by temperature-dependent redundancy with the phytochrome A photoreceptor. As with vernalization and photoperiod, ambient temperature ultimately affects expression of the floral pathway integrator FT.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Max Planck Inst Dev Biol, Dept Biol Mol, D-72076 Tubingen, Germany	Salk Institute; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP); Korea University; Max Planck Society	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	weigel@weigelworld.org	Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022; Ahn, Ji Hoon/A-4141-2011; Blazquez, Miguel A/B-1495-2008; Weigel, Detlef/C-1418-2008	Weigel, Detlef/0000-0002-2114-7963; Ahn, Ji Hoon/0000-0003-0347-3922; Blazquez, Miguel A/0000-0001-5743-0448; Weigel, Detlef/0000-0002-2114-7963				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; Borner R, 2000, PLANT J, V24, P591, DOI 10.1046/j.1365-313x.2000.00906.x; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Halevy H., 1985, CRC HDB FLOWERING; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; *INT PAN CLIM CHAN, 2002, CLIM CHANG 2001 SYNT; Johansson J, 2002, CELL, V110, P551, DOI 10.1016/S0092-8674(02)00905-4; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Long S. P., 1988, PLANTS TEMPERATURE; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Menzel A, 2001, GLOBAL CHANGE BIOL, V7, P657, DOI 10.1046/j.1365-2486.2001.00430.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; Mockler TC, 1999, DEVELOPMENT, V126, P2073; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Sparks TH, 2000, INT J BIOMETEOROL, V44, P82, DOI 10.1007/s004840000049; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; WILSON RN, 1992, PLANT PHYSIOL, V100, P403, DOI 10.1104/pp.100.1.403; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596	30	344	388	6	133	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2003	33	2					168	171		10.1038/ng1085	http://dx.doi.org/10.1038/ng1085			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12548286				2022-12-25	WOS:000180773700014
J	Desbarats, J; Birge, RB; Mimouni-Rongy, M; Weinstein, DE; Palerme, JS; Newell, MK				Desbarats, J; Birge, RB; Mimouni-Rongy, M; Weinstein, DE; Palerme, JS; Newell, MK			Fas engagement induces neurite growth through ERK activation and p35 upregulation	NATURE CELL BIOLOGY			English	Article							HUMAN FETAL ASTROCYTES; TUMOR NECROSIS FACTOR; MAP KINASE KINASE; NF-KAPPA-B; MONOCLONAL-ANTIBODY; CELL-DEATH; T-CELLS; INDUCED APOPTOSIS; LPR MICE; EXPRESSION	Fas (also known as CD95), a member of the tumour-necrosis receptor factor family of 'death receptors', can induce apoptosis or, conversely, can deliver growth stimulatory signals. Here we report that crosslinking Fas on primary sensory neurons induces neurite growth through sustained activation of the extracellular-signal regulated kinase (ERK) pathway and the consequent upregulation of p35, a mediator of neurite outgrowth. In addition, functional recovery after sciatic nerve injury is delayed in Fas-deficient lpr mice and accelerated by local administration of antibodies against Fas, which indicates that Fas engagement may contribute to nerve regeneration in vivo. Our findings define a role for Fas as an inducer of both neurite growth in vitro and accelerated recovery after nerve injury in vivo.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Rockefeller Univ, Oncol Mol Lab, New York, NY 10021 USA; Univ Colorado, Dept Biol, Colorado Springs, CO 80918 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	McGill University; Rockefeller University; University of Colorado System; University of Colorado at Colorado Springs; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Desbarats, J (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			Palerme, Jean-Sebastien/0000-0001-7459-708X; Desbarats, Julie/0000-0002-2495-7152				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; BIEDLER JL, 1978, CANCER RES, V38, P3751; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Gomez C, 2001, J NEUROSCI RES, V63, P421, DOI 10.1002/1097-4547(20010301)63:5<421::AID-JNR1037>3.0.CO;2-4; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JU ST, 1995, NATURE, V373, P345; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Kury P, 2001, CURR OPIN NEUROL, V14, P635, DOI 10.1097/00019052-200110000-00013; Ledda F, 2002, NEURON, V36, P387, DOI 10.1016/S0896-6273(02)01002-4; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1954, CANCER RES, V14, P49; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newell MK, 1999, ANN NY ACAD SCI, V887, P77, DOI 10.1111/j.1749-6632.1999.tb07923.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Sakic B, 1998, J NEUROIMMUNOL, V87, P162, DOI 10.1016/S0165-5728(98)00085-X; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Shinohara H, 2000, CANCER RES, V60, P1766; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074-7613(00)80111-9; Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486; Wohlleben G, 2000, GLIA, V30, P373, DOI 10.1002/(SICI)1098-1136(200006)30:4<373::AID-GLIA60>3.3.CO;2-R; Wosik K, 2001, GLIA, V33, P217, DOI 10.1002/1098-1136(200103)33:3<217::AID-GLIA1020>3.0.CO;2-W; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	50	246	261	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					118	125		10.1038/ncb916	http://dx.doi.org/10.1038/ncb916			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545171				2022-12-25	WOS:000180802100011
J	Dekel, B; Burakova, T; Arditti, FD; Reich-Zeliger, S; Milstein, O; Aviel-Ronen, S; Rechavi, G; Friedman, N; Kaminski, N; Passwell, JH; Reisner, Y				Dekel, B; Burakova, T; Arditti, FD; Reich-Zeliger, S; Milstein, O; Aviel-Ronen, S; Rechavi, G; Friedman, N; Kaminski, N; Passwell, JH; Reisner, Y			Human and porcine early kidney precursors as a new source for transplantation	NATURE MEDICINE			English	Article							CYTOLYTIC EFFECTOR MOLECULES; BLOOD MONONUCLEAR-CELLS; HUMAN FETAL KIDNEYS; ALLOGRAFT-REJECTION; RADIATION CHIMERA; MEDIATED-IMMUNITY; GENE-EXPRESSION; OSTEOPONTIN; METANEPHROI; CHEMOKINES	Kidney transplantation has been one of the major medical advances of the past 30 years. However, tissue availability remains a major obstacle. This can potentially be overcome by the use of undifferentiated or partially developed kidney precursor cells derived from early embryos and fetal tissue. Here, transplantation in mice reveals the earliest gestational time point at which kidney precursor cells, of both human and pig origin, differentiate into functional nephrons and not into other, non-renal professional cell types. Moreover, successful organogenesis is achieved when using the early kidney precursors, but not later-gestation kidneys. The formed, miniature kidneys are functional as evidenced by the dilute urine they produce. In addition, decreased immunogenicity of the transplants of early human and pig kidney precursors compared with adult kidney transplants is demonstrated in vivo. Our data pinpoint a window of human and pig kidney organogenesis that may be optimal for transplantation in humans.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pediat, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Funct Genom Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Israel; Hebrew Univ Jerusalem, Sch Engn & Comp Sci, Jerusalem, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem	Reisner, Y (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		Reisner, Yair/AAA-4772-2019; Friedman, Nir/H-9692-2012	Friedman, Nir/0000-0002-9678-3550; Reisner, Yair/0000-0002-3354-6945; Kaminski, Naftali/0000-0001-5917-4601				Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Benichou G, 1999, J IMMUNOL, V162, P352; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Briscoe DM, 1999, TRANSPLANTATION, V67, P1590, DOI 10.1097/00007890-199906270-00014; Cascalho M, 2001, IMMUNITY, V14, P437, DOI 10.1016/S1074-7613(01)00124-8; Dekel B, 1997, TRANSPLANTATION, V64, P1541, DOI 10.1097/00007890-199712150-00007; Dekel B, 1997, TRANSPLANTATION, V64, P1550, DOI 10.1097/00007890-199712150-00008; Dekel B, 1999, INT IMMUNOL, V11, P1673, DOI 10.1093/intimm/11.10.1673; Dekel B, 2000, TRANSPLANTATION, V69, P1470, DOI 10.1097/00007890-200004150-00044; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GRITSCH HA, 1994, TRANSPLANTATION, V57, P906, DOI 10.1097/00007890-199403270-00024; Hammerman MR, 2002, CURR OPIN NEPHROL HY, V11, P11, DOI 10.1097/00041552-200201000-00002; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Kreisel D, 2002, NAT MED, V8, P233, DOI 10.1038/nm0302-233; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; O'Regan AW, 2000, IMMUNOL TODAY, V21, P475, DOI 10.1016/S0167-5699(00)01715-1; Oliver JA, 2002, AM J PHYSIOL-RENAL, V283, pF799, DOI 10.1152/ajprenal.00375.2001; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Rogers SA, 2001, AM J PHYSIOL-REG I, V281, pR661, DOI 10.1152/ajpregu.2001.281.2.R661; Rogers SA, 1998, KIDNEY INT, V54, P27, DOI 10.1046/j.1523-1755.1998.00971.x; Rogers SA, 2001, AM J PHYSIOL-REG I, V280, pR132, DOI 10.1152/ajpregu.2001.280.1.R132; Rogers SA, 2001, AM J PHYSIOL-REG I, V280, pR1865, DOI 10.1152/ajpregu.2001.280.6.R1865; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6; WOOLF AS, 1990, KIDNEY INT, V38, P991, DOI 10.1038/ki.1990.303; WOOLF AS, 1999, PEDIAT NEPHROLOGY, P1; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	37	204	218	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					53	60		10.1038/nm812	http://dx.doi.org/10.1038/nm812			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496960				2022-12-25	WOS:000180209900022
J	Dyrskjot, L; Thykjaer, T; Kruhoffer, M; Jensen, JL; Marcussen, N; Hamilton-Dutoit, S; Wolf, H; Orntoft, TF				Dyrskjot, L; Thykjaer, T; Kruhoffer, M; Jensen, JL; Marcussen, N; Hamilton-Dutoit, S; Wolf, H; Orntoft, TF			Identifying distinct classes of bladder carcinoma using microarrays	NATURE GENETICS			English	Article							GENE-EXPRESSION PATTERNS; GENOME-WIDE; PREDICTION; CANCER; TUMOR; IDENTIFICATION; CLASSIFICATION	Bladder cancer is a common malignant disease characterized by frequent recurrences(1,2). The stage of disease at diagnosis and the presence of surrounding carcinoma in situ are important in determining the disease course of an affected individual(3). Despite considerable effort, no accepted immunohistological or molecular markers have been identified to define clinically relevant subsets of bladder cancer. Here we report the identification of clinically relevant subclasses of bladder carcinoma using expression microarray analysis of 40 well characterized bladder tumors. Hierarchical cluster analysis identified three major stages, Ta, T1 and T2-4, with the Ta tumors further classified into subgroups. We built a 32-gene molecular classifier using a cross-validation approach that was able to classify benign and muscle-invasive tumors with close correlation to pathological staging in an independent test set of 68 tumors. The classifier provided new predictive information on disease progression in Ta tumors compared with conventional staging (P < 0.005). To delineate non-recurring Ta tumors from frequently recurring Ta tumors, we analyzed expression patterns in 31 tumors by applying a supervised learning classification methodology, which classified 75% of the samples correctly (P < 0.006). Furthermore, gene expression profiles characterizing each stage and subtype identified their biological properties, producing new potential targets for therapy.	Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus N, Denmark; Aros Appl Biotechnol, Aarhus, Denmark; Aarhus Univ Hosp, Dept Urol, DK-8000 Aarhus N, Denmark; Dept Theoret Stat, Aarhus, Denmark; Dept Math Sci, Aarhus, Denmark; Aarhus Univ Hosp, Univ Inst Pathol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus N, Denmark.	orntoft@kba.sks.au.dk	Jensen, Jens Ledet/B-7172-2008; Dyrskjot, Lars/H-4922-2012	Dyrskjot, Lars/0000-0001-7061-9851; Jensen, Jens Ledet/0000-0002-8776-5764; Hamilton-Dutoit, Stephen/0000-0003-2158-3885				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bergkvist A, 1965, Acta Chir Scand, V130, P371; Cheng L, 1999, CANCER-AM CANCER SOC, V85, P2469, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.3.CO;2-L; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fox SB, 2001, LANCET ONCOL, V2, P278, DOI 10.1016/S1470-2045(00)00323-5; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Kerr JS, 2000, EXPERT OPIN INV DRUG, V9, P1271, DOI 10.1517/13543784.9.6.1271; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Luo J, 2001, CANCER RES, V61, P4683; Notterman DA, 2001, CANCER RES, V61, P3124; Orntoft TF, 2002, MOL CELL PROTEOMICS, V1, P37, DOI 10.1074/mcp.M100019-MCP200; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Seymour L, 1999, CANCER TREAT REV, V25, P301, DOI 10.1053/ctrv.1999.0134; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Thykjaer T, 2001, CANCER RES, V61, P2492; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wolf H, 1986, Prog Clin Biol Res, V221, P223	26	387	398	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2003	33	1					90	96		10.1038/ng1061	http://dx.doi.org/10.1038/ng1061			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12469123				2022-12-25	WOS:000180136100024
J	Stock, RP; Bialy, H				Stock, RP; Bialy, H			The sigmoidal curve of cancer	NATURE BIOTECHNOLOGY			English	Editorial Material							ANEUPLOIDY; CELLS; TRANSFORMATION; INSTABILITY		Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca, Morelos, Mexico	Universidad Nacional Autonoma de Mexico	Stock, RP (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca, Morelos, Mexico.	rstock@ibt.unam.mx; bialy@ibt.unam.mx						Bialy H, 2001, NAT BIOTECHNOL, V19, P22, DOI 10.1038/83463; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Duesberg P, 2001, P NATL ACAD SCI USA, V98, P11283, DOI 10.1073/pnas.201398998; Fabarius A, 2002, P NATL ACAD SCI USA, V99, P6778, DOI 10.1073/pnas.251670699; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rasnick D, 2000, BIOCHEM J, V348, P497, DOI 10.1042/0264-6021:3480497; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Rasnick D, 2002, CANCER GENET CYTOGEN, V136, P66, DOI 10.1016/S0165-4608(01)00665-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	14	21	24	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2003	21	1					13	14		10.1038/nbt0103-13	http://dx.doi.org/10.1038/nbt0103-13			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	632DV	12511899				2022-12-25	WOS:000180209200008
J	Yuan, XB; Jin, M; Xu, XH; Song, YQ; Wu, CP; Poo, MM; Duan, SM				Yuan, XB; Jin, M; Xu, XH; Song, YQ; Wu, CP; Poo, MM; Duan, SM			Signalling and crosstalk of Rho GTPases in mediating axon guidance	NATURE CELL BIOLOGY			English	Article							MYOSIN-II ACTIVATION; NERVE GROWTH; FAMILY GTPASES; PROTEIN; PHOSPHORYLATION; DROSOPHILA; CDC42; RAC; PROMOTES; COLLAPSE	Axon extension during development of the nervous system is guided by many factors, but the signalling mechanisms responsible for triggering this extension remain mostly unknown. Here we have examined the role of Rho family small guanosine triphosphatases (GTPases) in mediating axon guidance by diffusible factors. Expression of either dominant-negative or constitutively active Cdc42 in cultured Xenopus laevis spinal neurons, at a concentration that does not substantially affect filopodial formation and neurite extension, abolishes the chemoattractive growth cone turning induced by a gradient of brain-derived neurotrophic factor that can activate Cdc42 and Rac in cultured neurons. Chemorepulsion induced by a gradient of lysophosphatidic acid is also abolished by the expression of dominant-negative RhoA. We also show that an asymmetry in Rho kinase or filopodial initiation across the growth cone is sufficient to trigger the turning response and that there is a crosstalk between the Cdc42 and RhoA pathways through their converging actions on the myosin activity essential for growth cone chemorepulsion.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Univ Calif Berkeley, Div Neurobiol, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of California System; University of California Berkeley	Yuan, XB (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	yuanxb@ion.accn; shumin@ion.ac.cn	Song, Yuanquan/E-2603-2012	Yuan, Xiaobing/0000-0002-1632-8460				Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; Bashaw GJ, 2001, J CELL BIOL, V155, P1117, DOI 10.1083/jcb.200110077; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Cahoon-Metzger SM, 2001, DEV BIOL, V232, P246, DOI 10.1006/dbio.2001.0172; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Crawford JM, 2001, EUR J CELL BIOL, V80, P240, DOI 10.1078/0171-9335-00156; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Eddy RJ, 2000, J CELL SCI, V113, P1287; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HERRMANN C, 1992, BIOCHEMISTRY-US, V31, P12227, DOI 10.1021/bi00163a036; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jin Z, 1997, J NEUROSCI, V17, P6256; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Meinhardt H, 1999, J CELL SCI, V112, P2867; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Connor R, 1999, NEURON, V24, P165, DOI 10.1016/S0896-6273(00)80830-2; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang Q, 1998, J NEUROSCI, V18, P4973; Wang X, 1998, WORLD J GASTROENTERO, V4, P18, DOI 10.3748/wjg.v4.i1.18; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Whitford KL, 2001, NEURON, V32, P1, DOI 10.1016/S0896-6273(01)00459-7; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Zheng JQ, 1996, J NEUROSCI, V16, P1140; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	49	245	258	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					38	45		10.1038/ncb895	http://dx.doi.org/10.1038/ncb895			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510192				2022-12-25	WOS:000180223700011
J	Ramoz, N; Rueda, LA; Bouadjar, B; Montoya, LS; Orth, G; Favre, M				Ramoz, N; Rueda, LA; Bouadjar, B; Montoya, LS; Orth, G; Favre, M			Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis	NATURE GENETICS			English	Article							PAPILLOMAVIRUSES; LESIONS; MODEL	Epidermodysplasia verruciformis (OMIM 226400) is a rare autosomal recessive genodermatosis associated with a high risk of skin carcinoma that results from an abnormal susceptibility to infection by specific human papillomaviruses (HPVs). We recently mapped a susceptibility locus for epidermodysplasia verruciformis (EV1) to chromosome 17q25. Here we report the identification of nonsense mutations in two adjacent novel genes, EVER1 and EVER2, that are associated with the disease. The gene products EVER1 and EVER2 have features of integral membrane proteins and are localized in the endoplasmic reticulum.	Inst Pasteur, Unite Papillomavirus, F-75724 Paris 15, France; Unidad Dermatol LA Rueda, Bogota, Colombia; Ctr Hosp Univ Bab el Oued, Algiers, Algeria; Univ Ind Santander, Bucaramanga, Colombia	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad Industrial de Santander	Orth, G (corresponding author), Inst Pasteur, Unite Papillomavirus, 25 Rue Dr Roux, F-75724 Paris 15, France.	gorth@pasteur.fr	ORTH, Gérard C/C-2518-2009; ramoz, nicolas/K-3316-2015	ramoz, nicolas/0000-0002-8070-9938				Antonsson A, 2000, J VIROL, V74, P11636, DOI 10.1128/JVI.74.24.11636-11641.2000; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; JABLONSKA S, 1972, CANCER RES, V32, P583; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Majewski S, 1997, CLIN DERMATOL, V15, P321, DOI 10.1016/S0738-081X(96)00169-1; ORTH G, 1979, CANCER RES, V39, P1074; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; ORTH G, 1987, PAPOVAVIRIDAE, V2, P199; Ramoz N, 2000, J INVEST DERMATOL, V114, P1148, DOI 10.1046/j.1523-1747.2000.00996.x; Ramoz N, 1999, J INVEST DERMATOL, V112, P259, DOI 10.1046/j.1523-1747.1999.00536.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	14	278	290	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2002	32	4					579	581		10.1038/ng1044	http://dx.doi.org/10.1038/ng1044			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12426567				2022-12-25	WOS:000179593000008
J	Sun, YL; Chen, HM; Subudhi, SK; Chen, J; Koka, R; Chen, LP; Fu, YX				Sun, YL; Chen, HM; Subudhi, SK; Chen, J; Koka, R; Chen, LP; Fu, YX			Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease	NATURE MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-4-1BB MONOCLONAL-ANTIBODIES; T-CELL; MURINE LUPUS; IFN-GAMMA; INTERFERON-GAMMA; IMMUNE-RESPONSES; MRL/LPR MICE; NITRIC-OXIDE; LPR MICE	Humans and mice deficient in Fas, a tumor necrosis factor (TNF)-receptor family member, cannot induce apoptosis of autoreactive cells, and consequently develop progressive lymphoproliferative disorders and lupus-like autoimmune diseases. Previous studies have shown that short-term administrations of agonistic monoclonal antibodies against CD137, another TNF-receptor family member, activate T cells and induce rejection of allografts and established tumors. Here we report that treatment with an agonistic monoclonal antibody to CD137 (2A) blocks lymphadenopathy and spontaneous autoimmune diseases in Fas-deficient MRL/Ipr mice, ultimately leading to their prolonged survival. Notably, 2A treatment rapidly augments IFN-production, and induces the depletion of autoreactive B cells and abnormal double-negative T cells, possibly by increasing their apoptosis through Fas- and TNF receptor-independent mechanisms. This study demonstrates that agonistic monoclonal antibodies specific for costimulatory molecules can be used as novel therapeutic agents to delete autoreactive lymphocytes and block autoimmune disease progression.	Univ Chicago, Dept Pathol & Committee Immunol, Chicago, IL 60637 USA; Mayo Clin, Dept Immunol, Rochester, MN USA	University of Chicago; Mayo Clinic	Fu, YX (corresponding author), Univ Chicago, Dept Pathol & Committee Immunol, Chicago, IL 60637 USA.			Subudhi, Sumit/0000-0001-5208-7732; fu, yang-xin/0000-0001-8441-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK058891, P30DK020595] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-37104] Funding Source: Medline; NIDDK NIH HHS [DK-20595-25, DK-58891] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; Blazar BR, 2001, J IMMUNOL, V166, P3174, DOI 10.4049/jimmunol.166.5.3174; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DING AH, 1988, J IMMUNOL, V141, P2407; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Haas C, 1997, J IMMUNOL, V158, P5484; Haendeler J, 1999, VITAM HORM, V57, P49; Halstead ES, 2002, NAT IMMUNOL, V3, P536, DOI 10.1038/ni798; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hoffman RW, 2001, FRONT BIOSCI-LANDMRK, V6, pD1369, DOI 10.2741/Hoffman; Jacobson BA, 1997, IMMUNOL REV, V156, P103, DOI 10.1111/j.1600-065X.1997.tb00962.x; Kaliyaperumal A, 1999, J IMMUNOL, V162, P5775; Kalled SL, 1998, J IMMUNOL, V160, P2158; Kelley VR, 1999, SEMIN NEPHROL, V19, P57; Kwon B, 2000, MOL CELLS, V10, P119, DOI 10.1007/s10059-000-0119-0; Lawson BR, 2000, J CLIN INVEST, V106, P207, DOI 10.1172/JCI10167; Liang BL, 2000, J IMMUNOL, V165, P3436, DOI 10.4049/jimmunol.165.6.3436; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORSE HC, 1982, J IMMUNOL, V129, P2612; Nicoletti F, 2000, EUR J IMMUNOL, V30, P438; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; Peng SL, 1997, J CLIN INVEST, V99, P1936, DOI 10.1172/JCI119361; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Schwarting A, 1998, J IMMUNOL, V161, P494; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; SUDA T, 1997, J ALLERGY CLIN IMMUN, V100, P97; Sun YL, 2002, J IMMUNOL, V168, P1457, DOI 10.4049/jimmunol.168.3.1457; THEOFILOPOULOS AN, 1981, IMMUNOL REV, V55, P179, DOI 10.1111/j.1600-065X.1981.tb00343.x; Vinay DS, 1998, SEMIN IMMUNOL, V10, P481, DOI 10.1006/smim.1998.0157; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Williams MS, 1998, J IMMUNOL, V161, P6526; WOFSY D, 1984, J IMMUNOL, V132, P2686; Wofsy D, 1993, Immunol Ser, V59, P221	42	151	177	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1405	1413		10.1038/nm796	http://dx.doi.org/10.1038/nm796			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426559				2022-12-25	WOS:000179552000037
J	Lu, QL; Mann, CJ; Lou, F; Bou-Gharios, G; Morris, GE; Xue, SA; Fletcher, S; Partridge, TA; Wilton, SD				Lu, QL; Mann, CJ; Lou, F; Bou-Gharios, G; Morris, GE; Xue, SA; Fletcher, S; Partridge, TA; Wilton, SD			Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; REVERTANT FIBERS; SKELETAL-MUSCLES; GENE; THERAPY; MICE; RNA; OLIGONUCLEOTIDES; RESTORATION; EXPRESSION	As a target for gene therapy, Duchenne muscular dystrophy (DMD) presents many obstacles but also an unparalleled prospect for correction by alternative splicing. The majority of mutations in the dystrophin gene occur in the region encoding the spectrin-like central rod domain, which is largely dispensable. Thus, splicing around mutations can generate a shortened but in-frame transcript, permitting translation of a partially functional dystrophin protein. We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining a potent transfection protocol with a 2-O-methylated phosphorothioated antisense oligoribonucleotide (2OMeAO) designed to promote skipping of the mutated exon. The treated mice show persistent production of dystrophin at normal levels in large numbers of muscle fibers and show functional improvement of the treated muscle. Repeated administration enhances dystrophin expression without eliciting immune responses. Our data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy.	Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Nedlands, WA 6009, Australia; Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England; NE Wales Inst, MRIC Biochem Grp, Wrexham LL11 2AW, Wales; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Immunol, London W12 0NN, England	Imperial College London; University of Western Australia; University of Hertfordshire; Glyndwr University; Imperial College London	Lu, QL (corresponding author), Hammersmith Hosp, MRC, Ctr Clin Sci, Du Cane Rd, London W12 0NN, England.		Xue, Shao-An/A-2735-2011; lu, qi/HHS-2115-2022	Fletcher, Sue/0000-0002-8632-641X; Wilton, Steve/0000-0002-9400-893X				Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; Dickson G, 2002, NEUROMUSCULAR DISORD, V12, pS67, DOI 10.1016/S0960-8966(02)00085-8; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Laing N G, 1993, Mol Cell Biol Hum Dis Ser, V3, P37; Liu F, 2001, MOL THER, V4, P45, DOI 10.1006/mthe.2001.0419; Lou F, 2002, J EXP BIOL, V205, P1585; Lu QL, 2000, J CELL BIOL, V148, P985, DOI 10.1083/jcb.148.5.985; Lu QL, 1998, J HISTOCHEM CYTOCHEM, V46, P977, DOI 10.1177/002215549804600813; Lu QL, 2003, GENE THER, V10, P396, DOI 10.1038/sj.gt.3301913; Lu QL, 2003, GENE THER, V10, P131, DOI 10.1038/sj.gt.3301874; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Mann CJ, 2002, J GENE MED, V4, P644, DOI 10.1002/jgm.295; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Rando TA, 2000, P NATL ACAD SCI USA, V97, P5363, DOI 10.1073/pnas.97.10.5363; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; SHERRAT TG, 1993, AM J HUM GENET, V53, P1007; Wagner KR, 2001, ANN NEUROL, V49, P706, DOI 10.1002/ana.1023.abs; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085; Wilton SD, 1997, NEUROMUSCULAR DISORD, V7, P329, DOI 10.1016/S0960-8966(97)00058-8; Yuasa K, 2002, GENE THER, V9, P1576, DOI 10.1038/sj.gt.3301829	26	296	334	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1009	1014		10.1038/nm897	http://dx.doi.org/10.1038/nm897			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847521				2022-12-25	WOS:000184484900023
J	Mattiasson, G; Shamloo, M; Gido, G; Mathi, K; Tomasevic, G; Yi, SL; Warden, CH; Castilho, RF; Melcher, T; Gonzalez-Zulueta, M; Nikolich, K; Wieloch, T				Mattiasson, G; Shamloo, M; Gido, G; Mathi, K; Tomasevic, G; Yi, SL; Warden, CH; Castilho, RF; Melcher, T; Gonzalez-Zulueta, M; Nikolich, K; Wieloch, T			Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; PERMEABILITY TRANSITION; MITOCHONDRIAL CONTROL; PROTON LEAK; BETA-CELLS; RAT-BRAIN; SUPEROXIDE; INJURY; MICE	Whereas uncoupling protein 1 (UCP-1) is clearly involved in thermogenesis, the role of UCP-2 is less clear. Using hybridization, cloning techniques and cDNA array analysis to identify inducible neuroprotective genes, we found that neuronal survival correlates with increased expression of Ucp2. In mice overexpressing human UCP-2, brain damage was diminished after experimental stroke and traumatic brain injury, and neurological recovery was enhanced. In cultured cortical neurons, UCP-2 reduced cell death and inhibited caspase-3 activation induced by oxygen and glucose deprivation. Mild mitochondrial uncoupling by 2,4-dinitrophenol (DNP) reduced neuronal death, and UCP-2 activity was enhanced by palmitic acid in isolated mitochondria. Also in isolated mitochondria, UCP-2 shifted the release of reactive oxygen species from the mitochondrial matrix to the extramitochondrial space. We propose that UCP-2 is an inducible protein that is neuroprotective by activating cellular redox signaling or by inducing mild mitochondrial uncoupling that prevents the release of apoptogenic proteins.	Wallenberg Neurosci Ctr, S-22184 Lund, Sweden; AGY Therapeut Inc, San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Div Biol Sci, Neurobiol Sect, Davis, CA 95616 USA; State Univ Campinas, Sch Med Sci, Dept Clin Pathol, BR-13083970 Campinas, SP, Brazil	University of California System; University of California Davis; Universidade Estadual de Campinas	Wieloch, T (corresponding author), Wallenberg Neurosci Ctr, BMC A13, S-22184 Lund, Sweden.		Castilho, Roger F/G-3906-2012	Wieloch, Tadeusz/0000-0002-7669-2520; Castilho, Roger/0000-0003-2338-8717	NIDDK NIH HHS [R01 DK53993] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053993] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Fuller PM, 2000, J APPL PHYSIOL, V89, P1491, DOI 10.1152/jappl.2000.89.4.1491; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Grabb MC, 1999, J NEUROSCI, V19, P1657; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Jarmuszkiewicz W, 2002, FEBS LETT, V532, P459, DOI 10.1016/S0014-5793(02)03734-1; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NOWICKI JP, 1988, J CEREBR BLOOD F MET, V8, P462, DOI 10.1038/jcbfm.1988.87; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shamloo M, 1999, J CEREBR BLOOD F MET, V19, P173, DOI 10.1097/00004647-199902000-00009; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; Wieloch T, 2001, IUBMB LIFE, V52, P247, DOI 10.1080/15216540152846064; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	48	425	443	0	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1062	1068		10.1038/nm903	http://dx.doi.org/10.1038/nm903			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858170				2022-12-25	WOS:000184484900031
J	Van Nhieu, GT; Clair, C; Bruzzone, R; Mesnil, M; Sansonetti, P; Combettes, L				Van Nhieu, GT; Clair, C; Bruzzone, R; Mesnil, M; Sansonetti, P; Combettes, L			Connexin-dependent inter-cellular communication increases invasion and dissemination of Shigella in epithelial cells	NATURE CELL BIOLOGY			English	Article							GAP JUNCTIONAL COMMUNICATION; ESCHERICHIA-COLI; MOLECULAR-BASIS; CALCIUM WAVES; ATP RELEASE; FLEXNERI; EXPRESSION; CA2+; HEMICHANNELS; ASTROCYTES	Shigella flexneri, the causative agent of bacillar dystentery, invades the colonic mucosa where it elicits an intense inflammatory reaction responsible for destruction of the epithelium(1,2). During cell invasion, contact with host cells activates the type-III secretion of the Shigella lpaB and IpaC proteins(3,4). lpaB and IpaC are inserted into host cell plasma membranes and trigger initial signals that result in actin polymerization, while allowing cytosolic access of other bacterial effectors that further reorganize the cytoskeleton(5,6). After internalization, Shigella moves intracellularly and forms protrusions that infect neighbouring cells, promoting bacterial dissemination a cross the epithelium(2,6). Here, we show that during cell invasion, Shigella induces transient peaks in intracellular calcium concentration that are dependent on a functional type-III secretory apparatus. In addition, Shigella invasion induces the opening of Connexin 26 (Cx26) hemichannels in an actin- and phospholipase-C-dependent manner, allowing release of ATP into the medium. The released ATP, in turn, increases bacterial invasion and spreading, as well as calcium signalling induced by Shigella. These results provide evidence that pathogen-induced opening of connexin channels promotes signalling events that favour bacterial invasion and dissemination.	Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Neurovirol & Regenerat Syst Nerveux, F-75724 Paris, France; Univ Poitiers, Lab Biomembranes & Signalisat Cellulaire, CNRS, UMR 6558, Poitiers, France; Univ Paris 11, INSERM, U442, Unite Signalisat Cellulaire & Calcium,IBAIC, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Van Nhieu, GT (corresponding author), Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France.		Combettes, Laurent/L-1842-2013; Van Nhieu, Guy Tran/Y-6359-2018; Bruzzone, Roberto/C-4719-2009; Bruzzone, Roberto/G-9355-2017	Combettes, Laurent/0000-0002-1376-4574; Van Nhieu, Guy Tran/0000-0002-3901-2186; Bruzzone, Roberto/0000-0003-4373-1447; Bruzzone, Roberto/0000-0003-4373-1447; Mesnil, Marc/0000-0003-4922-0365				BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHANTRET I, 1994, J CELL SCI, V107, P213; Clair C, 2001, J CELL SCI, V114, P1999; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Garcia MI, 1996, MOL MICROBIOL, V19, P683, DOI 10.1046/j.1365-2958.1996.394935.x; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; Manthey D, 2001, METH MOL B, V154, P187; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Nhieu GTV, 2000, CELL MICROBIOL, V2, P187; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Rathman M, 2000, MOL MICROBIOL, V35, P974, DOI 10.1046/j.1365-2958.2000.01770.x; Sansonetti PJ, 1998, FOLIA MICROBIOL, V43, P239, DOI 10.1007/BF02818608; SANSONETTI PJ, 1994, CELL, V76, P829, DOI 10.1016/0092-8674(94)90358-1; Schuch R, 1999, MOL MICROBIOL, V34, P675, DOI 10.1046/j.1365-2958.1999.01627.x; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Suzuki T, 2001, INFECT IMMUN, V69, P5959, DOI 10.1128/IAI.69.10.5959-5966.2001; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	30	136	138	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					720	726		10.1038/ncb1021	http://dx.doi.org/10.1038/ncb1021			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12844145				2022-12-25	WOS:000184687300013
J	Curiel, TJ; Wei, S; Dong, HD; Alvarez, X; Cheng, P; Mottram, P; Krzysiek, R; Knutson, KL; Daniel, B; Zimmermann, MC; David, O; Burow, M; Gordon, A; Dhurandhar, N; Myers, L; Berggren, R; Hemminki, A; Alvarez, RD; Emilie, D; Curiel, DT; Chen, LP; Zou, WP				Curiel, TJ; Wei, S; Dong, HD; Alvarez, X; Cheng, P; Mottram, P; Krzysiek, R; Knutson, KL; Daniel, B; Zimmermann, MC; David, O; Burow, M; Gordon, A; Dhurandhar, N; Myers, L; Berggren, R; Hemminki, A; Alvarez, RD; Emilie, D; Curiel, DT; Chen, LP; Zou, WP			Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; T-HELPER; B7 FAMILY; EXPRESSION; CANCER; TUMORS; PROLIFERATION; RECEPTOR; ANTIGEN; INTERLEUKIN-10	Suppression of dendritic cell function in cancer patients is thought to contribute to the inhibition of immune responses and disease progression. Molecular mechanisms of this suppression remain elusive, however. Here, we show that a fraction of blood monocyte-derived myeloid dendritic cells (MDCs) express B7-H1, a member of the B7 family, on the cell surface. B7-H1 could be further upregulated by tumor environmental factors. Consistent with this finding, virtually all MDCs isolated from the tissues or draining lymph nodes of ovarian carcinomas express B7-H1. Blockade of B7-H1 enhanced MDC-mediated T-cell activation and was accompanied by downregulation of T-cell interleukin (IL)-10 and upregulation of IL-2 and interferon (IFN)-gamma. T cells conditioned with the B7-H1-blocked MDCs had a more potent ability to inhibit autologous human ovarian carcinoma growth in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. Therefore, upregulation of B7-H1 on MDCs in the tumor microenvironment downregulates T-cell immunity. Blockade of B7-H1 represents one approach for cancer immunotherapy.	Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; Mayo Clin, Dept Immunol, Rochester, MN USA; INSERM, U131, Clamart, France; Univ Washington, Div Oncol, Seattle, WA 98195 USA; Baylor Univ, Med Ctr, Div Gynecol, Dallas, TX USA; Univ Alabama, Gene Therapy Ctr, Birmingham, AL USA	Tulane University; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Washington; University of Washington Seattle; Baylor University; Baylor University Medical Center; University of Alabama System; University of Alabama Birmingham	Zou, WP (corresponding author), Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA.		Burow, Matthew/D-6351-2013	Burow, Matthew/0000-0002-0642-6630; Dong, Haidong/0000-0002-5782-2983; Mottram, Peter/0000-0001-8560-2358	NATIONAL CANCER INSTITUTE [P50CA089019, R01CA097085, R01CA086881, R01CA092562] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067962] Funding Source: NIH RePORTER; NCI NIH HHS [CA8661, CA89019, CA97085, CA092562, CA86881] Funding Source: Medline; NCRR NIH HHS [RR00164] Funding Source: Medline; NHLBI NIH HHS [HL67962] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; LLORENTE L, 1995, J EXP MED, V181, P839, DOI 10.1084/jem.181.3.839; Loercher AE, 1999, J IMMUNOL, V163, P6251; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Pardoll D, 2001, NATURE, V411, P1010, DOI 10.1038/35082676; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Strome SE, 2002, CANCER RES, V62, P1884; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tamura H, 2001, BLOOD, V97, P1809, DOI 10.1182/blood.V97.6.1809; Toi M, 1996, CANCER, V77, P1101, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5; Trinchieri G, 1999, CURR TOP MICROBIOL, V238, P57; WANG SD, IN PRESS J EXP MED; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388; Zou WP, 1995, EUR CYTOKINE NETW, V6, P257; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	37	948	1067	5	83	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					562	567		10.1038/nm863	http://dx.doi.org/10.1038/nm863			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704383				2022-12-25	WOS:000182610600037
J	Meeks, JJ; Weiss, J; Jameson, JL				Meeks, JJ; Weiss, J; Jameson, JL			Dax1 is required for testis determination	NATURE GENETICS			English	Article							ADRENAL HYPOPLASIA CONGENITA; SEX REVERSAL; CHROMOSOME; GENE	The orphan nuclear receptor, Dax1, was originally proposed to act as an 'anti-testis' factor. We find, however, that Nr0b1 (also called Dax1 and Ahch, which encodes Dax1) is in fact required for testis differentiation.	Northwestern Univ, Dept Med, Div Endocrinol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Jameson, JL (corresponding author), Northwestern Univ, Dept Med, Div Endocrinol, Feinberg Sch Med, Chicago, IL 60611 USA.			Jameson, James/0000-0001-9538-4059				BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Meeks JJ, 2003, DEVELOPMENT, V130, P1029, DOI 10.1242/dev.00316; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Tevosian SG, 2002, DEVELOPMENT, V129, P4627; VALERIE VPI, 2001, NAT GENET, V28, P216; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822	11	131	140	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					32	33		10.1038/ng1141	http://dx.doi.org/10.1038/ng1141			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12679814				2022-12-25	WOS:000182667900013
J	Amiel, J; Laudier, B; Attie-Bitach, T; Trang, H; de Pontual, L; Gener, B; Trochet, D; Etchevers, H; Ray, P; Simonneau, M; Vekemans, M; Munnich, A; Gaultier, C; Lyonnet, S				Amiel, J; Laudier, B; Attie-Bitach, T; Trang, H; de Pontual, L; Gener, B; Trochet, D; Etchevers, H; Ray, P; Simonneau, M; Vekemans, M; Munnich, A; Gaultier, C; Lyonnet, S			Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome	NATURE GENETICS			English	Article								Congenital central hypoventilation syndrome (CCHS or Ondine's curse; OMIM 209880) is a life-threatening disorder involving an impaired ventilatory response to hypercarbia and hypoxemia. This core phenotype is associated with lower-penetrance anomalies of the autonomic nervous system (ANS) including Hirschsprung disease and tumors of neural-crest derivatives such as ganglioneuromas and neuroblastomas. In mice, the development of ANS reflex circuits is dependent on the paired-like homeobox gene Phox2b. Thus, we regarded its human ortholog, PHOX2B, as a candidate gene in CCHS. We found heterozygous de novo mutations in PHOX2B in 18 of 29 individuals with CCHS. Most mutations consisted of 5-9 alanine expansions within a 20-residue polyalanine tract probably resulting from non-homologous recombination. We show that PHOX2B is expressed in both the central and the peripheral ANS during human embryonic development. Our data support an essential role of PHOX2B in the normal patterning of the autonomous ventilation system and, more generally, of the ANS in humans.	Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM, U393, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Genet, F-75743 Paris, France; Hop Robert Debre, Serv Physiol, CIC INSERM 9202, F-75019 Paris, France; Hop Robert Debre, Equipe INSERM E9935, F-75019 Paris, France; Hosp Cruces, Clin Maternoinfantil, Baracaldo 48903, Spain	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hospital Universitario Cruces	Amiel, J (corresponding author), Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM, U393, 149 Rue de Sevres, F-75743 Paris 15, France.		ATTIE-BITACH, Tania/K-1453-2017; Etchevers, Heather C./B-5813-2012; amiel, jeanne/H-3501-2017; amiel, jeanne/AGX-1124-2022; Gener, Blanca/E-4310-2012; Ray, Pierre/B-9326-2012; Lyonnet, Stanislas/H-5483-2017; Ray, Pierre F/D-7315-2019	ATTIE-BITACH, Tania/0000-0002-1155-3626; Etchevers, Heather C./0000-0003-0201-3799; amiel, jeanne/0000-0001-5973-4728; Lyonnet, Stanislas/0000-0001-5426-9417; Ray, Pierre F/0000-0003-1544-7449; Trochet, Delphine/0000-0002-9216-6117; DE PONTUAL, LOIC/0000-0002-3123-0453				Amiel J, 1998, AM J HUM GENET, V62, P715, DOI 10.1086/301759; Bolk S, 1996, NAT GENET, V13, P395, DOI 10.1038/ng0896-395; BROWN SA, 2002, AM J HUM GENET S166, V71; Bruneau S, 2001, DEV BIOL, V237, P345, DOI 10.1006/dbio.2001.0382; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; Goodman FR, 2001, CLIN GENET, V59, P1, DOI 10.1034/j.1399-0004.2001.590101.x; Gozal D, 1998, PEDIATR PULM, V26, P273; KHALIFA MM, 1988, J PEDIATR-US, V113, P853, DOI 10.1016/S0022-3476(88)80016-7; Nakano M, 2001, NAT GENET, V29, P315, DOI 10.1038/ng744; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Sritippayawan S, 2002, AM J RESP CRIT CARE, V166, P367, DOI 10.1164/rccm.2112087; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Weese-Mayer DE, 2002, AM J MED GENET, V107, P306, DOI 10.1002/ajmg.10133; WEESEMAYER DE, 1993, AM J MED GENET, V47, P360, DOI 10.1002/ajmg.1320470313	15	593	623	0	22	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					459	461		10.1038/ng1130	http://dx.doi.org/10.1038/ng1130			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12640453	Bronze			2022-12-25	WOS:000181928600013
J	Knight, JC; Keating, BJ; Rockett, KA; Kwiatkowski, DR				Knight, JC; Keating, BJ; Rockett, KA; Kwiatkowski, DR			In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading	NATURE GENETICS			English	Article							C-TERMINAL DOMAIN; NECROSIS-FACTOR-ALPHA; PRADER-WILLI-SYNDROME; LYMPHOTOXIN-ALPHA; FACTOR GENES; TNF-ALPHA; HISTONE ACETYLATION; MASS-SPECTROMETRY; CEREBRAL MALARIA; DNA METHYLATION	In vivo characterization of regulatory polymorphisms is a key requirement for next-generation human genetic analysis. Here we describe haploChIP, a method that uses chromatin immunoprecipitation (ChIP) and mass spectrometry to identify differential protein-DNA binding in vivo associated with allelic variants of a gene. We demonstrate this approach with the imprinted gene SNRPN. HaploChIP showed close correlation between the level of bound phosphorylated RNA polymerase II at the SNRPN locus and allele-specific expression. Application of the approach to the TNF/LTA locus identified functionally important haplotypes that correlate with allele-specific transcription of LTA. The haploChIP method may be useful in high-throughput screening for common DNA polymorphisms that affect gene regulation in vivo.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Oxford, John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England	University of Oxford; Wellcome Centre for Human Genetics; Harvard University; University of Oxford	Knight, JC (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Knight, Julian Charles/W-2399-2019; Knight, Julian/C-7242-2009	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536				BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; Braun A, 1997, CLIN CHEM, V43, P1151; Brinkman BMN, 1996, J INFLAMM, V46, P32; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Griffin TJ, 2000, TRENDS BIOTECHNOL, V18, P77, DOI 10.1016/S0167-7799(99)01401-8; Hu JF, 1998, BIOCHEM BIOPH RES CO, V251, P403, DOI 10.1006/bbrc.1998.9401; Jurinke C, 2001, Methods Mol Biol, V170, P103; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789; Roach DR, 2001, J EXP MED, V193, P239, DOI 10.1084/jem.193.2.239; Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917; Sakatani T, 2001, BIOCHEM BIOPH RES CO, V283, P1124, DOI 10.1006/bbrc.2001.4916; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Shaw MA, 2001, GENES IMMUN, V2, P196, DOI 10.1038/sj.gene.6363754; Takahashi Y, 2000, GENE DEV, V14, P804; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Whichelow CE, 1996, EUR J IMMUNOGENET, V23, P425, DOI 10.1111/j.1744-313X.1996.tb00133.x; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Yamamoto S, 2001, MOL CELL BIOL, V21, P1, DOI 10.1128/MCB.21.1.1-15.2001	41	200	208	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2003	33	4					469	475		10.1038/ng1124	http://dx.doi.org/10.1038/ng1124			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12627232	Bronze			2022-12-25	WOS:000181928600017
J	Patterson, SD				Patterson, SD			Data analysis - the Achilles heel of proteomics	NATURE BIOTECHNOLOGY			English	Editorial Material									Farmal Biomed LLC, Pasadena, CA 91106 USA		Patterson, SD (corresponding author), Farmal Biomed LLC, Pasadena, CA 91106 USA.							Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Keller Andrew, 2002, OMICS A Journal of Integrative Biology, V6, P207, DOI 10.1089/153623102760092805; MacCoss MJ, 2002, ANAL CHEM, V74, P5593, DOI 10.1021/ac025826t; Patterson SD, 2003, NAT GENET, V33, P311, DOI 10.1038/ng1106; Ryan TE, 2002, TRENDS BIOTECHNOL, V20, pS45, DOI 10.1016/S1471-1931(02)00199-4	6	89	92	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					221	222		10.1038/nbt0303-221	http://dx.doi.org/10.1038/nbt0303-221			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610558				2022-12-25	WOS:000181312500007
J	Jackman, M; Lindon, C; Nigg, EA; Pines, J				Jackman, M; Lindon, C; Nigg, EA; Pines, J			Active cyclin B1-Cdk1 first appears on centrosomes in prophase	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE; M-PHASE; STARFISH OOCYTES; NUCLEAR EXPORT; CHROMOSOME CONDENSATION; XENOPUS EGGS; HISTONE H3; PHOSPHORYLATION; B1; LOCALIZATION	Cyclin B1-Cdk1 is the key initiator of mitosis, but when and where activation occurs has not been precisely determined in mammalian cells. Activation may occur in the nucleus or cytoplasm, as just before nuclear envelope breakdown, Polo-like kinase1 (Plk1) is proposed to phosphorylate cyclin B1 in its nuclear export sequence (NES), to trigger rapid nuclear import. We raised phosphospecific antibodies against cyclin B1 that primarily recognise the active form of the complex. We show that cyclin B1 is initially phosphorylated on centrosomes in prophase and that Plk1 phosphorylates cyclin B1, but not in the NES. Furthermore, phosphorylation by Plk1 does not cause cyclin B1 to move into the nucleus. We conclude that cyclin B1-Cdk1 is first activated in the cytoplasm and that centrosomes may function as sites of integration for the proteins that trigger mitosis.	Wellcome Trust Canc Res UK Inst, Cambridge CB2 1QR, England; Dept Zool, Cambridge CB2 1QR, England; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Pines, J (corresponding author), Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	j.pines@welc.cam.ac.uk		nigg, erich/0000-0003-4835-5719; Pines, Jonathon/0000-0002-5227-6004; Lindon, Catherine/0000-0003-3554-2574				BAILLY E, 1992, J CELL SCI, V101, P529; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bridge AJ, 1998, GENE DEV, V12, P927, DOI 10.1101/gad.12.7.927; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lindon C, 2000, MOL CELL BIOL, V20, P8923, DOI 10.1128/MCB.20.23.8923-8932.2000; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; Perez-Mongiovi D, 2000, J CELL BIOL, V150, P963, DOI 10.1083/jcb.150.5.963; Peter M, 2002, EMBO REP, V3, P551, DOI 10.1093/embo-reports/kvf111; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	36	480	495	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					143	148		10.1038/ncb918	http://dx.doi.org/10.1038/ncb918			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12524548				2022-12-25	WOS:000180802100014
J	Kaupp, UB; Solzin, J; Hildebrand, E; Brown, JE; Helbig, A; Hagen, V; Beyermann, M; Pampaloni, F; Weyand, I				Kaupp, UB; Solzin, J; Hildebrand, E; Brown, JE; Helbig, A; Hagen, V; Beyermann, M; Pampaloni, F; Weyand, I			The signal flow and motor response controling chemotaxis of sea urchin sperm	NATURE CELL BIOLOGY			English	Article							EGG PEPTIDE SPERACT; ADENYLATE-CYCLASE; OUTER SEGMENTS; ACTIVATION; SPERMATOZOA; IDENTIFICATION; CHANNELS; CALCIUM; RESACT; SPREAD	The signalling pathway and the behavioural strategy underlying chemotaxis of sperm are poorly understood. We have studied the cellular events and motor responses that mediate chemotaxis of sperm from the sea urchin Arbacia punctulata. Here we show that resact, a chemoattractant peptide, initiates a rapid and transient rise in the concentration of cyclic GMP, followed by a transient influx of Ca2+. The binding of a single resact molecule elicits a Ca2+ response, and 50-100 bound molecules saturate the response. The ability to register single molecules is reminiscent of the single-photon sensitivity of rod photoreceptors. Both resact and cyclic nucleotides cause a turn or brief tumbling in the swimming path of sperm. We conclude that a cGMP-mediated increase in the Ca2+ concentration induces the primary motor response of sperm to the chemoattractant.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Marine Biol Lab, Woods Hole, MA 02543 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Ophthalmol, Bronx, NY 10461 USA; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Helmholtz Association; Research Center Julich; Marine Biological Laboratory - Woods Hole; Yeshiva University; Albert Einstein College of Medicine	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	a.eckert@fz-juelich.de	Pampaloni, Francesco/AAU-9705-2021; Pampaloni, Francesco/B-1110-2011	Pampaloni, Francesco/0000-0003-4357-7320; Solzin, Johannes/0000-0001-9224-4296				BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; Beltran C, 1996, BIOCHEMISTRY-US, V35, P7591, DOI 10.1021/bi952806v; BOOKBINDER LH, 1990, J CELL BIOL, V111, P1859, DOI 10.1083/jcb.111.5.1859; BOOKBINDER LH, 1991, MOL REPROD DEV, V28, P150, DOI 10.1002/mrd.1080280208; BROKAW CJ, 1974, BIOCHEM BIOPH RES CO, V58, P795, DOI 10.1016/S0006-291X(74)80487-0; COOK SP, 1993, J BIOL CHEM, V268, P22408; COOK SP, 1993, J BIOL CHEM, V268, P22402; COOK SP, 1994, DEV BIOL, V165, P10, DOI 10.1006/dbio.1994.1229; Cosson M.P., 1990, P103; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Darszon A, 2001, DEV BIOL, V240, P1, DOI 10.1006/dbio.2001.0387; Eisenbach M, 1999, BIOESSAYS, V21, P203, DOI 10.1002/(SICI)1521-1878(199903)21:3<203::AID-BIES4>3.0.CO;2-T; Eisenbach M, 1999, REV REPROD, V4, P56, DOI 10.1530/revreprod/4.1.56; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gray-Keller M, 1999, J PHYSIOL-LONDON, V519, P679, DOI 10.1111/j.1469-7793.1999.0679n.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hagen V, 2001, ANGEW CHEM INT EDIT, V40, P1046; Hagen V, 2002, ANGEW CHEM INT EDIT, V41, P3625, DOI 10.1002/1521-3773(20021004)41:19<3625::AID-ANIE3625>3.0.CO;2-J; Ho HC, 2001, REPRODUCTION, V122, P519, DOI 10.1530/rep.0.1220519; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; Miller R.L., 1985, P275; Nishigaki T, 2000, DEV BIOL, V223, P17, DOI 10.1006/dbio.2000.9734; Nishigaki T, 2001, BIOCHEM BIOPH RES CO, V284, P531, DOI 10.1006/bbrc.2001.5000; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; SHIMOMURA H, 1986, BIOCHEMISTRY-US, V25, P3405, DOI 10.1021/bi00359a046; SUZUKI N, 1995, ZOOL SCI, V12, P13, DOI 10.2108/zsj.12.13; Tatsu Y, 2002, FEBS LETT, V525, P20, DOI 10.1016/S0014-5793(02)03000-4; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WARD GE, 1985, J CELL BIOL, V101, P2324, DOI 10.1083/jcb.101.6.2324	31	176	178	4	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					109	117		10.1038/ncb915	http://dx.doi.org/10.1038/ncb915			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12563276				2022-12-25	WOS:000180802100010
J	Olofsson, P; Holmberg, J; Tordsson, J; Lu, SM; Akerstrom, B; Holmdahl, R				Olofsson, P; Holmberg, J; Tordsson, J; Lu, SM; Akerstrom, B; Holmdahl, R			Positional identification of Ncf1 as a gene that regulates arthritis severity in rats	NATURE GENETICS			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ADJUVANT-INDUCED ARTHRITIS; COLLAGEN-INDUCED ARTHRITIS; OLIGOMERIC MATRIX PROTEIN; PHAGOCYTE NADPH OXIDASE; OIL-INDUCED ARTHRITIS; GENOME-WIDE LINKAGE; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ENCEPHALOMYELITIS; SUSCEPTIBILITY LOCUS	The identification of genes underlying quantitative-trait loci (QTL) for complex diseases, such as rheumatoid arthritis, is a challenging and difficult task for the human genome project. Through positional cloning of the Pia4 QTL in rats, we found that a naturally occurring polymorphism of Ncf1 (encoding neutrophil cytosolic factor 1, a component of the NADPH oxidase complex) regulates arthritis severity. The disease-related allele of Ncf1 has reduced oxidative burst response and promotes activation of arthritogenic T cells. Pharmacological treatment with substances that activate the NADPH oxidase complex is shown to ameliorate arthritis. Hence, Ncf1 is associated with a new autoimmune mechanism leading to severe destructive arthritis, notably similar to rheumatoid arthritis in humans.	Lund Univ, Sect Med Inflammat Res, S-22184 Lund, Sweden; Lund Univ, Dept Cell & Mol Biol, Sect Mol Pathogenesis, S-22184 Lund, Sweden	Lund University; Lund University	Holmdahl, R (corresponding author), Lund Univ, Sect Med Inflammat Res, Solvegatan 19,I11 BMC, S-22184 Lund, Sweden.		Lu, Shemin/AAI-6479-2021; Lu, Shemin/M-3350-2018; Holmdahl, Rikard/AAI-7682-2020	Lu, Shemin/0000-0002-5535-8320; Lu, Shemin/0000-0001-8250-850X; Olofsson, Peter/0000-0003-4849-8541				AKERSTROM B, 1985, J BIOL CHEM, V260, P4839; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bergsteinsdottir K, 2000, J IMMUNOL, V164, P1564, DOI 10.4049/jimmunol.164.3.1564; CANNON GW, 1993, ARTHRITIS RHEUM, V36, P126, DOI 10.1002/art.1780360120; CASIMIR CM, 1991, P NATL ACAD SCI USA, V88, P2753, DOI 10.1073/pnas.88.7.2753; Cooper AM, 2000, INFECT IMMUN, V68, P1231, DOI 10.1128/IAI.68.3.1231-1234.2000; Cornelis F, 1998, P NATL ACAD SCI USA, V95, P10746, DOI 10.1073/pnas.95.18.10746; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Dahlman I, 1999, J IMMUNOL, V162, P2581; DeSilva U, 2002, GENOME RES, V12, P3, DOI 10.1101/gr.214802; Geiszt M, 2001, J LEUKOCYTE BIOL, V69, P191; Gosele C, 2000, GENOMICS, V69, P287, DOI 10.1006/geno.2000.6352; Griffiths MM, 2000, ARTHRITIS RHEUM, V43, P1278, DOI 10.1002/1529-0131(200006)43:6<1278::AID-ANR10>3.0.CO;2-S; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Holmdahl R, 2001, IMMUNOL REV, V184, P184, DOI 10.1034/j.1600-065x.2001.1840117.x; HOLMDAHL R, 1992, CLIN EXP IMMUNOL, V88, P96; Huang CK, 2000, J LEUKOCYTE BIOL, V67, P210, DOI 10.1002/jlb.67.2.210; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; Morel L, 2000, Int Rev Immunol, V19, P423, DOI 10.3109/08830180009055506; Nordquist N, 2000, J AUTOIMMUN, V15, P425, DOI 10.1006/jaut.2000.0450; Olofsson P, 2002, ARTHRITIS RHEUM, V46, P259, DOI 10.1002/1529-0131(200201)46:1<259::AID-ART10035>3.0.CO;2-2; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; Schneider SM, 2001, INFLAMMATION, V25, P17, DOI 10.1023/A:1007019510569; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sun SH, 1999, INT IMMUNOL, V11, P529, DOI 10.1093/intimm/11.4.529; Svelander L, 1997, IMMUNOLOGY, V91, P260, DOI 10.1046/j.1365-2567.1997.00251.x; TAUROG JD, 1983, CELL IMMUNOL, V80, P198, DOI 10.1016/0008-8749(83)90106-5; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; van der Veen RC, 2000, J IMMUNOL, V164, P5177, DOI 10.4049/jimmunol.164.10.5177; Vingsbo C, 1996, AM J PATHOL, V149, P1675; Vingsbo-Lundberg C, 1998, ARTHRITIS RHEUM, V41, P544, DOI 10.1002/1529-0131(199803)41:3<544::AID-ART21>3.0.CO;2-#; Vingsbo-Lundberg C, 1998, NAT GENET, V20, P401, DOI 10.1038/3887; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Weis JJ, 1999, J IMMUNOL, V162, P948; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Zhang L, 1999, IMMUNOLOGY, V98, P267; Zheng CL, 2002, CLIN IMMUNOL, V103, P204, DOI 10.1006/clim.2002.5205; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287	50	299	309	2	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					25	32		10.1038/ng1058	http://dx.doi.org/10.1038/ng1058			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12461526				2022-12-25	WOS:000180136100013
J	Schmaltz, C; Alpdogan, O; Kappel, BJ; Muriglan, SJ; Rotolo, JA; Ongchin, J; Willis, LM; Greenberg, AS; Eng, JM; Crawford, JM; Murphy, GF; Yagita, H; Walczak, H; Peschon, JJ; van den Brink, MRM				Schmaltz, C; Alpdogan, O; Kappel, BJ; Muriglan, SJ; Rotolo, JA; Ongchin, J; Willis, LM; Greenberg, AS; Eng, JM; Crawford, JM; Murphy, GF; Yagita, H; Walczak, H; Peschon, JJ; van den Brink, MRM			T cells require TRAIL for optimal graft-versus-tumor activity	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; HOST DISEASE; FAS LIGAND; TUMORICIDAL ACTIVITY; PERFORIN; TRANSPLANTATION; EXPRESSION; METASTASIS; DEFICIENT; LEUKEMIA	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that exhibits specific tumoricidal activity against a variety of tumors(1,2). It is expressed on different cells of the immune system and plays a role in natural killer cell-mediated tumor surveillance(3-5). In allogeneic hematopoietic-cell transplantation, the reactivity of the donor T cell against malignant cells is essential for the graft-versus-tumor (GVT) effect(6). Cytolytic activity of T cells is primarily mediated through the Fas-Fas ligand and perforin-granzyme pathways. However, T cells deficient for both Fas ligand and perforin can still exert GVT activity in vivo in mouse models(7,8). To uncover a potential role for TRAIL in donor T cell-mediated GVT activity, we compared donor T cells from TRAIL-deficient and wild-type mice in clinically relevant mouse bone-marrow transplantation models. We found that alloreactive T cells can express TRAIL, but the absence of TRAIL had no effect on their proliferative and cytokine response to alloantigens. TRAIL-deficient T cells showed significantly lower GVT activity than did TRAIL-expressing T cells, but no important differences in graft-versus-host disease, a major complication of allogeneic hematopoietic cell transplantation, were observed. These data suggest that strategies to enhance TRAIL-mediated GVT activity could decrease relapse rates of malignancies after hematopoietic cell transplantation without exacerbation of graft-versus-host disease.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; Thomas Jefferson Med Ctr, Dept Pathol, Philadelphia, PA USA; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; German Canc Res Ctr, Div Apoptosis Regulat, D-6900 Heidelberg, Germany; Immunex Corp, Dept Mol Immunol, Seattle, WA USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University System of Florida; University of Florida; Jefferson University; Juntendo University; Helmholtz Association; German Cancer Research Center (DKFZ); Immunex Corporation	van den Brink, MRM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.		van den Brink, Marcel R. M./HGB-9434-2022	van den Brink, Marcel/0000-0003-0696-4401; Rotolo, Jim/0000-0003-4195-6167; Walczak, Henning/0000-0002-6312-4591	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NHLBI NIH HHS [HL69929, HL72412] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072412, R01HL069929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BORDIGNON C, 1989, BLOOD, V74, P2237; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Crawford JM., 1997, GRAFT VERSUS HOST DI, P315; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; FERRARA J, 1986, J INVEST DERMATOL, V86, P371, DOI 10.1111/1523-1747.ep12285612; Hattori K, 1998, BLOOD, V91, P4051, DOI 10.1182/blood.V91.11.4051.411k16_4051_4055; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; van den Brink MRM, 2000, J IMMUNOL, V164, P469, DOI 10.4049/jimmunol.164.1.469; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Winter H, 1999, J IMMUNOL, V163, P4462	24	124	127	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1433	1437		10.1038/nm797	http://dx.doi.org/10.1038/nm797			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426560				2022-12-25	WOS:000179552000041
J	Ghosh, PK; Vasanji, A; Murugesan, G; Eppell, SJ; Graham, LM; Fox, PL				Ghosh, PK; Vasanji, A; Murugesan, G; Eppell, SJ; Graham, LM; Fox, PL			Membrane microviscosity regulates endothelial cell motility	NATURE CELL BIOLOGY			English	Article							LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE; VITAMIN-E; CHOLESTEROL; MIGRATION; LYSOPHOSPHATIDYLCHOLINE; INHIBITION; BEHAVIOR; BILAYERS; RAFTS	Endothelial cell (EC) movement is an initiating and rate-limiting event in the neogenesis and repair of blood vessels. Here, we explore the hypothesis that microviscosity of the plasma membrane (PM) is a key physiological regulator of cell movement. Aortic ECs treated with membrane-active agents, such as alpha-tocopherol, cholesterol and lysophospholipids, exhibited a biphasic dependency on membrane microviscosity, in which moderate increases enhanced EC migration, but increases beyond a threshold markedly inhibited migration. Surprisingly, angiogenic growth factors, that is, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), also increased membrane microviscosity, as measured in live cells by fluorescence recovery after photobleaching (FRAP). The localization of Rac to the PM was modified in cells treated with membrane-active agents or growth factors, suggesting a molecular mechanism for how membrane microviscosity influences cell movement. Our data show that angiogenic growth factors, as well as certain lipophilic molecules, regulate cell motility through alterations in membrane properties and the consequent relocalization of critical signalling molecules to membranes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Vasc Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ghosh, PK (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@ccf.org		Eppell, Steven/0000-0002-0302-1910	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R56HL064357, R01HL064357, R01HL054519] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64357, HL29582, HL/CA54519] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CHANG HM, 1995, J MEMBRANE BIOL, V145, P13; CHATTERJEE S, 1982, P NATL ACAD SCI-BIOL, V79, P835, DOI 10.1073/pnas.79.3.835; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Isshiki M, 2002, J CELL SCI, V115, P475; Kugiyama K, 1999, ATHEROSCLEROSIS, V143, P201, DOI 10.1016/S0021-9150(98)00288-3; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUNDBAEK JA, 1994, J GEN PHYSIOL, V104, P645, DOI 10.1085/jgp.104.4.645; MAROM M, 1994, CELL MOL NEUROBIOL, V14, P119, DOI 10.1007/BF02090780; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Pryor WA, 2000, FREE RADICAL BIO MED, V28, P141, DOI 10.1016/S0891-5849(99)00224-5; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SHEETZ MP, 1976, J CELL BIOL, V70, P193, DOI 10.1083/jcb.70.1.193; Shklar G, 1996, ORAL ONCOL, V32B, P114, DOI 10.1016/0964-1955(95)00077-1; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SOMMER A, 1992, J BIOL CHEM, V267, P24217; Stillwell W, 1996, BIOCHEMISTRY-US, V35, P13353, DOI 10.1021/bi961058m; URANO S, 1992, J BIOL CHEM, V267, P18365; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YEAGLE PL, 1990, BIOPHYS J, V57, P413, DOI 10.1016/S0006-3495(90)82558-3; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	30	72	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					894	900		10.1038/ncb873	http://dx.doi.org/10.1038/ncb873			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402046				2022-12-25	WOS:000179137700019
J	Lazarov, M; Kubo, Y; Cai, T; Dajee, M; Tarutani, M; Lin, Q; Fang, M; Tao, SY; Green, CL; Khavari, PA				Lazarov, M; Kubo, Y; Cai, T; Dajee, M; Tarutani, M; Lin, Q; Fang, M; Tao, SY; Green, CL; Khavari, PA			CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; DEPENDENT KINASE-4 CDK4; HUMAN BREAST-CANCER; CYCLIN D1; ONCOGENIC TRANSFORMATION; BINDING DOMAIN; IN-VIVO; GENE; EXPRESSION; ACTIVATION	Ras acts with other proteins to induce neoplasia. By itself, however, strong Ras signaling can suppress proliferation of normal cells. In primary epidermal cells, we found that oncogenic Ras transiently decreases cyclin-dependent kinase (CDK) 4 expression in association with cell cycle arrest in G1 phase. CDK4 co-expression circumvents Ras growth suppression and induces invasive human neoplasia resembling squamous cell carcinoma. Tumorigenesis is dependent on CDK4 kinase function, with cyclin D1 required but not sufficient for this process. In facilitating escape from G1 growth restraints, Ras and CDK4 alter the composition of cyclin D and cyclin E complexes and promote resistance to growth inhibition by INK4 cyclin-dependent kinase inhibitors. These data identify a new role for oncogenic Ras in CDK4 regulation and highlight the functional importance of CDK4 suppression in preventing uncontrolled growth.	VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799, R29AR043799, R01AR045192] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45192, AR43799] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; BENJAMIN T, 1990, VIROLOGY, P317; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eisma RJ, 1997, AM J SURG, V174, P513; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Koontongkaew S, 2000, ORAL ONCOL, V36, P334, DOI 10.1016/S1368-8375(99)00093-7; Koseki Shin, 1999, Journal of Dermatology (Tokyo), V26, P416; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsumoto M, 1999, BRIT J CANCER, V80, P256, DOI 10.1038/sj.bjc.6690348; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Proby CM, 2000, EXP DERMATOL, V9, P104, DOI 10.1034/j.1600-0625.2000.009002104.x; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKOTZKO M, 1995, CANCER RES, V55, P5493; Sui L, 2000, GYNECOL ONCOL, V79, P230, DOI 10.1006/gyno.2000.5961; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUSPA SH, 1994, CANCER RES, V54, P1178; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	45	154	156	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1105	1114		10.1038/nm779	http://dx.doi.org/10.1038/nm779			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357246				2022-12-25	WOS:000178311000037
J	Mollet, G; Salomon, R; Gribouval, O; Silbermann, F; Bacq, D; Landthaler, G; Milford, D; Nayir, A; Rizzoni, G; Antignac, C; Saunier, S				Mollet, G; Salomon, R; Gribouval, O; Silbermann, F; Bacq, D; Landthaler, G; Milford, D; Nayir, A; Rizzoni, G; Antignac, C; Saunier, S			The gene mutated in juvenile nephronophthisis type 4 encodes a novel protein that interacts with nephrocystin	NATURE GENETICS			English	Article							P130(CAS); DELETIONS; ELEGANS; LINKAGE; DOMAIN; MAP	Nephronophthisis, the most common genetic cause of chronic renal failure in children, is a progressive tubulo-interstitial kidney disorder that is inherited as an autosomal recessive trait. The disease is characterized by polyuria, growth retardation and deterioration of renal function during childhood or adolescence. The most prominent histological features are modifications of the tubules with thickening of the basement membrane, interstitial fibrosis and, in the advanced stages, medullary cysts(1). Nephronophthisis can also be associated with conditions affecting extrarenal organs, such as retinitis pigmentosa (Senior-Loken syndrome) (2,3) and ocular motor apraxia (Cogan syndrome)(4). Three loci are associated with the juvenile, infantile and adolescent forms, on chromosomes 2q13 (NPHP1; refs 5,6), 9q22 (NPHP2; ref. 7) and 3q21 (NPHP3; ref. 8), respectively. NPHP1, the only gene identified so far, encodes nephrocystin(9,10), which contains a Src homology 3 (SH3) domain and interacts with intracytoplasmic proteins involved in cell adhesion (11-13). Recently, a second locus associated with the juvenile form of the disease, NPHP4, was mapped to chromosome 1p36 (ref. 14). We carried out haplotype analysis of families affected with nephronophthisis that were not linked to the NPHP1, NPHP2 or NPHP3 loci, using markers covering this region. This allowed us to reduce the NPHP4 interval to a one centimorgan interval between D1S2795 and D1S2870, which contains six genes. We identified five different mutations in one of these genes, designated NPHP4, in unrelated individuals with nephronophthisis. The NPHP4 gene encodes a 1,250-amino acid protein of unknown function that we named nephrocystin-4. We demonstrated the interaction of nephrocystin-4 with nephrocystin suggesting that these two proteins participate in a common signaling pathway.	Univ Paris 05, Hop Necker Enfants Malad, INSERM, U423, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Serv Neprol Pediat, Paris, France; Hop Charles Nicolle, Serv Nephrol pediat, Rouen, France; Ctr Natl Genotypage, Evry, France; Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England; Istanbul Univ, Fac Med, Dept Pediat Nephrol, Istanbul, Turkey; Bambino Gesu Pediat Hosp, Div Nephrol & Dialysis, Rome, Italy; Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Rouen; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Birmingham; Istanbul University; IRCCS Bambino Gesu; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Antignac, C (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, INSERM, U423, Tour Lavoisier, Paris, France.	antignac@necker.fr	Gribouval, Olivier/A-7689-2015; Saunier, Sophie/G-6044-2015; Mollet, Geraldine/E-8049-2017; ANTIGNAC, Corinne/H-8945-2017	Gribouval, Olivier/0000-0003-0238-8224; Saunier, Sophie/0000-0002-1069-0047; Mollet, Geraldine/0000-0003-4685-5736; ANTIGNAC, Corinne/0000-0002-9934-4940; legendre, flora/0000-0002-4149-1913				ANTIGNAC C, 1993, NAT GENET, V3, P342, DOI 10.1038/ng0493-342; ANTIGNAC C, 1998, CLIN NEPHROL, P2417; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Betz R, 2000, J PEDIATR-US, V136, P828, DOI 10.1067/mpd.2000.106225; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Caridi G, 1998, AM J KIDNEY DIS, V32, P1059, DOI 10.1016/S0272-6386(98)70083-6; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COGAN D G, 1952, Trans Am Acad Ophthalmol Otolaryngol, V56, P853; Desrosiers RR, 2000, J BIOL CHEM, V275, P14949, DOI 10.1074/jbc.275.20.14949; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Donaldson JC, 2002, J BIOL CHEM, V277, P29028, DOI 10.1074/jbc.M111697200; Haider NB, 1998, AM J HUM GENET, V63, P1404, DOI 10.1086/302108; HEIDET L, 1995, HUM MOL GENET, V4, P99, DOI 10.1093/hmg/4.1.99; HILDEBRANDT F, 1993, AM J HUM GENET, V53, P1256; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LOKEN AC, 1961, ACTA PAEDIATR, V50, P177, DOI 10.1111/j.1651-2227.1961.tb08037.x; Omran H, 2002, J AM SOC NEPHROL, V13, P75, DOI 10.1681/ASN.V13175; Omran H, 2001, NEPHROL DIAL TRANSPL, V16, P755, DOI 10.1093/ndt/16.4.755; Otto E, 2000, J AM SOC NEPHROL, V11, P270, DOI 10.1681/ASN.V112270; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; Schuermann MJ, 2002, AM J HUM GENET, V70, P1240, DOI 10.1086/340317; SENIOR B, 1961, AM J OPHTHALMOL, V52, P625, DOI 10.1016/0002-9394(61)90147-7	27	165	174	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					300	305		10.1038/ng996	http://dx.doi.org/10.1038/ng996			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244321				2022-12-25	WOS:000178311100021
J	Stenoien, DL; Mielke, M; Mancini, MA				Stenoien, DL; Mielke, M; Mancini, MA			Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components	NATURE CELL BIOLOGY			English	Article							CREB-BINDING PROTEIN; PROTEASOME COMPONENTS; LIVING CELLS; POLYGLUTAMINE; NEURODEGENERATION; TRANSCRIPTION; CHAPERONE; MOBILITY; IDENTIFICATION; SUPPRESSION	A hallmark of neurodegenerative diseases caused by polyglutamine expansion is the abnormal accumulation of mutant proteins into ubiquitin-positive inclusions(1). The local build-up of these ubiquitinated proteins suggests that the proteasome machinery inadequately clears mis-folded proteins, resulting in their increase to potentially toxic levels(2). Inclusions may disrupt normal cell homeostasis by sequestering vital cellular factors, such as chaperones, proteasomes and transcription components(3-7). Here, we used fluorescence recovery after photobleaching (FRAP) to examine the intranuclear dynamics of polyglutamine-expanded ataxin1 and inclusion-associated proteins. These experiments demonstrated that at least two types of ataxin1 inclusions exist; those that undergo rapid and complete exchange with a nucleoplasmic pool and those that contain varying levels of slow-exchanging ataxin1. Slow-exchanging inclusions contain high ubiquitin levels, but surprisingly low proteasome levels, suggesting an impairment in the ability of proteasomes to recognize ubiquitinated substrates. Proteasomes and CBP remained highly dynamic components of inclusions, indicating that although enriched with ataxin1, they are not irreversibly trapped. These results redefine our perception of polyglutamine inclusions and demonstrate the usefulness of FRAP and live cell imaging to study factors that modulate their behaviour.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Mancini, MA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061859, R01DK055622] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55622, 1F32DK61859-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; CUMMINGS CJ, 1999, THESIS BAYLOR COLL M; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; HERSKO A, 1992, REV BIOCH, V61, P761; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nandi D, 1996, J IMMUNOL, V156, P2361; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	25	104	107	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					806	810		10.1038/ncb859	http://dx.doi.org/10.1038/ncb859			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360291				2022-12-25	WOS:000178316500018
J	Zuccato, C; Tartari, M; Crotti, A; Goffredo, D; Valenza, M; Conti, L; Cataudella, T; Leavitt, BR; Hayden, MR; Timmusk, T; Rigamonti, D; Cattaneo, E				Zuccato, C; Tartari, M; Crotti, A; Goffredo, D; Valenza, M; Conti, L; Cataudella, T; Leavitt, BR; Hayden, MR; Timmusk, T; Rigamonti, D; Cattaneo, E			Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes	NATURE GENETICS			English	Article							RESTRICTIVE SILENCER FACTOR; WILD-TYPE HUNTINGTIN; HISTONE DEACETYLASE; MULTIPLE PROMOTERS; MUTANT HUNTINGTIN; BDNF-GENE; DISEASE; EXPRESSION; BRAIN; MOUSE	Huntingtin protein is mutated in Huntington disease(1). We previously reported that wild-type but not mutant huntingtin stimulates transcription of the gene encoding brain-derived neurotrophic factor (BDNF; ref. 2). Here we show that the neuron restrictive silencer element (NRSE) is the target of wildtype huntingtin activity on BDNF promoter II. Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE3,4. In contrast, aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease. We also report that wild-type huntingtin acts as a positive transcriptional regulator for other NRSE-containing genes involved in the maintenance of the neuronal phenotype(5). Consistently, loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease. We conclude that wild-type huntingtin acts in the cytoplasm of neurons to regulate the availability of REST/NRSF to its nuclear NRSE-binding site and that this control is lost in the pathology of Huntington disease. These data identify a new mechanism by which mutation of huntingtin causes loss of transcription of neuronal genes.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ British Columbia, Dept Med Genet, Ctr mol Med & Therapeut, Vancouver, BC, Canada; Univ Helsinki, Inst Biotechnol, Helsinki, Finland; Tallinn Univ Technol, Dept Gene Technol, EE-200108 Tallinn, Estonia; NICPB, Tallinn, Estonia	University of Milan; University of Milan; University of British Columbia; University of Helsinki; Tallinn University of Technology; National Institute of Chemical Physics & Biophysics (NICPB)	Cattaneo, E (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	elena.cattaneo@unimi.it	Conti, Luciano/H-4184-2012; Leavitt, Blair R/G-1934-2012; Hayden, Michael R/D-8581-2011; Timmusk, Tonis/H-4889-2015; VALENZA, MARTA/B-7763-2017	Conti, Luciano/0000-0002-2050-9846; Hayden, Michael R/0000-0001-5159-1419; ZUCCATO, CHIARA/0000-0003-1771-3392; Timmusk, Tonis/0000-0002-1015-3348; VALENZA, MARTA/0000-0002-7048-9257; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [E.0840] Funding Source: Medline	Telethon(Fondazione Telethon)		Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745; Ehrlich ME, 2001, EXP NEUROL, V167, P215, DOI 10.1006/exnr.2000.7551; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Goffredo D, 2002, J BIOL CHEM, V277, P39594, DOI 10.1074/jbc.C200353200; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Koenigsberger C, 2000, P NATL ACAD SCI USA, V97, P2291, DOI 10.1073/pnas.050578797; Lee JH, 2000, MOL BRAIN RES, V80, P88, DOI 10.1016/S0169-328X(00)00129-7; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; Timmusk T, 1999, J BIOL CHEM, V274, P1078; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; ZHANG Y, IN PRESS J NEUROCHEM; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	30	675	698	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2003	35	1					76	83		10.1038/ng1219	http://dx.doi.org/10.1038/ng1219			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12881722				2022-12-25	WOS:000185018500014
J	Maillet, M; Robert, SJ; Cacquevel, M; Gastineau, M; Vivien, D; Bertoglio, J; Zugaza, JL; Fischmeister, R; Lezoualc'h, F				Maillet, M; Robert, SJ; Cacquevel, M; Gastineau, M; Vivien, D; Bertoglio, J; Zugaza, JL; Fischmeister, R; Lezoualc'h, F			Crosstalk between Rap1 and Rac regulates secretion of sAPP alpha	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; PHARMACOLOGICAL PROFILE; CAMP ANALOG; ACTIVATION; EPAC; CELLS; CDC42; PHOSPHORYLATION; MECHANISM	Cyclic AMP ( cAMP) is produced by activation of Gs protein-coupled receptors and regulates many physiological processes through activation of protein kinase A (PKA)(1,2). However, a large body of evidence indicates that cAMP also regulates specific cellular functions through PKA-independent pathways(3,4). Here, we show that a small GTPase of the Rho family, Rac, is regulated by cAMP in a PKA-independent manner. We also show that Rac activation results from activation of Rap1 through the cAMP guanine nucleotide-exchange factor (GEF) Epac1. Activation of the Gs-coupled serotonin 5-HT4 receptor initiates this signalling cascade in various cell types. Furthermore, we demonstrate that crosstalk between the Ras and Rho GTPase families is involved in cAMP-dependent processing of amyloid precursor protein (APP), a key protein in Alzheimer's disease. Indeed, Epac1 regulates secretion of the non-amyloidogenic soluble form of APP (sAPPalpha) through Rap1 and Rac. Our data identify an unsuspected connection between two families of small GTPases and imply that Rac can function downstream of cAMP/Epac1/Rap1 in a novel signal transduction secretory pathway.	INSERM, U446, F-75654 Paris 13, France; INSERM, U461, F-75654 Paris 13, France; Univ Paris Sud, Inst Signalisat & Innovat Therapeut, IFR 75, Fac Pharm, F-92296 Chatenay Malabry, France; Ctr Cyceron, UMR CNRS 6551, IFR 47, F-14074 Caen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite de Caen Normandie	Zugaza, JL (corresponding author), Ctr Invest Canc, Campus Miguel Unamuno, Salamanca 37007, Spain.	jzugaza@usal.es; Lezoualch@cep.u-psud.fr	Lezoualc'h, Frank/E-5031-2016; Bustelo, Xose R./A-9526-2010; Fischmeister, Rodolphe/L-6061-2018	Bustelo, Xose R./0000-0001-9398-6072; Fischmeister, Rodolphe/0000-0003-2086-9865; VIVIEN, DENIS/0000-0002-7636-2185; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; Briejer MR, 2001, EUR J PHARMACOL, V423, P71, DOI 10.1016/S0014-2999(01)01087-1; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; GOTTESMAN MM, 1980, SOMAT CELL GENET, V6, P45, DOI 10.1007/BF01538695; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Hung SH, 2002, BIOORG CHEM, V30, P16, DOI 10.1006/bioo.2001.1226; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Mialet J, 2000, BRIT J PHARMACOL, V129, P771, DOI 10.1038/sj.bjp.0703101; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Murthy KS, 2002, AM J PHYSIOL-CELL PH, V282, pC508, DOI 10.1152/ajpcell.00373.2001; Pruyne D, 2000, J CELL SCI, V113, P571; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Robert SJ, 2001, J BIOL CHEM, V276, P44881, DOI 10.1074/jbc.M109008200; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023	30	160	167	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					633	U36		10.1038/ncb1007	http://dx.doi.org/10.1038/ncb1007			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12819788	Green Submitted			2022-12-25	WOS:000183911600013
J	Kapuscinski, AR; Goodman, RM; Hann, SD; Jacobs, LR; Pullins, EE; Johnson, CS; Kinsey, JD; Krall, RL; La Vina, AG; Mellon, MG; Ruttan, VW				Kapuscinski, AR; Goodman, RM; Hann, SD; Jacobs, LR; Pullins, EE; Johnson, CS; Kinsey, JD; Krall, RL; La Vina, AG; Mellon, MG; Ruttan, VW			Making 'safety first' a reality for biotechnology products	NATURE BIOTECHNOLOGY			English	Editorial Material									Dept Fisheries Wildlife & Conservat Biol, St Paul, MN 55108 USA; Inst Social Econ & Ecol Sustainabil, St Paul, MN 55108 USA; Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; Univ Wisconsin, Gaylord Nelson Inst Environm Studies, Madison, WI 53706 USA; Univ Minnesota, Dept Polit Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA; Univ Minnesota, Food Ind Ctr, St Paul, MN 55108 USA; GlaxoSmithKline, King Of Prussia, PA 19406 USA; World Resources Inst, Washington, DC 20002 USA; Union Concerned Sci, Food & Environm Program, Washington, DC 20006 USA; Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; GlaxoSmithKline; University of Minnesota System; University of Minnesota Twin Cities	Kapuscinski, AR (corresponding author), Dept Fisheries Wildlife & Conservat Biol, 200 Hodson Hall,1980 Folwell Ave, St Paul, MN 55108 USA.	isees@fw.umn.edu						Aldrich M., 1997, SAFETY 1 TECHNOLOGY; Davison John, 2002, Environmental Biosafety Research, V1, P9, DOI 10.1051/ebr:2002001; Gibbons M, 1999, NATURE, V402, pC81, DOI 10.1038/35011576; Johnson B, 2002, NAT BIOTECHNOL, V20, P871, DOI 10.1038/nbt0902-871a; KAPUSCINSKI AR, 2002, SAFETY 1 MAKING REAL; LETOURNEAU DK, 2001, GENETICALLY ENG ORGA; *NAT RES COUNC, 2000, GEN MOD PEST PROT PL; *NAT RES COUNC, 2002, ENV EFF TRANSG PLANT; National Research Council, 2002, AN BIOT SCI BAS; Ruttan V., 2001, TECHNOLOGY GROWTH DE; Schubert D, 2002, NAT BIOTECHNOL, V20, P969, DOI 10.1038/nbt1002-969; Scientists' Working Group on Biosafety, 1998, MAN ASS EC HUM HLTH; Smyth S, 2002, NAT BIOTECHNOL, V20, P537, DOI 10.1038/nbt0602-537; Snow AA, 2002, NAT BIOTECHNOL, V20, P542, DOI 10.1038/nbt0602-542; STERN PC, 1997, UNDERSTANDING RISK; UNEP (United Nations Environment Programme), 2000, CART PROT BIOS CONV; *USDA ABRAC WORK G, 1995, 952004 USDA OFF AGR; 2002, NAT BIOTECHNOL, V20, P527	18	31	32	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2003	21	6					599	601		10.1038/nbt0603-599	http://dx.doi.org/10.1038/nbt0603-599			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	684RR	12776139				2022-12-25	WOS:000183220800010
J	Pollock, PM; Cohen-Solal, K; Sood, R; Namkoong, J; Martino, JJ; Koganti, A; Zhu, H; Robbins, C; Makalowska, I; Shin, SS; Marin, Y; Roberts, KG; Yudt, LM; Chen, A; Cheng, J; Incao, A; Pinkett, HW; Graham, CL; Dunn, K; Crespo-Carbone, SM; Mackason, KR; Ryan, KB; Sinsimer, D; Goydos, J; Reuhl, KR; Eckhaus, M; Meltzer, PS; Pavan, WJ; Trent, JM; Chen, S				Pollock, PM; Cohen-Solal, K; Sood, R; Namkoong, J; Martino, JJ; Koganti, A; Zhu, H; Robbins, C; Makalowska, I; Shin, SS; Marin, Y; Roberts, KG; Yudt, LM; Chen, A; Cheng, J; Incao, A; Pinkett, HW; Graham, CL; Dunn, K; Crespo-Carbone, SM; Mackason, KR; Ryan, KB; Sinsimer, D; Goydos, J; Reuhl, KR; Eckhaus, M; Meltzer, PS; Pavan, WJ; Trent, JM; Chen, S			Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia	NATURE GENETICS			English	Article							PROTEIN-COUPLED RECEPTORS; MGLUR1 MUTANT MICE; TRANSGENIC MICE; CELL-GROWTH; DEFICIT	To gain insight into melanoma pathogenesis, we characterized an insertional mouse mutant, TG3, that is predisposed to develop multiple melanomas(1,2). Physical mapping identified multiple tandem insertions of the transgene into intron 3 of Grm1 (encoding metabotropic glutamate receptor 1) with concomitant deletion of 70 kb of intronic sequence. To assess whether this insertional mutagenesis event results in alteration of transcriptional regulation, we analyzed Grm1 and two flanking genes for aberrant expression in melanomas from TG3 mice. We observed aberrant expression of only Grm1. Although we did not detect its expression in normal mouse melanocytes, Grm1 was ectopically expressed in the melanomas from TG3 mice. To confirm the involvement of Grm1 in melanocytic neoplasia, we created an additional transgenic line with Grm1 expression driven by the dopachrome tautomerase promoter. Similar to the original TG3, the Tg(Grm1)EPv line was susceptible to melanoma. In contrast to human melanoma, these transgenic mice had a generalized hyperproliferation of melanocytes with limited transformation to fully malignant metastasis. We detected expression of GRM1 in a number of human melanoma biopsies and cell lines but not in benign nevi and melanocytes. This study provides compelling evidence for the importance of metabotropic glutamate signaling in melanocytic neoplasia.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genom Technol Branch, NIH, Bethesda, MD 20892 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ 08903 USA; NIH, Vet Resources Program, Off Res Serv, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; National Institutes of Health (NIH) - USA	Chen, S (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA.	suziec@rci.rutgers.edu	Makalowska, Izabela/AAF-4967-2021; Makalowska, Izabela/AAU-2682-2021; Pinkett, Heather Wendy/M-9235-2014; Goydos, James/AAR-8990-2020	Makalowska, Izabela/0000-0002-8144-5671; Goydos, James/0000-0001-9811-939X; Pollock, Pamela/0000-0001-8420-1026	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000070, Z01HG000070, ZIAHG000136, Z01HG000136, Z01HG000037] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BUDD PS, 1995, GENOMICS, V29, P35, DOI 10.1006/geno.1995.1212; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; COLONTEICHER L, 1993, NUCLEIC ACIDS RES, V21, P2223, DOI 10.1093/nar/21.9.2223; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Reedy MV, 1998, PIGMENTARY SYSTEM PH; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; SOOD R, IN PRESS GENOMICS; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Zhu H, 1999, MOL BRAIN RES, V73, P93, DOI 10.1016/S0169-328X(99)00239-9; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x; Zhu H, 2000, PIGM CELL RES, V13, P158, DOI 10.1034/j.1600-0749.2000.130307.x	20	214	228	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2003	34	1					108	112		10.1038/ng1148	http://dx.doi.org/10.1038/ng1148			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12704387				2022-12-25	WOS:000182667900026
J	McCormick, AW; Whitney, CG; Farley, MM; Lynfield, R; Harrison, LH; Bennett, NM; Schaffner, W; Reingold, A; Hadler, J; Cieslak, P; Samore, MH; Lipsitch, M				McCormick, AW; Whitney, CG; Farley, MM; Lynfield, R; Harrison, LH; Bennett, NM; Schaffner, W; Reingold, A; Hadler, J; Cieslak, P; Samore, MH; Lipsitch, M			Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States	NATURE MEDICINE			English	Article							ANTIBIOTIC-RESISTANCE; CONJUGATE VACCINE; PREVALENCE; EPIDEMIOLOGY; PNEUMOCOCCI; INFECTIONS; SEROTYPES; CARRIAGE; CHILDREN; NETWORK	Resistance of Streptococcus pneumoniae to antibiotics is increasing throughout the United States, with substantial variation among geographic regions. We show that patterns of geographic variation are best explained by the intensity of selection for resistance, which is reflected by differences between the proportions of resistance within individual serotypes, rather than by differences between the frequencies of particular serotypes. Using a mathematical transmission model, we analyzed temporal trends in the proportions of singly and dually resistant organisms and found that pneumococcal strains resistant to both penicillin and erythromycin are increasing faster than strains singly resistant to either. Using the model, we predict that by 1 July 2004, in the absence of a vaccine, 41% of pneumococci at the Centers for Disease Control and Prevention (CDC)'s Active Bacterial Core surveillance (ABCs) sites, taken together, will be dually resistant, with 5% resistant to penicillin only and 5% to erythromycin only.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Act Bacterial Core Surveillance & Emerging Infect, Atlanta, GA USA; Emory Univ, Emory Dept Med, Atlanta, GA 30322 USA; Minnesota Dept Hlth, Minnesota Emerging Infect Program, Minneapolis, MN USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Monroe Cty Hlth Dept, Rochester, NY USA; Vanderbilt Univ, Sch Med, Vanderbilt Med Ctr, Nashville, TN 37212 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Connecticut Dept Publ Hlth, Connecticut Emerging Infect Program, Hartford, CT USA; Dept Human Serv, Oregon Emerging Infect Program, Hlth Serv, Off Dis Prevent & Epidemiol, Portland, OR USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA	Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; Emory University; Minnesota Department of Health (MHD); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Vanderbilt University; University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	Lipsitch, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.			Lipsitch, Marc/0000-0003-1504-9213	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048935] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48935] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; de Neeling AJ, 2001, J ANTIMICROB CHEMOTH, V48, P441, DOI 10.1093/jac/48.3.441; Diekema DJ, 2000, EMERG INFECT DIS, V6, P552, DOI 10.3201/eid0605.000519; Doern GV, 2001, CLIN INFECT DIS, V33, pS187, DOI 10.1086/321847; Fenoll A, 1998, J CLIN MICROBIOL, V36, P3447, DOI 10.1128/JCM.36.12.3447-3454.1998; Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P159, DOI 10.1128/JCM.40.1.159-164.2002; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Jones ME, 2002, ANTIMICROB AGENTS CH, V46, P3106, DOI 10.1128/AAC.46.9.3106-3107.2002; Lipsitch M, 2001, TRENDS MICROBIOL, V9, P438, DOI 10.1016/S0966-842X(01)02130-8; Lipsitch M, 2001, AM J EPIDEMIOL, V154, P85, DOI 10.1093/aje/154.1.85; McEllistrem MC, 2002, CLIN INFECT DIS, V34, P704, DOI 10.1086/338717; McGee L, 2001, J CLIN MICROBIOL, V39, P2565, DOI 10.1128/JCM.39.7.2565-2571.2001; *NAT CTR HLTH STAT, 2001, NAT HOSP AMB MED CAR; *NAT CTR HLTH STAT, 2001, NAT AMB MED CAR SURV; National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS; Pihlajamaki M, 2001, CLIN INFECT DIS, V33, P483, DOI 10.1086/322735; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Schrag SJ, 2000, CLIN MICROBIOL REV, V13, P588, DOI 10.1128/CMR.13.4.588-601.2000; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; 1999, MMWR MORB MORTAL WKL, V48, P656	27	174	177	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					424	430		10.1038/nm839	http://dx.doi.org/10.1038/nm839			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627227				2022-12-25	WOS:000181987400032
J	Wyss-Coray, T; Loike, JD; Brionne, TC; Lu, E; Anankov, R; Yan, FR; Silverstein, SC; Husemann, J				Wyss-Coray, T; Loike, JD; Brionne, TC; Lu, E; Anankov, R; Yan, FR; Silverstein, SC; Husemann, J			Adult mouse astrocytes degrade amyloid-beta in vitro and in situ	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ALZHEIMERS-DISEASE; SCAVENGER RECEPTOR; MICROGLIAL CELLS; PLAQUE-FORMATION; TRANSGENIC MICE; NERVOUS-SYSTEM; SENILE PLAQUES; GLIAL-CELLS; CHEMOKINES	Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by excessive deposition of amyloid-beta (Abeta) peptides in the brain. One of the earliest neuropathological changes in AD is the accumulation of astrocytes at sites of Abeta deposition(1), but the cause or significance of this cellular response is unclear. Here we show that cultured adult mouse astrocytes migrate in response to monocyte chemoattractant protein-1 (MCP-1), a chemokine present in AD lesions(1), and cease migration upon interaction with immobilized Abeta(1-42). We also show that astrocytes bind and degrade Abeta(1-42). Astrocytes plated on Abeta-laden brain sections from a mouse model of AD associate with the Abeta deposits and reduce overall Abeta levels in these sections. Our results suggest a novel mechanism for the accumulation of astrocytes around Abeta deposits, indicate a direct role for astrocytes in degradation of Abeta and implicate deficits in astroglial clearance of Abeta in the pathogenesis of AD. Treatments that increase removal of Abeta by astrocytes may therefore be a critical mechanism to reduce the neurodegeneration associated with AD.	Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10027 USA; VA Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Gladstone Inst Neurol Dis, San Francisco, CA USA	Columbia University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Husemann, J (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10027 USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	NIA NIH HHS [AG-15871, AG-08702, AG-19772] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019772, P50AG008702, R01AG015871] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heesen M, 1996, J NEUROSCI RES, V45, P382; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kurt MA, 1999, EXP NEUROL, V158, P221, DOI 10.1006/exnr.1999.7096; Mehlhorn G, 2000, INT J DEV NEUROSCI, V18, P423, DOI 10.1016/S0736-5748(00)00012-5; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TERRY RD, 1999, ALZHEIMERS DIS, P390; Tezel G, 2001, GLIA, V34, P178, DOI 10.1002/glia.1052; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790	25	687	702	0	39	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					453	457		10.1038/nm838	http://dx.doi.org/10.1038/nm838			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12612547				2022-12-25	WOS:000181987400036
J	Cheng, T; Liu, D; Griffin, JH; Fernandez, JA; Castellino, F; Rosen, ED; Fukudome, K; Zlokovic, BV				Cheng, T; Liu, D; Griffin, JH; Fernandez, JA; Castellino, F; Rosen, ED; Fukudome, K; Zlokovic, BV			Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective	NATURE MEDICINE			English	Article							CELL-DEATH; GENE-EXPRESSION; SEVERE SEPSIS; P53; RECEPTOR; THROMBIN; HYPOXIA; STROKE; MECHANISMS; BARRIER	Activated protein C (APC) is a systemic anti-coagulant and anti-inflammatory factor(1-3). It reduces organ damage in animal models of sepsis, ischemic injury and stroke(1,4,5) and substantially reduces mortality in patients with severe sepsis(6). It was not known whether APC acts as a direct cell survival factor or whether its neuroprotective effect(5,7) is secondary to its anticoagulant and anti-inflammatory effects(1-3). We report that APC directly prevents apoptosis in hypoxic human brain endothelium through transcriptionally dependent inhibition of tumor suppressor protein p53, normalization of the pro-apoptotic Bax/Bcl-2 ratio and reduction of caspase-3 signaling. These mechanisms are distinct from those involving upregulation of the genes encoding the anti-apoptotic Bcl-2 homolog A1 and inhibitor of apoptosis protein-1 (IAP-1) by APC in umbilical vein endothelial cells(8,9). Cytoprotection of brain endothelium by APC in vitro required endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), as did its in vivo neuroprotective activity in a stroke model of mice with a severe deficiency of EPCR10. This is consistent with work showing the direct effects of APC on cultured cells via EPCR and PAR-1 (ref. 9). Moreover, the in vivo neuroprotective effects of low-dose mouse APC seemed to be independent of its anti-coagulant activity. Thus, APC protects the brain from ischemic injury by acting directly on brain cells.	Univ Rochester, Med Ctr, Frank P Smith Neurosurg Res Lab, Dept Neurosurg, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Div Neurovasc Biol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Saga Med Sch, Dept Immunol, Saga, Japan; Socratech Labs, Rochester, NY USA	University of Rochester; University of Rochester; Scripps Research Institute; University of Notre Dame; University of Notre Dame; Saga University	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Neurosurg Res Lab, Dept Neurosurg, Rochester, NY 14642 USA.		Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063290, R37HL052246, R01HL052246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52246, HL63290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Castellino FJ, 2002, THROMB HAEMOSTASIS, V88, P462; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736; Gale AJ, 1997, PROTEIN SCI, V6, P132; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; MIYASHITA T, 1995, CELL, V80, P293; Mizutani A, 2000, BLOOD, V95, P3781; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Turgeon VL, 1998, J NEUROSCI, V18, P6882; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yamamoto K, 2001, HYPERTENSION, V37, P1341, DOI 10.1161/01.HYP.37.5.1341; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	31	491	518	3	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					338	342		10.1038/nm826	http://dx.doi.org/10.1038/nm826			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563316				2022-12-25	WOS:000181312300035
J	Baird, DM; Rowson, J; Wynford-Thomas, D; Kipling, D				Baird, DM; Rowson, J; Wynford-Thomas, D; Kipling, D			Extensive allelic variation and ultrashort telomeres in senescent human cells	NATURE GENETICS			English	Article							HUMAN FIBROBLASTS; LIFE-SPAN; STOCHASTIC MECHANISM; LENGTH; REPEAT; PROLIFERATION; MODEL	By imposing a limit on the proliferative lifespan of most somatic cells, telomere erosion represents an innate mechanism for tumor suppression(1) and may contribute to age-related disease(2). A detailed understanding of the pathways that link shortened telomeres to replicative senescence has been severely hindered by the inability of current methods to analyze telomere dynamics in detail. Here we describe single telomere length analysis (STELA), a PCR-based approach that accurately measures the full spectrum of telomere lengths from individual chromosomes. STELA analysis of human XpYp telomeres in fibroblasts identifies several features of telomere biology. We observe bimodal distributions of telomeres in normal fibroblasts; these distributions result from inter-allelic differences of up to 6.5 kb, indicating that unexpectedly large-scale differences in zygotic telomere length are maintained throughout development. Most telomeres shorten in a gradual fashion consistent with simple losses through end replication, and the rates of erosion are independent of allele size. Superimposed on this are occasional, more substantial changes in length, which may be the consequence of additional mutational mechanisms. Notably, some alleles show almost complete loss of TTAGGG repeats at senescence.	Univ Wales Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Baird, DM (corresponding author), Univ Wales Coll Med, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Baird, Duncan M/C-9671-2011	Baird, Duncan M/0000-0001-8408-5467				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Coleman J, 1999, HUM MOL GENET, V8, P1637, DOI 10.1093/hmg/8.9.1637; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kipling D, 2001, MATURITAS, V38, P25, DOI 10.1016/S0378-5122(00)00189-4; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; McSharry BP, 2001, J GEN VIROL, V82, P855, DOI 10.1099/0022-1317-82-4-855; Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599; Rubelj I, 1999, J THEOR BIOL, V197, P425, DOI 10.1006/jtbi.1998.0886; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH JR, 1980, SCIENCE, V207, P82; Tan Z, 1999, EXP GERONTOL, V34, P831, DOI 10.1016/S0531-5565(99)00056-X; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Varley H, 2002, NAT GENET, V30, P301, DOI 10.1038/ng834; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	29	382	407	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					203	207		10.1038/ng1084	http://dx.doi.org/10.1038/ng1084			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12539050				2022-12-25	WOS:000180773700021
J	Devonald, MAJ; Smith, AN; Poon, JR; Ihrke, G; Karet, FE				Devonald, MAJ; Smith, AN; Poon, JR; Ihrke, G; Karet, FE			Non-polarized targeting of AE1 causes autosomal dominant distal renal tubular acidosis	NATURE GENETICS			English	Article							EPITHELIAL-CELLS; SORTING SIGNALS; EXCHANGER; MUTATIONS; BAND-3; GENE	Autosomal dominant distal renal tubular acidosis (ddRTA) is caused by mutations in SLC4A1, which encodes the polytopic chloride-bicarbonate exchanger AE1 that is normally expressed at the basolateral surface of alpha-intercalated cells in the distal nephron. Here we report that, in contrast with many disorders in which mutant membrane proteins are retained intracellularly and degraded, ddRTA can result from aberrant targeting of AE1 to the apical surface.	Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Addenbrookes Hosp, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Div Nephrol, Addenbrookes Hosp, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Clin Biochem, Addenbrookes Hosp, Cambridge CB2 2XY, England	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	Karet, FE (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Addenbrookes Hosp, Box 139, Cambridge CB2 2XY, England.			Karet, Fiona/0000-0002-2457-2869; Ihrke, Gudrun/0000-0003-4604-735X				Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Ihrke G, 2001, EMBO J, V20, P6256, DOI 10.1093/emboj/20.22.6256; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; Karet FE, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000023433.08833.88; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; Low SH, 2000, MOL BIOL CELL, V11, P3045, DOI 10.1091/mbc.11.9.3045; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Obrador G, 1998, J AM SOC NEPHROL, V9, P746; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342	15	115	116	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					125	127		10.1038/ng1082	http://dx.doi.org/10.1038/ng1082			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12539048				2022-12-25	WOS:000180773700008
J	Lee, SS; Lee, RYN; Fraser, AG; Kamath, RS; Ahringer, J; Ruvkun, G				Lee, SS; Lee, RYN; Fraser, AG; Kamath, RS; Ahringer, J; Ruvkun, G			A systematic RNAi screen identifies a critical role for mitochondria in C-elegans longevity	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; LIFE-SPAN; OXIDATIVE STRESS; TELOMERE LENGTH; FAMILY MEMBER; GENE; INSULIN; YEAST; DAF-2; RESISTANCE	We report a systematic RNA interference (RNAi) screen of 5,690 Caenorhabditis elegans genes for gene inactivations that increase lifespan. We found that genes important for mitochondrial function stand out as a principal group of genes affecting C. elegans lifespan. A classical genetic screen identified a mutation in the mitochondrial leucyl-tRNA synthetase gene (lrs-2) that impaired mitochondrial function and was associated with longer-lifespan. The long-lived worms with impaired mitochondria had lower ATP content and oxygen consumption, but differential responses to free-radical and other stresses. These data suggest that the longer lifespan of C. elegans with compromised mitochrondria cannot simply be assigned to lower free radical production and suggest a more complex coupling of metabolism and longevity.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Dept Genet, Sch Med, Boston, MA 02114 USA; Univ Cambridge, Wellcome Trust Canc Res UK Inst, Cambridge, England	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Cambridge	Ruvkun, G (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.			Fraser, Andrew/0000-0001-9939-6014; Lee, Raymond/0000-0002-8151-7479; Ahringer, Julie/0000-0002-7074-4051	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Benard C, 2001, DEVELOPMENT, V128, P4045; Braeckman BP, 2002, MECH AGEING DEV, V123, P105, DOI 10.1016/S0047-6374(01)00331-1; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Finch CE, 1990, LONGEVITY SENESCENCE; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; FRIEDMAN DB, 1988, GENETICS, V118, P75; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Jazwinski SM, 2001, MECH AGEING DEV, V122, P865, DOI 10.1016/S0047-6374(01)00244-5; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; KAMATH R, 2002, IN PRESS NATURE; Kelly WG, 1997, GENETICS, V146, P227; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirchman PA, 1999, GENETICS, V152, P179; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lim CS, 2001, CURR BIOL, V11, P1706, DOI 10.1016/S0960-9822(01)00526-7; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OKIMOTO R, 1992, GENETICS, V130, P471; Osiewacz HD, 2002, AGEING RES REV, V1, P425, DOI 10.1016/S1568-1637(02)00010-7; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pearl R., 1928, RATE LIVING; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Rose MR, 1999, EXP GERONTOL, V34, P577, DOI 10.1016/S0531-5565(99)00042-X; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Tzagoloff A, 1990, Prog Nucleic Acid Res Mol Biol, V39, P129, DOI 10.1016/S0079-6603(08)60625-X; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	46	707	767	1	53	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					40	48		10.1038/ng1056	http://dx.doi.org/10.1038/ng1056			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12447374				2022-12-25	WOS:000180136100015
J	Silvie, O; Rubinstein, E; Franetich, JF; Prenant, M; Belnoue, E; Renia, L; Hannoun, L; Eling, W; Levy, S; Boucheix, C; Mazier, D				Silvie, O; Rubinstein, E; Franetich, JF; Prenant, M; Belnoue, E; Renia, L; Hannoun, L; Eling, W; Levy, S; Boucheix, C; Mazier, D			Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; CELLS; CD9; IDENTIFICATION; ANTIBODY; SURFACE; TAPA-1; TARGET; LIVER; MICE	Plasmodium sporozoites are transmitted through the bite of infected mosquitoes and first invade the liver of the mammalian host, as an obligatory step of the life cycle of the malaria parasite. Within hepatocytes, Plasmodium sporozoites reside in a membrane-bound vacuole, where they differentiate into exoerythrocytic forms and merozoites that subsequently infect erythrocytes and cause the malaria disease. Plasmodium sporozoite targeting to the liver is mediated by the specific binding of major sporozoite surface proteins, the circumsporozoite protein and the thrombospondin-related anonymous protein, to glycosaminoglycans on the hepatocyte surface(1). Still, the molecular mechanisms underlying sporozoite entry and differentiation within hepatocytes are largely unknown. Here we show that the tetraspanin CD81, a putative receptor for hepatitis C virus(2), is required on hepatocytes for human Plasmodium falciparum and rodent Plasmodium yoelii sporozoite infectivity. P. yoelii sporozoites fail to infect CD81-deficient mouse hepatocytes, in vivo and in vitro, and antibodies against mouse and human CD81 inhibit in vitro the hepatic development of P. yoelii and P. falciparum, respectively. We further demonstrate that the requirement for CD81 is linked to sporozoite entry into hepatocytes by formation of a parasitophorous vacuole, which is essential for parasite differentiation into exoerythrocytic forms.	Univ Paris 11, Hop Paul Brousse, INSERM, U268,Inst Andre Lwoff, Villejuif, France; Univ Paris 05, Hop Cochin, Inst Cochin, Dept Immunol, Paris, France; Hop La Pitie Salpetriere, Serv Chirurg Digest Hepatobiliopancreat & Transpl, Paris, France; Univ Med Ctr St Radboud, Dept Med Microbiol, Nijmegen, Netherlands; Stanford Univ, Med Ctr, Dept Med, Div Oncol, Stanford, CA 94305 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Radboud University Nijmegen; Stanford University	Mazier, D (corresponding author), Univ Paris 06, CHU Pitie Salpetriere, INSERM, U Immunobiol Cellulaire & Mol Infect Parasitaires, Paris, France.		Franetich, Jean-François/GZA-9674-2022; Silvie, Olivier/AAF-5437-2021; Renia, Laurent/E-2117-2011; Silvie, Olivier/K-7290-2017; Rubinstein, Eric/B-4650-2019	Silvie, Olivier/0000-0002-0525-6940; Renia, Laurent/0000-0003-0349-1557; Silvie, Olivier/0000-0002-0525-6940; Rubinstein, Eric/0000-0001-7623-9665; Boucheix, Claude/0000-0003-4184-7008	NIAID NIH HHS [AI45900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HOLLINGDALE MR, 1983, AM J TROP MED HYG, V32, P685, DOI 10.4269/ajtmh.1983.32.685; Hulier E, 1996, MOL BIOCHEM PARASIT, V77, P127, DOI 10.1016/0166-6851(96)02584-4; Kelic S, 2001, MOL CELL NEUROSCI, V17, P551, DOI 10.1006/mcne.2000.0955; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 2000, HYBRIDOMA, V19, P15, DOI 10.1089/027245700315752; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Pradel G, 2001, HEPATOLOGY, V33, P1154, DOI 10.1053/jhep.2001.24237; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Silvie O, 2002, PARASITE IMMUNOL, V24, P221, DOI 10.1046/j.1365-3024.2002.00450.x; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404	25	236	244	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					93	96		10.1038/nm808	http://dx.doi.org/10.1038/nm808			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483205				2022-12-25	WOS:000180209900028
J	Chen, P; Zindy, F; Abdala, C; Liu, F; Li, XK; Roussel, MF; Segil, N				Chen, P; Zindy, F; Abdala, C; Liu, F; Li, XK; Roussel, MF; Segil, N			Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d	NATURE CELL BIOLOGY			English	Article							CELL-PROLIFERATION; REGENERATION; ORGAN	Maintenance of the post-mitotic state in the post-natal mammalian brain is an active process that requires the cyclin-dependent kinase inhibitors (CKIs) p19(Ink4d) (Ink4d) and p27(Kip1) (Kip1)(1). In animals with targeted deletions of both Ink4d and Kip1, terminally differentiated, post-mitotic neurons are observed to re-enter the cell cycle, divide and undergo apoptosis. However, when either Ink4d or Kip1 alone are deleted, the post-mitotic state is maintained, suggesting a redundant role for these genes in mature neurons(1). In the organ of Corti-the auditory sensory epithelium of mammals-sensory hair cells and supporting cells become post-mitotic during embryogenesis(2) and remain quiescent for the life of the animal. When lost as a result of environmental insult or genetic abnormality, hair cells do not regenerate, and this loss is a common cause of deafness in humans(3). Here, we report that targeted deletion of Ink4d alone is sufficient to disrupt the maintenance of the post-mitotic state of sensory hair cells in post-natal mice. In Ink4d(-/-) animals, hair cells are observed to aberrantly re-enter the cell cycle and subsequently undergo apoptosis, resulting in progressive hearing loss. Our results identify a novel mechanism underlying a non-syndromic form of progressive hearing loss in mice.	House Ear Res Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; House Ear Res Inst, Childrens Auditory Res & Evaluat Ctr, Los Angeles, CA 90057 USA; St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA	House Research Institute; House Research Institute; St Jude Children's Research Hospital; University of Southern California; University of Southern California	Segil, N (corresponding author), House Ear Res Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St,5th Floor, Los Angeles, CA 90057 USA.	nsegil@hei.org	Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NIDCD NIH HHS [R01 DC004189] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003552, R01DC004189] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		CHARDIN S, 1995, SCIENCE, V267, P707, DOI 10.1126/science.7839151; Chen P, 2002, DEVELOPMENT, V129, P2495; Chen P, 1999, DEVELOPMENT, V126, P1581; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Herrup K, 2001, TRENDS MOL MED, V7, P527, DOI 10.1016/S1471-4914(01)02158-X; Jimenez AM, 1999, HEARING RES, V138, P91, DOI 10.1016/S0378-5955(99)00154-9; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V247, P780, DOI 10.1006/bbrc.1998.8815; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Ohlemiller KK, 2002, JARO-J ASSOC RES OTO, V3, P444, DOI 10.1007/s10162-002-2041-y; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; SCHROTT A, 1991, HEARING RES, V52, P245, DOI 10.1016/0378-5955(91)90204-M; Schuknecht H., 1993, PATHOLOGY EAR, V2nd ed.; White PM, 1999, DEVELOPMENT, V126, P4351; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	22	133	142	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					422	426		10.1038/ncb976	http://dx.doi.org/10.1038/ncb976			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717441				2022-12-25	WOS:000182691400015
J	Nicolas, G; Viatte, L; Lou, DQ; Bennoun, M; Beaumont, C; Kahn, A; Andrews, NC; Vaulont, S				Nicolas, G; Viatte, L; Lou, DQ; Bennoun, M; Beaumont, C; Kahn, A; Andrews, NC; Vaulont, S			Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis	NATURE GENETICS			English	Article							HEREDITARY HEMOCHROMATOSIS; ANTIMICROBIAL PEPTIDE; TRANSGENIC MICE; CHRONIC DISEASE; GENE; HFE; ANEMIA; METABOLISM; LIVER; DEFICIENCY	Hereditary hemochromatosis is a prevalent genetic disorder of iron hyperabsorption leading to hyperferremia, tissue iron deposition and complications including cirrhosis, hepatocarcinoma, cardiomyopathy and diabetes. Most individuals affected with hereditary hemochromatosis are homozygous with respect to a missense mutation that disrupts the conformation of HFE, an atypical HLA class I molecule (ref. 1; OMIM 235200). Mice lacking Hfe(2-4) or producing a C282Y mutant Hfe protein(3) develop hyperferremia and have high hepatic iron levels. in both humans and mice, hereditary hemochromatosis is associated with a paucity of iron in reticuloendothelial cells. It has been suggested that HFE modulates uptake of transferrin-bound iron by undifferentiated intestinal crypt cells, thereby programming the absorptive capacity of enterocytes derived from these cells(5,6); however, this model is unproven and controversial(7,8). Hepcidin, a peptide hormone (HAMP; OMIM 606464), seems to act in the same regulatory pathway as HFE. Although expression of mouse Hamp is normally greater during iron overload, Hfe(-/-) mice have inappropriately low expression of Hamp. We crossed Hfe(-/-) mice with transgenic mice overexpressing Hamp and found that Hamp inhibited the iron accumulation normally observed in the Hfe(-/-) mice. This argues against the crypt programming model and suggests that failure of Hamp induction contributes to the pathogenesis of hemochromatosis, providing a rationale for the use of HAMP in the treatment of this disease.	CNRS, INSERM, Inst Cochin, Dept Genet Dev & Pathol Mol, F-75014 Paris, France; Univ Paris 05, Fac Med Cochin Port Royal, F-75014 Paris, France; Univ Paris 07, INSERM, U409, F-75018 Paris, France; Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Vaulont, S (corresponding author), CNRS, INSERM, Inst Cochin, Dept Genet Dev & Pathol Mol, 24 Rue Fg St Jacques, F-75014 Paris, France.		NICOLAS, Gaël/D-7611-2013; Vaulont, Sophie/O-6732-2017; NICOLAS, Gaël/X-9555-2019	NICOLAS, Gaël/0000-0002-1671-8274; NICOLAS, Gaël/0000-0002-1671-8274; Andrews, Nancy/0000-0003-0243-4462				Ahmad KA, 2002, BLOOD CELL MOL DIS, V29, P361, DOI 10.1006/bcmd.2002.0575; Ajioka RS, 2002, BLOOD, V100, P1465, DOI 10.1182/blood-2001-11-0037; Bahram S, 1999, P NATL ACAD SCI USA, V96, P13312, DOI 10.1073/pnas.96.23.13312; Bothwell, 1980, METHODS HEMATOLOGY, V1, P90; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Courselaud B, 2002, J BIOL CHEM, V277, P41163, DOI 10.1074/jbc.M202653200; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FINCH C, 1994, BLOOD, V84, P1697; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Levy JE, 1999, BLOOD, V94, P9, DOI 10.1182/blood.V94.1.9.413a43_9_11; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Roy CN, 2000, BLOOD, V96, P4020, DOI 10.1182/blood.V96.13.4020.h8004020_4020_4027; Townsend A, 2002, LANCET, V359, P786, DOI 10.1016/S0140-6736(02)07885-6; Trinder D, 2002, P NATL ACAD SCI USA, V99, P5622, DOI 10.1073/pnas.082112299; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	24	250	272	0	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					97	101		10.1038/ng1150	http://dx.doi.org/10.1038/ng1150			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12704388				2022-12-25	WOS:000182667900024
J	Oelke, M; Maus, MV; Didiano, D; June, CH; Mackensen, A; Schneck, JP				Oelke, M; Maus, MV; Didiano, D; June, CH; Mackensen, A; Schneck, JP			Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells	NATURE MEDICINE			English	Article							ADOPTIVE TRANSFER; LYMPHOCYTES; CD8(+); COSTIMULATION; GENERATION; ACTIVATION; RESPONSES; IMMUNITY; AVIDITY; CD4(+)	Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs). As a result, there are only limited reports of expansion of antigen-specific CTLs to the levels required for clinical therapy. To address this issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) and CD28-specific antibody to beads. HLA-Ig-based aAPCs were used to induce and expand CTLs specific for cytomegalovirus (CMV) or melanoma. aAPC-induced cultures showed robust antigen-specific CTL expansion over successive rounds of stimulation, resulting in the generation of clinically relevant antigen-specific CTLs that recognized endogenous antigen-major histocompatibility complex complexes presented on melanoma cells. These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTLs for clinical approaches to adoptive immunotherapy.	Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Baltimore, MD 21218 USA; Abramson Family Canc Res Inst, Philadelphia, PA USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Regensburg, Dept Hematol Oncol, D-8400 Regensburg, Germany	Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Regensburg	Oelke, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Baltimore, MD 21218 USA.			Oelke, Mathias/0000-0003-2253-6167; Maus, Marcela/0000-0002-7578-0393; June, Carl/0000-0003-0241-3557	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029575, R01AI044129] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44129, AI-29575] Funding Source: Medline; NIDDK NIH HHS [DK07748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD P, 1991, JNCI-J NATL CANCER I, V83, P932, DOI 10.1093/jnci/83.13.932; Deeths MJ, 1997, EUR J IMMUNOL, V27, P598, DOI 10.1002/eji.1830270305; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Laux I, 2000, CLIN IMMUNOL, V96, P187, DOI 10.1006/clim.2000.4902; LEE SP, 1993, J VIROL, V67, P7428, DOI 10.1128/JVI.67.12.7428-7435.1993; Levine BL, 1998, J HEMATOTHER, V7, P437, DOI 10.1089/scd.1.1998.7.437; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Oelke M, 2000, CLIN CANCER RES, V6, P1997; Oelke M, 2000, SCAND J IMMUNOL, V52, P544, DOI 10.1046/j.1365-3083.2000.00810.x; Perez-Diez A, 1998, CANCER RES, V58, P5305; Salgaller ML, 1998, PROSTATE, V35, P144, DOI 10.1002/(SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO;2-J; Tham EL, 2001, J IMMUNOL METHODS, V249, P111, DOI 10.1016/S0022-1759(00)00335-5; Valmori D, 2002, J IMMUNOL, V168, P4231, DOI 10.4049/jimmunol.168.8.4231; Valmori D, 1999, INT IMMUNOL, V11, P1971, DOI 10.1093/intimm/11.12.1971; von Bergwelt-Baildon MS, 2002, BLOOD, V99, P3319, DOI 10.1182/blood.V99.9.3319; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Yee C, 1999, J IMMUNOL, V162, P2227	20	245	298	3	35	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					619	624		10.1038/nm869	http://dx.doi.org/10.1038/nm869			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704385				2022-12-25	WOS:000182610600045
J	Schmidt, M; Carbonaro, DA; Speckmann, C; Wissler, M; Bohnsack, J; Elder, M; Aronow, BJ; Nolta, JA; Kohn, DB; von Kalle, C				Schmidt, M; Carbonaro, DA; Speckmann, C; Wissler, M; Bohnsack, J; Elder, M; Aronow, BJ; Nolta, JA; Kohn, DB; von Kalle, C			Clonality analysis after retroviral-mediated gene transfer to CD34(+) cells from the cord blood of ADA-deficient SCID neonates	NATURE MEDICINE			English	Article							CLONES; PROGENITOR; THERAPY; DNA	A clinical trial of retroviral-mediated transfer of the adenosine deaminase (ADA) gene into umbilical cord blood CD34(+) cells was started in 1993. ADA-containing peripheral blood mononuclear cells (PBMCs) have persisted in patients from this trial, with T lymphocytes showing the highest prevalence of gene marking(1,2). To gain a greater understanding of the nature and number of the transduced cells that were engrafted, we used linear amplification-mediated PCR (LAM-PCR) to identify clonal vector proviral integrants(3,4). In one patient, a single vector integrant was predominant in T lymphocytes at a stable level over most of the eight-year time span analyzed and was also detected in some myeloid samples. T-cell clones with the predominant integrant, isolated after eight years, showed multiple patterns of T-cell receptor (TCR) gene rearrangement, indicating that a single pre-thymic stem or progenitor cell served as the source of the majority of the gene-marked cells over an extended period of time. It is important to distinguish the stable pattern of monoclonal gene marking that we observed here from the progressive increase of a T-cell clone with monoclonal gene marking that results from leukemic transformation, as observed in two subjects in a clinical trial of gene therapy for X-linked severe combined immunodeficiency (SCID)(5,6).	Childrens Hosp Los Angeles, Div Res Immunol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA; Univ Freiburg, Dept Internal Med 1, Freiburg, Germany; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Univ So Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Microbiol, Keck Sch Med, Los Angeles, CA 90089 USA; Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Pediat Rheumatol & Immunol, Salt Lake City, UT USA; Univ Calif San Francisco, Sch Med, Dept Pediat, Div Pediat Immunol & Allergy, San Francisco, CA 94143 USA; Cincinnati Childrens Hosp, Med Ctr, Childrens Res Fdn, Div Pediat Informat, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH USA; Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Children's Hospital Los Angeles; University of Freiburg; University of Freiburg; University of Southern California; University of Southern California; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Washington University (WUSTL)	Kohn, DB (corresponding author), Childrens Hosp Los Angeles, Div Res Immunol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA.	dkohn@chla.usc.edu	Aronow, Bruce J/F-8438-2012; Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087; Speckmann, Carsten/0000-0002-6217-1556; Nolta, Jan/0000-0003-4576-8542	NCRR NIH HHS [3 M01 RR0043-35S1] Funding Source: Medline; NHLBI NIH HHS [1P50 HL54850] Funding Source: Medline; NIDDK NIH HHS [R01 DK061848, R01 DK053041-06, R01 DK053041, R01 DK061848-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061848, R01DK053041] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAPEL B, 1990, BLOOD, V75, P2267; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Jensen MC, 2000, MOL THER, V1, P49, DOI 10.1006/mthe.1999.0012; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kim HJ, 2000, BLOOD, V96, P1; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Willenbrock K, 2001, AM J PATHOL, V158, P1851, DOI 10.1016/S0002-9440(10)64141-7	16	112	117	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					463	468		10.1038/nm844	http://dx.doi.org/10.1038/nm844			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12640448				2022-12-25	WOS:000181987400038
J	Bae, KH; Do Kwon, Y; Shin, HC; Hwang, MS; Ryu, EH; Park, KS; Yang, HY; Lee, D; Lee, Y; Park, J; Kwon, HS; Kim, HW; Yeh, BI; Lee, HW; Sohn, SH; Yoon, J; Seol, W; Kim, JS				Bae, KH; Do Kwon, Y; Shin, HC; Hwang, MS; Ryu, EH; Park, KS; Yang, HY; Lee, D; Lee, Y; Park, J; Kwon, HS; Kim, HW; Yeh, BI; Lee, HW; Sohn, SH; Yoon, J; Seol, W; Kim, JS			Human zinc fingers as building blocks in the construction of artificial transcription factors	NATURE BIOTECHNOLOGY			English	Article							DNA-BINDING SPECIFICITY; RECOGNITION CODE; PROTEIN-DNA; SELECTION; DESIGN; GENE; SEQUENCES; YEAST; SITE; ACTIVATION	We describe methods for generating artificial transcription factors capable of up- or downregulating the expression of genes whose promoter regions contain the target DNA sequences. To accomplish this, we screened zinc fingers derived from sequences in the human genome and isolated 56 zinc fingers with diverse DNA-binding specificities. We used these zinc fingers as modular building blocks in the construction of novel, sequence-specific DNA-binding proteins. Fusion of these zinc-finger proteins with either a transcriptional activation or repression domain yielded potent transcriptional activators or repressors, respectively. These results show that the human genome encodes zinc fingers with diverse DNA-binding specificities and that these domains can be used to design sequence-specific DNA-binding proteins and artificial transcription factors.	ToolGen Inc, Taejon 305390, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Yonsei Univ, Wonju Coll Med, Dept Biochem, Wonju 220701, South Korea; Yonsei Univ, Wonju Coll Med, Inst Basic Med Sci, Wonju 220701, South Korea; Yonsei Univ, Wonju Coll Med, IFBB, Wonju 220701, South Korea	Seoul National University (SNU); Yonsei University; Yonsei University; Yonsei University	Kim, JS (corresponding author), ToolGen Inc, 461-6 Jeonmin Dong, Taejon 305390, South Korea.		KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306; Bae, Kwang-Hee/0000-0002-5868-2556				Bartsevich VV, 2000, MOL PHARMACOL, V58, P1; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Cheng XJ, 1997, P NATL ACAD SCI USA, V94, P14120, DOI 10.1073/pnas.94.25.14120; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297; Kang JS, 2000, J BIOL CHEM, V275, P8742, DOI 10.1074/jbc.275.12.8742; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 2002, J BIOL CHEM, V277, P3850, DOI 10.1074/jbc.M110669200; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Sera T, 2002, BIOCHEMISTRY-US, V41, P7074, DOI 10.1021/bi020095c; TAYLOR WE, 1995, BIOCHEMISTRY-US, V34, P3222, DOI 10.1021/bi00010a011; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2001, STRUCTURE, V9, P717, DOI 10.1016/S0969-2126(01)00632-3; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	35	148	186	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					275	280		10.1038/nbt796	http://dx.doi.org/10.1038/nbt796			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12592413				2022-12-25	WOS:000181312500023
J	Latour, S; Roncagalli, R; Chen, RY; Bakinowski, M; Shi, XC; Schwartzberg, PL; Davidson, D; Veillette, A				Latour, S; Roncagalli, R; Chen, RY; Bakinowski, M; Shi, XC; Schwartzberg, PL; Davidson, D; Veillette, A			Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation	NATURE CELL BIOLOGY			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; NATURAL-KILLER-CELLS; CUTTING EDGE; PROTEIN; KINASE; GENE; VIRUS; RESPONSIVENESS; PHOSPHATASE; ACTIVATION	SAP (or SH2D1A), an adaptor-like molecule expressed in immune cells, is composed almost exclusively of a Src homology 2 (SH2) domain(1-4). In humans, SAP is mutated and either absent or non-functional in X-linked lymphoproliferative (XLP) syndrome, a disease characterized by an inappropriate response to Epstein-Barr virus (EBV) infection(5). Through its SH2 domain, SAP associates with tyrosines in the cytoplasmic domain of the SLAM family of immune cell receptors, and is absolutely required for the function of these receptors(1,6-10). This property results from the ability of SAP to promote the selective recruitment and activation of FynT, a cytoplasmic Src-related protein tyrosine kinase (PTK)(8). Here, we demonstrate that SAP operates in this pathway by binding to the SH3 domain of FynT, through a second region in the SAP SH2 domain distinct from the phosphotyrosine-binding motif. We demonstrate that this interaction is essential for SAP-mediated signalling in T cells, and for the capacity of SAP to modulate immune cell function. These observations characterize a biologically important signalling mechanism in which an adaptor molecule composed only of an SH2 domain links a receptor devoid of intrinsic catalytic activity to the kinase required for its function.	Clin Res Inst Montreal, Oncol Mol Lab, Montreal, PQ H2W 1R7, Canada; Hop Necker Enfants Malad, INSERM, U429, Paris, France; Univ Montreal, Program Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H2W 1R7, Canada; NHGRI, NIH, Bethesda, MD 20892 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); McGill University; McGill University; McGill University	Veillette, A (corresponding author), Clin Res Inst Montreal, Oncol Mol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	veillea@ircm.qc.ca	Roncagalli, Romain/ABB-8786-2020; Latour, Sylvain/H-3652-2017	Latour, Sylvain/0000-0001-8238-4391; Roncagalli, Romain/0000-0001-7554-0552	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000123, ZIAHG000123] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Hwang PM, 2002, EMBO J, V21, P314, DOI 10.1093/emboj/21.3.314; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Tangye SG, 2000, J IMMUNOL, V165, P2932, DOI 10.4049/jimmunol.165.6.2932; Tangye SG, 1999, J IMMUNOL, V162, P6981; Thompson AD, 1996, ONCOGENE, V13, P2649; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 2002, SCI STKE, pE8; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yu J, 2001, MOL CELL BIOL, V21, P6102, DOI 10.1128/MCB.21.18.6102-6112.2001	29	217	228	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					149	154		10.1038/ncb919	http://dx.doi.org/10.1038/ncb919			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545173				2022-12-25	WOS:000180802100015
J	Pinilla, C; Appel, JR; Borras, E; Houghten, RA				Pinilla, Clemencia; Appel, Jon R.; Borras, Eva; Houghten, Richard A.			Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries	NATURE MEDICINE			English	Article							SOLID-PHASE SYNTHESIS; POSITIONAL-SCANNING LIBRARIES; EXTENDED SUBSTRATE-SPECIFICITY; T-CELL EPITOPES; PEPTIDE LIBRARIES; ORGANIC-SYNTHESIS; BICYCLIC GUANIDINES; CHEMICAL LIBRARIES; POLYMER SUPPORTS; LARGE NUMBERS	The conceptual and technical approaches that led to the explosive growth of combinatorial chemistry began approximately 20 years ago. In the past decade, combinatorial chemistry has continued to expand with new chemistries, technological improvements and, most importantly, a clear demonstration of its utility in the identification of active compounds for research and drug-discovery programs. This article describes the conceptual and practical breakthroughs that have been critical for the development of synthetic combinatorial methods and includes the most recent developments and applications of mixture-based combinatorial libraries.	[Pinilla, Clemencia; Appel, Jon R.; Borras, Eva; Houghten, Richard A.] Torrey Pines Inst Mol Studies, San Diego, CA USA; [Pinilla, Clemencia; Houghten, Richard A.] Mixture Sci Inc, San Diego, CA USA	Torrey Pines Institute for Molecular Studies, California	Houghten, RA (corresponding author), Torrey Pines Inst Mol Studies, San Diego, CA USA.	rhoughten@tpims.org		Borras, Eva/0000-0001-5100-7809	NCI [PO1 CA78040]; NIDA [RO1 DA09410]; MSNRI; NATIONAL CANCER INSTITUTE [P01CA078040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009410] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); MSNRI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank R. Martin and R. Simon for their contributions to the development of the biometrical analysis first used in T-cell studies; C. Dooley for the opioid receptor research; D. Wilson and S. Blondelle for their involvement in the use of combinatorial libraries in many different biological assays; and J. Ostresh, A. Nefzi and the chemistry group at Torrey Pines Institute for Molecular Studies for the continuing development of synthetic chemistry for the preparation of mixture-based combinatorial libraries. Supported by NCI grant PO1 CA78040, NIDA grant RO1 DA09410 and MSNRI funding.	Acharya AN, 2001, J COMB CHEM, V3, P189, DOI 10.1021/cc0000803; Anderson B, 1999, P NATL ACAD SCI USA, V96, P9311, DOI 10.1073/pnas.96.16.9311; Appel JR, 1998, MOL DIVERS, V4, P91, DOI 10.1023/A:1026441400053; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Barkley A, 2001, CHEM-EUR J, V7, P555, DOI 10.1002/1521-3765(20010202)7:3<555::AID-CHEM555>3.3.CO;2-9; Berman J, 1997, J MED CHEM, V40, P827, DOI 10.1021/jm960702s; Blondelle SE, 1999, ANTIMICROB AGENTS CH, V43, P106, DOI 10.1128/AAC.43.1.106; Boger DL, 2000, J AM CHEM SOC, V122, P6382, DOI 10.1021/ja994192d; Borras E, 2002, J IMMUNOL METHODS, V267, P81; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; Cheng Y, 2002, BIOORG MED CHEM LETT, V12, P529, DOI 10.1016/S0960-894X(01)00824-1; CROWLEY JI, 1976, ACCOUNTS CHEM RES, V9, P135, DOI 10.1021/ar50100a003; Dauber DS, 2002, J VIROL, V76, P1359, DOI 10.1128/JVI.76.3.1359-1368.2002; Dolle RE, 2001, J COMB CHEM, V3, P477, DOI 10.1021/cc010049g; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GIANNIS A, 1993, ANGEW CHEM INT EDIT, V32, P1244, DOI 10.1002/anie.199312441; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Hemmer B, 2000, J IMMUNOL, V164, P861, DOI 10.4049/jimmunol.164.2.861; Hemmer B, 1999, NAT MED, V5, P1375; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hiemstra HS, 1997, P NATL ACAD SCI USA, V94, P10313, DOI 10.1073/pnas.94.19.10313; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Houghten RA, 1999, J MED CHEM, V42, P3743, DOI 10.1021/jm990174v; Houghten Richard A., 1994, Methods (Orlando), V6, P354, DOI 10.1006/meth.1994.1035; Judkowski V, 2001, J IMMUNOL, V166, P908, DOI 10.4049/jimmunol.166.2.908; La Rosa C, 2001, BLOOD, V97, P1776; Lam KS, 1997, CHEM REV, V97, P411, DOI 10.1021/cr9600114; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEZNOFF CC, 1973, CAN J CHEM, V51, P3756, DOI 10.1139/v73-561; Linnemann T, 2001, EUR J IMMUNOL, V31, P156, DOI 10.1002/1521-4141(200101)31:1<156::AID-IMMU156>3.0.CO;2-P; LISKAMP RMJ, 1994, ANGEW CHEM INT EDIT, V33, P633, DOI 10.1002/anie.199406331; Mathieu MA, 2002, MOL BIOCHEM PARASIT, V121, P99, DOI 10.1016/S0166-6851(02)00026-9; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; Nefzi A, 2000, TETRAHEDRON, V56, P3319, DOI 10.1016/S0040-4020(00)00253-2; Nefzi A, 1997, CHEM REV, V97, P449, DOI 10.1021/cr960010b; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Ostresh JM, 1998, J ORG CHEM, V63, P8622, DOI 10.1021/jo9810617; OSTRESH JM, 1994, P NATL ACAD SCI USA, V91, P11138, DOI 10.1073/pnas.91.23.11138; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Pinilla C, 2001, CANCER RES, V61, P5153; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Reixach N, 2000, J STRUCT BIOL, V130, P247, DOI 10.1006/jsbi.2000.4245; Rubio-Godoy V, 2002, EUR J IMMUNOL, V32, P2292, DOI 10.1002/1521-4141(200208)32:8<2292::AID-IMMU2292>3.0.CO;2-K; Rubio-Godoy V, 2002, CANCER RES, V62, P2058; Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200; Sternson SM, 2001, ORG LETT, V3, P4239, DOI 10.1021/ol016915f; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Udaka K, 1996, J IMMUNOL, V157, P670; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P93, DOI 10.1016/S0960-894X(01)00665-5; WONG JY, 1973, CAN J CHEM, V51, P2452, DOI 10.1139/v73-367; Zhao YD, 2001, J IMMUNOL, V167, P2130, DOI 10.4049/jimmunol.167.4.2130	64	78	96	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					118	122		10.1038/nm0103-118	http://dx.doi.org/10.1038/nm0103-118			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514724				2022-12-25	WOS:000208640400006
J	Shirane, M; Nakayama, KI				Shirane, M; Nakayama, KI			Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis	NATURE CELL BIOLOGY			English	Article							TETRATRICOPEPTIDE REPEAT; CYTOCHROME-C; PROTEIN; RELEASE; PATHWAY; FAMILY; DEATH; BAX; IMMUNOPHILINS; ONCOPROTEIN	The mitochondrial localization of the membrane proteins Bcl-2 and Bcl-x(L) is essential for their anti-apoptotic function. Here we show that mitochondrial FK506-binding protein 38 (FKBP38), unlike FKBP12, binds to and inhibits calcineurin in the absence of the immunosuppressant FK506, suggesting that FKBP38 is an inherent inhibitor of this phosphatase. FKBP38 is associated with Bcl-2 and Bcl-x(L) in immunoprecipitation assays and colocalizes with these proteins in mitochondria; in addition, the expression of FKBP38 mutant proteins induces a marked redistribution of Bcl-2 and Bcl-x(L). Overexpression of FKBP38 blocks apoptosis, whereas functional inhibition of this protein by a dominant-negative mutant or by RNA interference promotes apoptosis. Thus, FKBP38 might function to inhibit apoptosis by anchoring Bcl-2 and Bcl-x(L) to mitochondria.	Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, KI (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp		Shirane, Michiko/0000-0002-8297-9245				Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; Kantrow SP, 2000, FEBS LETT, V483, P119, DOI 10.1016/S0014-5793(00)02083-4; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pedersen KM, 1999, ELECTROPHORESIS, V20, P249, DOI 10.1002/(SICI)1522-2683(19990201)20:2<249::AID-ELPS249>3.0.CO;2-F; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	49	248	256	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					28	37		10.1038/ncb894	http://dx.doi.org/10.1038/ncb894			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12510191				2022-12-25	WOS:000180223700010
J	Aubert, J; Dunstan, H; Chambers, I; Smith, A				Aubert, J; Dunstan, H; Chambers, I; Smith, A			Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO DIFFERENTIATION; FRIZZLED-RELATED PROTEIN; PAIRED BOX GENE; MESSENGER-RNA; SELF-RENEWAL; EXPRESSION; FAMILY; SUGGESTS; CLONING; DOMAIN	The multilineage differentiation capacity of mouse embryonic stem (ES) cells offers a potential testing platform for gene products that mediate mammalian lineage determination and cellular specialization. Identification of such differentiation regulators is crucial to harnessing ES cells for pharmaceutical discovery and cell therapy. Here we describe the use of episomal expression technology for functional evaluation of cDNA clones during ES-cell differentiation in vitro. Several candidate cDNAs identified by subtractive cloning and expression profiling were introduced into ES cells in episomal expression constructs. Subsequent differentiation revealed that the Wnt antagonist Sfrp2 stimulates production of neural progenitors. The significance of this observation was substantiated by forced expression of Wnt-1 and treatment with lithium chloride, both of which inhibit neural differentiation. These findings reveal the importance of Wnt signaling in regulating ES-cell lineage diversification. More generally, this study establishes a path for rapid and direct validation of candidate genes in ES cells.	Univ Edinburgh, Inst Stem Cell Res, Edinburgh EH3 9JQ, Midlothian, Scotland	University of Edinburgh	Smith, A (corresponding author), Univ Edinburgh, Inst Stem Cell Res, Kings Bldg,W Mains Rd, Edinburgh EH3 9JQ, Midlothian, Scotland.	Austin.smith@ed.ac.uk		Smith, Austin/0000-0002-3029-4682; Chambers, Ian/0000-0003-2605-1597				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Camenisch G, 1996, NUCLEIC ACIDS RES, V24, P3707, DOI 10.1093/nar/24.19.3707; Caubit X, 2000, MECH DEVELOP, V91, P445, DOI 10.1016/S0925-4773(99)00318-4; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cox GA, 2000, NAT GENET, V26, P198, DOI 10.1038/79923; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Ellies DL, 2000, DEVELOPMENT, V127, P5285; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Furushima K, 2000, MECH DEVELOP, V98, P161, DOI 10.1016/S0925-4773(00)00456-1; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kiss H, 1999, HUM GENET, V105, P552, DOI 10.1007/s004390051144; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Lee CS, 2000, DEVELOPMENT, V127, P109; Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Li M, 2002, Methods Mol Biol, V185, P205; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pevny LH, 1998, DEVELOPMENT, V125, P1967; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Salic AN, 1997, DEVELOPMENT, V124, P4739; Smith A, 2001, COLD SPRING HARBOR M, P205; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502; Zhang WJ, 1998, MOL CELL BIOL, V18, P676, DOI 10.1128/MCB.18.2.676	50	246	263	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1240	1245		10.1038/nbt763	http://dx.doi.org/10.1038/nbt763			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12447396	Green Published			2022-12-25	WOS:000179552600044
J	Xie, YM; Varshavsky, A				Xie, YM; Varshavsky, A			UFD4 lacking the proteasome-binding region catalyses ubiquitination but is impaired in proteolysis	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; 26S PROTEASOME; PROTEIN; DEGRADATION; SUBSTRATE; COMPONENT; PATHWAY; DOMAIN; ATPASE	The ubiquitin system recognizes degradation signals of protein substrates through E3-E2 ubiquitin ligases, which produce a substrate-linked multi-ubiquitin chain. Ubiquitinated substrates are degraded by the 26S proteasome, which consists of the 20S protease and two 19S particles. We previously showed that UBR1 and UFD4, two E3 ligases of the yeast Saccharomyces cerevisiae, interact with specific proteasomal subunits. Here we advance this analysis for UFD4 and show that it interacts with RPT4 and RPT6, two subunits of the 19S particle. The 201-residue amino-terminal region of UFD4 is essential for its binding to RPT4 and RPT6. UFD4(DeltaN), which lacks this N-terminal region, adds ubiquitin to test substrates with apparently wild-type activity, but is impaired in conferring short half-lives on these substrates. We propose that interaction of a targeted substrate with the 26S proteasome involves contacts of specific proteasomal subunits with the substrate-bound ubiquitin ligase, with the substrate-linked multi-ubiquitin chain and with the substrate itself. This multiple-site binding may function to slow down dissociation of the substrate from the proteasome and to facilitate the unfolding of substrate through ATP-dependent movements of the chaperone subunits of the 19S particle.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Xie, YM (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.							BAKER RT, 1991, P NATL ACAD SCI USA, V87, P2374; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Jager S, 2001, EMBO J, V20, P4423, DOI 10.1093/emboj/20.16.4423; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; XIEY, 2000, P NATLA CAD SCI US, V97, P2497; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	30	73	73	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					1003	1007		10.1038/ncb889	http://dx.doi.org/10.1038/ncb889			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447385				2022-12-25	WOS:000179571800023
J	Rhind, SM; King, TJ; Harkness, LM; Bellamy, C; Wallace, W; DeSousa, P; Wilmut, I				Rhind, SM; King, TJ; Harkness, LM; Bellamy, C; Wallace, W; DeSousa, P; Wilmut, I			Cloned lambs - lessons from pathology	NATURE BIOTECHNOLOGY			English	Editorial Material							BECKWITH-WIEDEMANN-SYNDROME; ALAGILLE-SYNDROME; CONGENITAL MISALIGNMENT; PULMONARY-HYPERTENSION; HUMAN JAGGED1; MUTATIONS; SHEEP; OVERGROWTH; GENE; FETUSES		Univ Edinburgh, Easter Bush Vet Ctr, Roslin EH25 9RG, Midlothian, Scotland; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh	Rhind, SM (corresponding author), Univ Edinburgh, Easter Bush Vet Ctr, Roslin EH25 9RG, Midlothian, Scotland.		Harkness, Linda/A-5654-2017; De Sousa, Paul A/H-7416-2013	Harkness, Linda/0000-0002-1648-9301; De Sousa, Paul A/0000-0003-0745-2504				Alagille D, 1969, J PEDIAT, V301, P301; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Cibelli JB, 2002, NAT BIOTECHNOL, V20, P13, DOI 10.1038/nbt0102-13; De Sousa PA, 2001, BIOL REPROD, V65, P23, DOI 10.1095/biolreprod65.1.23; Denning C, 2001, NAT BIOTECHNOL, V19, P559, DOI 10.1038/89313; Gutierrez C, 2000, PEDIATR DEVEL PATHOL, V3, P271, DOI 10.1007/s100249910035; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Jones EA, 2000, J MED GENET, V37, P658, DOI 10.1136/jmg.37.9.658; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; NG PC, 1995, ACTA PAEDIATR, V84, P349, DOI 10.1111/j.1651-2227.1995.tb13644.x; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAINE J, 1991, ARCH DIS CHILD-FETAL, V66, P398, DOI 10.1136/adc.66.4_Spec_No.398; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	18	48	48	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2003	21	7					744	745		10.1038/nbt0703-744	http://dx.doi.org/10.1038/nbt0703-744			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	696KL	12833090				2022-12-25	WOS:000183886000020
J	McCaffrey, AP; Nakai, H; Pandey, K; Huang, Z; Salazar, FH; Xu, H; Wieland, SF; Marion, PL; Kay, MA				McCaffrey, AP; Nakai, H; Pandey, K; Huang, Z; Salazar, FH; Xu, H; Wieland, SF; Marion, PL; Kay, MA			Inhibition of hepatitis B virus in mice by RNA interference	NATURE BIOTECHNOLOGY			English	Article							GENE-EXPRESSION; MAMMALIAN-CELLS; PLASMID DNA; REPLICATION; HEPATOCYTES; INFECTION; SIRNA	Hepatitis B virus (HBV) infection substantially increases the risk of chronic liver disease and hepatocellular carcinoma in humans. RNA interference (RNAi) of virus-specific genes has emerged as a potential antiviral mechanism. Here we show that RNAi can be applied to inhibit production of HBV replicative intermediates in cell culture and in immunocompetent and immunodeficient mice transfected with an HBV plasmid. Cotransfection with plasmids expressing short hairpin RNAs (shRNAs) homologous to HBV mRNAs induced an RNAi response. Northern and Southern analyses of mouse liver RNA and DNA showed substantially reduced levels of HBV RNAs and replicated HBV genomes upon RNAi treatment. Secreted HBV surface antigen (HBsAg) was reduced by 94.2% in cell culture and 84.5% in mouse serum, whereas immunohistochemical detection of HBV core antigen (HBcAg) revealed >99% reduction in stained hepatocytes upon RNAi treatment. Thus, RNAi effectively inhibited replication initiation in cultured cells and mammalian liver, showing that such an approach could be useful in the treatment of viral diseases.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Hepadnavirus Testing Inc, Mountain View, CA USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Stanford University; Stanford University; Scripps Research Institute	Kay, MA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, 300 Pasteur Dr,Room G305, Stanford, CA 94305 USA.			Kay, Mark/0000-0002-2799-2615	NIAID NIH HHS [AI40034] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Marion PL, 2003, FRONTIERS IN VIRAL HEPATITIS, P197, DOI 10.1016/B978-044450986-4/50069-2; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McLachlan A., 1991, MOL BIOL HEPATITIS B; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Shlomai A, 2003, HEPATOLOGY, V37, P764, DOI 10.1053/jhep.2003.50146; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	24	512	638	0	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2003	21	6					639	644		10.1038/nbt824	http://dx.doi.org/10.1038/nbt824			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	684RR	12740585				2022-12-25	WOS:000183220800021
J	Pediconi, N; Ianari, A; Costanzo, A; Belloni, L; Gallo, R; Cimino, L; Porcellini, A; Screpanti, I; Balsano, C; Alesse, E; Gulino, A; Levrero, M				Pediconi, N; Ianari, A; Costanzo, A; Belloni, L; Gallo, R; Cimino, L; Porcellini, A; Screpanti, I; Balsano, C; Alesse, E; Gulino, A; Levrero, M			Differential regulation of E2F1 apoptotic target genes in response to DNA damage	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE; C-ABL; P73; ACTIVATION; ACETYLATION; P53; EXPRESSION; RB; TRANSCRIPTION; REPLICATION	E2F1, a member of the E2F family of transcription factors, in addition to its established proliferative effect(1), has also been implicated in the induction of apoptosis through p53-dependent and p53-independent pathways(2). Several genes involved in the activation or execution of the apoptotic programme have recently been shown to be upregulated at the transcriptional level by E2F1 overexpression, including the genes encoding INK4a/ARF, Apaf-1, caspase 7 and p73 (refs 3-5). E2F1 is stabilized in response to DNA damage(6,7) but it has not been established how this translates into the activation of specific subsets of E2F target genes. Here, we applied a chromatin immunoprecipitation approach to show that, in response to DNA damage, E2F1 is directed from cell cycle progression to apoptotic E2F target genes. We identify p73 as an important E2F1 apoptotic target gene in DNA damage response and we show that acetylation is required for E2F1 recruitment on the P1p73 promoter and for its transcriptional activation.	Univ Roma La Sapienza, Gene Express Lab, Fdn Andrea Cesalpino, I-00161 Rome, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy; Ist Neuromed, I-86077 Pozzilli, Italy; Univ Aquila, Dipartimento Med Interna, I-67100 Laquila, Italy; Univ Cagliari, Dipartimento Sci Med Internistiche, I-09124 Cagliari, Italy	Sapienza University Rome; Sapienza University Rome; University of Rome Tor Vergata; University of L'Aquila; IRCCS Neuromed; University of L'Aquila; University of Cagliari	Gulino, A (corresponding author), Univ Roma La Sapienza, Gene Express Lab, Fdn Andrea Cesalpino, Viale Policlin 155, I-00161 Rome, Italy.		Costanzo, Antonio/D-3896-2012; Balsano, Clara/AAK-9870-2020; Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011; Costanzo, Antonio/GZG-2433-2022; Belloni, Laura/S-1432-2019; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Porcellini, Antonio/0000-0001-6882-9518; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875				Agami R, 1999, NATURE, V399, P809; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gong JG, 1999, NATURE, V399, P806; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598	29	224	228	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					552	558		10.1038/ncb998	http://dx.doi.org/10.1038/ncb998			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12766778				2022-12-25	WOS:000183202800017
J	Samlowski, WE; Petersen, R; Cuzzocrea, S; Macarthur, H; Burton, D; McGregor, JR; Salvemini, D				Samlowski, WE; Petersen, R; Cuzzocrea, S; Macarthur, H; Burton, D; McGregor, JR; Salvemini, D			A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects	NATURE MEDICINE			English	Article							ACTIVATED KILLER-CELLS; NATURAL-KILLER; RECOMBINANT INTERLEUKIN-2; PERITONEAL-MACROPHAGES; NK CELLS; IN-VITRO; INTERFERON; HISTAMINE; CATECHOLAMINES; IMMUNOTHERAPY	Interleukin-2 (IL-2) is used to treat metastatic renal cell carcinoma and malignant melanoma, but its use is limited by the severe hypotension it produces. We have shown here that M40403, a superoxide dismutase (SOD) mimetic, blocked IL-2-induced hypotension and allowed the dose of IL-2 to be increased in mice. The reversal of IL-2-mediated hypotension was associated with an increase in plasma catecholamines. In addition, M40403 increased lymphokine-activated killer (LAK) cell cytotoxicity in vitro and in vivo, through inhibition of macrophage superoxide production. Treatment of methylcholanthrene-induced (Meth A) ascites tumors with IL-2 and 3 mg per kg body weight M40403 induced 50% complete remissions lasting for more than 200 d, which was longer than those of untreated mice (15-d median survival) or mice treated with IL-2 alone (22-d median). Growth of subcutaneous implants of RENCA renal carcinoma was also inhibited by the combination of IL-2 and M40403. These results established that M40403 prevented IL-2 from causing dose-limiting hypotension, while enhancing its anticancer activity.	MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, St Louis, MO 63114 USA; Univ Utah, Huntsman Canc Inst, Melanoma Program, Salt Lake City, UT 84112 USA; Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Messina; Saint Louis University	Salvemini, D (corresponding author), MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com		Samlowski, Wolfram/0000-0002-0713-914X	NCI NIH HHS [R43-CA933203] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker JC, 1996, J EXP MED, V183, P2361, DOI 10.1084/jem.183.5.2361; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; BRUNDA MJ, 1987, INT J CANCER, V40, P365, DOI 10.1002/ijc.2910400314; DOHLSTEN M, 1986, SCAND J IMMUNOL, V24, P49, DOI 10.1111/j.1365-3083.1986.tb02069.x; ETTINGHAUSEN SE, 1986, CANCER RES, V46, P2784; ETTINGHAUSEN SE, 1988, JNCI-J NATL CANCER I, V80, P177, DOI 10.1093/jnci/80.3.177; FAGGIONI R, 1994, J IMMUNOTHER, V15, P194, DOI 10.1097/00002371-199404000-00005; Fisher RI, 1997, CANCER J SCI AM, V3, pS70; GAYNOR ER, 1988, ANN INTERN MED, V109, P953, DOI 10.7326/0003-4819-109-12-953; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRIMM EA, 1985, CELL IMMUNOL, V94, P568, DOI 10.1016/0008-8749(85)90280-1; Hansson M, 1996, J IMMUNOL, V156, P42; HARKER WG, 1990, CANCER RES, V50, P5931; HELLSTRAND K, 1987, J IMMUNOL, V139, P869; HELLSTRAND K, 1986, J IMMUNOL, V137, P656; HELLSTRAND K, 1990, INT ARCH ALLER A IMM, V92, P379, DOI 10.1159/000235169; Hellstrand K, 1997, SCAND J CLIN LAB INV, V57, P193, DOI 10.3109/00365519709060027; HELLSTRAND K, 1994, J LEUKOCYTE BIOL, V55, P392, DOI 10.1002/jlb.55.3.392; JOHNSTON RB, 1978, J EXP MED, V148, P115; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; Kwak JY, 1998, CELL IMMUNOL, V188, P33, DOI 10.1006/cimm.1998.1337; LANIER LL, 1986, J IMMUNOL, V136, P4480; LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7; LINDEN O, 1987, SCAND J IMMUNOL, V26, P223, DOI 10.1111/j.1365-3083.1987.tb02255.x; Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753; MANN H, 1990, RADIOLOGY, V176, P191, DOI 10.1148/radiology.176.1.2353090; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; MERTELSMANN R, 1986, IMMUNOBIOLOGY, V172, P400, DOI 10.1016/S0171-2985(86)80121-8; Moulian N, 2001, BLOOD, V97, P3521, DOI 10.1182/blood.V97.11.3521; OGNIBENE FP, 1988, CHEST, V94, P750, DOI 10.1378/chest.94.4.750; PABST MJ, 1980, J EXP MED, V151, P101, DOI 10.1084/jem.151.1.101; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Samlowski WE, 1995, J IMMUNOTHER, V18, P166, DOI 10.1097/00002371-199510000-00004; Samlowski WE, 2001, PROG INFLAM RES, P249; SEAMAN WE, 1982, J CLIN INVEST, V69, P876, DOI 10.1172/JCI110527; SEAMAN WE, 1981, J CLIN INVEST, V67, P1324, DOI 10.1172/JCI110161; SIEGEL JP, 1991, J CLIN ONCOL, V9, P694, DOI 10.1200/JCO.1991.9.4.694; SUZUKI K, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1176; Uotila P, 1996, CANCER IMMUNOL IMMUN, V43, P1; Weiss Arthur, 1993, P467; YIM CY, 1995, J IMMUNOL, V155, P4382	44	61	74	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					750	755		10.1038/nm874	http://dx.doi.org/10.1038/nm874			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12730689				2022-12-25	WOS:000183444100031
J	Paw, BH; Davidson, AJ; Zhou, Y; Li, R; Pratt, SJ; Lee, C; Trede, NS; Brownlie, A; Donovan, A; Liao, EC; Ziai, JM; Drejer, AH; Guo, W; Kim, CH; Gwynn, B; Peters, LL; Chernova, MN; Alper, SL; Zapata, A; Wickramasinghe, SN; Lee, MJ; Lux, SE; Fritz, A; Postlethwait, JH; Zon, LI				Paw, BH; Davidson, AJ; Zhou, Y; Li, R; Pratt, SJ; Lee, C; Trede, NS; Brownlie, A; Donovan, A; Liao, EC; Ziai, JM; Drejer, AH; Guo, W; Kim, CH; Gwynn, B; Peters, LL; Chernova, MN; Alper, SL; Zapata, A; Wickramasinghe, SN; Lee, MJ; Lux, SE; Fritz, A; Postlethwait, JH; Zon, LI			Cell-specific mitotic defect and dyserythropoiesis associated with erythroid band 3 deficiency	NATURE GENETICS			English	Article							ANEMIA TYPE-II; POLYMERASE CHAIN-REACTION; STRUCTURAL PROTEIN-4.1; MEMBRANE SKELETON; IDENTIFICATION; LOCALIZATION; BINDING; LINKAGE; GENE; AE1	Most eukaryotic cell types use a common program to regulate the process of cell division. During mitosis, successful partitioning of the genetic material depends on spatially coordinated chromosome movement and cell cleavage(1). Here we characterize a zebrafish mutant, retsina (ret), that exhibits an erythroid-specific defect in cell division with marked dyserythropoiesis similar to human congenital dyserythropoietic anemia. Erythroblasts from ret fish show binuclearity and undergo apoptosis due to a failure in the completion of chromosome segregation and cytokinesis. Through positional cloning, we show that the ret mutation is in a gene (slc4a1) encoding the anion exchanger 1 (also called band 3 and AE1), an erythroid-specific cytoskeletal protein. We further show an association between deficiency in Slc4a1 and mitotic defects in the mouse. Rescue experiments in ret zebrafish embryos expressing transgenic slc4a1 with a variety of mutations show that the requirement for band 3 in normal erythroid mitosis is mediated through its protein 4.1R-binding domains. Our report establishes an evolutionarily conserved role for band 3 in erythroid-specific cell division and illustrates the concept of cell-specific adaptation for mitosis.	Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Maine, Dept Biochem Microbiol & Mol Biol, Orono, ME USA; Jackson Lab, Bar Harbor, ME 04609 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA USA; Univ Complutense, Dept Cell Biol, E-28040 Madrid, Spain; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ London Imperial Coll Sci Technol & Med, Dept Hematol, London, England; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Maine System; University of Maine Orono; Jackson Laboratory; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Complutense University of Madrid; University of Oxford; Imperial College London; Emory University; University of Oregon	Zon, LI (corresponding author), Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA.			Paw, Barry/0000-0002-0492-1419; Kim, Carol/0000-0002-0465-4496; Cutts, Alison/0000-0002-4986-573X; Liao, Eric/0000-0001-6385-7448; Zapata, Agustin G/0000-0003-0576-2672; Peters, Luanne/0000-0002-0784-0534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064885] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064885] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alloisio N, 1996, BLOOD, V87, P4433, DOI 10.1182/blood.V87.10.4433.bloodjournal87104433; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; De Franceschi L, 1998, EXP HEMATOL, V26, P869; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Fritz A, 1996, GENETICS, V144, P1735; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; Gasparini P, 1997, AM J HUM GENET, V61, P1112, DOI 10.1086/301609; Iolascon A, 1998, BLOOD, V92, P2593, DOI 10.1182/blood.V92.7.2593; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 2002, J BIOL CHEM, V277, P44339, DOI 10.1074/jbc.M204135200; Liao EC, 2000, DEVELOPMENT, V127, P5123; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Perez-Ferreiro CM, 2001, J BIOL CHEM, V276, P44785, DOI 10.1074/jbc.M107369200; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; PETERS LL, 1998, BLOOD S, V92, P301; Ransom DG, 1996, DEVELOPMENT, V123, P311; Rosse W., 1995, BLOOD PRINCIPLES PRA, P367; SEKLER I, 1995, J BIOL CHEM, V270, P28751, DOI 10.1074/jbc.270.48.28751; Shafizadeh E, 2002, DEVELOPMENT, V129, P4359; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wickramasinghe SN, 1998, BLOOD REV, V12, P178, DOI 10.1016/S0268-960X(98)90016-9	29	100	101	0	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					59	64		10.1038/ng1137	http://dx.doi.org/10.1038/ng1137			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12669066				2022-12-25	WOS:000182667900017
J	Rubinson, DA; Dillon, CP; Kwiatkowski, AV; Sievers, C; Yang, LL; Kopinja, J; Zhang, MD; McManus, MT; Gertler, FB; Scott, ML; Van Parijs, L				Rubinson, DA; Dillon, CP; Kwiatkowski, AV; Sievers, C; Yang, LL; Kopinja, J; Zhang, MD; McManus, MT; Gertler, FB; Scott, ML; Van Parijs, L			A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference	NATURE GENETICS			English	Article							NONDIVIDING CELLS; HAIRPIN RNAS; EXPRESSION; DELIVERY; VECTORS	RNA interference (RNAi) has recently emerged as a specific and efficient method to silence gene expression in mammalian cells either by transfection of short interfering RNAs (siRNAs; ref. 1) or, more recently, by transcription of short hairpin RNAs (shRNAs) from expression vectors and retroviruses(2-10). But the resistance of important cell types to transduction by these approaches, both in vitro and in vivo(11), has limited the use of RNAi. Here we describe a lentiviral system for delivery of shRNAs into cycling and non-cycling mammalian cells, stem cells, zygotes and their differentiated progeny. We show that lentivirus-delivered shRNAs are capable of specific, highly stable and functional silencing of gene expression in a variety of cell types and also in transgenic mice. Our lentiviral vectors should permit rapid and efficient analysis of gene function in primary human and animal cells and tissues and generation of animals that show reduced expression of specific genes. They may also provide new approaches for gene therapy.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany; CALTECH, Pasadena, CA 91125 USA; Biogen Inc, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin; California Institute of Technology; Biogen	Van Parijs, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Dillon, Christopher/P-4457-2014; mcmanus, michael/AAB-1239-2020; Rubinson, Douglas/G-3502-2019	Dillon, Christopher/0000-0002-9458-0266; mcmanus, michael/0000-0003-3013-6569; Rubinson, Douglas/0000-0002-5337-5231				Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lois C, 2001, CURR OPIN IMMUNOL, V13, P496, DOI 10.1016/S0952-7915(00)00247-8; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Scherr Michaela, 2002, Current Gene Therapy, V2, P45, DOI 10.2174/1566523023348237; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	28	1049	1329	2	102	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					401	406		10.1038/ng1117	http://dx.doi.org/10.1038/ng1117			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12590264				2022-12-25	WOS:000181312700019
J	Albertson, R; Doe, CQ				Albertson, R; Doe, CQ			Dlg, Scrib and Lgl regulate neuroblast cell size and mitotic spindle asymmetry	NATURE CELL BIOLOGY			English	Article							LARGE TUMOR-SUPPRESSOR; DROSOPHILA NEUROBLASTS; HUMAN HOMOLOG; PROTEIN; LOCALIZATION; DIVISION; POLARITY; BAZOOKA; PROSPERO; ENCODES	Asymmetric cell division is important in generating cell diversity from bacteria to mammals. Drosophila melanogaster neuroblasts are a useful model system for investigating asymmetric cell division because they establish distinct apical-basal cortical domains, have an asymmetric mitotic spindle aligned along the apical-basal axis, and divide unequally to produce a large apical neuroblast and a small basal daughter cell (GMC)(1,2). Here we show that Discs large (Dlg), Scribble (Scrib) and Lethal giant larvae (Lgl) tumour suppressor proteins regulate multiple aspects of neuroblast asymmetric cell division. Dlg/Scrib/Lgl proteins show apical cortical enrichment at prophase/metaphase, and then have a uniform cortical distribution. Mutants have defects in basal protein targeting, a reduced apical cortical domain and reduced apical spindle size. Defects in apical cell and spindle pole size result in symmetric or inverted neuroblast cell divisions. Inverted divisions correlate with the appearance of abnormally small neuroblasts and large GMCs, showing that neuroblast/GMC identity is more tightly linked to cortical determinants than cell size. We conclude that Dlg/Scrib/Lgl are important in regulating cortical polarity, cell size asymmetry and mitotic spindle asymmetry in Drosophila neuroblasts.	Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon	Doe, CQ (corresponding author), Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, Eugene, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brenman JE, 1998, J NEUROSCI, V18, P8805; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Cai Y, 2001, EMBO J, V20, P1704, DOI 10.1093/emboj/20.7.1704; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Gomes JE, 2001, DEVELOPMENT, V128, P4301; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STRAND D, 1995, ONCOGENE, V11, P291; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	29	191	194	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					166	170		10.1038/ncb922	http://dx.doi.org/10.1038/ncb922			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545176				2022-12-25	WOS:000180802100018
J	Hurd, TW; Gao, L; Roh, MH; Macara, IG; Margolis, B				Hurd, TW; Gao, L; Roh, MH; Macara, IG; Margolis, B			Direct interaction of two polarity complexes implicated in epithelial tight junction assembly	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; ADHESION MOLECULE JAM; CELL-POLARITY; CAENORHABDITIS-ELEGANS; DROSOPHILA STARDUST; EMBRYONIC POLARITY; PKC-ZETA; NEUROBLASTS; CRUMBS; CDC42	Tight junctions help establish polarity in mammalian epithelia by forming a physical barrier that separates apical and basolateral membranes. Two evolutionarily conserved multiprotein complexes, Crumbs (Crb)-PALS1 (Stardust)-PATJ (DiscsLost)(1-4) and Cdc42-Par6-Par3- atypical protein kinase C (aPKC), have been implicated in the assembly of tight junctions and in polarization of Drosophila melanogaster epithelia(5-8). Here we identify a biochemical and functional link between these two complexes that is mediated by Par6 and PALS1 (proteins associated with Lin7). The interaction between Par6 and PALS1 is direct, requires the amino terminus of PALS1 and the PDZ domain of Par6, and is regulated by Cdc42-GTP. The transmembrane protein Crb can recruit wild-type Par6, but not Par6 with a mutated PDZ domain, to the cell surface. Expression of dominant-negative PALS1-associated tight junction protein (PATJ) in MDCK cells results in mis-localization of PALS1, members of the Par3-Par6-aPKC complex and the tight junction marker, ZO-1. Similarly, overexpression of Par6 in MDCK cells inhibits localization of PALS1 to the tight junction. Our data highlight a previously unrecognized link between protein complexes that are essential for epithelial polarity and formation of tight junctions.	Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Virginia, Hlth Sci Ctr, Ctr Cell Signalling, Charlottesville, VA 22908 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia	Hurd, TW (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA40042] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Horne-Badovinac S, 2001, CURR BIOL, V11, P1492, DOI 10.1016/S0960-9822(01)00458-4; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; MAKAROVA O, IN PRESS GENE; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Tepass U, 2002, BIOESSAYS, V24, P690, DOI 10.1002/bies.10129; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	28	394	401	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					137	142		10.1038/ncb923	http://dx.doi.org/10.1038/ncb923			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545177				2022-12-25	WOS:000180802100013
J	Naya, FJ; Black, BL; Wu, H; Bassel-Duby, R; Richardson, JA; Hill, JA; Olson, EN				Naya, FJ; Black, BL; Wu, H; Bassel-Duby, R; Richardson, JA; Hill, JA; Olson, EN			Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor	NATURE MEDICINE			English	Article							DILATED CARDIOMYOPATHY; MUSCLE DEVELOPMENT; HEART; GENE; DISORDERS; DISEASES; ENHANCER	The four MEF2 transcription factors (MEF2A, -B, -C, and -D) regulate differentiation and calcium-dependent gene expression in muscle cells. We generated mice deficient in MEF2A, the predominant Mef2 gene product expressed in post-natal cardiac muscle. Most mice lacking Mef2a died suddenly within the first week of life and exhibited pronounced dilation of the right ventricle, myofibrillar fragmentation, mitochondrial disorganization and activation of a fetal cardiac gene program. The few Mef2a(-/-) mice that survived to adulthood also showed a deficiency of cardiac mitochondria and susceptibility to sudden death. Paradoxically, MEF2 transcriptional activity, revealed by the expression of a MEF2-dependent transgene, was enhanced in the hearts of Mef2a-mutant mice, reflecting the transcriptional activation of residual MEF2D. These findings reveal specific roles for MEF2A in maintaining appropriate mitochondrial content and cyto-architectural integrity in the post-natal heart and show that other MEF2 isoforms cannot support these activities.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa; University of Iowa	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu		Black, Brian/0000-0002-6664-8913				Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bonnet D, 1999, CIRCULATION, V100, P2248, DOI 10.1161/01.CIR.100.22.2248; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Ibdah JA, 2001, J CLIN INVEST, V107, P1403, DOI 10.1172/JCI12590; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Marin-Garcia J, 2001, CARDIOVASC RES, V49, P17, DOI 10.1016/S0008-6363(00)00241-8; MarinGarcia J, 1997, PEDIATR CARDIOL, V18, P251, DOI 10.1007/s002469900169; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Muscat George E. O., 1992, Gene Expression, V2, P111; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Spooner PM, 2001, CIRCULATION, V103, P2361; Towbin JA, 1999, CURR OPIN CARDIOL, V14, P250, DOI 10.1097/00001573-199905000-00010; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; WILLIAMS RS, 1995, CIRCULATION, V91, P1266, DOI 10.1161/01.CIR.91.4.1266; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	32	245	261	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1303	1309		10.1038/nm789	http://dx.doi.org/10.1038/nm789			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379849				2022-12-25	WOS:000179221200038
J	Bluteau, O; Jeannot, E; Bioulac-Sage, P; Marques, JM; Blanc, JF; Bui, H; Beaudoin, JC; Franco, D; Balabaud, C; Laurent-Puig, P; Zucman-Rossi, J				Bluteau, O; Jeannot, E; Bioulac-Sage, P; Marques, JM; Blanc, JF; Bui, H; Beaudoin, JC; Franco, D; Balabaud, C; Laurent-Puig, P; Zucman-Rossi, J			Bi-allelic inactivation of TCF1 in hepatic adenomas	NATURE GENETICS			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; LIVER-CELL ADENOMAS; I ALPHA-GENE; TRANSCRIPTION FACTOR; DNA-BINDING; HEPATOCELLULAR-CARCINOMA; DIABETES-MELLITUS; MUTATIONS; HOMEODOMAIN; DOMAIN	Liver adenomas are benign tumors at risk of malignant transformation. In a genome-wide search for loss of heterozygosity (LOH) associated with liver adenomas, we found a deletion in chromosome 12q in five of ten adenomas. In most cases, LOH at 12q was the only recurrent genetic alteration observed, suggesting the presence of a tumor-suppressor gene in that region. A minimal common region of deletion was defined in 12q24 that included the gene TCF1 (transcription factor 1), encoding hepatocyte nuclear factor 1 (HNF1; refs 1,2). Heterozygous germline mutations of TCF1 have been identified in individuals affected with maturity-onset diabetes of the young type 3 (MODY3; ref. 3). Bi-allelic inactivation of TCF1 was found in 10 of 16 screened adenomas, and heterozygous germline mutation were present in three affected individuals. Furthermore, 2 well-differentiated hepatocellular carcinomas (HCCs) occurring in normal liver contained somatic bi-allelic mutations of 30 screened HCCs. These results indicate that inactivation of TCF1, whether sporadic or associated with MODY3, is an important genetic event in the occurrence of human liver adenoma, and may be an early step in the development of some HCCs.	Fdn Jean Dausset, INSERM, U434, F-75010 Paris, France; Foie Univ Bordeaux 2, Grp Rech Etud, Bordeaux, France; Hop Pellegrin, Serv Anatomopathol, F-33076 Bordeaux, France; Fdn Jean Dausset, Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Hop Antoine Beclere, Assistance Publ Hop Paris, Serv Chirurg Digest, Clamart, France	Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Foundation Jean Dausset-CEPH; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Zucman-Rossi, J (corresponding author), Fdn Jean Dausset, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	bluteau, olivier/A-8844-2008; Laurent-Puig, Pierre/K-3641-2019; Bluteau, Olivier/T-9907-2017; j, zucman-rossi/AAV-3594-2021; zucman-rossi, Jessica/B-5098-2009; laurent-puig, pierre/B-2226-2013	Laurent-Puig, Pierre/0000-0001-8475-5459; Bluteau, Olivier/0000-0002-6943-8858; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; laurent-puig, pierre/0000-0001-8475-5459				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Boland CR, 1998, CANCER RES, V58, P5248; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Chiche L, 2000, ANN SURG, V231, P74, DOI 10.1097/00000658-200001000-00011; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Collet C, 2002, DIABETES METAB, V28, P39; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; EDMONDSON HA, 1976, NEW ENGL J MED, V294, P470, DOI 10.1056/NEJM197602262940904; Ellard S, 2000, HUM MUTAT, V16, P377, DOI 10.1002/1098-1004(200011)16:5<377::AID-HUMU1>3.0.CO;2-2; FERRELL LD, 1993, AM J SURG PATHOL, V17, P525, DOI 10.1097/00000478-199305000-00013; FLEJOU JF, 1985, GASTROENTEROLOGY, V89, P1132, DOI 10.1016/0016-5085(85)90220-3; FOSTER JH, 1978, NEW ENGL J MED, V299, P239, DOI 10.1056/NEJM197808032990508; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOLDFARB S, 1976, CANCER RES, V36, P2584; HOWELL RR, 1976, JAMA-J AM MED ASSOC, V236, P1481, DOI 10.1001/jama.236.13.1481; Kaisaki PJ, 1997, DIABETES, V46, P528, DOI 10.2337/diabetes.46.3.528; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; SALE GE, 1977, ARCH PATHOL LAB MED, V101, P600; Schott O, 1997, J MOL BIOL, V267, P673, DOI 10.1006/jmbi.1997.0905; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Vaxillaire M, 1999, J BIOL CHEM, V274, P35639, DOI 10.1074/jbc.274.50.35639; Yamagata K, 1998, DIABETES, V47, P1231, DOI 10.2337/diabetes.47.8.1231; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	29	241	250	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					312	315		10.1038/ng1001	http://dx.doi.org/10.1038/ng1001			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355088				2022-12-25	WOS:000178311100023
J	Chau, BN; Borges, HL; Chen, TT; Masselli, A; Hunton, IC; Wang, YJY				Chau, BN; Borges, HL; Chen, TT; Masselli, A; Hunton, IC; Wang, YJY			Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb	NATURE CELL BIOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; CELL-DEATH; CYTOCHROME-C; FACTOR RECEPTOR; NERVOUS-SYSTEM; CLEAVAGE; PATHWAYS; ACTIVATION	The retinoblastoma tumour suppressor protein RB is cleaved by caspases during apoptosis. Here we have mutated the caspase cleavage site in the carboxy terminus of the murine Rb protein in the mouse germ line to create the Rb-MI allele. After endotoxic shock, expression of Rb-MI inhibits apoptosis in the intestines, but not in the spleen, and promotes the survival of male mice. Fibroblasts expressing Rb-MI protein are protected from apoptosis induced by the tumour-necrosis factor-alpha type I receptor (TNFRI) but remain sensitive to cell death induced by DNA damage. Correspondingly, the release of cytochrome c and the activation of caspase-3 induced by TNFRI, but not by DNA damage, are defective in cells expressing Rb-MI. Our results highlight the importance of Rb cleavage in TNFRI-induced apoptosis.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Chau, BN (corresponding author), Univ Calif San Diego, Div Biol, 9500 Gilman Dr 0322, La Jolla, CA 92093 USA.		Borges, Helena L/E-5044-2013; Borges, Helena/AAG-3701-2020; Borges, Helena/W-7533-2019; Chen, Tsute/ABC-2676-2020	Borges, Helena L/0000-0003-2866-4223; Borges, Helena/0000-0003-2866-4223; 	NCI NIH HHS [R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, CANCER RES, V56, P438; Borges HL, 1999, J CELL SCI, V112, P4315; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Guo Z, 2001, CANCER RES, V61, P8395; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jupp OJ, 2001, BIOCHEM J, V359, P525, DOI 10.1042/0264-6021:3590525; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Piguet PF, 1998, EUR J IMMUNOL, V28, P3499, DOI 10.1002/(SICI)1521-4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang XD, 2001, GENE DEV, V15, P2922; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	45	76	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					757	765		10.1038/ncb853	http://dx.doi.org/10.1038/ncb853			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360286				2022-12-25	WOS:000178316500012
J	Perez, LH; Antonio, C; Flament, S; Vernos, I; Nebreda, AR				Perez, LH; Antonio, C; Flament, S; Vernos, I; Nebreda, AR			Xkid chromokinesin is required for the meiosis I to meiosis II transition in Xenopus laevis oocytes	NATURE CELL BIOLOGY			English	Article							MEIOTIC CELL-CYCLE; MOS PROTO-ONCOGENE; MAP KINASE; CHROMOSOME ALIGNMENT; INHIBITORY KINASE; MITOTIC SPINDLE; MATURATION; ACTIVATION; MPF; PHOSPHORYLATES	Xkid chromokinesin is required for chromosome alignment on the metaphase plate of spindles formed in Xenopus laevis egg extracts. We have investigated the role of Xkid in Xenopus oocyte meiotic maturation, a progesterone-triggered process that reinitiates the meiotic cell cycle in oocytes arrested at the G2/M border of meiosis I. Here we show that Xkid starts to accumulate at the time of germinal vesicle breakdown and reaches its largest quantities at metaphase II in oocytes treated with progesterone. Both germinal vesicle breakdown and spindle assembly at meiosis I can occur normally in the absence of Xkid. But Xkid-depleted oocytes cannot reactivate Cdc2/cyclin B after meiosis I and, instead of proceeding to meiosis II, they enter an interphase-like state and undergo DNA replication. Expression of a Xkid mutant that lacks the DNA-binding domain allows Xkid-depleted oocytes to complete meiotic maturation. Our results show that Xkid has a role in the meiotic cell cycle that is independent from its role in metaphase chromosome alignment.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Nancy 1, F-54506 Vandoeuvre Les Nancy, France	European Molecular Biology Laboratory (EMBL); Universite de Lorraine	Perez, LH (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Nebreda, Angel Rodriguez/R-9594-2019; Perez, Laurent/ABA-4145-2021; Vernos, Isabelle/C-1687-2015	Perez, Laurent/0000-0002-8860-7928; Vernos, Isabelle/0000-0003-1469-9214				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; Flament S, 1996, INT J DEV BIOL, V40, P471; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GARD DL, 1991, DEV BIOL, V143, P346, DOI 10.1016/0012-1606(91)90085-H; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GOTOH Y, 1995, MOL REPROD DEV, V42, P486, DOI 10.1002/mrd.1080420417; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Iwabuchi M, 2000, EMBO J, V19, P4513, DOI 10.1093/emboj/19.17.4513; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Lefebvre C, 2002, J CELL BIOL, V157, P603, DOI 10.1083/jcb.200202052; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Masui Y, 2001, DIFFERENTIATION, V69, P1, DOI 10.1046/j.1432-0436.2001.690101.x; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nakajo N, 2000, GENE DEV, V14, P328; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Schmitt A, 2002, P NATL ACAD SCI USA, V99, P4361, DOI 10.1073/pnas.022056399; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x	28	25	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					737	742		10.1038/ncb850	http://dx.doi.org/10.1038/ncb850			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360284				2022-12-25	WOS:000178316500009
J	Yvert, G; Brem, RB; Whittle, J; Akey, JM; Foss, E; Smith, EN; Mackelprang, R; Kruglyak, L				Yvert, G; Brem, RB; Whittle, J; Akey, JM; Foss, E; Smith, EN; Mackelprang, R; Kruglyak, L			Trans-acting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors	NATURE GENETICS			English	Article							HUMAN GENE-EXPRESSION; CELL-CYCLE; ALLELIC VARIATION; BUDDING YEAST; GENOME; DISRUPTION; EVOLUTION; IDENTIFICATION; RECEPTORS; DELETION	Natural genetic variation can cause significant differences in gene expression, but little is known about the polymorphisms that affect gene regulation. We analyzed regulatory variation in a cross between laboratory and wild strains of Saccharomyces cerevisiae. Clustering and linkage analysis defined groups of coregulated genes and the loci involved in their regulation. Most expression differences mapped to trans-acting loci. Positional cloning and functional assays showed that polymorphisms in GPA1 and AMN1 affect expression of genes involved in pheromone response and daughter cell separation, respectively. We also asked whether particular classes of genes were more likely to contain trans-regulatory polymorphisms. Notably, transcription factors showed no enrichment, and trans-regulatory variation seems to be broadly dispersed across classes of genes with different molecular functions.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98103 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98103 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kruglyak, L (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Mailstop D4-100,1100 Fairview Ave N, Seattle, WA 98103 USA.		Smith, Erin/E-5933-2011; Mackelprang, Romel/GWV-4748-2022	Akey, Joshua/0000-0002-4411-1330; Yvert, Gael/0000-0003-1955-4786				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brachmann CB, 1998, YEAST, V14, P115; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Foss EJ, 2001, GENETICS, V157, P567; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Guelzim N, 2002, NAT GENET, V31, P60, DOI 10.1038/ng873; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jansen RC, 2003, NAT REV GENET, V4, P145, DOI 10.1038/nrg996; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MORTIMER RK, 1994, YEAST, V10, P1543, DOI 10.1002/yea.320101203; Oleksiak MF, 2002, NAT GENET, V32, P261, DOI 10.1038/ng983; Olson MV, 1999, AM J HUM GENET, V64, P18, DOI 10.1086/302219; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Rockman MV, 2002, MOL BIOL EVOL, V19, P1991, DOI 10.1093/oxfordjournals.molbev.a004023; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Souciet JL, 2000, FEBS LETT, V487, P3, DOI 10.1016/S0014-5793(00)02272-9; Spector MS, 1997, MOL CELL BIOL, V17, P545, DOI 10.1128/MCB.17.2.545; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Wang YC, 2003, CELL, V112, P697, DOI 10.1016/S0092-8674(03)00121-1; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; [No title captured]	40	496	509	0	31	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					57	64		10.1038/ng1222	http://dx.doi.org/10.1038/ng1222			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12897782				2022-12-25	WOS:000185018500011
J	Parrinello, S; Samper, E; Krtolica, A; Goldstein, J; Melov, S; Campisi, J				Parrinello, S; Samper, E; Krtolica, A; Goldstein, J; Melov, S; Campisi, J			Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE EMBRYO CELLS; TELOMERE LENGTH; CATALYTIC SUBUNIT; SENESCENCE; MICE; REPAIR; CULTURE; TRANSCRIPTION; P16(INK4A)	Most mammalian cells do not divide indefinitely, owing to a process termed replicative senescence. In human cells, replicative senescence is caused by telomere shortening, but murine cells senesce despite having long stable telomeres'. Here, we show that the phenotypes of senescent human fibroblasts and mouse embryonic fibroblasts (MEFs) differ under standard culture conditions, which include 20% oxygen. MEFs did not senesce in physiological (3%) oxygen levels, but underwent a spontaneous event that allowed indefinite proliferation in 20% oxygen. The proliferation and cytogenetic profiles of DNA repair-deficient MEFs suggested that DNA damage limits MEF proliferation in 20% oxygen. Indeed, MEFs accumulated more DNA damage in 20% oxygen than 3% oxygen, and more damage than human fibroblasts in 20% oxygen. Our results identify oxygen sensitivity as a critical difference between mouse and human cells, explaining their proliferative differences in culture, and possibly their different rates of cancer and ageing.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Buck Inst Age Res, Novato, CA 94945 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Buck Institute for Research on Aging	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	jcampisi@lbl.gov	Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834	NATIONAL CANCER INSTITUTE [Z01BC010658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000266, R01AG018679, P01AG017242] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC010658] Funding Source: Medline; NIA NIH HHS [R01 AG018679, AG17242, P01 AG017242, AG18679, T32 AG000266, AG00266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BOERRIGTER METI, 1995, MECH AGEING DEV, V82, P31, DOI 10.1016/0047-6374(95)01603-W; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Helma C, 2000, MUTAT RES-GEN TOX EN, V466, P9, DOI 10.1016/S1383-5718(99)00232-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Kodama S, 2001, RADIAT RES, V155, P254, DOI 10.1667/0033-7587(2001)155[0254:CCDSLG]2.0.CO;2; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; Okayasu R, 2000, CANCER RES, V60, P4342; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VAUPEL P, 1989, CANCER RES, V49, P6449; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	30	824	850	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					741	747		10.1038/ncb1024	http://dx.doi.org/10.1038/ncb1024			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12855956	Green Accepted			2022-12-25	WOS:000184687300016
J	Zheng, YH; Yu, HF; Peterlin, BM				Zheng, YH; Yu, HF; Peterlin, BM			Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells	NATURE CELL BIOLOGY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REV FUNCTION; TRANSGENIC MICE; RNA-BINDING; TAT; EXPRESSION; EXON; INFECTIVITY; ELONGATION; INHIBITION	In the mouse, replication of human immunodeficiency virus type 1 (HIV) is blocked at the levels of entry, transcription and assembly. For the latter effect, the amounts of unspliced viral genomic RNA could have an important function. Indeed, in murine cells, HIV transcripts are spliced excessively, a process that is not inhibited by the murine splicing inhibitor p32 (mp32). In marked contrast, its human counterpart, hp32, not only blocks this splicing but promotes the accumulation of viral genomic transcripts and structural proteins, resulting in the assembly and release of infectious virions. A single substitution in hp32 of Gly 35 to Asp 35, which is found in mp32, abrogates this activity. Thus, hp32 overcomes an important post-transcriptional block to HIV replication in murine cells.	Univ Calif San Francisco, Dept Med, Rosalind Russell Med Sci Ctr, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Microbiol, Rosalind Russell Med Sci Ctr, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Immunol, Rosalind Russell Med Sci Ctr, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Peterlin, BM (corresponding author), Univ Calif San Francisco, Dept Med, Rosalind Russell Med Sci Ctr, Mt Zion Res Bldg Room N231,2340 Sutter St, San Francisco, CA 94115 USA.		Zheng, Yong-Hui/AAP-4492-2021	Zheng, Yong-Hui/0000-0002-1098-7385				AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; Chen BK, 2001, P NATL ACAD SCI USA, V98, P15239, DOI 10.1073/pnas.261563198; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; Li JL, 2002, J VIROL, V76, P4526, DOI 10.1128/JVI.76.9.4526-4535.2002; LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; Mariani R, 2000, J VIROL, V74, P3859, DOI 10.1128/JVI.74.8.3859-3870.2000; Mariani R, 2001, J VIROL, V75, P3141, DOI 10.1128/JVI.75.7.3141-3151.2001; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pongoski J, 2002, J VIROL, V76, P5108, DOI 10.1128/JVI.76.10.5108-5120.2002; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reed M, 2002, J VIROL, V76, P436, DOI 10.1128/JVI.76.1.436-443.2002; SAWADA S, 1998, J EXP MED, V187, P1439; Shukla RR, 1996, J VIROL, V70, P9064, DOI 10.1128/JVI.70.12.9064-9068.1996; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; Tange TO, 2001, J MOL BIOL, V312, P649, DOI 10.1006/jmbi.2001.4971; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Tokunaga K, 1998, J GEN VIROL, V79, P2447, DOI 10.1099/0022-1317-79-10-2447; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; Wang SW, 2002, J VIROL, V76, P11853, DOI 10.1128/JVI.76.23.11853-11865.2002; Wentz MP, 1997, J VIROL, V71, P8542, DOI 10.1128/JVI.71.11.8542-8551.1997	44	78	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					611	618		10.1038/ncb1000	http://dx.doi.org/10.1038/ncb1000			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12833064				2022-12-25	WOS:000183911600010
J	Binder, CJ; Horkko, S; Dewan, A; Chang, MK; Kieu, EP; Goodyear, CS; Shaw, PX; Palinski, W; Witztum, JL; Silverman, GJ				Binder, CJ; Horkko, S; Dewan, A; Chang, MK; Kieu, EP; Goodyear, CS; Shaw, PX; Palinski, W; Witztum, JL; Silverman, GJ			Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; DEFICIENT MICE; MONOCLONAL-ANTIBODIES; RECEPTOR-DEFICIENT; APOPTOTIC CELLS; T15 IDIOTYPE; B-1 CELLS; B-CELLS; EPITOPES; PHOSPHORYLCHOLINE	During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (oxLDL) and active immunization of hypercholesterolemic mice with oxLDL ameliorates atherogenesis. We unexpectedly found that many autoantibodies to oxLDL derived from 'naive' atherosclerotic mice share complete genetic and structural identity with antibodies from the classic anti-phosphorylcholine B-cell clone, T15, which protect against common infectious pathogens, including pneumococci. To investigate whether in vivo exposure to pneumococci can affect atherogenesis, we immunized Ldlr(-/-) mice with Streptococcus pneumoniae. This induced high circulating levels of oxLDL-specific IgM and a persistent expansion of oxLDL-specific T15 IgM-secreting B cells primarily in the spleen, which were cross-reactive with pneumococcal determinants. Pneumococcal immunization decreased the extent of atherosclerosis, and plasma from these mice had an enhanced capacity to block the binding of oxLDL to macrophages. These studies show molecular mimicry between epitopes of oxLDL and S. pneumoniae and indicate that these immune responses can have beneficial effects.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Oulu, Bioctr, SF-90220 Oulu, Finland	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oulu; University of Oulu	Witztum, JL (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jwitztum@ucsd.edu	Palinski, Wulf/AAW-8032-2021	Goodyear, Carl/0000-0001-5926-5941; Silverman, Gregg/0000-0001-9480-9457; Palinski, Wulf/0000-0002-5113-0169; Binder, Christoph J./0000-0001-8313-7050	NHLBI NIH HHS [HL6946, HL57505, HL56989] Funding Source: Medline; NIAID NIH HHS [AI40305] Funding Source: Medline; NIAMS NIH HHS [P30 AR47360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057505, P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177; BROWN M, 1984, J IMMUNOL, V132, P1323; Caligiuri G, 2002, J CLIN INVEST, V109, P745, DOI 10.1172/JCI200207272; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; DESAYMARD C, 1984, MOL IMMUNOL, V21, P961, DOI 10.1016/0161-5890(84)90154-8; Freigang S, 1998, ARTERIOSCL THROM VAS, V18, P1972, DOI 10.1161/01.ATV.18.12.1972; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; HALPERN R, 1991, J CLIN INVEST, V88, P476, DOI 10.1172/JCI115328; Hansen PR, 2001, ATHEROSCLEROSIS, V158, P87, DOI 10.1016/S0021-9150(01)00418-X; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Horkko S, 1997, P NATL ACAD SCI USA, V94, P10356, DOI 10.1073/pnas.94.19.10356; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; KEARNEY JF, 1981, EUR J IMMUNOL, V11, P877, DOI 10.1002/eji.1830111106; KENNY JJ, 1992, J EXP MED, V176, P1637, DOI 10.1084/jem.176.6.1637; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; MASMOUDI H, 1990, INT IMMUNOL, V2, P515, DOI 10.1093/intimm/2.6.515; Mi QS, 2000, P NATL ACAD SCI USA, V97, P6031, DOI 10.1073/pnas.110039497; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; Reid RR, 1997, J IMMUNOL, V159, P970; Schenkein HA, 2001, INFECT IMMUN, V69, P6612, DOI 10.1128/IAI.69.11.6612-6617.2001; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Silverman GJ, 2000, J EXP MED, V192, P87, DOI 10.1084/jem.192.1.87; Silverman GJ, 1998, J IMMUNOL, V161, P5720; Silverman GJ, 2000, CURR TOP MICROBIOL, V252, P189; Snapper CM, 2001, TRENDS IMMUNOL, V22, P308, DOI 10.1016/S1471-4906(01)01926-3; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Wardemann H, 2002, J EXP MED, V195, P771, DOI 10.1084/jem.20011140; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	45	562	590	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					736	743		10.1038/nm876	http://dx.doi.org/10.1038/nm876			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740573				2022-12-25	WOS:000183444100029
J	Huang, E; Ishida, S; Pittman, J; Dressman, H; Bild, A; Kloos, M; D'Amico, M; Pestell, RG; West, M; Nevins, JR				Huang, E; Ishida, S; Pittman, J; Dressman, H; Bild, A; Kloos, M; D'Amico, M; Pestell, RG; West, M; Nevins, JR			Gene expression phenotypic models that predict the activity of oncogenic pathways	NATURE GENETICS			English	Article							BREAST-CANCER; E2F; PROTEINS; GROWTH	High-density DNA microarrays measure expression of large numbers of genes in one assay. The ability to find underlying structure in complex gene expression data sets and rigorously test association of that structure with biological conditions is essential to developing multi-faceted views of the gene activity that defines cellular phenotype. We sought to connect features of gene expression data with biological hypotheses by integrating metagene patterns from DNA microarray experiments in the characterization and prediction of oncogenic phenotypes. We applied these techniques to the analysis of regulatory pathways controlled by the genes HRAS (Harvey rat sarcoma viral oncogene homolog), MYC (myelocytomatosis viral oncogene homolog) and E2F1, E2F2 and E2F3 (encoding E2F transcription factors 1, 2 and 3, respectively). The phenotypic models accurately predict the activity of these pathways in the context of normal cell proliferation. Moreover, the metagene models trained with gene expression patterns evoked by ectopic production of Myc or Ras proteins in primary tissue culture cells properly predict the activity of in vivo tumor models that result from deregulation of the MYC or HRAS pathways. We conclude that these gene expression phenotypes have the potential to characterize the complex genetic alterations that typify the neoplastic state, whether in vitro or in vivo, in a way that truly reflects the complexity of the regulatory pathways that are affected.	Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Computat & Appl Genom Program, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27710 USA; Duke Univ, Ctr Genome Technol, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Georgetown University; Duke University; Howard Hughes Medical Institute	Nevins, JR (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.		Huang, Erich/B-1894-2008	Huang, Erich/0000-0001-5547-9408; Clarke, Jennifer/0000-0002-2723-7249				Bearss DJ, 2002, CANCER RES, V62, P2077; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	14	195	206	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					226	230		10.1038/ng1167	http://dx.doi.org/10.1038/ng1167			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12754511				2022-12-25	WOS:000183200500032
J	Gill, SS; Patel, NK; Hotton, GR; O'Sullivan, K; McCarter, R; Bunnage, M; Brooks, DJ; Svendsen, CN; Heywood, P				Gill, SS; Patel, NK; Hotton, GR; O'Sullivan, K; McCarter, R; Bunnage, M; Brooks, DJ; Svendsen, CN; Heywood, P			Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease	NATURE MEDICINE			English	Article							F-18 DOPA-PET; DOPAMINERGIC-NEURONS; IN-VIVO; GDNF; DELIVERY; NEUROPROTECTION; TRANSPLANTATION; PROGRESSION; MIDBRAIN; SURVIVAL	Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor with restorative effects in a wide variety of rodent and primate models of Parkinson disease, but penetration into brain tissue from either the blood or the cerebro-spinal fluid is limited. Here we delivered GDNF directly into the putamen of five Parkinson patients in a phase 1 safety trial. One catheter needed to be repositioned and there were changes in the magnetic resonance images that disappeared after lowering the concentration of GDNF. After one year, there were no serious clinical side effects, a 39% improvement in the off-medication motor sub-score of the Unified Parkinson's Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub-score. Medication-induced dyskinesias were reduced by 64% and were not observed off medication during chronic GDNF delivery. Positron emission tomography (PET) scans of [F-18] dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, suggesting a direct effect of GDNF on dopamine function. This study warrants careful examination of GDNF as a treatment for Parkinson disease.	Frenchay Hosp, Inst Neurosci, Bristol BS16 1LE, Avon, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, MRC,Clin Sci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Div Neurosci, London, England; Univ Wisconsin, Waisman Ctr, Stem Cell Res Program, Madison, WI 53705 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA	Imperial College London; Imperial College London; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gill, SS (corresponding author), Frenchay Hosp, Inst Neurosci, Bristol BS16 1LE, Avon, England.	steven.gill@north-bristol.swest.nhs.uk; svendsen@waisman.wisc.edu		Brooks, David/0000-0003-2602-2518; Patel, Nikunj/0000-0001-5438-2356				Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Beck M, 2001, AMYOTROPH LATERAL SC, V2, pS55, DOI 10.1080/146608201300079454; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; BROOKS DJ, 1990, BRAIN, V113, P1539, DOI 10.1093/brain/113.5.1539; DANIEL SE, 1992, LANCET, V340, P186, DOI 10.1016/0140-6736(92)93275-R; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gash DM, 1998, ANN NEUROL, V44, pS121, DOI 10.1002/ana.410440718; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hoffman AF, 1997, EXP NEUROL, V147, P130, DOI 10.1006/exnr.1997.6571; Kordower JH, 1999, ANN NEUROL, V46, P419, DOI 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Kordower JH, 1999, EXP NEUROL, V159, P4, DOI 10.1006/exnr.1999.7156; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindvall O, 2000, Prog Brain Res, V127, P299; McCarter RJ, 2000, J NEUROL NEUROSUR PS, V69, P60, DOI 10.1136/jnnp.69.1.60; Miyoshi Y, 1997, ANN NEUROL, V42, P208, DOI 10.1002/ana.410420212; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PETO V, 1995, QUAL LIFE RES, V4, P241, DOI 10.1007/BF02260863; QUINN NP, 1987, J NEUROL NEUROSUR PS, V50, P88, DOI 10.1136/jnnp.50.1.88; Rakshi JS, 1999, BRAIN, V122, P1637, DOI 10.1093/brain/122.9.1637; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Whone AL, 2002, NEUROLOGY, V58, pA82; Zurn AD, 2001, BRAIN RES REV, V36, P222, DOI 10.1016/S0165-0173(01)00098-4	37	967	1138	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					589	595		10.1038/nm850	http://dx.doi.org/10.1038/nm850			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669033				2022-12-25	WOS:000182610600041
J	Jamain, S; Quach, H; Betancur, C; Rastam, M; Colineaux, C; Gillberg, IC; Soderstrom, H; Giros, B; Leboyer, M; Gillberg, C; Bourgeron, T; Gillberg, C; Rastam, M; Gillberg, C; Nyden, A; Soderstrom, H; Leboyer, M; Betancur, C; Philippe, A; Giros, B; Colineaux, C; Cohen, D; Chabane, N; Mouren-Simeoni, MC; Brice, A; Sponheim, E; Spurkland, I; Skjeldal, OH; Coleman, M; Pearl, PL; Cohen, IL; Tsiouris, J; Zappella, M; Menchetti, G; Pompella, A; Aschauer, H; Van Maldergem, L				Jamain, S; Quach, H; Betancur, C; Rastam, M; Colineaux, C; Gillberg, IC; Soderstrom, H; Giros, B; Leboyer, M; Gillberg, C; Bourgeron, T; Gillberg, C; Rastam, M; Gillberg, C; Nyden, A; Soderstrom, H; Leboyer, M; Betancur, C; Philippe, A; Giros, B; Colineaux, C; Cohen, D; Chabane, N; Mouren-Simeoni, MC; Brice, A; Sponheim, E; Spurkland, I; Skjeldal, OH; Coleman, M; Pearl, PL; Cohen, IL; Tsiouris, J; Zappella, M; Menchetti, G; Pompella, A; Aschauer, H; Van Maldergem, L		Paris Autism Res Int Sibpair Study	Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism	NATURE GENETICS			English	Article							BINDING; EXPRESSION; DISORDERS	Many studies have supported a genetic etiology for autism. Here we report Mutations in two X-linked genes encoding neuroligins NLGN3 and NLGN4 in siblings with autism-spectrum disorders. These mutations affect cell-adhesion molecules localized at the synapse and suggest that a defect of synaptogenesis may predispose to autism.	Univ Paris 07, Lab Genet Humaine & Fonct Cognit, INSERM, E0021,Inst Pasteur, F-75015 Paris, France; Univ Paris 12, INSERM, U513, Fac Med, F-94000 Creteil, France; Univ Gothenburg, Dept Child & Adolescent Psychiat, S-41119 Gothenburg, Sweden; Hop Robert Debre, Dept Child & Adolescent Psychiat, F-75019 Paris, France; Hop Albert Chenevier & Henri Mondor, Dept Psychiat, F-94000 Creteil, France; Univ London St Georges Hosp, Sch Med, London 5W17 ORE, England; Gothenburg Univ, Dept Child & Adolescent Psychiat, Gothenburg, Sweden; Hop Albert Chenevier & Henri Mondor, Dept Psychiat, Creteil, France; INSERM, U513, Fac Med, Creteil, France; Hop Robert Debre, Serv Psychopathol Enfant & Adolescent, Paris, France; Hop La Pitie Salpetriere, INSERM, U289, Paris, France; Univ Oslo, Ctr Child & Adolescent Psychiat, Oslo, Norway; Univ Oslo, Rikshosp, Dept Pediat, Oslo, Norway; Georgetown Univ, Sch Med, Dept Pediat, Washington, DC 20007 USA; George Washington Univ, Childrens Natl Med Ctr, Sch Med, Washington, DC USA; New York State Inst Basic Res Dev Disabil, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA; Azienda Osped Senese, Div Neuropsichiatria Infantile, Siena, Italy; Univ Hosp, Dept Gen Psychiat, Vienna, Austria; Inst Pathol & Genet, Ctr Genet Humaine, Gerpinnes, Loverval, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Gothenburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; St Georges University London; University of Gothenburg; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Oslo; University of Oslo; National Hospital Norway; Georgetown University; Children's National Health System; George Washington University; Institute for Basic Research in Developmental Disabilities; University of Siena; University Hospital of Siena; University Hospital Vienna	Bourgeron, T (corresponding author), Univ Paris 07, Lab Genet Humaine & Fonct Cognit, INSERM, E0021,Inst Pasteur, F-75015 Paris, France.	thomasb@pasteur.fr	Betancur, Catalina/K-3791-2017; Van Maldergem, Lionel/G-9849-2017; Anckarsater, Henrik/C-2244-2009; GIROS, Bruno/ABD-5790-2021; Jamain, Stéphane/L-1822-2019; Leboyer, Marion/AAW-3648-2021; brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; Aschauer, Harald/G-8850-2016; Jamain, Stéphane/P-3710-2017; Van Maldergem, Lionel/O-3242-2019	Betancur, Catalina/0000-0002-3327-4804; Van Maldergem, Lionel/0000-0001-8880-5214; GIROS, Bruno/0000-0001-5876-9822; Leboyer, Marion/0000-0001-5473-3697; brice, alexis/0000-0002-0941-3990; Aschauer, Harald/0000-0002-4449-372X; Jamain, Stéphane/0000-0002-4321-4100; Van Maldergem, Lionel/0000-0001-8880-5214; Bourgeron, Thomas/0000-0001-8164-9220; Quach, Helene/0000-0002-3493-0973				American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.; Auranen M, 2002, AM J HUM GENET, V71, P777, DOI 10.1086/342720; Bolliger MF, 2001, BIOCHEM J, V356, P581, DOI 10.1042/0264-6021:3560581; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Gillberg C, 1998, BRIT J PSYCHIAT, V172, P200, DOI 10.1192/bjp.172.3.200; Gillberg C, 1998, J AUTISM DEV DISORD, V28, P415, DOI 10.1023/A:1026004505764; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; Jamain S, 2002, MOL PSYCHIATR, V7, P302, DOI 10.1038/sj.mp.4000979; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Philibert RA, 2000, GENE, V246, P303, DOI 10.1016/S0378-1119(00)00049-4; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shao YJ, 2002, AM J MED GENET, V114, P99, DOI 10.1002/ajmg.10153; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Thomas NS, 1999, HUM GENET, V104, P43, DOI 10.1007/s004390050908; Tsigelny I, 2000, PROTEIN SCI, V9, P180	15	1263	1326	3	193	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2003	34	1					27	29		10.1038/ng1136	http://dx.doi.org/10.1038/ng1136			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12669065	Green Submitted, Green Accepted			2022-12-25	WOS:000182667900011
J	Pomerening, JR; Sontag, ED; Ferrell, JE				Pomerening, JR; Sontag, ED; Ferrell, JE			Building a cell cycle oscillator: hysteresis and bistability in the activation of Cdc2	NATURE CELL BIOLOGY			English	Article							XENOPUS EGGS; KINASE PLX1; MODEL; EXTRACTS; PROTEIN; OOCYTES; PHOSPHORYLATION; AMPLIFICATION; MATURATION; MECHANISMS	In the early embryonic cell cycle, Cdc2-cyclin B functions like an autonomous oscillator, whose robust biochemical rhythm continues even when DNA replication or mitosis is blocked(1). At the core of the oscillator is a negative feedback loop; cyclins accumulate and produce active mitotic Cdc2-cyclin B-2,B-3; Cdc2 activates the anaphase-promoting complex (APC); the APC then promotes cyclin degradation and resets Cdc2 to its inactive, interphase state. Cdc2 regulation also involves positive feedback 4, with active Cdc2-cyclin B stimulating its activator Cdc25 (refs 5-7) and inactivating its inhibitors Wee1 and Myt1 (refs 8-11). Under the correct circumstances, these positive feedback loops could function as a bistable trigger for MitoSiS(12,13), and oscillators with bistable triggers may be particularly relevant to biological applications such as cell cycle regulation(14-17). Therefore, we examined whether Cdc2 activation is bistable. We confirm that the response of Cdc2 to non-degradable cyclin B is temporally abrupt and switch-like, as would be expected if Cdc2 activation were bistable. We also show that Cdc2 activation exhibits hysteresis, a property of bistable systems with particular relevance to biochemical oscillators. These findings help establish the basic systems-level logic of the mitotic oscillator.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Rutgers State Univ, Dept Math, New Brunswick, NJ 08903 USA	Stanford University; Rutgers State University New Brunswick	Pomerening, JR (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Sontag, Eduardo D/J-4420-2012	Sontag, Eduardo D/0000-0001-8020-5783; Pomerening, Joseph/0000-0003-4120-9081	NIGMS NIH HHS [GM61276, GM46383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; McMillen D, 2002, P NATL ACAD SCI USA, V99, P679, DOI 10.1073/pnas.022642299; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NOVAK B, 1993, J CELL SCI, V106, P1153; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; REYNHOUT JK, 1974, DEV BIOL, V38, P394, DOI 10.1016/0012-1606(74)90016-5; SCHORDERET-SLATKINE S, 1972, Cell Differentiation, V1, P179, DOI 10.1016/0045-6039(72)90027-9; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; Tyson JJ, 2002, BIOESSAYS, V24, P1095, DOI 10.1002/bies.10191; Vilar JMG, 2002, P NATL ACAD SCI USA, V99, P5988, DOI 10.1073/pnas.092133899	30	554	560	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					346	351		10.1038/ncb954	http://dx.doi.org/10.1038/ncb954			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12629549				2022-12-25	WOS:000182080700019
J	Hemann, MT; Fridman, JS; Zilfou, JT; Hernando, E; Paddison, PJ; Cordon-Cardo, C; Hannon, GJ; Lowe, SW				Hemann, MT; Fridman, JS; Zilfou, JT; Hernando, E; Paddison, PJ; Cordon-Cardo, C; Hannon, GJ; Lowe, SW			An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo	NATURE GENETICS			English	Article							C-ELEGANS; INTERFERENCE; SUPPRESSION; CANCER; MOUSE; GENES; DICER	The application of RNA interference (RNAi) to mammalian systems has the potential to revolutionize genetics and produce novel therapies. Here we investigate whether RNAi applied to a well-characterized gene can stably suppress gene expression in hematopoietic stem cells and produce detectable phenotypes in mice. Deletion of the Trp53 tumor suppressor gene greatly accelerates Myc-induced lymphomagenesis, resulting in highly disseminated disease(1,2). To determine whether RNAi suppression of Trp53 could produce a similar phenotype, we introduced several Trp53 short hairpin RNAs (shRNAs) into hematopoietic stem cells derived from Emu-Myc transgenic mice, and monitored tumor onset and overall pathology in lethally irradiated recipients. Different Trp53 shRNAs produced distinct phenotypes in vivo, ranging from benign lymphoid hyperplasias to highly disseminated lymphomas that paralleled Trp53(-/-) lymphomagenesis in the Emu-Myc mouse. In all cases, the severity and type of disease correlated with the extent to which specific shRNAs inhibited p53 activity. Therefore, RNAi can stably suppress gene expression in stem cells and reconstituted organs derived from those cells. In addition, intrinsic differences between individual shRNA expression vectors targeting the same gene can be used to create an 'epi-allelic series' for dissecting gene function in vivo.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Cold Spring Harbor Laboratory; Memorial Sloan Kettering Cancer Center	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, POB 100, Cold Spring Harbor, NY 11724 USA.		Hannon, Gregory/AAB-3568-2019	Hernando, Eva/0000-0003-1023-0312	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; McCurrach ME, 2001, METHOD CELL BIOL, V66, P197; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	14	286	339	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					396	400		10.1038/ng1091	http://dx.doi.org/10.1038/ng1091			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12567186				2022-12-25	WOS:000181312700018
J	Arkhipova, IR; Pyatkov, KI; Meselson, M; Evgen'ev, MB				Arkhipova, IR; Pyatkov, KI; Meselson, M; Evgen'ev, MB			Retroelements containing introns in diverse invertebrate taxa	NATURE GENETICS			English	Article							TRANSPOSABLE ELEMENTS; DROSOPHILA-VIRILIS; RETROTRANSPOSITION; PENELOPE; TELOMERASE; EVOLUTION	We report that two structurally similar transposable elements containing reverse transcriptase (RT), Penelope in Drosophila virilis and Athena in bdelloid rotifers, have proliferated as copies containing introns. The ability of Penelope-like elements (PLEs) to retain introns, their separate phylogenetic placement and their peculiar structural features make them a novel class of eukaryotic retroelements.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Inst Cell Biophys, Pushchino, Russia; Inst Mol Biol, Moscow, Russia	Harvard University; Russian Academy of Sciences; Institute of Cell Biophysics RAS	Meselson, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	msm@wjh.harvard.edu		Arkhipova, Irina/0000-0002-4805-1339				Arkhipova I, 2000, P NATL ACAD SCI USA, V97, P14473, DOI 10.1073/pnas.97.26.14473; ARKHIPOVA IR, 1995, GENETICS, V139, P1359; Belfort M, 2002, MOBILE DNA; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Evgenev MB, 1997, P NATL ACAD SCI USA, V94, P196, DOI 10.1073/pnas.94.1.196; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Lyozin GT, 2001, J MOL EVOL, V52, P445, DOI 10.1007/s002390010174; Moore M. J., 1993, RNA WORLD; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nogare DED, 2002, MOL BIOL EVOL, V19, P247, DOI 10.1093/oxfordjournals.molbev.a004078; Volff JN, 2001, MOL GENET GENOMICS, V265, P711, DOI 10.1007/s004380100468; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211	15	99	103	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2003	33	2					123	124		10.1038/ng1074	http://dx.doi.org/10.1038/ng1074			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12524543				2022-12-25	WOS:000180773700007
J	Zhang, Q; Zhao, BH; Li, W; Oiso, N; Novak, EK; Rusiniak, ME; Gautam, R; Chintala, S; O'Brien, EP; Zhang, Y; Roe, BA; Elliott, RW; Eicher, EM; Liang, P; Kratz, C; Legius, E; Spritz, RA; O'Sullivan, TN; Copeland, NG; Jenkins, NA; Swank, RT				Zhang, Q; Zhao, BH; Li, W; Oiso, N; Novak, EK; Rusiniak, ME; Gautam, R; Chintala, S; O'Brien, EP; Zhang, Y; Roe, BA; Elliott, RW; Eicher, EM; Liang, P; Kratz, C; Legius, E; Spritz, RA; O'Sullivan, TN; Copeland, NG; Jenkins, NA; Swank, RT			Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6	NATURE GENETICS			English	Article							STORAGE POOL DEFICIENCY; PALE EAR EP; MUTATIONS; TRAFFICKING; MELANOSOMES; BIOGENESIS; DISORDERS; TRANSPORT; PROTEINS; ADAPTER	Hermansky-Pudlak syndrome (HPS) is a genetically heterogeneous disease involving abnormalities of melanosomes, platelet dense granules and lysosomes. Here we have used positional candidate and transgenic rescue approaches to identify the genes mutated in ruby-eye 2 and ruby-eye mice (ru2 and ru, respectively), two 'mimic' mouse models of HPS. We also show that these genes are orthologs of the genes mutated in individuals with HPS types 5 and 6, respectively, and that their protein products directly interact. Both genes are previously unknown and are found only in higher eukaryotes, and together represent a new class of genes that have evolved in higher organisms to govern the synthesis of highly specialized lysosome-related organelles.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Dusseldorf, Klin Padiat Hamatol & Onkol, D-4000 Dusseldorf, Germany; Univ Ziekenhuizen Leuven, Ctr Human Genet, Louvain, Belgium; Natl Canc Inst, Mouse Canc Genet Program, Frederick, MD USA	Roswell Park Cancer Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Oklahoma System; University of Oklahoma - Norman; Jackson Laboratory; Roswell Park Cancer Institute; Heinrich Heine University Dusseldorf; KU Leuven; University Hospital Leuven; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Swank, RT (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.		Oiso, Naoki/H-6540-2019; Legius, Eric/H-1735-2011; Liang, Ping/D-2709-2009; Liang, Ping/S-3790-2018; Kratz, Christian/AAC-9726-2021	Oiso, Naoki/0000-0001-5593-6496; Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636; 				Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; CHISSOE SL, 1991, METHODS COMPANION ME, V3; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; DUNN LC, 1945, P NATL ACAD SCI USA, V31, P343, DOI 10.1073/pnas.31.11.343; EICHER EM, 1969, GENETICS, V64, P495; EICHER EM, 1977, MOUSE NEWS LETT, V56, P42; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Feng LJ, 2002, BLOOD, V99, P1651, DOI 10.1182/blood.V99.5.1651.h8001651_1651_1658; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lee ST, 1995, MOL CELLS, V5, P668; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; MOORE KJ, 1990, GENETICS, V125, P421; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; NOVAK EK, 1984, BLOOD, V63, P536; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; NOVAK EK, 1980, BIOCHEM GENET, V18, P549, DOI 10.1007/BF00484401; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; OBRIEN EP, 1994, MAMM GENOME, V5, P356, DOI 10.1007/BF00356554; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; RUSSELL LB, 1995, GENETICS, V141, P1547; SILVERS WK, 1979, COAT COLORS MICE MOD, P103; Spritz RA, 1999, CLIN GENET, V55, P309, DOI 10.1034/j.1399-0004.1999.550503.x; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; SUZUKI T, IN PRESS P NATL ACAD; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; [No title captured]	42	137	146	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					145	153		10.1038/ng1087	http://dx.doi.org/10.1038/ng1087			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12548288				2022-12-25	WOS:000180773700011
J	Huo, YQ; Schober, A; Forlow, SB; Smith, DF; Hyman, MC; Jung, S; Littman, DR; Weber, C; Ley, K				Huo, YQ; Schober, A; Forlow, SB; Smith, DF; Hyman, MC; Jung, S; Littman, DR; Weber, C; Ley, K			Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E	NATURE MEDICINE			English	Article							CELL-ADHESION MOLECULE-1; P-SELECTIN; INTEGRIN AFFINITY; LESION FORMATION; IN-VIVO; RECEPTOR; DEPOSITION; CHEMOKINES; ARREST; THROMBOCYTOPENIA	We studied whether circulating activated platelets and platelet-leukocyte aggregates cause the development of atherosclerotic lesions in apolipoprotein-E-deficient (Apoe(-/-)) mice. Circulating activated platelets bound to leukocytes, preferentially monocytes, to form platelet-monocyte/leukocyte aggregates. Activated platelets and platelet-leukocyte aggregates interacted with atherosclerotic lesions. The interactions of activated platelets with monocytes and atherosclerotic arteries led to delivery of the platelet-derived chemokines CCL5 (regulated on activation, normal T cell expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endothelium of atherosclerotic arteries. The presence of activated platelets promoted leukocyte binding of vascular cell adhesion molecule-1 (VCAM-1) and increased their adhesiveness to inflamed or atherosclerotic endothelium. Injection of activated wild-type, but not P-selectin-deficient, platelets increased monocyte arrest on the surface of atherosclerotic lesions and the size of atherosclerotic lesions in Apoe(-/-) mice. Our results indicate that circulating activated platelets and platelet-leukocyte/monocyte aggregates promote formation of atherosclerotic lesions. This role of activated platelets in atherosclerosis is attributed to platelet P-selectin-mediated delivery of platelet-derived proinflammatory factors to monocytes/leukocytes and the vessel wall.	Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA USA; Univ Hosp Aachen, Dept Mol Cardiovasc Res, Aachen, Germany; Skirball Inst Biomol Med, New York, NY USA; Howard Hughes Med Inst, New York, NY USA	University of Virginia; University of Virginia; RWTH Aachen University; RWTH Aachen University Hospital; Howard Hughes Medical Institute	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22903 USA.	klausley@virginia.edu	Schober, Andreas/B-2866-2013; Jung, Steffen/K-1409-2012; Weber, Christian/AAW-2153-2020	Schober, Andreas/0000-0001-7798-136X; Jung, Steffen/0000-0003-4290-5716; Weber, Christian/0000-0003-4610-8714; Smith, David/0000-0002-0048-4012; Hyman, Matthew/0000-0002-4050-6925	NHLBI NIH HHS [HL-58108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; BECKER RC, 1994, CORONARY ARTERY DIS, V5, P339, DOI 10.1097/00019501-199404000-00010; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Broijersen A, 1998, ATHEROSCLEROSIS, V137, P107, DOI 10.1016/S0021-9150(97)00260-8; Broijersen A, 1998, THROMB HAEMOSTASIS, V79, P268; BURGER PC, 2002, IN PRESS BLOOD; Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; Furman MI, 1998, J AM COLL CARDIOL, V31, P352, DOI 10.1016/S0735-1097(97)00510-X; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HAMBURGER SA, 1990, BLOOD, V75, P550; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Mannaioni PF, 1997, INFLAMM RES, V46, P4, DOI 10.1007/PL00000158; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MENDELSOHN ME, 1988, J CLIN INVEST, V81, P62, DOI 10.1172/JCI113311; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Newman PM, 2000, BLOOD, V96, P182, DOI 10.1182/blood.V96.1.182.013k18_182_187; NUNNARI JJ, 1989, EXP MOL PATHOL, V51, P1, DOI 10.1016/0014-4800(89)90002-6; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; RINDER CS, 1992, BLOOD, V79, P1201; RINDER HM, 1991, BLOOD, V78, P1760; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schober A, 2002, CIRCULATION, V106, P1523, DOI 10.1161/01.CIR.0000028590.02477.6F; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; Theilmeier G, 2002, BLOOD, V99, P4486, DOI 10.1182/blood.V99.12.4486; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	45	796	834	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					61	67		10.1038/nm810	http://dx.doi.org/10.1038/nm810			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483207				2022-12-25	WOS:000180209900023
J	Levine, MM				Levine, Myron M.			Can needle-free administration of vaccines become the norm in global immunization?	NATURE MEDICINE			English	Article							ORAL CHOLERA VACCINE; HEAT-LABILE TOXIN; ADP-RIBOSYLTRANSFERASE; INFLUENZA VACCINE; UNSAFE INJECTIONS; IMMUNOGENICITY; SAFETY; TRIVALENT; EFFICACY; CHILDREN	If vaccines could be administered without needles and syringes ('sharps'), immunization practice would become safer, more accepted and more suitable for mass use. The author explores the status of technologies that could achieve this aim and the barriers that must be overcome for their implementation.	[Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Levine, MM (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.	mlevine@medicine.umaryland.edu						Agren LC, 1999, J IMMUNOL, V162, P2432; American Academy of Family Physicians American Academy of Pediatrics Advisory Committee on Immunization Practices Public Health Service, 2000, MMWR-MORBID MORTAL W, V49, P631; AYLWARD B, 1995, B WORLD HEALTH ORGAN, V73, P531; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P631; Cooper PJ, 2000, J INFECT DIS, V182, P1199, DOI 10.1086/315837; Dilraj A, 2000, LANCET, V355, P798, DOI 10.1016/S0140-6736(99)95140-1; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; duChatelet IP, 1997, VACCINE, V15, P449, DOI 10.1016/S0264-410X(96)00173-9; Fernandez-de Castro J, 1997, Salud Publica Mex, V39, P53; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337; GOTUZZO E, 1993, INFECT IMMUN, V61, P3994, DOI 10.1128/IAI.61.9.3994-3997.1993; Guerena-Burgueno F, 2002, INFECT IMMUN, V70, P1874, DOI 10.1128/IAI.70.4.1874-1880.2002; HANLON P, 1987, LANCET, V1, P1342; HINGSON RA, 1963, MIL MED, V128, P516, DOI 10.1093/milmed/128.6.516; Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0; Jodar L, 2001, VACCINE, V19, P1594, DOI 10.1016/S0264-410X(00)00358-3; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; King JC, 1998, J INFECT DIS, V177, P1394, DOI 10.1086/517822; Lagos R, 1999, J INFECT DIS, V180, P1709, DOI 10.1086/315051; Levine MM, 1998, LANCET, V351, P1375, DOI 10.1016/S0140-6736(05)79439-3; Levine MM, 2002, BRIT MED BULL, V62, P1, DOI 10.1093/bmb/62.1.1; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5; Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Pasetti MF, 1999, CLIN IMMUNOL, V92, P76, DOI 10.1006/clim.1999.4733; Reis EC, 1998, PEDIATR ANN, V27, P375, DOI 10.3928/0090-4481-19980601-12; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; TACKET CO, 1994, VACCINE, V12, P1270, DOI 10.1016/S0264-410X(94)80038-2; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Tacket CO, 2000, CLIN IMMUNOL, V97, P146, DOI 10.1006/clim.2000.4924; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Yamamoto S, 1997, J EXP MED, V185, P1203, DOI 10.1084/jem.185.7.1203	41	114	119	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					99	103		10.1038/nm0103-99	http://dx.doi.org/10.1038/nm0103-99			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514720				2022-12-25	WOS:000208640400002
J	Ostertag, EM; DeBerardinis, RJ; Goodier, JL; Zhang, Y; Yang, N; Gerton, GL; Kazazian, HH				Ostertag, EM; DeBerardinis, RJ; Goodier, JL; Zhang, Y; Yang, N; Gerton, GL; Kazazian, HH			A mouse model of human L1 retrotransposition	NATURE GENETICS			English	Article							HIGH-FREQUENCY RETROTRANSPOSITION; SPERMATOGENIC CELLS; CULTURED-CELLS; LINE-1; GENE; EXPRESSION; ELEMENTS; SPECIFICITY; SEQUENCE; PROTEIN	The L1 retrotransposon has had an immense impact on the size and structure of the human genome through a variety of mechanisms, including insertional mutagenesis(1,2). To study retrotransposition in a living organism, we created a mouse model of human L1 retrotransposition. Here we show that L1 elements can retrotranspose in male germ cells, and that expression of a human L1 element under the control of its endogenous promoter is restricted to testis and ovary. In the mouse line with the highest level of L1 expression, we found two de novo L1 insertions in 135 offspring. Both insertions were structurally indistinguishable from natural endogenous insertions. This suggests that an individual L1 element can have substantial mutagenic potential. In addition to providing a valuable in vivo model of retrotransposition in mammals, these mice are an important step in the development of a new random mutagenesis system.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Kazazian, HH (corresponding author), Univ Penn, Sch Med, Dept Genet, 475 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	kazazian@mail.med.upenn.edu	Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640				Boissinot S, 2000, MOL BIOL EVOL, V17, P915, DOI 10.1093/oxfordjournals.molbev.a026372; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; Kimberland ML, 1999, HUM MOL GENET, V8, P1557, DOI 10.1093/hmg/8.8.1557; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li XM, 2001, HUM MUTAT, V17, P511, DOI 10.1002/humu.1134; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; Nakanishi T, 1999, FEBS LETT, V449, P277, DOI 10.1016/S0014-5793(99)00433-0; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; PADGETT RW, 1988, NUCLEIC ACIDS RES, V16, P739, DOI 10.1093/nar/16.2.739; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Steger K, 1999, ANAT EMBRYOL, V199, P471, DOI 10.1007/s004290050245; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; WELCH JE, 1992, BIOL REPROD, V46, P869, DOI 10.1095/biolreprod46.5.869	30	152	156	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					655	660		10.1038/ng1022	http://dx.doi.org/10.1038/ng1022			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12415270				2022-12-25	WOS:000179593000020
J	Harroch, S; Furtado, GC; Brueck, W; Rosenbluth, J; Lafaille, J; Chao, M; Buxbaum, JD; Schlessinger, J				Harroch, S; Furtado, GC; Brueck, W; Rosenbluth, J; Lafaille, J; Chao, M; Buxbaum, JD; Schlessinger, J			A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions	NATURE GENETICS			English	Article							MICE LACKING; RAT-BRAIN; RPTP-BETA; OLIGODENDROCYTE; DIFFERENTIATION; MYELINATION; SIGMA; GENE	Several lines of evidence suggest that tyrosine phosphorylation is a key element in myelin formation, differentiation of oligodendrocytes and Schwann cells, and recovery from demyelinating lesions(1-7). Multiple sclerosis is a demyelinating disease of the human central nervous system, and studies of experimental demyelination indicate that remyelination in vivo requires the local generation(8), migration or maturation 9 of new oligodendrocytes, or some combination of these. Failure of remyelination in multiple sclerosis could result from the failure of any of these processes or from the death of oligodendrocytes. Ptprz encodes protein tyrosine phosphatase receptor type Z (Ptpz, also designated Rptpbeta), which is expressed primarily in the nervous system but also in oligodendrocytes(10,11), astrocytes and neurons(12). Here we examine the susceptibility of mice deficient in Ptprz to experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. We observe that mice deficient in Ptprz show impaired recovery from EAE induced by myelin oligodendrocyte glycoprotein (MOG) peptide. This sustained paralysis is associated with increased apoptosis of mature oligodendrocytes in the spinal cords of mutant mice at the peak of inflammation. We further demonstrate that expression of PTPRZ1, the human homolog of Ptprz, is induced in multiple sclerosis lesions and that the gene is specifically expressed in remyelinating oligodendrocytes in these lesions. These results support a role for Ptprz in oligodendrocyte survival and in recovery from demyelinating disease.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA; Dept Neuropathol, Charite, Berlin, Germany; NYU, Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA; Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; Mt Sinai Sch Med, Dept Neurobiol, New York, NY USA	Yale University; New York University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; New York University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Harroch, S (corresponding author), Inst Pasteur, Unite Neurovirol & Regenerscence Syst Nerveux, 25 Rue Dr Roux, F-75724 Paris 15, France.		Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313; Chao, Moses/0000-0002-6969-3744				BREITSCHOPF H, 1992, ACTA NEUROPATHOL, V84, P581; Canoll PD, 1996, J NEUROSCI RES, V44, P199, DOI 10.1002/(SICI)1097-4547(19960501)44:3<199::AID-JNR1>3.0.CO;2-B; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Garratt AN, 2000, J CELL BIOL, V148, P1035, DOI 10.1083/jcb.148.5.1035; Harroch S, 2000, MOL CELL BIOL, V20, P7706, DOI 10.1128/MCB.20.20.7706-7715.2000; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; Liu X, 1998, GLIA, V24, P390, DOI 10.1002/(SICI)1098-1136(199812)24:4<390::AID-GLIA4>3.0.CO;2-1; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; Ranjan M, 1996, MOL CELL NEUROSCI, V7, P404, DOI 10.1006/mcne.1996.0029; Shintani T, 1998, NEUROSCI LETT, V247, P135, DOI 10.1016/S0304-3940(98)00295-X; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Umemori H, 1999, J NEUROSCI, V19, P1393; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866	17	113	118	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					411	414		10.1038/ng1004	http://dx.doi.org/10.1038/ng1004			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12355066				2022-12-25	WOS:000179034800018
J	Martin, N; Jaubert, J; Gounon, P; Salido, E; Haase, G; Szatanik, M; Guenet, JL				Martin, N; Jaubert, J; Gounon, P; Salido, E; Haase, G; Szatanik, M; Guenet, JL			A missense mutation in Tbce causes progressive motor neuronopathy in mice	NATURE GENETICS			English	Article							FISSION YEAST; TUBULIN; PROTEINS; DYNAMICS	Mice that are homozygous with respect to the progressive motor neuronopathy (pmn) mutation (chromosome 13) develop a progressive caudio-cranial degeneration of their motor axons from the age of two weeks and die four to six weeks after birth(1). The mutation is fully penetrant, and expressivity does not depend on the genetic background. Based on its pathological features, the pmn mutation has been considered an excellent model for the autosomal recessive proximal childhood form of spinal muscular atrophy (SMA). Previously, we demonstrated that the genes responsible for these disorders were not orthologous(2,3). Here, we identify the pmn mutation as resulting in a Trp524Gly substitution at the last residue of the tubulin-specific chaperone e (Tbce) protein that leads to decreased protein stability. Electron microscopy of the sciatic and phrenic nerves of affected mice showed a reduced number of microtubules, probably due to defective stabilization. Transgenic complementation with a wildtype Tbce cDNA restored a normal phenotype in mutant mice. Our observations indicate that Tbce is critical for the maintenance of microtubules in mouse motor axons, and suggest that altered function of tubulin cofactors might be implicated in human motor neuron diseases.	Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Inst Pasteur, Stn Cent Microscopie Elect, Paris, France; Hosp Univ Canarias, Unidad Invest, Tenerife, Spain; Univ Mediterranee, INSERM, CNRS, Inst Biol Dev Marseille, Marseille, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad de la Laguna; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Guenet, JL (corresponding author), Inst Pasteur, Unite Genet Mammiferes, 25 Rue Dr Roux, F-75724 Paris, France.		Salido, Eduardo C/I-2232-2015	Salido, Eduardo C/0000-0001-9599-9854				BRUNIALTI ALB, 1995, GENOMICS, V29, P131, DOI 10.1006/geno.1995.1223; Fleming JA, 2000, GENETICS, V156, P69; Grishchuk EL, 1999, J CELL SCI, V112, P1979; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hoyt MA, 1997, GENETICS, V146, P849; Hunter AW, 2000, J CELL SCI, V113, P4379; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Martin N, 2001, GENOMICS, V75, P9, DOI 10.1006/geno.2001.6595; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; Parvari R, 2002, NAT GENET, V32, P448, DOI 10.1038/ng1012; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Viollet L, 1997, GENOMICS, V40, P185, DOI 10.1006/geno.1996.4551	15	130	133	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					443	447		10.1038/ng1016	http://dx.doi.org/10.1038/ng1016			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12389029				2022-12-25	WOS:000179034800024
J	Kim, S; Nollen, EAA; Kitagawa, K; Bindokas, VP; Morimoto, RI				Kim, S; Nollen, EAA; Kitagawa, K; Bindokas, VP; Morimoto, RI			Polyglutamine protein aggregates are dynamic	NATURE CELL BIOLOGY			English	Article							MAMMALIAN-CELLS; LIVING CELLS; HD MUTATION; LOCALIZATION; CHAPERONE; BINDING; SUPPRESSION; COMPONENTS; INTERPHASE; APOPTOSIS	Protein aggregation and the formation of inclusion bodies are hallmarks of the cytopathology of neurodegenerative diseases, including Huntington's disease, Amyotropic lateral sclerosis, Parkinson's disease and Alzheimer's disease. The cellular toxicity associated with protein aggregates has been suggested to result from the sequestration of essential proteins that are involved in key cellular events, such as transcription, maintenance of cell shape and motility, protein folding and protein degradation. Here, we use fluorescence imaging of living cells to show that polyglutamine protein aggregates are dynamic structures in which glutamine-rich proteins are tightly associated, but which exhibit distinct biophysical interactions. In contrast, the interaction between wild-type, but not mutant, Hsp70 exhibits rapid kinetics of association and dissociation similar to interactions between Hsp70 and thermally unfolded substrates. These studies provide new insights into the composite organization and formation of protein aggregates and show that molecular chaperones are not sequestered into aggregates, but are instead transiently associated.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Osaka Univ, Sch Med, Dept Mol Pathol, Suita, Osaka 565, Japan; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60537 USA	Northwestern University; Osaka University; University of Chicago	Kim, S (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.				NIGMS NIH HHS [R37 GM038109] Funding Source: Medline; PHS HHS [38109] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANLUCK PK, 2002, SCIENCE, V295, P865; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; NAGLE JF, 1992, BIOPHYS J, V63, P366, DOI 10.1016/S0006-3495(92)81602-8; Nollen EAA, 2001, P NATL ACAD SCI USA, V98, P12038, DOI 10.1073/pnas.201112398; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Patterson GH, 1998, YEAST, V14, P813, DOI 10.1002/(SICI)1097-0061(19980630)14:9<813::AID-YEA280>3.0.CO;2-2; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	30	236	246	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2002	4	10					826	831		10.1038/ncb863	http://dx.doi.org/10.1038/ncb863			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	599CL	12360295				2022-12-25	WOS:000178316500022
J	Peng, JM; Schwartz, D; Elias, JE; Thoreen, CC; Cheng, DM; Marsischky, G; Roelofs, J; Finley, D; Gygi, SP				Peng, JM; Schwartz, D; Elias, JE; Thoreen, CC; Cheng, DM; Marsischky, G; Roelofs, J; Finley, D; Gygi, SP			A proteomics approach to understanding protein ubiquitination	NATURE BIOTECHNOLOGY			English	Article							DNA-REPAIR; CHROMATOGRAPHY; PROTEOLYSIS	There is a growing need for techniques that can identify and characterize protein modifications on a large or global scale. We report here a proteomics approach to enrich, recover, and identify ubiquitin conjugates from Saccharomyces cerevisiae lysate. Ubiquitin conjugates from a strain expressing 6xHis-tagged ubiquitin were isolated, proteolyzed with trypsin and analyzed by multidimensional liquid chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for amino acid sequence determination. We identified 1,075 proteins from the sample. In addition, we detected 110 precise ubiquitination sites present in 72 ubiquitin-protein conjugates. Finally, ubiquitin itself was found to be modified at seven lysine residues providing evidence for unexpected diversity in polyubiquitin chain topology in vivo. The methodology described here provides a general tool for the large-scale analysis and characterization of protein ubiquitination.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Mol Pharmacol & Biochem, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gygi, SP (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	steven_gygi@hms.harvard.edu	Roelofs, Jeroen/AAC-5119-2021; Peng, Junmin/N-2614-2018	Roelofs, Jeroen/0000-0003-0944-2465; Peng, Junmin/0000-0003-0472-7648	NHGRI NIH HHS [HG00041] Funding Source: Medline; NIGMS NIH HHS [GM67945, GM43601] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043601, R01GM067945, R37GM043601] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Finley D, 2001, NATURE, V412, P283, DOI 10.1038/35085671; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; GYGI MP, 2003, IN PRESS PROTEIN ANA; Gygi SP, 2002, J PROTEOME RES, V1, P47, DOI 10.1021/pr015509n; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	28	1225	1358	10	164	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					921	926		10.1038/nbt849	http://dx.doi.org/10.1038/nbt849			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12872131				2022-12-25	WOS:000184484600036
J	McGregor, L; Makela, V; Darling, SM; Vrontou, S; Chalepakis, G; Roberts, C; Smart, N; Rutland, P; Prescott, N; Hopkins, J; Bentley, E; Shaw, A; Roberts, E; Mueller, R; Jadeja, S; Philip, N; Nelson, J; Francannet, C; Perez-Aytes, A; Megarbane, A; Kerr, B; Wainwright, B; Woolf, AS; Winter, RM; Scambler, PJ				McGregor, L; Makela, V; Darling, SM; Vrontou, S; Chalepakis, G; Roberts, C; Smart, N; Rutland, P; Prescott, N; Hopkins, J; Bentley, E; Shaw, A; Roberts, E; Mueller, R; Jadeja, S; Philip, N; Nelson, J; Francannet, C; Perez-Aytes, A; Megarbane, A; Kerr, B; Wainwright, B; Woolf, AS; Winter, RM; Scambler, PJ			Fraser syndrome and mouse blebbed phenotype caused by mutations in FRAS1/Fras1 encoding a putative extracellular matrix protein	NATURE GENETICS			English	Article							RENAL DEVELOPMENT; DOMAINS; CRYPTOPHTHALMOS; MESENCHYME; BINDING; MODEL	Fraser syndrome (OMIM 219000) is a multisystem malformation usually comprising cryptophthalmos, syndactyly and renal defects(1). Here we report autozygosity mapping and show that the locus FS1 at chromosome 4q21 is associated with Fraser syndrome, although the condition is genetically heterogeneous. Mutation analysis identified five frameshift mutations in FRAS1, which encodes one member of a family of novel proteins related to an extracellular matrix (ECM) blastocoelar protein found in sea urchin. The FRAS1 protein contains a series of N-terminal cysteine-rich repeat motifs previously implicated in BMP metabolism, suggesting that it has a role in both structure and signal propagation in the ECM. It has been speculated that Fraser syndrome is a human equivalent of the blebbed phenotype in the mouse(2), which has been associated with mutations in at least five loci including bl(3). As mapping data were consistent with homology of FRAS1 and bl, we screened DNA from bl/bl mice and identified a premature termination of mouse Fras1. Thus, the bl mouse is a model for Fraser syndrome in humans, a disorder caused by disrupted epithelial integrity in utero.	Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Inst Child Hlth, Clin & Mol Genet Unit, London WC1N 1EH, England; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Univ Crete, Inst Mol Biol & Biotechnol, FORTH, Iraklion, Greece; Univ Crete, Dept Biol, Iraklion, Greece; St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Hosp Enfants Timone, Marseille, France; King Edward Mem Hosp Women, Perth, WA, Australia; Ctr Hosp Univ, Clermont Ferrand, France; Hosp Infantil La Fe, Valencia, Spain; Univ St Joseph, Beirut, Lebanon; St Marys Hosp, Manchester M13 0JH, Lancs, England; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Inst Child Hlth, Nephrourol Unit, London WC1N 1EH, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Crete; University of Crete; Saint James's University Hospital; University of Leeds; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; King Edward Memorial Hospital; University of Western Australia; CHU Clermont Ferrand; Saint Joseph University Beirut; University of Manchester; University of Queensland; University of London; University College London	Scambler, PJ (corresponding author), Inst Child Hlth, Mol Med Unit, 30 Guilford St, London WC1N 1EH, England.	pscamble@hgmp.mrc.ac.uk	Smart, Nicola/AAD-3874-2020; Scambler, Peter/AAZ-6026-2020; Megarbane, Andre/ABD-5574-2021; Philip, Nicole/I-2881-2016; Scambler, Peter J/C-4998-2008; Prescott, Natalie J/F-6490-2011; Smart, Nicola/AAN-4011-2020; Woolf, Adrian S./AAZ-1075-2020	Smart, Nicola/0000-0002-3501-7254; Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Prescott, Natalie J/0000-0002-5901-7371; Woolf, Adrian S./0000-0001-5541-1358; Wainwright, Brandon/0000-0003-0406-2092; Perez-Aytes, Antonio/0000-0003-3401-6943				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arin MJ, 2001, TRENDS MOL MED, V7, P422, DOI 10.1016/S1471-4914(01)02095-0; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Carter T. C., 1959, Journal of Genetics, V56, P401, DOI 10.1007/BF02984794; Center EM, 1997, HISTOL HISTOPATHOL, V12, P901; Conley CA, 2000, DEVELOPMENT, V127, P3947; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Darling S, 1994, Clin Dysmorphol, V3, P91; Davies JA, 2002, EXP NEPHROL, V10, P102; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Hodor PG, 2000, DEV BIOL, V222, P181, DOI 10.1006/dbio.2000.9696; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Matsui M, 2000, P NATL ACAD SCI USA, V97, P5291, DOI 10.1073/pnas.090020497; Mellerio JE, 1999, CLIN EXP DERMATOL, V24, P25; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; Nodder S, 1997, ANAT EMBRYOL, V195, P215, DOI 10.1007/s004290050041; ROBERTS C, 1991, DEVELOPMENT, V112, P959; Slavotinek AM, 2002, J MED GENET, V39, P623, DOI 10.1136/jmg.39.9.623; SORENSON CM, 1995, AM J PHYSIOL-RENAL, V268, pF73, DOI 10.1152/ajprenal.1995.268.1.F73; THOMAS IT, 1986, AM J MED GENET, V25, P85, DOI 10.1002/ajmg.1320250111; TIDMAN MJ, 1984, J INVEST DERMATOL, V83, P448, DOI 10.1111/1523-1747.ep12273562; Warkany J, 1944, P SOC EXP BIOL MED, V57, P49, DOI 10.3181/00379727-57-14695P; WINTER RM, 1990, CLIN GENET, V37, P494; Winyard PJD, 1996, KIDNEY INT, V49, P135, DOI 10.1038/ki.1996.18	27	172	178	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					203	208		10.1038/ng1142	http://dx.doi.org/10.1038/ng1142			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12766769				2022-12-25	WOS:000183200500028
J	Obici, S; Feng, ZH; Arduini, A; Conti, R; Rossetti, L				Obici, S; Feng, ZH; Arduini, A; Conti, R; Rossetti, L			Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production	NATURE MEDICINE			English	Article							FATTY-ACID; BODY-WEIGHT; GENE-EXPRESSION; LEPTIN; BRAIN; COA; CARBOXYLASE; PERFORMANCE; RECEPTOR; OBESITY	The enzyme carnitine palmitoyltransferase-1 (CPT1) regulates long-chain fatty acid (LCFA) entry into mitochondria, where the LCFAs undergo beta-oxidation. To investigate the mechanism(s) by which central metabolism of lipids can modulate energy balance, we selectively reduced lipid oxidation in the hypothalamus. We decreased the activity of CPT1 by administering to rats a ribozyme-containing plasmid designed specifically to decrease the expression of this enzyme or by infusing pharmacological inhibitors of its activity into the third cerebral ventricle. Either genetic or biochemical inhibition of hypothalamic CPT1 activity was sufficient to substantially diminish food intake and endogenous glucose production. These results indicated that changes in the rate of lipid oxidation in selective hypothalamic neurons signaled nutrient availability to the hypothalamus, which in turn modulated the exogenous and endogenous inputs of nutrients into the circulation.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10461 USA; Sigma Tau Pharmaceut Ind, Dept Endocrinol & Metab, I-00040 Pomezia, Italy	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Leadiant Biosciences	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu	Arduini, Arduino/ABH-5284-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048321, R29DK045024, R37DK048321, R01DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45024, DK48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; ARDUINI A, 1994, J NEUROCHEM, V62, P1530; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; ESSER V, 1993, J BIOL CHEM, V268, P5817; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GOTO M, 1971, P SOC EXP BIOL MED, V136, P1294; Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Kopelman PG, 1998, LANCET, V352, P5; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; Makimura H, 2001, DIABETES, V50, P733, DOI 10.2337/diabetes.50.4.733; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Zammit V.A., 1994, DIABETES REV, V2, P132	33	403	420	1	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					756	761		10.1038/nm873	http://dx.doi.org/10.1038/nm873			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754501				2022-12-25	WOS:000183444100032
J	Stocker, H; Radimerski, T; Schindelholz, B; Wittwer, F; Belawat, P; Daram, P; Breuer, S; Thomas, G; Hafen, E				Stocker, H; Radimerski, T; Schindelholz, B; Wittwer, F; Belawat, P; Daram, P; Breuer, S; Thomas, G; Hafen, E			Rheb is an essential regulator of S6K in controlling cell growth in Drosophila	NATURE CELL BIOLOGY			English	Article							INSULIN-RECEPTOR; ORGAN SIZE; PTEN; PROLIFERATION; TARGET; GENE; TSC; APOPTOSIS; HOMOLOGS; TUBERIN	Understanding the mechanisms through which multicellular organisms regulate cell, organ and body growth is of relevance to developmental biology and to research on growth-related diseases such as cancer. Here we describe a new effector in growth control, the small GTPase Rheb (Ras homologue enriched in brain). Mutations in the Drosophila melanogaster Rheb gene were isolated as growth-inhibitors, whereas overexpression of Rheb promoted cell growth. Our genetic and biochemical analyses suggest that Rheb functions downstream of the tumour suppressors Tsc1 (tuberous sclerosis 1)-Tsc2 in the TOR ( target of rapamycin) signalling pathway to control growth, and that a major effector of Rheb function is ribosomal S6 kinase (S6K).	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Genet Co Inc, CH-8952 Zurich, Switzerland	University of Zurich; Friedrich Miescher Institute for Biomedical Research	Hafen, E (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hafen@zool.unizh.ch	Thomas, George/K-9235-2014; Stoecker, Horst/F-8382-2012	Thomas, George/0000-0003-3518-8149; Stoecker, Horst/0000-0002-3282-3664				ANDJELKOVIC M, 1995, J BIOL CHEM, V270, P4066, DOI 10.1074/jbc.270.8.4066; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Huang H, 1999, DEVELOPMENT, V126, P5365; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Mach KE, 2000, GENETICS, V155, P611; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Nairz K, 2002, P NATL ACAD SCI USA, V99, P10575, DOI 10.1073/pnas.162136299; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Oldham S, 2002, DEVELOPMENT, V129, P4103; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	35	404	421	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					559	565		10.1038/ncb995	http://dx.doi.org/10.1038/ncb995			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12766775	Green Accepted			2022-12-25	WOS:000183202800018
J	Bossard, C; Laurell, H; Van den Berghe, L; Meunier, S; Zanibellato, C; Prats, H				Bossard, C; Laurell, H; Van den Berghe, L; Meunier, S; Zanibellato, C; Prats, H			Translokin is an intracellular mediator of FGF-2 trafficking	NATURE CELL BIOLOGY			English	Article							FIBROBLAST-GROWTH-FACTOR; NUCLEAR ACCUMULATION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; BASIC FGF; FACTOR-II; PROTEIN; DIFFERENTIATION; TRANSLOCATION	Basic fibroblast growth factor (bFGF or FGF-2) exerts its pleiotropic activities both as an exogenous and an intracellular factor. FGF-1 and FGF-2 are prototypes for this dual signalling, but the mechanisms of their intracellular actions remain unknown. Here we show that Translokin, a cytoplasmic protein of relative molecular mass 55,000 (M-r 55K), interacts specifically with the 18K form of FGF-2. Translokin is ubiquitously expressed and colocalizes with the microtubular network. As Translokin does not interact with FGF-1, we used a strategy based on FGF-1-FGF-2 chimaeras to map the interacting regions in FGF-2 and to generate Nb1a2, a non-interacting variant of FGF-2. Although most of the FGF-2 properties are preserved in Nb1a2, this variant is defective in intracellular translocation and in stimulating proliferation. The fusion of a nuclear localization signal to Nb1a2 restores its mitogenic activity and its nuclear association. Inhibiting Translokin expression by RNA interference reduces the translocation of FGF-2 without affecting the intracellular trafficking of FGF-1. Our data show that the nuclear association of internalized FGF-2 is essential for its mitogenic activity and that Translokin is important in this translocation pathway.	CHU Rangueil, INSERM, U589, IFR 31,Inst Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, H (corresponding author), CHU Rangueil, INSERM, U589, IFR 31,Inst Louis Bugnard, Bat L3, F-31403 Toulouse 04, France.		Meunier, Sylvain/H-7078-2015; VAN DEN BERGHE, Loïc/X-6705-2019	Meunier, Sylvain/0000-0003-1696-9265; Prats, Herve/0000-0002-4861-2167; Laurell, Henrik/0000-0001-7328-935X				Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; Gleizes PE, 1996, EUR J CELL BIOL, V71, P144; Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Ornitz D.M., 2001, GENOME BIOL, V2; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PATRY V, 1994, GROWTH FACTORS, V11, P163, DOI 10.3109/08977199409046914; Patry V, 1997, BIOCHEM J, V326, P259, DOI 10.1042/bj3260259; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; REILAND J, 1993, J CELL SCI, V105, P1085; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Skjerpen CS, 2002, EMBO J, V21, P4058, DOI 10.1093/emboj/cdf402; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	33	62	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					433	439		10.1038/ncb979	http://dx.doi.org/10.1038/ncb979			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717444				2022-12-25	WOS:000182691400017
J	Chalhoub, N; Benachenhou, N; Rajapurohitam, V; Pata, M; Ferron, M; Frattini, A; Villa, A; Vacher, J				Chalhoub, N; Benachenhou, N; Rajapurohitam, V; Pata, M; Ferron, M; Frattini, A; Villa, A; Vacher, J			Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human	NATURE MEDICINE			English	Article							BONE-RESORPTION; TARGETED DISRUPTION; MICE; GENE; LOCALIZATION; DEFECTS; TRANSPLANTATION; DEFICIENCY; MEMBRANE; SUBUNIT	The spontaneous mouse grey-lethal (gl) mutation is responsible for a coat color defect and for the development of the most severe autosomal recessive form of osteopetrosis. Using a positional cloning approach, we have mapped and isolated the gl locus from a similar to1.5 cM genetic interval. The gl locus was identified in a bacterial artificial chromosome (BAC) contig by functional genetic complementation in transgenic mice. Genomic sequence analysis revealed that the gl mutation is a deletion resulting in complete loss of function. The unique similar to3 kb wild-type transcript is expressed primarily in osteoclasts and melanocytes as well as in brain, kidney, thymus and spleen. The gl gene is predicted to encode a 338-amino acid type I transmembrane protein that localizes to the intracellular compartment. Mutation in the human GL gene leads to severe recessive osteopetrosis. Our studies show that mouse Gl protein function is absolutely required for osteoclast and melanocyte maturation and function.	Univ Montreal, Inst Rech Clin Montreal, Fac Med, Montreal, PQ, Canada; CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Vacher, J (corresponding author), Univ Montreal, Inst Rech Clin Montreal, Fac Med, Montreal, PQ, Canada.	vacherj@ircm.qc.ca	Ferron, Mathieu/M-7794-2013; Frattini, Annalisa/B-7684-2015	Frattini, Annalisa/0000-0002-1166-3091; Villa, Anna/0000-0003-4428-9013				BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; Chalhoub N, 2001, MAMM GENOME, V12, P887, DOI 10.1007/s00335-001-1014-5; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Eapen M, 1998, BONE MARROW TRANSPL, V22, P941, DOI 10.1038/sj.bmt.1701474; EMERSON JA, 1992, DEV DYNAM, V195, P55, DOI 10.1002/aja.1001950106; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GERRITSEN EJA, 1994, J PEDIATR-US, V125, P896, DOI 10.1016/S0022-3476(05)82004-9; Gruneberg H, 1936, J HERED, V27, P105; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Marcinkiewicz M, 1998, MOL BRAIN RES, V59, P229, DOI 10.1016/S0169-328X(98)00141-7; Palokangas H, 1997, J CELL SCI, V110, P1767; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756-3282(01)00416-1; REEVES JD, 1979, PEDIATRICS, V64, P202; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Vacher J, 1999, MAMM GENOME, V10, P239, DOI 10.1007/s003359900980; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	40	197	204	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2003	9	4					399	406		10.1038/nm842	http://dx.doi.org/10.1038/nm842			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627228				2022-12-25	WOS:000181987400029
J	Kramer, J; Hawley, RS				Kramer, J; Hawley, RS			The spindle-associated transmembrane protein Axs identifies a membranous structure ensheathing the meiotic spindle	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; ACHIASMATE SEGREGATION; DROSOPHILA FEMALES; OOCYTE MATURATION; SPERMATOCYTES; BEHAVIOR; MEIOSIS; SYSTEM	Mutations in the aberrant X segragation (Axs) gene disrupt the segregation of achiasmate chromosomes during female meiosis in Drosophila melanogaster. We show that Axs encodes the founding member of an eukaryotic family of transmembrane proteins. Axs protein colocalizes with components of the endoplasmic reticulum and is present within a structure ensheathing the meiotic spindle. In both meiotic and mitotic cells, Axs is recruited to the microtubules of assembling spindles. We propose that Axs and the sheath represent novel mediators of meiotic spindle assembly and chromosome segregation.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Hawley, RS (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.			Hawley, R. Scott/0000-0002-6478-0494				Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HENSON JH, 1990, DEV BIOL, V142, P255, DOI 10.1016/0012-1606(90)90347-L; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Li KJ, 1998, J CELL BIOL, V141, P455, DOI 10.1083/jcb.141.2.455; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEHLMANN LM, 1995, DEV BIOL, V170, P607, DOI 10.1006/dbio.1995.1240; Terasaki M, 2001, MOL BIOL CELL, V12, P1103, DOI 10.1091/mbc.12.4.1103; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; WHYTE WL, 1993, GENETICS, V134, P825; WISE D, 1984, CHROMOSOMA, V90, P156, DOI 10.1007/BF00292453; WISE D, 1984, CHROMOSOMA, V90, P50, DOI 10.1007/BF00352278	12	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					261	263		10.1038/ncb944	http://dx.doi.org/10.1038/ncb944			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12646877				2022-12-25	WOS:000181322500021
J	Coronini, R; de Looze, MA; Puget, P; Bley, G; Ramani, SV				Coronini, R; de Looze, MA; Puget, P; Bley, G; Ramani, SV			Decoding the literature on genetic variation	NATURE BIOTECHNOLOGY			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS		Univ Pierre Mendes France, INRA, Grenoble, France; CEA, Lab Elect & Technol Informat, Grenoble, France	Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); INRAE; CEA	Coronini, R (corresponding author), Univ Pierre Mendes France, INRA, Grenoble, France.		Puget, Pierre/C-6921-2008					DELOOZE MA, 2001, INT J BIOTECHNOL, V3, P1; Drabek J, 2001, ELECTROPHORESIS, V22, P1024, DOI 10.1002/1522-2683()22:6<1024::AID-ELPS1024>3.0.CO;2-U; Gut IG, 2001, HUM MUTAT, V17, P475; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Saviotti PP, 2000, NAT BIOTECHNOL, V18, P1247, DOI 10.1038/82351; Syvanen AC, 2001, NAT REV GENET, V2, P930, DOI 10.1038/35103535	6	8	9	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2003	21	1					21	29		10.1038/nbt0103-21	http://dx.doi.org/10.1038/nbt0103-21			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	632DV	12511903				2022-12-25	WOS:000180209200011
J	Carroll, CW; Morgan, DO				Carroll, CW; Morgan, DO			The Doc1 subunit is a processivity factor for the anaphase-promoting complex	NATURE CELL BIOLOGY			English	Article							PROTEIN; UBIQUITIN; YEAST; APC11; PURIFICATION; CDC20; HCT1; BOX	Ubiquitin-mediated proteolysis of securin and mitotic cyclins is essential for exit from mitosis. The final step in ubiquitination of these and other proteins is catalysed by the anaphase-promoting complex (APC), a multi-subunit ubiquitin-protein ligase (H). Little is known about the molecular reaction resulting in APC-dependent substrate ubiquitination or the role of individual APC subunits in the reaction. Using a well-defined in vitro system, we show that highly purified APC from Saccharomyces cerevisiae ubiquitinates a model cyclin substrate in a processive manner. Analysis of mutant APC lacking the Doc1/Apc10 subunit (APC(doc1Delta)) indicates that Doc1 is required for processivity. The specific molecular defect in APC(doc1Delta) is identified by a large increase in apparent K-M for the cyclin substrate relative to the wild-type enzyme. This suggests that Doc1 stimulates processivity by limiting substrate dissociation. Addition of recombinant Doc1 to APC(doc1Delta) fully restores enzyme function. Doc1-related domains are found in mechanistically distinct ubiquitin-ligase enzymes and may generally stimulate ubiquitination by contributing to substrate-enzyme affinity.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Carroll, CW (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Morgan, David/0000-0001-8753-4416	NIGMS NIH HHS [GM53270, R01 GM053270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053270, R37GM053270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Au SWN, 2002, J MOL BIOL, V316, P955, DOI 10.1006/jmbi.2002.5399; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rose MD., 1990, METHODS YEAST GENETI; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784	25	112	116	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					880	887		10.1038/ncb871	http://dx.doi.org/10.1038/ncb871			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402045				2022-12-25	WOS:000179137700017
J	Fitzpatrick, GV; Soloway, PD; Higgins, MJ				Fitzpatrick, GV; Soloway, PD; Higgins, MJ			Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1	NATURE GENETICS			English	Article							BECKWITH-WIEDEMANN-SYNDROME; GENE-CLUSTER; CONTROL ELEMENT; MOUSE MODEL; EXPRESSION; P57(KIP2); DISRUPTION; DOMAIN; IGF2; H19	Genomic imprinting is an epigenetic modification that results in expression from only one of the two parental copies of a gene. Differences in methylation between the two parental chromosomes are often observed at or near imprinted genes. Beckwith-Wiedemann syndrome (BWS), which predisposes to cancer and excessive growth, results from a disruption of imprinted gene expression in chromosome band 11p15.5. One third of individuals with BWS lose maternal-specific methylation at KvDMR1, a putative imprinting control region within intron 10 of the KCNQ1 gene(1-3), and it has been proposed that this epimutation results in aberrant imprinting and, consequently, BWS1,2. Here we show that paternal inheritance of a deletion of KvDMR1 results in the de-repression in cis of six genes, including Cdkn1c, which encodes cyclin-dependent kinase inhibitor 1C. Furthermore, fetuses and adult mice that inherited the deletion from their fathers were 20-25% smaller than their wildtype littermates. By contrast, maternal inheritance of this deletion had no effect on imprinted gene expression or growth. Thus, the unmethylated paternal KvDMR1 allele regulates imprinted expression by silencing genes on the paternal chromosome. These findings support the hypothesis that loss of methylation in BWS patients activates the repressive function of KvDMR1 on the maternal chromosome, resulting in abnormal silencing of CDKN1C and the development of BWS.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Higgins, MJ (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.		Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437				Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Caspary T, 1999, GENE DEV, V13, P3115, DOI 10.1101/gad.13.23.3115; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691; Grandjean V, 2000, P NATL ACAD SCI USA, V97, P5279, DOI 10.1073/pnas.080409297; Hata K, 2002, DEVELOPMENT, V129, P1983; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; SINGERSAM J, 1994, PCR METH APPL, V3, pS48; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Srivastava M, 2000, GENE DEV, V14, P1186; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201	29	377	385	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					426	431		10.1038/ng988	http://dx.doi.org/10.1038/ng988			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12410230				2022-12-25	WOS:000179034800021
J	Wood, W; Jacinto, A; Grose, R; Woolner, S; Gale, J; Wilson, C; Martin, P				Wood, W; Jacinto, A; Grose, R; Woolner, S; Gale, J; Wilson, C; Martin, P			Wound healing recapitulates morphogenesis in Drosophila embryos	NATURE CELL BIOLOGY			English	Article							ACTIN STRESS FIBERS; DORSAL CLOSURE; EPITHELIAL MORPHOGENESIS; ADHERENS JUNCTIONS; DYNAMIC ANALYSIS; FUSION PROTEIN; SMALL GTPASES; RHO; MOVEMENT; LAMELLIPODIA	The capacity to repair a wound is a fundamental survival mechanism that is activated at any site of damage throughout embryonic and adult life(1). To study the cell biology and genetics of this process, we have developed a wounding model in Drosophila melanogaster embryos that allows live imaging of rearrangements and changes in cell shape, and of the cytoskeletal machinery that draws closed an in vivo wound. Using embryos expressing green fluorescent protein (GFP) fusion proteins, we show that two cytoskeletal-dependent elements - an actin cable and dynamic filopodial/lamellipodial protrusions - are expressed by epithelial cells at the wound edge and are pivotal for repair. Modulating the activities of the small GTPases Rho and Cdc42 demonstrates that these actin-dependent elements have differing cellular functions, but that either alone can drive wound closure. The actin cable operates as a 'purse-string' to draw the hole closed, whereas filopodia are essential for the final 'knitting' together of epithelial cells at the end of repair. Our data suggest a more complex model for epithelial repair than previously envisaged and highlight remarkable similarities with the well-characterized morphogenetic movement of dorsal closure in Drosophila.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Dept Physiol, London WC1E 6BT, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England	University of London; University College London; University of London; University College London; University of Oxford	Wood, W (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	paul.martin@ucl.ac.uk	Wood, William/A-4939-2012; Woolner, Sarah/N-2429-2016; Jacinto, Antonio/F-5729-2013; Gale, Jonathan/AAG-6874-2019	Wood, William/0000-0001-5485-0236; Jacinto, Antonio/0000-0002-4193-6089; Woolner, Sarah/0000-0001-5680-4030; Martin, Paul/0000-0002-2665-5086; Grose, Richard/0000-0002-4738-0173; Gale, Jonathan/0000-0003-4678-4878				BEMENT WM, 1993, J CELL BIOL, V121, P565, DOI 10.1083/jcb.121.3.565; Bloor JW, 2002, DEVELOPMENT, V129, P3173; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; Danjo Y, 1998, J CELL SCI, V111, P3323; FOE VE, 1989, DEVELOPMENT, V107, P1; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Harden N, 1999, J CELL SCI, V112, P273; Jacinto A, 2002, CURR BIOL, V12, P1245, DOI 10.1016/S0960-9822(02)00955-7; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Magie CR, 1999, DEVELOPMENT, V126, P5353; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MARTIN P, 1992, NATURE, V360, P179, DOI 10.1038/360179a0; Martinez Arias Alfonso, 1993, P517; Mizuno T, 2002, DEVELOPMENT, V129, P1215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oda H, 1999, DEV GENES EVOL, V209, P218, DOI 10.1007/s004270050246; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	29	306	308	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					907	912		10.1038/ncb875	http://dx.doi.org/10.1038/ncb875			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12402048				2022-12-25	WOS:000179137700021
J	Bridge, AJ; Pebernard, S; Ducraux, A; Nicoulaz, AL; Iggo, R				Bridge, AJ; Pebernard, S; Ducraux, A; Nicoulaz, AL; Iggo, R			Induction of an interferon response by RNAi vectors in mammalian cells	NATURE GENETICS			English	Article							EXPRESSION; VIRUS; GENE	DNA vectors that express short hairpin RNAs (shRNAs) from RNA polymerase III (Pol III) promoters are a promising new tool to reduce gene expression in mammalian cells. shRNAs are processed to small interfering RNAs (siRNAs) of 21 nucleotides (nt) that guide the cleavage of the cognate mRNA by the RNA-induced silencing complex. Although siRNAs are thought to be too short to induce interferon expression, we report here that a substantial number of shRNA vectors can trigger an interferon response.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, R (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Käser-Pébernard, Stéphanie GM/C-4219-2014; Iggo, Richard/G-3546-2014; Bridge, Alan/U-4209-2018	Käser-Pébernard, Stéphanie GM/0000-0002-6035-6979; Bridge, Alan/0000-0003-2148-9135				AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Yochum GS, 2002, MOL CELL BIOL, V22, P7868, DOI 10.1128/MCB.22.22.7868-7876.2002	6	790	882	1	31	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					263	264		10.1038/ng1173	http://dx.doi.org/10.1038/ng1173			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12796781				2022-12-25	WOS:000183815300011
J	De Palma, M; Venneri, MA; Roca, C; Naldini, L				De Palma, M; Venneri, MA; Roca, C; Naldini, L			Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells	NATURE MEDICINE			English	Letter							BONE-MARROW; LENTIVIRAL VECTORS; EXPRESSION; GROWTH; CANCER; MICE; MACROPHAGES; RECEPTOR; ORIGIN; MARKER	Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutics(1,2). The bone marrow contributes different cell types to the tumor stroma, including hematopoietic cells(3,4) and, as recently suggested, vascular endothelial cells (ECs)(5). Thus, transplantation of genetically modified bone marrow progenitors may represent a vehicle for the transport of gene therapy to tumors. We transduced bone marrow progenitors with lentiviral vectors expressing genes from transcription-regulatory elements of Tie2/Tek gene(6). When tumors were grown in the transplanted mice, the new vector marked a distinct hematopoietic population that 'homed' to the tumor and closely interacted with vascular ECs at the tumor periphery. These Tie2-expressing mononuclear (TEM) cells had a distinguishable phenotype and were present selectively at angiogenic sites. Unexpectedly, we did not find bone marrow-derived ECs in tumor vessels when we transplanted bone marrow progenitors constitutively expressing a marker gene from the Tie2 or ubiquitously active promoters. By delivering a 'suicide' gene, we selectively eliminated the TEM cells and achieved substantial inhibition of angiogenesis and slower tumor growth without systemic toxicity. Thus, TEM cells may account for the proangiogenic activity of bone marrow-derived cells in tumors, may represent a new target for drug development and may provide the means for selective gene delivery and targeted inhibition of tumor angiogenesis.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Gene Transfer & Therapy, I-10060 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Div Mol Angiogenesis, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy, HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.		De Palma, Michele/L-5350-2016; Naldini, Luigi/E-9083-2012	De Palma, Michele/0000-0001-9128-5459; NALDINI, Luigi/0000-0002-7835-527X; VENNERI, MARY ANNA/0000-0002-0687-8135	Telethon [A.143] Funding Source: Medline	Telethon(Fondazione Telethon)		Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Follenzi A, 2002, HUM GENE THER, V13, P243, DOI 10.1089/10430340252769770; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; JONES SE, 1967, INT J NONLIN MECH, V2, P257; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tanaka S, 2002, HEPATOLOGY, V35, P861, DOI 10.1053/jhep.2002.32535	25	444	466	3	38	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					789	795		10.1038/nm871	http://dx.doi.org/10.1038/nm871			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740570				2022-12-25	WOS:000183444100037
J	Marillonnet, S; Klimyuk, V; Gleba, Y				Marillonnet, S; Klimyuk, V; Gleba, Y			Encoding technical information in GM organisms	NATURE BIOTECHNOLOGY			English	Editorial Material							OLIGONUCLEOTIDE		Icon Genet AG, D-80539 Munich, Germany		Marillonnet, S (corresponding author), Icon Genet AG, Maximilianstr 38-40, D-80539 Munich, Germany.			Gleba, Yuri/0000-0003-4675-7474				Dorey E, 2001, NAT BIOTECHNOL, V19, P795, DOI 10.1038/nbt0901-795a; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Schiermeier Q, 2001, NATURE, V409, P967, DOI 10.1038/35059267; Thomas R., 1988, VIRGIL GEORGICS; Tillib SV, 2001, CURR OPIN BIOTECH, V12, P53, DOI 10.1016/S0958-1669(00)00168-3; von Neumann J, 1966, THEORY SELF PRODUCIN	6	12	13	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2003	21	3					224	226		10.1038/nbt0303-224	http://dx.doi.org/10.1038/nbt0303-224			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	651GQ	12610560				2022-12-25	WOS:000181312500009
J	Stalmans, I; Lambrechts, D; De smet, F; Jansen, S; Wang, J; Maity, S; Kneer, P; von der Ohe, M; Swillen, A; Maes, C; Gewillig, M; Molin, DGM; Hellings, P; Boetel, T; Haardt, M; Compernolle, V; Dewerchin, M; Plaisance, S; Vlietinck, R; Emanuel, B; Gittenberger-de Groot, AC; Scambler, P; Morrow, B; Driscol, DA; Moons, L; Esguerra, CV; Carmeliet, G; Behn-Krappa, A; Devriendt, K; Collen, D; Conway, SJ; Carmeliet, P				Stalmans, I; Lambrechts, D; De smet, F; Jansen, S; Wang, J; Maity, S; Kneer, P; von der Ohe, M; Swillen, A; Maes, C; Gewillig, M; Molin, DGM; Hellings, P; Boetel, T; Haardt, M; Compernolle, V; Dewerchin, M; Plaisance, S; Vlietinck, R; Emanuel, B; Gittenberger-de Groot, AC; Scambler, P; Morrow, B; Driscol, DA; Moons, L; Esguerra, CV; Carmeliet, G; Behn-Krappa, A; Devriendt, K; Collen, D; Conway, SJ; Carmeliet, P			VEGF: A modifier of the del22q11 (DiGeorge) syndrome?	NATURE MEDICINE			English	Article							MONOZYGOTIC TWINS; 22Q11 DELETION; MICE LACKING; AORTIC-ARCH; GENE; ANGIOGENESIS; TBX1; DEFECTS; REGION; POLYMORPHISM	Hemizygous deletion of chromosome 22q11 (del22q11) causes thymic, parathyroid, craniofacial and life-threatening cardiovascular birth defects in 1 in 4,000 infants. The del22q11 syndrome is likely caused by haploinsufficiency of TBX1, but its variable expressivity indicates the involvement of additional modifiers. Here, we report that absence of the Vegf(164) isoform caused birth defects in mice, reminiscent of those found in del22q11 patients. The close correlation of birth and vascular defects indicated that vascular dysgenesis may pathogenetically contribute to the birth defects. Vegf interacted with Tbx1, as Tbx1 expression was reduced in Vegf(164)-deficient embryos and knocked-down vegf levels enhanced the pharyngeal arch artery defects induced by tbx1 knockdown in zebrafish. Moreover, initial evidence suggested that a VEGF promoter haplotype was associated with an increased risk for cardiovascular birth defects in del22q11 individuals. These genetic data in mouse, fish and human indicate that VEGF is a modifier of cardiovascular birth defects in the del22q11 syndrome.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Louvain, Belgium; Katholieke Univ Leuven, Dept Pediat, Louvain, Belgium; Mermaid Pharmaceut GmbH, Falkenried CiM 88, Hamburg, Germany; Leiden Univ, Dept Anat & Embryol, Med Ctr, Leiden, Netherlands; Univ Maastricht, Dept Populat Genet Genom & Bioinformat, Maastricht, Netherlands; Univ Penn, Sch Med, Dept Pediat,Div Reprod Genet, Dept Obstet & Gynecol,Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Inst Child Hlth, Mol Med Unit, London, England; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA	University System of Georgia; Augusta University; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven; KU Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; University of Pennsylvania; University of London; University College London; Yeshiva University; Albert Einstein College of Medicine	Conway, SJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.	sconway@mail.mcg.edu; peter.carmeliet@med.kuleuven.ac.be	Lambrechts, Diether/AAJ-3167-2020; De Smet, Frederik/Q-7808-2016; Esguerra, Camila/N-6159-2015; Scambler, Peter J/C-4998-2008; Hellings, Peter W/I-4068-2018; Plaisance, Stephane/B-3488-2009; Scambler, Peter/AAZ-6026-2020; Esguerra, Camila/D-7657-2014; Carmeliet, Peter/AAQ-5140-2020; Plaisance, Stephane/ABI-6307-2020; Verdrengh, Evelien/H-4571-2012	Lambrechts, Diether/0000-0002-3429-302X; De Smet, Frederik/0000-0002-6669-3335; Esguerra, Camila/0000-0002-2271-8094; Scambler, Peter J/0000-0002-1487-4628; Hellings, Peter W/0000-0001-6898-688X; Plaisance, Stephane/0000-0002-1651-241X; Scambler, Peter/0000-0002-1487-4628; Esguerra, Camila/0000-0001-7891-1427; Carmeliet, Peter/0000-0001-7961-1821; Plaisance, Stephane/0000-0002-1651-241X; Maes, Christa/0000-0003-4243-5486; Gewillig, Marc/0000-0002-4595-5922; Swillen, Ann/0000-0003-4258-4537; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Morrow, Bernice/0000-0002-8076-4726; Maity, Sunit/0000-0001-6667-3249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060104, R01HL060714] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60714, HL60104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Conway SJ, 2000, CARDIOVASC RES, V47, P314, DOI 10.1016/S0008-6363(00)00098-5; Conway SJ, 1997, DEVELOPMENT, V124, P505; Creazzo TL, 1998, ANNU REV PHYSIOL, V60, P267, DOI 10.1146/annurev.physiol.60.1.267; Driscoll DA, 2001, GENET MED, V3, P14, DOI 10.1097/00125817-200101000-00004; Emanuel B S, 2001, Adv Pediatr, V48, P39; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; Gong W, 2001, J Med Genet, V38, pE45, DOI 10.1136/jmg.38.12.e45; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lu JH, 2001, PEDIATR CARDIOL, V22, P260, DOI 10.1007/s002460010219; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Mansir T, 1999, GENET COUNSEL, V10, P67; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; McDermid HE, 2002, AM J HUM GENET, V70, P1077, DOI 10.1086/340363; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Piotrowski T, 2000, DEV BIOL, V225, P339, DOI 10.1006/dbio.2000.9842; Robinson H B Jr, 1975, Perspect Pediatr Pathol, V2, P173; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; SCHINZEL AAGL, 1979, J PEDIATR-US, V95, P921, DOI 10.1016/S0022-3476(79)80278-4; Schreiber C, 1997, EUR J CARDIO-THORAC, V12, P466, DOI 10.1016/S1010-7940(97)00194-2; Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260; SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x; Shprintzen RJ, 2000, MENT RETARD DEV D R, V6, P142, DOI 10.1002/1098-2779(2000)6:2<142::AID-MRDD9>3.0.CO;2-H; Shprintzen RJ, 1997, AM J HUM GENET, V61, pA5; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Vincent MC, 1999, GENET COUNSEL, V10, P43; Vitelli F, 2002, DEVELOPMENT, V129, P4605; Westerfield M, 1994, ZEBRAFISH BOOK GUIDE	43	222	233	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					173	182		10.1038/nm819	http://dx.doi.org/10.1038/nm819			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539040				2022-12-25	WOS:000180801900021
J	Ciana, P; Raviscioni, M; Mussi, P; Vegeto, E; Que, I; Parker, MG; Lowik, C; Maggi, A				Ciana, P; Raviscioni, M; Mussi, P; Vegeto, E; Que, I; Parker, MG; Lowik, C; Maggi, A			In vivo imaging of transcriptionally active estrogen receptors	NATURE MEDICINE			English	Article							TISSUE-SPECIFIC REGULATION; NUCLEAR RECEPTORS; GENE-EXPRESSION; ACTIVATION; GROWTH	Through intracellular receptors, estrogens control growth, differentiation and function of not only reproductive tissues, but also other systems(1-3). Estrogen receptors are ligand-dependent transcription factors whose activity is modulated either by estrogens, or by alternative intracellular signaling pathways downstream of growth factors and neurotransmitters(4-6). To determine the dynamics of estrogen receptor activity and the dependence of estrogen receptor on 17beta-estradiol in vivo, we generated a transgenic mouse that expresses a luciferase reporter gene under the control of activated estrogen receptors. As expected, luciferase activity, monitored with a cooled charged coupled device camera, paralleled circulating estrogen levels in reproductive tissues and in liver, indicating that the peak transcriptional activity of the estrogen receptor occurred at proestrus. In contrast, in tissues such as bone and brain, the peak activity of estrogen receptors was observed at diestrus. These tissue-specific responses are masked when mice undergo conventional hormone treatment. We also demonstrate that estrogen receptors are active in immature mice before gonadal production of sex hormones as well as in ovariectomized adult mice. These findings emphasize the importance of hormone-independent activation of the estrogen receptor, and have implications for the therapeutic use of estrogens, such as hormone replacement therapy.	Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy; Univ Milan, Inst Pharmacol Sci, Milan, Italy; Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands; Hammersmith Hosp, ICSM, Inst Reprod & Dev Biol, London, England	University of Milan; University of Milan; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London	Maggi, A (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy.	adriana.maggi@unimi.it	Ciana, Paolo/F-9224-2012	Maggi, Adriana/0000-0001-5700-5273; CIANA, PAOLO/0000-0001-5771-5638	Telethon [E.0600, E.C0699] Funding Source: Medline	Telethon(Fondazione Telethon)		Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104; Ciana P, 2002, EMBO REP, V3, P125, DOI 10.1093/embo-reports/kvf029; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GOMEZBENITEZ J, 1984, REV ESP FISIOL, V40, P311; Hashizume T, 2000, DOMEST ANIM ENDOCRIN, V18, P253, DOI 10.1016/S0739-7240(99)00082-X; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; OVERPECK JG, 1978, J TOXICOL ENV HEALTH, V4, P785, DOI 10.1080/15287397809529700; PLOURDE PV, 1995, J STEROID BIOCHEM, V53, P175, DOI 10.1016/0960-0760(95)00045-2; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SHUPNIK MA, 1989, MOL ENDOCRINOL, V3, P660, DOI 10.1210/mend-3-4-660; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VOURET JF, 1991, EMBO J, V10, P1875; WAKELING AE, 1991, CANCER RES, V51, P3867; WENGER NK, 2002, NIH PUBLICATION; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460	25	234	241	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					82	86		10.1038/nm809	http://dx.doi.org/10.1038/nm809			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483206				2022-12-25	WOS:000180209900026
J	Maier, AG; Duraisingh, MT; Reeder, JC; Patel, SS; Kazura, JW; Zimmerman, PA; Cowman, AF				Maier, AG; Duraisingh, MT; Reeder, JC; Patel, SS; Kazura, JW; Zimmerman, PA; Cowman, AF			Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations	NATURE MEDICINE			English	Article							BLOOD-GROUP; RED-CELLS; MALARIA; RECEPTOR; ANTIGENS; EBA-175; LIGAND; MELANESIANS; MEMBRANE; DELETION	Geographic overlap between malaria and the occurrence of mutant hemoglobin and erythrocyte surface proteins has indicated that polymorphisms in human genes have been selected by severe malaria(1,2). Deletion of exon 3 in the glycophorin C gene (called GYPCDeltaex3 here) has been found in Melanesians; this alteration changes the serologic phenotype of the Gerbich (Ge) blood group system, resulting in Ge negativity(3,4). The GYPCDeltaex3 allele reaches a high frequency (46.5%) in coastal areas of Papua New Guinea where malaria is hyperendemic(5). The Plasmodium falciparum erythrocyte-binding antigen 140 (EBA140, also known as BAEBL)(6-8) binds with high affinity to the surface of human erythrocytes. Here we show that the receptor for EBA140 is glycophorin C (GYPC) and that this interaction mediates a principal P. falciparum invasion pathway into human erythrocytes. EBA140 does not bind to GYPC in Ge-negative erythrocytes, nor can P. falciparum invade such cells using this invasion pathway. This provides compelling evidence that Ge negativity has arisen in Melanesian populations through natural selection by severe malaria.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; Case Western Reserve Univ, Div Geog Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Walter & Eliza Hall Institute; PNG Institute Of Medical Research; Case Western Reserve University; University Hospitals of Cleveland	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Maier, Alex G/A-6499-2009; Cowman, Alan F/C-7642-2013	Maier, Alex G/0000-0001-7369-1058; Cowman, Alan F/0000-0001-5145-9004; Reeder, John/0000-0003-1395-1289	NIAID NIH HHS [AI36478-07, AI46919-01A2, K23 AI049390, AI49390-01, R01 AI036478, R01 AI046919] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036478, K23AI049390, R01AI046919, R01AI036478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P494, DOI 10.1016/0035-9203(92)90083-O; BOOTH PB, 1972, VOX SANG, V22, P73, DOI 10.1111/j.1423-0410.1972.tb03968.x; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Haldane J. B. S., 1949, P 8 INT C GEN, P267; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Issitt, 1998, APPL BLOOD GROUP SER; JUNGERY M, 1983, P NATL ACAD SCI-BIOL, V80, P1018, DOI 10.1073/pnas.80.4.1018; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; PASVOL G, 1978, NATURE, V274, P701, DOI 10.1038/274701a0; PASVOL G, 1984, LANCET, V1, P907; Patel SS, 2001, BLOOD, V98, P3489, DOI 10.1182/blood.V98.12.3489; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SERJEANTSON SW, 1994, IMMUNOL CELL BIOL, V72, P23, DOI 10.1038/icb.1994.4; SIM BKL, 1994, EXP PARASITOL, V78, P259, DOI 10.1006/expr.1994.1027; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; TELEN MJ, 1987, TRANSFUSION, V27, P309, DOI 10.1046/j.1537-2995.1987.27487264736.x; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807	29	238	247	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					87	92		10.1038/nm807	http://dx.doi.org/10.1038/nm807			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12469115	Green Accepted			2022-12-25	WOS:000180209900027
J	Margolis, L				Margolis, L			Cytokines - strategic weapons in germ warfare?	NATURE BIOTECHNOLOGY			English	Editorial Material							GB-VIRUS-C; FUNCTIONAL EXPRESSION; LYMPHOID-TISSUE; T-CELLS; REPLICATION; INFECTION; HIV-1; CHEMOKINES; MIP-1-ALPHA; SUPPRESSION		NICHHD, Sect Intercellular Interact, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; NICHHD, NASA NIH, Ctr 3 Dimens Tissue Culture, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Margolis, L (corresponding author), NICHHD, Sect Intercellular Interact, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001416] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001416] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; BONER AL, 1985, ANN ALLERGY, V55, P605; Casoli C, 2000, BLOOD, V95, P2760, DOI 10.1182/blood.V95.9.2760.009k04_2760_2769; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Grivel JC, 2001, NAT MED, V7, P1232, DOI 10.1038/nm1101-1232; Guidotti LG, 1996, P NATL ACAD SCI USA, V93, P4589, DOI 10.1073/pnas.93.10.4589; Hjelmslev L., 1961, PROLEGOMENA THEORY L; HUTCHINS G, 1947, AM J DIS CHILD, V73, P242; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; LIN CY, 1986, PEDIATR RES, V20, P685, DOI 10.1203/00006450-198607000-00022; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; Marie JC, 2001, IMMUNITY, V14, P69, DOI 10.1016/S1074-7613(01)00090-5; Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689; Moss WJ, 2002, J INFECT DIS, V185, P1035, DOI 10.1086/340027; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SAUSSURE FD, 1993, GEN LINGUISTICS; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364	23	20	21	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2003	21	1					15	16		10.1038/nbt0103-15	http://dx.doi.org/10.1038/nbt0103-15			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	632DV	12511900				2022-12-25	WOS:000180209200009
J	Bond, J; Roberts, E; Mochida, GH; Hampshire, DJ; Scott, S; Askham, JM; Springell, K; Mahadevan, M; Crow, YJ; Markham, AF; Walsh, CA; Woods, CG				Bond, J; Roberts, E; Mochida, GH; Hampshire, DJ; Scott, S; Askham, JM; Springell, K; Mahadevan, M; Crow, YJ; Markham, AF; Walsh, CA; Woods, CG			ASPM is a major determinant of cerebral cortical size	NATURE GENETICS			English	Article							RECESSIVE MICROCEPHALY MAPS; NEURONAL MIGRATION; MOLECULAR-GENETICS; ABNORMAL SPINDLE; DROSOPHILA; LOCUS; ADULT; NEUROGENESIS; CENTROSOMES; MUTATIONS	One of the most notable trends in mammalian evolution is the massive increase in size of the cerebral cortex, especially in primates. Humans with autosomal recessive primary microcephaly (MCPH) show a small but otherwise grossly normal cerebral cortex associated with mild to moderate mental retardation(1-4). Genes linked to this condition offer potential insights into the development and evolution of the cerebral cortex. Here we show that the most common cause of MCPH is homozygous mutation of ASPM, the human ortholog of the Drosophila melanogaster abnormal spindle gene (asp)(5), which is essential for normal mitotic spindle function in embryonic neuroblasts(6). The mouse gene Aspm is expressed specifically in the primary sites of prenatal cerebral cortical neurogenesis. Notably, the predicted ASPM proteins encode systematically larger numbers of repeated 'IQ' domains between flies, mice and humans, with the predominant difference between Aspm and ASPM being a single large insertion coding for IQ domains. Our results and evolutionary considerations suggest that brain size is controlled in part through modulation of mitotic spindle activity in neuronal progenitor cells.	Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St Jamess Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurol,Div Neurogenet,Harvard Inst Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Neurol, Pediat Neurol Unit, Boston, MA 02114 USA	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Woods, CG (corresponding author), Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.		Hampshire, Daniel/Q-3540-2019; woods, christopher g/A-1361-2010; Crow, Yanick J/N-6120-2014	Crow, Yanick J/0000-0001-7211-7564; Mochida, Ganeshwaran/0000-0001-7912-4097; Walsh, Christopher/0000-0002-0156-2238				AICARDI J, 1998, DIS NERVOUS SYSTEM C, V2, P90; Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; ANGEVINE JB, 1970, ANAT REC, V166, P257, DOI 10.1002/ar.1091660214; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bienz M, 2001, NAT CELL BIOL, V3, pE67, DOI 10.1038/35060140; BUNDEY S, 1997, EMERY RIMOINS PRINCI, P730; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Craig R, 1998, J CELL SCI, V111, P3609; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; GONZALEZ C, 1990, J CELL SCI, V96, P605; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Jackson AP, 1998, AM J HUM GENET, V63, P541, DOI 10.1086/301966; Jamieson CR, 2000, AM J HUM GENET, V67, P1575, DOI 10.1086/316909; Jamieson CR, 1999, AM J HUM GENET, V65, P1465, DOI 10.1086/302640; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; Mochida GH, 2001, CURR OPIN NEUROL, V14, P151, DOI 10.1097/00019052-200104000-00003; Moynihan L, 2000, AM J HUM GENET, V66, P724, DOI 10.1086/302777; Pattison L, 2000, AM J HUM GENET, V67, P1578, DOI 10.1086/316910; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RIPOLL P, 1985, CELL, V41, P907, DOI 10.1016/S0092-8674(85)80071-4; Roberts E, 1999, EUR J HUM GENET, V7, P815, DOI 10.1038/sj.ejhg.5200385; ROBERTS E, 2002, IN PRESS J MED GENET; Roegiers F, 2001, NAT CELL BIOL, V3, P58, DOI 10.1038/35050568; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131	30	414	437	1	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					316	320		10.1038/ng995	http://dx.doi.org/10.1038/ng995			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12355089				2022-12-25	WOS:000178311100024
J	Chung, EN; Chen, RH				Chung, EN; Chen, RH			Phosphorylation of Cdc20 is required for its inhibition by the spindle checkpoint	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; ASSEMBLY CHECKPOINT; MAP KINASE; KINETOCHORE LOCALIZATION; MITOTIC CHECKPOINT; CENP-E; MAD2; BUBR1; ACTIVATION	The spindle checkpoint delays anaphase until all chromosomes are properly attached to spindle microtubules. When the spindle checkpoint is activated at unattached kinetochores, the checkpoint proteins BubR1, Bub3 and Mad2 bind and inhibit Cdc20, an activator of the anaphase-promoting complex (APC). Here, we show that Xenopus laevis Cdc20 is phosphorylated at Ser 50, Thr 64, Thr 68 and Thr 79 during mitosis and that mitogen-activated protein kinase (MAPK) contributes to the phosphorylation at Thr 64 or Thr 68. Cdc20 mutants that are phosphorylation-deficient are able to activate the APC in X. laevis egg extracts. However, Cdc20 mutants in which any of the four phosphorylation sites were altered to Ala or Val failed to respond to the spindle checkpoint signal, owing to their reduced affinity for the spindle checkpoint proteins. This study demonstrates that the spindle checkpoint stops anaphase by inhibiting fully-phosphorylated Cdc20. Our results also have implications for the spindle checkpoint silencing mechanism.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Chen, RH (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	rc70@cornell.edu	Chen, Rey-Huei/AAA-5087-2021	Chen, Rey-Huei/0000-0002-6006-2137; Chung, Eunah/0000-0003-4020-5863				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	27	124	127	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2003	5	8					748	753		10.1038/ncb1022	http://dx.doi.org/10.1038/ncb1022			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	710NX	12855955				2022-12-25	WOS:000184687300017
J	Bok, D; Galbraith, G; Lopez, I; Woodruff, M; Nusinowitz, S; BeltrandelRio, H; Huang, WH; Zhao, SL; Geske, R; Montgomery, C; Van Sligtenhorst, I; Friddle, C; Platt, K; Sparks, MJ; Pushkin, A; Abuladze, N; Ishiyama, A; Dukkipati, R; Liu, WX; Kurtz, I				Bok, D; Galbraith, G; Lopez, I; Woodruff, M; Nusinowitz, S; BeltrandelRio, H; Huang, WH; Zhao, SL; Geske, R; Montgomery, C; Van Sligtenhorst, I; Friddle, C; Platt, K; Sparks, MJ; Pushkin, A; Abuladze, N; Ishiyama, A; Dukkipati, R; Liu, WX; Kurtz, I			Blindness and auditory impairment caused by loss of the sodium bicarbonate cotransporter NBC3	NATURE GENETICS			English	Article							EXPRESSION; FIBROCYTES; PROTONS; COLOCALIZATION; CHANNELS; ISOFORMS; SUBUNIT; USH2B; GENE	Normal sensory transduction requires the efficient disposal of acid (H+) generated by neuronal and sensory receptor activity(1,2). Multiple highly sensitive transport mechanisms have evolved in prokaryotic and eukaryotic organisms to maintain acidity within strict limits(3-5). It is currently assumed that the multiplicity of these processes provides a biological robustness(6). Here we report that the visual and auditory systems have a specific requirement for H+ disposal mediated by the sodium bicarbonate cotransporter NBC3 (refs. 7,8). Mice lacking NBC3 develop blindness and auditory impairment because of degeneration of sensory receptors in the eye and inner ear as in Usher syndrome(9). Our results indicate that in certain sensory organs, in which the requirement to transduce specific environmental signals with speed, sensitivity and reliability is paramount, the choice of the H+ disposal mechanism used is limited.	Univ Calif Los Angeles, Div Nephrol, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurobiol, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Head & Neck Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurtz, I (corresponding author), Univ Calif Los Angeles, Div Nephrol, Dept Med, David Geffen Sch Med, Room 7-155 Factor Bldg,10833 Conte Ave, Los Angeles, CA 90095 USA.	Ikurtz@mednet.ucla.edu	lopez, ivan/GSM-8495-2022; Lopez, Ivan A/U-2177-2019	Lopez, Ivan A/0000-0001-5205-7293				BARNES S, 1993, P NATL ACAD SCI USA, V90, P10081, DOI 10.1073/pnas.90.21.10081; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Denison SH, 2000, FUNGAL GENET BIOL, V29, P61, DOI 10.1006/fgbi.2000.1188; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Gross E, 2002, AM J PHYSIOL-RENAL, V283, pF876, DOI 10.1152/ajprenal.00148.2002; Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984; Hmani M, 1999, EUR J HUM GENET, V7, P363, DOI 10.1038/sj.ejhg.5200307; Hmani-Aifa M, 2002, J MED GENET, V39, P281, DOI 10.1136/jmg.39.4.281; Kimberling WJ, 2000, ADV OTO-RHINO-LARYNG, V56, P11; Koulen P, 1998, J NEUROSCI, V18, P10136; Krizaj D, 2002, J COMP NEUROL, V451, P1, DOI 10.1002/cne.10281; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; KRULWICH TA, 1995, MOL MICROBIOL, V15, P403, DOI 10.1111/j.1365-2958.1995.tb02253.x; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Pushkin A, 2000, J ANDROL, V21, P708; Pushkin A, 1999, GENOMICS, V57, P321, DOI 10.1006/geno.1999.5781; Pushkin A, 2003, AM J PHYSIOL-CELL PH, V284, pC667, DOI 10.1152/ajpcell.00225.2002; Pushkin A, 1999, AM J PHYSIOL-RENAL, V277, pF974, DOI 10.1152/ajprenal.1999.277.6.F974; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; SALT AN, 2001, PHYSL EAR, P333; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; Spicer SS, 1997, HEARING RES, V111, P93, DOI 10.1016/S0378-5955(97)00097-X; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Trapp S, 1996, NEUROREPORT, V7, P2000, DOI 10.1097/00001756-199608120-00029; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; Waldmann R, 2001, ADV EXP MED BIOL, V502, P293	30	96	99	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2003	34	3					313	319		10.1038/ng1176	http://dx.doi.org/10.1038/ng1176			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12808454				2022-12-25	WOS:000183815300020
J	Bulavin, DV; Higashimoto, Y; Demidenko, ZN; Meek, S; Graves, P; Phillips, C; Zhao, H; Moody, SA; Appella, E; Piwnica-Worms, H; Fornace, AJ				Bulavin, DV; Higashimoto, Y; Demidenko, ZN; Meek, S; Graves, P; Phillips, C; Zhao, H; Moody, SA; Appella, E; Piwnica-Worms, H; Fornace, AJ			Dual phosphorylation controls Cdc25 phosphatases and mitotic entry	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE; NUCLEAR EXPORT; P38 KINASE; CHECKPOINT; MITOSIS; RADIATION; BINDING; LOCALIZATION; INITIATION; ACTIVATION	Negative regulation of the Cdc25C protein phosphatase by phosphorylation on Ser 216, the 14-3-3-binding site, is an important regulatory mechanism used by cells to block mitotic entry under normal conditions and after DNA damage. During mitosis, Cdc25C is not phosphorylated on Ser 216 and ionizing radiation (IR) does not induce either phosphorylation of Ser 216, or binding to 14-3-3. Here, we show that Cdc25C is phosphorylated on Ser 214 during mitosis, which in turn prevents phosphorylation of Ser 216. Mutation of Ser 214 to Ala reconstitutes Ser 216 phosphorylation and 14-3-3 binding during mitosis. Introduction of exogenous Cdc25C(S214A) into HeLa cells depleted of endogenous Cdc25C results in a substantial delay to mitotic entry. This effect was fully reversed in a S214A/S216A double-mutant, implying that the inhibitory effect of S214A mutant was entirely dependent on Ser 216 phosphorylation. A similar regulatory mechanism may also apply to another mitotic phosphatase, Cdc25B, as well as mitotic phosphatases of other species, including Xenopus laevis. We propose that this pathway ensures that Cdc2 remains active once mitosis is initiated and is a key control mechanism for maintaining the proper order of cell-cycle transitions.	NCI, Gene Response Sect, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Bulavin, DV (corresponding author), NCI, Gene Response Sect, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008; Piwnica-Worms, Helen/C-5214-2012; Moody, Sally A./AAI-3660-2020	Fornace, Albert J/0000-0001-9695-085X; Moody, Sally A./0000-0003-4192-1087; Higashimoto, Yuichiro/0000-0003-1382-8598; Dudgeon, Crissy/0000-0001-9010-2569				Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	17	142	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					545	551		10.1038/ncb994	http://dx.doi.org/10.1038/ncb994			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12766774				2022-12-25	WOS:000183202800016
J	Planet, PJ; Kachlany, SC; Fine, DH; DeSalle, R; Figurski, DH				Planet, PJ; Kachlany, SC; Fine, DH; DeSalle, R; Figurski, DH			The widespread colonization island of Actinobacillus actinomycetemcomitans	NATURE GENETICS			English	Article							LENGTH DIFFERENCE TEST; NONSPECIFIC ADHERENCE; CAULOBACTER-CRESCENTUS; GENE; IDENTIFICATION; INCONGRUENCE; PHYLOGENY; REQUIRES; PROTEIN; TREE	Genomic islands, such as pathogenicity islands, contribute to the evolution and diversification of microbial life(1). Here we report on the Widespread Colonization Island, which encompasses the tad (tight adherence) locus for colonization of surfaces and biofilm formation by the human pathogen Actinobacillus actinomycetemcomitans. At least 12 of the 14 genes at the tad locus are required for tenacious biofilm formation and synthesis of bundled Flp pili (fibrils) that mediate adherence. The pilin subunit(2), Flp1, remains inside the cell in tad-locus mutants, indicating that these genes encode a secretion system for export and assembly of fibrils. We found tad-related regions in a wide variety of Bacterial and Archaeal species(3), and their sequence characteristics indicate possible horizontal transfer. To test the hypothesis of horizontal transfer, we compared the phylogeny of the tad locus to a robust organismal phylogeny using statistical tests of congruence and tree reconciliation techniques. Our analysis strongly supports a complex history of gene shuffling by recombination and multiple horizontal transfers, duplications and losses. We present evidence for a specific horizontal transfer event leading to the establishment of this region as a determinant of disease.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Univ Med & Dent New Jersey, Dept Oral Biol, Newark, NJ 07103 USA; Amer Museum Nat Hist, Mol Biol Lab, New York, NY 10024 USA	Columbia University; Rutgers State University New Brunswick; Rutgers State University Medical Center; American Museum of Natural History (AMNH)	Figurski, DH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERGEY DH, 1984, BERGEYS MANUAL SYSTE, V4; Bhattacharjee MK, 2001, J BACTERIOL, V183, P5927, DOI 10.1128/JB.183.20.5927-5936.2001; Brochier C, 2002, TRENDS GENET, V18, P1, DOI 10.1016/S0168-9525(01)02522-7; Brown EW, 2002, MOL PHYLOGENET EVOL, V24, P102, DOI 10.1016/S1055-7903(02)00222-1; Charleston MA, 1998, MATH BIOSCI, V149, P191, DOI 10.1016/S0025-5564(97)10012-8; Dolphin K, 2000, MOL PHYLOGENET EVOL, V17, P401, DOI 10.1006/mpev.2000.0845; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Farris JS, 1995, SYST BIOL, V44, P570, DOI 10.2307/2413663; Fine DH, 2001, ARCH ORAL BIOL, V46, P1065, DOI 10.1016/S0003-9969(01)00067-X; Fuller TE, 2000, MICROB PATHOGENESIS, V29, P25, DOI 10.1006/mpat.2000.0365; Haase EM, 1999, INFECT IMMUN, V67, P2901, DOI 10.1128/IAI.67.6.2901-2908.1999; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Inoue T, 1998, MICROBIOL IMMUNOL, V42, P253, DOI 10.1111/j.1348-0421.1998.tb02280.x; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Kachlany SC, 2000, J BACTERIOL, V182, P6169, DOI 10.1128/JB.182.21.6169-6176.2000; Kachlany SC, 2001, TRENDS MICROBIOL, V9, P429, DOI 10.1016/S0966-842X(01)02161-8; Kachlany SC, 2001, MOL MICROBIOL, V40, P542, DOI 10.1046/j.1365-2958.2001.02422.x; Nika JR, 2002, INFECT IMMUN, V70, P2965, DOI 10.1128/IAI.70.6.2965-2975.2002; Nixon KC, 1999, CLADISTICS, V15, P407, DOI 10.1111/j.1096-0031.1999.tb00277.x; Page RDM, 1997, MOL PHYLOGENET EVOL, V7, P231, DOI 10.1006/mpev.1996.0390; Planet PJ, 2001, P NATL ACAD SCI USA, V98, P2503, DOI 10.1073/pnas.051436598; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Skerker JM, 2000, EMBO J, V19, P3223, DOI 10.1093/emboj/19.13.3223; SOMMER JM, 1989, J BACTERIOL, V171, P392, DOI 10.1128/jb.171.1.392-401.1989; Thomas NA, 2002, MOL MICROBIOL, V46, P879, DOI 10.1046/j.1365-2958.2002.03220.x; Thomson VJ, 1999, J BACTERIOL, V181, P7298, DOI 10.1128/JB.181.23.7298-7307.1999; Thornton JW, 2000, SYST BIOL, V49, P183, DOI 10.1093/sysbio/49.2.183; Wang Y, 2002, J BACTERIOL, V184, P3442, DOI 10.1128/JB.184.13.3442-3449.2002	30	114	122	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					193	198		10.1038/ng1154	http://dx.doi.org/10.1038/ng1154			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12717435				2022-12-25	WOS:000183200500026
J	Saucedo, LJ; Gao, XS; Chiarelli, DA; Li, L; Pan, D; Edgar, BA				Saucedo, LJ; Gao, XS; Chiarelli, DA; Li, L; Pan, D; Edgar, BA			Rheb promotes cell growth as a component of the insulin/TOR signalling network	NATURE CELL BIOLOGY			English	Article							RAS-RELATED PROTEIN; DROSOPHILA-MELANOGASTER; NITROGEN STARVATION; TUBEROUS SCLEROSIS; EGF RECEPTOR; TSC2; GENE; TARGET; IDENTIFICATION; PATHWAY	Insulin signalling is a potent inhibitor of cell growth and has been proposed to function, at least in part, through the conserved protein kinase TOR (target of rapamycin). Recent studies suggest a that the tuberous sclerosis complex Tsc1-Tsc2 may couple insulin signalling to Tor activity. However, the regulatory mechanism involved remains unclear, and additional components are most probably involved. In a screen for novel regulators of growth, we identified Rheb (Ras homologue enriched in brain), a member of the Ras superfamily of GTP-binding proteins. Increased levels of Rheb in Drosophila melanogaster promote cell growth and alter cell cycle kinetics in multiple tissues. In mitotic tissues, overexpression of Rheb accelerates passage through G1-S phase without affecting rates of cell division, whereas in endoreplicating tissues, Rheb increases DNA ploidy. Mutation of Rheb suspends larval growth and prevents progression from first to second instar. Genetic and biochemical tests indicate that Rheb functions in the insulin signalling pathway downstream of Tsc1-Tsc2 and upstream of TOR. Levels of rheb mRNA are rapidly induced in response to protein starvation, and overexpressed Rheb can drive cell growth in starved animals, suggesting a role for Rheb in the nutritional control of cell growth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Texas, Dept Physiol, SW Med Ctr, Dallas, TX 75390 USA	Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.				NIGMS NIH HHS [GM51186, GM20590, GM61805, GM62323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062323, R01GM061805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Clark GJ, 1997, J BIOL CHEM, V272, P10608; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mach KE, 2000, GENETICS, V155, P611; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Panepinto JC, 2002, FUNGAL GENET BIOL, V36, P207, DOI 10.1016/S1087-1845(02)00022-1; Pignoni F, 1997, DEVELOPMENT, V124, P271; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; ROBERTSON HM, 1988, GENETICS, V118, P461; Toba G, 1999, GENETICS, V151, P725; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	30	500	528	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2003	5	6					566	571		10.1038/ncb996	http://dx.doi.org/10.1038/ncb996			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	684JP	12766776				2022-12-25	WOS:000183202800019
J	Segal, E; Shapira, M; Regev, A; Pe'er, D; Botstein, D; Koller, D; Friedman, N				Segal, E; Shapira, M; Regev, A; Pe'er, D; Botstein, D; Koller, D; Friedman, N			Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; OSMOTIC-STRESS; GENOME; MOTIFS; TRANSCRIPTION; IDENTIFICATION; LOCALIZATION; ORGANIZATION; DISCOVERY; SEQUENCES	Much of a cell's activity is organized as a network of interacting modules: sets of genes coregulated to respond to different conditions. We present a probabilistic method for identifying regulatory modules from gene expression data. Our procedure identifies modules of coregulated genes, their regulators and the conditions under which regulation occurs, generating testable hypotheses in the form regulator X regulates module Y under conditions W'. We applied the method to a Saccharomyces cerevisiae expression data set, showing its ability to identify functionally coherent modules and their correct regulators. We present microarray experiments supporting three novel predictions, suggesting regulatory roles for previously uncharacterized proteins.	Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Comp Sci, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Sch Engn & Comp Sci, IL-91904 Jerusalem, Israel	Stanford University; Stanford University; Tel Aviv University; Weizmann Institute of Science; Hebrew University of Jerusalem	Segal, E (corresponding author), Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.	eran@cs.stanford.edu; koller@cs.stanford.edu	Friedman, Nir/H-9692-2012; Segal, Eran/AAF-4855-2019	Friedman, Nir/0000-0002-9678-3550; Pe'er, Dana/0000-0002-9259-8817; Segal, Eran/0000-0002-6859-1164				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; D'haeseleer P, 2000, BIOINFORMATICS, V16, P707, DOI 10.1093/bioinformatics/16.8.707; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duda R. O., 1973, PATTERN CLASSIFICATI; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRIEDMAN N, 1998, P 14 C UNC ART INT, P129; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Halfon MS, 2002, GENOME RES, V12, P1019, DOI 10.1101/gr.228902; HARTEMINK AJ, 2002, PAC S BIOC KAUAI; Heckerman D, 1998, NATO ADV SCI I D-BEH, V89, P301; Hlavacek WS, 1996, J MOL BIOL, V255, P121, DOI 10.1006/jmbi.1996.0011; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lenssen E, 2002, MOL MICROBIOL, V43, P1023, DOI 10.1046/j.1365-2958.2002.02799.x; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Pe'er D, 2001, Bioinformatics, V17 Suppl 1, pS215; Pe'er Dana, 2002, Bioinformatics, V18 Suppl 1, pS258; Pearl J., 1988, PROBABILISTIC REASON, DOI 10.1016/B978-0-08-051489-5.50008-4; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Segal E, 2001, Bioinformatics, V17 Suppl 1, pS243; SEGAL E, 2002, P 6 INT C RES COMP M, P263; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tanay A, 2001, Bioinformatics, V17 Suppl 1, pS270; Tanay Amos, 2002, Bioinformatics, V18 Suppl 1, pS136; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Zahringer H, 2000, MOL MICROBIOL, V35, P397, DOI 10.1046/j.1365-2958.2000.01706.x	46	1154	1207	1	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2003	34	2					166	176		10.1038/ng1165	http://dx.doi.org/10.1038/ng1165			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12740579				2022-12-25	WOS:000183200500022
J	Tartaglia, M; Niemeyer, CM; Fragale, A; Song, XL; Buechner, J; Jung, A; Hahlen, K; Hasle, H; Licht, JD; Gelb, BD				Tartaglia, M; Niemeyer, CM; Fragale, A; Song, XL; Buechner, J; Jung, A; Hahlen, K; Hasle, H; Licht, JD; Gelb, BD			Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia	NATURE GENETICS			English	Article							TYROSINE-PHOSPHATASE SHP-2; NOONAN-SYNDROME	We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML. Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML). Functional analyses documented that the two most common mutations in PTPN11 associated with JMML caused a gain of function.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Ist Super Sanita, Lab Metab & Biochim Patol, I-00161 Rome, Italy; Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; Ist Super Sanita, Lab Biol Cellulare, I-00161 Rome, Italy; Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany; Sophia Childrens Univ Hosp, Rotterdam, Netherlands; Skejby Hosp, Dept Pediat, Aarhus, Denmark; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Istituto Superiore di Sanita (ISS); University of Freiburg; Istituto Superiore di Sanita (ISS); University of Erlangen Nuremberg; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Aarhus University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gelb, BD (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.		Tartaglia, Marco/K-2955-2018; Licht, Jonathan/L-4239-2019; Fragale, Alessandra/K-1071-2016	Tartaglia, Marco/0000-0001-7736-9672; Fragale, Alessandra/0000-0002-0362-1983; Hasle, Henrik/0000-0003-3976-9231; Buechner, Jochen/0000-0001-5848-4501; Licht, Jonathan/0000-0002-3942-1369				BaderMeunier B, 1997, J PEDIATR-US, V130, P885, DOI 10.1016/S0022-3476(97)70273-7; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; Choong K, 1999, J PEDIAT HEMATOL ONC, V21, P523, DOI 10.1097/00043426-199911000-00014; Emanuel PD, 1996, MOL MED TODAY, V2, P468, DOI 10.1016/1357-4310(96)10044-7; Fukuda M, 1997, J PEDIAT HEMATOL ONC, V19, P177, DOI 10.1097/00043426-199703000-00019; Hasle H, 1999, LEUKEMIA, V13, P376, DOI 10.1038/sj.leu.2401342; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847	10	754	789	1	39	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					148	150		10.1038/ng1156	http://dx.doi.org/10.1038/ng1156			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12717436				2022-12-25	WOS:000183200500018
J	Yamanaka, K; Ishikawa, H; Megumi, Y; Tokunaga, F; Kanie, M; Rouault, TA; Morishima, I; Minato, N; Ishimori, K; Iwai, K				Yamanaka, K; Ishikawa, H; Megumi, Y; Tokunaga, F; Kanie, M; Rouault, TA; Morishima, I; Minato, N; Ishimori, K; Iwai, K			Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2	NATURE CELL BIOLOGY			English	Article							IRON-REGULATORY PROTEIN-2; BINDING PROTEIN; MESSENGER-RNA; HIF-ALPHA; DEGRADATION; METABOLISM; DISEASE; RING; UBIQUITYLATION; HYDROXYLATION	The ubiquitin system is involved in several basic cellular functions(1-3). Ubiquitination is carried out by a cascade of three reactions catalysed by the El, E2 and E3 enzymes. Among these, the E3 ubiquitin-protein ligases have a pivotal role in determining the specificity of the system by recognizing the target substrates through defined targeting motifs(1-3). Although RING finger proteins constitute an important family of E3 ligases(4), only a few post-transcriptional modifications, including phosphorylation(1), proline hydroxylation(5,6) and glycosylation(7), are known to function as recognition signals for E3. Iron regulatory protein 2 (IRP2), a modulator of iron metabolism, is regulated by iron-induced ubiquitination and degradation(8). Here we show that the RING finger protein HOIL-1 functions as an E3 ligase for oxidized IRP2, suggesting that oxidation is a specific recognition signal for ubiquitination. The oxidation of IRP2 is generated by haem, which binds to IRP2 in iron-rich cells, and by oxygen, indicating that the iron sensing of IRP2 depends on the synthesis and availability of haem.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Sakyo Ku, Kyoto 6068501, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan; Japan Sci & Technol Corp, JST, CREST, Kawaguchi, Saitama 3320012, Japan; NICHHD, Cell Biol & Metab Branch, Bethesda, MD 20892 USA	Kyoto University; Kyoto University; Osaka Metropolitan University; Japan Science & Technology Agency (JST); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yamanaka, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Sakyo Ku, Kyoto 6068501, Japan.		Yamanaka, Koji/ABD-1034-2020; Ishimori, Koichiro/S-1247-2016; IWAI, KAZUHIRO/GSN-7385-2022; Ishimori, Koichiro/AAQ-4434-2021; Yamanaka, Koji/H-5806-2011; Ishikawa, Haruto/B-1562-2012	Yamanaka, Koji/0000-0003-4655-0035; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Yamanaka, Koji/0000-0003-4655-0035; Ishikawa, Haruto/0000-0001-6362-5719; Tokunaga, Fuminori/0000-0003-3626-9119; Iwai, Kazuhiro/0000-0001-5620-5951	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AFT RL, 1984, J BIOL CHEM, V259, P301; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Goessling LS, 1998, J BIOL CHEM, V273, P12555, DOI 10.1074/jbc.273.20.12555; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	25	140	148	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					336	340		10.1038/ncb952	http://dx.doi.org/10.1038/ncb952			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12629548				2022-12-25	WOS:000182080700017
J	Tugizov, SM; Berline, JW; Palefsky, JM				Tugizov, SM; Berline, JW; Palefsky, JM			Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells	NATURE MEDICINE			English	Article							CARCINOMA-CELLS; B-CELLS; HUMAN CYTOMEGALOVIRUS; FIBRONECTIN RECEPTOR; MIGRATION STRATEGIES; MATRIX INTERACTIONS; REPLICATION; LYMPHOCYTES; EXPRESSION; ENTRY	Epstein-Barr virus (EBV) initially enters the body through the oropharyngeal mucosa and subsequently infects B lymphocytes through their CD21 (CR2) complement receptor. Mechanisms of EBV entry into and release from epithelial cells are poorly understood. To study EBV infection in mucosal oropharyngeal epithelial cells, we established human polarized tongue and pharyngeal epithelial cells in culture. We show that EBV enters these cells through three CD21-independent pathways: (i) by direct cell-to-cell contact of apical cell membranes with EBV-infected lymphocytes; (ii) by entry of cell-free virions through basolateral membranes, mediated in part through an interaction between beta(1) or alpha(5)beta(1) integrins and the EBV BMRF-2 protein; and (iii) after initial infection, by virus spread directly across lateral membranes to adjacent epithelial cells. Release of progeny virions from polarized cells occurs from both their apical and basolateral membranes. These data indicate that multiple approaches to prevention of epithelial infection with EBV will be necessary.	Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tugizov, SM (corresponding author), Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01-RR-00079] Funding Source: Medline; NIDCR NIH HHS [P01 DE07946] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; Chang Y, 1999, J VIROL, V73, P8857, DOI 10.1128/JVI.73.10.8857-8866.1999; Chang Y, 1998, LAB INVEST, V78, P715; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Friedl P, 1998, CELL ADHES COMMUN, V6, P225, DOI 10.3109/15419069809004478; Gavrilovskaya IN, 1999, J VIROL, V73, P3951, DOI 10.1128/JVI.73.5.3951-3959.1999; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Haan KM, 2000, J VIROL, V74, P2451, DOI 10.1128/JVI.74.5.2451-2454.2000; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HANZEL D, 1991, CELL BIOL, V2, P341; HURLEY EA, 1991, J VIROL, V65, P3958, DOI 10.1128/JVI.65.7.3958-3963.1991; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; Iwata S, 2000, J DERMATOL SCI, V23, P75, DOI 10.1016/S0923-1811(99)00096-1; Jackson T, 1997, J VIROL, V71, P8357, DOI 10.1128/JVI.71.11.8357-8361.1997; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002; KIM LT, 1992, J CELL SCI, V103, P743; Lagenaur LA, 1999, J VIROL, V73, P6566, DOI 10.1128/JVI.73.8.6566-6572.1999; Lembo D, 1998, J GEN VIROL, V79, P2803, DOI 10.1099/0022-1317-79-11-2803; LEMON SM, 1977, NATURE, V268, P268, DOI 10.1038/268268a0; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; MODROW S, 1992, ARCH VIROL, V127, P379, DOI 10.1007/BF01309601; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Palefsky J M, 1997, Oral Dis, V3 Suppl 1, pS171; Penaranda ME, 1998, J GEN VIROL, V79, P1321; Penaranda ME, 1997, J GEN VIROL, V78, P3361; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Tugizov S, 1996, J GEN VIROL, V77, P61, DOI 10.1099/0022-1317-77-1-61; Tugizov S, 1998, J VIROL, V72, P7374, DOI 10.1128/JVI.72.9.7374-7386.1998; Wang X, 1998, J VIROL, V72, P5552, DOI 10.1128/JVI.72.7.5552-5558.1998; Wang X, 1998, J VIROL, V72, P158, DOI 10.1128/JVI.72.1.158-163.1998; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOLF H, 1984, J VIROL, V51, P795, DOI 10.1128/JVI.51.3.795-798.1984; Yoshiyama H, 1997, J VIROL, V71, P5688, DOI 10.1128/JVI.71.7.5688-5691.1997; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	47	197	204	2	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					307	314		10.1038/nm830	http://dx.doi.org/10.1038/nm830			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592401				2022-12-25	WOS:000181312300031
J	He, ZH; Ong, CHP; Halper, J; Bateman, A				He, ZH; Ong, CHP; Halper, J; Bateman, A			Progranulin is a mediator of the wound response	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; EPITHELIAL-CELL GROWTH; ANGIOGENESIS IN-VITRO; GRANULIN/EPITHELIN PRECURSOR; GENE-EXPRESSION; IDENTIFICATION; ACROGRANIN; MODULATION; GRANULINS; COLLAGEN	Annually, 1.25 million individuals suffer burns in the United States and 6.5 million experience chronic skin ulcers, often from diabetes, pressure or venous stasis(1). Growth factors are essential mediators of wound repair(1,2), but their success as therapeutics in wound treatment has, so far, been limited(1,2). Therefore, there is a need to identify new wound-response regulatory factors, but few have appeared in recent years(1,2). Progranulin(3) (also called granulin or epithelin precursor(4), acrogranin(5) or PC-derived growth factor(6)) is a growth factor involved in tumorigenesis(6-11) and development(12,13). Peptides derived from progranulin have been isolated from inflammatory cells(14), which led to suggestions that progranulin gene products are involved in the wound response(10,14), but this remains undemonstrated. We report that in murine transcutaneous puncture wounds, progranulin mRNA is expressed in the inflammatory infiltrate and is highly induced in dermal fibroblasts and endothelia following injury. When applied to a cutaneous wound, progranulin increased the accumulation of neutrophils, macrophages, blood vessels and fibroblasts in the wound. It acts directly on isolated dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structures. Progranulin is, therefore, a probable wound-related growth factor.	McGill Univ, Div Expt Med, Montreal, PQ, Canada; Royal Victoria Hosp, Endocrine Res Lab, Montreal, PQ H3A 1A1, Canada; Univ Georgia, Coll Vet Med, Dept Pathol, Soft Tissue Ctr, Athens, GA 30602 USA	McGill University; McGill University; Royal Victoria Hospital; University System of Georgia; University of Georgia	Bateman, A (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.		Halper, Jaroslava/AAF-8245-2020; Halper, Jaroslava/AAE-6674-2020	Bateman, Andrew/0000-0003-0597-769X	NCI NIH HHS [CA71023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA071023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Carter Bobbie J., 1996, Wound Repair and Regeneration, V4, P259, DOI 10.1046/j.1524-475X.1996.40215.x; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Diaz-Cueto L, 2000, DEV BIOL, V217, P406, DOI 10.1006/dbio.1999.9564; FIDDES JC, 1991, ANN NY ACAD SCI, V638, P316; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2002, CANCER RES, V62, P5590; Kitajima I, 1999, ANTISENSE NUCLEIC A, V9, P233, DOI 10.1089/oli.1.1999.9.233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Liau LM, 2000, CANCER RES, V60, P1353; LU R, 1998, P NATL ACAD SCI USA, V97, P3993; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; ZHOU J, 1993, J BIOL CHEM, V268, P10863	25	383	405	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					225	229		10.1038/nm816	http://dx.doi.org/10.1038/nm816			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12524533				2022-12-25	WOS:000180801900028
J	Kumagai, A; Dunphy, WG				Kumagai, A; Dunphy, WG			Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE CHECKPOINT; XENOPUS EGG EXTRACTS; BUDDING YEAST RAD9; REPLICATION CHECKPOINT; FHA DOMAIN; PROTEIN; ATR; PHOSPHORYLATION; KINASE; ACTIVATION	In vertebrates, the checkpoint-regulatory kinase Chk1 mediates cell-cycle arrest in response to a block in DNA replication or to DNA damaged by ultraviolet radiation. The activation of Chk1 depends on both Claspin and the upstream regulatory kinase ATR. Claspin is a large acidic protein that becomes phosphorylated and binds to Chk1 in the presence of checkpoint-inducing DNA templates in Xenopus egg extracts. Here we identify, by means of deletion analysis, a region of Claspin of 57 amino acids that is both necessary and sufficient for binding to Xenopus Chk1. This Chk1-binding domain contains two highly conserved repeats of approximately ten amino acids. A serine residue in each repeat (serine 864 and serine 895) undergoes phosphorylation during a checkpoint response. A mutant of Claspin containing non-phosphorylatable amino acids at positions 864 and 895 cannot bind to Chk1 and is unable to mediate its activation. Our results indicate that two phosphopeptide motifs in Claspin are essential for checkpoint signalling.	CALTECH, Howard Hughes Med Inst, Div Biol 21676, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Dunphy, WG (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol 21676, Pasadena, CA 91125 USA.							Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HUSE M, 2002, CELL, V275, P282; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Liu QH, 2000, GENE DEV, V14, P1448; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Pawson T, 2000, GENE DEV, V14, P1027; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	28	132	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					161	165		10.1038/ncb921	http://dx.doi.org/10.1038/ncb921			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545175				2022-12-25	WOS:000180802100017
J	Pollock, PM; Harper, UL; Hansen, KS; Yudt, LM; Stark, M; Robbins, CM; Moses, TY; Hostetter, G; Wagner, U; Kakareka, J; Salem, G; Pohida, T; Heenan, P; Duray, P; Kallioniemi, O; Hayward, NK; Trent, JM; Meltzer, PS				Pollock, PM; Harper, UL; Hansen, KS; Yudt, LM; Stark, M; Robbins, CM; Moses, TY; Hostetter, G; Wagner, U; Kakareka, J; Salem, G; Pohida, T; Heenan, P; Duray, P; Kallioniemi, O; Hayward, NK; Trent, JM; Meltzer, PS			High frequency of BRAF mutations in nevi	NATURE GENETICS			English	Article								To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Queensland Inst Med Res, Canc & Cell Biol Div, Herston, Qld 4006, Australia; NIH, Ctr Informat Technol, Bethesda, MD 20892 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Pathol, Nedlands, WA 6009, Australia; NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); QIMR Berghofer Medical Research Institute; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); University of Western Australia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Meltzer, PS (corresponding author), NHGRI, Canc Genet Branch, NIH, 50 South Dr, Bethesda, MD 20892 USA.		hayward, nick/AAV-8802-2020; Stark, Mitchell S/E-3542-2010; Stark, Mitchell/K-3874-2019; Kallioniemi, Olli P/H-5111-2011; Stark, Mitchell/K-6794-2019; hayward, nicholas k/C-1367-2015	Stark, Mitchell S/0000-0002-4510-2161; Kallioniemi, Olli P/0000-0002-3231-0332; Stark, Mitchell/0000-0002-4510-2161; hayward, nicholas k/0000-0003-4760-1033; Pollock, Pamela/0000-0001-8420-1026; Kakareka, John/0000-0003-0072-0035	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000261, ZIACT000261] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		ARMSTRONG BK, 1996, CANC EPIDEMIOLOGY PR; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; ELDER DE, 1991, ATLAS TUMOR PATHOL, P5; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844	6	1237	1267	0	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					19	20		10.1038/ng1054	http://dx.doi.org/10.1038/ng1054			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12447372				2022-12-25	WOS:000180136100010
J	Frigerio, S; Junt, T; Lu, B; Gerard, C; Zumsteg, U; Hollander, GA; Piali, L				Frigerio, S; Junt, T; Lu, B; Gerard, C; Zumsteg, U; Hollander, GA; Piali, L			beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT; MOLECULAR-CLONING; INTERFERON-GAMMA; CHEMOKINE; EXPRESSION; IDENTIFICATION; PROGRESSION; PROTEIN-1; CYTOKINE; RANTES	T cell-mediated loss of insulin-secreting betacells in the islets of Langerhans is the hallmark of type 1 diabetes. The molecular basis for the directed migration of autoreactive T cells leading to insulitis is presently unknown. Here we demonstrate that in response to inflammation, betacells secrete the chemokines CXC ligand 10 and CXC ligand 9, which specifically attract T-effector cells via the CXC chemokine receptor 3. In mice deficient for this receptor, the onset of type 1 diabetes is substantially delayed. Thus, in the absence of known etiological agents, CXC receptor 3 represents a novel target for therapeutic interference early in type 1 diabetes.	Res Dept, Basel, Switzerland; Dept Clin Biol Sci, Basel, Switzerland; Univ Childrens Hosp, Basel, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8006 Zurich, Switzerland; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Perlmutter Lab, Boston, MA 02115 USA	University of Zurich; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Hollander, GA (corresponding author), Res Dept, Basel, Switzerland.	georg-a.hollaender@unibas.ch	Junt, Tobias/AAE-4389-2021	Hollander, Georg/0000-0002-8790-0874				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chen MC, 2001, DIABETOLOGIA, V44, P325, DOI 10.1007/s001250051622; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Falcone M, 1999, CLIN IMMUNOL, V90, P2, DOI 10.1006/clim.1998.4619; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Kagi D, 1997, J EXP MED, V186, P989, DOI 10.1084/jem.186.7.989; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu B, 1999, EUR J IMMUNOL, V29, P3804, DOI 10.1002/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Savinov AY, 2001, J IMMUNOL, V167, P6637, DOI 10.4049/jimmunol.167.11.6637; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Suri A, 1999, IMMUNOL REV, V169, P55, DOI 10.1111/j.1600-065X.1999.tb01306.x; Tabiin MT, 2001, J AUTOIMMUN, V17, P229, DOI 10.1006/jaut.2001.0539; VANGURI P, 1990, J BIOL CHEM, V265, P15049; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Wang B, 1997, P NATL ACAD SCI USA, V94, P13844, DOI 10.1073/pnas.94.25.13844; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	45	236	248	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1414	1420		10.1038/nm792	http://dx.doi.org/10.1038/nm792			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415259				2022-12-25	WOS:000179552000038
J	Garcia-Cao, M; Gonzalo, S; Dean, D; Blasco, MA				Garcia-Cao, M; Gonzalo, S; Dean, D; Blasco, MA			A role for the Rb family of proteins in controlling telomere length	NATURE GENETICS			English	Article							HUMAN EPITHELIAL-CELLS; G-STRAND OVERHANG; CHROMOSOMAL INSTABILITY; MICE; FUSIONS; TRF1	The molecular mechanisms of cellular mortality have recently begun to be unraveled. In particular, it has been discovered that cells that lack telomerase are subject to telomere attrition with each round of replication, eventually leading to loss of telomere capping function at chromosome ends(1-5). Critically short telomeres and telomeres lacking telomere-binding proteins lose their functionality and are metabolized as DNA breaks, thus generating chromosomal fusions(1-8). Telomerase activity is sufficient to rescue short telomeres and confers an unlimited proliferative capacity(9-11). In addition, the tumor-suppressor pathway Cdkn2a/Rb1 has also been implicated as a barrier to immortalization(12-14). Here, we report a connection between the members of the retinoblastoma family of proteins, Rb1 (retinoblastoma 1), Rbl1 (retinoblastoma-like 1) and Rbl2 (retinoblastoma-like 2), and the mechanisms that regulate telomere length. In particular, mouse embryonic fibroblasts doubly deficient in Rbl1 and Rbl2 or triply deficient in Rbl1, Rbl2 and Rb1 have markedly elongated telomeres compared with those of wildtype or Rb1-deficient cells. This deregulation of telomere length is not associated with increased telomerase activity. Notably, the abnormally elongated telomeres in doubly or triply deficient cells retain their end-capping function, as shown by the normal frequency of chromosomal fusions. These findings demonstrate a connection between the Rb1 family and the control of telomere length in mammalian cells.	Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO USA	Washington University (WUSTL)	Blasco, MA (corresponding author), Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain.		Gonzalo, Susana/T-8275-2019; Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Gonzalo, Susana/0000-0001-9631-1206				Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; McIlrath J, 2001, CANCER RES, V61, P912; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; STOPPLER H, 1997, J BIOL CHEM, V272, P1332; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	29	97	100	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					415	419		10.1038/ng1011	http://dx.doi.org/10.1038/ng1011			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12379853				2022-12-25	WOS:000179034800019
J	Gruss, OJ; Wittmann, M; Yokoyama, H; Pepperkok, R; Kufer, T; Sillje, H; Karsenti, E; Mattaj, IW; Vernos, I				Gruss, OJ; Wittmann, M; Yokoyama, H; Pepperkok, R; Kufer, T; Sillje, H; Karsenti, E; Mattaj, IW; Vernos, I			Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; SMALL GTPASE RAN; MITOTIC-SPINDLE; SELF-ORGANIZATION; MAMMALIAN-CELLS; IMPORTIN-BETA; BOUND RAN; DROSOPHILA; PROTEIN; EMBRYOGENESIS	In Xenopus laevis egg extracts, TPX2 is required for the Ran-GTP-dependent assembly of microtubules around chromosomes. Here we show that interfering with the function of the human homologue of TPX2 in HeLa cells causes defects in microtubule organization during mitosis. Suppressing the expression of human TPX2 by RNA interference leads to the formation of two microtubule asters that do not interact and do not form a spindle. Our results suggest that in vivo, even in the presence of duplicated centrosomes, spindle formation requires the function of TPX2 to generate a stable bipolar spindle with overlapping antiparallel microtubule arrays. This indicates that chromosome-induced microtubule production is a general requirement for the formation of functional spindles in animal cells.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Gruss, OJ (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Kufer, Thomas A/I-5146-2015; Vernos, Isabelle/C-1687-2015	Kufer, Thomas A/0000-0003-4563-0412; Vernos, Isabelle/0000-0003-1469-9214; Mattaj, Iain/0000-0002-5537-8284; Pepperkok, Rainer/0000-0002-9762-3583				Bamba C, 2002, CURR BIOL, V12, P503, DOI 10.1016/S0960-9822(02)00741-8; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heidebrecht HJ, 1997, BLOOD, V90, P226; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llamazares S, 1999, J CELL SCI, V112, P659; Megraw TL, 2001, CURR BIOL, V11, P116, DOI 10.1016/S0960-9822(01)00017-3; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pepperkok R, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P23; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; STEIN GS, 1994, CELL BIOL LAB HDB, P282; Vaizel-Ohayon D, 1999, CURR BIOL, V9, P889, DOI 10.1016/S0960-9822(99)80393-5; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhang CM, 1999, J CELL SCI, V112, P2453; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	39	229	242	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					871	879		10.1038/ncb870	http://dx.doi.org/10.1038/ncb870			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12389033				2022-12-25	WOS:000179137700016
J	McLaurin, J; Cecal, R; Kierstead, ME; Tian, X; Phinney, AL; Manea, M; French, JE; Lambermon, MHL; Darabie, AA; Brown, ME; Janus, C; Chishti, MA; Horne, P; Westaway, D; Fraser, PE; Mount, HTJ; Przybylski, M; St George-Hyslop, P				McLaurin, J; Cecal, R; Kierstead, ME; Tian, X; Phinney, AL; Manea, M; French, JE; Lambermon, MHL; Darabie, AA; Brown, ME; Janus, C; Chishti, MA; Horne, P; Westaway, D; Fraser, PE; Mount, HTJ; Przybylski, M; St George-Hyslop, P			Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MOUSE MODEL; PROTEIN; EPITOPE; MICE; IDENTIFICATION; NEUROTOXICITY; IMMUNIZATION; DEPOSITION	Immunization of transgenic mouse models of Alzheimer disease using amyloid-beta pepticle (Abeta) reduces both the Alzheimer disease-like neuropathology and the spatial memory impairments of these mice. However, a therapeutic trial of immunization with Abeta(42) in humans was discontinued because a few patients developed significant meningo-encephalitic cellular inflammatory reactions. Here we show that beneficial effects in mice arise from antibodies selectively directed against residues 4-10 of Abeta(42), and that these antibodies inhibit both Abeta fibrillogenesis and cytotoxicity without eliciting an inflammatory response. These findings provide the basis for improved immunization antigens as well as attempts to design small-molecule mimics as alternative therapies.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; Univ Toronto, Dept Lab Med, Toronto, ON, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Konstanz, Dept Chem, Analyt Chem Lab, D-7750 Constance, Germany; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Konstanz; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada.	j.mclaurin@utoronto.ca; Michael.Przybylski@uni-konstanz.de	Mount, Howard/B-4097-2013					ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bauer SHJ, 2001, ANAL BIOCHEM, V298, P25, DOI 10.1006/abio.2001.5330; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Craig DB, 1996, ANAL CHEM, V68, P697, DOI 10.1021/ac950650z; Delgado M, 2001, Arch Physiol Biochem, V109, P372, DOI 10.1076/apab.109.4.372.4240; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Fligge TA, 2000, BIOCHEMISTRY-US, V39, P8491, DOI 10.1021/bi9922751; Frenkel D, 2000, J NEUROIMMUNOL, V106, P23, DOI 10.1016/S0165-5728(99)00232-5; FRIDMAN WH, 1997, MOL BIOL INTELLIGENC; GOWING E, 1994, J BIOL CHEM, V269, P10987; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hochleitner EO, 2000, PROTEIN SCI, V9, P487, DOI 10.1110/ps.9.3.487; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; KOHLMANN M, IN PRESS J PEPT SCI; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Macht M, 1996, BIOCHEMISTRY-US, V35, P15633, DOI 10.1021/bi961727w; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; Mayer-Fligge P, 1998, J PEPT SCI, V4, P355, DOI 10.1002/(SICI)1099-1387(199808)4:5<355::AID-PSC153>3.0.CO;2-3; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Papanastassiou M., 1994, J ECON BUS, V2, P199; Przybylski M, 1998, NATO ADV SCI I C-MAT, V510, P17; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; SUCKAU D, 1990, P NATL ACAD SCI USA, V87, P9848, DOI 10.1073/pnas.87.24.9848; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yang DS, 2001, AMYLOID, V8, P10; YOUHNOVSKI N, IN PRESS ANGEW CHEM	36	367	433	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1263	1269		10.1038/nm790	http://dx.doi.org/10.1038/nm790			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379850				2022-12-25	WOS:000179221200032
J	Wilson, SM; Bhattacharyya, B; Rachel, RA; Coppola, V; Tessarollo, L; Householder, DB; Fletcher, CF; Miller, RJ; Copeland, NG; Jenkins, NA				Wilson, SM; Bhattacharyya, B; Rachel, RA; Coppola, V; Tessarollo, L; Householder, DB; Fletcher, CF; Miller, RJ; Copeland, NG; Jenkins, NA			Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease	NATURE GENETICS			English	Article							NEUROMUSCULAR-JUNCTION; RECEPTORS; SUSCEPTIBILITY; MONOUBIQUITIN; LOCUS	Mice that are homozygous with respect to a mutation (ax J) in the ataxia (ax) gene develop severe tremors by 2-3 weeks of age followed by hindlimb paralysis and death by 6-10 weeks of age(1). Here we show that ax encodes ubiquitin-specific protease 14 (Usp14). Ubiquitin proteases are a large family of cysteine proteases that specifically cleave ubiquitin conjugates. Although Usp14 can cleave a ubiquitin-tagged protein in vitro, it is unable to process polyubiquitin 2, which is believed to be associated with the protein aggregates seen in Parkinson disease 3, spinocerebellar ataxia type 1 (SCA1; ref. 4) and gracile axonal dystrophy (GAD)(5). The physiological substrate of Usp14 may therefore contain a mono-ubiquitin side chain, the removal of which would regulate processes such as protein localization 6 and protein activity(7,8). Expression of Usp14 is significantly altered in ax(J)/ax(J) mice as a result of the insertion of an intracisternal-A particle (IAP) into intron 5 of Usp14. In contrast to other neurodegenerative disorders such as Parkinson disease and SCA1 in humans and GAD in mice, neither ubiquitin-positive protein aggregates nor neuronal cell loss is detectable in the central nervous system (CNS) of ax(J) mice. Instead, ax(J) mice have defects in synaptic transmission in both the central and peripheral nervous systems. These results suggest that ubiquitin proteases are important in regulating synaptic activity in mammals.	NCI, Mouse Canc Genet Program, Ft Detrick, MD 21702 USA; Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Novartis Fdn, Genom Inst, San Diego, CA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Northwestern University; Novartis	Jenkins, NA (corresponding author), NCI, Mouse Canc Genet Program, Ft Detrick, MD 21702 USA.		Coppola, Vincenzo/D-5352-2014; Coppola, Vincenzo/E-2917-2011	Coppola, Vincenzo/0000-0001-6163-1779; Coppola, Vincenzo/0000-0001-6163-1779; Wilson, Scott/0000-0001-9376-9430				Bhattacharyya BJ, 1997, SYNAPSE, V27, P367, DOI 10.1002/(SICI)1098-2396(199712)27:4<367::AID-SYN10>3.0.CO;2-P; BURT AM, 1980, ANAT REC, V196, P61, DOI 10.1002/ar.1091960107; Chain DG, 1999, MOL NEUROBIOL, V20, P125, DOI 10.1007/BF02742438; DAMATO CJ, 1965, ARCH PATHOL, V80, P604; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; DIONNE VE, 1975, J PHYSIOL-LONDON, V251, P245, DOI 10.1113/jphysiol.1975.sp011090; DUCHEN LW, 1968, Q J EXP PHYSIOL CMS, V53, P84, DOI 10.1113/expphysiol.1968.sp001948; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; KATZ B, 1957, J PHYSIOL-LONDON, V137, P267, DOI 10.1113/jphysiol.1957.sp005811; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; *MGD, 2001, MOUS GEN INF PROJ; Plomp JJ, 2000, BRAIN, V123, P463, DOI 10.1093/brain/123.3.463; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Royaux I, 1997, GENOMICS, V42, P479, DOI 10.1006/geno.1997.4772; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Schwab SG, 1998, AM J HUM GENET, V63, P1139, DOI 10.1086/302046; Sellin LC, 1996, PFLUG ARCH EUR J PHY, V431, P325, DOI 10.1007/BF02207269; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Silva AJ, 1996, CURR BIOL, V6, P1509, DOI 10.1016/S0960-9822(96)00756-7; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; WILSON DF, 1982, AM J PHYSIOL, V242, pC366, DOI 10.1152/ajpcell.1982.242.5.C366; Wilson SM, 2001, GENOMICS, V74, P228, DOI 10.1006/geno.2001.6554; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	30	218	225	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					420	425		10.1038/ng1006	http://dx.doi.org/10.1038/ng1006			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12368914				2022-12-25	WOS:000179034800020
J	Yamauchi, T; Kamon, J; Minokoshi, Y; Ito, Y; Waki, H; Uchida, S; Yamashita, S; Noda, M; Kita, S; Ueki, K; Eto, K; Akanuma, Y; Froguel, P; Foufelle, F; Ferre, P; Carling, D; Kimura, S; Nagai, R; Kahn, BB; Kadowaki, T				Yamauchi, T; Kamon, J; Minokoshi, Y; Ito, Y; Waki, H; Uchida, S; Yamashita, S; Noda, M; Kita, S; Ueki, K; Eto, K; Akanuma, Y; Froguel, P; Foufelle, F; Ferre, P; Carling, D; Kimura, S; Nagai, R; Kahn, BB; Kadowaki, T			Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; OBESITY; MICE; EXPRESSION; MECHANISM	Adiponectin (Ad) is a hormone secreted by adipocytes that regulates energy homeostasis and glucose and lipid metabolism. However, the signaling pathways that mediate the metabolic effects of Ad remain poorly identified. Here we show that phosphorylation and activation of the 5'-AMP-activated protein kinase (AMPK) are stimulated with globular and full-length Ad in skeletal muscle and only with full-length Ad in the liver. In parallel with its activation of AMPK, Ad stimulates phosphorylation of acetyl coenzyme A carboxylase (ACC), fatty-acid oxidation, glucose uptake and lactate production in myocytes, phosphorylation of ACC and reduction of molecules involved in gluconeogenesis in the liver, and reduction of glucose levels in vivo. Blocking AMPK activation by dominant-negative mutant inhibits each of these effects, indicating that stimulation of glucose utilization and fatty-acid oxidation by Ad occurs through activation of AMPK. Our data may provide a novel paradigm that an adipocyte-derived antidiabetic hormone, Ad, activates AMPK, thereby directly regulating glucose metabolism and insulin sensitivity in vitro and in vivo.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Saitama, Japan; Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo, Japan; Inst Pasteur, CNRS, Inst Biol, F-59019 Lille, France; Ctr Rech Biomed Cordeliers, INSERM, U465, Paris, France; Hammersmith Hosp, Imperial Coll Sch Med, MRC, Clin Sci Ctr,Cellular Stress Grp, London, England	University of Tokyo; Japan Science & Technology Agency (JST); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Asahi Life Foundation; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Imperial College London	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan.		Carling, David/F-1943-2014; Robles-Sardin, Alma E/M-7714-2015; Ferré, Pascal/K-1250-2013; FROGUEL, Philippe/O-6799-2017; sheng, jian/E-9474-2012; Noda, Mitsuhiko/W-3905-2019; Waki, Hironori/AAE-3942-2020	Carling, David/0000-0002-2316-1830; Robles-Sardin, Alma E/0000-0003-2044-7793; Ferré, Pascal/0000-0003-0115-7045; FROGUEL, Philippe/0000-0003-2972-0784; Noda, Mitsuhiko/0000-0003-0413-4631; Waki, Hironori/0000-0002-5302-9793; Minokoshi, Yasuhiko/0000-0002-7119-4805; FOUFELLE, Fabienne/0000-0002-0752-622X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056116, R01DK043051] Funding Source: NIH RePORTER; Medical Research Council [G0000477] Funding Source: Medline; NIDDK NIH HHS [R01 DK 43051, P01 DK 56116] Funding Source: Medline; MRC [G0000477] Funding Source: UKRI	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsubamoto Y, 2001, J BIOL CHEM, V276, P2979, DOI 10.1074/jbc.M005816200; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	25	3192	3416	8	387	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1288	1295		10.1038/nm788	http://dx.doi.org/10.1038/nm788			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368907				2022-12-25	WOS:000179221200036
J	Lindsten, K; Menendez-Benito, V; Masucci, MG; Dantuma, NP				Lindsten, K; Menendez-Benito, V; Masucci, MG; Dantuma, NP			A transgenic mouse model of the ubiquitin/proteasome system	NATURE BIOTECHNOLOGY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; NEURODEGENERATIVE DISEASES; INTRANUCLEAR INCLUSIONS; KAPOSI-SARCOMA; PROTEIN; DEGRADATION; INHIBITORS; CELLS; AGGREGATION; ALZHEIMERS	Impairment of the ubiquitin/proteasome system has been proposed to play a role in neurodegenerative disorders such as Alzheimer and Parkinson diseases. Although recent studies confirmed that some disease-related proteins block proteasomal degradation, and despite the existence of excellent animal models of both diseases, in vivo data about the system are lacking. We have developed a model for in vivo analysis of the ubiquitin/proteasome system by generating mouse strains transgenic for a green fluorescent protein (GFP) reporter carrying a constitutively active degradation signal. Administration of proteasome inhibitors to the transgenic animals resulted in a substantial accumulation of GFP in multiple tissues, confirming the in vivo functionality of the reporter. Moreover, accumulation of the reporter was induced in primary neurons by UBB+1, an aberrant ubiquitin found in Alzheimer disease. These transgenic animals provide a tool for monitoring the status of the ubiquitin/proteasome system in physiologic or pathologic conditions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Dantuma, NP (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.		Masucci, Maria/AAC-6666-2019; Masucci, Maria G/B-8588-2009	Masucci, Maria/0000-0002-5541-2809; Menendez-Benito, Victoria/0000-0001-5312-3037; Dantuma, Nico/0000-0002-6090-4170				Aghajanian C, 2002, CLIN CANCER RES, V8, P2505; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Denk H, 2000, J HEPATOL, V32, P689, DOI 10.1016/S0168-8278(00)80233-0; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Floyd JA, 1999, NEURON, V24, P765, DOI 10.1016/S0896-6273(00)81022-3; French BA, 2001, EXP MOL PATHOL, V71, P241, DOI 10.1006/exmp.2001.2401; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hosseini H, 2001, J NEUROIMMUNOL, V118, P233, DOI 10.1016/S0165-5728(01)00352-6; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034; LINDSTEN K, IN PRESS AGEING RES; Luo HY, 2001, TRANSPLANTATION, V72, P196, DOI 10.1097/00007890-200107270-00005; McCormack T, 1997, J BIOL CHEM, V272, P26103, DOI 10.1074/jbc.272.42.26103; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Meng LH, 1999, CANCER RES, V59, P2798; Mizuno Y, 2001, CURR OPIN NEUROL, V14, P477, DOI 10.1097/00019052-200108000-00008; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pati S, 2002, BLOOD, V99, P3771, DOI 10.1182/blood.V99.10.3771; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zollner TM, 2002, J CLIN INVEST, V109, P671, DOI 10.1172/JCI200212736	47	176	186	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					897	902		10.1038/nbt851	http://dx.doi.org/10.1038/nbt851			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12872133				2022-12-25	WOS:000184484600032
J	Cao, BH; Zheng, B; Jankowski, RJ; Kimura, S; Ikezawa, M; Deasy, B; Cummins, J; Epperly, M; Qu-Petersen, Z; Huard, J				Cao, BH; Zheng, B; Jankowski, RJ; Kimura, S; Ikezawa, M; Deasy, B; Cummins, J; Epperly, M; Qu-Petersen, Z; Huard, J			Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential	NATURE CELL BIOLOGY			English	Article							BONE-MARROW; PROGENITOR CELLS; MDX MICE; DYSTROPHIN; REGENERATION; TRANSPLANTATION; PLASTICITY; PROTEINS; SKELETAL; THERAPY	Muscle-derived stem cells (MDSCs) can differentiate into multiple lineages, including haematopoietic lineages(1-12). However, it is unknown whether MDSCs preserve their myogenic potential after differentiation into other lineages. To address this issue, we isolated from dystrophic muscle a population of MDSCs that express stem-cell markers and can differentiate into various lineages(1,13). After systemic delivery of three MDSC clones into lethally irradiated mice, we found that differentiation of the donor cells into various lineages of the haematopoietic system resulted in repopulation of the recipients' bone marrow. Donor-derived bone-marrow cells, isolated from these recipients by fluorescence-activated cell sorting (FACS), also repopulated the bone marrow of secondary, lethally irradiated, recipients and differentiated into myogenic cells both in vitro and in vivo in normal mdx mice. These findings demonstrate that MDSC clones retain their myogenic potential after haematopoietic differentiation.	Childrens Hosp, Dept Orthopaed Surg & Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA 15213 USA; Kumamoto Univ, Sch Med, Dept Child Dev, Kumamoto 860, Japan; Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kumamoto University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huard, J (corresponding author), Childrens Hosp, Dept Orthopaed Surg & Mol Genet & Biochem, Pittsburgh, PA 15213 USA.	jhuard@pitt.edu			NIAMS NIH HHS [P01 AR 45925, R01 AR 49684-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045925, R01AR049684] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Geiger H, 2002, BLOOD, V100, P721, DOI 10.1182/blood.V100.2.721; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Goldring K, 2002, J PATHOL, V197, P457, DOI 10.1002/path.1157; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson KA, 2002, J CELL BIOCHEM, P1, DOI 10.1002/jcb.10045; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	29	194	216	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2003	5	7					640	646		10.1038/ncb1008	http://dx.doi.org/10.1038/ncb1008			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	696WY	12792651				2022-12-25	WOS:000183911600014
J	Clyne, RK; Katis, VL; Jessop, L; Benjamin, KR; Herskowitz, I; Lichten, M; Nasmyth, K				Clyne, RK; Katis, VL; Jessop, L; Benjamin, KR; Herskowitz, I; Lichten, M; Nasmyth, K			Polo-like kinase Cdc5 promotes chiasmata formation and cosegregation of sister centromeres at meiosis I	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; MEIOTIC RECOMBINATION; PROTEIN; COHESIN; ANAPHASE; CHROMOSOMES; SEGREGATION; SPORULATION; CLEAVAGE; COMPLEX	During meiosis, two rounds of chromosome segregation occur after a single round of DNA replication, producing haploid progeny from diploid progenitors. Three innovations in chromosome behaviour during meiosis I accomplish this unique division. First, crossovers between maternal and paternal sister chromatids (detected cytologically as chiasmata) bind replicated maternal and paternal chromosomes together. Second, sister kinetochores attach to microtubules from the same pole (mono-polar orientation), causing maternal and paternal centromere pairs (and not sister chromatids) to be separated. Third, sister chromatid cohesion near centromeres is preserved at anaphase I when cohesion along chromosome arms is destroyed. The finding that destruction of mitotic cohesion is regulated by Polo-like kinases(1,2) prompted us to investigate the meiotic role of the yeast Polo-like kinase Cdc5. We show here that cells lacking Cdc5 synapse homologues and initiate recombination normally, but fail to efficiently resolve recombination intermediates as crossovers. They also fail to properly localize the Lrs4 (ref. 3) and Mam1 (ref. 4) monopolin proteins, resulting in bipolar orientation of sister kinetochores. Cdc5 is thus required both for the formation of chiasmata and for cosegregation of sister centromeres at meiosis I.	Res Inst Mol Pathol, A-1030 Vienna, Austria; NCI, Biochem Lab, Canc Res Ctr, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Lichten, Michael/C-5795-2013	Lichten, Michael/0000-0001-9707-2956; Nasmyth, Kim/0000-0001-7030-4403; Benjamin, Kirsten/0000-0003-4267-1972				Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Allers T, 2001, MOL CELL, V8, P225, DOI 10.1016/S1097-2765(01)00280-5; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6	24	170	176	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					480	485		10.1038/ncb977	http://dx.doi.org/10.1038/ncb977			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717442				2022-12-25	WOS:000182691400024
J	Fantes, J; Ragge, NK; Lynch, SA; McGill, NI; Collin, JRO; Howard-Peebles, PN; Hayward, C; Vivian, AJ; Williamson, K; van Heyningen, V; FitzPatrick, DR				Fantes, J; Ragge, NK; Lynch, SA; McGill, NI; Collin, JRO; Howard-Peebles, PN; Hayward, C; Vivian, AJ; Williamson, K; van Heyningen, V; FitzPatrick, DR			Mutations in SOX2 cause anophthalmia	NATURE GENETICS			English	Article							EXPRESSION; GENE; ARM	A submicroscopic deletion containing SOX2 was identified at the 3q breakpoint in a child with t(3;11)(q26.3;p11.2) associated with bilateral anophthalmia. Subsequent SOX2 mutation analysis identified de novo truncating mutations of SOX2 in 4 of 35 (11%) individuals with anophthalmia. Both eyes were affected in all cases with an identified mutation.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; St Thomas Hosp, Dept Ophthalmol, London, England; Moorfields Eye Hosp, Adnexal Serv, London, ON, Canada; Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England; Genet & IVF Inst, Fairfax, VA 22039 USA; W Suffolk Hosp, Dept Ophthalmol, Bury St Edmunds, Suffolk, England; Addenbrookes Hosp, Cambridge, England	University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	FitzPatrick, DR (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	david.fitzpatrick@hgu.mrc.ac.uk	FitzPatrick, David R/B-8311-2008; Hayward, Caroline/M-8818-2016; VAN HEYNINGEN, Veronica/GYE-0531-2022; FitzPatrick, David R/C-7301-2013; van Heyningen, Veronica/B-8039-2008	Hayward, Caroline/0000-0002-9405-9550; van Heyningen, Veronica/0000-0003-0359-0141; Lynch, Sally Ann/0000-0003-3540-1333; FitzPatrick, David R./0000-0003-4861-969X	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Chitayat D, 1996, AM J MED GENET, V61, P45, DOI 10.1002/(SICI)1096-8628(19960102)61:1<45::AID-AJMG9>3.0.CO;2-W; Driggers RW, 1999, AM J MED GENET, V87, P201, DOI 10.1002/(SICI)1096-8628(19991126)87:3<201::AID-AJMG1>3.0.CO;2-H; Guan XY, 1996, NAT GENET, V12, P10, DOI 10.1038/ng0196-10; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kurbasic M, 2000, Ophthalmic Genet, V21, P239, DOI 10.1076/1381-6810(200012)21:4;1-H;FT239; Le Rouedec D, 2002, J ANAT, V200, P51, DOI 10.1046/j.0021-8782.2001.00007.x; Male A, 2002, EUR J HUM GENET, V10, P807, DOI 10.1038/sj.ejhg.5200890; STEVANOVIC M, 1994, MAMM GENOME, V5, P640, DOI 10.1007/BF00411460; Szymanski M, 2002, GENOME BIOL, V3; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Zappone MV, 2000, DEVELOPMENT, V127, P2367	13	400	415	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2003	33	4					461	463		10.1038/ng1120	http://dx.doi.org/10.1038/ng1120			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	662CM	12612584	Bronze			2022-12-25	WOS:000181928600014
J	Kawasaki, Y; Sato, R; Akiyama, T				Kawasaki, Y; Sato, R; Akiyama, T			Mutated APC and Asef are involved in the migration of colorectal tumour cells	NATURE CELL BIOLOGY			English	Article							EPITHELIAL-CELLS; SUPPRESSOR; MUTATIONS; MOTILITY; ADHESION; MICROTUBULES; PROMOTES; CANCER; GENE; RAC		Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.	akiyama@iam.u-tokyo.ac.jp						Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Oshima H, 1997, CANCER RES, V57, P1644; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SMITH KJ, 1994, CANCER RES, V54, P3672; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	27	176	185	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					211	215		10.1038/ncb937	http://dx.doi.org/10.1038/ncb937			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598901				2022-12-25	WOS:000181322500013
J	Phillips, MS; Lawrence, R; Sachidanandam, R; Morris, AP; Balding, DJ; Donaldson, MA; Studebaker, JF; Ankener, WM; Alfisi, SV; Kuo, FS; Camisa, AL; Pazorov, V; Scott, KE; Carey, BJ; Faith, J; Katari, G; Bhatti, HA; Cyr, JM; Derohannessian, V; Elosua, C; Forman, AM; Grecco, NM; Hock, CR; Kuebler, JM; Lathrop, JA; Mockler, MA; Nachtman, EP; Restine, SL; Varde, SA; Hozza, MJ; Gelfand, CA; Broxholme, J; Abecasis, GR; Boyce-Jacino, MT; Cardon, LR				Phillips, MS; Lawrence, R; Sachidanandam, R; Morris, AP; Balding, DJ; Donaldson, MA; Studebaker, JF; Ankener, WM; Alfisi, SV; Kuo, FS; Camisa, AL; Pazorov, V; Scott, KE; Carey, BJ; Faith, J; Katari, G; Bhatti, HA; Cyr, JM; Derohannessian, V; Elosua, C; Forman, AM; Grecco, NM; Hock, CR; Kuebler, JM; Lathrop, JA; Mockler, MA; Nachtman, EP; Restine, SL; Varde, SA; Hozza, MJ; Gelfand, CA; Broxholme, J; Abecasis, GR; Boyce-Jacino, MT; Cardon, LR			Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots	NATURE GENETICS			English	Article							GENOME SEQUENCE VARIATION; LINKAGE DISEQUILIBRIUM; MEIOTIC RECOMBINATION; DIVERSITY; MAP	Recent studies of human populations suggest that the genome consists of chromosome segments that are ancestrally conserved ('haplotype blocks'; refs. 1-3) and have discrete boundaries defined by recombination hot spots(4,5). Using publicly available genetic markers(6), we have constructed a first-generation haplotype map of chromosome 19. As expected for this marker density(7), approximately one-third of the chromosome is encompassed within haplotype blocks. Evolutionary modeling of the data indicates that recombination hot spots are not required to explain most of the observed blocks, providing that marker ascertainment and the observed marker spacing are considered. In contrast, several long blocks are inconsistent with our evolutionary models, and different mechanisms could explain their origins.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Orchid Biosci Inc, Princeton, NJ 08540 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, Fac Med, London W2 1PG, England; Univ Michigan, Ann Arbor, MI 48109 USA	University of Oxford; Wellcome Centre for Human Genetics; Cold Spring Harbor Laboratory; Imperial College London; University of Michigan System; University of Michigan	Cardon, LR (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	lon.cardon@well.ox.ac.uk	Abecasis, Goncalo R/B-7840-2010; sachidanandam, ravi/Q-6916-2019; Bhatti, Huma Aslam/AAX-1837-2021; Balding, David/G-9898-2011	sachidanandam, ravi/0000-0001-9844-4459; Balding, David/0000-0002-1480-6115; Abecasis, Goncalo/0000-0003-1509-1825; Kuo, Fengshen/0000-0003-1797-2896				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Bell PA, 2002, BIOTECHNIQUES, P70; Casci T, 2002, NAT REV GENET, V3, P573, DOI 10.1038/nrg867; Couzin J, 2002, SCIENCE, V296, P1391, DOI 10.1126/science.296.5572.1391; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; Eberle MA, 2000, GENET EPIDEMIOL, V19, pS29, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI5>3.0.CO;2-P; Fan JB, 2000, GENOME RES, V10, P853, DOI 10.1101/gr.10.6.853; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; Griffiths RC, 1996, J COMPUT BIOL, V3, P479, DOI 10.1089/cmb.1996.3.479; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; McKeigue PM, 1997, AM J HUM GENET, V60, P188; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Reich DE, 2002, NAT GENET, V32, P135, DOI 10.1038/ng947; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Smith RA, 1998, BLOOD, V92, P4415, DOI 10.1182/blood.V92.11.4415.423a07_4415_4421; Subrahmanyan L, 2001, AM J HUM GENET, V69, P381, DOI 10.1086/321297; Thompson EA, 1986, PEDIGREE ANAL HUMAN; WEIR BS, 1996, GENETIC DATA ANAL, V2, P113; Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1	30	225	251	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2003	33	3					382	387		10.1038/ng1100	http://dx.doi.org/10.1038/ng1100			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12590262				2022-12-25	WOS:000181312700015
J	Chen, WY; Zeng, XB; Carter, MG; Morrell, CN; Yen, RWC; Esteller, M; Watkins, DN; Herman, JG; Mankowski, JL; Baylin, SB				Chen, WY; Zeng, XB; Carter, MG; Morrell, CN; Yen, RWC; Esteller, M; Watkins, DN; Herman, JG; Mankowski, JL; Baylin, SB			Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors	NATURE GENETICS			English	Article							SUPPRESSOR GENE; DNA HYPERMETHYLATION; CANCER; TUMORIGENESIS; METHYLATION; P53; EXPRESSION; P16(INK4A); RETENTION	The gene hypermethylated in cancer-1 (HIC1) encodes a zinc-finger transcription factor(1) that belongs to a group of proteins known as the POZ family(2). HIC1 is hypermethylated and transcriptionally silent in several types of human cancer(1,3-5). Homozygous disruption of Hic1 impairs development and results in embryonic and perinatal lethality in mice(6). Here we show that mice disrupted in the germ line for only one allele of Hic1 develop many different spontaneous malignant tumors, including a predominance of epithelial cancers in males and lymphomas and sarcomas in females. The complete loss of Hic1 function in the heterozygous mice seems to involve dense methylation of the promoter of the remaining wild-type allele. We conclude that HIC1 is a candidate tumor-suppressor gene for which loss of function in both mouse and human cancers is associated only with epigenetic modifications.	Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Div Tumor Biol, Baltimore, MD 21231 USA; NIA, Genet Lab, Dev Genom & Aging Sect, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21205 USA; Ctr Nacl Invest Oncol, Mol Pathol Program, Canc Epigenet Lab, Madrid, Spain	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Div Tumor Biol, 1650 Orleans St, Baltimore, MD 21231 USA.		Carter, Mark/B-5089-2010; Chen, WenYong/D-6748-2012; Watkins, David N/I-6113-2013; Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Chen, WenYong/0000-0001-6913-5729				BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 1997, CANCER RES, V57, P1678; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; KAWADA K, 1978, ACTA PATHOL JAPON, V28, P25; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LUONGO C, 1994, CANCER RES, V54, P5947; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	23	171	189	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					197	202		10.1038/ng1077	http://dx.doi.org/10.1038/ng1077			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12539045				2022-12-25	WOS:000180773700020
J	Kreitzer, G; Schmoranzer, J; Low, SH; Li, X; Gan, YB; Weimbs, T; Simon, SM; Rodriguez-Boulan, E				Kreitzer, G; Schmoranzer, J; Low, SH; Li, X; Gan, YB; Weimbs, T; Simon, SM; Rodriguez-Boulan, E			Three-dimensional analysis of post-Golgi carrier exocytosis in epithelial cells	NATURE CELL BIOLOGY			English	Article							BASOLATERAL PLASMA-MEMBRANE; PROTEIN DELIVERY; APICAL TRANSPORT; CYTOPLASMIC TAIL; SEC6/8 COMPLEX; MICROTUBULES; RECEPTOR; TRAFFICKING; NOCODAZOLE; ORGANIZATION	Targeted delivery of proteins to distinct plasma membrane domains is critical to the development and maintenance of polarity in epithelial cells. We used confocal and time-lapse total internal reflection fluorescence microscopy (TIR-FM) to study changes in localization and exocytic sites of post-Golgi transport intermediates (PGTIs) carrying GFP-tagged apical or basolateral membrane proteins during epithelial polarization. In non-polarized Madin Darby Canine Kidney (MDCK) cells, apical and basolateral PGTIs were present throughout the cytoplasm and were observed to fuse with the basal domain of the plasma membrane. During polarization, apical and basolateral PGTIs were restricted to different regions of the cytoplasm and their fusion with the basal membrane was completely abrogated. Quantitative analysis suggested that basolateral, but not apical, PGTIs fused with the lateral membrane in polarized cells, correlating with the restricted localization of Syntaxins 4 and 3 to lateral and apical membrane domains, respectively. Microtubule disruption induced Syntaxin 3 depolarization and fusion of apical PGTIs with the basal membrane, but affected neither the lateral localization of Syntaxin 4 or Sec6, nor promoted fusion of basolateral PGTIs with the basal membrane.	Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA; Free Univ Berlin, Dept Biol Chem Pharmacol, D-14195 Berlin, Germany; Cleveland Clin, Glickman Urol Inst, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cornell University; Cornell University; Rockefeller University; Free University of Berlin; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kreitzer, G (corresponding author), Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, New York, NY 10021 USA.	ggurlan@med.cornell.edu; boulan@med.cornell.edu		Schmoranzer, Jan/0000-0002-4482-7080; Simon, Sanford/0000-0002-8615-4224; Weimbs, Thomas/0000-0001-9423-5561; Li, Xin/0000-0002-7414-5734	NEI NIH HHS [R01 EY008538, EY06886] Funding Source: Medline; NIDDK NIH HHS [DK62338] Funding Source: Medline; NIGMS NIH HHS [GM34107, R01 GM034107] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DEALMEIDA JB, 1991, AM J PHYSIOL, V261, pC691, DOI 10.1152/ajpcell.1991.261.1.C691; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HUGON JS, 1987, CELL TISSUE RES, V248, P653, DOI 10.1007/BF00216496; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; LAFONT F, 1994, NATURE, V372, P801; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEGALL AH, 1995, SEMIN NEPHROL, V15, P272; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 2000, MOL BIOL CELL, V11, P3045, DOI 10.1091/mbc.11.9.3045; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Lowe M, 2000, CURR BIOL, V10, pR407, DOI 10.1016/S0960-9822(00)00505-4; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Toomre D, 1999, J CELL SCI, V112, P21; Wacker I, 1997, J CELL SCI, V110, P1453; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9	50	174	179	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2003	5	2					126	136		10.1038/ncb917	http://dx.doi.org/10.1038/ncb917			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	642KF	12545172				2022-12-25	WOS:000180802100012
J	Kaltschmidt, JA; Lawrence, N; Morel, V; Balayo, T; Fernandez, BG; Pelissier, A; Jacinto, A; Arias, AM				Kaltschmidt, JA; Lawrence, N; Morel, V; Balayo, T; Fernandez, BG; Pelissier, A; Jacinto, A; Arias, AM			Planar polarity and actin dynamics in the epidermis of Drosophila	NATURE CELL BIOLOGY			English	Article							AMINO-TERMINAL KINASE; CELL SHEET MOVEMENT; DORSAL CLOSURE; MORPHOGENESIS; JUN; WINGLESS; PROTEIN; PATHWAY; ROLES; JNK	Dorsal closure is a morphogenetic process involving the coordinated convergence of two epithelial sheets to enclose the Drosophila melanogaster embryo. Specialized populations of cells at the edges of each epithelial sheet, the dorsal-most epidermal cells, emit actin-based processes that are essential for the proper enclosure of the embryo. Here we show that actin dynamics at the leading edge is preceded by a planar polarization of the dorsal-most epidermal cells associated with a reorganization of the cytoskeleton. An important consequence of this planar polarization is the formation of actin-nucleating centres at the leading edge, which are important in the dynamics of actin. We show that Wingless (Wg) signalling and Jun amino-terminal kinase (JNK) signalling have overlapping but different roles in these events.	Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal	University of Cambridge; Instituto Gulbenkian de Ciencia	Kaltschmidt, JA (corresponding author), Univ Cambridge, Dept Genet, Downing St, Cambridge CB2 3EH, England.		Martinez Arias, Alfonso/F-1966-2010; Jacinto, Antonio/F-5729-2013; Morel, Veronique/ABF-8617-2020	Jacinto, Antonio/0000-0002-4193-6089; Morel, Veronique/0000-0001-7741-1228; Lawrence, Nicola/0000-0001-9773-2360; Balayo, Tina/0000-0002-2185-6989; Garcia Fernandez, Beatriz/0000-0001-9215-2447				Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; ARIAS AM, 1993, DEV DROSOPHILA MELAN, P517; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHOU TB, 1992, GENETICS, V131, P643; CRAIG G, UNPUB NOTCH REGULATE; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Eaton S, 1997, CURR OPIN CELL BIOL, V9, P860, DOI 10.1016/S0955-0674(97)80089-0; Fernandez R, 2000, GENE DEV, V14, P604; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Harden N, 2002, J CELL SCI, V115, P2119; HARDEN N, 1995, DEVELOPMENT, V121, P903; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Klein T, 1998, DEV BIOL, V194, P196, DOI 10.1006/dbio.1997.8829; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Magie CR, 1999, DEVELOPMENT, V126, P5353; McEwen DG, 2000, DEVELOPMENT, V127, P3607; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Pai LM, 1997, DEVELOPMENT, V124, P2255; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; Reed BH, 2001, CURR BIOL, V11, P1098, DOI 10.1016/S0960-9822(01)00318-9; Ricos MG, 1999, J CELL SCI, V112, P1225; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RING JM, 1993, DEVELOPMENT, P251; Shimada Y, 2001, CURR BIOL, V11, P859, DOI 10.1016/S0960-9822(01)00233-0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Tada M, 2000, DEVELOPMENT, V127, P2227; Takahashi K, 1998, MECH DEVELOP, V78, P97, DOI 10.1016/S0925-4773(98)00151-8; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5	49	95	97	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2002	4	12					937	944		10.1038/ncb882	http://dx.doi.org/10.1038/ncb882			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	621CW	12447392				2022-12-25	WOS:000179571800013
J	Thomas, SM; Hopkins, MM; Brady, M				Thomas, SM; Hopkins, MM; Brady, M			Shares in the human genome - the future of patenting DNA	NATURE BIOTECHNOLOGY			English	Editorial Material									Nuffield Council Bioeth, London, England; Univ Sussex, SPRU, Brighton, E Sussex, England; Perexel MMS, Hackensack, NJ USA	University of Sussex	Thomas, SM (corresponding author), Nuffield Council Bioeth, London, England.							Barton JH, 2000, SCIENCE, V287, P1933, DOI 10.1126/science.287.5460.1933; Cho M. K., 1998, PREPARING MILLENNIUM, P47; Commission on Intellectual Property Rights, 2002, INT INT PROP RIGHTS; *GEN INC, 2002, ANN REP 2001; *HYS PHARM INC, 2002, ANN REP 2001; Merz JF, 2002, NATURE, V415, P577, DOI 10.1038/415577a; *MYR GEN INC, 2002, ANN REP 2001; *NAT AC COMM INT P, 2001, P C OP PAT SYST INS; *NUFF COUNC BIOETH, 2002, ETH PAT DNA; STRAUSS J, 2001, GEWERBLICHER RECHTSS, V10, P1016; Thomas SM, 1996, NATURE, V380, P387, DOI 10.1038/380387a0	11	19	19	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1185	1188		10.1038/nbt1202-1185	http://dx.doi.org/10.1038/nbt1202-1185			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12454661				2022-12-25	WOS:000179552600023
J	Schubeler, D; Scalzo, D; Kooperberg, C; van Steensel, B; Delrow, J; Groudine, M				Schubeler, D; Scalzo, D; Kooperberg, C; van Steensel, B; Delrow, J; Groudine, M			Genome-wide DNA replication profile for Drosophila melanogaster: a link between transcription and replication timing	NATURE GENETICS			English	Article							MAMMALIAN-CELLS; GENE-EXPRESSION; HETEROCHROMATIN; ORGANIZATION; ASSOCIATION; REGION; LOCUS	Replication of the genome before mitotic cell division is a highly regulated process that ensures the fidelity of DNA duplication. DNA replication initiates at specific locations, termed origins of replication, and progresses in a defined temporal order during the S phase of the cell cycle. The relationship between replication timing and gene expression has been the subject of some speculation(1). A recent genome-wide analysis in Saccharomyces cerevisiae showed no association between replication timing and gene expression(2). In higher eukaryotes, the limited number of genomic loci analyzed has not permitted a firm conclusion regarding this association. To explore the relationship between DNA replication and gene expression in higher eukaryotes, we developed a strategy to measure the timing of DNA replication for thousands of genes in a single DNA array hybridization experiment. Using this approach, we generated a genome-wide map of replication timing for Drosophila melanogaster. Moreover, by surveying over 40% of all D. melanogaster genes, we found a strong correlation between DNA replication early in S phase and transcriptional activity. As this correlation does not exist in S. cerevisiae, this interplay between DNA replication and transcription may be a unique characteristic of higher eukaryotes.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Netherlands Canc Inst, Amsterdam, Netherlands; Fred Hutchinson Canc Res Ctr, DNA Array Facil, Seattle, WA 98104 USA; Univ Washington, Dept Radiat Oncol, Seattle, WA USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Netherlands Cancer Institute; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Schubeler, D (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.							Ahmad K, 2001, J CELL BIOL, V153, P101, DOI 10.1083/jcb.153.1.101; CAIZZI R, 1993, GENETICS, V133, P335; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DOLFINI S, 1970, EXPERIENTIA, V26, P1020, DOI 10.1007/BF02114171; EBERL DF, 1993, GENETICS, V134, P277; Fan J., 1996, LOCAL POLYNOMIAL MOD; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; HANSEN RS, 1995, HUM MOL GENET, V4, P813; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; JAKUBCZAK JL, 1992, GENETICS, V131, P129; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kooperberg C, 2002, J COMPUT BIOL, V9, P55, DOI 10.1089/10665270252833190; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; Sullivan B, 2001, J CELL BIOL, V154, P683, DOI 10.1083/jcb.200103001; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; WAKIMOTO BT, 1990, GENETICS, V125, P141; Yang YH, 2001, MICROARRAYS OPTICAL	25	263	272	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2002	32	3					438	442		10.1038/ng1005	http://dx.doi.org/10.1038/ng1005			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	611TX	12355067				2022-12-25	WOS:000179034800023
J	Mongkolsapaya, J; Dejnirattisai, W; Xu, XN; Vasanawathana, S; Tangthawornchaikul, N; Chairunsri, A; Sawasdivorn, S; Duangchinda, T; Dong, T; Rowland-Jones, S; Yenchitsomanus, PT; McMichael, A; Malasit, P; Screaton, G				Mongkolsapaya, J; Dejnirattisai, W; Xu, XN; Vasanawathana, S; Tangthawornchaikul, N; Chairunsri, A; Sawasdivorn, S; Duangchinda, T; Dong, T; Rowland-Jones, S; Yenchitsomanus, PT; McMichael, A; Malasit, P; Screaton, G			Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; HETEROLOGOUS ANTIVIRAL IMMUNITY; VIRUS-INFECTION; CHORIOMENINGITIS VIRUS; DISEASE SEVERITY; PERSISTENT VIRUS; CELLS; RESPONSES; ANTIBODY; IMMUNOPATHOGENESIS	Dengue virus presents a growing threat to public health in the developing world. Four major serotypes of dengue virus have been characterized, and epidemiological evidence shows that dengue hemorrhagic fever (DHF), the more serious manifestation of the disease, occurs more frequently upon reinfection with a second serotype. We have studied dengue virus-specific T-cell responses in Thai children. During acute infection, few dengue-responsive CD8(+) T cells were recovered; most of those present showed an activated phenotype and were undergoing programmed cell death. Many dengue-specific T cells were of low affinity for the infecting virus and showed higher affinity for other, probably previously encountered strains. Profound T-cell activation and death may contribute to the systemic disturbances leading to DHF, and original antigenic sin in the T-cell responses may suppress or delay viral elimination, leading to higher viral loads and increased immunopathology.	John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Mahidol Univ, Siriraj Hosp, Fac Med, Med Mol Biol Unit, Bangkok 10700, Thailand; Minist Publ Hlth, Khon Kaen Hosp, Dept Pediat, Khon Kaen 40000, Thailand; Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Med Biotechnol Unit, Pathum Thani 12120, Thailand; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Queen Sirikit Natl Inst Child Hlth, Bangkok 10400, Thailand	University of Oxford; Mahidol University; Ministry of Public Health - Thailand; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); University of Oxford	Screaton, G (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.			Dong, Tao/0000-0003-3545-3758; Screaton, Gavin/0000-0002-3549-4309				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Chandanayingyong D, 1997, HUM IMMUNOL, V53, P174, DOI 10.1016/S0198-8859(96)00284-4; Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; Combadiere B, 1998, J EXP MED, V187, P349, DOI 10.1084/jem.187.3.349; Davenport MP, 2002, J IMMUNOL, V168, P3309, DOI 10.4049/jimmunol.168.7.3309; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Guzman MG, 2000, AM J EPIDEMIOL, V152, P793, DOI 10.1093/aje/152.9.793; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; Klenerman P, 1997, IMMUNOL REV, V159, P5, DOI 10.1111/j.1600-065X.1997.tb01003.x; Klenerman P, 1998, NATURE, V394, P482, DOI 10.1038/28860; KRAUSA P, 1995, EUR J IMMUNOGENET, V22, P283, DOI 10.1111/j.1744-313X.1995.tb00243.x; Kurane I, 1994, Curr Top Microbiol Immunol, V189, P93; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001; Mathew A, 1996, J CLIN INVEST, V98, P1684, DOI 10.1172/JCI118964; Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656; RUSSELL PK, 1967, J IMMUNOL, V99, P285; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; VonHerrath MG, 1997, VIROLOGY, V229, P349, DOI 10.1006/viro.1997.8442; VORRIDAM V, 1997, DENGUE DENGUE HEMORR, P313; WHO, 1997, DENG HAEM FEV DIAGN; *WHO, 2002, 117 WHO; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553; Yenchitsomanus Pa-Thai, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P228; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959	39	605	629	0	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					921	927		10.1038/nm887	http://dx.doi.org/10.1038/nm887			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808447				2022-12-25	WOS:000183979300034
J	Person, RE; Li, FQ; Duan, ZJ; Benson, KF; Wechsler, J; Papadaki, HA; Eliopoulos, G; Kaufman, C; Bertolone, SJ; Nakamoto, B; Papayannopoulou, T; Grimes, HL; Horwitz, M				Person, RE; Li, FQ; Duan, ZJ; Benson, KF; Wechsler, J; Papadaki, HA; Eliopoulos, G; Kaufman, C; Bertolone, SJ; Nakamoto, B; Papayannopoulou, T; Grimes, HL; Horwitz, M			Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2	NATURE GENETICS			English	Article							SEVERE CONGENITAL NEUTROPENIA; HERMANSKY-PUDLAK-SYNDROME; ELASTASE; GENE; DIFFERENTIATION	Mice lacking the transcriptional repressor oncoprotein Gfi1 are unexpectedly neutropenic(1,2). We therefore screened GFI1 as a candidate for association with neutropenia in affected individuals without mutations in ELA2 (encoding neutrophil elastase), the most common cause of severe congenital neutropenia (SCN; ref. 3). We found dominant negative zinc finger mutations that disable transcriptional repressor activity. The phenotype also includes immunodeficient lymphocytes and production of a circulating population of myeloid cells that appear immature. We show by chromatin immunoprecipitation, gel shift, reporter assays and elevated expression of ELA2 in vivo in neutropenic individuals that GFI1 represses ELA2, linking these two genes in a common pathway involved in myeloid differentiation.	Univ Washington, Div Med Genet, Dept Med, Sch Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ Crete, Dept Hematol, Sch Med, Univ Hosp Heraklion, Iraklion, Greece; Univ Louisville, Inst Cellular Therapeut, Sch Med, Louisville, KY 40202 USA; Univ Louisville, Dept Surg, Sch Med, Louisville, KY 40202 USA; Univ Louisville, Div Hematol Oncol, Sch Med, Dept Pediat, Louisville, KY 40202 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University Hospital of Heraklion; University of Crete; University of Louisville; University of Louisville; University of Louisville; University of Washington; University of Washington Seattle	Horwitz, M (corresponding author), Univ Washington, Div Med Genet, Dept Med, Sch Med, Box 357720, Seattle, WA 98195 USA.			Grimes, H. Leighton/0000-0001-8162-6758; Horwitz, Marshall/0000-0002-1683-1680	NATIONAL CANCER INSTITUTE [R01CA105152] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105152-02, R01 CA105152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Horwitz M, 2003, CURR OPIN HEMATOL, V10, P49, DOI 10.1097/00062752-200301000-00008; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Li FQ, 2001, J BIOL CHEM, V276, P14230, DOI 10.1074/jbc.M010279200; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Papadaki HA, 2002, ANN HEMATOL, V81, P50, DOI 10.1007/s00277-001-0401-z; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190; ZWEIDLERMCKAY PA, 1996, MOL CELL BIOL, V16, P40242	19	269	281	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2003	34	3					308	312		10.1038/ng1170	http://dx.doi.org/10.1038/ng1170			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12778173	Green Accepted			2022-12-25	WOS:000183815300019
J	Zhang, YM; Leaves, NI; Anderson, GG; Ponting, CP; Broxholme, J; Holt, R; Edser, P; Bhattacharyya, S; Dunham, A; Adcock, IM; Pulleyn, L; Barnes, PJ; Harper, JI; Abecasis, G; Cardon, L; White, M; Burton, J; Matthews, L; Mott, R; Ross, M; Cox, R; Moffatt, MF; Cookson, WOCM				Zhang, YM; Leaves, NI; Anderson, GG; Ponting, CP; Broxholme, J; Holt, R; Edser, P; Bhattacharyya, S; Dunham, A; Adcock, IM; Pulleyn, L; Barnes, PJ; Harper, JI; Abecasis, G; Cardon, L; White, M; Burton, J; Matthews, L; Mott, R; Ross, M; Cox, R; Moffatt, MF; Cookson, WOCM			Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma	NATURE GENETICS			English	Article							IGE LEVELS; ASSOCIATION; LINKAGE; ATOPY; POLYMORPHISM; GENE; MAP	Atopic or immunoglobulin E (IgE)-mediated diseases include the common disorders of asthma, atopic dermatitis and allergic rhinitis(1). Chromosome 13q14 shows consistent linkage to atopy and the total serum IgE concentration(2-6). We previously identified association between total serum IgE levels and a novel 13q14 microsatellite (USAT24G1; ref. 7) and have now localized the underlying quantitative-trait locus (QTL) in a comprehensive single-nucleotide polymorphism (SNP) map. We found replicated association to IgE levels that was attributed to several alleles in a single gene, PHF11. We also found association with these variants to severe clinical asthma. The gene product (PHF11) contains two PHD zinc fingers and probably regulates transcription. Distinctive splice variants were expressed in immune tissues and cells.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford OX1 2JD, England; Wellcome Trust Sanger Inst, Cambridge, England; Natl Heart & Lung Inst, Dept Thorac Med, London, England; Great Ormond St Hosp Sick Children, London, England; Inst Child Hlth, London, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Wellcome Trust Sanger Institute; Imperial College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Cookson, WOCM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	william.cookson@ndm.ox.ac.uk	Ponting, Chris/AAV-2621-2021; Adcock, Ian/L-3217-2019; Abecasis, Goncalo R/B-7840-2010; Cookson, William/HHC-1790-2022; White, Melanie/J-5565-2019	White, Melanie/0000-0002-7399-8348; Adcock, Ian/0000-0003-2101-8843; Ponting, Chris/0000-0003-0202-7816; Abecasis, Goncalo/0000-0003-1509-1825; Cox, Roger/0000-0001-7170-5014; Barnes, Peter/0000-0002-5122-4018; Mott, Richard/0000-0002-1022-9330; Zhang, Youming/0000-0001-5403-4044				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Anderson GG, 2002, EUR J HUM GENET, V10, P266, DOI 10.1038/sj.ejhg.5200801; Angioni A, 1998, CANCER GENET CYTOGEN, V107, P107, DOI 10.1016/S0165-4608(98)00105-8; Beyer K, 1998, J ALLERGY CLIN IMMUN, V101, pS152; Bhattacharyya S, 2000, GENOMICS, V70, P286, DOI 10.1006/geno.2000.6398; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; EIBERG H, 1985, CYTOGENET CELL GENET, V40, P622; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Jarvis D, 1998, BRIT MED J, V316, P607, DOI 10.1136/bmj.316.7131.607; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Monks SA, 1998, AM J HUM GENET, V63, P1507, DOI 10.1086/302104; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; OSCIER DG, 1994, BLOOD REV, V8, P88, DOI 10.1016/S0268-960X(05)80013-X; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Risch NJ, 1996, AM J HUM GENET, V58, P836; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668	32	237	255	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2003	34	2					181	186		10.1038/ng1166	http://dx.doi.org/10.1038/ng1166			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12754510	Green Submitted			2022-12-25	WOS:000183200500024
J	Hernandez, PA; Gorlin, RJ; Lukens, JN; Taniuchi, S; Bohinjec, J; Francois, F; Klotman, ME; Diaz, GA				Hernandez, PA; Gorlin, RJ; Lukens, JN; Taniuchi, S; Bohinjec, J; Francois, F; Klotman, ME; Diaz, GA			Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease	NATURE GENETICS			English	Article							SEVERE CONGENITAL NEUTROPENIA; LINKAGE ANALYSIS; MYELOKATHEXIS; LYMPHOPOIESIS; MYELOPOIESIS; DISORDER; MICE; INTERNALIZATION; HEMATOPOIESIS; APOPTOSIS	WHIM syndrome is an immunodeficiency disease characterized by neutropenia, hypogammaglobulinemia and extensive human papillomavirus (HPV) infection(1). Despite the peripheral neutropenia, bone marrow aspirates from affected individuals contain abundant mature myeloid cells, a condition termed myelokathexis(2). The susceptibility to HPV is disproportionate compared with other immunodeficiency conditions, suggesting that the product of the affected gene may be important in the natural control of this infection. We describe here the localization of the gene associated with WHIM syndrome to a region of roughly 12 cM on chromosome 2q21 and the identification of truncating mutations in the cytoplasmic tail domain of the gene encoding chemokine receptor 4 (CXCR4). Haplotype and mutation analyses in a pedigree transmitting myelokathexis as an apparently autosomal recessive trait support genetic heterogeneity for this aspect of the WHIM syndrome phenotype. Lymphoblastoid cell lines carrying a 19-residue truncation mutation show significantly greater calcium flux relative to control cell lines in response to the CXCR4 ligand, SDF-1, consistent with dysregulated signaling by the mutant receptor. The identification of mutations in CXCR4 in individuals with WHIM syndrome represents the first example of aberrant chemokine receptor function causing human disease and suggests that the receptor may be important in cell-mediated immunity to HPV infection.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Minnesota, Sch Dent, Dept Oral Biol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Dent, Dept Genet, Minneapolis, MN 55455 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Kansai Med Univ, Dept Pediat, Osaka, Japan; Univ Med Ctr, Dept Haematol, Ljubljana, Slovenia; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University; Kansai Medical University; University Medical Centre Ljubljana; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Diaz, GA (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1 Gustave L Levy Pl, New York, NY 10029 USA.		klotman, mary e/A-1921-2016; Diaz, George/AAF-6199-2021					Aprikyan AAG, 2000, BLOOD, V95, P320, DOI 10.1182/blood.V95.1.320.001k23_320_327; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; BOHINJEC J, 1981, BLUT, V42, P191, DOI 10.1007/BF01026389; Burger JA, 2000, BLOOD, V96, P2655; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; Diaz GA, 1998, GENOMICS, V54, P13, DOI 10.1006/geno.1998.5530; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hord JD, 1997, J PEDIAT HEMATOL ONC, V19, P443, DOI 10.1097/00043426-199709000-00007; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LATHROP GM, 1985, AM J HUM GENET, V37, P482; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MENTZER WC, 1977, BRIT J HAEMATOL, V36, P313, DOI 10.1111/j.1365-2141.1977.tb00654.x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Onai N, 2000, BLOOD, V96, P2074; OREGAN S, 1977, AM J DIS CHILD, V131, P655, DOI 10.1001/archpedi.1977.02120190049011; Signoret N, 1998, J CELL SCI, V111, P2819; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Taniuchi S, 1999, AM J HEMATOL, V62, P106, DOI 10.1002/(SICI)1096-8652(199910)62:2<106::AID-AJH8>3.3.CO;2-4; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	30	461	498	2	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2003	34	1					70	74		10.1038/ng1149	http://dx.doi.org/10.1038/ng1149			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12692554				2022-12-25	WOS:000182667900019
J	Sullivan, M; Uhlmann, F				Sullivan, M; Uhlmann, F			A non-proteolytic function of separase links the onset of anaphase to mitotic exit	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING-YEAST; HUMAN CDC14A; MITOSIS; PHOSPHATASE; PROTEIN; SPINDLE; NETWORK; LOCALIZATION; NUCLEOLUS	Separase is a protease that triggers chromosome segregation at anaphase onset by cleaving cohesin, the chromosomal protein complex responsible for sister chromatid cohesion(1,2). After anaphase, cells exit from mitosis; that is, they complete downregulation of cyclin-dependent kinase activity, undergo cytokinesis and enter G1 of the next cell cycle. Here we show that separase activation at the onset of anaphase is sufficient to promote release from the nucleolus and activation of the budding yeast phosphatase, Cdc14, a key step in mitotic exit(3-5). The ability of separase to activate Cdc14 is independent of its protease function but may involve promoting phosphorylation of the Cdc14 inhibitor Net1. This novel separase function is coregulated with its proteolytic activity by the separase inhibitor securin. This helps to explain the coupling of anaphase and mitotic exit - after securin degradation at anaphase onset, separase cleaves cohesin to trigger chromosome segregation and concurrently uses a non-proteolytic mechanism to initiate mitotic exit.	Canc Res UK, Lincolns Inn Fields Labs, Chromosome Segregat Lab, London WC2A 3PX, England	Cancer Research UK	Uhlmann, F (corresponding author), Canc Res UK, Lincolns Inn Fields Labs, Chromosome Segregat Lab, London WC2A 3PX, England.			Uhlmann, Frank/0000-0002-3527-6619	Cancer Research UK [A3592] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; BARDIN AJ, 2001, NATURE REV MOL CELL, V2, P1; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-3; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Yeong FM, 2001, MOL CELL BIOL, V21, P5071, DOI 10.1128/MCB.21.15.5071-5081.2001; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Yoshida S, 2002, CURR BIOL, V12, P944, DOI 10.1016/S0960-9822(02)00870-9	33	134	136	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					249	254		10.1038/ncb940	http://dx.doi.org/10.1038/ncb940			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598903	Green Accepted			2022-12-25	WOS:000181322500019
J	Tanikawa, C; Matsuda, K; Fukuda, S; Nakamura, Y; Arakawa, H				Tanikawa, C; Matsuda, K; Fukuda, S; Nakamura, Y; Arakawa, H			p53RDL1 regulates p53-dependent apoptosis	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE CHECKPOINT; POTENTIAL MEDIATOR; DNA-DAMAGE; P53; GENE; NETRIN-1; DCC; MECHANISM; PATHWAY	Although a number of targets for p53 have been reported, the mechanism of p53-dependent apoptosis still remains to be elucidated. Here we report a new p53 target-gene, designated p53RDL1 (p53-regulated receptor for death and life; also termed UNC5B). The p53RDL1 gene product contains a cytoplasmic carboxy-terminal death domain that is highly homologous to rat Unc5H2, a dependence receptor involved in the regulation of apoptosis, as well as in axon guidance and migration of neural cells(1). We found that p53RDL1 mediated p53-dependent apoptosis. Conversely, when p53RDL1 interacted with its ligand, Netrin-1, p53-dependent apoptosis was blocked. Therefore, p53RDL1 seems to be a previously un-recognized target of p53 that may define a new pathway for p53-dependent apoptosis. We suggest that p53 might regulate the survival of damaged cells by balancing the regulation of Netrin-p53RDL1 signalling, and cell death through cleavage of p53RDL1 for apoptosis.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Arakawa, H (corresponding author), Natl Canc Ctr, Res Inst, Canc Med & Biophys Div, Chuou Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	harakawa@gan2.res.ncc.go.jp	Arakawa, Hirofumi/L-3459-2013; Matsuda, Koichi/D-4597-2011	Arakawa, Hirofumi/0000-0001-6077-0638; Tanikawa, Chizu/0000-0003-4759-4793; Matsuda, Koichi/0000-0001-7292-2686				COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Matsuda K, 2002, CANCER RES, V62, P2883; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi T, 2001, CANCER RES, V61, P8256	21	140	153	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					216	223		10.1038/ncb943	http://dx.doi.org/10.1038/ncb943			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12598906				2022-12-25	WOS:000181322500014
J	Hieronymus, H; Silver, PA				Hieronymus, H; Silver, PA			Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-FACTOR; YEAST; MEX67P; YRA1P; SUB2P	Nuclear export of mRNA is mediated by a complex machinery of RNA-binding proteins that recognizes and routes mRNAs through a messenger ribonucleoprotein (mRNP) network. The full spectrum of mRNA cargoes for any dedicated mRNA export factor is unknown. We identified the mRNAs that bind two conserved yeast mRNA export factors, Yra1 (refs. 1-5) and Mex67 (refs. 6,7), on a genome-wide scale and determined their level of binding. Yra1 and Mex67 bind approximately 1,000 and 1,150 mRNAs, respectively, corresponding to almost 20% of the yeast genome and roughly 36% of all transcriptional events each. The binding level of Yra1 targets is related to their transcriptional frequency, but that of Mex67 targets is not. Yra1-bound transcripts are enriched in mRNAs that are regulated by a number of transcription factors. Yra1- and Mex67-bound populations also show enrichment of mRNAs encoding distinct functional classes of proteins, some of which are regulated by these transcription factors. We determined that one such transcription factor, Abf1 (refs. 8-10), associates with Yra1. These results indicate a previously unidentified specificity of mRNA export factors, which coordinates the export of transcriptionally co-regulated, functional classes of transcripts, perhaps through interactions with the transcriptional machinery.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Silver, PA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Cole CN, 2000, NAT CELL BIOL, V2, pE55, DOI 10.1038/35008681; constanzo M. C., 2001, NUCLEIC ACIDS RES, V29, P75; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; LOO S, 1995, GENETICS, V141, P889; Lopez PJ, 1999, RNA, V5, P1135, DOI 10.1017/S135583829999091X; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Reed SH, 1999, GENE DEV, V13, P3052, DOI 10.1101/gad.13.23.3052; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stevenson LF, 2001, P NATL ACAD SCI USA, V98, P3946, DOI 10.1073/pnas.051013498; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	30	170	176	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					155	161		10.1038/ng1080	http://dx.doi.org/10.1038/ng1080			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12524544				2022-12-25	WOS:000180773700012
J	Panse, VG; Kuster, B; Gerstberger, T; Hurt, E				Panse, VG; Kuster, B; Gerstberger, T; Hurt, E			Unconventional tethering of Ulp1 to the transport channel of the nuclear pore complex by karyopherins	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA EXPORT; PROTEIN; SUMO; RANBP2; PATHWAY; IMPORT; NMD3P	The ubiquitin-like protein SUMO-1 (small ubiquitin-related modifier 1) is covalently attached to substrate proteins by ligases and cleaved by isopeptidases. Yeast has two SUMO-1-deconjugating enzymes, Ulp1 and Ulp2, which are located at nuclear pores and in the nucleoplasm, respectively. Here we show that the catalytic C-domain of Ulp1 must be excluded from the nucleoplasm for cell viability. This is achieved by the noncatalytic N-domain, which tethers Ulp1 to the nuclear pores. The bulk of cellular Ulp1 is not associated with nucleoporins but instead associates with three karyopherins (Pse1, Kap95 and Kap60), in a complex that is not dissociated by RanGTP in vitro. The Ulp1 N-domain has two distinct binding sites for Pse1 and Kap95/Kap60, both of which are required for anchoring to the nuclear pore complex. We propose that Ulp1 is tethered to the nuclear pores by a Ran-insensitive interaction with karyopherins associated with nucleoporins. This location could allow Ulp1 to remove SUMO-1 from sumoylated cargo proteins during their passage through the nuclear pore channel.	BZH, D-69120 Heidelberg, Germany; Cellzome AG, D-69117 Heidelberg, Germany	Ruprecht Karls University Heidelberg; GlaxoSmithKline; Cellzome GmbH	Hurt, E (corresponding author), BZH, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Kuster, Bernhard/Q-6031-2016	Ed Hurt, Dr./0000-0002-4535-8255; Kuster, Bernhard/0000-0002-9094-1677; Panse, Vikram/0000-0001-7950-5746				Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajani SM, 1997, ORG PROCESS RES DEV, V1, P97, DOI 10.1021/op960002x; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Taylor DL, 2002, J CELL SCI, V115, P1113; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	32	106	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2003	5	1					21	27		10.1038/ncb893	http://dx.doi.org/10.1038/ncb893			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	632LA	12471376				2022-12-25	WOS:000180223700009
J	Tafti, M; Petit, B; Chollet, D; Neidhart, E; de Bilbao, F; Kiss, JZ; Wood, PA; Franken, P				Tafti, M; Petit, B; Chollet, D; Neidhart, E; de Bilbao, F; Kiss, JZ; Wood, PA; Franken, P			Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep	NATURE GENETICS			English	Article							DEHYDROGENASE-DEFICIENCY; RHYTHM; MICE	In rodents, the electroencephalogram (EEG) during paradoxical sleep and exploratory behavior is characterized by theta oscillations. Here we show that a deficiency in short-chain acylcoenzyme A dehydrogenase (encoded by Acads) in mice causes a marked slowing in theta frequency during paradoxical sleep only. We found Acads expression in brain regions involved in theta generation, notably the hippocampus. Microarray analysis of gene expression in mice with mutations in Acads indicates overexpression of Glo1 (encoding glyoxylase 1), a gene involved in the detoxification of metabolic by-products. Administration of acetyl-L-carnitine (ALCAR) to mutant mice significantly recovers slow theta and Glo1 overexpression. Thus, an underappreciated metabolic pathway involving fatty acid beta-oxidation also regulates theta oscillations during sleep.	Univ Geneva, Biochem & Genet Unit, Dept Psychiat, CH-1225 Chene Bourg, Switzerland; Univ Hosp Geneva, CH-1225 Chene Bourg, Switzerland; Univ Hosp Geneva, Div Neuropsychiat, Dept Psychiat, CH-1225 Chene Bourg, Switzerland; Ctr Med Univ Geneva, Dept Morphol, CH-1211 Geneva, Switzerland; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Alabama System; University of Alabama Birmingham; Stanford University	Tafti, M (corresponding author), Univ Geneva, Biochem & Genet Unit, Dept Psychiat, Chemin Petit Bel Air 2, CH-1225 Chene Bourg, Switzerland.	mehdi.tafti@medecine.unige.ch	Tafti, Mehdi/A-8887-2017; Franken, Paul/A-9633-2018	Tafti, Mehdi/0000-0002-6997-3914; Franken, Paul/0000-0002-2500-2921				AMENDT BA, 1992, PEDIATR RES, V31, P552, DOI 10.1203/00006450-199206000-00003; BHALA A, 1995, J PEDIATR-US, V126, P910, DOI 10.1016/S0022-3476(95)70207-5; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Datta S, 1997, SYNAPSE, V27, P69, DOI 10.1002/(SICI)1098-2396(199709)27:1<69::AID-SYN7>3.3.CO;2-6; Franken P, 1999, SLEEP, V22, P155; Franken P, 1998, AM J PHYSIOL-REG I, V275, pR1127, DOI 10.1152/ajpregu.1998.275.4.R1127; Guerra C, 1998, J CLIN INVEST, V102, P1724, DOI 10.1172/JCI4532; Huang EP, 1997, CURR BIOL, V7, pR141, DOI 10.1016/S0960-9822(97)70073-3; Korotkova N, 2002, J BACTERIOL, V184, P1750, DOI 10.1128/JB.184.6.1750-1758.2002; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; MIZUMORI SJY, 1990, BRAIN RES, V528, P12, DOI 10.1016/0006-8993(90)90188-H; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450, DOI 10.1152/ajplegacy.1973.224.6.1450; Rao KVR, 1997, CAN J PHYSIOL PHARM, V75, P423, DOI 10.1139/cjpp-75-5-423; REICHMANN H, 1988, J NEUROCHEM, V51, P339, DOI 10.1111/j.1471-4159.1988.tb01044.x; Reue K, 1996, MAMM GENOME, V7, P694, DOI 10.1007/s003359900208; SCHIFFER SP, 1989, BIOCHEM GENET, V27, P47, DOI 10.1007/BF00563017; Spitzer J J, 1973, Physiologist, V16, P55; Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vertes RP, 2000, BEHAV BRAIN SCI, V23, P867, DOI 10.1017/S0140525X00004003; Vertes RP, 1997, NEUROSCIENCE, V81, P893; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; WOOD PA, 1989, PEDIATR RES, V25, P38, DOI 10.1203/00006450-198901000-00010	28	108	112	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2003	34	3					320	325		10.1038/ng1174	http://dx.doi.org/10.1038/ng1174			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	695DF	12796782				2022-12-25	WOS:000183815300021
J	Herman, H; Lu, M; Anggraini, M; Sikora, A; Chang, YJ; Yoon, BJ; Soloway, PD				Herman, H; Lu, M; Anggraini, M; Sikora, A; Chang, YJ; Yoon, BJ; Soloway, PD			Trans allele methylation and paramutation-like effects in mice	NATURE GENETICS			English	Article							DNA METHYLATION; IMPRINTED GENE; MOUSE; LOCUS; MAIZE; RASGRF1	In mammals, imprinted genes have parent-of-origin specific patterns of DNA methylation that cause allele-specific expression. At Rasgrf1 (encoding RAS protein-specific guanine nucleotide-releasing factor 1), a repeated DNA element is needed to establish methylation and expression of the active paternal allele(1). At Igf2r (encoding insulin-like growth factor 2 receptor), a sequence called region 2 is needed for methylation of the active maternal allele(2,3). Here we show that replacing the Rasgrf1 repeats on the paternal allele with region 2 allows both methylation and expression of the paternal copy of Rasgrf1, indicating that sequences that control methylation can function ectopically. Paternal transmission of the mutated allele also induced methylation and expression in trans of the normally unmethylated and silent wild-type maternal allele. Once activated, the wild-type maternal Rasgrf1 allele maintained its activated state in the next generation independently of the paternal allele. These results recapitulate in mice several features in common with paramutation described in plants(4).	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Padjadjaran State Univ, Dept Orthopaed Surg, Sch Med, Sadikin Gen Hosp, Bandung, Indonesia	Cornell University; Roswell Park Cancer Institute; Universitas Padjadjaran	Soloway, PD (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.		Yoon, Bong June/L-7126-2017; Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NCI NIH HHS [R01 CA098597-01, R01 CA098597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BRINK RA, 1956, GENETICS, V41, P872; Chandler VL, 2000, PLANT MOL BIOL, V43, P121, DOI 10.1023/A:1006499808317; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; de la Puente A, 2002, GENE, V291, P287, DOI 10.1016/S0378-1119(02)00601-7; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; Hatada I, 1997, J BIOL CHEM, V272, P9120, DOI 10.1074/jbc.272.14.9120; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KENNISON JA, 2002, ADV GENET, V46, P699; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; PATTERSON GI, 1993, GENETICS, V135, P881; Pearsall RS, 1999, GENOMICS, V55, P194, DOI 10.1006/geno.1998.5660; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Rassoulzadegan M, 2002, EMBO J, V21, P440, DOI 10.1093/emboj/21.3.440; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Stam M, 2002, GENE DEV, V16, P1906, DOI 10.1101/gad.1006702; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Walker EL, 1998, GENETICS, V148, P1973; Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795	22	87	94	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2003	34	2					199	202		10.1038/ng1162	http://dx.doi.org/10.1038/ng1162			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	684HZ	12740578	Green Accepted			2022-12-25	WOS:000183200500027
J	Pym, AS; Brodin, P; Majlessi, L; Brosch, R; Demangel, C; Williams, A; Griffiths, KE; Marchal, G; Leclerc, C; Cole, ST				Pym, AS; Brodin, P; Majlessi, L; Brosch, R; Demangel, C; Williams, A; Griffiths, KE; Marchal, G; Leclerc, C; Cole, ST			Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis	NATURE MEDICINE			English	Article							MYCOBACTERIUM-BOVIS BCG; T-CELL ANTIGENS; COMPARATIVE GENOMICS; GUINEA-PIGS; VACCINES; IMMUNITY; PROTEIN; IDENTIFICATION; VACCINATION; EPITOPES	The live tuberculosis vaccines Mycobacterium bovis BCG (bacille Calmette-Guerin) and Mycobacterium microti both lack the potent, secreted T-cell antigens ESAT-6 (6-kDa early secretory antigenic target) and CFP-10 (10-kDa culture filtrate protein). This is a result of independent deletions in the region of deletion-1 (RD1) locus, which is intact in virulent members of the Mycobacterium tuberculosis complex. To increase their immunogenicity and protective capacity, we complemented both vaccines with different constructs containing the esxA and esxB genes, which encode ESAT-6 and CFP-10 respectively, as well as a variable number of flanking genes. Only reintroduction of the complete locus, comprising at least 11 genes, led to full secretion of the antigens and resulted in specific ESAT-6-dependent immune responses; this suggests that the flanking genes encode a secretory apparatus. Mice and guinea pigs vaccinated with the recombinant strain BCG:: RD1-2F9 were better protected against challenge with M. tuberculosis, showing less severe pathology and reduced dissemination of the pathogen, as compared with control animals immunized with BCG alone.	Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Inst Pasteur, INSERM, EO352, Unite Biol Regulat Immunitaires, F-75724 Paris, France; Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England; Inst Pasteur, Lab Reference Mycobacteries, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Liverpool School of Tropical Medicine; University of Liverpool; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France.		Brosch, Roland/ABB-4108-2021; Brodin, Priscille/E-5802-2014; Demangel, Caroline/H-9570-2014; Brosch, Roland/AAZ-3850-2021; Brodin, Priscille/N-6979-2019	Brodin, Priscille/0000-0003-0991-7344; Demangel, Caroline/0000-0001-7848-586X; Brosch, Roland/0000-0003-2587-3863; Brodin, Priscille/0000-0003-0991-7344; deboosere, Nathalie/0000-0002-2873-5485; Pym, Alexander/0000-0002-6260-8180				Baldwin SL, 1998, INFECT IMMUN, V66, P2951, DOI 10.1128/IAI.66.6.2951-2959.1998; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; BOESEN H, 1995, INFECT IMMUN, V63, P1491, DOI 10.1128/IAI.63.4.1491-1497.1995; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; Brandt L, 1996, J IMMUNOL, V157, P3527; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; Brodin P, 2002, INFECT IMMUN, V70, P5568, DOI 10.1128/IAI.70.10.5568-5578.2002; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chambers MA, 2000, INFECT IMMUN, V68, P7094, DOI 10.1128/IAI.68.12.7094-7099.2000; Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coler RN, 2001, J IMMUNOL, V166, P6227, DOI 10.4049/jimmunol.166.10.6227; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Garay S, 1996, TUBERCULOSIS, P373; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Harboe M, 1998, INFECT IMMUN, V66, P717, DOI 10.1128/IAI.66.2.717-723.1998; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000; Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; HUYGEN K, 1994, INFECT IMMUN, V62, P363, DOI 10.1128/IAI.62.2.363-370.1994; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Lagranderie MRR, 1996, INFECT IMMUN, V64, P1; LECLERC C, 1991, J VIROL, V65, P711, DOI 10.1128/JVI.65.2.711-718.1991; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Neuwald AF, 1999, GENOME RES, V9, P27; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; SULA L, 1976, J HYG EPID MICROB IM, V20, P1; Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220; Van Pittius NG, 2001, GENOME BIOL, V2; Williams A, 2000, CLIN INFECT DIS, V30, pS299, DOI 10.1086/313878; YOUNG DB, 1997, NEW GENERATION VACCI, P631	44	504	554	2	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					533	539		10.1038/nm859	http://dx.doi.org/10.1038/nm859			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692540	Bronze			2022-12-25	WOS:000182610600033
J	Strohman, R				Strohman, R			Thermodynamics - old laws in medicine and complex disease	NATURE BIOTECHNOLOGY			English	Editorial Material							STATE		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Strohman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 237 Hildebrand Hall MC 3206, Berkeley, CA 94720 USA.	Strohman@uclimk4.berkeley.edu						Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BORTZ IV, 1996, J GERONTOL A-BIOL, V54, pM65; KACSER H, 1981, GENETICS, V97, P639; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KAWAGUCHI T, 2002, P NATL ACAD SCI USA, V98, P13700; LEWIN R, 1981, SCIENCE, V214, P42, DOI 10.1126/science.7280679; Miklos GLG, 2001, PROTEOMICS, V1, P30; MOROWITZ H, 2003, COMPLEXITY, V8, P12; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; Oliver S, 2002, NATURE, V418, P33, DOI 10.1038/418033a; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Sehl ME, 2001, J GERONTOL A-BIOL, V56, pB198, DOI 10.1093/gerona/56.5.B198; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Veech RL, 2001, IUBMB LIFE, V51, P241; Williams N, 1997, SCIENCE, V277, P476, DOI 10.1126/science.277.5325.476; Williams RJP, 2002, BIOCHEM BIOPH RES CO, V297, P689, DOI 10.1016/S0006-291X(02)02289-1; Zhang QH, 2002, SCIENCE, V295, P1895	20	23	23	2	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2003	21	5					477	479		10.1038/nbt0503-477	http://dx.doi.org/10.1038/nbt0503-477			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	674WN	12721560				2022-12-25	WOS:000182660300006
J	Wang, J; Parsons, LM; Derbyshire, KM				Wang, J; Parsons, LM; Derbyshire, KM			Unconventional conjugal DNA transfer in mycobacteria	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; PLASMID; RECOMBINATION; BACTERIAL; TRANSFORMATION; STREPTOMYCES; SMEGMATIS	Bacterial conjugation is an active process that results in unidirectional transfer of DNA from a donor to a recipient cell. Most transfer systems are plasmid-encoded and require proteins to act at a unique cis-acting site to initiate and complete DNA transfer. By contrast, the Mycobacterium smegmatis DNA transfer system is chromosomally encoded. Here we show that multiple cis-acting sequences present on the chromosome can mediate transfer of a non-mobilizable test plasmid. Moreover, unlike conventional plasmid transfer, recipient recombination functions are required to allow this plasmid, and derivatives of it, to re-circularize through a process similar to gap repair. Extended DNA homology with the recipient chromosome is required to facilitate repair, resulting in acquisition of recipient chromosomal DNA by the plasmid. Together, these results show that DNA transfer in M. smegmatis occurs by a mechanism different from that of prototypical plasmid transfer systems.	New York State Dept Hlth, Wadsworth Ctr, Div Infect Dis, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Derbyshire, KM (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Infect Dis, Albany, NY 12201 USA.	keith.derbyshire@wadsworth.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042308] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI042308] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1996, ESCHERICHIA COLI SAL; Bhatt A, 2002, MOL MICROBIOL, V43, P135, DOI 10.1046/j.1365-2958.2002.02722.x; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; CANOSI U, 1981, MOL GEN GENET, V181, P434, DOI 10.1007/BF00428732; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Derbyshire KM, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P93; DONNELLYWU MK, 1993, MOL MICROBIOL, V7, P407, DOI 10.1111/j.1365-2958.1993.tb01132.x; Ducote MJ, 2000, J BACTERIOL, V182, P6834, DOI 10.1128/JB.182.23.6834-6841.2000; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; Griffin TJ, 1999, NUCLEIC ACIDS RES, V27, P3859, DOI 10.1093/nar/27.19.3859; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; Hopwood D.A., 1993, BACTERIAL CONJUGATIO, P293, DOI DOI 10.1007/978-1-4757-9357-4_11; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LLOYD RG, 1996, ESCHERICHIA COLI SAL, V2, P2236; Maas RM, 1998, MICROBIOL-SGM, V144, P2809, DOI 10.1099/00221287-144-10-2809; MIZUGUCHI Y, 1971, JPN J MICROBIOL, V15, P359, DOI 10.1111/j.1348-0421.1971.tb00592.x; Papavinasasundaram KG, 1998, MOL MICROBIOL, V30, P525, DOI 10.1046/j.1365-2958.1998.01083.x; Parsons LM, 1998, MOL MICROBIOL, V28, P571, DOI 10.1046/j.1365-2958.1998.00818.x; PETTIS GS, 1994, MOL MICROBIOL, V13, P955, DOI 10.1111/j.1365-2958.1994.tb00487.x; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; WARREN GJ, 1978, NATURE, V274, P259, DOI 10.1038/274259a0; Waters VL, 2001, NAT GENET, V29, P375, DOI 10.1038/ng779; WOLLMAN EL, 1956, COLD SPRING HARB SYM, V21, P141, DOI 10.1101/SQB.1956.021.01.012; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; Zechner E. L., 2000, HORIZONTAL GENE POOL, P87	28	28	30	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2003	34	1					80	84		10.1038/ng1139	http://dx.doi.org/10.1038/ng1139			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	674ZK	12669068				2022-12-25	WOS:000182667900021
J	Schachter, B				Schachter, B			Slimy business-the biotechnology of biofilms	NATURE BIOTECHNOLOGY			English	Article							STRUCTURAL IDENTIFICATION; BACTERIAL BIOLUMINESCENCE; ANTIBIOTIC-RESISTANCE; IN-VITRO											Bachmann SP, 2002, ANTIMICROB AGENTS CH, V46, P3591, DOI 10.1128/AAC.46.11.3591-3596.2002; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Cook G, 2000, INT J ANTIMICROB AG, V13, P169, DOI 10.1016/S0924-8579(99)00120-X; COSTERTON JW, 1978, SCI AM, V238, P86, DOI 10.1038/scientificamerican0178-86; Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008; Donlan RM, 2002, EMERG INFECT DIS, V8, P881, DOI 10.3201/eid0809.020063; Donlan RM, 2001, CLIN INFECT DIS, V33, P1387, DOI 10.1086/322972; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; HASTINGS JW, 1977, ANNU REV MICROBIOL, V31, P549, DOI 10.1146/annurev.mi.31.100177.003001; Kolenbrander PE, 2002, MICROBIOL MOL BIOL R, V66, P486, DOI 10.1128/MMBR.66.3.486-505.2002; Labrenz M, 2000, SCIENCE, V290, P1744, DOI 10.1126/science.290.5497.1744; Li YH, 2002, J BACTERIOL, V184, P2699, DOI 10.1128/JB.184.10.2699-2708.2002; RASMUSSEN K, 2002, WATER CONDITIONING P, V44, P71; Singh PK, 2002, NATURE, V417, P552, DOI 10.1038/417552a; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Yoon SS, 2002, DEV CELL, V3, P593, DOI 10.1016/S1534-5807(02)00295-2	19	80	89	0	20	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					361	365		10.1038/nbt0403-361	http://dx.doi.org/10.1038/nbt0403-361			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	664VH	12665817				2022-12-25	WOS:000182082400013
J	Grassme, H; Jendrossek, V; Riehle, A; von Kurthy, G; Berger, J; Schwarz, H; Weller, M; Kolesnick, R; Gulbins, E				Grassme, H; Jendrossek, V; Riehle, A; von Kurthy, G; Berger, J; Schwarz, H; Weller, M; Kolesnick, R; Gulbins, E			Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts	NATURE MEDICINE			English	Article							ORDERED LIPID DOMAINS; EPITHELIAL-CELLS; INDUCED APOPTOSIS; PHORBOL ESTERS; ENTRY; SPHINGOMYELINASE; CLEARANCE; TRAFFICKING; CHOLESTEROL; CAVEOLAE	Pseudomonas aeruginosa infection is a serious complication in patients with cystic fibrosis and in immunocompromised individuals. Here we show that P. aeruginosa infection triggers activation of the acid sphingomyelinase and the release of ceramide in sphingolipid-rich rafts. Ceramide reorganizes these rafts into larger signaling platforms that are required to internalize P. aeruginosa, induce apoptosis and regulate the cytokine response in infected cells. Failure to generate ceramide-enriched membrane platforms in infected cells results in an unabated inflammatory response, massive release of interleukin (IL)-1 and septic death of mice. Our findings show that ceramide-enriched membrane platforms are central to the host defense against this potentially lethal pathogen.	Univ Essen Gesamthsch, Dept Biol Mol, Essen, Germany; Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany; Univ Tubingen, Dept Neurol, Tubingen, Germany; Max Planck Inst Dev Biol, Tubingen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Max Planck Society; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Essen Gesamthsch, Dept Biol Mol, Essen, Germany.	erich.gulbins@uni-essen.de	Jendrossek, Verena/AAH-4967-2019; Gulbins, Erich/L-6989-2014	Jendrossek, Verena/0000-0003-1058-2107; Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X	NCI NIH HHS [CA85704, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA085704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CROUCH BS, 1996, CHEST, V109, P1019, DOI DOI 10.1378/CHEST.109.4.1019; Esen M, 2001, INFECT IMMUN, V69, P281, DOI 10.1128/IAI.69.1.281-287.2001; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hauser AR, 1999, INFECT IMMUN, V67, P5530, DOI 10.1128/IAI.67.10.5530-5537.1999; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Jendrossek V, 2001, INFECT IMMUN, V69, P2675, DOI 10.1128/IAI.69.4.2675-2683.2001; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Manie SN, 2000, J VIROL, V74, P305, DOI 10.1128/JVI.74.1.305-311.2000; Olliaro P, 1997, INT J PARASITOL, V27, P1007, DOI 10.1016/S0020-7519(97)00083-0; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Rajan S, 2000, AM J RESP CELL MOL, V23, P304, DOI 10.1165/ajrcmb.23.3.4098; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Schroeder TH, 2001, J IMMUNOL, V166, P7410, DOI 10.4049/jimmunol.166.12.7410; Schultz MJ, 2002, AM J PHYSIOL-LUNG C, V282, pL285, DOI 10.1152/ajplung.00461.2000; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Vidal F, 1996, ARCH INTERN MED, V156, P2121, DOI 10.1001/archinte.156.18.2121; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wooldridge KG, 1996, MICROB PATHOGENESIS, V21, P299, DOI 10.1006/mpat.1996.0063; Xue ML, 2001, CURR EYE RES, V23, P406	37	428	441	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					322	330		10.1038/nm823	http://dx.doi.org/10.1038/nm823			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563314				2022-12-25	WOS:000181312300033
J	Isermann, B; Sood, R; Pawlinski, R; Zogg, M; Kalloway, S; Degen, JL; Mackman, N; Weiler, H				Isermann, B; Sood, R; Pawlinski, R; Zogg, M; Kalloway, S; Degen, JL; Mackman, N; Weiler, H			The thrombomodulin-protein C system is essential for the maintenance of pregnancy	NATURE MEDICINE			English	Article							TISSUE FACTOR; PLASMINOGEN-ACTIVATOR; THROMBIN RECEPTOR; BLEEDING EVENTS; FETAL LOSS; EXPRESSION; MICE; APOPTOSIS; PLACENTA; WOMEN	Disruption of the mouse gene encoding the blood coagulation inhibitor thrombomodulin (Thbd) leads to embryonic lethality caused by an unknown defect in the placenta. We show that the abortion of thrombomodulin-deficient embryos is caused by tissue factor-initiated activation of the blood coagulation cascade at the feto-maternal interface. Activated coagulation factors induce cell death and growth inhibition of placental trophoblast cells by two distinct mechanisms. The death of giant trophoblast cells is caused by conversion of the thrombin substrate fibrinogen to fibrin and subsequent formation of fibrin degradation products. In contrast, the growth arrest of trophoblast cells is not mediated by fibrin, but is a likely result of engagement of protease-activated receptors (PAR)-2 and PAR-4 by coagulation factors. These findings show a new function for the thrombomodulin-protein C system in controlling the growth and survival of trophoblast cells in the placenta. This function is essential for the maintenance of pregnancy.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53233 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; Scripps Research Institute; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Medical College of Wisconsin	Weiler, H (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 1701 W Wisconsin Ave, Milwaukee, WI 53233 USA.	hweiler@bcsew.edu	PAwlinski, Rafal/AAD-6090-2022; Sood, Rashmi/AAT-2491-2020	Sood, Rashmi/0000-0002-4523-9512	NHLBI NIH HHS [HL-60655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blumenfeld Z, 1999, FERTIL STERIL, V72, P765, DOI 10.1016/S0015-0282(99)00360-X; BRAISSANT O, 1998, BIOCHEMICA, V3, P10; Brenner B, 1999, THROMB HAEMOSTASIS, V82, P6; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Crawley JTB, 2002, THROMB HAEMOSTASIS, V88, P259; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fazel A, 1998, PLACENTA, V19, P261, DOI 10.1016/S0143-4004(98)90057-1; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GOGJIAN MA, 1981, LAB ANIM SCI, V31, P710; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Gu JM, 2002, J BIOL CHEM, V277, P43335, DOI 10.1074/jbc.M207538200; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Hu ZY, 1999, J ANAT, V194, P183, DOI 10.1046/j.1469-7580.1999.19420183.x; Isermann B, 2001, J CLIN INVEST, V108, P537, DOI 10.1172/JCI13077; Isermann B, 2001, DEVELOPMENT, V128, P827; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; OUT HJ, 1991, EUR J OBSTET GYN R B, V41, P179, DOI 10.1016/0028-2243(91)90021-C; Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Ratts VS, 2000, PLACENTA, V21, P361, DOI 10.1053/plac.1999.0486; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685; Teesalu T, 1998, DEV DYNAM, V213, P27, DOI 10.1002/(SICI)1097-0177(199809)213:1<27::AID-AJA3>3.3.CO;2-0; Toki T, 1999, MOL HUM REPROD, V5, P246, DOI 10.1093/molehr/5.3.246; Toomey JR, 1996, BLOOD, V88, P1583; TSUMAGARI T, 1984, KIDNEY INT, V26, P712, DOI 10.1038/ki.1984.206; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; WeilerGuettler H, 1996, CIRC RES, V78, P180, DOI 10.1161/01.RES.78.2.180; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814	45	210	212	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					331	337		10.1038/nm825	http://dx.doi.org/10.1038/nm825			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579195				2022-12-25	WOS:000181312300034
J	Battersby, BJ; Loredo-Osti, JC; Shoubridge, EA				Battersby, BJ; Loredo-Osti, JC; Shoubridge, EA			Nuclear genetic control of mitochondrial DNA segregation	NATURE GENETICS			English	Article							RAGGED-RED FIBERS; SKELETAL-MUSCLE; POINT MUTATION; HETEROPLASMIC MICE; MTDNA MUTATION; MUTANT; SELECTION; ENCEPHALOMYOPATHY; REPLICATION; ADVANTAGE	Mammalian mitochondrial DNA (mtDNA) is a high copy-number, maternally inherited genome that codes for a small number of essential proteins involved in oxidative phosphorylation. Mutations in mtDNA are responsible for a broad spectrum of clinical disorders'. The segregation pattern of pathogenic mtDNA mutants is an important determinant of the nature and severity of mitochondrial disease, but it varies with the specific mutation, cell type and nuclear background and generally does not correlate well with mitochondrial dysfunction(2-11). To identify nuclear genes that modify the segregation behavior of mtDNA, we used a heteroplasmic mouse model derived from two inbred strains (BALB/c and NZB; ref. 12), in which we had previously demonstrated tissue-specific and age-dependent directional selection for different mtDNA genotypes in the same mouse(13). Here we show that this phenotype segregates in F2 mice from a genetic cross (BALB/c x CAST/Ei) and that it maps to at least three quantitative-trait loci (QTLs). Genome-wide scans showed linkage of the trait to loci on Chromosomes 2, 5 and 6, accounting for 16-35% of the variance in the trait, depending on the tissue and age of the mouse. This is the first genetic evidence for nuclear control of mammalian mtDNA segregation.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Shoubridge, EA (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							Basten C.J., 1997, QTL CARTOGRAPHER REF; Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469; Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231; BOULET L, 1992, AM J HUM GENET, V51, P1187; Chinnery PF, 1999, AM J MED GENET, V85, P498; CHURCHILL GA, 1994, GENETICS, V138, P963; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DESTORDEUR E, 1989, MOL GEN GENET, V220, P127, DOI 10.1007/BF00260866; Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392; Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Flint J, 2001, NAT REV GENET, V2, P437, DOI 10.1038/35076585; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; GROSS NJ, 1969, J BIOL CHEM, V244, P1552; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; North BV, 2002, AM J HUM GENET, V71, P439, DOI 10.1086/341527; PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449; Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Tang YY, 2000, MOL BIOL CELL, V11, P2349, DOI 10.1091/mbc.11.7.2349; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Weber K, 1997, AM J HUM GENET, V60, P373; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	30	104	109	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2003	33	2					183	186		10.1038/ng1073	http://dx.doi.org/10.1038/ng1073			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	641YB	12539044				2022-12-25	WOS:000180773700017
J	Sollars, V; Lu, XY; Xiao, L; Wang, XY; Garfinkel, MD; Ruden, DM				Sollars, V; Lu, XY; Xiao, L; Wang, XY; Garfinkel, MD; Ruden, DM			Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution	NATURE GENETICS			English	Article							DROSOPHILA-MELANOGASTER; KRUPPEL ACTIVITY; MODIFIER SCREEN; EYE DEVELOPMENT; MUTATIONS; POLYCOMB; GENES	Morphological alterations have been shown to occur in Drosophila melanogaster when function of Hsp90 (heat shock 90-kDa protein 1alpha, encoded by Hsp83) is compromised during development(1). Genetic selection maintains the altered phenotypes in subsequent generations(1). Recent experiments have shown, however, that phenotypic variation still occurs in nearly isogenic recombinant inbred strains of Arabidopsis thaliana(2). Using a sensitized isogenic D. melanogaster strain, iso-Krlf-1, we confirm this finding and present evidence supporting an epigenetic mechanism for Hsp90's capacitor function, whereby reduced activity of Hsp90 induces a heritably altered chromatin state. The altered chromatin state is evidenced by ectopic expression of the morphogen wingless in eye imaginal discs and a corresponding abnormal eye phenotype, both of which are epigenetically heritable in subsequent generations, even when function of Hsp90 is restored. Mutations in nine different genes of the trithorax group that encode chromatin-remodeling proteins also induce the abnormal phenotype. These findings suggest that Hsp90 acts as a capacitor for morphological evolution through epigenetic and genetic mechanisms.	Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	University of Alabama System; University of Alabama Birmingham; Jefferson University; Columbia University	Ruden, DM (corresponding author), Univ Alabama, Dept Environm Hlth Sci, RPHB 530, Birmingham, AL 35294 USA.		Sollars, Vincent/R-3769-2019; Ruden, Douglas/A-5008-2016; Ruden, Douglas/ABE-1418-2021	Ruden, Douglas/0000-0002-0070-437X; Sollars, Vincent/0000-0002-5602-3610	NCI NIH HHS [R01 CA105349] Funding Source: Medline; NIAAA NIH HHS [R01 AA012276] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abrell S, 2000, CHROMOSOMA, V109, P334, DOI 10.1007/s004120000092; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashburner M., 1989, DROSOPHILA LAB HDB; Bender J, 2002, CURR BIOL, V12, pR412, DOI 10.1016/S0960-9822(02)00910-7; Carrera P, 1998, P NATL ACAD SCI USA, V95, P10779, DOI 10.1073/pnas.95.18.10779; Dickson BJ, 1996, GENETICS, V142, P163; Gibson MC, 2002, DEV CELL, V3, P451, DOI 10.1016/S1534-5807(02)00264-2; Goldstein LSB, 1994, DROSOPHILA MELANOGAS; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; JACKLE H, 1985, COLD SPRING HARB SYM, V50, P465, DOI 10.1101/SQB.1985.050.01.058; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Kohler C, 2002, CURR BIOL, V12, pR129, DOI 10.1016/S0960-9822(02)00705-4; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Mollaaghababa R, 2001, P NATL ACAD SCI USA, V98, P3958, DOI 10.1073/pnas.061497798; Paro R, 1998, CIBA F SYMP, V214, P51; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747	22	305	321	0	56	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2003	33	1					70	74		10.1038/ng1067	http://dx.doi.org/10.1038/ng1067			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	630XH	12483213				2022-12-25	WOS:000180136100020
J	Collins, N; Poot, RA; Kukimoto, I; Garcia-Jimenez, C; Dellaire, G; Varga-Weisz, PD				Collins, N; Poot, RA; Kukimoto, I; Garcia-Jimenez, C; Dellaire, G; Varga-Weisz, PD			An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin	NATURE GENETICS			English	Article							CELL-CYCLE; ISWI; INHIBITION; SUBUNITS; CONTAINS; PROTEINS; CLONING; HOMOLOG; SITES; CHRAC	The mechanism by which the eukaryotic DNA-replication machinery penetrates condensed chromatin structures to replicate the underlying DNA is poorly understood. Here we provide evidence that an ACF1-ISWI chromatin-remodeling complex is required for replication through heterochromatin in mammalian cells. ACF1(ATP-utilizing chromatin assembly and remodeling factor 1) and an ISWI isoform, SNF2H (sucrose nonfermenting-2 homolog), become specifically enriched in replicating pericentromeric heterochromatin. RNAi-mediated depletion of ACF1 specifically impairs the replication of pericentromeric heterochromatin. Accordingly, depletion of ACF1 causes a delay in cell-cycle progression through the late stages of S phase. In vivo depletion of SNF2H slows the progression of DNA replication throughout S phase, indicating a functional overlap with ACF1. Decondensing the heterochromatin with 5-aza-2-deoxycytidine reverses the effects of ACF1 and SNF2H depletion. Expression of an ACF1 mutant that cannot interact with SNF2H also interferes with replication of condensed chromatin. Our data suggest that an ACF1-SNF2H complex is part of a dedicated mechanism that enables DNA replication through highly condensed regions of chromatin.	Marie Curie Res Inst, Surrey RH8 0TL, England; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	University of Edinburgh	Varga-Weisz, PD (corresponding author), Marie Curie Res Inst, Chart, Surrey RH8 0TL, England.		García-Jiménez, Custodia/AAS-7744-2020; Kukimoto, I/I-3995-2019; Dellaire, Graham/L-9948-2014	García-Jiménez, Custodia/0000-0003-0146-4424; Kukimoto, I/0000-0001-9080-1642; Dellaire, Graham/0000-0002-3466-6316; Varga-Weisz, Patrick/0000-0001-7409-8686				Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Bernard P, 2002, TRENDS CELL BIOL, V12, P419, DOI 10.1016/S0962-8924(02)02344-9; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; FOX MH, 1991, J CELL SCI, V99, P247; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Haaf T, 2000, CYTOGENET CELL GENET, V91, P113, DOI 10.1159/000056830; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Langst G, 2001, J CELL SCI, V114, P2561; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tate P, 1998, J CELL SCI, V111, P2575; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	30	236	242	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					627	632		10.1038/ng1046	http://dx.doi.org/10.1038/ng1046			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12434153				2022-12-25	WOS:000179593000015
J	Steinberg, D				Steinberg, D			Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime	NATURE MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN-1; MOUSE PERITONEAL-MACROPHAGES; ENDOTHELIAL-CELL EXPRESSION; LEUKOCYTE ADHESION MOLECULE; SMOOTH-MUSCLE-CELLS; OXIDIZED-LDL; ATHEROSCLEROTIC LESIONS; ARTERIAL PROTEOGLYCANS; CORONARY EVENTS	A historical perspective on atherosclerosis allows us to reflect on the once controversial hypotheses in the field. Plaque formation was once thought to be dependent upon hypercholesterolemia alone, or solely in response to injury. More recently, inflammatory cascades were thought to be at the root of lesion development. A more realistic view may be that atherosclerosis is neither exclusively an inflammatory disease nor solely a lipid disorder: it is both.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Steinberg, D (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	dsteinberg@ucsd.edu						Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bird DA, 1999, P NATL ACAD SCI USA, V96, P6347, DOI 10.1073/pnas.96.11.6347; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Bourdillon MC, 2000, ARTERIOSCL THROM VAS, V20, P2630, DOI 10.1161/01.ATV.20.12.2630; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUSCHKE AVG, 1989, AM HEART J, V117, P296, DOI 10.1016/0002-8703(89)90772-2; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Chatterjee S, 1996, GLYCOBIOLOGY, V6, P303, DOI 10.1093/glycob/6.3.303; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; DAVIES PF, 1976, ATHEROSCLEROSIS, V25, P125, DOI 10.1016/0021-9150(76)90054-X; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; FRANK JS, 1989, J LIPID RES, V30, P967; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gould AL, 1998, CIRCULATION, V97, P946; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Han KH, 1999, J LIPID RES, V40, P1053; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; JIMI S, 1995, ATHEROSCLEROSIS, V116, P15, DOI 10.1016/0021-9150(95)05515-X; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1992, ARTERIOSCLER THROMB, V12, P1258, DOI 10.1161/01.ATV.12.11.1258; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LaRosa JC, 2001, AM J CARDIOL, V88, P291, DOI 10.1016/S0002-9149(01)01643-5; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marathe S, 2000, ARTERIOSCL THROM VAS, V20, P2607, DOI 10.1161/01.ATV.20.12.2607; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MILLS GL, 1971, COMP BIOCHEM PHYSIOL, V40, P489, DOI 10.1016/0305-0491(71)90234-3; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PEDERSEN TR, 1994, LANCET, V344, P1383; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PODREZ EA, 2002, J BIOL CHEM; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; STEINBERG D, 1989, CIRCULATION, V80, P1070, DOI 10.1161/01.CIR.80.4.1070; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D., 1999, MOL BASIS CARDIOVASC, P458; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Sukhova GK, 2002, ARTERIOSCL THROM VAS, V22, P1452, DOI 10.1161/01.ATV.0000030360.72503.56; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; THORIN E, 1995, ATHEROSCLEROSIS, V114, P185, DOI 10.1016/0021-9150(94)05482-X; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WEINSTEIN DB, 1976, BIOCHIM BIOPHYS ACTA, V424, P404, DOI 10.1016/0005-2760(76)90030-8; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Yokoya K, 1999, CIRCULATION, V100, P903, DOI 10.1161/01.CIR.100.9.903; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	94	532	591	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1211	1217		10.1038/nm1102-1211	http://dx.doi.org/10.1038/nm1102-1211			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411947				2022-12-25	WOS:000179221200025
J	Yant, SR; Ehrhardt, A; Mikkelsen, JG; Meuse, L; Pham, T; Kay, MA				Yant, SR; Ehrhardt, A; Mikkelsen, JG; Meuse, L; Pham, T; Kay, MA			Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo	NATURE BIOTECHNOLOGY			English	Article							SITE-SPECIFIC INTEGRATION; VIRUS VECTOR; GENE-EXPRESSION; VIRAL-ANTIGENS; CHROMOSOMAL INTEGRATION; STABLE TRANSDUCTION; GENOMIC INTEGRATION; IMMUNE-RESPONSES; SLEEPING-BEAUTY; HYBRID VECTOR	A major limitation of adenovirus-mediated gene therapy for inherited diseases is the instability of transgene expression in vivo, which originates at least in part from the loss of the linear, extrachromosomal vector genomes. Herein we describe the production of a gene-deleted adenovirus- transposon vector that stably maintains virus-encoded transgenes in vivo through integration into host cell chromosomes. This system utilizes a donor transposon vector that undergoes Flp-mediated recombination and excision of its therapeutic payload in the presence of the Flp and Sleeping Beauty recombinases. Systemic in vivo delivery of this system resulted in efficient generation of transposon circles and stable transposase-mediated integration in mouse liver. Somatic integration was sufficient to maintain therapeutic levels of human coagulation Factor IX for more than six months in mice undergoing extensive liver proliferation. These vectors combine the versatility of adenoviral vectors with the integration capabilities of a eukaryotic DNA transposon and should prove useful in the treatment of genetic diseases.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Kay, MA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	markay@stanford.edu	Wilson, Matthew H/K-3193-2013	Yant, Stephen R,/0000-0002-4444-7483; Kay, Mark/0000-0002-2799-2615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49022] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balague C, 2000, BLOOD, V95, P820, DOI 10.1182/blood.V95.3.820.003k32_820_828; BURR AW, 1993, J PATHOL, V170, P95, DOI 10.1002/path.1711700115; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; Clemens PR, 1996, GENE THER, V3, P965; Crellin P, 2001, EMBO J, V20, P3882, DOI 10.1093/emboj/20.14.3882; Ehrhardt A, 2002, BLOOD, V99, P3923, DOI 10.1182/blood.V99.11.3923; Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997-866; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Harui A, 1999, J VIROL, V73, P6141, DOI 10.1128/JVI.73.7.6141-6146.1999; Hillgenberg M, 2001, J VIROL, V75, P9896, DOI 10.1128/JVI.75.20.9896-9908.2001; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; Kanatsu-Shinohara M, 2002, P NATL ACAD SCI USA, V99, P1383, DOI 10.1073/pnas.022646399; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; Lieber A, 1999, J VIROL, V73, P9314, DOI 10.1128/JVI.73.11.9314-9324.1999; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Miller DG, 2002, NAT GENET, V30, P147, DOI 10.1038/ng824; Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Murphy SJ, 2002, HUM GENE THER, V13, P745, DOI 10.1089/104303402317322302; Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Ng P, 2001, MOL THER, V3, P809, DOI 10.1006/mthe.2001.0323; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Peters AHFM, 2001, MOL THER, V4, P603, DOI 10.1006/mthe.2001.0500; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; Shayakhmetov DM, 2002, J VIROL, V76, P1135, DOI 10.1128/JVI.76.3.1135-1143.2002; Soifer H, 2002, MOL THER, V5, P599, DOI 10.1006/mthe.2002.0586; Soifer H, 2001, HUM GENE THER, V12, P1417, DOI 10.1089/104303401750298571; Steinwaerder DS, 2000, GENE THER, V7, P556, DOI 10.1038/sj.gt.3301139; Tallone T, 2001, P NATL ACAD SCI USA, V98, P7910, DOI 10.1073/pnas.141223398; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; Yang Y, 1996, GENE THER, V3, P137; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zheng CY, 2000, NAT BIOTECHNOL, V18, P176, DOI 10.1038/72628	49	156	173	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					999	1005		10.1038/nbt738	http://dx.doi.org/10.1038/nbt738			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12244327				2022-12-25	WOS:000178313100016
J	Seki, Y; Inoue, H; Nagata, N; Hayashi, K; Fukuyama, S; Matsumoto, K; Komine, O; Hamano, S; Himeno, K; Inagaki-Ohara, K; Cacalano, N; O'Garra, A; Oshida, T; Saito, H; Johnston, JA; Yoshimura, A; Kubo, M				Seki, Y; Inoue, H; Nagata, N; Hayashi, K; Fukuyama, S; Matsumoto, K; Komine, O; Hamano, S; Himeno, K; Inagaki-Ohara, K; Cacalano, N; O'Garra, A; Oshida, T; Saito, H; Johnston, JA; Yoshimura, A; Kubo, M			SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses	NATURE MEDICINE			English	Article							CYTOKINE SIGNALING SOCS; LINEAGE COMMITMENT; TH2 DIFFERENTIATION; ATOPIC-DERMATITIS; T-CELLS; SUPPRESSORS; EXPRESSION; RECEPTOR; MICE; PROTEINS	Members of the suppressor of cytokine signaling (SOCS) family are involved in the pathogenesis of many inflammatory diseases. SOCS-3 is predominantly expressed in T-helper type 2 (T(H)2) cells, but its role in T(H)2-related allergic diseases remains to be investigated. In this study we provide a strong correlation between SOCS-3 expression and the pathology of asthma and atopic dermatitis, as well as serum IgE levels in allergic human patients. SOCS-3 transgenic mice showed increased T(H)2 responses and multiple pathological features characteristic of asthma in an airway hypersensitivity model system. In contrast, dominant-negative mutant SOCS-3 transgenic mice, as well as mice with a heterozygous deletion of Socs3, had decreased T(H)2 development. These data indicate that SOCS-3 has an important role in regulating the onset and maintenance of T(H)2-mediated allergic immune disease, and suggest that SOCS-3 may be a new therapeutic target for the development of antiallergic drugs.	Sci Univ Tokyo, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Kyushu Univ, Grad Sch Med Sci, Res Inst Dis chest, Higashi Ku, Fukuoka 8128582, Japan; Genox Res Inc, Kawasaki, Kanagawa 2190001, Japan; Kyushu Univ, Fac Med Sci, Dept Parasitol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Radiat Oncol, Los Angeles, CA 90095 USA; Natl Inst Med Res, Immunoregulat Lab, London NW7 1AA, England; Natl Res Inst Child Hlth & Dev, RIKEN Res Ctr Allergy & Immunol, Setagaya Ku, Tokyo 1548567, Japan; Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland	Tokyo University of Science; Kyushu University; Kyushu University; Kyushu University; University of California System; University of California Los Angeles; MRC National Institute for Medical Research; National Center for Child Health & Development - Japan; RIKEN; Queens University Belfast	Kubo, M (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.		Yoshimura, Akihiko/K-5515-2013; Komine, Okiru/I-6155-2014; Hamano, Shinjiro/A-7932-2011	Hamano, Shinjiro/0000-0003-3881-8337; Saito, Hirohisa/0000-0002-6630-8337; O'Garra, Anne/0000-0001-9845-6134				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Krebs DL, 2000, J CELL SCI, V113, P2813; Kubo M, 1999, J IMMUNOL, V163, P2432; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Makino S, 2000, INT ARCH ALLERGY IMM, V121, P1; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 2003, J EXP MED, V197, P425, DOI 10.1084/jem.20020939; MATSUMOTO Y, IN PRESS INT ARCH AL; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Ring J, 2001, Curr Allergy Rep, V1, P39, DOI 10.1007/s11882-001-0095-2; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; WUTHRICH B, 1978, CLIN ALLERGY, V8, P241, DOI 10.1111/j.1365-2222.1978.tb03220.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	37	286	325	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1047	1054		10.1038/nm896	http://dx.doi.org/10.1038/nm896			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847520				2022-12-25	WOS:000184484900029
J	Bezard, E; Ferry, S; Mach, U; Stark, H; Leriche, L; Boraud, T; Gross, C; Sokoloff, P				Bezard, E; Ferry, S; Mach, U; Stark, H; Leriche, L; Boraud, T; Gross, C; Sokoloff, P			Attenuation of levodopa-induced dyskinesia by normalizing dopamine D-3 receptor function	NATURE MEDICINE			English	Article							PARKINSONS-DISEASE; NIGROSTRIATAL DEGENERATION; BEHAVIORAL SENSITIZATION; SUBSTANTIA-NIGRA; MONKEY STRIATUM; MESSENGER-RNA; CELL-LINE; EXPRESSION; NEURONS; ANTAGONIST	In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the dopamine D 3 receptor was decreased. However, levodopa-induced dyskinesia (LID), similar to the debilitating and pharmacoresistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson disease (PD), was associated with overexpression of this receptor. Administration of a D-3 receptor-selective partial agonist strongly attenuated levodopa-induced dyskinesia, but left unaffected the therapeutic effect of levodopa. In contrast, attenuation of dyskinesia by D-3 receptor antagonists was accompanied by the reappearance of PD-like symptoms. These results indicated that the D-3 receptor participated in both dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D-3 receptor function and correct side effects of levodopa therapy in patients with PD.	INSERM, U573, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, F-33076 Bordeaux, France; Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Goethe University Frankfurt	Bezard, E (corresponding author), INSERM, U573, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France.		Stark, Holger/A-4235-2009; Boraud, Thomas/A-6260-2008; Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021	Stark, Holger/0000-0003-3336-1710; Bezard, Erwan/0000-0002-0410-4638				Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Bordet R, 1997, P NATL ACAD SCI USA, V94, P3363, DOI 10.1073/pnas.94.7.3363; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Carlsson A, 2001, SCIENCE, V294, P1021, DOI 10.1126/science.1066969; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Grondin R, 2000, N-S ARCH PHARMACOL, V361, P181, DOI 10.1007/s002109900167; Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076; Gurevich EV, 1997, ARCH GEN PSYCHIAT, V54, P225; HORNYKIEWICZ O., 1963, WIENER KLIN WOCHENSCHR, V75, P309; Hurley MJ, 1996, NEUROSCI LETT, V214, P75, DOI 10.1016/0304-3940(96)12884-6; Imbert C, 2000, J NEUROSCI METH, V96, P71, DOI 10.1016/S0165-0270(99)00184-3; Jenner P, 2002, NEUROLOGY, V58, pS1, DOI 10.1212/WNL.58.suppl_1.S1; Levant B, 1996, SYNAPSE, V24, P60; LEVESQUE D, 1995, P NATL ACAD SCI USA, V92, P1719, DOI 10.1073/pnas.92.5.1719; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1048; Morissette M, 1998, EUR J NEUROSCI, V10, P2565, DOI 10.1046/j.1460-9568.1998.00264.x; Pearce RKB, 1995, MOVEMENT DISORD, V10, P731, DOI 10.1002/mds.870100606; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; Pulvirenti L, 2002, TRENDS PHARMACOL SCI, V23, P151, DOI 10.1016/S0165-6147(00)01991-X; Quik M, 2000, NEUROSCIENCE, V98, P263, DOI 10.1016/S0306-4522(00)00130-5; Rascol O, 2000, ANN NEUROL, V47, pS179; Reavill C, 2000, J PHARMACOL EXP THER, V294, P1154; Ryoo HL, 1998, MOVEMENT DISORD, V13, P788, DOI 10.1002/mds.870130506; Sautel F, 1995, J PHARMACOL EXP THER, V275, P1239; SOKOLOFF P, 1992, EUR J PHARM-MOLEC PH, V225, P331, DOI 10.1016/0922-4106(92)90107-7; Suzuki M, 1998, BRAIN RES, V779, P58, DOI 10.1016/S0006-8993(97)01078-0; Weber B, 2001, BRIT J PHARMACOL, V133, P1243, DOI 10.1038/sj.bjp.0704192	33	331	338	2	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					762	767		10.1038/nm875	http://dx.doi.org/10.1038/nm875			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740572				2022-12-25	WOS:000183444100033
J	Doll, JA; Stellmach, VM; Bouck, NP; Bergh, ARJ; Lee, C; Abramson, LP; Cornwell, ML; Pins, MR; Borensztajn, J; Crawford, SE				Doll, JA; Stellmach, VM; Bouck, NP; Bergh, ARJ; Lee, C; Abramson, LP; Cornwell, ML; Pins, MR; Borensztajn, J; Crawford, SE			Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VENTRAL PROSTATE; TISSUE MASS; FACTOR PEDF; CELL-DEATH; BLOOD-FLOW; IN-VIVO; ANGIOGENESIS; CASTRATION; CANCER	Angiogenesis sustains tumor growth and metastasis, and recent studies indicate that the vascular endothelium regulates tissue mass. In the prostate, androgens drive angiogenic inducers to stimulate growth, whereas androgen withdrawal leads to decreased vascular endothelial growth factor, vascular regression and epithelial cell apoptosis. Here, we identify the angiogenesis inhibitor pigment epithelium-derived factor (PEDF) as a key inhibitor of stromal vasculature and epithelial tissue growth in mouse prostate and pancreas. In PEDF-deficient mice, stromal vessels were increased and associated with epithelial cell hyperplasia. Androgens inhibited prostatic PEDF expression in cultured cells. In vivo, androgen ablation increased PEDF in normal rat prostates and in human cancer biopsies. Exogenous PEDF induced tumor epithelial apoptosis in vitro and limited in vivo tumor xenograft growth, triggering endothelial apoptosis. Thus, PEDF regulates normal pancreas and prostate mass. Its androgen sensitivity makes PEDF a likely contributor to the anticancer effects of androgen ablation.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA; Childrens Mem Hosp, Div Surg, Chicago, IL 60614 USA; Umea Univ, Dept Biomed Sci, S-90187 Umea, Sweden	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Umea University	Crawford, SE (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NCI NIH HHS [CA64329] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Burchardt M, 2000, PROSTATE, V43, P184, DOI 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO;2-6; Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CHUNG LWK, 1995, CANCER SURV, V23, P33; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Crawford SE, 2001, J CELL SCI, V114, P4421; Cvetkovic D, 2001, UROLOGY, V57, P821, DOI 10.1016/S0090-4295(00)01044-X; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Doll JA, 2001, PROSTATE, V49, P293, DOI 10.1002/pros.10025; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Joseph IBJK, 1997, CLIN CANCER RES, V3, P2507; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lekas E, 1997, UROL RES, V25, P309, DOI 10.1007/BF01294656; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Offield MF, 1996, DEVELOPMENT, V122, P983; PIGNOLO RJ, 1995, J CELL PHYSIOL, V162, P110, DOI 10.1002/jcp.1041620113; Rowley DR, 1998, CANCER METAST REV, V17, P411, DOI 10.1023/A:1006129420005; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shabisgh A, 1999, ENDOCRINOLOGY, V140, P1920, DOI 10.1210/en.140.4.1920; Shabsigh A, 2001, J CELL BIOCHEM, V81, P437, DOI 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.3.CO;2-Y; Shabsigh A, 1998, PROSTATE, V36, P201, DOI 10.1002/(SICI)1097-0045(19980801)36:3<201::AID-PROS9>3.0.CO;2-J; Sordello S, 1998, BIOCHEM BIOPH RES CO, V251, P287, DOI 10.1006/bbrc.1998.9328; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Tombran-Tink J, 1996, Mol Vis, V2, P11; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; van Bokhoven A, 2001, CANCER RES, V61, P6340; Wong YC, 2000, INT REV CYTOL, V199, P65, DOI 10.1016/S0074-7696(00)99002-8	45	256	270	0	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					774	780		10.1038/nm870	http://dx.doi.org/10.1038/nm870			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740569				2022-12-25	WOS:000183444100035
J	Di Guglielmo, GM; Le Roy, C; Goodfellow, AF; Wrana, JL				Di Guglielmo, GM; Le Roy, C; Goodfellow, AF; Wrana, JL			Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover	NATURE CELL BIOLOGY			English	Article							FYVE DOMAIN PROTEIN; LIPID RAFTS; MEMBRANE DOMAINS; EARLY ENDOSOMES; INTERNALIZATION; CLATHRIN; CHOLESTEROL; SMAD7; LOCALIZATION; TRANSPORT	Endocytosis of cell surface receptors is an important regulatory event in signal transduction. The transforming growth factor beta (TGF-beta) superfamily signals to the Smad pathway through heteromeric Ser-Thr kinase receptors that are rapidly internalized and then downregulated in a ubiquitin-dependent manner. Here we demonstrate that TGF-beta receptors internalize into both caveolin- and EEA1-positive vesicles and reside in both lipid raft and non-raft membrane domains. Clathrin-dependent internalization into the EEA1-positive endosome, where the Smad2 anchor SARA is enriched, promotes TGF-beta signalling. In contrast, the lipid raft-caveolar internalization pathway contains the Smad7-Smurf2 bound receptor and is required for rapid receptor turnover. Thus, segregation of TGF-beta receptors into distinct endocytic compartments regulates Smad activation and receptor turnover.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Wrana, JL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	wrana@mshri.on.ca	Le Roy, Christine/N-3718-2017; Wrana, Jeffrey/F-8857-2013	Le Roy, Christine/0000-0003-3538-6487; 				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ehrlich M, 2001, J CELL SCI, V114, P1777; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Prevostel C, 2000, J CELL SCI, V113, P2575; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Razani B, 2000, J CELL SCI, V113, P2103; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Torgersen ML, 2001, J CELL SCI, V114, P3737; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	50	894	916	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					410	421		10.1038/ncb975	http://dx.doi.org/10.1038/ncb975			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717440				2022-12-25	WOS:000182691400014
J	Krutzik, SR; Ochoa, MT; Sieling, PA; Uematsu, S; Ng, YW; Legaspi, A; Liu, PT; Cole, ST; Godowski, PJ; Maeda, YM; Sarno, EN; Norgard, MV; Brennan, PJ; Akira, S; Rea, TH; Modlin, RL				Krutzik, SR; Ochoa, MT; Sieling, PA; Uematsu, S; Ng, YW; Legaspi, A; Liu, PT; Cole, ST; Godowski, PJ; Maeda, YM; Sarno, EN; Norgard, MV; Brennan, PJ; Akira, S; Rea, TH; Modlin, RL			Activation and regulation of Toll-like receptors 2 and 1 in human leprosy	NATURE MEDICINE			English	Article							MYD88-DEPENDENT SIGNALING PATHWAY; MYCOBACTERIUM-TUBERCULOSIS; HOST-DEFENSE; CUTTING EDGE; BACTERIAL LIPOPROTEINS; MICROBIAL LIPOPROTEINS; ANTIMICROBIAL ACTIVITY; CYTOKINE PRODUCTION; IMMUNE-RESPONSE; T-CELLS	The expression and activation of Toll-like receptors (TLRs) was investigated in leprosy, a spectral disease in which clinical manifestations correlate with the type of immune response mounted toward Mycobacterium leprae. TLR2-TLR1 heterodimers mediated cell activation by killed M. leprae, indicating the presence of triacylated lipoproteins. A genome-wide scan of M. leprae detected 31 putative lipoproteins. Synthetic lipopeptides representing the 19-kD and 33-kD lipoproteins activated both monocytes and dendritic cells. Activation was enhanced by type-1 cytokines and inhibited by type-2 cytokines. In addition, interferon (IFN)-gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhanced TLR1 expression in monocytes and dendritic cells, respectively, whereas IL-4 downregulated TLR2 expression. TLR2 and TLR1 were more strongly expressed in lesions from the localized tuberculoid form (T-lep) as compared with the disseminated lepromatous form (L-lep) of the disease. These data provide evidence that regulated expression and activation of TLRs at the site of disease contribute to the host defense against microbial pathogens.	Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol & Immunol, Los Angeles, CA USA; Osaka Univ, Japan Sci & Technol Corp, Microbial Dis Res Inst, Dept Host Def, Osaka, Japan; Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Natl Inst Infect Dis, Leprosy Res Ctr, Dept Microbiol, Tokyo, Japan; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST); Osaka University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding; Genentech; National Institute of Infectious Diseases (NIID); Fundacao Oswaldo Cruz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Colorado State University; University of Southern California	Modlin, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.		Liu, Philip/C-2524-2009; Modlin, Robert L/M-7941-2014; Akira, Shizuo/C-3134-2009; Liu, Philip/C-9638-2011	Modlin, Robert L/0000-0003-4720-031X; Ochoa, Maria T/0000-0001-6550-5008; Nunes Sarno, Euzenir/0000-0003-0129-2159; Liu, Philip/0000-0002-6144-0304	NIAID NIH HHS [AI22553, AI47866, AI07126] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI047866, R01AI022553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ANDERSON GW, 1980, INFECT IMMUN, V28, P132, DOI 10.1128/IAI.28.1.132-136.1980; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Garcia VE, 1999, J IMMUNOL, V162, P6114; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kang TJ, 2001, FEMS IMMUNOL MED MIC, V31, P53, DOI 10.1111/j.1574-695X.2001.tb01586.x; Maeda Y, 2002, INFECT IMMUN, V70, P4106, DOI 10.1128/IAI.70.8.4106-4111.2002; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Medina E, 1998, IMMUNOLOGY, V93, P270, DOI 10.1046/j.1365-2567.1998.00419.x; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MODLIN RL, 1984, J IMMUNOL, V132, P3085; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Post FA, 2001, INFECT IMMUN, V69, P1433, DOI 10.1128/IAI.69.3.1433-1439.2001; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SIELING PA, 1994, J IMMUNOL, V153, P3639; Staege H, 2000, IMMUNOL LETT, V71, P1, DOI 10.1016/S0165-2478(99)00168-6; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; WEINSTEIN DL, 1986, CELL IMMUNOL, V102, P68, DOI 10.1016/0008-8749(86)90326-6; Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yeremeev VV, 2000, TUBERCLE LUNG DIS, V80, P243, DOI 10.1054/tuld.2000.0252	46	252	260	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					525	532		10.1038/nm864	http://dx.doi.org/10.1038/nm864			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692544				2022-12-25	WOS:000182610600032
J	Stevens, C; Smith, L; La Thangue, NB				Stevens, C; Smith, L; La Thangue, NB			Chk2 activates E2F-1 in response to DNA damage	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CHECKPOINT; P53; EXPRESSION; MICE; P73; PHOSPHORYLATION; ACETYLATION; MECHANISMS	The E2F-1 transcription factor is regulated during cell cycle progression and induced by cellular stress, such as DNA damage. We report that checkpoint kinase 2 (Chk2) regulates E2F-1 activity in response to the DNA-damaging agent etoposide. A Chk2 consensus phosphorylation site in E2F-1 is phosphorylated in response to DNA damage, resulting in protein stabilization, increased half-life, transcriptional activation and localization of phosphorylated E2F-1 to discrete nuclear structures. Expression of a dominant-negative Chk2 mutant blocks induction of E2F-1 and prevents E2F-1-dependent apoptosis. Moreover, E2F-1 is resistant to induction by etoposide in tumour cells expressing mutant chk2. Therefore, Chk2 phosphorylates and activates E2F-1 in response to DNA damage, resulting in apoptosis. These results suggest a role for E2F-1 in checkpoint control and provide a plausible explanation for the tumour suppressor activity of E2F-1.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	N.LaThangue@bio.gla.ac.uk			MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Allen KE, 1997, J CELL SCI, V110, P2819; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Botz J, 1996, MOL CELL BIOL, V16, P3401; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chehab NH, 2000, GENE DEV, V14, P278; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOH L, 1996, GENE DEV, V10, P1054; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 2000, GENE DEV, V14, P289; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	46	316	328	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2003	5	5					401	409		10.1038/ncb974	http://dx.doi.org/10.1038/ncb974			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	675JR	12717439				2022-12-25	WOS:000182691400013
J	Plattner, R; Irvin, BJ; Guo, SL; Blackburn, K; Kazlauskas, A; Abraham, RT; York, JD; Pendergast, AM				Plattner, R; Irvin, BJ; Guo, SL; Blackburn, K; Kazlauskas, A; Abraham, RT; York, JD; Pendergast, AM			A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma 1	NATURE CELL BIOLOGY			English	Article							CELL ANTIGEN RECEPTOR; FACTOR-BETA-RECEPTOR; GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA-1; FILAMENTOUS ACTIN; FAMILY KINASES; DNA-SYNTHESIS; PHOSPHORYLATION; ACTIVATION; PROTEIN	The c-Abl tyrosine (Tyr) kinase is activated after platelet-derived-growth factor receptor (PDGFR) stimulation in a manner that is partially dependent on Src kinase activity. However, the activity of Src kinases alone is not sufficient for activation of c-Abl by PDGFR. Here we show that functional phospholipase C-gamma1 (PLC-gamma1) is required for c-Abl activation by PDGFR. Decreasing cellular levels of phosphatidylinositol-4,5-bisphosphate (Ptdlns(4,5)P-2) by PLC-gamma1-mediated hydrolysis or dephosphorylation by an inositol polyphosphate 5-phosphatase (Inp54) results in increased AN kinase activity. c-Abl functions downstream of PLC-gamma1, as expression of kinase-inactive c-Abl blocks PLC-gamma1-induced chemotaxis towards PDGF-BB. PLC-gamma1 and c-Abl form a complex in cells that is enhanced by PDGF stimulation. After activation, c-Abl phosphorylates PLC-gamma1 and negatively modulates its function in vivo. These findings uncover a newly discovered functional interdependence between non-receptor Tyr kinase and lipid signalling pathways.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Prote Technol GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; GlaxoSmithKline; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Duke University; Howard Hughes Medical Institute	Plattner, R (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	pende014@mc.duke.edu		Pendergast, Ann Marie/0000-0002-1250-6880	NCI NIH HHS [CA70940, CA09111-25] Funding Source: Medline; NIGMS NIH HHS [GM62375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Firth JD, 2001, WOUND REPAIR REGEN, V9, P86, DOI 10.1046/j.1524-475x.2001.00086.x; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; GILBERT SH, 1994, J CELL BIOL, V127, P489, DOI 10.1083/jcb.127.2.489; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JI QS, 1997, MOL BIOL CELL, V9, P749; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Osborne SL, 2001, NEURON, V32, P9, DOI 10.1016/S0896-6273(01)00455-X; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang YX, 2001, P NATL ACAD SCI USA, V98, P14865, DOI 10.1073/pnas.251249298; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	46	111	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2003	5	4					309	319		10.1038/ncb949	http://dx.doi.org/10.1038/ncb949			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	664UR	12652307				2022-12-25	WOS:000182080700014
J	Bienz, M; Clevers, H				Bienz, M; Clevers, H			Armadillo/beta-catenin signals in the nucleus - proof beyond a reasonable doubt?	NATURE CELL BIOLOGY			English	Article							POLARITY GENE ARMADILLO; APC TUMOR-SUPPRESSOR; BETA-CATENIN; WINGLESS SIGNAL; DROSOPHILA HOMOLOG; AXIS SPECIFICATION; XENOPUS EMBRYOS; ENCODES; LEF-1; PROTEIN	Wnt signalling results in transcriptional stimulation of genes controlling normal and malignant development. A key effector of the canonical Wnt pathway is beta-catenin (also known as Drosophila melanogaster Armadillo (Arm)), thought to function as a nuclear co-activator of TCF transcription factors. This has been challenged by unexpected observations of membrane-bound Arm/beta-catenin signalling activity. Plausible explanations allow these observations to be reconciled with the large body of evidence supporting a nuclear function of Arm/beta-catenin.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Netherlands Inst Dev Biol, NL-3584 CT Utrecht, Netherlands	MRC Laboratory Molecular Biology; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mb2@mrc-lamb.cam.ac.uk						Ahmed Y, 2002, DEVELOPMENT, V129, P1751; Akong K, 2002, DEV BIOL, V250, P91, DOI 10.1006/dbio.2002.0776; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Cox RT, 1999, DEVELOPMENT, V126, P1327; Cox RT, 1999, GENETICS, V153, P319; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Galceran J, 2001, P NATL ACAD SCI USA, V98, P8668, DOI 10.1073/pnas.151258098; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; KIRMIZIS A, 2003, IN PRESS CANC THERAP; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Logan CY, 1999, DEVELOPMENT, V126, P345; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Montross WT, 2000, J CELL SCI, V113, P1759; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Parker DS, 2002, DEVELOPMENT, V129, P2565; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 2000, GENE DEV, V14, P1837; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	57	119	127	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					179	182		10.1038/ncb0303-179	http://dx.doi.org/10.1038/ncb0303-179			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12646868				2022-12-25	WOS:000181322500003
J	Fan, J; Malik, AB				Fan, J; Malik, AB			Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors	NATURE MEDICINE			English	Article							KAPPA-B ACTIVATION; KINASE; MICE; LIPOPOLYSACCHARIDE; DESENSITIZATION; CXCR2; BACTERIAL; ENDOTOXIN; GENE; IDENTIFICATION	Polymorphonuclear leukocytes (PMNs) are critical effector cells of the innate immune system that protect the host by migrating to inflammatory sites and killing pathogenic microbes. We addressed the role of chemokine receptor desensitization induced by G-protein-coupled receptor kinases (GRKs) in the feedback control of PMN migration. We show that the chemokine macrophage inflammatory protein-2 (MIP-2) induces GRK2 and GRK5 expression in PMNs through phosphoinositide-3-kinase (PI3K)-gamma signaling. We also show that lipopolysaccharide (LPS)-activated signaling through the Toll-like receptor (TLR)-4 pathway transcriptionally downregulates the expression of GRK2 and GRK5 in response to MIP-2. The reduced expression of GRKs lowers chemokine receptor desensitization and markedly augments the PMN migratory response. These data indicate that TLR4 modulation of PMN surface chemokine receptor expression subsequent to the downregulation of GRK2 and GRK5 expression is a critical determinant of PMN migration.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Malik, AB (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60680 USA.			Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL027016, P01HL060678, T32HL007829, R01HL045638, R01HL027016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60678, HL27016, HL45638, T32 HL07829] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Eckhart AD, 2002, MOL PHARMACOL, V61, P749, DOI 10.1124/mol.61.4.749; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fan J, 2002, J IMMUNOL, V168, P5252, DOI 10.4049/jimmunol.168.10.5252; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Hisatomi O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang J, 1999, J IMMUNOL, V162, P2217; HUNTER R, 1970, P SOC EXP BIOL MED, V133, P989; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; KALMAR JR, 1994, METHOD ENZYMOL, V236, P58; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Khandaker MH, 1998, J IMMUNOL, V161, P1930; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lira S, 1999, Forum (Genova), V9, P286; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; PENN RB, 1994, J BIOL CHEM, V269, P14924; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SZUCS S, 1994, J IMMUNOL METHODS, V167, P245, DOI 10.1016/0022-1759(94)90093-0; Ulevitch RJ, 1999, NATURE, V401, P755, DOI 10.1038/44490; Wiekowski MT, 2001, J IMMUNOL, V167, P7102, DOI 10.4049/jimmunol.167.12.7102; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	37	209	224	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					315	321		10.1038/nm832	http://dx.doi.org/10.1038/nm832			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592402				2022-12-25	WOS:000181312300032
J	Neptune, ER; Frischmeyer, PA; Arking, DE; Myers, L; Bunton, TE; Gayraud, B; Ramirez, F; Sakai, LY; Dietz, HC				Neptune, ER; Frischmeyer, PA; Arking, DE; Myers, L; Bunton, TE; Gayraud, B; Ramirez, F; Sakai, LY; Dietz, HC			Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; MOUSE MODEL; IN-VIVO; LUNG; ALVEOGENESIS; MICROFIBRILS; GENE	Marfan syndrome is an autosomal dominant disorder of connective tissue caused by mutations in fibrillin-1 (encoded by FBN1 in humans and Fbn1 in mice), a matrix component of extracellular microfibrils. A distinct subgroup of individuals with Marfan syndrome have distal airspace enlargement, historically described as emphysema, which frequently results in spontaneous lung rupture (pneumothorax; refs.(1-3)). To investigate the pathogenesis of genetically imposed emphysema, we analyzed the lung phenotype of mice deficient in fibrillin-1, an accepted model of Marfan syndrome(4). Lung abnormalities are evident in the immediate postnatal period and manifest as a developmental impairment of distal alveolar septation. Aged mice deficient in fibrillin-1 develop destructive emphysema consistent with the view that early developmental perturbations can predispose to late-onset, seemingly acquired phenotypes. We show that mice deficient in fibrillin-1 have marked dysregulation of transforming growth factor-beta (TGF-beta) activation and signaling, resulting in apoptosis in the developing lung. Perinatal antagonism of TGF-beta attenuates apoptosis and rescues alveolar septation in vivo. These data indicate that matrix sequestration of cytokines is crucial to their regulated activation and signaling and that perturbation of this function can contribute to the pathogenesis of disease.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Dupont Merck Pharmaceut Co, Dept Safety Assessment, Newark, DE 19714 USA; Hosp Special Surg, New York, NY 10021 USA; Shriners Hosp Children, Portland, OR 97201 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; DuPont; Howard Hughes Medical Institute; Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA.			Gayraud-Morel, Barbara/0000-0002-1168-8504				BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DWYER EM, 1965, ANN INTERN MED, V62, P1285, DOI 10.7326/0003-4819-62-6-1285; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; HALL JR, 1984, ANN THORAC SURG, V37, P500, DOI 10.1016/S0003-4975(10)61142-3; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; THURLBEC.WM, 1967, AM REV RESPIR DIS, V95, P752; Tomita H, 1998, HYPERTENSION, V32, P273, DOI 10.1161/01.HYP.32.2.273; Unsold C, 2001, J CELL SCI, V114, P187; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Wendel DP, 2000, AM J RESP CELL MOL, V23, P320, DOI 10.1165/ajrcmb.23.3.3906; WOOD JR, 1984, THORAX, V39, P780, DOI 10.1136/thx.39.10.780; Yamamoto T, 1999, CLIN IMMUNOL, V92, P6, DOI 10.1006/clim.1999.4720; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	24	1048	1087	4	94	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2003	33	3					407	411		10.1038/ng1116	http://dx.doi.org/10.1038/ng1116			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	651GT	12598898				2022-12-25	WOS:000181312700020
J	Tsai, MY; Wiese, C; Cao, K; Martin, O; Donovan, P; Ruderman, J; Prigent, C; Zheng, YX				Tsai, MY; Wiese, C; Cao, K; Martin, O; Donovan, P; Ruderman, J; Prigent, C; Zheng, YX			A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE; CELL-CYCLE; MICROTUBULE DYNAMICS; IMPORTIN-BETA; ORGANIZATION; PHOSPHATASE; CENTROSOME; TPX2; PHOSPHORYLATION; KINETOCHORES	The activated form of Ran (Ran-GTP) stimulates spindle assembly in Xenopus laevis egg extracts, presumably by releasing spindle assembly factors, such as TPX2 (target protein for Xenopus kinesin-like protein 2) and NuMA (nuclear-mitotic apparatus protein) from the inhibitory binding of importin-alpha and -beta. We report here that Ran-GTP stimulates the interaction between TPX2 and the Xenopus Aurora A kinase, Eg2. This interaction causes TPX2 to stimulate both the phosphorylation and the kinase activity of Eg2 in a microtubule-dependent manner. We show that TPX2 and microtubules promote phosphorylation of Eg2 by preventing phosphatase I (PPI)-induced dephosphorylation. Activation of Eg2 by TPX2 and microtubules is inhibited by importin-alpha and -beta, although this inhibition is overcome by Ran-GTP both in the egg extracts and in vitro with purified proteins. As the phosphorylation of Eg2 stimulated by the Ran-GTP-TPX2 pathway is essential for spindle assembly, we hypothesize that the Ran-GTP gradient established by the condensed chromosomes is translated into the Aurora A kinase gradient on the microtubules to regulate spindle assembly and dynamics.	Carnegie Inst Sci, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Rennes 1, CNRS, UPR 41, Fac Med, F-35043 Rennes, France	Carnegie Institution for Science; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; Jefferson University; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Zheng, YX (corresponding author), Carnegie Inst Sci, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	zheng@ciwemb.edu			NICHD NIH HHS [HD23696] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023696] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GEIT R, 2002, J CELL BIOL, V156, P437; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Roghi C, 1998, J CELL SCI, V111, P557; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	39	289	297	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2003	5	3					242	248		10.1038/ncb936	http://dx.doi.org/10.1038/ncb936			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	651LY	12577065				2022-12-25	WOS:000181322500018
J	Coco, WM; Encell, LP; Levinson, WE; Crist, MJ; Loomis, AK; Licato, LL; Arensdorf, JJ; Sica, N; Pienkos, PT; Monticello, DJ				Coco, WM; Encell, LP; Levinson, WE; Crist, MJ; Loomis, AK; Licato, LL; Arensdorf, JJ; Sica, N; Pienkos, PT; Monticello, DJ			Growth factor engineering by degenerate homoduplex gene family recombination	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO; DIRECTED EVOLUTION; PROTEIN EVOLUTION; SHUFFLING METHOD; FACTOR RECEPTOR; EGF RECEPTOR; DNA; AFFINITY; ANALOGS; BINDING	There is great interest in engineering human growth factors as potential therapeutic agonists and antagonists. We approached this goal with a synthetic DNA recombination method. We aligned a pool of "top-strand" oligonucleotides incorporating polymorphisms from mammalian genes encoding epidermal growth factor (EGF) using multiple polymorphic "scaffold" oligonucleotides. Top strands were then linked by gap filling and ligation. This approach avoided heteroduplex annealing in the linkage of highly degenerate oligonucleotides and thus achieved completely random recombination. Cloned genes from a human-mouse chimeric library captured every possible permutation of the parental polymorphisms, creating an apparently complete recombined gene-family library, which has not been previously described. This library yielded a chimeric protein whose agonist activity was enhanced 123-fold. A second library from five mammalian EGF homologs possessed the highest reported recombination density (1 crossover per 12.4 bp). The five-homolog library yielded the strongest-binding hEGF variant yet reported. In addition, it contained strongly binding EGF variants with antagonist properties. Our less biased approach to DNA shuffling should be useful for the engineering of a wide variety of proteins.	Enchira Biotechnol Corp, The Woodlands, TX 77381 USA		Coco, WM (corresponding author), Tanox Inc, Houston, TX 77025 USA.							Coco WM, 2001, NAT BIOTECHNOL, V19, P354, DOI 10.1038/86744; COCO WM, 2003, IN PRESS METHODS MOL; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Gibbs MD, 2001, GENE, V271, P13, DOI 10.1016/S0378-1119(01)00506-6; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Kikuchi M, 2000, GENE, V243, P133, DOI 10.1016/S0378-1119(99)00547-8; Levichkin I V, 1995, Mol Biol (Mosk), V29, P983; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Moore GL, 2001, P NATL ACAD SCI USA, V98, P3226, DOI 10.1073/pnas.051631498; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Mullenbach GT, 1998, PROTEIN ENG, V11, P473, DOI 10.1093/protein/11.6.473; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; PAABO S, 1990, J BIOL CHEM, V265, P4718; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Souriau C, 1999, BIOL CHEM, V380, P451, DOI 10.1515/BC.1999.059; Souriau C, 1997, NUCLEIC ACIDS RES, V25, P1585, DOI 10.1093/nar/25.8.1585; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; van de Poll MLM, 1998, J BIOL CHEM, V273, P16075, DOI 10.1074/jbc.273.26.16075; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Voigt CA, 2001, ADV PROTEIN CHEM, V55, P79	26	52	82	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2002	20	12					1246	1250		10.1038/nbt757	http://dx.doi.org/10.1038/nbt757			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	620VF	12426576				2022-12-25	WOS:000179552600045
J	Dowsett, M; Howell, A				Dowsett, M; Howell, A			Breast cancer: Aromatase inhibitors take on tamoxifen	NATURE MEDICINE			English	Editorial Material							ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE THERAPY; LETROZOLE; RESISTANT		Royal Marsden NHS Trust, Acad Dept Biochem, London, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Canc Res UK, Manchester, Lancs, England	Royal Marsden NHS Foundation Trust; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Dowsett, M (corresponding author), Royal Marsden NHS Trust, Acad Dept Biochem, Fulham Rd, London, England.	mitch@icr.ac.uk		Howell, Anthony/0000-0002-6233-719X				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Baum M, 2002, LANCET, V359, P2131; Bentrem D J, 2002, Minerva Endocrinol, V27, P127; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Cuzick J, 2002, LANCET, V360, P817; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fuqua SAW, 2000, CANCER RES, V60, P4026; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Harper-Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614; Heshmati HM, 2002, J BONE MINER RES, V17, P172, DOI 10.1359/jbmr.2002.17.1.172; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Howell A, 1997, BRIT MED J, V315, P863, DOI 10.1136/bmj.315.7112.863; Kurokawa H, 2000, CANCER RES, V60, P5887; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Zhang QX, 1997, CANCER RES, V57, P1244	20	26	26	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1341	1344		10.1038/nm1202-1341	http://dx.doi.org/10.1038/nm1202-1341			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12457166				2022-12-25	WOS:000179552000015
J	Ozaki, K; Ohnishi, Y; Iida, A; Sekine, A; Yamada, R; Tsunoda, T; Sato, H; Sato, H; Hori, M; Nakamura, Y; Tanaka, T				Ozaki, K; Ohnishi, Y; Iida, A; Sekine, A; Yamada, R; Tsunoda, T; Sato, H; Sato, H; Hori, M; Nakamura, Y; Tanaka, T			Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction	NATURE GENETICS			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MAXIMUM-LIKELIHOOD-ESTIMATION; E-SELECTIN; HEART-DISEASE; MAST-CELLS; ATHEROSCLEROSIS; RUPTURE; PLAQUE; GENOME; VCAM-1	By means of a large-scale, case-control association study using 92,788 gene-based single-nucleotide polymorphism (SNP) markers, we identified a candidate locus on chromosome 6p21 associated with susceptibility to myocardial infarction. Subsequent linkage-disequilibrium (LD) mapping and analyses of haplotype structure showed significant associations between myocardial infarction and a single 50 kb halpotype comprised of five SNPs in LTA (encoding lymphotoxin-alpha), NFKBIL1 (encoding nuclear factor of kappa light polypeptide gene enhancer in B cells, inhibitor-like 1) and BAT1 (encoding HLA-B associated transcript 1). Homozygosity with respect to each of the two SNPs in LTA was significantly associated with increased risk for myocardial infarction (odds ratio=1.78, chi(2)=21.6, P=0.00000033; 1,133 affected individuals versus 1,006 controls). In vitro functional analyses indicated that one SNP in the coding region of LTA, which changed an amino-acid residue from threonine to asparagine (Thr26Asn), effected a twofold increase in induction of several cell-adhesion molecules, including VCAM1, in vascular smooth-muscle cells of human coronary artery. Moreover, the SNP, in intron 1 of LTA, enhanced the transcriptional level of LTA. These results indicate that variants in the LTA are risk factors for myocardial infraction and implicate LTA in the pathogenesis of the disorder.	RIKEN, Inst Phys & Chem Res, Lab Cardiovasc Dis, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Genotyping, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Rheumat Dis, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Med Informat,SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan	RIKEN; RIKEN; RIKEN; RIKEN; Osaka University; University of Tokyo	Tanaka, T (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cardiovasc Dis, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014; Iida, Aritoshi/CAA-1373-2022; Tanaka, Toshihiro/J-9310-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Iida, Aritoshi/0000-0001-7538-1651; Tanaka, Toshihiro/0000-0001-6201-9784; Ozaki, Kouichi/0000-0003-0028-1570; Yamada, Ryo/0000-0002-1587-630X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Belch JJF, 1997, CIRCULATION, V95, P2027, DOI 10.1161/01.CIR.95.8.2027; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Breslow JL, 1997, NAT MED, V3, P600, DOI 10.1038/nm0697-600; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; GALLIS ZS, 1994, CIRC RES, V75, P181; Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092; Hwang SJ, 1997, CIRCULATION, V96, P4219; Iida A, 2001, J HUM GENET, V46, P668, DOI 10.1007/s100380170019; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Morisaki N, 1997, ATHEROSCLEROSIS, V131, P43, DOI 10.1016/S0021-9150(97)06083-8; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200; Squadrito F, 1996, INFLAMM RES, V45, P14, DOI 10.1007/BF02263499; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Yamada R, 2001, AM J HUM GENET, V68, P674, DOI 10.1086/318789	27	690	738	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2002	32	4					650	654		10.1038/ng1047	http://dx.doi.org/10.1038/ng1047			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	621MH	12426569				2022-12-25	WOS:000179593000019
J	Rebar, EJ; Huang, Y; Hickey, R; Nath, AK; Meoli, D; Nath, S; Chen, BL; Xu, L; Liang, YX; Jamieson, AC; Zhang, L; Spratt, SK; Case, CC; Wolffe, A; Giordano, FJ				Rebar, EJ; Huang, Y; Hickey, R; Nath, AK; Meoli, D; Nath, S; Chen, BL; Xu, L; Liang, YX; Jamieson, AC; Zhang, L; Spratt, SK; Case, CC; Wolffe, A; Giordano, FJ			Induction of angiogenesis in a mouse model using engineered transcription factors	NATURE MEDICINE			English	Article							GENE-TRANSFER; ZINC FINGERS; SELECTION; ACTIVATION; DESIGN	The relationship between the structure of zinc-finger protein (ZFP) transcription factors and DNA sequence binding specificity has been extensively studied(1). Advances in this field have made it possible to design ZFPs de novo that will bind to specific targeted DNA sequences(2-10). It has been proposed that such designed ZFPs may eventually be useful in gene therapy(6,7,10). A principal advantage of this approach is that activation of an endogenous gene ensures expression of the natural array of splice variants(2). Preliminary studies in tissue culture have validated the feasibility of this approach(2-4). The studies reported here were intended to test whether engineered transcription factors are effective in a whole-organism model. ZFPs were designed to regulate the endogenous gene encoding vascular endothelial growth factor-A (Vegfa). Expression of these new ZFPs in vivo led to induced expression of the protein VEGF-A, stimulation of angiogenesis and acceleration of experimental wound healing. In addition, the neovasculature resulting from ZFP-induced expression of Vegfa was not hyperpermeable as was that produced by expression of murine Vegfa(164) cDNA. These data establish, for the first time, that specifically designed transcription factors can regulate an endogenous gene in vivo and evoke a potentially therapeutic biophysiologic effect.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Sangamo Biosci, Richmond, CA USA	Yale University; Sangamo Therapeutics, Inc.	Giordano, FJ (corresponding author), Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA.	fjg9@email.med.yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064001] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vincent KA, 2000, CIRCULATION, V102, P2255; Wolffe A., 1998, CHROMATIN STRUCTURE; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	22	207	264	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1427	1432		10.1038/nm795	http://dx.doi.org/10.1038/nm795			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415262				2022-12-25	WOS:000179552000040
J	Camp, RL; Chung, GG; Rimm, DL				Camp, RL; Chung, GG; Rimm, DL			Automated subcellular localization and quantification of protein expression in tissue microarrays	NATURE MEDICINE			English	Article							BETA-CATENIN EXPRESSION; COLORECTAL-CANCER; TECHNOLOGY; CARCINOMA	The recent development of tissue microarrays-composed of hundreds of tissue sections from different tumors arrayed on a single glass slide-facilitates rapid evaluation of large-scale outcome studies. Realization of this potential depends on the ability to rapidly and precisely quantify the protein expression within each tissue spot. We have developed a set of algorithms that allow the rapid, automated, continuous and quantitative analysis of tissue microarrays, including the separation of tumor from stromal elements and the sub-cellular localization of signals. Validation studies using estrogen receptor in breast carcinoma show that automated analysis matches or exceeds the results of conventional pathologist-based scoring. Automated analysis and sub-cellular localization of beta-catenin in colon cancer identifies two novel, prognostically significant tumor subsets, not detected by traditional pathologist-based scoring. Development of automated analysis technology empowers tissue microarrays for use in discovery-type experiments (more typical of cDNA microarrays), with the added advantage of inclusion of long-term demographic and patient outcome information.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.			Rimm, David/0000-0001-5820-4397	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES011571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057604] Funding Source: NIH RePORTER; NIEHS NIH HHS [K0-8 ES11571] Funding Source: Medline; NIGMS NIH HHS [R0-1 GM57604] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacus S, 1997, ANAL QUANT CYTOL, V19, P316; Chung GG, 2001, CLIN CANCER RES, V7, P4013; Gunther K, 1998, DIS COLON RECTUM, V41, P1256, DOI 10.1007/BF02258226; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kobayashi M, 2000, BRIT J CANCER, V82, P1689; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Osborne C K, 1981, Adv Exp Med Biol, V138, P377; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rao JY, 2002, BIOTECHNIQUES, V32, P924, DOI 10.2144/02324pt04; Rimm DL, 2001, CANCER J, V7, P24; Robinson JP, 2001, METHOD CELL BIOL, V63, P89; Tarnok A, 2002, CYTOMETRY, V50, P133, DOI 10.1002/cyto.10099; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R	19	618	663	2	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1323	1327		10.1038/nm791	http://dx.doi.org/10.1038/nm791			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12389040				2022-12-25	WOS:000179221200041
J	Kjaerulff, O; Verstreken, P; Bellen, HJ				Kjaerulff, O; Verstreken, P; Bellen, HJ			Synaptic vesicle retrieval: still time for a kiss	NATURE CELL BIOLOGY			English	Article							FROG NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; RAPID ENDOCYTOSIS; CHROMAFFIN CELLS; COATED VESICLES; NERVE-TERMINALS; CLATHRIN; MEMBRANE; EXOCYTOSIS; FUSION	After exocytosis, synaptic vesicles are reformed by slow clathrin-mediated endocytosis. However, evidence also supports the existence of faster retreival mechanisms in neurons, including 'kiss-and-run', where vesicles fuse only partially with the presynaptic membrane before being retrieved. New insights in synaptic vesicle dynamics have been obtained from vesicle imaging and from studies with mutant animals. Recently, measurements of capacitance changes induced by the fusion of single synaptic vesicles in synapses corroborate the hypothesis that kiss-and-run operates in neurons. ere, we review the evidence supporting fast vesicle retrieval and evaluate its role in neurotransmitter release.	Univ Copenhagen, Dept Med Physiol, Div Neurophysiol, DK-2200 Copenhagen, Denmark; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Div Neurosci, Houston, TX 77030 USA	University of Copenhagen; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Kjaerulff, O (corresponding author), Univ Copenhagen, Dept Med Physiol, Div Neurophysiol, DK-2200 Copenhagen, Denmark.		Verstreken, Patrik/AAC-7591-2022; Kjaerulff, Ole/Q-6996-2018	Verstreken, Patrik/0000-0002-5073-5393; Kjaerulff, Ole/0000-0002-8654-1435; Bellen, Hugo/0000-0001-5992-5989				Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Artalejo CR, 1998, CURR BIOL, V8, pR62, DOI 10.1016/S0960-9822(98)70036-3; Artalejo CR, 2002, P NATL ACAD SCI USA, V99, P6358, DOI 10.1073/pnas.082658499; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Delgado R, 2000, NEURON, V28, P941, DOI 10.1016/S0896-6273(00)00165-3; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Elhamdani A, 2001, NEURON, V31, P819, DOI 10.1016/S0896-6273(01)00418-4; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GALLI T, 2001, SCI STKE        0626; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; Kawasaki F, 2000, NAT NEUROSCI, V3, P859, DOI 10.1038/78753; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2002, J BIOL CHEM, V277, P15957, DOI 10.1074/jbc.C200051200; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1	36	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2002	4	11					E245	E248		10.1038/ncb1102-e245	http://dx.doi.org/10.1038/ncb1102-e245			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	613NE	12415277				2022-12-25	WOS:000179137700002
J	Park, KI; Teng, YD; Snyder, EY				Park, KI; Teng, YD; Snyder, EY			The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue	NATURE BIOTECHNOLOGY			English	Article							SYNTHETIC EXTRACELLULAR MATRICES; BIODEGRADABLE POLYMERS; BIOTINYLATED DEXTRAN; NEUROPROTECTION; TRANSPLANTATION; ANTEROGRADE; REPLACEMENT; PROGENITOR; DELIVERY; NEURONS	Hypoxic-ischemic injury is a prototype for insults characterized by extensive tissue loss. Seeding neural stem cells (NSCs) onto a polymer scaffold that was subsequently implanted into the infarction cavities of mouse brains injured by hypoxia-ischemia allowed us to observe the multiple reciprocal interactions that spontaneously ensue between NSCs and the extensively damaged brain: parenchymal loss was dramatically reduced, an intricate meshwork of many highly arborized neurites of both host- and donor-derived neurons emerged, and some anatomical connections appeared to be reconstituted. The NSC-scaffold complex altered the trajectory and complexity of host cortical neurites. Reciprocally, donor-derived neurons were seemingly capable of directed, target-appropriate neurite outgrowth (extending axons to the opposite hemisphere) without specific external instruction, induction, or genetic manipulation of host brain or donor cells. These "bio-bridges" appeared to unveil or augment a constitutive reparative response by facilitating a series of reciprocal interactions between NSC and host, including promoting neuronal differentiation, enhancing the elaboration of neural processes, fostering the re-formation of cortical tissue, and promoting connectivity. Inflammation and scarring were also reduced, facilitating reconstitution.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Yonsei Univ, Coll Med, Dept Pediat Pharmacol & Brain, Korea Project Med Sci 21, Seoul 120752, South Korea; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Yonsei University; Yonsei University Health System; Harvard University; Harvard Medical School	Snyder, EY (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	esnyder1@caregroup.harvard.edu						Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S; Davenport R, 2000, J NEUROL NEUROSUR PS, V68, P277, DOI 10.1136/jnnp.68.3.277; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Deuel T.F., 1997, PRINCIPLES TISSUE EN, P133; duPlessis AJ, 1997, CLIN PERINATOL, V24, P627, DOI 10.1016/S0095-5108(18)30162-3; Gage FH, 1998, NATURE, V392, P18; Hodges H, 2000, NEUROSCIENCE, V101, P945, DOI 10.1016/S0306-4522(00)00408-5; Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167-7799(98)01191-3; KIM WS, 1994, PLAST RECONSTR SURG, V94, P233, DOI 10.1097/00006534-199408000-00001; Labhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5; Nerem R M, 1995, Tissue Eng, V1, P3, DOI 10.1089/ten.1995.1.3; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; PUELACHER WC, 1994, BIOMATERIALS, V15, P774, DOI 10.1016/0142-9612(94)90031-0; Putnam AJ, 1996, NAT MED, V2, P824, DOI 10.1038/nm0796-824; RAJAKUMAR N, 1993, BRAIN RES, V607, P47, DOI 10.1016/0006-8993(93)91488-E; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; Rosario CM, 1997, DEVELOPMENT, V124, P4213; Shalaby SW, 1994, BIOMEDICAL POLYM, P2; SHARP FR, 1993, ANN NEUROL, V34, P322, DOI 10.1002/ana.410340303; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Snyder EY, 2002, NAT MED, V8, P928, DOI 10.1038/nm0902-928; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Tan S, 1999, CLIN PERINATOL, V26, P733, DOI 10.1016/S0095-5108(18)30048-4; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Vacanti JP, 1999, LANCET, V354, pSI32; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; VANNUCCI RC, 1993, APMIS, V101, P89; VEENMAN CL, 1992, J NEUROSCI METH, V41, P239, DOI 10.1016/0165-0270(92)90089-V	35	445	460	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2002	20	11					1111	1117		10.1038/nbt751	http://dx.doi.org/10.1038/nbt751			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	611WV	12379868				2022-12-25	WOS:000179041500021
